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 1This manuscript describes an attempt of elucidating only a minute aspect of a complex 
problem, known as coronary artery disease (CAD). With an estimated 8 million deaths 
per year, CAD remains among the leading causes of premature death in the world, 
despite the fact that prevention, lifestyle interventions, pharmacologic strategies and 
revascularization have led to a decline in mortality rates over the past decades. Never-
theless, the fact that the number of life years lost to premature deaths is increasing in 
low- and middle-income regions is alarming.[1]
Patients with a formal diagnosis of CAD are at the scope of this thesis. For these patients, 
epidemiologists have been able to successfully create prediction models that aim to 
estimate the risk of death or myocardial infarction within a set timeframe. These models 
depend on the presence and recognition of traditional risk factors (such as hyperten-
sion, diabetes, smoking etc.) and cardiovascular history complemented by biometric 
factors. However, traditional cardiovascular risk factors are absent in a significant part 
of the population that nevertheless will develop CAD and its sequelae. In contrast, the 
prevalence of traditional risk factors is also high among the fraction of the population 
that will never endure a major adverse cardiovascular event (MACE) [2].
According to the key philosophy behind existing risk prediction models, the individual 
patient is considered to be a member of a group that is exposed to a certain (low-interme-
diate-high) constant risk over time, whereas the incidence of acute cardiovascular events 
is considered a random process, with event probabilities directly related to that group risk. 
Consequently, cardiovascular risk models usually predict reasonably well on a group level, 
but only poorly outline the course of individuals. [2] In addition, current risk prediction 
models do not account for the dynamic nature of the coronary pathophysiology. Individual 
patients with CAD actually do not have constant risks over time. Long periods of stability, 
with minimal plaque progression and low risk of cardiovascular events, are alternated by 
periods of increased plaque instability and rapid plaque progression, during which the risk 
of sudden plaque disruption and thrombotic coronary occlusion increases. [2]
Against this background, the common thread throughout parts 1 to 3 of this thesis is the 
search for improvement of risk prediction in patients with known CAD, i.e. more precise 
identification of those vulnerable for suffering a coronary event in the future.
Part 1, “Vulnerable Blood”, focusses on the additional value of several serum biomark-
ers for the prediction of MACE on a relatively long term (4 to 10 years of follow-up). 
These markers are traditionally measured once at the start of follow-up and hence as-
sumed to reflect a constant cardiovascular risk, in a similar way as traditional risk models 
incorporate clinical risk factors.
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Part 2, “Vulnerable Period”, focusses on serum biomarkers as well, but here the train 
of thought is more in line with the dynamics of coronary pathophysiology, i.e. that the 
risk of MACE within an individual patient is not constant, but variable over time. Hence, 
repeated biomarker measurements are explored in the BIOMarker study to identify the 
Acute risk of a Coronary Syndrome (BIOMArCS), in order to evaluate whether fluctua-
tions in biomarker levels can predict the risk of an imminent MACE within the days to 
weeks to come.
In Part 3, “Vulnerable Plaque”, the centre of interest is around invasive coronary imag-
ing, including coronary angiography, intravascular ultrasound (IVUS) and near-infrared 
spectroscopy (NIRS), for the prediction of MACE, as well as cross-sectional analyses 
evaluating the relation between these imaging techniques and serum biomarkers.
Accurate risk prediction is important to understand future risks of CAD patients, but 
clearly prediction alone will not alter their outcome. For that purpose, intervention 
studies are required in those deemed at high risk. Such studies, often combined with 
the search for those patient subsets to derive most benefit from the interventions, are 
described in Part 4, “Intervention Studies”.
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absTRaCT
Objective: To evaluate the predictive value of seven biomarkers, which individually have 
been shown to be independent predictors, for use in a combined multimarker model 
for long-term cardiovascular outcome after non-ST-segment elevation acute coronary 
syndrome (NSTEACS).
Design and setting: Levels of high-sensitivity C-reactive protein (hsCRP), myeloper-
oxidase, pregnancy-associated plasma protein A, placental growth factor (PlGF), soluble 
CD40 ligand (sCD40L), interleukin 10 (IL-10) and troponin-T (TnT) were determined in 
patients enrolled in the CAPTURE trial. Cox proportional hazard regression analyses 
were applied to evaluate the relation between biomarkers and the occurrence of all-
cause mortality or non-fatal myocardial infarction (MI).
Patients: 1090 patients with NSTEACS.
Main outcome measure: All-cause mortality and non-fatal MI during a median follow-
up of 4 years.
Results: The composite endpoint was reached by 15.3% of patients. Admission levels of 
TnT >0.01 µg/l (adjusted HR 1.8), IL-10 <3.5 ng/l (1.7), myeloperoxidase >350 µg/l (1.5) 
and PlGF >27 ng/l (1.9) remained significant predictors for the incidence of all-cause 
mortality or non-fatal MI after multivariable adjustment for other biomarkers and clini-
cal characteristics, whereas hsCRP, pregnancy-associated plasma protein A and sCD40L 
were only associated with the endpoint in univariate analysis. A multimarker model con-
sisting of TnT, IL-10, myeloperoxidase and PlGF predicted 4-year event rates that varied 
between 6.0% (all markers normal) and 35.8% (three or more biomarkers abnormal).
Conclusion: In patients with NSTEACS, biomarkers characterising distinct aspects of the 
underlying atherosclerotic process and myocardial damage of the initial cardiac event 
can assist in predicting long-term adverse cardiac outcomes. The use of combinations of 
selected biomarkers adds incremental predictive value to further risk stratification in an 
otherwise seemingly homogeneous NSTEACS population.
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Atherosclerosis and plaque destabilisation leading to coronary thrombosis and an 
acute coronary syndrome (ACS) are the result of a very heterogeneous process, involv-
ing vascular inflammation, endothelial dysfunction and hypercoagulability.1 Several 
novel serum biomarkers are thought to reflect these pathophysiological constituents 
of coronary artery disease (CAD) and have also proved to be independent predictors 
of future coronary events. C-reactive protein is the most extensively studied biomarker 
in this respect. It has been shown to be useful not only as a prognostic tool in patients 
with ACS,2 but also in predicting the future risk of CAD in apparently healthy men and 
women.3 Myeloperoxidase, a leucocytic enzyme that appears as part of the host de-
fence in inflammatory disorders, and also present in soft plaque, was associated with 
an increased risk of major adverse cardiac events in patients with documented ACS,2 
as well as in those presenting with chest pain without evidence of myocardial necro-
sis.4 Also expressed in ruptured and eroded plaques, but not in stable plaques, is the 
metalloproteinase pregnancy-associated plasma protein A (PAPP-A).5,6 Placental growth 
factor (PlGF), a member of the vascular endothelial growth factor family, is considered 
a primary inflammatory instigator in atherosclerotic lesions,7 and has prognostic value 
in patients with ACS.8 In contrast, elevated levels of the anti-inflammatory cytokine 
interleukin 10 (IL-10) were associated with a lower risk of coronary events in patients 
with ACS and elevated high-sensitivity C-reactive protein (hsCRP) levels,9 emphasising 
the importance of an inflammatory balance in the vascular wall. Finally, elevated levels 
of soluble CD40 ligand (sCD40L), which is primarily released from activated platelets,10 
were associated with an increased cardiovascular risk during 6 months of follow-up of 
ACS-patients.11
The prognostic value of these and other biomarkers for the risk of future cardiovascu-
lar events in ACS patients has previously been studied. These analyses typically assess 
each marker individually with adjustment for clinical patient characteristics.
In certain cases, two markers are combined in one model.12 There are only two reports, 
however, in which the specific combination of three biomarkers provided incremental 
value for risk prediction after ACS.13,14 Furthermore, the follow-up duration of previous 
multimarker studies in ACS patients was often limited to periods consisting of several 
months up to a maximum of 1 year after admission.2,5,8,9,11,13-15 Nevertheless, coronary 
pathophysiology is sustained after acute interventional or pharmacological treatment 
and continuously triggers cardiovascular events during long-term follow-up. We 
therefore studied the relation between baseline levels of seven biomarkers, includ-
ing troponin-T (TnT) as a marker of myocardial necrosis, both independently and in a 
combined multimarker risk model, and the incidence of allcause mortality or non-fatal 
myocardial infarction (MI) during an extended 4-year follow-up period in ACS patients 
who were enrolled in the CAPTURE trial.
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MeTHODs
Patients and treatment
Patients admitted with unstable angina pectoris or non ST-elevation MI were eligible 
for CAPTURE if they had refractory unstable angina defined as: chest pain at rest with 
concomitant ECG abnormalities compatible with myocardial ischaemia (ST-segment-
depression, ST-segment elevation, or abnormal T waves) and one or more episodes of 
typical chest pain, ECG abnormalities, or both, compatible with myocardial ischaemia 
during therapy with intravenous heparin and nitrates, started at least 2 h previously. 
The latest episode of ischaemia should have occurred within the 48 h before enrolment, 
corresponding to Braunwald class III unstable angina. All patients had undergone 
angiography and had significant CAD, with a culprit lesion suitable for percutaneous 
coronary intervention (PCI). Patients were enrolled within 24 h of coronary angiography 
and were randomly assigned to abciximab (ReoPro, Centocor BV, Leiden, The Nether-
lands; 0.25 mg/kg bolus plus 10 μg/min continuous infusion) or placebo after providing 
written informed consent. PCI was scheduled 18-24 h after the start of study medication. 
Study medication was started within 2 h of randomisation and continued until 1 h after 
the procedure. All patients received aspirin, heparin and nitrates, whereas β-blockers, 
calcium channel antagonists and other cardiovascular drugs were given at the discre-
tion of the investigator.
analytical techniques
Blood samples were drawn 8.7±4.9 h after the last episode of angina, but before PCI and 
before the incidence of adverse events. Serum and heparin plasma samples were avail-
able for the measurement of TnT, hsCRP, sCD40L, IL-10, myeloperoxidase, PAPP-A and 
PlGF levels. Biomarker measurements were performed blinded to the patients’ histories. 
Levels of sCD40L, high-sensitivity IL-10, myeloperoxidase and PlGF were measured by 
ELISA (sCD40L, IL-10 and PlGF from R&D Systems, Wiesbaden, Germany and myeloper-
oxidase from Calbiochem, Merck KGaA, Darmstadt, Germany). Diagnostic thresholds 
were 5.0 µg/ l for sCD40L, 3.5 ng/l for IL-10, 350 μg/l for myeloperoxidase and 27 ng/l 
for PlGF. Levels of TnT and PAPP-A were determined using a electrochemiluminescence 
immunoassay (Elecsys, Roche Diagnostics, Mannheim, Germany). A diagnostic threshold 
value of 0.01 µg/l for TnT and 12.6 mIU/l for PAPP-A was used. Levels of hsCRP were 
measured using the Behring BN II Nephelometer (Dade Behring, Deerfield, Illinois, USA). 
A diagnostic threshold value of 10 mg/l was used. All cut-off values were consistent with 
previous biomarker publications within this cohort in which the markers were described 
independently.2,5,8,9,11,15
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study endpoints
The endpoint of the present analysis was a composite of all-cause mortality and non-
fatal MI during 4-year (median) follow-up. Follow-up at 6 months was part of the initial 
study protocol, and a clinical endpoint committee adjudicated these events.
MI during the index hospital stay was defined as values of creatine kinase or its 
myocardial type (MB) isoenzyme more than three times the upper limit of normal in at 
least two samples, with an increase by 50% over the previous value, or an ECG with new 
significant Q waves in two or more contiguous leads. MI after discharge was defined as 
concentrations of creatine kinase or its myocardial type isoenzyme above two times the 
upper limit of normal, or new significant Q waves in two or more contiguous ECG leads. 
Survival status and information on MI during extended follow-up (ie, after 6 months af-
ter randomisation) were obtained from the treating physician, the general practitioner, 
through self-reporting or municipal registries. These events were not adjudicated.
Data analysis
Continuous variables were summarised by median values with corresponding 25th 
and 75th percentiles. Discrete variables were summarised in terms of frequencies and 
percentages. Kaplan-Meier analyses were performed to evaluate the incidence of events 
over time. Univariable and multivariable Cox proportional hazards regression analyses 
were applied to evaluate the relation between all biomarkers and long-term outcome. 
In the multivariate model we adjusted variables known to be important predictors of 
outcome including age, gender, smoking, diabetes mellitus, hypertension, hypercho-
lesterolaemia, left ventricular ejection fraction, ST-depression, ST-elevation or T-wave 
changes on the admittance ECG and history of MI, peripheral vascular disease, chronic 
heart failure or previous PCI. Crude and adjusted HR are presented with 95% CI. p Values 
were two-sided, with p≤0.05 being considered significant.
In case patients had more than one event (MI or death), the first was counted. In 
previous analyses of the CAPTURE study, significant interactions were observed be-
tween certain biomarkers (TnT and sCD40L) and allocated treatment with respect to 
the incidence of cardiovascular events during 6-month follow-up.11,15 Formal statistical 
tests demonstrated that these interactions were no longer present with respect to the 
incidence of such events during long-term follow-up. Therefore, we decided to conduct 
all analyses on the patients allocated to placebo (N=544), as well as on the entire study 
population (placebo and abciximab combined; N=1090). The results of both sets of 
analyses are presented.
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ResulTs
One thousand two hundred and sixty-five patients were enrolled in the CAPTURE trial. 
Multiple biomarker analysis proved feasible in 1090 patients. Baseline characteristics 
and clinical variables of these 1090 patients (546 abciximab, 544 placebo) who were 
included in our analyses are provided in table 1. The median follow-up duration was 47 
months (25th and 75th percentile: 38, 55). The composite endpoint was reached in 167 
(15.3%) patients (58 deaths and 109 non-fatal MIs).
Patients with elevated levels of most of the studied biomarkers had a higher risk of 
death or non-fatal MI than those with levels below the threshold (figure 1 and table 2), 
whereas elevated levels of IL-10 were associated with a better prognosis. For example, 
in the entire study population, those with TnT levels greater than 0.01 µg/l had a 20.3% 
incidence of death or nonfatal MI at 4 years of follow-up versus 11.1% in those with low 
TnT levels (unadjusted HR 2.1 and 95% CI 1.4 to 3.0). In patients receiving placebo, 4-year 
event rates were 23.5% and 11.6% in those with and without elevated TnT, respectively 
(unadjusted HR 2.2 and 95% CI 1.3 to 3.6; table 2). The results for all (other) biomarkers 
are given in table 2.
TnT, IL-10, myeloperoxidase and PlGF remained significant predictors for the incidence 
of all-cause mortality or non-fatal MI in the entire study population as well as in patients 
receiving placebo (table 2) after multivariable adjustment for clinical characteristics 
and all other biomarkers, whereas hsCRP, sCD40L and PAPP-A did not. Only two of the 
Table 1. baseline characteristics
Age, years 62 (54, 69)
Male gender 73 (796)
Body mass index 26 (24, 28)
Diabetes mellitus 14 (153)
Hypercholesterolaemia 41 (447)
Current smoker or quitted within 1 year before 40 (436)
Previous angina 50 (545)
Previous MI 39 (425)
Previous heart failure 2 (22)
Peripheral artery disease 8 (87)
Previous coronary artery bypass graft 3 (33)
Previous PCI 13 (142)
History of any vascular disease 67 (730)
ST depression at presentation 43 (469)
Non-ST-elevation myocardial infarction at presentation 58 (632)
Age and body mass index are presented as median (IQR). All other data are presented in percentages 
(numbers). MI, myocardial infarction; PCI, percutaneous coronary intervention.
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baseline clinical variables remained significant: age and ejection fraction (HR 1.03; 95% 
CI 1.01 to 1.04 per year and HR 0.98; 95% CI 0.96 to 0.99 per percentage point increase in 
ejection fraction, respectively; not given in table 2) in a multivariate model that included 
all biomarkers and baseline clinical variables.
We created a simple risk model for 4-year mortality and nonfatal MI by counting the 
presence or absence of an abnormal biomarker value that significantly predicted risk 
for an event. The percentages of patients with none, one, two or three or more abnor-
mal biomarker levels were 5.2%, 22.1%, 43.5% and 29.2%, respectively. Four-year event 
rates varied between 6.0% (all markers normal) and 35.8% (three or more biomarkers 
feasible in 1090 patients. Baseline characteristics and clinical
variables of these 1090 patients (546 abciximab, 544 placebo)
who were included in our analyses are provided in table 1. The
median follow-up duration was 47 months (25th and 75th
percentile: 38, 55). The composite endpoint was reached in 167
(15.3%) patients (58 deaths and 109 non-fatal MIs).
Patients with elevated levels of most of the studied biomarkers
had a higher risk of death or non-fatal MI than those with levels
below the threshold (ﬁgure 1 and table 2), whereas elevated
levels of IL-10 were associated with a better prognosis. For
example, in the entire study population, those with TnT levels
greater than 0.01 mg/l had a 20.3% incidence of death or non-
fatal MI at 4 years of follow-up versus 11.1% in those with low
TnT levels (unadjusted HR 2.1 and 95% CI 1.4 to 3.0). In
patients receiving placebo, 4-year event rates were 23.5% and
11.6% in those with and without elevated TnT, respectively
(unadjusted HR 2.2 and 95% CI 1.3 to 3.6; table 2). The results
for all (other) biomarkers are given in table 2.
TnT, IL-10, myeloperoxidase and PlGF remained signiﬁcant
predictors for the incidence of all-cause mortality or non-fatal
MI in the entire study population as well as in patients receiving
placebo (table 2) after multivariable adjustment for clinical
characteristics and all other biomarkers, whereas hsCRP, sCD40L
and PAPP-A did not. Only two of the baseline clinical variables
remained signiﬁcant: age and ejection fraction (HR 1.03; 95% CI
1.01 to 1.04 per year and HR 0.98; 95% CI 0.96 to 0.99 per
percentage point increase in ejection fraction, respectively; not
given in table 2) in a multivariate model that included all
biomarkers and baseline clinical variables.
We created a simple risk model for 4-year mortality and non-
fatal MI by counting the presence or absence of an abnormal
biomarker value that signiﬁcantly predicted risk for an event.
Figure 1 KaplaneMeier curves for each independent biomarker. KaplaneMeier curves of the composite endpoint of all-cause mortality or non-fatal
myocardial infarction during 4-year follow-up according to levels of different markers for placebo patients (left panels) and the entire study population
(right panels). TnT, troponin-T (bold line indicates TnT >0.01 mg/l); hsCRP, high-sensitivity CRP (bold line is >10.0 mg/l); IL-10, interleukin 10 (bold line
is $3.5 ng/l); MPO, myeloperoxidase (bold line is >350 mg/l); PAPP-A, pregnancy associated plasma protein A (bold line is >12.6 mIU/l); PlGF,
placental growth factor (bold line is >27 ng/l); sCD40L, soluble CD40 ligand (bold line is >5.0 mg/l). The x-axis are days of follow-up.
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sensitivity CRP (bold line is >10.0 mg/l); IL-10, interleukin 10 (bold line is ≥3.5 ng/l); MPO, myeloperoxi-
dase (bold line is >350 µg/l); PAPP-A, pregnancy associated plasma protein A (bold line is >12.6 mIU/l); 
PlGF, placental growth factor (bold line is >27 ng/l); sCD40L, soluble CD40 ligand (bold line is >5.0 µg/l). 
The x-axis are days of follow-up.
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abnormal) in all patients, and between 3.3% and 38.6% in those receiving placebo 
(figures 2 and 3).
The percentages of patients with none, one, two or three or
more abnormal biomarker levels were 5.2%, 22.1%, 43.5% and
29.2%, respectively. Four-year event rates varied between 6.0%
(all markers normal) and 35.8% (three or more biomarkers
abnormal) in all patients, and between 3.3% and 38.6% in those
receiving placebo (ﬁgures 2 and 3).
DISCUSSION
The present study is the ﬁrst to report a long-term post-ACS
multimarker risk prediction model for which biomarkers are
selected on the basis of adjustment for baseline clinical patient
characteristics as well as adjustment for all other analysed
biomarkers. The results add to the growing body of evidence
that novel biomarkers reﬂecting atherosclerotic burden or disease
activity independently predict the long-term risk of death and
non-fatal infarction in patients with an ACS. Elevated baseline
levels of placental growth factor, myeloperoxidase and low levels
of the anti-inﬂammatory cytokine IL-10 were independently
associated with adverse long-term outcomes in patients with
non-ST-segment elevation acute coronary syndrome
(NSTEACS). These ﬁndings support the pathophysiological
concept of a chronic (vascular) inﬂammatory basis of athe-
rosclerosis,16e18 with an acute superimposed process in the
setting of an ACS.1 The present data indirectly suggest that
elevated biomarkers at baseline reﬂect a chronic inﬂammatory
process in the coronary vessel wall that may indeed result in
repetitive occurrences of cardiovascular events during long-term
follow-up. The predictive value of the selected inﬂammatory
markers was independent of baseline clinical patient character-
istics and index diagnosis experienced during the initial incident
Table 2 Relation between biomarkers of vascular inflammation, myocardial necrosis, platelet activation and a composite of all-cause mortality and
non-fatal MI during 4-year follow-up
HR and 95% CI
Patients receiving placebo (N[544) All patients (N[1090)
Biomarker Result
Events at 4-year
follow-up, %
(KaplaneMeier
estimate)*
Unadjusted
Adjusted, for
all other
biomarkers
onlyy
Adjusted, for
all other
biomarkers
and clinical
characteristicsz Unadjusted
Adjusted, for
all other
biomarkers
onlyy
Adjusted, for
all other
biomarkers
and clinical
characteristicszPlacebo All patients
TnT >0.01 mg/l 23.5 20.3 2.2 (1.3 to 3.6) 2.3 (1.4 to 3.9) 2.0 (1.1 to 3.6) 2.1 (1.4 to 3.0) 2.1 (1.4 to 3.0) 1.8 (1.2 to 2.6)
#0.01 mg/l 11.6 11.1 1 1 1 1 1 1
hsCRP >10 mg/l 23.0 20.3 1.6 (1.0 to 2.4) 0.9 (0.5 to 1.4) 0.8 (0.5 to 1.3) 1.6 (1.2 to 2.3) 1.1 (0.8 to 1.6) 1.0 (0.7 to 1.5)
#10 mg/l 15.3 13.5 1 1 1 1 1 1
sCD40L >5.0 mg/l 21.8 18.7 1.6 (1.1 to 2.4) 1.5 (0.9 to 2.3) 1.5 (0.9 to 2.3) 1.4 (1.0 to 1.8) 1.3 (0.9 to 1.7) 1.2 (0.9 to 1.6)
#5.0 mg/l 15.1 15.0 1 1 1 1 1 1
IL-10 <3.5 ng/l 21.7 20.8 1.7 (1.1 to 2.6) 1.6 (1.1 to 2.5) 1.7 (1.1 to 2.7) 1.7 (1.1 to 2.5) 1.6 (1.1 to 2.5) 1.7 (1.1 to 2.6)
$3.5 ng/l 13.7 14.2 1 1 1 1 1 1
Myeloperoxidase >350 mg/l 24.6 21.4 1.7 (1.1 to 2.5) 1.8 (1.2 to 2.9) 1.6 (1.0 to 2.6) 1.5 (1.1 to 2.1) 1.5 (1.1 to 2.1) 1.5 (1.1 to 2.1)
#350 mg/l 15.9 14.9 1 1 1 1 1 1
PAPP-A >12.6 mIU/l 22.4 19.7 1.6 (1.1 to 2.5) 1.3 (0.8 to 1.9) 1.2 (0.8 to 1.9) 1.4 (1.1 to 1.9) 1.1 (0.8 to 1.6) 1.1 (0.8 to 1.6)
#12.6 mIU/l 14.7 14.1 1 1 1 1 1 1
PlGF >27 ng/l 27.6 24.0 2.6 (1.7 to 3.9) 2.4 (1.6 to 3.7) 2.4 (1.4 to 4.1) 2.2 (1.6 to 3.0) 2.0 (1.4 to 2.8) 1.9 (1.3 to 2.8)
#27 ng/l 11.3 11.5 1 1 1 1 1 1
Non-significant results are reported in Italics.
*Events include all-cause mortality and non-fatal myocardial infarction (MI).
yAll biomarkers as presented in this table.
zAll biomarkers as presented in this table, as well as index diagnosis, age, gender, smoking, diabetes mellitus, hypertension, left ventricular ejection fraction and hypercholesterolaemia,
ST-depression, ST-elevation or T-wave changes on the admittance ECG and history of myocardial infarction, peripheral vascular disease, chronic heart failure or previous percutaneous coronary
intervention.
TnT, troponin-T; hsCRP, high-sensitivity C-reactive protein; IL-10, interleukin-10; PAPP-A, pregnancy-associated plasma protein A; PlGF, placental growth factor; sCD40L, soluble CD40 ligand.
Figure 2 Multimarker risk score.
Multimarker risk score with separate
risks for all-cause mortality (black
squares) and non-fatal myocardial
infarction (white squares) in patients
treated with placebo (left panel) and in
the entire study population (right
panel) at 4 years of follow-up after
counting the absence or presence of
one, two, or three or more biomarkers
above the threshold levels. The
markers used are: troponin-T (TnT),
interleukin 10 (IL-10), myeloperoxidase
(MPO), placental growth factor (PlGF).
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figure 2. Multimarker risk score.
Multimarker risk score with separate risks for all-cause mortality (black squares) and non-fatal myocardial 
infarction (white squares) in patients treated with placebo (left panel) and in the entire study population 
(right panel) at 4 years of follow-up after counting the absence or presence of one, two, or three or more 
biomarkers above the threshold levels. The markers used are: troponin-T (TnT), interleukin 10 (IL-10), my-
eloperoxidase (MPO), placental growth factor (PlGF).
(correction for unstable angina or non ST-elevation MI took
place by adding TnT as a covariate in all our multivariate anal-
ysis). Moreover, multivariate analysis in a model including all
biomarkers and baseline clinical patient characteristics proved
that four out of seven biomarkers, but only two out of 14
baseline clinical patient characteristics (as described in table 2)
remained signiﬁcantly associated with the endpoint. The incre-
mental value of novel biomarkers as risk predictors over tradi-
tional patient characteristics was previously described in another
large cohort of non ST-elevation ACS patients in the GUSTO IV
trial.12 Our data might suggest that biomarkers improve risk
prediction through their proposed capability to reﬂect disease
biology, instead of mere patient characteristics. Accordingly,
a combination of multiple biomarkers, which reﬂect different
pathophysiological components of CAD, might aggregate risk
prediction properties. The risk of death or non-fatal MI was
calculated in this same line of thought using a simple risk
stratiﬁcation model by counting the number of markers outside
the normal range. We investigated the role of myocardial
necrosis (TnT) together with oxidative stress (myeloperoxidase),
and chronic background vascular inﬂammation (PlGF and IL-10)
for the development of a future cardiovascular event. As there
was indeed an important increase in risk if patients showed an
increasing number of abnormal biomarker values (ﬁgures 2 and 3),
this simple stratiﬁcation might aid to adjust and intensify
treatment in such patients with a detrimental biomarker proﬁle.
A more aggressive therapeutic strategy, for instance, might prove
to be useful not only in treating the current acute event, but also
to prevent later events. In the future, this strategy might even
include a more speciﬁc anti-inﬂammatory treatment such
as blocking of the PlGF receptor or reducing the activity of
circulating PlGF levels by the administration of soluble vascular
endothelial growth factor receptor 1.19
Multimarker strategies also provide a window of opportunity
for the selection of candidate biomarkers for risk stratiﬁcation.
Previous studies of the same patient cohort reported that, after
multivariate adjustment only for baseline clinical patient vari-
ables, hsCRP,2 sCD40L11 and PAPP-A5 remained independent risk
predictors of adverse cardiac events at 6 months follow-up. In
this 4-year analysis, however, we observed that hsCRP, sCD40L
and PAPP-Awere signiﬁcant predictors in univariate analysis, but
lost signiﬁcance after correction for other biomarkers, suggesting
that the remaining biomarkers might be better post-ACS
predictors for long-term risk. This is remarkable, particularly for
hsCRP as this marker has been the focus of extensive research
and has been suggested as the most likely candidate for clinical
application.20 21 Obviously, the selection of valuable candidate
biomarkers for risk prediction of future coronary events on the
basis of a single biomarker as well as in the setting of a multi-
marker model requires further elucidation. Preferably, future
research will also clarify the appropriate cut-off values and the
actual prediction windows of novel biomarkers across different
patient groups.
Previous studies have shown an interaction between allocated
treatment and levels of biomarkers for short-term follow-
up.11e15 Although formal testing did not show a signiﬁcant
interaction between the biomarkers and treatment with abcix-
imab with respect to long-term event rates, we performed
separate analyses for the placebo group and the entire study
population. As the obtained data consistently indicate that TnT,
IL-10, myeloperoxidase and PlGF are independent predictors for
long-term outcome, we conclude that our ﬁndings have general
applicability if conﬁrmed in other trials including more hetero-
geneous study populations of patients with atherosclerosis and
ischaemic coronary syndromes.
We acknowledge that this investigation has some limitations.
First, the long-term follow-up data that were obtained from
multiple sources were not adjudicated by an independent clinical
event committee. The applied criteria for MI might thus have
differed between investigators, and some events may actually
have been missed. Second, no information is available on long-
term medical treatment such as statin therapy or ACE inhibi-
tion22 23 with their suggested anti-inﬂammatory effects, which
might have inﬂuenced patient outcomes. However, it is unlikely
that this has resulted in a differential bias between patients with
or without elevated biomarker levels. In this respect, it should be
emphasised that the investigators who collected long-term
follow-up data (EB, TL) were blinded for any information on
baseline data (including biomarker levels).
When using such a simple risk model with dichotomised
biomarker data, quantitative information might be lost as higher
levels for one or another biomarker could correspond with
different individual risk. However, by using simple cut-off
values, physicians might be able to calculate the patients’ risk
more easily. With the help of this model in conjunction with the
careful selection of other biomarkers and clinical variables, we
might be able to provide tailored treatment for the individual
patient not only at the time of hospitalisation but also following
discharge. The threshold levels of the markers are based on
exploratory analyses illustrated in previous publications. Natu-
rally, if possible, prospective validation should be performed.
Finally, it remains to be determined whether assessment of these
biomarkers at discharge, or at even later time points in stabilised
patients, might demonstrate an even closer relationship between
abnormal biomarker levels and the risk of future cardiovascular
events.
Certain biomarkers have speciﬁc evolutionary patterns during
admission for ACS24 and thus the role of the exact timing of the
biomarker measurements should be emphasised. In our study,
blood samples were drawn at admission, on average 9 h after the
last episode of angina. Its results should therefore not be
extrapolated to biomarker measurements at other time points,
for example, at discharge, when the same biomarkers (at the
same cut-off levels) theoretically might demonstrate a different
predictive value. Although new troponin elevations are seldom
found after the ﬁrst 6e9 h,25 the possibility exists that some
patients who were classiﬁed ‘troponin-negative’ in fact would
Figure 3 KaplaneMeier analysis for the multimarker model.
KaplaneMeier curves of all-cause mortality or non-fatal myocardial
infarction during 4-year follow-up for patients treated with placebo (left
panel) and the entire study population (right panel) with none, one, two,
or three or more biomarkers above the threshold levels. The markers
used here are: troponin-T, interleukin 10, myeloperoxidase and placental
growth factor.
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figure 3. Kaplan–Meier analysis for the multimarker model.
Kaplan–Meier curves of all-cause mortality or non-fatal myocardial i farction during 4-year follow-up for 
patients treated with placebo (left panel) and the entire study population (right panel) with none, one, 
two, or three or more biomarkers above the threshold levels. The markers used here are: troponin-T, inter-
leukin 10, myeloperoxidase and placental growth factor.
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DIsCussIOn
The present study is the first to report a long-term post-ACS multimarker risk predic-
tion model for which biomarkers are selected on the basis of adjustment for baseline 
clinical patient characteristics as well as adjustment for all other analysed biomarkers. 
The results add to the growing body of evidence that novel biomarkers reflecting ath-
erosclerotic burden or disease activity independently predict the long-term risk of death 
and non-fatal infarction in patients with an ACS. Elevated baseline levels of placental 
growth factor, myeloperoxidase and low levels of the anti-inflammatory cytokine IL-10 
were independently associated with adverse long-term outcomes in patients with non-
ST-segment elevation acute coronary syndrome (NSTEACS). These findings support the 
pathophysiological concept of a chronic (vascular) inflammatory basis of atherosclero-
sis,16-18 with an acute superimposed process in the setting of an ACS.1 The present data 
indirectly suggest that elevated biomarkers at baseline reflect a chronic inflammatory 
process in the coronary vessel wall that may indeed result in repetitive occurrences of 
cardiovascular events during long-term follow-up. The predictive value of the selected 
inflammatory markers was independent of baseline clinical patient characteristics and 
index diagnosis experienced during the initial incident (correction for unstable angina 
or non ST-elevation MI took place by adding TnT as a covariate in all our multivariate 
analysis). Moreover, multivariate analysis in a model including all biomarkers and base-
line clinical patient characteristics proved that four out of seven biomarkers, but only 
two out of 14 baseline clinical patient characteristics (as described in table 2) remained 
significantly associated with the endpoint. The incremental value of novel biomarkers 
as risk predictors over traditional patient characteristics was previously described in 
another large cohort of non ST-elevation ACS patients in the GUSTO IV trial.12 Our data 
might suggest that biomarkers improve risk prediction through their proposed capabil-
ity to reflect disease biology, instead of mere patient characteristics. Accordingly, a com-
bination of multiple biomarkers, which reflect different pathophysiological components 
of CAD, might aggregate risk prediction properties. The risk of death or non-fatal MI 
was calculated in this same line of thought using a simple risk stratification model by 
counting the number of markers outside the normal range. We investigated the role of 
myocardial necrosis (TnT) together with oxidative stress (myeloperoxidase), and chronic 
background vascular inflammation (PlGF and IL-10) for the development of a future car-
diovascular event. As there was indeed an important increase in risk if patients showed 
an increasing number of abnormal biomarker values (figures 2 and 3), this simple strati-
fication might aid to adjust and intensify treatment in such patients with a detrimental 
biomarker profile. A more aggressive therapeutic strategy, for instance, might prove to 
be useful not only in treating the current acute event, but also to prevent later events. In 
the future, this strategy might even include a more specific anti-inflammatory treatment 
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such as blocking of the PlGF receptor or reducing the activity of circulating PlGF levels 
by the administration of soluble vascular endothelial growth factor receptor 1.19
Multimarker strategies also provide a window of opportunity for the selection of 
candidate biomarkers for risk stratification. Previous studies of the same patient cohort 
reported that, after multivariate adjustment only for baseline clinical patient variables, 
hsCRP,2 sCD40L11 and PAPP-A5 remained independent risk predictors of adverse cardiac 
events at 6 months follow-up. In this 4-year analysis, however, we observed that hsCRP, 
sCD40L and PAPP-A were significant predictors in univariate analysis, but lost signifi-
cance after correction for other biomarkers, suggesting that the remaining biomarkers 
might be better post-ACS predictors for long-term risk. This is remarkable, particularly 
for hsCRP as this marker has been the focus of extensive research and has been sug-
gested as the most likely candidate for clinical application.20,21 Obviously, the selection of 
valuable candidate biomarkers for risk prediction of future coronary events on the basis 
of a single biomarker as well as in the setting of a multimarker model requires further 
elucidation. Preferably, future research will also clarify the appropriate cut-off values and 
the actual prediction windows of novel biomarkers across different patient groups.
Previous studies have shown an interaction between allocated treatment and levels of 
biomarkers for short-term follow-up.11-15 Although formal testing did not show a significant 
interaction between the biomarkers and treatment with abciximab with respect to long-
term event rates, we performed separate analyses for the placebo group and the entire study 
population. As the obtained data consistently indicate that TnT, IL-10, myeloperoxidase and 
PlGF are independent predictors for long-term outcome, we conclude that our findings 
have general applicability if confirmed in other trials including more heterogeneous study 
populations of patients with atherosclerosis and ischaemic coronary syndromes.
We acknowledge that this investigation has some limitations. First, the long-term 
follow-up data that were obtained from multiple sources were not adjudicated by an 
independent clinical event committee. The applied criteria for MI might thus have dif-
fered between investigators, and some events may actually have been missed. Second, 
no information is available on longterm medical treatment such as statin therapy or ACE 
inhibition22,23 with their suggested anti-inflammatory effects, which might have influ-
enced patient outcomes. However, it is unlikely that this has resulted in a differential bias 
between patients with or without elevated biomarker levels. In this respect, it should be 
emphasised that the investigators who collected long-term follow-up data (EB, TL) were 
blinded for any information on baseline data (including biomarker levels).
When using such a simple risk model with dichotomised biomarker data, quantitative 
information might be lost as higher levels for one or another biomarker could corre-
spond with different individual risk. However, by using simple cut-off values, physicians 
might be able to calculate the patients’ risk more easily. With the help of this model 
in conjunction with the careful selection of other biomarkers and clinical variables, we 
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might be able to provide tailored treatment for the individual patient not only at the 
time of hospitalisation but also following discharge. The threshold levels of the markers 
are based on exploratory analyses illustrated in previous publications. Naturally, if pos-
sible, prospective validation should be performed. Finally, it remains to be determined 
whether assessment of these biomarkers at discharge, or at even later time points in 
stabilised patients, might demonstrate an even closer relationship between abnormal 
biomarker levels and the risk of future cardiovascular events.
Certain biomarkers have specific evolutionary patterns during admission for ACS24 
and thus the role of the exact timing of the biomarker measurements should be empha-
sised. In our study, blood samples were drawn at admission, on average 9 h after the last 
episode of angina. Its results should therefore not be extrapolated to biomarker mea-
surements at other time points, for example, at discharge, when the same biomarkers 
(at the same cut-off levels) theoretically might demonstrate a different predictive value. 
Although new troponin elevations are seldom found after the first 6-9 h,25 the possibility 
exists that some patients who were classified ‘troponin-negative’ in fact would prove to 
have elevated levels of circulating troponin in case of measurement at later time points. 
As troponin elevations are related to a worse prognosis, this type of potential unidirec-
tional misclassification might have led to an underestimation of the relation between 
troponin elevation and adverse outcomes in our analyses.
COnClusIOn
In patients with NSTEACS, biomarkers reflecting distinct aspects of the underlying 
atherosclerotic process, and myocardial damage of the initial cardiac event can assist in 
predicting longterm adverse cardiac outcomes. The use of combinations of selected bio-
markers adds incremental predictive value to further risk stratification in an otherwise 
seemingly homogeneous NSTEACS population.
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absTRaCT
background: This prospective study investigated the association between preproce-
dural biomarker levels and incident major adverse cardiac events (MACE) in complex 
patients undergoing percutaneous coronary intervention (PCI) with sirolimus-eluting 
stenting.
Hypothesis: Lipoprotein(a) (Lp[a]), interleukin-10 (IL-10), and high-sensitivity C-reactive 
protein (CRP) have long-term prognostic value in patients undergoing PCI.
Methods: Between April 2002 and February 2003, 161 patients were included in the 
study. Blood was drawn before the procedure, and biomarkers were measured. Patients 
were followed-up for MACE (death, nonfatal myocardial infarction, and repeat revascu-
larization). Cox proportional hazard models were used to determine risk of MACE for 
tertiles of biomarkers. Both 1-year and long-term follow-up (median, 6 years; maximum, 
8 years) were evaluated.
Results: Mean age was 59 years, and 68% were men. During long-term follow-up, 72 
MACE occurred (overall crude cumulative incidence: 45% [95% confidence interval (CI): 
37%-52%]). Lp(a) was associated with a higher 1-year risk of MACE, with an adjusted 
hazard ratio (HR) of 3.1 (95% CI: 1.1-8.6) for the highest vs the lowest tertile. This associa-
tion weakened and lost significance with long-term follow-up. IL-10 showed a tendency 
toward an association with MACE. The 1-year HR was 2.1 (95% CI: 0.92-5.0). Long-term 
follow-up rendered a similar result. The association of CRP with MACE did not reach 
statistical significance at 1-year follow-up. However, CRP was associated with long-term 
risk of MACE, with an HR of 1.9 (95% CI: 1.0-3.5).
Conclusions: In this prospective study, preprocedural Lp(a) level was associated with 
short-term prognosis after PCI. The preprocedural CRP level was associated with long-
term prognosis after PCI.
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InTRODuCTIOn
Coronary artery disease (CAD) remains a leading cause of morbidity and mortality in 
the Western world. Percutaneous coronary intervention (PCI) has significantly reduced 
consequences of CAD.1 Nevertheless, post-PCI patients still constitute a high-risk group 
for recurrent events and cardiovascular mortality. To improve long-term prognosis in 
post-PCI patients, first and foremost, further enhancement of risk stratification is needed. 
Identification of high-risk patients may then serve as a guide to apply or withhold more 
aggressive treatment.
Biomarkers have received much attention as predictors of CAD in the past decade. 
Several biomarkers have been associated with incident coronary events, both in the 
general population and in patients with known CAD.2,3 Furthermore, a body of research 
is growing on emerging biomarkers.4 Data on the association between preprocedural 
biomarker levels and prognosis after PCI are less elaborate.
In the current study, which was conceived nearly a decade ago, we postulated that 
early preprocedural markers may predict later cardiac events. At the time of study com-
mencement, several lines of evidence had already confirmed that inflammation plays 
a major role in the pathogenesis of atherosclerotic lesions of vascular walls. C-reactive 
protein (CRP) was strongly implicated5 and was considered a promising candidate for 
the present study. Furthermore, attention had also been directed toward interleukin 
(IL)-10 as 1 of the most important mediators that physiologically limits and downregu-
lates inflammation.6 With regard to lipid biomarkers, although evidence was not always 
consistent, lipoprotein(a) (Lp [a]) was deemed a promising novel biomarker.5 Therefore, 
we have investigated the long-term prognostic value of these 3 biomarkers in complex 
patients undergoing PCI with sirolimus eluting stenting.
Apart from assessing prognostic value at 1 year of follow-up, we also examined the 
value at a maximum follow-up of 8 years. Such extensive follow-up data are currently 
scarce and enabled us to examine the patterns of the associations between biomarkers 
and cardiac events over time.
MeTHODs
Patient Population and baseline Data Collection
The study population consisted of a subset (n = 161) of the RESEARCH registry (Rapamy-
cin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital), that has been described 
elsewhere.7 Briefly, RESEARCH is a single-center registry conducted with the main 
purpose of evaluating the safety and efficacy of sirolimus-eluting stent (SES) implanta-
tion for patients treated in daily practice. To include a patient population representative 
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of the real world, from April 2002 onward a policy was adopted of using SES (Cypher; 
Johnson & Johnson-Cordis, Cordis Europa NV, Roden, The Netherlands) as the default 
strategy for every PCI. The general indications for PCI included stable angina pectoris, 
unstable angina pectoris, and acute myocardial infarction (MI). For the current study, 
patients defined as complex undergoing PCI between April 2002 and February 2003 
were included. These complex patients typically had SES implanted in bifurcations, left 
main coronary, chronic total occlusions, very small vessels, and long stented length (>36 
mm). Patients were included during office hours, with the exception of random periods 
of absence of the responsible investigator. The study was approved by the hospital eth-
ics committee and is in accordance with the Declaration of Helsinki. Written informed 
consent was obtained from every patient.
Baseline characteristics were assessed by screening medical records at the time of the 
procedure and included demographics, medical history, medication use, and cardiovas-
cular risk factors. Information on cardiovascular risk factors included smoking, diabetes 
mellitus, hypertension, and hypercholesterolemia as diagnosed and registered in the 
medical records by treating physicians.
biomarker Measurements
Blood was drawn immediately before PCI. High-sensitivity CRP (hsCRP) was determined 
directly at the Clinical Chemistry Department of Erasmus Medical Center by using Rate 
Near Infrared Particle Immunoassay (Immage Immunochemistry System; Beckman 
Coulter, Inc., Brea, CA). This system measures concentrations from 0.2 to 1440 mg/L, with 
a within-run precision <5% and a total precision <7.5%.
Subsequently, blood samples were stored at −80°C at Erasmus Medical Center, after 
which they were transported on dry ice to Dunedin, New Zealand, where IL-10 and 
lipoprotein (a) (Lp [a]) were measured. IL-10 was measured using the Quantikine HS im-
munoassay (HS100B) (R&DSystems, Minneapolis, MN). The minimal detectable dose of 
this assay is 0.5 pg/mL, the intra-assay precision is <8.5%, and the interassay precision is 
<15.6%. Lp(a) was measured using a double sandwich enzyme-linked immunosorbent 
assay as previously described.8 This assay detects all apolipoprotein (a) isoforms on an 
equivalent molar basis and is considered the most accurate method for Lp(a) measure-
ment.9 This assay measures concentrations from 2 to 600 nmol/L, with coefficients of 
variation <10%.
end Point Definitions
The primary outcome was the occurrence of major adverse cardiac events (MACE), 
defined as: 1) death, 2) nonfatal MI, or 3) repeat revascularization. MI was defined as a 
diagnosis made by a cardiologist based on the combination of typical ischemic chest 
complaints and objective evidence of myocardial necrosis as demonstrated by the elec-
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trocardiogram or elevated cardiac markers. Revascularization was defined as a repeat in-
tervention (surgical or percutaneous) to treat a luminal stenosis in any epicardial vessel.
follow-up
Information about in-hospital outcomes was obtained from an electronic clinical da-
tabase for patients maintained at Erasmus Medical Center, Rotterdam and by review 
of hospital records for those discharged to referring hospitals. Postdischarge survival 
status was obtained from municipal civil registries. Postdischarge repeat interventions 
and rehospitalizations were prospectively assessed during follow-up. Yearly question-
naires with information about anginal status and medication use were sent to all living 
patients, and treating physicians and institutions were contacted whenever necessary 
for additional information.
statistical analysis
We calculated means and proportions of the baseline characteristics and crude cumula-
tive incidence. Subsequently, we divided biomarker levels into categories (tertiles and 
detectable vs nondetectable when appropriate) and calculated means and proportions 
of baseline characteristic according to these categories. To test for trends, we used 
linear regression for continuous variables, logistic regression for dichotomous variables, 
and multinomial regression for variables with more than 2 categories. We used ln-
transformed continuous levels of biomarkers as the independent variable.
To address the predictive value of baseline biomarker levels, we calculated relative 
risks of MACE associated with increasing tertiles of CRP (cutpoints 1.9 and 4.5 mg/L), 
Lp(a) (cutpoints 9.8 and 65.2 nmol/L), and IL-10 (cutpoints 0.4 and 3.2 ng/mL) by Cox 
proportional hazards analysis. The proportional hazards assumption was tested by draw-
ing log minus log plots of the survival function, which confirmed that the assumption 
was met. We adjusted for age and sex (model 1), and subsequently for age, sex, smoking, 
diabetes mellitus, hypertension, and hypercholesterolemia (model 2). First, we trun-
cated follow-up time at 1 year. Subsequently, we examined very long-term outcome by 
taking complete follow-up into account. We repeated all analyses using ln-transformed 
continuous values of the biomarker levels instead of tertiles to demonstrate trends.
Values for covariates were missing in <1% of the patients, except for previous MI 
(missing in <2%). Given these low percentages, we chose to perform a complete-case 
analysis. All analyses were conducted with SPSS 17.0 for Windows (IBM, Armonk, NY). All 
tests were 2-sided.
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ResulTs
The mean age of the patients was 59 years, and 68% were male (Table 1). The median 
follow-up was 6 years, with a maximum of 8 years. The total number of person-years of 
follow-up amounted to 709 years. A total of 39 and 72 MACE occurred after 1 year and 8 
years of follow-up, respectively. The overall crude cumulative incidence was 45% (95% 
confidence interval [CI]: 37%-52%).Occurrence of MACE was highest at the beginning of 
the follow-up period and subsequently declined. Crude cumulative incidence over the 
first year of follow-up was 24% (95% CI: 18%-31%).
The median (interquartile range) levels of biomarkers were 3.03 (1.33–5.72) mg/L for 
CRP, 20.8 (6.08–84.9) nmol/L for Lp(a), and 1.81 (0–4.48) ng/mL for IL-10, respectively. 
All biomarker distributions were right-skewed. CRP was available in all patients and 
Table 1. baseline Characteristics of the study Population (n = 161)
Variable
Age, y 59.4 ± 11.3
Men 110 (68%)
Hypertension 63 (39%)
Hypercholesterolemia 125 (78%)
Diabetes mellitus 31 (19%)
Current smoking 51 (32%)
History of myocardial infarction 53 (34%)
History of CABG 18 (11%)
History of PCI 43 (27%)
Family history of coronary disease 60 (38%)
Clinical presentation
Stable angina 85 (54%)
Unstable angina 45 (28%)
Acute myocardial infarction 29 (18%)
No. of diseased vessels
1 vessel 70 (44%)
2 vessels 51 (32%)
3 vessels 38 (24%)
C-reactive protein, mg/L 3.03 (1.33–5.72)
Lipoprotein (a), nmol/L 20.8 (6.08–84.9)
Interleukin-10, ng/mL 1.81 (0.00–4.48)
Abbreviations: CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention. Categorical 
variables are expressed as number (percentage). Valid percentages are reported.Values of continuous 
variables are expressed as mean ± standard deviation or as median (interquartile range) in case of skewed 
distribution.
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below the detection limit in 4 patients (2.5%). For trend analysis, the data points in these 
patients were imputed by dividing the lowest detectable limit of the assay (0.2 mg/L) by 
2. Lp(a) measurement was missing in 3 patients and below the detection limit in 16 pa-
tients (10%). The lower limit of detection (2 nmol/L), divided by 2, was imputed in these 
patients for trend analysis. IL-10 measurement was missing in 3 patients and below the 
detection limit in 49 patients (31%). Because of this high percentage of undetectable 
levels, values were not imputed, and the P for trend was not computed. IL-10 was thus 
only examined in tertiles and as a dichotomous variable (detectable vs not detectable).
Table 2 displays baseline characteristics according to categories of Lp(a), CRP, and IL-
10 level. CRP showed a positive association with diabetes mellitus (P = 0.004) and with 
number of diseased vessels (P = 0.04).
Table 3 shows hazard ratios (HRs) for MACE at 1 year of follow-up, where as Table 4 
shows those at maximum follow-up. Lp(a) was associated with 1-year risk of MACE, 
with an HR of 3.1 (95% CI: 1.1-8.6) for the highest vs the lowest tertile. This association 
weakened and lost significance with long-term follow-up, the HR becoming 1.6 (95% 
CI: 0.86 – 3.1). IL-10 showed a tendency toward an association with MACE. The 1-year 
HR was 2.1 (95% CI: 0.92 – 5.0) for the highest vs the lowest tertile. Long-term follow-up 
rendered a similar result, the HR becoming 1.7 (95% CI: 0.94 – 3.2). The association of CRP 
with MACE did not reach statistical significance at 1-year follow-up and was 1.7 (95% CI: 
0.77 – 3.8). However, CRP was associated with long-term risk of MACE, with a HR of 1.9 
(95% CI: 1.0 – 3.5) for the highest vs the lowest tertile. The Figure 1 further illustrates 
these associations.
DIsCussIOn
In this prospective study, we examined the association between preprocedural bio-
marker levels and incident MACE in patients undergoing PCI with sirolimus-eluting 
stenting. Lp(a) level was associated with MACE at 1-year follow-up. CRP level was associ-
ated with MACE at 8 years of follow-up. IL-10 showed a tendency toward an association 
with MACE.
Strengths of the current study include the collection of preprocedural biomarker lev-
els, the availability of extensive long-term follow-up, and the measurement of multiple 
biomarkers. Furthermore, the study population consisted of complex patients, which 
generally suffer a high event rate as evidenced by the high incidence rate in this study. 
This enriched population may especially benefit from additional measures for risk strati-
fication, enabling application or withholding of more aggressive treatment. However, at 
the same time, our focus on this selected patient group limits the generalizability of our 
findings to a broader PCI population.
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Several other aspects of this study warrant consideration. Sample size was limited, 
which was primarily due to the relative novelty and complexity of the laboratory mea-
surements at the time of study commencement in 2002. Nevertheless, our results on 
CRP, the marker that has been examined most elaborately in the past, confirm previous 
findings. As such, we expect that associations between other biomarkers and adverse 
events, if present, would be demonstrated in this cohort. We had a limited number of 
MACE available at 1-year follow-up (n = 39, 24%). This number of events suffices for the 
analyses adjusted for age and sex. However, we realize that use of a multivariate ad-
justed model for 1-year follow-up is not fully justified. In this regard, the choice to divide 
the sample into tertiles may also be debated. As such, we also performed the analyses 
using continuous biomarker levels to demonstrate trends. Nevertheless, using tertiles 
enables identification of a dose-response relationship. Lp(a) was below the detection 
limit in 10% of the patients and IL-10 in 30%. This is a commonly encountered challenge 
when measuring these types of biomarkers. An analysis based on tertiles circumvents 
this issue, and therefore we believe our findings are nevertheless informative.
Although we found an association of CRP, a sensitive marker of inflammation, with 
MACE at long-term follow-up of 6 years, the association was not significant at 1 year 
Table 3. Hazard Ratios for Major adverse Cardiac events at 1 Year of follow-up
Biomarker Cumulative Incidence 
(95% CI)
Hazard Ratio (95% CI)
MACE, Adjusted for Age 
and Sex
MACE, Multivariate 
Adjusted
Lipoprotein (a)
Tertile 1 10% (2-18) 1.00 (reference) 1.00 (reference)
Tertile 2 31% (19-44) 3.7 (1.4-10.1) 3.3 (1.2-9.2)
Tertile 3 31% (18-43) 3.5 (1.3-9.6) 3.1 (1.1-8.6)
P for trend 0.04 0.06
Interleukin-10
Tertile 1 17% (7-28) 1.00 (reference) 1.00 (reference)
Tertile 2 24% (13-35) 1.5 (0.63-3.5) 1.3 (0.52-3.3)
Tertile 3 29% (17-41) 2.1 (0.92-5.0) 2.1 (0.92-5.0)
Detectable vs nondetectable 1.6 (0.76-3.4) 1.5 (0.69-3.3)
C-reactive protein
Tertile 1 21% (10-32) 1.00 (reference) 1.00 (reference)
Tertile 2 20% (10-31) 0.93 (0.40-2.2) 0.87 (0.37-2.1)
Tertile 3 32% (20-45) 1.6 (0.72-3.3) 1.7 (0.77-3.8)
P for trend 0.20 0.17
Abbreviations: CI, confidence interval; MACE, major adverse cardiac events (death, nonfatal myocardial 
infarction, and repeat revascularization).
Multivariate adjusted: adjusted for age, sex, smoking, diabetes mellitus, hypertension, and hypercholes-
terolemia.
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of follow-up. Because the point-estimate at 1-year follow-up was comparable to that 
at long-term follow-up, this is probably due to lack of statistical power. Levels of CRP 
have been elaborately investigated, and have been found to be associated with poorer 
cardiovascular outcomes in both healthy populations and patients with coronary artery 
disease.3 Furthermore, several large studies have shown that higher preprocedural CRP 
levels are related to a greater long-term risk of adverse events after PCI.10–12 These studies 
examined outcomes for up to 2 years of follow-up. Fewer data are available on long-term 
follow-up beyond 2 years. Gach et al examined the effect of hsCRP in stable patients 
undergoing PCI on adverse events during a mean follow-up of nearly 80 months, and 
found that increase in CRP after PCI was more predictive of MACE than CRP level before 
PCI.13 However, this study was confined to 89 patients. Our results confirm association 
of preprocedural CRP levels with MACE during long-term follow-up, and expand these 
findings to a follow-up of 8 years.
Lp(a) showed an association with occurrence of MACE at 1-year follow-up, but the 
association lost statistical significance at 8-year follow-up. Lp(a) is a lipoprotein that may 
induce either a prothrombotic/antifibrinolytic effect, as apolipoprotein(a) resembles 
plasminogen but has no fibrinolytic activity, or may accelerate atherosclerosis, because 
Table 4. Hazard Ratios for Major adverse Cardiac events at 8 Years follow-up
Biomarker Cumulative Incidence 
(95% CI)
Hazard Ratio (95% CI)
MACE, Adjusted for Age 
and Sex
MACE, Multivariate 
Adjusted
Lipoprotein (a)
Tertile 1 33% (20-45) 1.00 (reference) 1.00 (reference)
Tertile 2 44% (31-58) 1.6 (0.86-3.0) 1.5 (0.79-2.9)
Tertile 3 56% (42-69) 1.9 (1.0-3.5) 1.6 (0.86-3.1)
P for trend 0.11 0.20
Interleukin-10
Tertile 1 40% (27-54) 1.00 (reference) 1.00 (reference)
Tertile 2 44% (31-58) 1.2 (0.69-3.3) 1.2 (0.62-2.3)
Tertile 3 48% (34-62) 1.7 (0.95-3.2) 1.7 (0.94-3.2)
Detectable vs nondetectable 1.4 (0.83-2.4) 1.4 (0.78-2.4)
C-reactive protein
Tertile 1 36% (23-49) 1.00 (reference) 1.00 (reference)
Tertile 2 39% (26-52) 0.98 (0.52-1.8) 0.93 (0.49-1.8)
Tertile 3 60% (47-74) 1.7 (0.98-3.1) 1.9 (1.0-3.5)
P for trend 0.016 0.009
Abbreviations: CI, confidence interval; MACE, major adverse cardiac events (death, nonfatal myocardial 
infarction, and repeat revascularization).
Multivariate adjusted: adjusted for age, sex, smoking, diabetes mellitus, hypertension, and hypercholes-
terolemia.
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like low-density lipoprotein, the Lp(a) particle is cholesterolrich, or both.14 Consequently, 
numerous studies have been performed on the role of Lp(a) in restenosis, rendering 
inconsistent results.15–21 Zairis et al investigated both in-stent restenosis and incidence 
of MACE in 483 consecutive patients with either stable or unstable coronary syndromes 
undergoing PCI with stenting.22 Although they found no associations of Lp(a) with reste-
nosis, they did find that high plasma levels of both CRP and Lp(a) were independently 
associated with MACE at long-term follow-up. They concluded that progression of ath-
erosclerosis to a significant lesion in vessels not previously intervened on may play a 
significant role in the underlying pathophysiology as opposed to in-stent restenosis. The 
results of 1-year follow-up in the current study are in accordance with these findings. 
Several other studies have demonstrated positive associations of Lp(a) with adverse 
Figure 1. Multivariate-adjusted event-free survival until major adverse cardiac events. All curves are adjusted for age, sex, smoking, diabetes mellitus,
hypertension, and hypercholesterolemia. Abbreviations: CRP, C-reactive protein; IL 10, interleukin-10; Lp (a), lipoprotein (a).
independently associated with MACE at long-term follow-
up. They concluded that progression of atherosclerosis to
a significant lesion in vessels not previously intervened on
mayplay a significant role in theunderlyingpathophysiology
as opposed to in-stent restenosis. The results of 1-year
follow-up in the current study are in accordance with these
findings. Several other studies have demonstrated positive
associations of Lp(a) with adverse events during long-
term follow-up.23,24 Our study confirms these results and
provides add tional information on very long-term follow-up,
demonstrating loss of significance of the association in our
(specific) patient population.
Il-10 displayed a tendency toward a positive association
with long-term occurrence of MACE in the current
study. IL-10 downregulates inflammatory activation of
monocytes and macrophages by transcriptional and post-
transcriptional inhibition of the entire range of proinflam-
matory cytokines.25 The largest prospective study on the
prognostic value of IL-10 levels in CAD examined 1090
patients with non–ST-segment elevation acute coronary
syndrome during 4 years of follow-up for all-cause mortality
and nonfatal MI, and found that a high IL-10 level is asso-
ciated with better prognosis.26 Other prospective studies in
patients with know CAD mostly had follow-up time li it d
to several months and showed inconsistent results.27–30
Data on IL-10 levels and restenosis after stenting are scarce,
and results are also conflicting.31,32 Further elucidation of
the mechanisms involved and of the role of IL-10 herein is
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figure 1. Multivariate-adjusted event-free survival until major a verse cardiac events.
All curves are adjusted for age, sex, smoking, diabetes mellitus, hypertension, and hypercholesterolemia. 
Abbreviations: CRP, C-reactive protein; IL 10, interleukin-10; Lp (a), lipoprotein (a).
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events during long-term follow-up.23,24 Our study confirms these results and provides 
additional information on very long-term follow-up, demonstrating loss of significance 
of the association in our (specific) patient population.
IL-10 displayed a tendency toward a positive association with long-term occurrence of 
MACE in the current study. IL-10 downregulates inflammatory activation of monocytes 
and macrophages by transcriptional and posttranscriptional inhibition of the entire 
range of proinflammatory cytokines.25 The largest prospective study on the prognostic 
value of IL-10 levels in CAD examined 1090 patients with non–ST-segment elevation 
acute coronary syndrome during 4 years of follow-up for all-cause mortality and non-
fatal MI, and found that a high IL-10 level is associated with better prognosis.26 Other 
prospective studies in patients with known CAD mostly had follow-up time limited to 
several months and showed inconsistent results.27–30 Data on IL-10 levels and restenosis 
after stenting are scarce, and results are also conflicting.31,32 Further elucidation of the 
mechanisms involved and of the role of IL-10 herein is warranted to disclose the reasons 
behind these seemingly inconsistent findings.
COnClusIOn
In this prospective study of patients undergoing PCI, preprocedural Lp(a) level was as-
sociated with short-term prognosis, and preprocedural CRP level was associated with 
long-term prognosis. IL-10 showed a tendency toward an association with long-term 
prognosis. Large studies with extensive follow-up and simultaneous measurement of 
multiple biomarkers are needed to provide further insight into the role of biomarkers in 
risk stratification of patients undergoing PCI.
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absTRaCT
aims: This study aims to evaluate the prognostic value of high-sensitivity CRP (hsCRP) 
during 10-year follow-up after percutaneous coronary intervention (PCI).
Methods and results: Between April and October 2002, hsCRP was measured in 468 all-
comer patients who underwent PCI with sirolimus-eluting stent implantation for stable 
coronary artery disease or acute coronary syndrome. Primary endpoint was the compos-
ite of all-cause mortality or myocardial infarction at 10-year follow-up. The Kaplan-Meier 
event curves displayed ongoing divergence of the hsCRP groups (hsCRP <1 mg/L: 14.7% 
vs. 1-3mg/L: 31.1% vs. >3mg/L: 43.1%). After adjustment for established cardiovascular 
risk factors and clinical presentation in a Cox regression model, higher CRP levels were 
associated with higher incidence of the composite endpoint (>3mg/L vs. <1 mg/L: HR 
2.87, 95%CI 1.69-4.87, p<0.001; 1-3mg/L vs. <1mg/L: HR 2.30, 95%CI 1.31-4.03, p=0.004). 
Although adding hsCRP to a prediction model containing conventional cardiovascular 
risk factors did not significantly improve discriminatory power (area under the receiver 
operating characteristic curve 0.71 to 0.73, p=0.56), hsCRP was able to improve risk clas-
sification (net reclassification index=0.40, p=<0.001).
Conclusions: In patients undergoing PCI, higher CRP levels at the time of the procedure 
are predictive for 10-year mortality and myocardial infarction. HsCRP may be an useful 
biomarker to further improve risk assessment in patients undergoing PCI.
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InTRODuCTIOn
Chronic inflammation is considered to be a essential component in the pathogenesis 
and progression of atherosclerosis.1-5 Increasing amounts of data suggest a possible role 
for C-reactive Protein (CRP) at different stages of atherogenesis and the atherosclerotic 
process.6 C-reactive Protein (CRP), member of the pentraxin family of innate immune re-
sponse proteins, is produced in the liver in response to various cytokines, such as Interleu-
kin-6, Interleukin-1β and Tumor Necrosis Factor-α.7 The precise pathophysiological role of 
CRP in the instigation and progression of atherosclerosis remains unclear. Still this lack of 
current basic pathophysiological insight detracts little from the accumulating evidence 
indicating an association between elevated CRP levels and adverse outcome in CAD 
patients undergoing percutaneous coronary intervention (PCI). CRP is associated with an 
increased incidence of cardiac events, including all-cause and/or cardiovascular mortality, 
(non-fatal) acute myocardial infarction and (urgent) revascularization in multiple stud-
ies.8-13 The majority of these results, however, derive from an era in which percutaneous re-
vascularization took place by plain balloon angioplasty or bare metal stent implantation. 
Less is known about the predictive value after drug-eluting stent implantation or about 
long-term follow-up. This study aims to evaluate the prognostic value of high-sensitivity 
CRP (hsCRP) during 10-year follow-up after (PCI) in the drug-eluting stent era.
MeTHODs
study population
The design of the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital 
(RESEARCH) registry has been described in detail elsewhere.14 RESEARCH is a single-
center all-comers registry conducted with the main purpose of evaluating the safety 
and efficacy of sirolimus-eluting stent (SES, Cypher; Johnson & Johnson-Cordis, Cordis 
Europa NV, Roden, The Netherlands) implantation. In brief, SES implantation has been 
used as the default strategy for all consecutive percutaneous coronary interventions 
between April 2002 and February 2003 in the Erasmus MC, Rotterdam, the Netherlands. 
High-sensitivity CRP was prospectively measured in a subset of 468 consecutive RE-
SEARCH patients that were enrolled between April 2002 and October 2002.
ethics
This is an observational study. Patients were not subject to acts, neither was any mode 
of behavior imposed, otherwise than as part of their regular treatment. Therefore, this 
study was not subject to the Dutch Medical Research Involving Human Subjects Act, and 
written informed consent for a patient to be enrolled was not required. This study was 
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conducted according to the Privacy Policy of the Erasmus MC, according to the Erasmus 
MC regulations for the appropriate use of data in patient oriented research, and accord-
ing to the Helsinki Declaration.
High sensitivity C-reactive protein
Serum samples were drawn immediately before the PCI procedure. High-sensitivity 
CRP (hsCRP) was determined at the Clinical Chemistry Department of Erasmus Medical 
Center by using Rate Near Infrared Particle Immunoassay (Immage Immunochemistry 
System; Beckman Coulter, Inc., Brea, CA). This system measures concentrations from 0.2 
to 1440 mg/L, with a within-run precision <5% and a total precision <7.5%.
Clinical endpoints
As part of the RESEARCH registry, information about in-hospital outcomes was ob-
tained from an electronic clinical database for patients maintained at our center and 
by review of hospital records for those discharged to referring hospitals. Postdischarge 
survival status was obtained from municipal civil registries. Yearly questionnaires were 
sent to all living patients to obtain information on anginal status and medication use. 
Subsequently, hospital discharge letters were obtained and treating physicians and in-
stitutions were contacted for additional information (i.e. discharge letters and coronary 
angiogram) whenever necessary.
The primary endpoint of this report was the composite of all-cause mortality or 
myocardial infarction at 10 years of follow-up. Myocardial infarction was defined as the 
clinical diagnosis of ST-segment elevation myocardial infarction (STEMI) or non-STEMI. 
The secondary endpoint was defined as all-cause mortality at 10 years of follow-up. All 
endpoints were adjudicated by trained personnel.
statistical analysis
CRP levels were also categorized as low (<1 mg/L), intermediate (1-3 mg/L) or high (>3 
mg/L) according to the recommendations from the Centers for Disease Control and 
Prevention and the American Heart Association.15 Continuous variables were compared 
by analysis of variance (ANOVA) test and are presented as mean ± standard deviation 
or as median [interquartile range]. Categorical variables were compared by chi-square 
test and are presented in numbers and percentages. Patients lost to follow-up were 
considered at risk for death until the date of last contact, at which time-point they 
were censored. Cumulative event rates were estimated according to the Kaplan-Meier 
method. Kaplan-Meier event curves were compared by log-rank test. Cox proportional 
hazards regression analyses were performed to evaluate the associations between CRP 
and study endpoints. In multivariable analyses, the variables age, gender, diabetes mel-
litus, hypertension, hypercholesterolemia, smoking, history of myocardial infarction, 
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clinical presentation and multivessel coronary disease were considered as potential 
confounders and were entered into the full model. The final results are presented as 
crude and adjusted hazard ratios (HR) with 95% confidence interval (95% CI). Receiver 
operating characteristic (ROC) curves were constructed to evaluate the supplemental 
value of these biomarkers for discrimination between cases and controls over conven-
tional cardiovascular risk factors. The area under the ROC curves were compared using 
the method that was described by Hanley et al.16 Additionally, continuous net reclas-
sification improvement indices (NRI) were calculated to evaluate improvement in risk 
classification by the new biomarkers over conventional cardiovascular risk factors.17 All 
data were analyzed with SPSS software (SPSS 20.0, IBM corp., Armonk, NY, USA). All sta-
tistical tests were two-tailed and p-values <0.05 were considered statistically significant.
ResulTs
baseline characteristics
Mean age of the patients was 61 ± 11 years and 69% were men (Table 1). Patients with 
diabetes (p=0.034), smokers (p=0.008) and patients with a history of myocardial infarc-
tion (p=0.001) had higher hsCRP levels (Table 2). Female patients tended to have higher 
CRP levels, although the difference compared to men was not statistically significant 
(p=0.074). Serum hsCRP concentrations were dependent on the clinical presentation 
(p<0.001). Patients with stable angina pectoris (median 2.0 [1.0-5.0] mg/L) had the 
lowest circulating CRP concentrations. Higher hsCRP levels were observed in patients 
with unstable angina pectoris (median 5.0 [2.0-11.0] mg/L) and patients with acute 
myocardial infarction (median 3.0 [1.0-6.0] mg/L) (p<0.001).
Incident events during follow-up
Vital status at 10-year follow-up was acquired for 464 (99.1%) patients. Response rate 
of the yearly questionnaires that were sent to all living patients was at least 79% in 
each year. After 10 years of follow-up, 146 patients reached the composite endpoint of 
all-cause mortality or myocardial infarction. The Kaplan-Meier event curves displayed 
ongoing divergence of the hsCRP groups (hsCRP <1 mg/L: 14.7% vs. 1-3mg/L: 31.1% vs. 
>3mg/L: 43.1%) (Figure 1).
Prediction of cardiovascular outcome
In univariable analysis, higher CRP levels were associated with a three-fold increased in-
cidence of the composite endpoint of all-cause mortality or myocardial infarction during 
follow-up (high vs. low hsCRP: HR 3.54, 95%CI 2.14-5.88, p<0.001; 1-3 vs. <1 mg/L: HR 2.52, 
95%CI 1.44-4.41, p=0.001) (Table 3). The association was observed in patients admitted 
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Table 1. baseline characteristics
TOTal
(n=468)
lOW
CRP <1
(n=125)
InTeRMeDIaTe
CRP 1-3
(n=128)
HIGH
CRP >3
(n=215) P
Patient characteristics
Age, years 61.1 ± 11.1 59.4 ± 11.1 62.0 ± 11.0 61.5 ± 11.1 0.14
Men, n (%) 325 (69.4) 92 (73.6) 95 (74.2) 138 (64.2) 0.074
Diabetes mellitus, n (%) 57 (12.2) 9 (7.2) 13 (10.2) 35 (16.3) 0.034
Hypertension. n (%) 187 (40.0) 45 (36.0) 53 (41.4) 89 (41.4) 0.57
Hypercholesterolemia, n (%) 282 (60.3) 82 (65.6) 81 (63.3) 119 (55.3) 0.13
Smoking, n (%) 129 (27.6) 29 (23.2) 26 (20.3) 74 (34.4) 0.008
Previous MI, n (%) 158 (33.8) 32 (25.6) 35 (27.3) 91 (42.3) 0.001
Previous PCI, n (%) 122 (26.1) 29 (23.2) 32 (25.0) 61 (28.4) 0.55
Previous CABG, n (%) 46 (9.8) 9 (7.2) 14 (10.9) 23 (10.7) 0.51
High sensitivity CRP, mg/L 3.0 [1.0-7.0]
Procedural characteristics
Clinical presentation <0.001
 Stable angina pectoris, n (%) 224 (47.9) 72 (57.6) 75 (58.6) 77 (35.8)
 Unstable angina pectoris, n (%) 169 (36.1) 29 (23.2) 35 (27.3) 105 (48.8)
 Acute MI, n (%) 75 (16.0) 24 (19.2) 18 (14.1) 33 (15.3)
Multivessel coronary disease, n (%) 273 (58.3) 65 (52.0) 79 (61.7) 129 (60.0) 0.23
Data are presented as mean ± standard deviation or as median [interquartile range].
CABG, coronary artery bypass grafting; CRP, C-reactive protein; MI, myocardial infarction; PCI, percutane-
ous coronary intervention.
Table 2. association between patient characteristics and circulating CRP concentration
Median hsCRP [IQR] P
Women 4.0 [2.0 – 9.0] 0.009
Men 3.0 [1.0 – 6.0]
History of myocardial infarction 4.0 [2.0 – 8.0] 0.003
No prior myocardial infarction 3.0 [1.0 – 6.0]
Diabetes Mellitus 4.0 [ 2.0 – 8.0] 0.035
Without Diabetes Mellitus 3.0 [1.0 – 7.0]
Smokers 4.0 [2.0 – 7.5] 0.039
Non-smokers 3.0 [1.0 – 7.0]
Clinical presentation <0.001
 Stable 2.0 [1.0 - 5.0]
 Unstable angina 5.0 [ 2.0 – 11.0]
 Acute myocardial infarction 3.0 [ 1.0 – 6.0]
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with ACS (high vs. low hsCRP: HR 3.64, 95%CI 1.74-7.61, p=0.001; 1-3 vs. <1 mg/L: HR 2.80, 
95%CI 1.22-6.44, p=0.015) as well as in patients with stable angina (high vs. low hsCRP: 
HR 3.18, 95%CI 1.54-6.57, p=0.002; 1-3 vs. <1 mg/L: HR 2.33, 95%CI 1.10-4.95, p=0.028) (p 
for heterogeneity = 0.80). Higher CRP levels were also associated with all-cause mortal-
ity only (>3 vs. <1 mg/L: HR 3.64, 95%CI 2.05-6.44, p<0.001; 1-3 vs. <1 mg/L: HR 2.04, 
95%CI 1.06-3.90, p=0.032). After adjustment for established cardiovascular risk factors 
and clinical presentation, CRP levels of >3 mg/L remained independently predictive for 
highest cardiovascular risk (HR 2.87, 95%CI 1.69-4.87, p<0.001), followed by CRP levels of 
1-3 mg/L (HR 2.30, 95%CI 1.31-4.03, p=0.004) compared to CRP levels of <1 mg/L.
figure 1. Prediction of cardiovascular outcome
CRP indicates C-reactive protein.
Table 3. Prediction of cardiovascular outcome
unadjusted
HR (95%CI) P
adjusted*
HR (95%CI) P
Composite of all-cause mortality or myocardial infarction
 CRP 1-3 vs <1 mg/L 2.52 (1.44-4.41) 0.001 2.30 (1.31-4.03) 0.004
 CRP >3 vs <1 mg/L 3.54 (2.14-5.88) <0.001 2.87 (1.69-4.87) <0.001
All-cause mortality
 CRP 1-3 vs <1 mg/L 2.04 (1.06-3.90) 0.032 1.81 (0.94-3.48) 0.075
 CRP >3 vs <1 mg/L 3.64 (2.05-6.44) <0.001 2.86 (1.57-5.22) 0.001
* Adjusted for age, gender, diabetes mellitus, hypertension, hypercholesterolemia, smoking, history of 
myocardial infarction, clinical presentation and multivessel coronary disease.
CRP indicates C-reactive protein; HR, hazard ratio.
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Discrimination
First, we evaluated a model for prediction of 10-year cardiovascular outcome that con-
tained conventional cardiovascular risk factors, including age, gender, diabetes mellitus, 
hypertension, hypercholesterolemia, smoking, history of myocardial infarction, clinical 
presentation and multivessel coronary disease. This model displayed an area under the 
ROC curve of 0.71 (95%CI 0.66-0.76) (Figure 2). Although not statistically significant, add-
ing CRP to this model slightly improved discriminatory ability (area under the ROC curve 
= 0.73, 95%CI 0.69-0.78, p=0.56).
Clinical risk factors
Clinical risk factors + hsCRP
AUC = 0.71
AUC = 0.73
0 0.2 0.4 0.6 0.8 1.0
0
0.2
0.4
0.6
0.8
1.0
Se
ns
iti
vi
ty
1-Specificity
figure 2. ROC curves displaying improved discrimination with C-reactive protein
Clinical risk factors include: age, gender, diabetes mellitus, hypertension, hypercholesterolemia, smoking, 
history of myocardial infarction, clinical presentation and multivessel coronary disease.
AUC indicates area under the curve; CRP, C-reactive protein.
Reclassification
We examined whether adding CRP to the model consisting of conventional cardiovascu-
lar risk factors results in correct reclassification of risk of death or myocardial infarction 
during follow-up (Table 4). Baseline CRP level significantly improved the risk classifica-
tion (NRI=0.40, 95%CI 0.20-0.60, p<0.001).
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DIsCussIOn
This study investigated the association between circulating hsCRP concentration and 
10-year cardiovascular outcome in patients undergoing PCI with drug-eluting stent 
implantation. The main finding is that a single baseline measurement of hsCRP is predic-
tive for cardiovascular outcome with ongoing divergence of the survival curves until 
10 years of follow-up. High hsCRP (>3 mg/L) levels were associated with a three-fold 
increased risk for mortality and the composite of mortality or myocardial infarction, 
while intermediate hsCRP (1-3 mg/L) were associated with a two-fold increased risk.
CRP is an acute phase protein and its concentration in serum reflects the inflammatory 
status of the patient.18 Despite a lack of specificity for the cause of inflammation, many 
epidemiologic studies have shown significant associations between elevated serum 
CRP concentrations and the risk of recurrent cardiovascular events among patients with 
established coronary artery disease, and the incidence of first cardiovascular events 
among individuals with cardiovascular risk factors.19-22 However, few studies are avail-
able on the prognostic value of hsCRP in patients undergoing PCI, while risk assessment 
at this certain time point is important and of particular interest in clinical practice. 
These studies have consistently showed that higher CRP levels measured at time of the 
PCI procedure for both acute coronary syndrome and stable CAD are predictive for an 
increased long-term risk of recurrent cardiovascular events and death. For example, Park 
et al. found that elevated CRP levels were significantly associated with increased risks of 
stent thrombosis, death, and MI during a median follow-up time of 3.9 years in patients 
receiving drug-eluting stents.23 The longest reported follow-up period is 6 years.21,24 To 
the best of our knowledge, this is the first study that extends the evidence on the predic-
tive value of CRP to 10-years after PCI.
The mechanism underlying the association of CRP with prognosis may be two-fold.25 
Firstly, high CRP levels are previously shown to be associated with stent-thrombosis and 
restenosis after PCI with first generation drug-eluting stents.15,23,25 A growing body of 
Table 4. Reclassification of predicted risk when adding C-reactive protein
Predicted risk 
classified downward 
in new model*
Predicted risk 
classified upward in 
new model* Total
Patients that reached
primary endpoint, n (%)
22 (15.1) 124 (84.9) 146
Patients that remained event-free, 
n (%)
113 (35.1) 209 (64.9) 322
* New model includes clinical risk factors and CRP. Old model includes clinical risk factors only. Clinical risk 
factors include: age, gender, diabetes mellitus, hypertension, hypercholesterolemia, smoking, history of 
myocardial infarction, clinical presentation and multivessel coronary disease.
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evidence suggests that late adverse reactions to drug-eluting stents and bare-metal 
stents may be different in relation to pathogenesis, histopathologic features, and clinical 
presentation.25 Although less evidence is available for second generation drug-eluting 
stents, Lasave et al. demonstrated that elevated CRP is also associated with neointimal 
hyperplasia in patients who received zotarolimus-eluting stent (a second generation 
drug-eluting stent) implantation.26 Secondly, another underlying mechanism of the 
association of CRP with prognosis may be that high CRP levels are associated with coro-
nary plaque burden and with new events in native vessels.27
Current clinical practice guidelines have indicated that measurement of hsCRP may 
be useful in 1. primary prevention, as an adjunct to other major risk factors to further 
assess absolute cardiovascular risk; and 2. in patients with stable coronary disease or 
acute coronary syndromes, as an independent marker for assessing the likelihood of 
recurrent events, including death, myocardial infarction, or restenosis after PCI.28 For 
the latter indication, it should be noted that secondary preventive interventions with 
proven efficacy should not be dependent on hsCRP levels. Furthermore, the guidelines 
have stated that serial testing of hsCRP should not be used to monitor the effects of 
treatment. The results of our study confirm that hsCRP may be a useful biomarker to 
assess the risk of death and myocardial infarction in patients with established coronary 
artery disease who undergo PCI. Furthermore, we demonstrated that only a single mea-
surement of hsCRP at the time of a PCI procedure is sufficient to provide information on 
cardiovascular risk for a period as long as 10 years. Therapeutic implications of increased 
inflammatory status after drug-eluting stent implantation are still under investigation.25 
Statins are shown to have anti-inflammatory properties.29 Patients with intense activa-
tion of inflammatory cells, as detected by systemic CRP levels, are likely to enjoy the 
highest benefit from an high-dosed statin treatment.
Some limitations of this study need to be acknowledged. Firstly, this is a single center 
study. Caution is urged in extrapolating these results to other populations. However, 
other studies have showed consistent results on the long-term predictive value of hsCRP. 
Secondly, in this study, the prognostic value of hsCRP was evaluated in patients who 
underwent PCI with first generation drug-eluting stent implantation. Caution is urged 
in extrapolating these results to patients with new-generation drug-eluting stent im-
plantation or patients with coronary artery disease in general. Thirdly, the number of 
patients at risk at the end of the follow-up period was relatively small. However, the 
10-year association was strongly significant. Finally, despite using multivariable analysis 
to adjust for possible confounders that may be correlated to study outcomes, we cannot 
exclude the possibility of residual confounding. For example, in patients who presented 
with myocardial infarction, time-to-presentation was not registered in our study data-
base. In these patients, CRP levels may be affected by on-going necrosis.
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In conclusion, in patients undergoing PCI with drug-eluting stent implantation, high 
(>3 mg/L) and intermediate (1-3 mg/L) hsCRP levels are independently associated with 
a three-fold and two-fold increased risk, respectively, for mortality and myocardial 
infarction during follow-up. The survival curves of patients with high and intermediate 
hsCRP levels displayed ongoing divergence from that of patients with low hsCRP levels 
until 10 years after PCI, indicating that a single measurement of hsCRP at the time of a 
PCI procedure is sufficient to provide information on cardiovascular risk during a period 
as long as 10 years. Although adding hsCRP to a prediction model that contains con-
ventional cardiovascular risk factors did not significantly improve discriminatory power, 
hsCRP was able to improve the risk classification over the conventional cardiovascular 
risk factors. Therefore, hsCRP may be an useful biomarker for long-term risk assessment 
in patients with established coronary artery disease and undergoing PCI.
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absTRaCT
Purpose: Progression of stable coronary artery disease (CAD) towards acute coronary 
syndrome (ACS) is a dynamic and heterogeneous process with many intertwined 
constituents, in which a plaque destabilising sequence could lead to ACS within short 
timeframes. Current CAD risk assessment models, however, are not designed to identify 
increased vulnerability for the occurrence of coronary events within a precise, short 
timeframe at the individual patient level. BIOMArCS was designed to evaluate whether 
repeated measurements of multiple biomarkers can predict such “vulnerable periods”.
Participants: BIOMArCS is a multicentre, prospective, observational study of 844 
patients presenting with ACS, either with or without ST-elevation and at least one ad-
ditional cardiovascular risk factor.
Methods and analysis: We hypothesize that patterns of circulating biomarkers that 
reflect the various pathophysiological components of CAD, such as distorted lipid me-
tabolism, vascular inflammation, endothelial dysfunction, increased thrombogenicity 
and ischemia, diverge in the days to weeks before a coronary event. Divergent biomarker 
patterns, identified by serial biomarker measurements during 1-year follow-up might 
then indicate ‘vulnerable periods’ during which CAD patients are at high short-term risk 
of developing an ACS. Venepuncture was performed every fortnight during the first 
half-year and monthly thereafter. As prespecified, patient enrolment was terminated af-
ter the primary endpoint of cardiovascular death or hospital admission for non-fatal ACS 
had occurred in 50 patients. A case-cohort design will explore differences in temporal 
patterns of circulating biomarkers prior to the repeat ACS.
future plans and dissemination: Follow-up and event adjudication have been com-
pleted. Prespecified biomarker analyses are currently being performed and dissemina-
tion through peer-reviewed publications and conference presentations is expected 
from the third quarter of 2016.
Should identification of a ‘vulnerable period’ prove to be feasible, then future research 
could focus on event reduction through pharmacological or mechanical intervention 
during such periods of high risk for ACS.
Trial registration: NTR 1698 and NTR1106
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InTRODuCTIOn
Generalized cardiovascular (CV) risk assessment models have proven to be valuable for 
longer term risk prediction in primary prevention settings, such as Framingham and 
SCORE [1,2], as well as in patients who experienced an acute coronary syndrome (ACS), 
such as the PURSUIT, TIMI and GRACE risk models. [3–5] Existing CV risk models largely 
depend on the presence and recognition of traditional risk factors and cardiovascular 
history complemented by biometric factors. Traditional CV risk factors, however, are 
absent in a significant part of the population that nevertheless develops CAD. [6] In 
contrast, the prevalence of traditional risk factors is also high among those fractions of 
the population that will never endure a CV event. [7]
According to the key philosophy behind existing CV risk prediction models, the indi-
vidual patient is considered to be a member of a group that is exposed to a certain (low-
intermediate-high) constant risk, whereas the incidence of acute CV events is considered 
a random process, with event probabilities directly related to that group risk. Conse-
quently, CV risk models usually predict reasonably well on a group level, but only poorly 
outline the course of individuals. [8] In addition, current risk prediction models do not 
account for the dynamic nature of the atherosclerotic vascular wall of individual patients. 
Individual CAD patients actually do not have constant risks over time. [9] Long periods 
of stability, with minimal plaque progression and low risk of CV events are alternated by 
periods of increased plaque instability and rapid plaque progression [10], during which 
the risk of sudden plaque disruption, and thrombotic coronary occlusion within short 
time spans is high [11,12]. This is a complex and multifactorial pathophysiological pro-
cess in which temporal variations in distorted lipid metabolism, vascular inflammation, 
endothelial dysfunction, increased thrombogenicity and myocardial ischemia play an 
important role. [9,11] Various established and novel serum biomarkers have been associ-
ated with each of these pathophysiological components, reflecting their presence and/
or activity. [11,13–20] Furthermore, the biomarker’s ability to fluctuate, at least in theory, 
perfectly suits monitoring short-term risks of a dynamic pathophysiologic process, as 
coronary artery disease. Integration of such dynamic information requires a conception-
ally different perspective on risk prediction. Ideally, such a different approach might 
result in more precise and time-specific risk assessment for the occurrence of adverse 
cardiac events.
Therefore, we hypothesized that divergent biomarker patterns, detected through 
ambulatory and highly frequent blood sampling, could identify patients in a “vulnerable 
period” for the occurrence of an imminent myocardial infarction. In order to investigate 
this hypothesis, our aim is to obtain serial biomarker measurements as closely as possible 
prior to an ischemic event, yet in a phase in which the patient is still asymptomatic. Sub-
sequent analysis of serial biomarker patterns up to the coronary event should elucidate 
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biomarker kinetics, patterns, appropriate cut-off values and prediction characteristics 
(such as timeframes), particularly shortly prior to the actual occurrence of an ACS.
COHORT DesCRIPTIOn
study objectives
We designed the BIOMarker study to identify the Acute risk of a Coronary Syndrome (BIO-
MArCS) to evaluate whether biomarker patterns of (vascular) inflammation, distorted 
lipid metabolism, endothelial dysfunction, decreased endothelial regenerative capacity, 
increased thrombogenicity and ischemia diverge in days to weeks prior to an ACS. If our 
hypothesis is confirmed, then serial biomarker measurements might identify ‘vulnerable 
periods’ in the lifetime of patients with prevalent CAD, during which they are at in-
creased risk of developing an ACS. Various hypothetically divergent biomarker patterns 
are depicted in Figure 1 (Panel A: divergence shortly prior to an ACS, Panel B: persistently 
higher (or lower) biomarker levels in the future cases, Panel C: higher intraindividual 
variability in the future cases).
study cohort
BIOMArCS is a multi-centre, prospective, observational study conducted in 18 participating 
hospitals in the Netherlands. Patients who were admitted for an ACS, including unstable 
angina pectoris (UAP), non ST-elevation myocardial infarction (NSTEMI) and ST-elevation 
myocardial infarction (STEMI) with at least one additional CV risk factor were eligible for 
enrolment (Table 1). A total of 844 patients were enrolled from March 1st 2008 until Janu-
ary 26th 2015. Table 2 describes the baseline clinical characteristics of the enrolled cohort.
Blood samples were collected at admission, at the day of hospital discharge and 
subsequently every fortnight during the first six months after discharge, followed by 
monthly blood sample collection until 1 year. Patients were offered some flexibility in 
the follow-up scheme: visit windows are ±1 week, and a maximum of 2 consecutive 
visits are allowed to be skipped (for personal reasons). If logistic circumstances hindered 
inclusion during hospitalisation, patients could be included on the first outpatient visit 
within 6 weeks after discharge. The sample collection schedule was then adapted ac-
cordingly. Follow-up blood sampling was terminated permanently after coronary artery 
bypass grafting, hospital admission for heart failure, or a deterioration of renal function 
leading to a glomerular filtration rate <30 ml/min/1.73 m², in order to minimize bias 
in circulating biomarker concentrations. During the course of the study we observed 
prespecified discontinuation of biomarker sampling in 13 patients who were revascular-
ized through CABG at a median follow-up duration of 116 days after the index-ACS. In 
these patients, samples were taken up until the bypass operation.
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This is an observational study. As such, it does not
interfere with patient treatment. All patients were
treated as per prevailing guidelines and at the discretion
of the investigator. Patients were only included after they
provided written informed consent. The consent
enables the investigators to enquire on the patients’
health status up to 15 years after enrolment.
Blood sample collection
Blood samples were ﬁrst handled and securely stored
on-site. After preparation, aliquots were frozen at −80°C
within 2 hours after withdrawal. Long-term storage and
biomarker analysis will take place at the department of
Clinical Chemistry of the Erasmus MC. Apart from
storage of serum, citrate-plasma and EDTA-plasma, the
BIOMArCS laboratory protocol also foresaw in collection
and preservation of leucocytes for the purpose of
genome analyses and ﬂow cytometric measurements of
certain circulating leucocyte (monocyte) subsets that are
thought to reﬂect endothelial regenerative capacity.21
Study end points
The primary end point is a composite of cardiac mortal-
ity or a clinical diagnosis of a non-fatal MI or unplanned
coronary revascularisation due to progressive angina
pectoris during 1-year follow-up. Any death will be con-
sidered cardiac unless documented to the contrary.
Incident non-fatal MI is deﬁned as the combination of
typical ischaemic chest symptoms and objective evidence
of myocardial ischaemia or myocardial necrosis as
demonstrated by ECG and/or elevated cardiac markers.
The criteria for non-fatal MI during follow-up share the
same deﬁnition as stated for the index event (points 1
and 2 of the study inclusion criteria). Study end points
at 1-year follow-up were adjudicated by a Clinical Event
Committee whose members were blinded for all bio-
marker data collected prior to the suspected incident
event. At a later stage, events that occur after the ﬁrst
year and up to 15 years of follow-up (ie, in the period
without repeated blood sampling) will be adjudicated
accordingly.
Sample size considerations
The incidence of the primary end point was estimated at
5–7%. Consequently, the number of patients who experi-
ence the primary end point (cases) will be far less than
those who remain end point-free. For reasons of efﬁ-
ciency, we will therefore apply the case–cohort design,22
and temporal biomarker patterns of all cases will be
compared with a limited number of non-cases.
For an adequate estimate of the required sample size,
we applied 500 simulations of linear mixed-effects
models for several scenarios (table 3), which were based
on repeated low-density lipoprotein-cholesterol (LDL-C)
measurements from a pilot study with up to ﬁve mea-
surements in 30 non-cases (non-published data). LDL-C
was considered the dependent variable and end point
status the explanatory variable. We assumed that, on
average, 6–10 repeated blood samples will be available in
cases prior to the primary end point. Then, if 50 cases
will be compared with 2–3 non-cases, a difference in the
intercept of 0.17–0.21 mmol/L, and a difference in the
Figure 1 Different hypothetical scenarios of biomarker
evolution during stable and vulnerable periods in the lifetime
of a patient with coronary artery disease. Panel A describes a
scenario in which biomarker patterns are relatively stable in a
period of low coronary vulnerability, but are clearly divergent
and upregulated shortly prior to the primary end point. Panel
B describes a potential scenario in which the ‘vulnerable
period’ for a coronary event is relatively longer and
characterised by persistently higher biomarker levels.
Depending on the specific biomarker, this scenario could also
apply in case of persistently lower (instead of higher) levels.
Panel C depicts a divergent biomarker pattern in which a high
degree of variability is associated with an increased risk of
adverse cardiac outcome. Naturally, numerous variations and
combinations of the aforementioned scenarios can be
proposed for each specific biomarker depending on its
characteristic pattern and kinetics.
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figure 1. Different hypothetical scenarios of biomarker evolution during stable and vulnerable pe-
riods in the lifetime of a patient with coronary artery disease
Panel A describes a scenario in which biomarker patterns are relatively stable in a period of low coronary 
vulnerability, but are clearly divergent and upregulated shortly prior to the primary endpoint. Panel B de-
scribes a potential scenario in which the “vulnerable period” for a coronary event is relatively longer and 
characterized by persistently higher biomarker levels. Depending on the specific biomarker, this scenario 
could also apply in case of persistently lower (instead of higher) levels. Panel C depicts a divergent bio-
marker pattern in which a high degree of variability is associated with an increased risk of adverse cardiac 
outcome. Naturally, numerous variations and combinations of the above mentioned scenarios can be 
proposed for each specific biomarker depending on its characteristic pattern and kinetics.
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A trained research nurse interviewed the patients at each visit and obtained data 
on anginal status (Canadian Cardiovascular Society classification), heart failure symp-
tomatology (New York Heart Association classification), and specific factors that might 
influence biomarker levels, e.g. smoking, the occurrence of infections, inflammatory or 
allergic responses, alterations in medication, interventional or operative procedures and 
hospital admission.
This is an observational study. As such, it does not interfere with patient treatment. All 
patients were treated to prevailing guidelines and at the discretion of the investigator. 
The study protocol has been approved by the Institutional Review Board of all participat-
ing hospitals. Patients were only included after they provided written informed consent. 
The consent enables the investigators to enquire on the patients health status up to 15 
years after enrolment.
Table 1. Inclusion and exclusion criteria
Inclusion: a patient must meet all criteria
1 Age ≥ 40 years
2 Complaints of typical ischemic chest pain, lasting 10 minutes or more within the preceding 24 hours 
prior to presentation
3a
3b
ECG: (non-)persistent ST segment elevation >1.0 mm in two or more contiguous leads, or dynamic ST 
segment depression >1.0 mm in two or more contiguous leads, OR
Biochemical evidence of myocardial injury: CK-MB or (high-sensitivity) Troponin I or (high-sensitivity) 
Troponin T elevation according to the applicable ESC guidelines of non ST-elevation acute coronary 
syndromes
4 Presence of at least 1 of the following risk factors: age ≥ 75 years, diabetes, prior cardiovascular 
disease, prior cerebrovascular disease and prior peripheral arterial disease. In addition, other risk 
factors mentioned below can be considered as well, but each only counts as half a risk factor, i.e. two 
of these are required for inclusion: age ≥ 65 years in men, age ≥ 70 years in females, hypertension, 
hypercholesterolemia, current smoking, or microalbuminuria†, positive family history of coronary 
artery disease ‡
5 Written informed consent
Exclusion: a patient cannot be included in case of any of the criteria below
1 Myocardial ischemia precipitated by a condition other than atherosclerotic coronary artery disease
2 Left ventricular ejection fraction <30%, or end-stage congestive heart failure (NYHA class III or IV)
3 Renal dialysis, or severe chronic kidney disease with measured or calculated GFR (Cockroft-Gault or 
MDRD4 formula) of <30 ml/min/1.73 m²
4 Co-existent condition with life-expectancy < 1 year or otherwise not expected to complete follow-up
GFR: glomerular filtration rate; MDRD: Modification of Diet in Renal Disease; NYHA: New York Heart As-
sociation classification
† defined as >2.5-25 mg albumin/mmol creatinine for men and >3.5-35 mg for women, or >20-200 mg/l 
urinary albumin concentration in a single urine sample
‡ angina pectoris, myocardial infarction, or sudden abrupt death without obvious cause, before the age 
of 55 in a first-degree blood relative
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Table 2. baseline characteristics of the entire cohort of 844 patients
Presentation and initial treatment
Age, years 62.5 (54.3, 70.2)
Man 77.9
Admission diagnosis
STEMI 51.7
NSTEMI 37.7
UAP 10.6
Culprit artery
RCA 33.1
LM 2.5
LAD 31.9
LCX 16.5
Coronary angiography performed 94.4
Percutaneous coronary intervention 86.3
Maximum CK during admission (iU/L) 513 (200, 1370)
Cardiovascular risk factors
Current smoking 40.5
Diabetes mellitus 23.5
Hypertension 55.5
Hypercholesterolemia 49.3
Cardiovascular history
Prior percutaneous coronary intervention 26.2
Prior coronary artery bypass grafting 10.0
Prior myocardial infarction 26.9
Prior heart failure 2.4
Valvular heart disease 2.2
Prior stroke 9.0
Peripheral artery disease 8.9
Medication at first blood sample moment
Aspirin 95.3
P2Y12 inhibitor 95.2
Vitamin K antagonist 6.8
Statin 96.2
Beta-blocker 89.8
ACE inhibitor or ARB 82.9
ACE: angiotensin converting enzyme; ARB: angiotensin II receptor blocker; CK: creatine kinase; LAD: left 
anterior descending artery; LCX: left circumflex artery; LM: left main coronary artery; MI: myocardial in-
farction; NSTEMI: non-ST-elevation myocardial infarcion; RCA: right coronary artery; STEMI: ST-elevation 
myocardial infarction; UAP: unstable angina pectoris
Continuous data are presented as median (25th, 75th percentile) values. Categorical data are presented 
as percentages. There are no missing data for any of the above mentioned variables.
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blood sample collection
Blood samples were first handled and securely stored on-site. After preparation, aliquots 
were frozen at −80 degrees Celsius within two hours after withdrawal. Long-term stor-
age and biomarker analysis will take place at the department of Clinical Chemistry of 
the Erasmus MC. Apart from storage of serum, citrate- and EDTA-plasma, the BIOMArCS 
laboratory protocol also foresaw in collection and preservation of leukocytes for the 
purpose of genome analyses and flow-cytometric measurements of certain circulat-
ing leukocyte (monocyte) subsets that are thought to reflect endothelial regenerative 
capacity. [21]
study endpoints
The primary endpoint is a composite of cardiac mortality or a clinical diagnosis of a non-
fatal myocardial infarction or unplanned coronary revascularization due to progressive 
angina pectoris during 1-year follow-up. Any death will be considered cardiac unless 
documented to the contrary. Incident non-fatal myocardial infarction is defined as the 
combination of typical ischemic chest complaints and objective evidence of myocar-
dial ischemia or myocardial necrosis as demonstrated by ECG and/or elevated cardiac 
markers. The criteria for non-fatal myocardial infarction during follow-up share the same 
definition as stated for the index event (points 1 and 2 of the study inclusion criteria). 
Study endpoints at 1-year follow-up were adjudicated by a Clinical Event Committee, 
which members were blinded for all biomarker data collected prior to the suspected 
incident event. At a later stage, events that occur after the first year and up to 15-years 
of follow-up (i.e. in the period without repeated blood sampling) will be adjudicated 
accordingly.
sample size considerations
The incidence of the primary endpoint was estimated at 5% to 7%. Consequently, the 
number of patients who experience the primary endpoint (‘cases’) will be far less than 
those who remain endpoint-free. For reasons of efficiency, we will therefore apply the 
case-cohort design, [22] and temporal biomarker patterns of all cases will be compared 
with a limited number of non-cases.
For an adequate estimate of the required sample size, we applied 500 simulations 
of linear mixed-effects models for several scenarios (Table 3), which were based on 
repeated LDL-cholesterol (LDL-C) measurements from a pilot study with up to 5 mea-
surements in 30 non-cases (non-published data). LDL-C was considered the dependent 
variable and endpoint-status the explanatory variable. We assumed that, on average, 6 
to 10 repeated blood samples will be available in cases prior to the primary endpoint. 
Then, if 50 cases will be compared with 2 to 3 non-cases, a difference in the intercept of 
0.17 to 0.21 mmol/l, and a difference in the slope of 0.06 to 0.11 mmol/l/month can be 
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demonstrated between cases and non-cases with a power of 80% (2-sided test with an 
alpha error of 5%). We judged that these differences are small in clinical terms, and we 
considered the observed variations in LDL-C levels representative of changes in other 
biomarkers. In order to obtain 50 cases, given the anticipated incidence, a total of 700 to 
1000 patients needed to be enrolled.
Construct of the case-cohort analysis set
A random, representative sample of 150 patients (random subcohort) will be chosen 
from all enrolled patients, and the patients who reach a study endpoint will be added. 
We anticipate that (50/1000)*150 = 8 to (50/700)*150 = 11 patients of the random 
subcohort will reach the primary endpoint. Hence, the expected ratio between patients 
with and without the primary study endpoint in the analysis set will be 1:2.8 to 1:2.9, 
which allows us to reveal clinically relevant differences in biomarker patterns with suf-
ficient statistical power (see Sample size considerations above).
biomarker selection and significance testing
Atherosclerosis and plaque destabilisation leading to intra-coronary thrombosis and an 
ACS is the result of a very heterogeneous process with many intertwined constituents. 
Vascular inflammation and endothelial disruption can result in thrombosis, which on 
its turn can exacerbate inflammation. [11] Many of the circulating biomarkers that have 
shown to adequately predict risks of future CV events, are therefore thought to reflect 
one or more of these distinct yet interdependent pathophysiological processes more 
Table 3. Results of simulations (500 for each scenario) to obtain an adequate estimate of the re-
quired sample size
Number of Cases Number of non-
cases
Number of 
repeated 
samples pp
Difference in intercept 
(mmol/l)
Difference in slope (mmol/l/
month)
45 90 6 0.22 0.11
45 90 10 0.19 0.06
45 135 6 0.20 0.10
45 135 10 0.17 0.06
50 100 6 0.21 0.11
50 100 10 0.18 0.06
50 150 6 0.19 0.10
50 150 10 0.17 0.06
70 140 6 0.17 0.09
70 140 10 0.15 0.05
70 210 6 0.16 0.08
70 210 10 0.14 0.05
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or less specifically. Currently, markers like those mentioned in Table 4 are considered 
to have high potential, and will be determined and reported in prespecified consecu-
tive phases. Their selection is hypothesis-driven and based on current literature which 
is mainly based on one single measurement in time. [13–19,23–30] The development 
of biomarker levels shortly after presentation for ACS, and, more importantly, the 
frequently sampled biomarker patterns during the (asymptomatic) period preceding 
a subsequent event are unknown. A call for epidemiological research to establish the 
clinical value of serial analysis of biomarkers in atherosclerotic disease during long-term 
follow-up has repeatedly sounded,[12,31,32] but has not been answered as yet.
Table 4. biomarker selection
The following biomarkers are considered of high-potential with regard to the BIOMArCS hypothesis
and will be determined and reported in prespecified consecutive phases. Their selection is hypothesis-driven 
and based on current literature.
Phase 1
High sensitivity C-reactive protein (hs CRP)1
High sensitivity Troponin I (hsTnI)1
High sensitivity Troponin T (hsTnT)2
NT-pro BNP3
ST-24
Creatinine1
Total cholesterol, HDL-Cholesterol1, LDL-Cholesterol5
Phase 2 (in alphabetical order)
Copeptin
Ceramide (d18:1/16:0) as well as the following ceramide ratios:
 Cer(d18:1/16:0)/Cer(d18:1/24:0)
 Cer(d18:1/20:0)/Cer(d18:1/24:0)
 Cer(d18:1/24:1)/Cer(d18:1/24:0)
Cystatin-C
Galectin-3
Growth Differentiation Factor-15 (GDF-15)
Interleukins 1, 6, 8, 10, 18
Monokine Induced by interferon-Gamma (MIG)
Myeloperoxidase3
Placental growth factor (PlGF),
Plasminogen Activator Inhibitor 1 (PAI-1)
Pregnancy-associated plasma protein A (PAPP-A)
Regulated upon activation normal T cell expressed and secreted (RANTES)
Soluble CD40 ligand (sCD40L)
Tumor necrosis factor (TNF)
Von Willebrand Factor
analyses of the markers in the first phase are to be performed on the following platforms/assays:
1) Coulter 5800 series, Beckman Coulter, Brea, California, USA
2) Cobas, Roche Diagnostics GmbH, Mannheim, Germany
3) custom built ELISA
4) Presage ST2 assay, Critical diagnostics, San Diego, California, USA
5) Friedewald Formula
Assays for the markers in the second phase have currently not been selected yet.
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We will not limit our analyses to a selected number of markers. Biomarker research 
is a very rapidly evolving field in which novel and promising markers are regularly 
discovered. Exploratory analyses using proton nuclear magnetic resonance (NMR) spec-
troscopy and mass spectrometry are also an option under consideration. [30]
We will perform several statistical tests to obtain significance levels for relations 
between biomarkers and study endpoints. For hypothesis-driven tests a two-tailed 
significance level of 0.05 will be used. For hypothesis-free tests corrections for inflation 
of the type I error due to multiple testing will be applied.
etiologic and prognostic analyses of selected biomarkers
Compared to an analysis of the entire cohort, the advantage of a case-cohort design lies 
in its efficiency, whereas the ability to calculate absolute risks and rates is maintained. 
[22] We will perform etiologic as well as prognostic analyses. We utilize the framework 
of linear mixed-effects models to assess changes in biomarker levels over time, while ac-
counting for the correlation between repeated follow-up measurements in each patient. 
[33] For both the fixed- and random-effects parts of the model we will test for possible 
nonlinear evolutions, which will be modelled by restricted cubic splines.
Biomarkers represent endogenous time-dependent covariate processes. We will 
therefore utilize the framework of joint models for longitudinal and survival data to 
investigate the relation between the serial biomarker measurements and the study 
endpoints. [34] Joint models combine the aforementioned linear mixed-effects models 
with a Cox regression model, adapted for a case-cohort design, [35] in order to measure 
the strength of the association between the two outcomes. We will test whether the 
(instantaneous) slope of the biomarker trajectory is associated with the study endpoint.
Both univariate and multivariate analyses will be applied. The biomarker trajectories 
in the linear models will be adjusted a) for age and sex, b) GRACE risk score, c) kidney 
function, d) body mass index, diabetes mellitus, prior CAD, prior cerebrovascular disease 
and prior peripheral vascular disease, and e) other variables that appear related with 
biomarker levels in the analysis set, to the extent that is permitted given the number of 
observations. The relation between biomarkers and study endpoints in the Cox model 
will be adjusted GRACE risk score and prognostic biomarkers, to the extent that is per-
mitted given the number of endpoint cases. For the purpose of multivariate adjustment, 
we will select the specific GRACE risk model that is best in line with the purpose of our 
study, namely an assessment of post discharge death and MI. That particular GRACE risk 
model consists of age, Troponin (or CKMB) elevation at admission, history of MI, conges-
tive heart failure and whether CABG was performed at the index hospitalization. [36]
84 Chapter 5
Risk models
Based on the results of the analyses above, multi-biomarker models will be constructed 
to predict the risk of the study endpoints based on the temporal evolvement of the 
biomarkers. We realize that the number of biomarkers (and covariates) will be limited by 
the number of endpoint events. [37]
early washout biomarker patterns and ancillary analyses
In an ancillary study of 68 patients (10% of the initially planned total study population of 
at least 700 patients), we aim to study the evolution/normalization of biomarker during 
the first 8 weeks after the index event. In these patients, (additional) blood samples are 
collected within 24, 48, 72 and 96 hours after admission, at the day of hospital discharge, 
and at 2, 4 and 8 weeks after discharge. Insight in these patterns will allow us to dif-
ferentiate whether observed divergent biomarkers patterns prior to a repeat ACS during 
longer-term follow-up are (partly) influenced by biochemical consequences of the index 
event.
Patients will use multiple medications that might influence biomarker levels (e.g. 
beta-blockers, ACE-inhibitors and especially statins are known for their pleiotropic ef-
fects). However, for ethical reasons, we will not interfere with the patient’s treatment. 
Biomarkers might also be influenced by inflammatory processes due to other illnesses. 
We will analyse these phenomena descriptively.
study organization
The study is conducted under the leadership of an executive committee that has overall 
responsibility for protocol design, study conduct and publication. The Clinical Epide-
miology unit of the Erasmus MC department of Cardiology serves as the coordinating 
centre for the study and oversees all activities including (out-patient) clinical follow-up, 
data management and statistics, as well as blood sample handling, transport and long-
term storage.
Current status
BIOMArCS enrolled 844 patients between March 1st 2008 until January 26th 2015 (Table 
2). Currently 1-year follow-up and event adjudication have been completed. Prespeci-
fied biomarker analyses are currently being performed and dissemination through 
peer-reviewed publications and conference presentations is expected from the third 
quarter of 2016.
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DIsCussIOn
Vulnerable period versus vulnerable plaque
The notion of the “vulnerable plaque” has gained currency in recent years, partly be-
cause the concept of an inflamed, rupture-prone, thin-capped fibroatheroma fits well 
within our current understanding of atherosclerosis biology. Still, it remains important 
to realise that ex vivo as well as in vivo studies using coronary intravascular ultrasound 
in patients with myocardial infarction have demonstrated the presence of vulnerable 
plaques in other than the culprit lesion or even culprit artery. [38,39] In other words, 
vulnerable plaques are numerous and a certain part of the plaques that we may classify 
as vulnerable will never disrupt. [11] Understanding of the clinical implications of the 
presence of vulnerable plaques becomes even more difficult given the observations 
that even in the case of plaque disruption and thrombus formation, this does not always 
imply a major symptomatic event, since many coronary thrombi remain mural and 
produce few if any symptoms. [40]
By selection of a clinically relevant endpoint and by analysis of biomarkers at vari-
ous time points prior to the endpoint, BIOMArCS is well-suited to identify a “vulnerable 
period” during the follow-up of a “vulnerable patient”, instead of merely detecting the 
presence and a certain degree of destabilisation of vulnerable plaques.
Rationale behind the time intervals for sample collection
The average time from collection of the last blood sample in asymptomatic condition 
until the occurrence of the coronary event will be 7 days in case of an event during 
the first 6 months after enrolment and 14 days during the latter half year of follow-up. 
Since similar studies have not been conducted before, there is a concern that altered 
biomarker patterns indicating an imminent event might be missed due to length of the 
intervals between individual samples. However, more frequent blood sampling than 
proposed in the current protocol would test the boundaries of an ethically acceptable 
burden for study patients. Furthermore it is important to realise that the longer term aim 
is to strive for implementation of serial multimarker testing in the routine follow-up of 
ambulatory patients. Recognition of distinct short-term future periods of high coronary 
vulnerability could in the near future serve to prevent the imminent event by intensifica-
tion of treatment (by pharmacological and/or percutaneous coronary intervention) in 
individuals that are selected on the basis of a divergent “biomarker signature”. Future 
long-term routine clinical follow-up of patients in an even more frequent scheme of 
sampling seems practically unfeasible and reliable point-of-care multimarker tests that 
are not semi-quantitative currently do not exist. Moreover, interventions to prevent the 
so-called imminent event require time as well.
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Although the BIOMArCS concept is very novel, there is some, though limited, evidence 
that the chosen time intervals of our exploratory and clinically adaptable protocol in fact 
do allow observation of upregulation of pathophysiological mechanisms leading to an 
ACS. Rittersma et al. used pathological classification of aspired intracoronary thrombi 
to demonstrate that in at least 50% of patients with ST-elevation myocardial infarction, 
coronary thrombi were days or even weeks old. [41] This supports our hypothesis that 
sudden coronary occlusion is often preceded by a variable period of coronary instability 
and thrombus formation, initiated days or weeks before onset of symptoms. A second 
study evaluated formalin stored hearts and tissue blocks of coronary arteries including 
the thrombosed culprit plaque of young adults (≤35 years), who had died within 1 hour 
after onset of symptoms due to a coronary thrombotic occlusion and drew a similar 
conclusion. [42] A third study used platelet mRNA profiling in order to demonstrate 
that the expression of a certain biomarker, myeloid-related protein-14, is upregu-
lated prior to STEMI. Because platelets are anuclear, the platelet transcriptome mirrors 
megakaryocyte-derived mRNAs and represents an averaged mRNA profile of variably 
aged platelets (platelets circulate for 7 to 10 days). [43] Finally, serial angiographic 
studies in the 1990s have demonstrated a sudden rapid lesion progression in weeks 
to months prior to myocardial infarction [10,44,45]. The possible mechanisms for such 
rapid plaque progression and consequent luminal obstruction include recurrent plaque 
rupture and healing, intraplaque neovascularization and hemorrhage with deposition 
of erythrocyte-derived free cholesterol. [10]
future directions
As indicated previously, the longer term perspective of this study is to recognize distinct 
periods of high coronary vulnerability in individual patients days to weeks in advance, 
so that a tailored therapy and intensification of treatment might prevent the imminent 
event. Biomarker patterns and kinetics following and prior to an ACS have not been de-
scribed at such short intervals during 1-year follow-up before. This study will therefore 
provide insight in the usefulness of combinations of certain markers for risk prediction 
at such short term. The descriptive data collected in this study could be used for the 
construction of both a short- and longer-term multimarker risk prediction model. Cur-
rent risk prediction models are generally characterized by their use of baseline patient 
characteristics and lack of account of disease characteristics and progression over time. 
A multimarker approach, in which a combination of different biomarkers actually reflects 
atherosclerosis biology and dynamics, might therefore improve overall risk prediction. 
Of course, such an assertion also implies epidemiological challenges. Prediction on the 
basis of short term repeated measurements that reflect risks that are dynamic over time, 
instead of linear and continuous, requires alternative statistical approaches.
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At a later stage (and dependent on the results of the above mentioned projects), the 
way could be paved towards intervention studies that evaluate the effectiveness and 
safety of a brief period of intensified medical treatment (or a percutaneous interven-
tion) in order to prevent an otherwise imminent coronary event, as characterized by 
an abnormal “high-risk” biomarker pattern. Future hypotheses could focus on plaque 
stabilization or regression and endothelial repair in patients with “high-risk” biomarker 
patterns such as a brief period of intravenous administration of Apolipoprotein-A1 Mi-
lano [46], Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition [47], or the use of the 
anti-inflammatory properties of P-selectin antagonists [48], low-dose colchicine [49], 
low-dose methothrexate or interleukin-1β inhibition [50]. Perhaps divergent biomarker 
patterns could be evaluated for selection of patients that benefit from prolonged dual 
antiplatelet therapy. Exogenous drugs amongst which agonists of vascular endothelial 
growth factor, peroxisomal proliferative activated receptor agonists and granulocyte-
colony-stimulating factor, which exert their actions partly through endothelial progeni-
tor cell-mediated re-endothelialisation may be of interest as well. [51]
Obviously, the data generated by this study could also be used for the identification 
of individuals with a “low risk” biomarker pattern. Tailored therapy for them might imply 
a reduction in pharmacological treatment regimes.
strengths and limitations
BIOMArCS is the only currently available study in which such frequent blood sampling has 
been performed on a large scale in order to thoroughly investigate multiple biomarker 
patterns in patients with coronary artery disease. As such, BIOMArCS is conceptionally 
different from all other biomarker studies in patients with coronary artery disease, as it 
aimed to obtain blood samples as shortly as possible prior to a future adverse cardiac 
event. Although sample collection was performed prospectively, biomarker and genetic 
analyses will be performed retrospectively. As a dedicated biomarker study if benefits 
from a strict and prespecified laboratory processing protocol in which pre-analytical 
confounding was minimized through standardization of methods and materials for 
blood collection in all centers. Time from collection to standardized processing and 
freeze and thaw cycles for biomarker analyses are limited by protocol. Patients were 
interviewed at each venapuncture to inquire on their cardiac status and medication 
use, but also to inquire on confounders of specific biomarkers (e.g. new onset of other 
illnesses, infection, allergic reactions.)
It is important to emphasize that a clinical observational study as BIOMArCS does 
not aim to unravel whether certain biomarkers are merely markers reflecting pathways 
of disease, or mediators that are directly involved within distinct pathophysiological 
cascades in the arterial wall. Definite delineation of biochemical events responsible for 
observed alterations in biomarker patterns prior to the endpoint, or final conclusions on 
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mechanisms of disease are beyond the scope of this study design. In addition, our study 
was performed in patients with known coronary artery disease. It is uncertain whether 
its conclusions may be extrapolated to the primary prevention setting.
Collaboration
Anyone can submit a prespecified analytical plan for biomarker analyses within the BIO-
MArCS data set to the principle investigator/Clinical Epidemiology unit of the Erasmus 
MC department of Cardiology.
Biomarker analyses can only be perfomed after evaluation and written approval 
thereof by the BIOMArCS Executive Committee.
Contributorship statement
Rohit M. Oemrawsingh (RMO), K. Martijn Akkerhuis (KMA), Eric Boersma (EB) and Maarten 
L. Simoons (MLS) were responsible for the design of the BIOMArCS study. RMO drafted 
the manuscript. All other authors, KMA, EB, MLS, V.A. Umans, B. Kietselaer, C. Schotborgh, 
E. Ronner, T. Lenderink, A. Liem, D. Haitsma, P. van der Harst, F.W. Asselbergs, A. Maas, A.J. 
Oude Ophuis, B. Ilmer, R. Dijkgraaf, R-J de Winter, S.H.K. The, A.J. Wardeh, W. Hermans, E. 
Cramer, R.H. van Schaik, I.E. Hoefer, P.A. Doevendans, revised it critically for important 
intellectual content and approved this version to be published. All authors contributed 
substantially to data acquisition for the BIOMArCS study and agree to be accountable for 
all aspects of this work in ensuring that questions related to the accuracy or integrity of 
any part of the work are appropriately investigated and resolved.
funding source and acknowledgements
The study is supported and funded by the Netherlands Heart Foundation (grant num-
ber 2007B012), the Netherlands Heart Institute-Interuniversity Cardiology Institute of 
the Netherlands (project number 071.01) and the Working Group on Cardiovascular 
Research Netherlands, all of which are non-commercial funding bodies. An unrestricted 
research grant is further obtained from Eli Lilly The Netherlands. Folkert W. Asselbergs is 
supported by a Dekker scholarship-Junior Staff Member 2014T001 – Netherlands Heart 
Foundation and UCL Hospitals NIHR Biomedical Research Centre.
Competing interests
BIOMArCS was designed and initiated by the principle investigators. The trial will be con-
ducted, and its results interpreted and reported independently of the aforementioned 
sponsors. All authors declare that there is no conflict of interest; no financial relation-
ships with any organisations that might have an interest in the submitted work; no other 
relationships or activities that could appear to have influenced the submitted work.
Cohort profile of BIOMArCS: BIOMarker study to identify the Acute risk of a Coronary Syndrome 89
C
h
a
p
te
r
 5
RefeRenCes
 1. Levy D, Wilson PW, Anderson KM, et al. Stratifying the patient at risk from coronary disease: new 
insights from the Framingham Heart Study. Am Heart J 1990; 119: 712–717; discussion 717.
 2. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular 
disease in Europe: the SCORE project. European Heart Journal 2003; 24: 987–1003. doi: 10.1016/
S0195-668X(03)00114-3
 3. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary 
syndromes without persistent ST-segment elevation. Results from an international trial of 9461 
patients. The PURSUIT Investigators. Circulation 2000; 101: 2557–67.
 4. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation 
MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284: 835–42.
 5. Fox KAA, Fitzgerald G, Puymirat E, et al. Should patients with acute coronary disease be stratified 
for management according to their risk? Derivation, external validation and outcomes using the 
updated GRACE risk score. BMJ Open 2014; 4: e004425. doi: 10.1136/bmjopen-2013-004425
 6. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coro-
nary heart disease. JAMA 2003; 290: 898–904. doi: 12928466
 7. Johnson KM, Dowe DA, Brink JA. Traditional clinical risk assessment tools do not accurately pre-
dict coronary atherosclerotic plaque burden: a CT angiography study. AJR Am J Roentgenol 2009; 
192: 235–43. doi: 10.2214/AJR.08.1056
 8. Naghavi M, Libby P, Falk E, et al. From Vulnerable Plaque to Vulnerable Patient: A Call for New 
Definitions and Risk Assessment Strategies: Part II. Circulation 2003; 108: 1772–8. doi: 10.1161/01.
CIR.0000087481.55887.C9
 9. Davies MJ. CORONARY DISEASE: The pathophysiology of acute coronary syndromes. Heart 2000; 
83: 361–6. doi: 10.1136/heart.83.3.361
 10. Ahmadi A, Leipsic J, Blankstein R, et al. Do Plaques Rapidly Progress Prior to Myocardial Infarc-
tion? The Interplay Between Plaque Vulnerability and Progression. Circulation Research 2015; 117: 
99–104. doi: 10.1161/CIRCRESAHA.117.305637
 11. Libby P. Atherosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol 2006; 98: 
3Q–9Q. doi: 10.1016/j.amjcard.2006.09.020
 12. Oemrawsingh RM, Akkerhuis KM, Boersma E. Tailor-made therapy for the prevention of acute 
coronary syndromes: future role of biomarkers in risk stratification and disease management. 
Expert Rev Cardiovasc Ther 2008; 6: 435–7. doi: 10.1586/14779072.6.4.435
 13. Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, et al. Relation of C-reactive protein to coronary 
plaque characteristics on grayscale, radiofrequency intravascular ultrasound, and cardiovas-
cular outcome in patients with acute coronary syndrome or stable angina pectoris (from the 
ATHEROREMO-IVUS study). Am J Cardiol 2014; 114: 1497–503. doi: 10.1016/j.amjcard.2014.08.013
 14. Oemrawsingh RM, Cheng JM, García-García HM, et al. High-sensitivity Troponin T in relation 
to coronary plaque characteristics in patients with stable coronary artery disease; results of 
the ATHEROREMO-IVUS study. Atherosclerosis 2016; 247: 135–41. doi: 10.1016/j.atherosclero-
sis.2016.02.012
 15. Cheng JM, Oemrawsingh RM, Akkerhuis KM, et al. Circulating chemokines in relation to coronary 
plaque characteristics on radiofrequency intravascular ultrasound and cardiovascular outcome. 
Biomarkers 2014; 19: 611–9. doi: 10.3109/1354750X.2014.957725
90 Chapter 5
 16. Battes LC, Akkerhuis KM, Cheng JM, et al. Circulating acute phase proteins in relation to extent 
and composition of coronary atherosclerosis and cardiovascular outcome: results from the 
ATHEROREMO-IVUS study. Int J Cardiol 2014; 177: 847–53. doi: 10.1016/j.ijcard.2014.11.001
 17. Cheng JM, Suoniemi M, Kardys I, et al. Plasma concentrations of molecular lipid species in relation 
to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-
IVUS study. Atherosclerosis 2015; 243: 560–6. doi: 10.1016/j.atherosclerosis.2015.10.022
 18. Battes LC, Cheng JM, Oemrawsingh RM, et al. Circulating cytokines in relation to the extent and 
composition of coronary atherosclerosis: results from the ATHEROREMO-IVUS study. Atheroscle-
rosis 2014; 236: 18–24. doi: 10.1016/j.atherosclerosis.2014.06.010
 19. Sonneveld MAH, Cheng JM, Oemrawsingh RM, et al. Von Willebrand factor in relation to coronary 
plaque characteristics and cardiovascular outcome. Results of the ATHEROREMO-IVUS study. 
Thromb Haemost 2015; 113: 577–84. doi: 10.1160/TH14-07-0589
 20. Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, et al. PCSK9 in relation to coronary plaque 
inflammation: Results of the ATHEROREMO-IVUS study. Atherosclerosis 2016; 248: 117–22. doi: 
10.1016/j.atherosclerosis.2016.03.010
 21. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular 
outcomes. N Engl J Med 2005; 353: 999–1007. doi: 10.1056/NEJMoa043814
 22. Grobbee DE, Hoes AW. Clinical Epidemiology: Principles, Methods, and Applications for Clinical 
Research. Boston: Jones and Bartlett Publishers 2009. 259–61.
 23. Kardys I, Oemrawsingh RM, Kay IP, et al. Lipoprotein(a), interleukin-10, C-reactive protein, and 
8-year outcome after percutaneous coronary intervention. Clin Cardiol 2012; 35: 482–9. doi: 
10.1002/clc.21988
 24. Oemrawsingh RM, Lenderink T, Akkerhuis KM, et al. Multimarker risk model containing troponin-
T, interleukin 10, myeloperoxidase and placental growth factor predicts long-term cardiovascular 
risk after non-ST-segment elevation acute coronary syndrome. Heart 2011; 97: 1061–6. doi: 
10.1136/hrt.2010.197392
 25. Everett BM, Brooks MM, Vlachos HEA, et al. Troponin and Cardiac Events in Stable Ischemic Heart 
Disease and Diabetes. N Engl J Med 2015; 373: 610–20. doi: 10.1056/NEJMoa1415921
 26. Giannitsis E, Spanuth E, Horsch A, et al. High-sensitivity cardiac troponin T and N-terminal pro-
B-type natriuretic peptide predict mortality in stable coronary artery disease: results from the 
Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chem Lab Med 2013; 51: 2019–28. 
doi: 10.1515/cclm-2012-0786
 27. Woitas RP, Kleber ME, Meinitzer A, et al. Cystatin C is independently associated with total and 
cardiovascular mortality in individuals undergoing coronary angiography. The Ludwigshafen 
Risk and Cardiovascular Health (LURIC) study. Atherosclerosis 2013; 229: 541–8. doi: 10.1016/j.
atherosclerosis.2013.04.027
 28. Maiolino G, Rossitto G, Pedon L, et al. Galectin-3 predicts long-term cardiovascular death in 
high-risk patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2015; 35: 725–32. doi: 
10.1161/ATVBAHA.114.304964
 29. Dieplinger B, Egger M, Haltmayer M, et al. Increased Soluble ST2 Predicts Long-term Mortality in 
Patients with Stable Coronary Artery Disease: Results from the Ludwigshafen Risk and Cardiovas-
cular Health Study. Clinical Chemistry 2014; 60: 530–40. doi: 10.1373/clinchem.2013.209858
 30. Hoefer IE, Steffens S, Ala-Korpela M, et al. Novel methodologies for biomarker discovery in athero-
sclerosis. European Heart Journal 2015; 36: 2635–42. doi: 10.1093/eurheartj/ehv236
 31. Sans S. In search of the grail: the never-ending story of biomarkers for coronary risk prediction. 
Eur Heart J 2004; 25: 1271–3. doi: 10.1016/j.ehj.2004.06.009
Cohort profile of BIOMArCS: BIOMarker study to identify the Acute risk of a Coronary Syndrome 91
C
h
a
p
te
r
 5
32. MacFadyen RJ, Ng Kam Chuen MJ. Developing the utility of blood biomarker associations beyond 
population sample linkage to events in cardiovascular patients. Eur Heart J 2008; 29: 837–9. doi:
10.1093/eurheartj/ehn075
33. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer-Verlag 
2000.
34. Rizopoulos R. Joint Models for Longitudinal and Time-to-Event Data. With Applications in R. London: 
Chapman and Hall/CRC 2012.
35. Ganna A, Reilly M, de Faire U, et al. Risk prediction measures for case-cohort and nested case-
control designs: an application to cardiovascular disease. Am J Epidemiol 2012; 175: 715–24. doi:
10.1093/aje/kwr374
36. Coordinating Center for the Global Registry of Acute Coronary Events, Center for Outcomes Re-
search, University of Massachusetts Medical School. Methods and formulas used to calculate the 
GRACE Risk Scores for patients presenting to hospital with an acute coronary syndrome. https:
//www.outcomes-umassmed.org/grace/files/GRACE_RiskModel_Coefficients.pdf (accessed 3 
May2016).
37. van Domburg R, Hoeks S, Kardys I, et al. Tools and techniques--statistics: how many variables are 
allowed in the logistic and Cox regression models? EuroIntervention 2014; 9: 1472–3. doi: 10.4244/
EIJV9I12A245
38. Cheng JM, Garcia-Garcia HM, de Boer SPM, et al. In vivo detection of high-risk coronary plaques 
by radiofrequency intravascular ultrasound and cardiovascular outcome: results of the ATHERO-
REMO-IVUS study. Eur Heart J 2014; 35: 639–47. doi: 10.1093/eurheartj/eht484
39. Oemrawsingh RM, Cheng JM, García-García HM, et al. Near-infrared spectroscopy predicts cardio-
vascular outcome in patients with coronary artery disease. J Am Coll Cardiol 2014; 64: 2510–8. doi:
10.1016/j.jacc.2014.07.998
40. van der Wal AC. Coronary artery pathology. Heart 2007; 93: 1484–9. doi: 10.1136/hrt.2004.038364
41. Rittersma SZH, van der Wal AC, Koch KT, et al. Plaque instability frequently occurs days or weeks 
before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutane-
ous coronary intervention. Circulation 2005; 111: 1160–5. doi: 01.CIR.0000157141.00778.AC
42. Henriques de Gouveia R, van der Wal AC, van der Loos CM, et al. Sudden unexpected death in 
young adults. Discrepancies between initiation of acute plaque complications and the onset of 
acute coronary death. Eur Heart J 2002; 23: 1433–40.
43. Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of 
myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 2006; 
113: 2278–84. doi: 10.1161/CIRCULATIONAHA.105.607333
44. Yokoya K, Takatsu H, Suzuki T, et al. Process of Progression of Coronary Artery Lesions From Mild 
or Moderate Stenosis to Moderate or Severe Stenosis: A Study Based on Four Serial Coronary 
Arteriograms per Year. Circulation 1999; 100: 903–9. doi: 10.1161/01.CIR.100.9.903
45. Ojio S, Takatsu H, Tanaka T, et al. Considerable time from the onset of plaque rupture and/or 
thrombi until the onset of acute myocardial infarction in humans: coronary angiographic findings 
within 1 week before the onset of infarction. Circulation 2000; 102: 2063–9.
46. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary athero-
sclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 
290: 2292–300. doi: 10.1001/jama.290.17.2292
47. Bergeron N, Phan BAP, Ding Y, et al. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: A 
New Therapeutic Mechanism for Reducing Cardiovascular Disease Risk. Circulation 2015; 132: 
1648–66. doi: 10.1161/CIRCULATIONAHA.115.016080
92 Chapter 5
48. Tardif J-C, Tanguay J-F, Wright SS, et al. Effects of the P-selectin antagonist inclacumab on myo-
cardial damage after percutaneous coronary intervention for non-ST-segment elevation myocar-
dial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol 2013; 61: 2048–55. doi: 10.1016/j.
jacc.2013.03.003
49. Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of 
cardiovascular disease. J Am Coll Cardiol 2013; 61: 404–10. doi: 10.1016/j.jacc.2012.10.027
50. Ridker PM. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and 
CANTOS trials? Trans Am Clin Climatol Assoc 2013; 124: 174–90.
51. Fuster V, Sanz J. Gene therapy and stem cell therapy for cardiovascular diseases today: a model 
for translational research. Nat Clin Pract Cardiovasc Med 2007; 4 suppl 1: S1-8. doi: 10.1038/ncpcar-
dio0737

Co
r
o
n
a
r
y 
vu
ln
er
a
b
ility
7
HIGH-FREQUENCY 
BIOMARKER 
MEASUREMENTS OF 
TROPONIN, NT-PROBNP 
AND C-REACTIVE PROTEIN 
FOR PREDICTION OF 
NEW CORONARY EVENTS 
AFTER ACUTE CORONARY 
SYNDROME: THE 
BIOMARCS STUDY
AUTHORS
Rohit M Oemrawsingh
K Martijn Akkerhuis
Maarten de Mulder
Victor A Umans
Bas Kietselaer
Carl Schotborgh
Eelko Ronner
Timo Lenderink
Anho Liem
David Haitsma
Pim van der Harst
Folkert W Asselbergs
Arthur Maas
Anton J Oude Ophuis
Ben Ilmer
René Dijkgraaf
Robbert J De Winter
S Hong Kie The
Alexander J Wardeh
Walter Hermans
Etienne Cramer
Ron H van Schaik
Imo E Hoefer
Pieter A Doevendans
Maarten L Simoons
Eric Boersma 
for the BIOMArCS 
investigators Circulation 2019 Jan 2;139(1):134-136
7
HIGH-FREQUENCY 
BIOMARKER 
MEASUREMENTS OF 
TROPONIN, NT-PROBNP 
AND C-REACTIVE PROTEIN 
FOR PREDICTION OF 
NEW CORONARY EVENTS 
AFTER ACUTE CORONARY 
SYNDROME: THE 
BIOMARCS STUDY
AUTHORS
Rohit M Oemrawsingh
K Martijn Akkerhuis
Maarten de Mulder
Victor A Umans
Bas Kietselaer
Carl Schotborgh
Eelko Ronner
Timo Lenderink
Anho Liem
David Haitsma
Pim van der Harst
Folkert W Asselbergs
Arthur Maas
Anton J Oude Ophuis
Ben Ilmer
René Dijkgraaf
Robbert J De Winter
S Hong Kie The
Alexander J Wardeh
Walter Hermans
Etienne Cramer
Ron H van Schaik
Imo E Hoefer
Pieter A Doevendans
Maarten L Simoons
Eric Boersma 
for the BIOMArCS 
investigators Circulation 2019 Jan 2;139(1):134-136

Biomarker measurements of Troponin, NT-proBNP and C-Reactive Protein for prediction of new coronary events 115
C
h
a
p
te
r
 7
The BIOMarker study to identify the Acute risk of a Coronary Syndrome (BIOMArCS) was 
designed to study the relation between temporal changes in cardiovascular (CV) bio-
markers and ischemic CV events in patients discharged after acute coronary syndrome 
(ACS) admission.1 844 ACS patients were enrolled in 18 hospitals in The Netherlands. 
Venipuncture was scheduled at 19 regular intervals during a year. Forty-five patients 
(cases) reached the study endpoint, defined as the first event of the composite of cardiac 
death (N=8), myocardial infarction (N=29), or unstable angina requiring urgent coronary 
revascularization (N=8) within one year. BIOMArCS was approved by the institutional 
review committees of the participating hospitals. All patients gave informed consent.
We used a case-cohort approach for biomarker determination and analysis.2 The case-
cohort study comprises a random subcohort from the full cohort, together with all cases. 
The main advantage of the case-cohort design over a cohort study is that full covariate 
data (in our situation: biomarker data) are only needed on the cases and subcohort indi-
viduals, not all the original cohort.3 Thus, the advantages of a cohort study are combined 
with the efficiency of a nested case-control study.3 We randomly selected a subcohort of 
150 (18%) individuals, including 8 cases. Our case-cohort therefore consisted of (all) 45 
cases and 142 noncases.
Four established CV biomarkers were then measured (in 1478 blood samples), reflect-
ing different components of CV pathophysiology: Troponin, which was assessed with 
high-sensitivity cardiac Troponin I and T assays (hs-cTnI, Abbott; hs-cTnT, Roche), N-
Terminal Pro-Brain Natriuretic Peptide (NT-proBNP, validated in-house sandwich ELISA), 
and high-sensitivity C-Reactive Protein (hs-CRP, Beckman Coulter).1 Biomarker measure-
ments were performed in a single batch; personnel were blinded to any patient data.
Patient-specific longitudinal biomarker trajectories were analyzed by linear mixed 
effect (LME) models, with adjustment for GRACE risk score (including age), sex, clini-
cal risk factors, recorded at inclusion, and creatinine value, recorded at each sampling 
moment. The relationships between biomarker levels (based on the LME models) and 
the endpoint were analyzed by Cox proportional hazard models. Unadjusted hazard 
ratio (HR) estimates for each biomarker were obtained, as well as estimates adjusted for 
GRACE risk score and multiple biomarkers. We applied Bayesian semi-parametric joint 
modeling, enabling simultaneous estimation of the LME- and Cox model parameters.4
Median age was 62.5 years, 77.9% were male, and 51.7% presented with ST-elevation. 
Measured biomarkers were elevated at the index ACS, subsequently decreased, and 
stabilized within 30 days. Canadian Cardiac Society angina class was ≤1 at 95.5% of the 
post 30-day visits, reflecting clinical stability. Renal function was preserved and stable: 
median (IQR) eGFR was 90 (73-114) ml/min/1.73m² at the final visit. Antiplatelets and 
statins were used at 98.7% and 95.9% of the visits.
Despite the absence of angina symptoms in the post 30-day period, cases had 
sustained and significant higher hs-cTnI than noncases (Figure). The mean values of 
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the patient-specific means were 13.0 and 6.7 pg/mL (P-value <0.001). Cases also had 
higher hs-cTnT (15.7 versus 8.6 pg/mL, P-value <0.001), and NT-proBNP (99.8 versus 47.1 
pmol/L, P-value 0.001), but not hs-CRP (2.7 versus 2.1 mg/L, p-value 0.138). Hazard ratios 
for the endpoint per standard deviation increase were 1.87 (1.27-2.72) for hs-cTnI, 1.87 
(1.27-2.75) for hs-cTnT, 2.38 (1.41-4.33) for NT-proBNP, and 1.46 (0.82-2.62) for hs-CRP. 
The significant associations remained after adjustment for GRACE risk score. Cardiac 
Troponins and NT-proBNP were correlated (Spearman r 0.54 and 0.46 for hs-cTnI and 
hs-cTnT), resulting in attenuated associations with the endpoint in multimarker models 
(Figure).
During the asymptomatic post 30-day period biomarkers tended to remain stable in 
the individual patient. We did not observe a (steady or more sudden) rise in the studied 
biomarkers prior to the endpoint. Nevertheless, 20.4% of patients had isolated peak 
values of hs-cTnI above the Reference Change Value (RCV)5 of 10 pg/mL. In a post-hoc 
analysis, there were no temporal associations between these peaks and the endpoint. 
Still, the HR for the endpoint for an incident hs-cTnI peak >RCV was 2.90 (95% CI 1.04-
7.27, P-value 0.045), adjusted for the patient-specific longitudinal stable hs-cTnI level 
(Figure). Incident hs-CRP peaks >RCV (10 mg/L) also contained independent predictive 
information, but hs-cTnT (10 pg/mL) and NT-proBNP (100 pmol/L) peaks did not.
Two limitations of our work need particular attention. First, differences in biomarker 
levels between cases and noncases might be explained by unmeasured factors, includ-
ing the severity of coronary disease and left ventricular remodeling – cardiac imaging 
was lacking. Second, despite the large number of measurements, the small number of 
events precluded full multivariable adjustment for the relation between biomarkers and 
the study endpoint.
BIOMArCS demonstrated that longitudinal hs-cTn and NT-proBNP elevations, and 
incident hs-cTnI and hs-CRP peaks were associated with coronary events in clinically 
stable post-ACS patients. Since the studied biomarkers did not rise prior to the event, 
longitudinal monitoring with these markers, within this particular sampling protocol, 
may not identify a high-risk timeframe in individuals.
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absTRaCT
aims: The European Collaborative Project on Inflammation and Vascular Wall Remodel-
ing in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study aims to in-
vestigate the relations of genetic profile and novel circulating biomarkers with coronary 
plaque phenotype and vulnerability as determined by intravascular ultrasound (IVUS).
Methods and results: ATHEROREMO-IVUS is a prospective, observational cohort study 
of 846 patients with stable angina pectoris or acute coronary syndrome (ACS) who 
are referred for coronary angiography. Prior to the catheterization procedure, blood 
samples are drawn for biomarker measurements and genetic analyses. During the cath-
eterization procedure, IVUS is performed in a non-culprit coronary artery. The primary 
endpoint is the presence of vulnerable plaque as determined by IVUS virtual histology. 
Secondary endpoints include the incidence of major adverse cardiac events during 
long-term follow-up.
Conclusions: Results from ATHEROREMO-IVUS are expected to improve our knowledge 
on the role of genetic profile and circulating biomarkers in relation to the development 
of atherosclerosis and vulnerable plaques. Assessment and early validation of the 
prognostic value of novel biomarkers and intracoronary imaging techniques will be 
performed. (Clinicaltrials.gov number: NCT01789411)
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InTRODuCTIOn
Coronary artery disease is projected to become the largest single cause of disease-burden 
worldwide.1 The traditional view that atherosclerosis is simply a lipid storage disease has 
been evolved, considering the growing body of evidence that genetic profile, inflam-
mation and blood coagulation play a pivotal role in all stages of atherosclerotic disease, 
from endothelial dysfunction to late-stage plaque rupture.2-5 Genetic markers and circu-
lating biomarkers of inflammation, lipids and coagulation may potentially improve risk 
stratification in patients with atherosclerotic cardiovascular disease, since they provide 
information on the biological processes in individuals.6-7 Furthermore, these markers 
may also have a role in the development of new therapeutical targets. Genome wide 
scanning of single nucleotide polymorphisms (SNPs) and plasma lipidomics are two 
potential methods to identify novel genetic and lipid-related markers of coronary artery 
disease. In-vivo intracoronary imaging may further improve coronary risk stratification. 
Intravascular ultrasound (IVUS) backscattering analysis allows for in-vivo differentiation 
of various plaque phenotypes and may therefore be well suited for detection of plaques 
that are at high risk to rupture.8-9
The European Collaborative Project on Inflammation and Vascular Wall Remodeling 
in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) is designed as an 
exploratory (non-pivotal) clinical study to investigate the associations between genetic 
profile, circulating biomarkers and coronary atherosclerosis phenotype and vulnerabil-
ity as determined by IVUS virtual histology Additionally, novel intracoronary imaging 
techniques, including near-infrared spectroscopy (NIRS), will be explored to identify 
lipid core plaques in the coronary arterial wall.10 Finally, the prognostic implications of 
(the combination) of established and novel biomarkers and plaque phenotypes will be 
studied.
MeTHODs
Target population
The ATHEROREMO-IVUS target population consists of patients with stable angina pec-
toris or acute coronary syndrome (ACS) who are referred for coronary angiography. The 
in- and exclusion criteria are presented in table 1. Stable angina pectoris was defined as 
having at least two of the following three criteria: 1. substernal chest discomfort of char-
acteristic quality and duration; 2. provoked by exertion or emotional stress; 3. relieved by 
rest and/or glyceryl trinitrate.11 ACS include ST-segment elevation myocardial infarction 
(STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) or unstable angina 
pectoris. STEMI was defined by ischaemic symptoms, persistent (>20 min) ST-segment 
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elevation in two contiguous electrocardiogram (ECG) leads and a raise in cardiac en-
zymes.12 Patients with acute chest pain and a typical raise and fall in cardiac enzymes 
but without persistent ST-segment elevation were classified as NSTEMI. Unstable angina 
was defined by acute or worsened chest pain without persistent ST-segment elevation 
and without elevated cardiac enzymes.13
study sample
The ATHEROREMO-IVUS study cohort mainly consists of patients who were included 
between 2008 and 2011 in the Erasmus MC, Rotterdam, the Netherlands, which is an 
academic tertiary referral hospital serving a population of approximately 1.9 million. 
Table 1. Inclusion and exclusion criteria
Inclusion criteria:
1. Aged 21 years or older.
2.  Presenting with stable angina pectoris (CCS angina class 1, 2, 3 or 4), unstable angina pectoris (Braunwald 
class 1-3, B-C), documented silent ischemia or acute myocardial infarction (STEMI and NSTEMI).
3. Eligible for coronary revascularization in the native coronary artery/arteries.
4. Willing and able to comply with the specified follow-up evaluation.
5. Willing to sign informed consent.
6.  Presence of a flow-limiting stenosis (diameter stenosis ≥50% by QCA or visual estimate) that is held 
responsible for angina pectoris or acute coronary syndrome
7. The study vessel has not undergone percutaneous coronary intervention in the last 8 months.
Exclusion criteria:
1. Angina caused by a non-cardiac illness (Braunwald class IA, IIA, IIIA).
2. Pregnant women or women of childbearing potential who do not use adequate contraception.
3.  Known allergies to aspirin, clopidogrel, ticlopdine, heparin, stainless steel, copper or a sensitivity to contrast 
media which cannot be adequately pre-medicated.
4.  Previous participation in this study or participation in another study with any investigational drug or device 
within the past 30 days (study participation ends after completion of the final follow-up).
5. Life expectancy of less than one year or factors making clinical and/or angiographic follow-up difficult.
6. Planned or being status post coronary bypass surgery.
7. Planned major non-cardiac surgery.
8. Impaired renal function (creatinine>2 mg/dl or ≥150 μmol/l).
9. History of bleeding diathesis or coagulopathy.
10. History of disabling stroke within the past year.
Exclusion criteria for intravascular ultrasound and near-infrared spectroscopy:
11. Three-vessel coronary artery disease or left main disease with ≥50% stenosis.
12. Minimal lumen diameter <2mm in the segments to be analyzed within the study vessel.
13. Diameter stenosis >70% or total occlusion of the study vessel.
14.  In case the study-vessel has been stented previously (>8 months ago), more than 1/3 proximal of the study 
vessel (at least 40mm in length) should be available for examination (i.e. outside the length of the stent plus 
5mm proximal to the stent).
15. Poor left ventricular function as assessed by echocardiography or by angiography.
16. Moderate or severe tortuosity of the study segment (i.e. 2 bends >75° or one bend > 90°).
17. Known tendency for coronary vasospasm.
CCS: Canadian Cardiovascular Society; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: 
ST-segment elevation myocardial infarction; QCA: quantitative coronary angiography.
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This cohort was enriched with eligible patients who participated in the Integrated Bio-
marker and Imaging Study-2 (IBIS-2) trial of darapladib versus placebo (inclusion period 
2005-2006).14
The ATHEROREMO-IVUS study was approved by the medical ethics committee of 
the Erasmus MC. The study was performed in accordance with the criteria described in 
the declaration of Helsinki. Written informed consent was obtained from all included 
patients.
blood sampling
Blood samples were collected to enable genome wide scans, lipid mass spectrometry 
and the analysis of circulating biomarkers. Blood samples were drawn from the arterial 
sheath prior to the coronary angiography or percutaneous coronary intervention (PCI) 
procedure. Blood samples were transported to the local clinical chemistry laboratory 
for further processing (i.e. centrifugation followed by serum, citrate- and EDTA-plasma 
aspiration and buffy coat separation from the EDTA tube) and storage at a temperature 
of −80°C within two hours.
Genome wide scans
Genome wide scans are preformed to identify a set of genetic variants that correlate 
with the extent and phenotype of coronary atherosclerosis. The Affymetrix GeneChip 
Human Mapping 6.0 Array is used for the genome wide scans of 906,600 SNPs. Quality 
control was performed, including correction for population structure, removal of related 
samples or samples with mismatched gender.
lipid extraction and mass spectrometry
An aliquot of plasma or serum is subjected to lipid extraction. Known amounts of in-
ternal standards are added to the samples before extraction and the final lipid extracts 
are dried under nitrogen. The extracts are reconstituted as described elsewhere.15 
Sphingolipids are analyzed on a 4000 QTRAP mass spectrometer (Applied Biosystems/
MDS Analytical Technologies) equipped with an ultra-high pressure liquid chromatog-
raphy (UHPLC) system; CTC PAL autosampler (Leap Technologies) and Rheos Allegro 
UHPLC (Flux Instruments) using multiple reaction monitoring.16 Shotgun lipidomics 
is performed by multiple precursor ion and neutral loss scanning on a QTRAP® 5500 
mass spectrometer (Applied Biosystems/MDS Analytical Technologies) equipped with 
a robotic nanoflow ion source NanoMate HD (Advion).17 Mass spectrometry data files 
are processed using MultiQuant™ 1.1.0.26 or Lipid Profiler™ (Applied Biosystems/MDS 
Analytical Technologies).18 Identified lipids are quantified by normalizing against their 
respective internal standard and tissue wet weight for aorta and volume for plasma. 
Quality control (QC) samples are utilized to monitor the overall quality of the lipid ex-
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traction and mass spectrometry analyses.19 The QC samples are mainly used to remove 
technical outliers and lipid species that are detected below the lipid class based lower 
limit of quantification (LLOQ).
Intravascular imaging
Following the standard coronary angiography, eligibility for intracoronary imaging was 
assessed. IVUS data was acquired in a non-culprit coronary vessel. The order of prefer-
ence for selection of the non-culprit vessel was: 1. left anterior descending (LAD) artery; 
2. right coronary artery (RCA); 3. left circumflex (LCX) artery. All IVUS data were acquired 
with the Volcano s5/s5i Imaging System (Volcano Corp., San Diego, CA, USA) using a 
Volcano Eagle Eye Gold IVUS catheter (20 MHz). An automatic pullback system was used 
with a standard pull back speed of 0.5 mm per second.
A number of selected patients in the Erasmus MC also participated in the ATHERORE-
MO-NIRS substudy (details are described in the supplement). In these patients, NIRS was 
performed in the same segment of the non-culprit vessel.
IVus virtual histology
The IVUS gray-scale and IVUS radiofrequency backscatter analyses, also known as IVUS 
virtual histology, were performed using pcVH 2.1 and qVH (Volcano Corp., San Diego, 
CA, USA) software. The baseline IVUS images were analyzed offline in an independent 
core laboratory (Cardialysis BV, Rotterdam, the Netherlands). The core laboratory 
personnel were blinded for baseline patient characteristics as well as for biomarker, 
genetic and clinical outcomes data. The external elastic membrane and luminal bor-
ders were contoured for each frame (median interslice distance, 0.40 mm). Extent and 
figure 1. Methodology for detection of lesion and reference segments
MLA: minimal luminal area; REF: reference segments; ROI: region of interest.
ATHEROREMO-IVUS study design 131
C
h
a
p
te
r
 8
phenotype of the atherosclerotic plaque were assessed. Plaque burden was defined as 
the plaque and media cross-sectional area divided by the external elastic membrane 
cross-sectional area. A coronary lesion was defined as a segment with a plaque burden 
of more than 40% in at least 3 consecutive frames (Figure 1). Using IVUS radiofrequency 
analyses, the composition of the atherosclerotic plaque was characterized into 4 dif-
ferent tissue types: fibrous, fibro-fatty, dense calcium and necrotic core.8 In consensus 
sessions with three investigators who were blinded to the patient characteristics and 
outcomes, the lesions were further classified into different lesion types (Table 2).9 A 
thin-cap fibroatheroma (TCFA) lesion was defined as a lesion with presence of >10% 
confluent necrotic core in direct contact with the lumen. Remodeling of a lesion was as-
sessed by means of the remodelling index, expressed as the external elastic membrane 
cross-sectional area at the site of minimal luminal area divided by the reference ex-
ternal elastic membrane cross-sectional area. The reference site was selected <10 mm 
proximal to the lesion, with no major side branches between the site of the minimal 
luminal area and the reference.
Table 2. Classification of lesions on intravascular ultrasound
lesion Type Definition
1. Adaptive intimal thickening Intimal thickening of <600 μm for <20% of the circumference
2. Pathological intimal thickening Intimal thickening ≥600 μm for >20% of the circumference 
with >15% fibrofatty tissue and no confluent necrotic core or 
dense-calcium
3. Fibrotic plaque Lesion consisting predominantly of fibrous tissue without 
confluent necrotic core or dense-calcium
4. Fibrocalcific plaque Presence of >10% confluent dense-calcium without confluent 
necrotic core
5. Fibroatheroma Presence of >10% confluent necrotic core with an overlying 
layer of fibrous tissue
6. Calcified fibroatheroma Fibroatheroma containing >10% confluent dense-calcium
7. Thin-cap fibroatheroma Presence of >10% confluent necrotic core in direct contact with 
the lumen
8. Calcified thin-cap fibroatheroma Thin-cap fibroatheroma containing >10% of confluent dense-
calcium
follow-up
Clinical follow-up started at inclusion and will last for at least 1 year. Post-discharge 
survival status will be obtained from municipal civil registries. Post-discharge rehos-
pitalizations will be prospectively assessed during follow-up. Questionnaires focusing 
on the occurrence of major adverse cardiac events (MACE) will be sent to all living 
patients. Treating physicians and institutions will be contacted for additional informa-
tion whenever necessary. If possible and clinically relevant, culprit and non-culprit 
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lesion related events will be distinguished. The occurrence of MACE will be adjudicated 
by an independent clinical events committee on the basis of original source data and 
without knowledge of other patient, biomarker, genetic or intracoronary imaging 
characteristics.
study endpoints
The primary objective of ATHEROREMO-IVUS is to correlate genetic markers and circu-
lating (lipid) biomarkers with coronary plaque phenotype as determined by IVUS virtual 
histology. Therefore, the primary endpoint is defined as the presence of TCFA lesions on 
the imaged non-culprit coronary segment.
The secondary objective is to assess the prognostic value of established biomarkers, 
novel genetic and lipid biomarkers and plaque phenotypes as determined by IVUS 
virtual histology. Therefore, the secondary endpoint is defined as the 1-year incidence 
of MACE, which includes all-cause mortality, ACS or unplanned coronary revasculariza-
tion. All-cause mortality is defined as death due to any cause.20 ACS was defined as the 
clinical diagnosis of STEMI, NSTEMI or unstable angina pectoris in accordance with the 
guidelines of the European Society of Cardiology.21 Unplanned coronary revasculariza-
tion was defined as unplanned repeat PCI or coronary artery bypass grafting (CABG) due 
to progressive angina or ACS.
sample size
ATHEROREMO-IVUS is designed to explore multiple relations. Its sample size is fixed 
at 800 patients, which is sufficient to reveal relations between ‘abnormal’ biomarkers 
(of any kind) and the presence of TCFA lesions with reasonable statistical certainty. We 
acknowledge that confirmatory studies might be required to more firmly establish rela-
tions that we will discover.
Based on prior studies, we expected that 30% of the patients will have a TCFA lesion in 
at least one coronary artery (i.e. TCFA positive), while 70% of the patients will not have 
any TCFA lesion (i.e. true TCFA negative) (Figure 2).9 Since TCFA lesions are more or less 
randomly distributed across the coronary system, we expected that 10% of the patients 
will have a TCFA lesion in the imaged coronary artery (i.e. classified as TCFA positive), 
while 90% of the patient will not have a TCFA lesion in the imaged coronary artery (i.e. 
classified as TCFA negative). In patients who are classified as TCFA negative, 77.8% is 
expected to be true TCFA negative.
A biomarker level in the upper quintile of its sample distribution is considered as 
‘abnormal’. We expect to observe abnormal biomarker levels in 5-15% of the true TCFA 
negative patients and in 10-40% of the TCFA positive patients. Hence, the proportion 
of abnormal biomarker levels in the patients who are classified as TCFA negative are 
expected to range from 6.1-20.6% (Table 3). Table 4 presents the statistical power to 
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detect differences in the frequency of abnormal biomarker levels between patients who 
are classified as TCFA negative versus those who are classified as TCFA positive (α-error 
5%, two-sided test). The power is adequate (≥80%) for the most realistic scenarios.
Power calculations were not performed for the secondary endpoint. Based on the 
results of other studies and previous registries in our hospital, we expect that MACE will 
occur in 5-10% of the patients within the first year of follow-up.22-25
800 patients planned to 
be included 
80 classified as TCFA 
positive  
(TCFA in imaged 
coronary artery) 
720 classified as TCFA 
negative  
(no TCFA in imaged 
coronary artery) 
160 TCFA positive 
(TCFA in a non-study 
coronary artery) 
560 true TCFA negative  
(no TCFA in any 
coronary artery) 
10-40% abnormal 
biomarkers levels 
5-15% abnormal 
biomarkers levels 
10-40% abnormal 
biomarkers levels 
figure 2. expected prevalence of thin-cap fibroatheroma lesions
TCFA: thin-cap fibroatheroma.
Table 3. expected percentage of patients with abnormal biomarker levels
Frequency of abnormal biomarker levels in true TCFA negative patients
5% 7.5% 10% 12.5% 15%
Frequency 
of abnormal 
biomarker levels 
in TCFA positive 
patients
10% 6.1% 6.9% – – –
15% 7.2% 9.2% 11.1% 13.1% –
20% 8.3% 10.3% 12.2% 14.2% 16.1%
25% 9.4% 11.4% 13.3% 15.3% 17.2%
30% 10.6% 12.5% 14.4% 16.4% 18.3%
40% 12.8% 14.7% 16.7% 18.6% 20.6%
Presented data are the expected percentage of patients with abnormal biomarker levels in those who did 
not have a TCFA in the imaged coronary artery (i.e. classified as TCFA negative). The results are displayed 
for different expected frequencies of abnormal biomarker levels in patients who have a TCFA in the im-
aged coronary vessel (i.e. TCFA positive) and for different expected frequencies of abnormal biomarker 
levels in patients who do not have any TCFA in any coronary vessel (i.e. true TCFA negative).
TCFA: thin-cap fibroatheroma.
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statistical analyses
Conventional linear regression will be applied to relate SNPs, sphingolipids and other 
biomarkers with IVUS virtual histology measures, corrected for segment length. Mixed 
linear models will be used for per-lesion analyses. The relation between biomarkers (in a 
broad sense) and clinical endpoints will be studied by Cox proportional hazard models.
The p-values that appear in the analyses of genetic variants and sphingolipids will be 
corrected for multiple testing with appropriate methods to adjust for inflation of the 
type I error (e.g. Bonferroni or simulation). Significant SNPs and lipid fractions need (and 
will be proposed for) validation in different datasets.
actual inclusion
A total of 846 patients with complete data for genetic and lipidomics analyses are in-
cluded in ATHEROREMO-IVUS: 581 patients were enrolled in the Erasmus MC and 265 
participated in IBIS-2 (Figure 3).14 Blood samples are available for 1098 patients. NIRS was 
performed in 203 patients.
DIsCussIOn
The ATHEROREMO-IVUS study was primarily designed to assess correlations of genetic 
profile and novel circulating biomarkers with the extent, phenotype and vulnerability 
of coronary atherosclerotic plaques as determined in-vivo by IVUS. Furthermore we 
Table 4. expected statistical power
Frequency of abnormal biomarker levels in true TCFA negative patients
5% 7.5% 10% 12.5% 15%
Frequency 
of abnormal 
biomarker levels 
in TCFA positive 
patients
10% 18% 12% – – –
15% 47% 26% 12% 5% –
20% 73% 54% 35% 20% 10%
25% 88% 76% 61% 44% 29%
30% 96% 90% 81% 68% 54%
40% 100% 99% 98% 95% 89%
Presented data are the statistical power to detect differences in the frequency of abnormal biomarker 
levels between patients with a TCFA in the imaged coronary vessel (i.e. TCFA positive) versus patients 
without a TCFA in the imaged coronary vessel (i.e. classified as TCFA negative) (α-error 5%, two-sided test). 
The results are displayed for different expected frequencies of abnormal biomarker levels in TCFA positive 
patients and for different expected frequencies of abnormal biomarker levels in patients who do not have 
a TCFA in any coronary vessel (true TCFA negative). The statistical power is adequate for the most realistic 
scenarios (grey shaded area).
TCFA: thin-cap fibroatheroma.
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would like to assess the potential prognostic value of novel biomarkers, IVUS and NIRS 
compositional features of atherosclerotic plaques in major cardiac events at long term 
follow-up.
Acute coronary syndromes are mostly caused by rupture of TCFA lesions that contain 
a lipid-rich necrotic core covered by a thin fibrous cap.2,26-29 IVUS virtual histology may be 
suitable for the detection of such vulnerable plaques. The PROSPECT study has shown 
that TCFA lesions as identified in-vivo by IVUS virtual histology were associated with 
increased risk for recurrent cardiovascular events in ACS patients. However, the events in 
PROSPECT were mainly driven by rehospitalizations for unstable or progressive angina, 
while less is known about the prognostic value of IVUS virtual histology for acute cardiac 
events as a consequence of spontaneous plaque rupture (i.e. recurrent ACS or death). 
The prognostic value of IVUS virtual histology in patients with stable angina remains 
unclear as well. Furthermore, the prognostic value of NIRS for the occurrence of MACE 
has not yet been investigated. The results of the ATHEROREMO-IVUS study will provide 
data on these questions.
Coronary artery disease has a strong genetic component. Epidemiological studies sug-
gest that up to 50% of its susceptibility is heritable.30 Genome wide scans may measure 
hundreds of thousands of SNPs that can be tested for an association with a coronary 
atherosclerosis. Although this method is shown to be successful in identifying genetic 
associations with complex traits,31 genotyping research programs for atherosclerosis 
ATHEROREMO-IVUS
Patients
IVUS of non-
culprit vessel
Blood samples 
available
1 year  
follow-up
NIRS of non-
culprit vessel
Included in Erasmus MC 
(n=768)
Yes 
(n=768)
(n=768)
Yes 
(n=581)
Yes 
(n=191)
No
(n=390)
No  
(n=187)
Yes 
(n=12)
No
(n=175)
Included in IBIS-2
(n=330)
Yes 
(n=265)
Yes 
(n=330)
No
(n=65)
figure 3. actual patient inclusion
Finally, blood samples were stored for 1098 patients, IVUS of a non-culprit vessel was performed in 846 
patients (grey shaded) and NIRS was performed in 203 patients.
IBIS-2: Integrated Biomarker and Imaging Study-2; IVUS: intravascular ultrasound; NIRS: near-infrared 
spectroscopy.
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have been of limited importance so far. One of the bottlenecks was the phenotypic com-
plexity of atherosclerotic vascular diseases. The ATHEROREMO-IVUS study is therefore 
regarded as a unique opportunity to link genotypes with extensive intracoronary imag-
ing data that reach far beyond the limited knowledge of luminal patency (or stenosis) 
from conventional coronary angiography.
Several biomarkers of inflammation, coagulation, myocardial necrosis and neurohu-
moral activation (e.g. C-reactive protein, high-sensitive troponin-T and natriuretic pep-
tides) have more or less been established.27 Our aim is to explore novel lipid biomarkers 
in first instance, while validation of more established biomarkers will be done in a later 
stage of the study.
The design of the ATHEROREMO-IVUS study has several strengths. To our best knowl-
edge, this is the first (large-scale) study to combine several novel intracoronary imaging 
techniques with extensive genetic analyses, biomarker exploration and validation and 
adverse clinical outcome during follow-up. Secondly, in this study we examine a single 
non-culprit vessel. Ex vivo as well as in vivo studies using IVUS in patients with myocardial 
infarction have demonstrated the presence of TCFAs in other than the culprit lesion or 
even culprit artery.5 Our approach will allow us to test the hypothesis that the phenotype 
of a non-culprit artery segment (indicating the patient’s atherosclerotic disease burden) 
can be linked to biomarker, genetic and outcome data. If the imaging characteristics 
of the non-culprit artery appear to be related to the incidence of MACE, then this can 
be seen as a confirmation that the non-culprit artery reflects atherosclerotic disease 
burden of the larger coronary vasculature.
Some limitations of this study have to be acknowledged. Firstly, the genetic profile 
and biomarkers will be correlated with the phenotype of the imaged non-culprit coro-
nary artery only. Although we expect that the presence of TCFA lesions is randomly dis-
tributed through the coronary system, we may miss the patient’s dominant phenotypic 
characteristic if this phenotype is only expressed in a coronary segment that has not 
been imaged (e.g. culprit lesion). Secondly, the ATHEROREMO-IVUS study was designed 
to explore and discover new genetic and circulating biomarkers. Newly discovered SNPs 
and lipid biomarkers remain to be validated in another patient cohort.
The results from the ATHEROREMO-IVUS study will improve our understanding on the 
role of genetic profile and circulating biomarkers in the development of atherosclerosis 
and vulnerable plaques. Genome wide scans and lipidomics may identify novel biomark-
ers in coronary artery disease. Furthermore, the prognostic value of novel circulating 
biomarkers as well as in-vivo detection of vulnerable plaques by IVUS virtual histology 
and NIRS will be assessed. These findings may further contribute to improve risk assess-
ment in patients with coronary artery disease, which may be important for the optimal 
choice of treatment in the individual patient.
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suPPleMenT: DeTaIls Of THe aTHeROReMO-nIRs subsTuDY
background
Near-infrared spectroscopy (NIRS) is a novel intracoronary imaging technique that may 
detect lipid core plaques in the coronary arterial wall.1-2 Therefore, it may be suitable for 
in vivo detection of vulnerable plaques. Currently, no data are available on the long-term 
prognostic value of NIRS in patients with coronary artery disease (CAD). Furthermore 
associations between NIRS measurements, genetic markers and circulating biomarkers 
have not been investigated yet. These associations however may further elucidate the 
pathophysiology of coronary lipid core plaques.
Objectives
The primary objective of the ATHEROREMO-NIRS substudy is to correlate genetic markers 
and circulating biomarkers with coronary plaque phenotype as determined by NIRS. The 
secondary objective is to assess the prognostic value of NIRS in patients who underwent 
coronary angiography for stable angina pectoris or acute coronary syndrome.
Methods
Prior to coronary angiography, a total of 203 patients provided written informed con-
sent for enrollment in the ATHEROREMO-NIRS substudy, in which NIRS imaging was 
performed in a single, non-stenotic segment of a non-culprit coronary artery. The order 
of preference for selection of the non-culprit vessel was: 1. left anterior descending 
artery; 2. right coronary artery artery; 3. left circumflex artery. The FDA-approved NIRS 
system, as used in this study, consists of a 3.2 French rapid exchange catheter, a pullback 
and rotation device and a console (InfraReDx, Burlington, Massachusetts, USA). Image 
acquisition is performed by a motorized catheter pullback at a speed of 0.5mm/s and 
240rpm in a proximal segment of a non-culprit artery, starting distal to a side branch. 
The system performs one thousand chemical measurements per 12.5 mm, in which each 
measurement interrogates one to two mm² of vessel wall from a depth of approximately 
1 mm in the direction from the luminal surface towards the adventitia.1-2 Tissue scatter-
ing and absorption of light in the NIR region result in a wavelength dependent return 
of light to optical detectors that produces a spectrum. Areas of the artery with spectral 
characteristics of lipid core are displayed as an image map (chemogram) of the studied 
vessel.
Yellow regions in the chemogram represent high probability for the presence of lipid 
core-containing coronary plaques (LCP), while red regions represent those with low 
probability. The x-axis of the chemogram indicates the pullback position in millimeters, 
while the y-axis indicates the circumferential position of the measurement from zero to 
360 degrees. The lipid core burden index (LCBI) score is computed on the basis of the 
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chemogram by multiplying the fraction of valid yellow pixels by 1.000. Hence, LCBI is a 
summary measure of the amount of LCP along the entire imaged section of the coronary 
artery on a 0-to-1000 scale. NIRS images are analyzed offline by an independent core 
laboratory (Cardialysis BV, Rotterdam, The Netherlands). Core laboratory personnel are 
blinded to all other baseline patient, biomarker, genetic and outcome data.
Major adverse cardiovascular events, defined as the composite of all-cause mortality, 
non-fatal ACS, stroke and unplanned coronary revascularization during 1-year follow-
up, were adjudicated by a clinical events committee (CEC) on the basis of original source 
data. Members of the CEC were blinded to other patient data, NIRS imaging characteris-
tics and genetic or biomarker information.
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absTRaCT
background: Near-infrared spectroscopy (NIRS) is capable of identifying lipid core-
containing plaques, which can subsequently be quantified as a lipid core burden index 
(LCBI). Currently, no data are available on the long-term prognostic value of NIRS in 
patients with coronary artery disease (CAD).
Objectives: This study sought to determine the long-term prognostic value of intra-
coronary NIRS as assessed in a nonculprit vessel in patients with CAD.
Methods: In this prospective, observational study, NIRS imaging was performed in 
a nonculprit coronary artery in 203 patients referred for angiography due to stable 
angina pectoris (SAP) or acute coronary syndrome (ACS). The primary endpoint was 
the composite of all-cause mortality, nonfatal ACS, stroke, and unplanned coronary 
revascularization.
Results: The 1-year cumulative incidence of the primary endpoint was 10.4%. Cumula-
tive 1-year rates in patients with an LCBI equal to and above the median (43.0) versus 
those with LCBI values below the median were 16.7% versus 4.0% (adjusted hazard ratio: 
4.04; 95% confidence interval: 1.33 to 12.29; p = 0.01). The relation between LCBI and 
the primary endpoint was similar in SAP and ACS patients (p value for heterogeneity 
= 0.14). Similar differences between high and low LCBI were observed in pre-specified 
secondary endpoints.
Conclusion: CAD patients with an LCBI equal to or above the median of 43.0, as assessed 
by NIRS in a nonculprit coronary artery, had a 4-fold risk of adverse cardiovascular events 
during 1-year follow-up. This observation warrants confirmation by larger studies with 
extended follow-up.
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InTRODuCTIOn
Near-infrared spectroscopy (NIRS) is a novel, catheter-based technique capable of iden-
tifying lipid core-containing plaques within the coronary artery wall (1). Currently, no 
data are available on the long-term prognostic value of NIRS in patients with coronary 
artery disease. We therefore performed a prospective study to assess the prognostic 
value of coronary plaque detection, as evaluated with NIRS, on the occurrence of 
major adverse cardiac and cerebrovascular events (MACCE) in the real-world setting of 
everyday clinical practice, in which patients with both stable angina and acute coronary 
syndrome (ACS) present for coronary angiography. Parallel to this objective, it was our 
aim to investigate whether imaging of a single segment without significant luminal nar-
rowing of a nonculprit coronary artery could be used for risk stratification.
MeTHODs
study population and design
The ATHEROREMO-NIRS (The European Collaborative Project on Inflammation and 
Vascular Wall Remodeling in Atherosclerosis–Near-Infrared Spectroscopy) substudy (2) 
was a prospective, single-center, observational study assessing the prognostic value of 
coronary NIRS, performed at the Thoraxcenter, Erasmus Medical Center, Rotterdam, the 
Netherlands. All patients had an indication, as determined by their treating physician 
(as part of routine clinical care), for diagnostic coronary angiography and/or percutane-
ous coronary intervention (PCI) due to either stable angina pectoris or an ACS. Detailed 
inclusion and exclusion criteria are listed in Supplemental table 1.
Subsequent to the standard angiography and PCI (when applicable), NIRS of a 
nonculprit coronary artery was performed. The NIRS target segment of the nonculprit 
coronary artery was required to be at least 40 mm in length and without significant 
luminal narrowing (<50% stenosis) as assessed by online angiography. The order of pref-
erence for selection of the nonculprit vessels was predefined in the study protocol: 1) 
left anterior descending artery; 2) right coronary artery; and 3) left circumflex artery. This 
study was approved by the Medical Ethics Committee of the Erasmus Medical Center, 
and performed in accordance to the Declaration of Helsinki (2008, 6th revision). Written 
informed consent was obtained from all participants.
sample size
The ATHEROREMO-IVUS (The European Collaborative Project on Inflammation and Vascu-
lar Wall Remodeling in Atherosclerosis–Intravascular Ultrasound) study had a pre-speci-
fied sample size of 800 patients, and was designed to explore multiple relations between 
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genetic and serum biomarkers and coronary plaque characteristics (2). It was during the 
course of the ATHEROREMO-IVUS study that intracoronary NIRS became commercially 
available and accessible for our cardiac catheterization lab. The ultimate sample size of 
the ATHEROREMO-NIRS substudy (203 consecutively consenting patients) was not based 
on prior effect estimates but rather on the time point of availability and local institutional 
review board approval (April 2009) of the NIRS technique as ATHEROREMO evolved.
near-infrared spectroscopy
The U.S. Food and Drug Administration–approved NIRS system, as used in this study, 
consists of a 3.2-F rapid exchange catheter, a pullback and rotation device, and a console 
(InfraReDx, Burlington, Massachusetts). Image acquisition was performed by a motor-
ized catheter pullback at a speed of 0.5 mm/s and 240 rpm in a proximal segment of a 
nonculprit artery, starting distal to a side branch. The system performed 1,000 chemical 
measurements per 12.5 mm, in which each measurement interrogated 1 to 2 mm² of 
vessel wall from a depth of approximately 1 mm in the direction from the luminal surface 
toward the adventitia (1). Areas of the artery with spectral characteristics of a lipid core 
were displayed in yellow within the image map, called a chemogram. NIRS images were 
analyzed offline by an independent core laboratory (Cardialysis, Rotterdam, the Nether-
lands). Core laboratory personnel were blinded to all other patient and outcome data.
study endpoints
The pre-specified primary endpoint was the incidence of MACCE, defined as the 
composite of all-cause mortality, nonfatal ACS, stroke, and unplanned coronary revas-
cularization during 1-year follow-up, exclusive of events related to the culprit lesion at 
the index angiography. Secondary endpoints included: 1) the composite of all-cause 
mortality and nonfatal ACS; 2) the composite of all-cause mortality, nonfatal ACS, 
and stroke; and 3) the composite of all-cause mortality, nonfatal ACS, and unplanned 
coronary revascularization during follow-up. Endpoints were adjudicated by a clinical 
events committee on the basis of original source data. Members of the clinical events 
committee were blinded to other patient data and NIRS imaging characteristics. Post-
discharge survival status was obtained from municipal civil registries. Nonfatal ACS 
included ST-segment elevation myocardial infarction (STEMI), non-STEMI, or unstable 
angina pectoris as defined in accordance with the guidelines of the European Society of 
Cardiology (3,4). Stroke was defined according to the guidelines of the European Stroke 
Organization (5). Unplanned coronary revascularization was defined as PCI or coronary 
artery bypass grafting, which initially was not planned after the index angiography and 
enrollment in the study.
Whenever possible, all events were further adjudicated as related or unrelated to 
the coronary site that was treated during the index procedure. In case of follow-up 
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angiography, events were classified either as a definite culprit lesion–related (CLR) event 
or as related to a coronary site that was not treated during the index procedure (non-CLR 
event). In case angiographic information on the endpoint related coronary site was not 
available, the event was classified as indeterminate. The pathophysiological processes 
of definite CLR events (e.g., in-stent restenosis and stent thrombosis) differ from the 
pathophysiology of spontaneous plaque rupture. Therefore, data are presented both 
exclusive of definite CLR events (by default), as well as inclusive of definite CLR events.
statistical analysis
Normally distributed continuous variables are presented as mean SD. Non-normally dis-
tributed continuous variables (e.g., the lipid core burden index [LCBI]) are presented as 
median (interquartile range [IQR]). Categorical variables are presented in numbers and 
percentages. Differences in baseline continuous variables between those with an LCBI 
below versus those equal to and above the median were analyzed by Mann-Whitney 
U tests, categorical variables by Fisher’s exact and Pearson chi-square tests (in case of 
more than 2 categories). Log or square root transformations were applied whenever 
homoscedasticity was a required assumption of the used statistical test. Linear regres-
sion was used to determine predictors of LCBI. No prior data were ever reported on 
LCBI distribution of the nonculprit artery. The statistical analytical plan therefore pre-
specified the median LCBI value as cutoff between “low” and “high” LCBI groups, in case 
LCBI would appear to be non-normally distributed.
Patients lost to follow-up were considered at risk until the date of last contact, at 
which time point they were censored. For patients with more than 1 event, the first was 
counted. Cumulative event rates were estimated according to the Kaplan-Meier method 
and compared by the log-rank test. Backward stepwise regression analyses were used 
to determine the predictors of the primary endpoint. Univariable and multivariable 
Cox proportional hazards regression analyses were applied to evaluate the association 
between LCBI and 1-year outcome. Three models were used throughout the manuscript: 
an unadjusted model, an age- and sex-adjusted model, and a “full model.” Given the 
number of events available, adjustment according to a propensity score was used in or-
der to assure parsimony of the full model (6). Variables for the propensity score of the full 
model were selected on the basis of clinical relevance and significance after backward 
stepwise regression. The propensity scores were derived from predicted probabilities in 
logistic regression models with LCBI above the median as dependent variable (7). The 
propensity score that was entered into the full model accounts for age, sex, hypercho-
lesterolemia, diabetes, hypertension, indication for index coronary angiography (stable 
angina pectoris versus ACS), history of myocardial infarction, peripheral artery disease 
(PAD) or stroke, and prior PCI. Crude and adjusted hazard ratios (HRs) are presented with 
95% confidence intervals (CIs). Discrimination of the full model with respect to event 
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prediction was evaluated with receiver-operating characteristic curves. Heterogeneity 
of the effect of LCBI on MACCE was tested between patients presenting with stable 
angina and those presenting with ACS at the time of enrollment (8). All statistical tests 
were 2-sided with a type I error level of 0.05. Analyses were performed with IBM SPSS 
statistics version 20.0 (IBM Corp., Armonk, New York).
ResulTs
Between April 16, 2009, and January 28, 2011, a total of 203 patients were enrolled prior 
to coronary angiography. Median follow-up was 1 year and follow-up data were com-
plete in 100% of the study sample. Mean age was 63.4 years. Men constituted 72.9% of 
the study sample and 46.8% of the patients presented with an ACS. A PCI was performed 
in 88.2% of the patients during the index coronary angiography.
LCBI values in the nonculprit vessel (median pullback length: 63.1 mm; IQR: 51.0 to 75.0 
mm) ranged from 0 to 571, with a median of 43.0 (IQR: 15.0 to 90.0) (Figure 1). Regression 
analysis demonstrated that men and patients with a history of hypercholesterolemia, 
stroke, or PAD had higher LCBI values. Differences in baseline characteristics between 
patients with an LCBI below the median versus those with an LCBI equal to or above the 
median value are presented in Table 1. LCBI of the nonculprit imaged segment did not 
differ between patients presenting with stable angina (median: 35.0; IQR: 14.0 to 85.5) or 
ACS (median: 47.0; IQR: 16.0 to 90.0; p = 0.24).
figure 1. Intracoronary near-infrared spectroscopy displayed as a chemogram
The figures display the graphical result of coronary wall evaluation with near-infrared spectroscopy in 3 
different patients. Spectral characteristics of lipid core– containing coronary plaques (LCP) are displayed 
along the length (x-axis, in mm) and circumference (y-axis, 0 to 360) of the scanned coronary artery. 
Yellow regions in the chemogram represent high probability for the presence of LCP, while red regions 
represent those with low probability. The lipid core burden index (LCBI) score is computed on the basis of 
the chemogram by multiplying the fraction of valid yellow pixels within the region of interest by 1,000. 
The LCBI for the different patients depicted are 0 (A), 43 (B), and 571 (C) (examples of the lowest, median, 
and highest value in our study, respectively).
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Table 1. baseline characteristics.
all patients
n = 203
lCbI < Median
n= 101
lCbI ≥ Median
n=102
P value
Patient characteristics
Age, years 63.4 ±10.9 64.8 ±10.8 62.1 ±11.0 0.083
Male, n (%) 148 (72.9) 67 (66.3) 81 (79.4) 0.041
Diabetes Mellitus, n (%) 41 (20.2) 18 (17.8) 23 (22.5) 0.485
Hypertension, n (%) 114 (56.2) 56 (55.4) 58 (56.9) 0.888
Hypercholesterolemia, n (%) 115 (56.7) 53 (52.5) 62 (60.8) 0.259
Smoking, n (%) 50 (24.6) 23 (22.8) 27 (26.5) 0.805
Positive family history, n (%) 120 (59.1) 62 (61.4) 58 (57.4) 0.667
Previous MI, n (%) 79 (38.9) 36 (35.6) 43 (42.2) 0.389
Previous PCI, n (%) 78 (38.4) 39 (35.6) 39 (38.2) 1.000
Previous CABG, n (%) 6 (3.0) 4 (4.0) 2 (2.0) 0.445
Previous stroke, n (%) 6 (3.0) 1 (1.0) 5 (4.9) 0.212
Peripheral artery disease, n (%) 11 (5.4) 4 (4.0) 7 (6.9) 0.537
History of renal insufficiency, n (%) 12 (5.9) 5 (5.0) 7 (6.9) 0.767
History of heart failure, n(%) 9 (4.4) 6 (5.9) 3 (2.9) 0.331
Statin at discharge 181 (89.2) 91 (90.1) 90 (88.2) 0.82
Median total cholesterol (IQR) 4.20 (3.60-5.20) 4.20 (3.40-5.00) 4.30 (3.68-5.30) 0.301
Median low-density lipoprotein (IQR) 2.47 (1.95-3.21) 2.44 (1.85-3.14) 2.49 (2.03-3.39) 0.381
Median high-density lipoprotein (IQR) 1.14 (0.92-1.36) 1.15 (0.93-1.37) 1.09 (0.92-1.32) 0.455
Median triglycerides (IQR) 1.26 (0.91-1.80) 1.18 (0.89-1.73) 1.35 (0.95-1.91) 0.152
Procedural characteristics
Indication for coronary angiography 0.261
ACS 95 (46.8) 43 (42.6) 52 (51.0)
Acute MI, n (%) 67 (33.0) 15 (14.9) 13 (12.7)
Unstable angina, n (%) 28 (13.8) 28 (27.7) 39 (38.2)
Stable angina 108 (53.2) 58 (57.4) 50 (49.0)
PCI / stent implantation 179 (88.2) 86 (85.1) 93 (91.2) 0.199
Extent of coronary artery disease 0.045
No significant stenosis, n (%) 16 (7.9) 10 (9.9) 6 (5.9)
1-vessel disease, n (%) 106 (52.2) 58 (57.4) 48 (47.1)
2-vessel disease, n (%) 58 (28.6) 28 (27.7) 30 (29.4)
3-vessel disease, n (%) 23 (11.3) 5 (5.0) 18 (17.6)
NIRS characteristics
Imaged coronary artery 0.299
Left anterior descending, n (%) 74 (36.5) 42 (41.6) 32 (31.4)
Left circumflex, n (%) 70 (34.5) 31 (30.7) 39 (38.2)
Right coronary artery, n (%) 59 (29.1) 28 (27.7) 31 (30.4)
Median LCBI (IQR) 43.0 (15.0-90.0) 15.0 (6.0-27.0) 88.5 (58.8-120.3) <0.001
LCBI, Lipid Core Burden Index; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, 
coronary artery bypass grafting; IQR, interquartile range, ACS, acute coronary syndrome.
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MACCE occurred in 28 patients (13.8%) during 1-year follow-up. Seven events (25% 
of the total number of events) were classified as definite CLR events, hence the primary 
endpoint (which excludes definite CLR events) occurred in 21 patients. The 1-year cumu-
lative incidence of the primary endpoint was 10.4%. The frequencies of all first events 
are described in Table 2. Unplanned coronary revascularization (5.9%; all events were 
revascularized by PCI) occurred most frequently, followed by all-cause mortality (3.4%), 
nonfatal ACS (3.0%), and stroke (1.5%). Only LCBI, a history of stroke, and PAD were as-
sociated with the primary endpoint.
The 1-year cumulative rate of the primary endpoint was 16.7% for patients with an 
LCBI equal to and above the median versus 4.0% for those with LCBI values below the 
median (log-rank p = 0.003) (Figure 2) (unadjusted HR: 4.56; 95% CI: 1.53 to 13.55). The 
secondary endpoint of all-cause mortality and nonfatal ACS occurred in 8.8% versus 
1.0% in those with high versus low LCBI (p = 0.010) (Figure 2). Cumulative event rates 
for other secondary endpoints – also exclusive of definite CLR events – also are shown 
in Figure 2.
The association between LCBI equal to and above the median value and the primary 
endpoint remained significant after adjustment for age and sex (adjusted HR: 5.16; 95% 
CI: 1.73 to 15.42) and after adjustment for the full model (adjusted HR: 4.04; 95% CI: 
1.33 to 12.29), as described in Table 3. LCBI values equal to and above the median were 
significantly associated with an increased risk of all secondary endpoints with point 
estimates of the (full model) adjusted HRs ranging from 3.56 to 10.59 (Table 3). With 
Table 2. Clinical event distribution during one-year follow-up.
all-cause 
mortality
non-fatal 
aCs
stroke unplanned
coronary 
revascularization
all events
(incl. ClR 
events)
all events 
(excl. ClR 
events)
Primary endpoint, n (%)
All-cause mortality,
non-fatal ACS, stroke 
and unplanned coronary 
revascularization
7 (3.4) 6 (3.0) 3 (1.5) 12 (5.9) 28 (13.8) 21 (10.3)
Secondary endpoint, n (%)
All-cause mortality
and non-fatal ACS
7 (3.4) 6 (3.0) n.a. n.a. 13 (6.4) 10 (4.9)
All-cause mortality,
non-fatal ACS and stroke
7 (3.4) 6 (3.0) 3 (1.5) n.a. 16 (7.8) 13 (6.4)
All-cause mortality,
non-fatal ACS and unplanned 
coronary revascularization
7 (3.4) 6 (3.0) n.a. 12 (5.9) 25 (12.3) 18 (8.9)
Percentages are given for the cumulative incidence. ACS, acute coronary syndrome; CLR events, culprit 
lesion-related events.
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respect to prediction of the primary endpoint, the full model resulted in an area under 
the receiver-operating characteristic curve of 0.83 (95% CI: 0.75 to 0.92).
There was a statistically significant difference in mortality between those below and 
above the median in univariate analysis (1.0% vs. 6.9%; log-rank p = 0.032), but not after 
adjusting for the full model (adjusted HR: 6.2; 95% CI: 0.73 to 52.0; p = 0.10).
The median LCBI in patients with stable coronary artery disease was 35.0 (IQR: 14.0 
to 85.5) and did not differ significantly from the median of 47.0 (IQR: 16.0 to 90.0) in 
patients with ACS at index angiography (p = 0.44). We found no heterogeneity of the 
effect of LCBI on the primary endpoint between patients presenting with stable angina 
versus ACS patients at the time of enrollment (p value for heterogeneity = 0.14).
figure 2. Time-to-event curves for the primary and pre-specified secondary composite endpoints 
exclusive of definite culprit lesion-related events
A 4-fold increase in major adverse cardiac and cerebrovascular events during 1-year follow-up was ob-
served in patients with a lipid core burden index (LCBI) above the median, as assessed by near-infrared 
spectroscopy of a nonstenotic nonculprit coronary artery segment (16.7% vs. 4.0% event rate [adjusted 
hazard ratio: 4.04; 95% confidence interval: 1.33 to 12.29; p = 0.01]). ACS = acute coronary syndrome; PCI 
= percutaneous coronary intervention.
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analyses inclusive of definite culprit lesion-related events
Unplanned PCI was required for 4 culprit lesions that had been treated during the index 
catheterization; in 3 other patients, initially treated culprit lesions led to unstable angina, 
non-STEMI, and death, respectively.
When definite culprit lesion-related events were also taken into account, an overall 
1-year cumulative rate of the primary endpoint was observed in 19.6% of the patients 
with an LCBI equal to and above the median versus 7.9% for those with LCBI values 
below the median (p = 0.015) (Supplemental Figure 1).
The secondary endpoint of all-cause mortality and nonfatal ACS occurred in 9.8% 
versus 3.0% in those with high versus low LCBI, respectively (p = 0.010). Similar results 
were observed for the other 2 secondary endpoints.
DIsCussIOn
We observed that high LCBI levels were associated with a 4-fold increase in MAC(C)E dur-
ing 1-year follow-up of a broad population of patients referred for coronary  angiography. 
Table 3. lCbI levels equal to and above the median value and major adverse cardiac events (exclu-
sive of definite culprit lesion-related events).
Primary endpoint
unadjusted model P 
value
age and gender 
adjusted model P 
value
full model P 
valueHazard ratio (95% CI) Hazard ratio (95% CI) Hazard ratio (95% CI)
All-cause mortality,
non-fatal ACS, 
stroke and 
unplanned coronary 
revascularization
4.56 (1.53-13.55) 0.006 5.16 (1.73-15.42) 0.003 4.04 (1.33-12.29) 0.014
Secondary endpoints
All-cause mortality
and non-fatal ACS
9.36 (1.19-73.87) 0.034 10.14 (1.27-80.67) 0.029 8.91 (1.10-72.33) 0.041
All-cause mortality,
non-fatal ACS and 
stroke
12.67 (1.65-97.46) 0.015 14.58 (1.89-112.71) 0.010 10.59 (1.35-83.28) 0.025
All-cause mortality,
non-fatal ACS and 
unplanned coronary 
revascularization
3.69 (1.21-11.20) 0.021 3.96 (1.29-12.11) 0.016 3.56 (1.14-11.20) 0.029
* Hazard ratios are given for patients with lipid core burden index (LCBI) levels equal to and above the 
median (n=102), versus those with LCBI below the median (n=101). Variables in the propensity score of 
the full model were age, gender, hypercholesterolemia, diabetes, hypertension, history of myocardial 
infarction, peripheral artery disease and stroke, indication for index coronary angiography (stable angina 
versus ACS) and prior PCI. ACS, acute coronary syndrome.
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This association between LCBI and adverse outcome was found by NIRS imaging of a 
single, nonstenotic segment of a nonculprit coronary artery.
Based on diffuse reflectance spectroscopy, NIRS provides a positive and specific chemi-
cal measure of cholesterol within the coronary vessel wall, as cholesterol has prominent 
molecular features in the near-infrared region that can be distinguished from other 
tissue constituents such as collagen (9). Its ability to recognize cholesterol monohydrate 
and cholesterol ester – both of which are abundant in necrotic cores and therefore key 
components of plaque vulnerability – appears to be superior to that of intravascular 
ultrasound (IVUS) – or optical coherence tomography-based techniques (10).
Against this background, the recently published, randomized YELLOW (Reduction in 
Yellow Plaque by Aggressive Lipid-Lowering Therapy) trial is of particular interest, as 
it is the first study to investigate whether a pharmacologic intervention may reduce 
lipid core plaque as assessed by intracoronary NIRS (11). High-dose statin therapy (vs. 
standard-of-care statin therapy) during 6 to 8 weeks in 87 patients resulted in a signifi-
cant reduction of LCBI as measured at the site of untreated obstructive coronary lesions 
with a fractional flow reserve below 0.80 (11). It is important to emphasize, however, that 
the association between LCBI and MAC(C)E in our study was found through imaging of a 
segment of a nonculprit coronary artery without significant stenosis. Consequently, the 
median LCBI of 43.0 (IQR: 15.0 to 90.0) in our study is lower than the median LCBI values 
of 95.4 (IQR: 29.6 to 174.6) and 132.4 (IQR: 99.0 to 201.2), for the standard-of-care and 
high-dose statin therapy groups, respectively, as measured in the obstructive lesions in 
the YELLOW trial (11). The prognostic value of NIRS imaging of such obstructive lesions 
has not yet been investigated for risk prediction of adverse cardiovascular events during 
long-term follow-up.
The currently ongoing IBIS-3 (Integrated Biomarker and Imaging Study-3) study is 
designed to assess the efficacy of high-dose rosuvastatin on the reduction of the ne-
crotic core and LCBI in a nonculprit coronary segment of patients who have undergone 
diagnostic angiography or PCI (12).
Our data were prospectively obtained and the conclusions seem applicable to a 
broad range of patients, including those with stable angina or ACS at the time of index 
angiography. Of great importance is that NIRS evaluation was performed in an inde-
pendent, dedicated core lab with personnel blinded for patient and outcome data. An 
independent and blinded clinical event committee adjudicated the events. Statistics 
were performed by authors who were not, in any way, involved with the study until the 
time of transfer of the finalized database.
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study limitations
There are several limitations to our findings. The small sample size and corresponding 
number of events are a limitation, although this study does represent the largest cohort 
of patients with NIRS analysis and long-term follow-up so far.
Furthermore, the ATHEROREMO-NIRS substudy was a single-center study by virtue 
of design. External validation, preferably in a larger sample size, is a fundamental pre-
requisite before any of our conclusions may be considered for possible future clinical 
implications.
Our cutoff value was based on the median LCBI value, similarly to a recent post hoc 
analysis of the SATURN (Study of Coronary Atheroma by Intravascular Ultrasound: Effect 
of Rosuvastatin vs. Atorvastatin) trial, which evaluated the median value of IVUS-derived 
percent atheroma volume as cutoff for predicting future MAC(C)E (13). We do not pro-
pose 43 as an absolute cutoff value. Larger sample sizes are required to determine and 
validate the sensitivity and specificity of NIRS imaging at different cutoff LCBI values.
Accordingly, future research will have to demonstrate whether the strength of NIRS is 
determined by its capability to detect or to rule out an increased risk for MAC(C)E during 
long-term follow-up.
Previous studies with IVUS have repeatedly demonstrated that IVUS-derived plaque 
volume in comparable nonstenotic, nonculprit coronary segments was associated 
with incident MAC(C)E during longterm follow-up (13,14). Similarly, the ATHEROREMO 
protocol proposed NIRS imaging in at least 4 cm (median pullback length: 63.1 mm) of 
only 1 proximal segment of a nonculprit coronary artery. Nevertheless, it should be em-
phasized that our findings relate to an increased risk of MAC(C)E throughout the entire 
coronary tree and not necessarily at the imaged segment or a lesion-specific risk. We did 
not aim to identify all “vulnerable” and potentially treatable plaques. Our study does not 
allow conclusions on whether the events during follow-up originated from regions of 
relatively high or low LCBI or whether more proximal cholesterol accumulation is associ-
ated with an increased event rate. Three-vessel NIRS imaging at index angiography and 
follow-up coronary angiography (or autopsy) at the moment of an endpoint are ideally 
required for such conclusions.
From an etiologic point of view, it is important to emphasize that the specificity of in 
vivo detection of potentially vulnerable plaques and knowledge about their temporal 
stability generally is limited given the current state of the art (15). As we did not repeat 
NIRS imaging of the same segment at a later time point, no conclusions can be drawn on 
temporal plaque stability and dynamics. Rather than an etiologic exploration to identify 
all coronary plaques and assess their temporal stability, our analyses should be seen 
as an evaluation of the prognostic value of NIRS imaging used as a global marker of 
intracoronary disease burden, which is not seen in the form of luminal narrowing on 
angiography.
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The majority of the endpoints in this study were due to unplanned revascularization. 
Future studies with a higher incidence of mortality and nonfatal ACS are required to 
properly assess the prognostic value of NIRS for these events.
Formal testing demonstrated that there was no heterogeneity of the ability of LCBI to 
predict outcome between the stable angina and ACS groups, although the interaction 
test may have been underpowered.
Intracoronary NIRS became commercially available during the course of ATHERO-
REMO. Thus, understandably, we were not able to enroll all ATHEROREMO patients in 
this NIRS substudy. The characteristics, treatment, and outcomes of the substudy cohort 
and the remaining ATHEROREMO patients were similar. Hence, differential selection is 
unlikely, although it cannot be excluded with absolute certainty.
A limitation of the NIRS technique is that the chemograms only provide plaque infor-
mation in a 2-dimensional manner and do not provide information on the depth of the 
cholesterol accumulation within the coronary artery wall. IVUS may therefore be used for 
additional evaluation of luminal stenosis, vessel remodeling, and plaque architecture.
COnClusIOns
This prospective observational study suggests that coronary LCBI, as assessed by NIRS 
in a nonculprit coronary artery, is associated with MAC(C)E during 1-year follow-up in 
patients referred for coronary angiography. However, our results are hypothesis gener-
ating and need confirmation by larger trials that overcome the limitations of our study.
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supplemental Table 1. Inclusion and exclusion criteria
Inclusion criteria:
8. Aged 21 years or older.
9.  Presenting with stable angina pectoris (CCS angina class 1, 2, 3 or 4), unstable angina pectoris (Braunwald 
class 1-3, B-C), documented silent ischemia or acute myocardial infarction (STEMI and NSTEMI).
10. Eligible for coronary revascularization in the native coronary artery/arteries.
11. Willing and able to comply with the specified follow-up evaluation.
12. Willing to sign informed consent.
13.  Presence of a flow-limiting stenosis (diameter stenosis ≥50% by QCA or visual estimate) that is held 
responsible for angina pectoris or acute coronary syndrome
14. The study vessel has not undergone percutaneous coronary intervention in the last 8 months.
Exclusion criteria:
17. Angina caused by a non-cardiac illness (Braunwald class IA, IIA, IIIA).
18. Pregnant women or women of childbearing potential who do not use adequate contraception.
19.  Known allergies to aspirin, clopidogrel, ticlopdine, heparin, stainless steel, copper or a sensitivity to contrast 
media which cannot be adequately pre-medicated.
20.  Previous participation in this study or participation in another study with any investigational drug or device 
within the past 30 days (study participation ends after completion of the final follow-up).
21. Life expectancy of less than one year or factors making clinical and/or angiographic follow-up difficult.
22. Planned or being status post coronary bypass surgery.
23. Planned major non-cardiac surgery.
24. Impaired renal function (creatinine>2 mg/dl or ≥150 μmol/l).
25. History of bleeding diathesis or coagulopathy.
26. History of disabling stroke within the past year.
Exclusion criteria for intravascular ultrasound and near-infrared spectroscopy:
27. Three-vessel coronary artery disease or left main disease with ≥50% stenosis.
28. Minimal lumen diameter <2mm in the segments to be analyzed within the study vessel.
29. Diameter stenosis >70% or total occlusion of the study vessel.
30.  In case the study-vessel has been stented previously (>8 months ago), more than 1/3 proximal of the study 
vessel (at least 40mm in length) should be available for examination (i.e. outside the length of the stent plus 
5mm proximal to the stent).
31. Poor left ventricular function as assessed by echocardiography or by angiography.
32. Moderate or severe tortuosity of the study segment (i.e. 2 bends >75° or one bend > 90°).
17. Known tendency for coronary vasospasm.
CCS: Canadian Cardiovascular Society; NSTEMI: non-ST-segment elevation myocardial infarction; STEMI: 
ST-segment elevation myocardial infarction; QCA: quantitative coronary angiography.
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supplemental figure  1. Time-to-event curves for the composite of all-cause mortality, stroke, 
non-fatal aCs or unplanned PCI, including definite culprit lesion-related events, during one-year 
follow-up of 203 patients.
The cumulative event rate applies to the analysis in which all 28 events, including the definite culprit 
lesion-related events, were assessed. LCBI = Lipid Core Burden Index; ACS = acute coronary syndrome; PCI 
= percutaneous coronary intervention; CLR events = culprit lesion-related events.
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absTRaCT
aims: Near-infrared spectroscopy (NIRS) is able to quantify cholesterol within coronary 
arteries by the lipid core burden index (LCBI). We studied the prognostic value of NIRS-
derived LCBI in patients with coronary artery disease (CAD) for adverse cardiac outcome 
during long-term follow-up.
Methods and results: During 2009-2013, NIRS was performed in a non-culprit artery of 
275 patients undergoing coronary angiography for acute coronary syndrome (ACS) or 
stable angina. LCBI was quantified by an independent corelab for the region of interest 
(LCBIROI) and the 4 and 10 mm long segment with the maximum LCBI (MaxLCBI4mm and 
MaxLCBI10mm). The primary endpoint was major adverse cardiac events (MACE), defined 
as the composite of all-cause death, non-fatal ACS, or unplanned revascularization. Haz-
ard ratios (HR) were adjusted for age, gender, clinical risk factors and segment plaque 
burden based on intravascular ultrasound. During a median follow-up of 4.1 years, 79 
patients (28.7%) had MACE. There was a statistically significant and independent con-
tinuous relationship between higher MaxLCBI4mm values and a higher risk of MACE. Each 
100 units increase of MaxLCBI4mm was associated with a 19% increase in MACE (HR 1.19, 
95%CI:1.07-1.32, p=0.001). Continuous MaxLCBI4mm remained independently associated 
with MACE after exclusion of target lesion-related events (HR 1.21, 95CI%:1.08-1.35), as 
well as after exclusion of adverse events related to the NIRS-imaged coronary segment 
(HR 1.19, 95%CI:1.06-1.34). Results for MaxLCBI10mm were comparable.
Conclusion: NIRS-derived LCBI is associated with adverse cardiac outcome in CAD 
patients during long-term follow-up independent of clinical risk factors and plaque 
burden.
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InTRODuCTIOn
Coronary artery disease (CAD) is projected to remain the leading cause of mortality and 
morbidity worldwide. Patients with a history of CAD are at higher risk of subsequent 
adverse cardiovascular events, such as an acute coronary syndrome (ACS). In approxi-
mately 75% of all cases, an ACS is caused by rupture or fissure of a vulnerable, lipid rich 
core-containing plaque in the coronary arteries.1,2 While coronary angiography (CAG) is 
unable to identify such lipid rich core-containing plaques in the coronary artery wall,3 
they can be identified by near-infrared spectroscopy (NIRS), a catheter-based intra-
coronary imaging technique based on diffuse reflectance spectroscopy.4-6 Therefore, 
NIRS may be useful in identifying patients at increased risk of adverse cardiovascular 
outcome.5-7
The European Collaborative Project on Inflammation and Vascular Wall Remodeling in 
Atherosclerosis (ATHEROREMO) and the Integrated Biomarker Imaging Study 3(IBIS-3) 
studies were designed to investigate phenotypes and vulnerability of coronary ath-
erosclerosis as determined by intravascular ultrasound (IVUS) and NIRS.8,9 NIRS became 
available in our cardiac catheterization laboratory during the course of both the ATH-
EROREMO and IBIS-3 study.10 In the current study, we performed long-term follow-up of 
both the ATHEROREMO-NIRS and IBIS-3-NIRS substudies, with the aim to investigate the 
long-term prognostic value of lipid rich core-containing plaques as assessed by NIRS in 
patients with CAD undergoing CAG.
MeTHODs
study design and population
The current investigation combines the populations of the ATHEROREMO-NIRS and the 
IBIS-3-NIRS substudies. Both of these studies were conducted at the Erasmus Medical 
Center, Rotterdam, The Netherlands, and had similar enrollment criteria and baseline 
study procedures. The study designs and methods of ATHEROREMO-NIRS and IBIS-3-
NIRS have been described in detail elsewhere.8-10 Briefly, patients undergoing diagnostic 
CAG or PCI for ACS or stable angina pectoris (SAP) underwent baseline invasive imag-
ing by NIRS and IVUS, and were subsequently followed-up on adverse cardiovascular 
events.11,12 The obtained images were analyzed off-line, and findings were not used for 
patient care. In ATHEROREMO-NIRS, patient management was left to the discretion of 
the treating physician. In IBIS-3, as per protocol, high-dose rosuvastatin was prescribed 
during the first year after the index event. ATHEROREMO-NIRS enrolled 203 patients 
between April 2009 and January 2011, and IBIS-3-NIRS enrolled 131 patients between 
January 2010 and June 2013. Since 48 patients participated in both studies, a total of 
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286 patients were available. Of these patients, 275 patients had baseline data available 
on both NIRS and IVUS, and were therefore included in the current analysis.
The medical ethics committee of the Erasmus MC approved both the ATHEROREMO-
NIRS and IBIS-3-NIRS substudy. These two studies were performed in accordance with 
the declaration of Helsinki. All patients provided written informed consent for their par-
ticipation and for compliance with the study protocols, including long-term follow-up. 
The ATHEROREMO study is registered in ClinicalTrials.gov, number NCT01789411, and 
the IBIS-3 study is registered in The Netherlands trial register, number NTR2872.
near-infrared spectroscopy
Subsequent to the standard index CAG, invasive imaging with IVUS and NIRS was 
performed in a non-culprit coronary artery. The NIRS target segment in this non-culprit 
coronary artery was required to be at least 40 mm in length and without significant 
luminal narrowing (<50% stenosis) as assessed by on-line angiography. The study pro-
tocol predefined the order of preference for the selection of the non-culprit vessel.8,9
The NIRS system included a 3.2-F rapid exchange catheter, a console and a rotation 
and pullback device (InfraRedx, Burlington, Massachusetts). Images were acquired by 
the NIRS catheter that was automatically pulled back at a speed of 0.5 mm/s and 240 
rotations per minute in a proximal segment of the non-culprit artery, as described in 
detail previously.5,10 The fraction of yellow pixels obtained from the chemogram, an im-
age map derived from the NIRS measurements, was multiplied by 1000 to compute the 
Lipid Core Burden Index (LCBI). Therefore, the 4 mm long segment with the maximum 
LCBI (MaxLCBI4mm) ranged from 0 to 1000 representing the percentage of lipid core in 
the investigated segment.6 Moreover, the 10 mm long segment with the maximum LCBI 
(MaxLCBI10mm) was quantified, and the same was done for the region of interest (LCBIROI) 
of the investigated segment. NIRS data were analyzed off-line by an independent corelab 
(Cardialysis, Rotterdam, The Netherlands) blinded to all other patient and outcome data.
Intravascular ultrasound
After the standard index CAG, the non-culprit segment was first examined by IVUS. IVUS 
images were acquired by the Volcano Eagle Eye Gold IVUS catheter (20 MHz).8 Analyses 
of the IVUS gray-scale data were performed using the pcVH 2.1 and qVH software (Vol-
cano Corp., San Diego, CA, USA). Segmental plaque burden was defined as the plaque 
and media cross-sectional area divided by the external elastic membrane cross-sectional 
area.8 IVUS gray-scale data were also analyzed off-line.
study endpoints
The primary endpoint consisted of major adverse cardiac events (MACE), defined as the 
composite of all-cause death, non-fatal ACS, or unplanned coronary revascularization 
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during long-term follow-up. A secondary analysis was performed on the composite 
endpoint of cardiac death, non-fatal ACS, or unplanned revascularization. Furthermore, 
additional analyses were performed on these two endpoints after exclusion of definite 
target lesion-related events, as well as after exclusion of adverse events related to the 
NIRS-imaged coronary segment.
Follow-up was conducted in January 2015. Vital status of the patients was obtained 
from municipal civil registries. Follow-up questionnaires were subsequently sent to 
all living patients as a first screening method for identifying possible adverse events. 
Thereafter, hospital discharge letters were obtained if any hospitalization or possible 
event was reported. In patients who did not return the questionnaire, the local hospital 
records were investigated for possible events. Cause of death was obtained from hospi-
tal records, autopsy reports or general practitioners notes.
MACE were adjudicated based on original source data by a clinical events committee 
blinded to patient characteristics and NIRS and IVUS data. In accordance with the guide-
lines of the European Society of Cardiology, non-fatal ACS was defined as the clinical 
diagnosis of ST-segment Elevation Myocardial Infarction (STEMI), non-STEMI (NSTEMI), 
or unstable angina pectoris.13,14 Unplanned coronary revascularization was defined as 
any PCI or coronary artery bypass grafting (CABG) that was not planned after the index 
angiography and enrollment in the study. Cardiac death was defined as any death due 
to proximate cardiac cause, unwitnessed death or death of unknown cause.
Furthermore, the clinical event committee adjudicated whether the cardiac events 
were related to the target lesion that was treated during the index procedure, as well 
as whether the events were related to the coronary artery segment that was imaged at 
baseline.
statistical analysis
Normality of continuous variables was assessed by the Kolmogorov-Smirnov test. 
Normally-distributed continuous variables were reported as means and standard de-
viations. Non-normally-distributed continuous variables were reported as medians and 
interquartile ranges (IQR), categorical variables as numbers and percentages.
Patients that were lost to follow-up were censored at the date of last contact. The first 
event was considered in case a patient had multiple events. The Kaplan-Meier method 
was used to estimate cumulative event rate. All subsequent analyses were performed for 
each of the three LCBI variables. The log-rank test was used to compare cumulative event 
rates between quartiles of the LCBI variables and pairwise comparisons were performed 
when the overall log-rank test showed statistical significant differences.
The association between LCBI and the long-term incidence of study endpoints was 
analyzed by Cox proportional hazard regression analyses. Furthermore, to evaluate 
whether the association between LCBI and log(hazard) was linear enough to fit as a single 
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degree of freedom regression term, a spline was inserted in each full Cox proportional 
hazard regression model and visual inspection of the estimated relation was performed. 
No evidence was found for non-linearity with respect to MaxLCBI4mm, whereas findings 
with respect to MaxLCBI10mm and LCBIROI were borderline significant. Visual inspection 
of the estimated relation showed that categorization of LCBI in quartiles resulted in an 
acceptable piece-wise linearity for all endpoints. For Cox regression analyses, consecu-
tively, unadjusted models and multivariable models containing clinical characteristics 
and IVUS derived plaque burden were used. Potential confounders were chosen based 
on existing literature. The multivariable models contained the following potential con-
founders: age, gender, indication for index CAG (ACS or SAP), diabetes mellitus, history 
of cerebrovascular accident, history of peripheral artery disease and IVUS derived seg-
mental plaque burden. Hazard ratios (HRs) were reported with 95% confidence intervals 
(CIs). Although this study did not aim to develop a prognostic model per se, a C-index 
was reported for each multivariable model to provide some indication of the prognostic 
value of continuous LCBI in addition to clinical risk factors and plaque burden.
All statistical tests were two-tailed and p-values <0.05 were considered statistically 
significant. Statistical analyses were performed using IBM SPSS statistics version 21.0 
(IBM Corp., Armonk, New York).
ResulTs
baseline characteristics
Mean age of the patients was 62.5 years and 76.7% were men (Table 1). A total of 42.5% 
of the patients presented with an ACS. MaxLCBI4mm values in the non-culprit artery 
ranged from 0 to 930, with a median of 227.0 (IQR:83.0-360.0). The LCBIROI values ranged 
from 0 to 571, with a median of 40.0 (IQR:13.0-79.0). PCI was performed in 88.4% of the 
patients during the index procedure.
Incidence of primary endpoint
Median follow-up time was 4.1(IQR:3.2-4.5) years. The follow-up questionnaire assessing 
the occurrence of MACE was completed by 90% of the patients. The primary composite 
endpoint of all-cause death, non-fatal ACS or unplanned revascularization occurred in 
79 patients (28.7%). All-cause death occurred in 20 patients, non-fatal ACS in 40 patients 
and unplanned revascularization in 62 patients. The composite endpoint of cardiac 
death, non-fatal ACS or unplanned revascularization occurred in 70 patients (25.5%).
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Table 1. baseline characteristics
N=275 patients
Clinical characteristics
Age, years 62.5 ± 10.7
Men, n(%) 211 (76.7)
Diabetes, n(%) 59 (21.5)
Hypertension, n(%) 165 (60.0)
Dyslipidemia, n(%) 158 (57.5)
Current smoking, n(%) 69 (25.1)
Previous MI, n(%) 94 (34.2)
Previous PCI, n(%) 98 (35.6)
Previous CABG, n(%) 6 (2.2)
Previous CVA, n(%) 16 (5.8)
History of PAD, n(%) 15 (5.5)
History of renal impairment, n(%) 14 (5.1)
Laboratory measurements, (mmol/l)
Median total cholesterol (IQR) 4.10 [3.60-5.00]
Median low-density lipoprotein (IQR) 2.42 [1.93-3.13]
Median high-density lipoprotein (IQR) 1.14 [0.92-1.35]
Procedural characteristics
Indication for coronary angiography
ACS, n(%) 117 (42.5)
Acute MI, n(%) 31 (11.3)
Unstable angina, n(%) 86 (31.3)
Stable angina, n(%) 158 (57.5)
PCI performed in non-imaged vessel, n(%) 243 (88.4)
Coronary artery disease
No significant stenosis, n(%) 18 (6.5)
1-vessel disease, n(%) 144 (52.4)
2-vessel disease, n(%) 87 (31.6)
3-vessel disease, n(%) 26 (9.5)
NIRS characteristics
Imaged coronary artery
Left anterior descending, n(%) 96 (34.9)
Left circumflex, n(%) 97 (35.3)
Right coronary artery, n(%) 82 (29.8)
Median imaged segment length, mm (IQR) 56.4 [45.3-67.2]
Median LCBIROI (IQR) 40.0 [13.0-79.0]
Median MaxLCBI10mm (IQR) 129.0 [48.0-234.0]
Median MaxLCBI4mm (IQR) 227.0 [83.0-360.0]
IVUS derived Segment Plaque Burden (%) 39.3 ± 11.0
MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary bypass grafting; CVA, 
cerebrovascular accident; PAD, peripheral artery disease; ACS, acute coronary syndrome; NIRS, near-infra-
red spectroscopy; LCBI, lipid core burden index; IQR, interquartile range; IVUS, intravascular ultrasound.
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association between lCbI and MaCe
The cumulative distribution of the MaxLCBI4mm values in patients with and without MACE 
shows that patients with MACE had higher MaxLCBI4mm values as compared to those 
without MACE (Figure 1).
Quartiles of MaxLCBI4mm, MaxLCBI10mm and LCBIROI, and cumulative MACE incidence 
were pairwise compared. Pairwise comparisons consequently showed that patients in 
the third and fourth quartiles had significantly higher event rates compared to those in 
the first quartile (Figure 2). After adjustment for clinical characteristics and IVUS-derived 
plaque burden in the multivariable model, the third and fourth quartile of MaxLCBI4mm 
remained significantly associated with MACE (HR 3.09 (95%CI: 1.41-6.74) and HR 3.58 
(95CI%: 1.67-7.70), respectively). Results for the LCBIROI and MaxLCBI10mm were compa-
rable (Table 2).
There was a statistically significant continuous relationship between higher Max-
LCBI4mm values and a higher risk of MACE (Table 3). After multivariable adjustment, 
MaxLCBI4mm remained significantly associated with MACE (HR 1.19 per 100 units increase 
in LCBI, 95%CI: 1.07-1.32), as well as with MACE after exclusion of target lesion-related 
events (HR 1.21 (95CI%: 1.08-1.35)). Similarly, MaxLCBI4mm remained also independently 
associated with MACE after exclusion of adverse events related to the NIRS-imaged 
coronary segment (HR 1.19 (95%CI:1.06-1.34)). Cox regression analysis with follow-up 
duration as time-dependent variable demonstrated that continuous MaxLCBI4mm also 
predicted MACE beyond 1-year of follow-up [HR (95%CI) 1.15 (1.00-1.33) versus 1.23 
(1.07-1.42) for the first year].
The C-indices indicate that NIRS-derived LCBI has prognostic value in addition to 
clinical risk factors and IVUS-derived plaque burden, with C-indices of the models with 
only covariates ranging from 0.607 to 0.617 and C-indices of the multivariable models 
including continuous LCBI ranging from 0.674 to 0.704 (Table 3).
association between lCbI and the composite endpoint of cardiac death, non-
fatal aCs or unplanned revascularization
The cumulative incidence of the composite of cardiac death, non-fatal ACS or unplanned 
revascularization was higher in patients in the second (25.0%), third (31.3%) and fourth 
(35.7%) quartile of MaxLCBI4mm as compared to those in the first (10.3%) quartile of Max-
LCBI4mm (log-rank pairwise comparisons p=0.031, p=0.002 and p=<0.001, respectively, 
Figure 3). The second, third and fourth quartiles of MaxLCBI4mm were significantly associ-
ated with the composite of cardiac death, non-fatal ACS or unplanned revascularization 
after adjustment for clinical characteristics and IVUS-derived plaque burden in the mul-
tivariable model (Table 4). A similar significant association was observed for MaxLCBI4mm 
as a continuous variable (Table 5). This association persisted after exclusion of target 
lesion-related events and after exclusion of events related to the imaged segment (Table 
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with MACE [HR 3.09 (95% CI: 1.41–6.74) and HR 3.58 (95% CI:
1.67–7.70), respectively]. Results for the LCBIROI and MaxLCBI10mm
were comparable (Table 2).
There was a statistically significant continuous relationship between
higher MaxLCBI4mm values and a higher risk of MACE (Table 3). After
multivariable adjustment, MaxLCBI4mm remained significantly associ-
ated with MACE (HR 1.19 per 100 units increase in LCBI, 95% CI:
1.07–1.32), as well as with MACE after exclusion of target lesion-
related events [HR 1.21 (95% CI: 1.08–1.35)]. Similarly, MaxLCBI4mm
remained also independently associated with MACE after exclusion of
adverse events related to the NIRS-imaged coronary segment [HR
1.19 (95% CI: 1.06–1.34)]. Cox regression analysis with follow-up
duration as time-dependent variable demonstrated that continuous
MaxLCBI4mm also predicted MACE beyond 1-year of follow-up [HR
(95% CI) 1.15 (1.00–1.33) vs. 1.23 (1.07–1.42) for the first year].
The C-indices indicate that NIRS-derived LCBI has prognostic
value in addition to clinical risk factors and IVUS-derived plaque bur-
den, with C-indices of the models with only covariates ranging from
0.607 to 0.617 and C-indices of the multivariable models including
continuous LCBI ranging from 0.674 to 0.704 (Table 3).
Association between LCBI and the
composite endpoint of cardiac death,
non-fatal ACS or unplanned
revascularization
The cumulative incidence of the composite of cardiac death, non-fatal
ACS or unplanned revascularization was higher in patients in the sec-
ond (25.0%), third (31.3%), and fourth (35.7%) quartile of
MaxLCBI4mm as compared with those in the first (10.3%) quartile of
MaxLCBI4mm (log-rank pairwise comparisons P=0.031, P=0.002,
and P=<0.001, respectively, Figure 3). The second, third, and fourth
quartiles of MaxLCBI4mm were significantly associated with the
composite of cardiac death, non-fatal ACS, or unplanned
revascularization after adjustment for clinical characteristics and
IVUS-derived plaque burden in the multivariable model (Table 4). A
similar significant association was observed for MaxLCBI4mm as a con-
tinuous variable (Table 5). This association persisted after exclusion
of target lesion-related events and after exclusion of events related
to the imaged segment (Table 5). In general, the associations
observed between MaxLCBI4mm, MaxLCBI10mm, and LCBIROI and the
occurrence of adverse events were stronger and more significant
when the composite endpoint included cardiac death instead of all-
cause mortality (Tables 2–5).
Discussion
This study investigated the association between lipid rich core-
containing plaques as identified by NIRS in a non-culprit coronary
artery and the occurrence of adverse cardiac events during long-
term follow-up in patients undergoing CAG. This study showed that
LCBI values were significantly and independently associated with the
incidence of adverse cardiac outcome in patients with CAD over
4 years of follow-up. To the best of our knowledge, this is the first
study to investigate the association between LCBI in a non-culprit
coronary artery and adverse cardiac outcome over 4 years of follow-
up, which represents the longest follow-up period so far reported.
Studies on the relationship between LCBI and (long-term) follow-
up are scarce. Recently, the COLOR study demonstrated that the
MaxLCBI4mm obtained prior to stenting in a culprit coronary segment
was not associated with culprit-related MACE during 2 years of fol-
low-up.15 Our study provides new evidence on the prognostic value
of NIRS, since we demonstrated that NIRS is predictive of MACE on
the long-term by identifying high-risk lipid rich core-containing pla-
ques in a non-culprit artery. The upcoming Lipid Rich Plaque (LRP)
and PROSPECT-2 studies are also investigating the ability of NIRS-
derived LCBI in non-culprit coronary arteries to predict adverse car-
diovascular outcome during 2-year follow-up.
Figure 1 Cumulative distribution of the MaxLCBI4mm of patients
with and without MACE (P= 0.001, Mann–Whitney U test).
MaxLCBI4mm, the 4mm long segment with the maximum LCBI.
MACE, major adverse cardiac events.
Figure 2 Assocation between quartiles of MaxLCBI4mm and the
occurrence of MACE. *P < 0.01 as compared with first quartile
(reference).
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figure 1. Cumulative distribution of the MaxlCbI4mm of patients with and without MaCe (p=0.001, 
Mann-Whitney u test).
MACE: major adverse cardiac events, MaxLCBI4mm: the 4 mm long segment with the maximum LCBI
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with MACE [HR 3.09 (95% CI: 1.41–6.74) and HR 3.58 (95% CI:
1.67–7.70), respectively]. Results for the LCBIROI and MaxLCBI10mm
were comparable (Table 2).
There was a statistically significant continuous relationship between
higher MaxLCBI4mm values and a higher risk of MACE (Table 3). After
multivariable adjustment, MaxLCBI4mm remained significantly associ-
ated with MACE (HR 1.19 per 100 units increase in LCBI, 95% CI:
1.07–1.32), as well as with MACE after exclusion of target lesion-
related events [HR 1.21 (95% CI: 1.08–1.35)]. Similarly, MaxLCBI4mm
remained also independently associated with MACE after exclusion of
adverse events related to the NIRS-imaged coronary segment [HR
1.19 (95% CI: 1.06–1.34)]. Cox regression analysis with follow-up
duration as time-dependent variable demonstrated that continuous
MaxLCBI4mm also predicted MACE beyond 1-year of follow-up [HR
(95% CI) 1.15 (1.00–1.33) vs. 1.23 (1.07–1.42) for the first year].
The C-indices indicate that NIRS-derived LCBI has prognostic
value in addition to clinical risk factors and IVUS-derived plaque bur-
den, with C-indices of the models with only covariates ranging from
0.607 to 0.617 and C-indices of the multivariable models including
continuous LCBI ranging from 0.674 to 0.704 (Table 3).
Association between LCBI and the
composite endpoint of cardiac death,
non-fatal ACS or unplanned
revascularization
The cumulative incidence of the composite of cardiac death, non-fatal
ACS or unplanned revascularization was higher in patients in the sec-
ond (25.0%), third (31.3%), and fourth (35.7%) quartile of
MaxLCBI4mm as compared with those in the first (10.3%) quartile of
MaxLCBI4mm (log-rank pairwise comparisons P=0.031, P=0.002,
and P=<0.001, respectively, Figure 3). The second, third, and fourth
quartiles of MaxLCBI4mm were significantly associated with the
composite of cardiac death, non-fatal ACS, or unplanned
revascularization after adjustment for clinical characteristics and
IVUS-derived plaque burden in the multivariable model (Table 4). A
similar significant association was observed for MaxLCBI4mm as a con-
tinuous variable (Table 5). This association persisted after exclusion
of target lesion-related events and after exclusion of events related
to the imaged segment (Table 5). In general, the associations
observed between MaxLCBI4mm, MaxLCBI10mm, and LCBIROI and the
occurrence of adverse events were stronger and more significant
when the composite endpoint included cardiac death instead of all-
cause mortality (Tables 2–5).
Discussion
This study investigated the association between lipid rich core-
containing plaques as identified by NIRS in a non-culprit coronary
artery and the occurrence of adverse cardiac events during long-
term follow-up in patients undergoing CAG. This study showed that
LCBI values were significantly and independently associated with the
incidence of adverse cardiac outcome in patients with CAD over
4 years of follow-up. To the best of our knowledge, this is the first
study to investigate the association between LCBI in a non-culprit
coronary artery and adverse cardiac outcome over 4 years of follow-
up, which represents the longest follow-up period so far reported.
Studies on the relationship between LCBI and (long-term) follow-
up are scarce. Recently, the COLOR study demonstrated that the
MaxLCBI4mm obtained prior to stenting in a culprit coronary segment
was not associated with culprit-related MACE during 2 years of fol-
low-up.15 Our study provides new evidence on the prognostic value
of NIRS, since we demonstrated that NIRS is predictive of MACE on
the long-term by identifying high-risk lipid rich core-containing pla-
ques in a non-culprit artery. The upcoming Lipid Rich Plaque (LRP)
and PROSPECT-2 studies are also investigating the ability of NIRS-
derived LCBI in non-culprit coronary arteries to predict adverse car-
diovascular outcome during 2-year follow-up.
Figure 1 Cumulative distribution of the MaxLCBI4mm of patients
with and without MACE (P= 0.001, Mann–Whitney U test).
MaxLCBI4mm, the 4mm long segment with the maximum LCBI.
MACE, major adverse cardiac events.
Figure 2 Assocation between quartiles of MaxLCBI4mm and the
occurrence of MACE. *P < 0.01 as compared with first quartile
(reference).
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figure 2. assocation between quartiles of MaxlCbI4mm and the occurrence of MaCe
*p<0.01 as compared to first quartile (reference).
LCBI: lipid core burden index, MACE: major adverse cardiac events
170 Chapter 10
Table 2. associations between quartiles of lCbI and risk of MaCe at 4-years follow-up
Cut-off LCBI 
value
Cumulative 
MACE 
incidence (%)
Unadjusted model Multivariable model
HR (95%CI) p-value HR (95%CI) p-value
MaxLCBI4mm
Quartile 1 0-83 14.7 1 1
Quartile 2 ≥83-227 27.9 1.99 (0.93-4.28) 0.078 2.11 (0.96-4.60) 0.062
Quartile 3 ≥227-360 34.3 2.77 (1.32-5.81) 0.007 3.09 (1.41-6.74) 0.005
Quartile 4 ≥360 38.6 3.22 (1.56-6.65) 0.002 3.58 (1.67-7.70) 0.001
MaxLCBI10mm
Quartile 1 0-48 13.2 1 1
Quartile 2 ≥48-129 30.9 2.56 (1.17-5.60) 0.018 2.66 (1.20-5.93) 0.017
Quartile 3 ≥129-234 36.8 3.36 (1.57-7.20) 0.002 3.47 (1.59-7.61) 0.002
Quartile 4 ≥234 34.3 3.06 (1.42-6.59) 0.004 3.27 (1.46-7.29) 0.004
LCBIROI
Quartile 1 0-13 15.4 1 1
Quartile 2 ≥13-40 25.7 1.72 (0.79-3.73) 0.17 1.93 (0.88-4.25) 0.10
Quartile 3 ≥40-79 37.1 2.90 (1.40-6.02) 0.004 3.24 (1.53-6.88) 0.002
Quartile 4 ≥79 35.7 2.67 (1.28-5.56) 0.009 3.14 (1.43-6.87) 0.004
Cumulative MACE incidence by Kaplan-Meier method. P-values obtained with Cox regression analyses on 
pairwise comparisons between each quartile and first quartile (reference).
HR: hazard ratio, LCBI, lipid core burden index; MACE, major adverse cardiac events, ROI: region of interest
Table 3. Continuous lCbI values and risk of MaCe at 4-years follow-up
Unadjusted model Multivariable model
C-index
HR(95%CI) p-value HR(95%CI) p-value
MACE
Covariates only 0.608
MaxLBCI4mm 1.19 (1.08-1.31) 0.001 1.19 (1.07-1.32) 0.001 0.674
MaxLBCI10mm 1.17 (1.04-1.31) 0.011 1.17 (1.03-1.34) 0.017 0.660
LCBIROI 1.18 (0.93-1.51) 0.18 1.24 (0.95-1.63) 0.12 0.652
MACE with exclusion of TLR-events
Covariates only 0.617
MaxLBCI4mm 1.22 (1.10-1.36) <0.001 1.21 (1.08-1.35) 0.001 0.704
MaxLBCI10mm 1.21 (1.07-1.37) 0.003 1.22 (1.06-1.40) 0.005 0.691
LCBIROI 1.24 (0.97-1.60) 0.087 1.31 (0.99-1.74) 0.059 0.683
MACE with exclusion of NIRS imaged segment-related events
Covariates only 0.607
MaxLBCI4mm 1.17 (1.06-1.30) 0.003 1.19 (1.06-1.34) 0.003 0.683
MaxLBCI10mm 1.13 (0.99-1.28) 0.072 1.15 (1.00-1.33) 0.050 0.665
LCBIROI 1.09 (0.81-1.46) 0.58 1.18 (0.86-1.62) 0.31 0.659
Hazard ratios per 100 units increase in MaxLCBI4mm, MaxLCBI10mm and LCBIROI.
HR: hazard ratio, LCBI: lipid core burden index, MACE: major adverse cardiac events, NIRS: near-infrared 
spectroscopy, ROI: region of interest, TLR: target lesion-related revascularization
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Table 4. associations between quartiles of lCbI and risk of composite of cardiac death, non-fatal 
aCs, or unplanned revascularization at 4-years follow-up
Cut-off LCBI 
value
Cumulative 
incidence (%)
Unadjusted model Multivariable model
HR(95%CI) p-value HR(95%CI) p-value
MaxLCBI4mm
Quartile 1 0-83 10.3 1 1
Quartile 2 ≥83-227 25.0 2.53 (1.05-6.11) 0.039 2.66 (1.09-6.50) 0.032
Quartile 3 ≥227-360 31.3 3.60 (1.53-8.46) 0.003 4.07 (1.67-9.92) 0.002
Quartile 4 ≥360 35.7 4.16 (1.80-9.62) 0.001 4.57 (1.90-10.98) 0.001
MaxLCBI10mm
Quartile 1 0-48 10.3 1 1
Quartile 2 ≥48-129 26.5 2.80 (1.17-6.70) 0.021 2.96 (1.21-7.21) 0.017
Quartile 3 ≥129-234 30.9 3.60 (1.53-8.47) 0.003 3.73 (1.55-8.94) 0.003
Quartile 4 ≥234 34.3 3.85 (1.66-8.93) 0.002 4.01 (1.66-9.67) 0.002
LCBIROI
Quartile 1 0-13 10.8 1 1
Quartile 2 ≥13-40 21.4 2.05 (0.84-5.02) 0.12 2.30 (0.93-5.73) 0.073
Quartile 3 ≥40-79 32.9 3.64 (1.56-8.49) 0.003 4.09 (1.72-9.73) 0.001
Quartile 4 ≥79 35.7 3.73 (1.61-8.62) 0.002 4.18 (1.72-10.17) 0.002
Cumulative endpoint incidence by Kaplan-Meier method. P-values obtained with Cox regression analyses 
on pairwise comparisons between each quartile and first quartile (reference).
ACS: acute coronary syndrome, CI: confidence interval, HR: hazard ratio, LCBI: lipid core burden index, ROI: 
region of interest
Table 5. Continuous lCbI values and risk of composite of cardiac death, non-fatal aCs or unplanned 
revascularization at 4-years follow-up
Unadjusted model Multivariable model
HR(95%CI) p-value HR(95%CI) p-value
MaxLBCI4mm 1.21 (1.10-1.34) <0.001 1.21 (1.08-1.35) 0.001
MaxLBCI10mm 1.20 (1.06-1.35) 0.003 1.20 (1.05-1.37) 0.007
LCBIROI 1.24 (0.98-1.58) 0.078 1.29 (0.98-1.70) 0.065
Composite endpoint with exclusion of TLR-events
MaxLBCI4mm 1.25 (1.12-1.40) <0.001 1.24 (1.10-1.39) <0.001
MaxLBCI10mm 1.25 (1.10-1.42) 0.001 1.25 (1.09-1.44) 0.002
LCBIROI 1.32 (1.03-1.68) 0.027 1.38 (1.04-1.83) 0.027
Composite endpoint with exclusion of NIRS imaged segment-related events
MaxLBCI4mm 1.20 (1.08-1.34) 0.001 1.22 (1.08-1.38) 0.001
MaxLBCI10mm 1.16 (1.02-1.33) 0.026 1.19 (1.03-1.38) 0.022
LCBIROI 1.16 (0.87-1.55) 0.31 1.24 (0.90-1.70) 0.18
Hazard ratios per 100 units increase in MaxLCBI4mm, MaxLCBI10mm and LCBIROI.
ACS: acute coronary syndrome, LCBI: lipid core burden index, NIRS: near-infrared spectroscopy, ROI: re-
gion of interest, TLR: target lesion-related revascularization
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5). In general, the associations observed between MaxLCBI4mm, MaxLCBI10mm and LCBIROI 
and the occurrence of adverse events were stronger and more significant when the 
composite endpoint included cardiac death instead of all-cause mortality (Tables 2-5).
DIsCussIOn
This study investigated the association between lipid rich core-containing plaques as 
identified by NIRS in a non-culprit coronary artery and the occurrence of adverse car-
diac events during long-term follow-up in patients undergoing CAG. This study showed 
that LCBI values were significantly and independently associated with the incidence of 
adverse cardiac outcome in patients with CAD over 4 years of follow-up. To the best 
of our knowledge, this is the first study to investigate the association between LCBI in 
a non-culprit coronary artery and adverse cardiac outcome over 4 years of follow-up, 
which represents the longest follow-up period so far reported.
Studies on the relationship between LCBI and (long-term) follow-up are scarce. Re-
cently, the COLOR study demonstrated that the MaxLCBI4mm obtained prior to stenting in 
a culprit coronary segment was not associated with culprit-related MACE during 2 years 
of follow-up.15 Our study provides new evidence on the prognostic value of NIRS, since 
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persisted, and remained essentially unchanged, when target-lesion
related adverse cardiac events (TLR) were excluded from the study
endpoint, as well as when adverse events related to the imaged coro-
nary segment were excluded. This indicates that LCBI values
obtained in a non-culprit coronary artery segment are associated
with adverse cardiac events throughout the entire coronary tree. As
such, this finding supports the hypothesis that NIRS imaging in a non-
culprit coronary artery segment may reflect vulnerability of the entire
coronary tree.8,16
Previously, the ATHEROREMO-IVUS study demonstrated that
IVUS-derived imaging parameters were predictive of MACE. For this
reason, we included IVUS-derived plaque burden in the multivariable
model to evaluate the independent prognostic value of NIRS. Given
that progression of coronary atherosclerosis depends on multiple
factors that are cumulative, interactive and non-linear, a combination
of these two imaging techniques is likely to result in a higher predic-
tive value.
Other studies used NIRS to investigate the effect of anti-
atherosclerotic therapy on the amount of lipid core-containing
plaques. The YELLOW study demonstrated that patients with multi-
vessel CAD treated for 6 to 8weeks with rosuvastatin showed a
reduction of lipid core in obstructive arteries.17 The IBIS-3 study
showed that high-dose rosuvastatin resulted in a neutral effect on
lipid rich core-containing plaques as determined by NIRS.18 Recently,
it was shown that addition of a PCSK9-inhibitor to stable statin ther-
apy resulted in a greater decrease of plaque burden as assessed by
IVUS.19 NIRS has improved ability to identify lipid core-containing
coronary plaques as compared with other invasive imaging modalities
including IVUS, since NIRS is able to distinguish cholesterol from
other tissue characteristics.6 In this context, NIRS may be used to
select patients with high LCBI values in future research to measure
the effect of anti-atherosclerotic therapy on lipid rich core-containing
plaques in the coronary artery wall and assess its association with
adverse cardiac outcome. Ultimately, this may result in improved risk
stratification and management of patients with CAD.
Limitations
Several study limitations warrant consideration. First, our study pop-
ulation also comprised patients from IBIS-3, who received high doses
of rosuvastatin after the index procedure. This may also in part have
Figure 3 Assocation between quartiles of MaxLCBI4mm and the
occurrence of cardiac death, non-fatal ACS and unplanned revascu-
larization. *P < 0.05 as compared with first quartile (reference).
....................................................................................................................................................................................................................
Table 4 Associations between quartiles of LCBI and risk of composite of cardiac death, non-fatal ACS, or unplanned
revascularization at 4-years follow-up
Cut-off LCBI
value
Cumulative
incidence (%)
Unadjusted
model HR
(95% CI)
P-value Multivariable
model HR
(95% CI)
P-value
MaxLCBI4mm
Quartile 1 0–83 10.3 Ref Ref Ref Ref
Quartile 2 >_83–227 25.0 2.53 (1.05–6.11) 0.039 2.66 (1.09–6.50) 0.032
Quartile 3 >_227–360 31.3 3.60 (1.53–8.46) 0.003 4.07 (1.67–9.92) 0.002
Quartile 4 >_360 35.7 4.16 (1.80–9.62) 0.001 4.57 (1.90–10.98) 0.001
MaxLCBI10mm
Quartile 1 0–48 10.3 Ref Ref Ref Ref
Quartile 2 >_48–129 26.5 2.80 (1.17–6.70) 0.021 2.96 (1.21–7.21) 0.017
Quartile 3 >_129–234 30.9 3.60 (1.53–8.47) 0.003 3.73 (1.55–8.94) 0.003
Quartile 4 >_234 34.3 3.85 (1.66–8.93) 0.002 4.01 (1.66–9.67) 0.002
LCBIROI
Quartile 1 0–13 10.8 Ref Ref Ref Ref
Quartile 2 >_13–40 21.4 2.05 (0.84–5.02) 0.12 2.30 (0.93–5.73) 0.073
Quartile 3 >_40–79 32.9 3.64 (1.56–8.49) 0.003 4.09 (1.72–9.73) 0.001
Quartile 4 >_79 35.7 3.73 (1.61–8.62) 0.002 4.18 (1.72–10.17) 0.002
Cumulative endpoint incidence by Kaplan–Meier. P-values by Cox regression analyses on pairwise comparisons between each quartile and first quartile (reference).
LCBI, lipid core burden index.
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figure 3. assocation between quartiles of MaxlCbI4mm and the occurrence of cardiac death, non-
fatal aCs and unplanned revascularization
*p<0.05 as compared to first quartile (reference).
LCBI: lipid core burden index, MACE: major adverse cardiac events, NIRS: near-infrared spectroscopy
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we demonstrated that NIRS is predictive of MACE on the long-term by identifying high-
risk lipid rich core-containing plaques in a non-culprit artery. The upcoming Lipid Rich 
Plaque (LRP) and PROSPECT-2 studies are also investigating the ability of NIRS-derived 
LCBI in non-culprit coronary arteries to predict adverse cardiovascular outcome during 
2-year follow-up.
This study extends our previous 1-year follow-up data of the ATHEROREMO-NIRS 
study, which investigated the 1-year prognostic value of NIRS in that cohort and showed 
that high LCBI values were associated with an increased incidence of MACE.10 The cur-
rent study demonstrated that these results persist over a period of 4 years, suggesting 
that the increased risk at 1-year was not due to chance and LCBI of a non-culprit artery 
also has prognostic value beyond 1-year after the index CAG. As compared to the 1-year 
follow-up, the current study was conducted over a longer follow-up period, had a larger 
sample size and, consequently, a larger number of endpoints. The latter allowed us to 
investigate the associations between continuous LCBI values, as well as quartiles of LCBI, 
and adverse cardiac outcome instead of using a median split for LCBI. These analyses 
showed a significant and independent continuous relationship between higher LCBI 
values in a non-culprit coronary artery and adverse cardiac outcome. Importantly, this 
relationship persisted, and remained essentially unchanged, when target-lesion related 
adverse cardiac events (TLR) were excluded from the study endpoint, as well as when 
adverse events related to the imaged coronary segment were excluded. This indicates 
that LCBI values obtained in a non-culprit coronary artery segment are associated with 
adverse cardiac events throughout the entire coronary tree. As such, this finding sup-
ports the hypothesis that NIRS imaging in a non-culprit coronary artery segment may 
reflect vulnerability of the entire coronary tree.8,16
Previously, the ATHEROREMO-IVUS study demonstrated that IVUS-derived imaging 
parameters were predictive of MACE. For this reason, we included IVUS-derived plaque 
burden in the multivariable model to evaluate the independent prognostic value of 
NIRS. Given that progression of coronary atherosclerosis depends on multiple factors 
that are cumulative, interactive and nonlinear, a combination of these two imaging 
techniques is likely to result in a higher predictive value.
Other studies used NIRS to investigate the effect of anti-atherosclerotic therapy on the 
amount of lipid core-containing plaques. The YELLOW study demonstrated that patients 
with multivessel CAD treated for 6 to 8 weeks with rosuvastatin showed a reduction of 
lipid core in obstructive arteries.17 The IBIS-3 study showed that high-dose rosuvastatin 
resulted in a neutral effect on lipid rich core-containing plaques as determined by NIRS.18 
Recently, it was shown that addition of a PCSK9-inhibitor to stable statin therapy resulted 
in a greater decrease of plaque burden as assessed by IVUS.19 NIRS has improved ability 
to identify lipid core-containing coronary plaques as compared to other invasive imag-
ing modalities including IVUS, since NIRS is able to distinguish cholesterol from other 
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tissue characteristics.6 In this context, NIRS may be used to select patients with high LCBI 
values in future research to measure the effect of anti-atherosclerotic therapy on lipid 
rich core-containing plaques in the coronary artery wall and assess its association with 
adverse cardiac outcome. Ultimately, this may result in improved risk stratification and 
management of patients with CAD.
limitations
Several study limitations warrant consideration. First, our study population also com-
prised patients from IBIS-3, who received high doses of rosuvastatin after the index 
procedure. This may also in part have affected the effect estimates. However, a post-hoc 
analysis did not display significant effect modification according to study.
Second, the follow-up questionnaire was completed by 90% of the patients. Although 
for the majority of the remaining patients, follow-up information was retrieved from our 
local hospital records, we cannot fully exclude the possibility that loss to follow-up was 
in part selective. However, a post-hoc analysis of clinical and NIRS characteristics of the 
non-responders as compared to those of the responders did not show any differences 
that indicated selective loss to follow-up.
Third, the sample size of this single-center study was relatively small. Nevertheless, our 
study had a large number of endpoints. This allowed us to analyse LCBI as quartiles and 
as a continuous variable, as well as to investigate the association with adverse cardiac 
outcome after exclusion of target lesion-related and imaged segment-related events. 
When the results of the LRP and PROSPECT-2 studies become available, a meta-analysis 
may provide more precise effect estimates. Furthermore, as the current study popula-
tion comprises a broad spectrum of CAD patients, the results are expected to apply to a 
broad population of CAD patients.
Conclusions
In conclusion, this study demonstrates for the first time that LCBI, as assessed by NIRS 
in one non-culprit coronary artery segment, predicts adverse cardiac outcome, inde-
pendent of clinical characteristics and IVUS, during long-term follow-up over 4 years in 
patients referred for CAG because of ACS or SAP.
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absTRaCT
aims: Acute coronary syndromes (ACS) are mostly caused by plaque rupture. This study 
aims to investigate the prognostic value of in-vivo detection of high risk coronary plaques 
by intravascular ultrasound (IVUS) in patients undergoing coronary angiography.
Methods and results: Between November 2008 and January 2011, IVUS of a non-culprit 
coronary artery was performed in 581 patients who underwent coronary angiography 
for ACS (n=318) or stable angina (n=263). Primary endpoint was major adverse car-
diac events (MACE), defined as mortality, ACS or unplanned coronary revascularization. 
Culprit lesion-related events were not counted. Cumulative Kaplan-Meier incidence 
of 1-year MACE was 7.8%. The presence of IVUS virtual histology-derived thin-cap fi-
broatheroma (TCFA) lesions (present 10.8% vs. absent 5.6%; adjusted HR 1.98, 95%CI 
1.09-3.60; p=0.026) and lesions with a plaque burden of ≥70% (present 16.2% vs. absent 
5.5%; adjusted HR 2.90, 95%CI 1.60-5.25; p<0.001) were independently associated with 
higher MACE rate. TCFA lesions were also independently associated with the composite 
of death or ACS only (present 7.5% vs. absent 3.0%; adjusted HR 2.51, 95%CI 1.15-5.49; 
p=0.021). TCFA lesions with a plaque burden of ≥70% were associated with higher MACE 
rate within (p=0.011) and after (p<0.001) 6 months of follow-up, while smaller TCFA le-
sions were only associated with higher MACE rate after 6 months (p=0.033).
Conclusion: In patients undergoing coronary angiography, the presence of IVUS virtual 
histology-derived TCFA lesions in a non-culprit coronary artery is strongly and inde-
pendently predictive for occurrence of MACE within 1 year, particularly of death and 
ACS. TCFA lesions with a large plaque burden carry higher risk than small TCFA lesions, 
especially on the short term.
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InTRODuCTIOn
Acute coronary syndromes (ACS) are expected to remain the leading cause of mortality 
and morbidity in the upcoming years.(1) Patients with a history of cardiovascular disease 
have an increased risk for ACS.(2) Post-mortem studies have shown that ACS is mostly 
caused by thin-cap fibroatheroma (TCFA) lesions.(3-5) Detection of these coronary le-
sions that are at high risk to rupture may be highly relevant for further improvement of 
prognostication and for optimal choice of treatment. However, these high risk lesions 
cannot be easily detected by coronary angiography.(6)
Intravascular ultrasound (IVUS) radiofrequency analyses, also known as IVUS virtual 
histology, allows for differentiation of various plaque phenotypes and may therefore be 
well suited for detection of plaques that are at high risk to rupture.(7-9) The Providing 
Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) 
study has shown that plaque characteristics as assessed by IVUS were independently 
predictive for recurrent cardiac events in patients admitted with an ACS.(10) However, 
the events in PROSPECT were mainly driven by rehospitalizations for unstable or pro-
gressive angina, while less is known about the prognostic value of IVUS for acute cardiac 
events as a consequence of spontaneous plaque rupture (i.e. recurrent ACS or death). 
Furthermore, the prognostic value of IVUS in patients with stable angina remains un-
clear. This study aims to investigate the prognostic value of in-vivo detection of high risk 
plaques by IVUS in patients undergoing coronary angiography for ACS or stable angina.
MeTHODs
study population
The design of The European Collaborative Project on Inflammation and Vascular Wall 
Remodeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study has 
been described elsewhere.(11) In brief, 581 patients who underwent diagnostic coronary 
angiography or percutaneous coronary intervention (PCI) for ACS or stable angina pectoris 
have been included between 2008 and 2011 in the Erasmus MC, Rotterdam, the Nether-
lands. Although this original ATHEROREMO-IVUS cohort was further enriched with eligible 
patients who participated in the Integrated Biomarker and Imaging Study-2 (IBIS-2) trial 
of darapladib versus placebo, these additional IBIS-2 patients were not included in the 
present analysis in order to prevent possible treatment interaction from darapladib.(12)
The ATHEROREMO-IVUS study was approved by the medical ethics committee of 
the Erasmus MC. The study was performed in accordance with the criteria described in 
the declaration of Helsinki. Written informed consent was obtained from all included 
patients. This study is registered with ClinicalTrials.gov, number NCT01789411.
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Intravascular ultrasound imaging
Following the standard coronary angiography procedure, IVUS imaging of a non-culprit 
coronary artery was performed. Selection of the non-culprit vessel was predefined in 
the study protocol. The order of preference for selection of the non-culprit vessel was: 
1. left anterior descending (LAD) artery; 2. right coronary artery (RCA); 3. left circum-
flex (LCX) artery. All IVUS data were acquired with the Volcano s5/s5i Imaging System 
(Volcano Corp., San Diego, CA, USA) using a Volcano Eagle Eye Gold IVUS catheter (20 
MHz). An automatic pullback system was used with a standard pull back speed of 0.5 
mm per second. The baseline IVUS images were sent to an independent core laboratory 
(Cardialysis BV, Rotterdam, the Netherlands) for offline analysis. The core laboratory 
personnel were blinded for baseline patient characteristics and clinical outcomes data. 
The IVUS gray-scale and virtual histology analyses were performed using pcVH 2.1 and 
qVH (Volcano Corp., San Diego, CA, USA) software. The external elastic membrane and 
luminal borders were contoured for each frame of the virtual histology-derived dataset. 
Extent and phenotype of the atherosclerotic plaque were assessed. Plaque burden was 
defined as plaque and media cross-sectional area divided by external elastic mem-
brane cross-sectional area. A coronary lesion was defined as a segment with a plaque 
burden of more than 40% in at least 3 consecutive frames. Using IVUS virtual histol-
ogy, the composition of the atherosclerotic lesions was characterized into 4 different 
tissue types: fibrous, fibro-fatty, dense calcium and necrotic core.(7) Confluency of the 
necrotic core and dense calcium, as well as the contact of the necrotic core with the 
lumen were independently assessed by visual examination, which was performed inde-
pendently by three investigators (HMG, SPB and JHH) who were blinded to the clinical 
outcomes. Consensus was reached in case of disagreement. The lesions were further 
classified into: 1. adaptive intimal thickening (intimal thickening of <600 μm for <20% 
of the circumference); 2. pathological intimal thickening (intimal thickening ≥600 μm 
for >20% of the circumference with >15% fibrofatty tissue and no confluent necrotic 
core or dense-calcium); 3. fibrotic plaque (consisting predominantly of fibrous tissue 
without confluent necrotic core or dense-calcium); 4. fibrocalcific plaque (presence 
of >10% confluent dense-calcium without confluent necrotic core); 5. fibroatheroma 
(presence of >10% confluent necrotic core with an overlying layer of fibrous tissue); 6. 
calcified fibroatheroma (fibroatheroma containing >10% confluent dense-calcium); 7. 
non-calcified TCFA (presence of >10% confluent necrotic core in direct contact with the 
lumen); 8. calcified TCFA (TCFA containing >10% of confluent dense-calcium) (Figure 
1).(8) All of the above mentioned criteria should be present in three consecutive frames 
for a lesion to be considered of a particular category. TCFA lesions with a plaque burden 
of at least 70% were classified as large TCFA lesions.
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study endpoints
Clinical follow-up started at inclusion and lasted 1 year. Post-discharge survival status 
was obtained from municipal civil registries. Post-discharge rehospitalizations were 
prospectively assessed during follow-up. Questionnaires focusing on the occurrence 
of major adverse cardiac events (MACE) were sent to all living patients. Subsequently, 
hospital discharge letters were obtained and treating physicians and institutions were 
contacted for additional information whenever necessary. ACS was defined as the 
clinical diagnosis of ST segment elevation myocardial infarction (STEMI), non-STEMI or 
unstable angina pectoris in accordance with the guidelines of the European Society of 
Cardiology.(13) Unplanned coronary revascularization was defined as unplanned repeat 
PCI or coronary artery bypass grafting (CABG). All events were adjudicated as related to 
a coronary site that was treated during the index procedure (culprit lesion related event) 
or as related to a coronary site that was not treated during the index procedure (non-
culprit lesion related event). Events that were related to both the culprit lesion and a 
non-culprit site (e.g. revascularization of multiple vessels with CABG) were classified into 
both categories. When information was not sufficient to classify an event as either culprit 
lesion related or non-culprit lesion related, the event was classified as indeterminate.
The primary endpoint was MACE, defined as non-culprit lesion related or indetermi-
nate mortality, ACS or unplanned coronary revascularization. The secondary endpoint 
was defined as the composite of non-culprit lesion related or indeterminate mortal-
ity or ACS. Definite culprit lesion related events were not counted in the primary and 
figure 1. Classification of plaque morphology with intravascular ultrasound virtual histology
IMT, intimal medial thickening; PIT, pathological intimal thickening; FT, fibrotic plaque; FC, fibrocalcific 
plaque; FA, fibroatheroma; CaFA, calcified fibroatheroma; TCFA, thin-cap fibroatheroma; CaTCFA, calcified 
thin-cap fibroatheroma.
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secondary endpoint. Occurrence of culprit lesions related events are most probably 
caused by in-stent restenosis or in-stent thrombosis, while we were only interested in 
unanticipated, spontaneous MACE. The endpoints were adjudicated by a clinical event 
committee that had no knowledge of the IVUS data.
statistical analysis
Under the previously described assumptions (design paper) that high risk lesions (e.g. 
TCFA) will be present in 30% of the patients and that MACE will occur in 10% of the total 
study population, our sample size of 581 patients would provide 85% to 99% power to 
detect a hazard ratio in the range of 2.0 to 2.5 with a two-sided alpha of 0.05.(11)
Normally distributed continuous variables are presented as mean ± standard deviation 
(SD). Non-normally distributed continuous variables are presented as median and inter-
quartile range (IQR). Categorical variables are presented in numbers and percentages. 
Patients lost to follow-up were considered at risk until the date of last contact, at which 
time-point they were censored. Cumulative event rates were estimated according to the 
Kaplan-Meier method. Cumulative Kaplan-Meier event curves were compared by the log-
rank test. Cox proportional hazards regression analyses were performed to evaluate the 
associations between IVUS characteristics and study endpoints. In multivariable analyses, 
the variables age, gender, diabetes mellitus, hypertension, history of PCI and indication 
for coronary angiography were considered as potential confounders and were entered 
into the full model. These covariates (except for indication for coronary angiography) 
were chosen based on the multivariable model that was used in the PROSPECT study, 
taking into account the number of events available.(10) The final results are presented 
as hazard ratios (HR) with 95% confidence interval (95% CI). Z-test for heterogeneity was 
performed to test for heterogeneity in effect estimates between patients admitted with 
and without ACS. All statistical analyses were performed at patient level. All data were 
analyzed with SPSS software (SPSS 20.0, IBM corp., Armonk, NY, USA). All statistical tests 
were two-tailed and p-values <0.05 were considered statistically significant.
ResulTs
baseline characteristics
Mean age of the study population was 61.6 ± 11.3 years, 75.6% were men and 17.0% 
had diabetes mellitus (Table 1). Coronary angiography or PCI was performed for various 
indications: 28.7% of the patients had an acute myocardial infarction (STEMI and non-
STEMI), 26.0% of the patients had unstable angina pectoris and 43.7% of patients had 
stable angina pectoris. Median length of the imaged coronary segment was 44.3 [33.8-
55.4] mm. Median interslice distance was 0.40 mm. A total of 724 lesions were identified 
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Table 1. baseline characteristics
n = 581 patients
Patient characteristics
Age, years 61.6 ± 11.3
Men, n (%) 439 (75.6)
Diabetes Mellitus, n (%) 99 (17.0)
Hypertension. n (%) 300 (51.6)
Hypercholesterolemia, n (%) 321 (55.2)
Smoking, n (%) 169 (29.1)
Positive family history, n (%) 301 (51.8)
Previous MI, n (%) 184 (31.7)
Previous PCI, n (%) 186 (32.0)
Previous CABG, n (%) 18 (3.1)
Previous stroke, n (%) 26 (4.5)
History of peripheral artery disease, n (%) 36 (6.2)
History of renal insufficiency, n (%) 32 (5.5)
History of heart failure, n(%) 19 (3.3)
C-reactive protein, mg/L 2.1 [0.9-5.4]
Procedural characteristics
Indication for angiography
 Acute MI, n (%) 167 (28.7)
 Unstable angina, n (%) 151 (26.0)
 Stable angina, n (%) 254 (43.7)
 Other, n (%) 9 (1.5)
Coronary artery disease*
 No significant stenosis, n (%) 43 (7.4)
 1-vessel disease, n (%) 308 (53.0)
 2-vessel disease, n (%) 168 (28.9)
 3-vessel disease, n (%) 62 (10.7)
PCI performed, n (%) 511 (88.0)
IVUS characteristics
Imaged coronary artery
 Left anterior descending, n (%) 210 (36.1)
 Left circumflex, n (%) 195 (33.6)
 Right coronary artery, n (%) 176 (30.3)
Imaged segment length, mm 44.3 [33.8-55.4]
* A significant stenosis was defined as a stenosis ≥50% of vessel diameter by visual assessment on the 
coronary angiogram.
CABG, coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary interven-
tion.
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in the imaged coronary segment of 508 (87.4%) patients, including 127 (17.5%) lesions 
with a plaque burden of at least 70% in 124 (21.3%) patients and 206 (28.5%) lesions 
with a minimal luminal area of 4.0 mm² or less in 182 (31.3%) patients (Figure 2 and 
Supplemental table 1). On the basis of radiofrequency IVUS, 271 (37.4%) of the lesions 
have been classified as TCFA in 242 (41.7%) patients, including 71 (9.8%) TCFA lesions 
with a plaque burden of at least 70% in 69 (11.9%) patients, 61 (8.4%) TCFA lesions with 
a minimal luminal area of 4.0 mm² or less in 61 (10.5%) patients, and 35 (4.8%) TCFA 
lesions with a plaque burden of at least 70% and a minimal luminal area of 4.0 mm² in 35 
(6.0%) patients. Antiplatelet medications and statins were prescribed to the majority of 
patients at time of discharge (Supplemental table 2).
Major adverse cardiac events
Vital status was complete for 580 (99.8%) patients. Response rate of the questionnaires 
that were sent to all living patients was 91.5%. After 1 year of follow-up, 56 patients 
had at least 1 event (Table 2). Unplanned coronary revascularization was performed 
in 4 patients who did not have PCI during the index procedure. A total of 11 patients 
had a definite culprit lesion related event, while 27 patients had a definite non-culprit 
lesion related event. Another 18 patients had an event that could not be judged to be 
IVUS of a non-culprit coronary artery (n=581) 
At least 1 lesion in imaged segment (n=508) 
At least 1 TCFA 
(n=242) 
At least 1 lesion with 
PB ≥70% (n=124) 
At least 1 lesion with 
MLA ≤4.0mm2 
(n=182) 
At least 1 TCFA with 
PB ≥70% (n=69) 
At least 1 TCFA with 
MLA ≤4.0mm2 (n=61) 
At least 1 TCFA with 
PB ≥70% and MLA 
≤4.0mm2 (n=35) 
At least 1 lesion with 
PB ≥70% and MLA 
≤4.0mm2 (n=74) 
figure 2. study participants and presence of high risk coronary lesions on intravascular ultrasound
IVUS, intravascular ultrasound; MLA, minimal luminal area; PB, plaque burden; TCFA, thin-cap fibroath-
eroma.
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either culprit lesion related or non-culprit lesion related and were therefore classified as 
having an indeterminate event. The cumulative Kaplan-Meier incidence of the 30-day, 
6-month and 1-year MACE (primary endpoint) was 0.7%, 4.7%, and 7.8%, respectively. 
The cumulative Kaplan-Meier incidence of the 30-day, 6-month and 1-year composite of 
death or ACS (secondary endpoint) was 0.7%, 3.1%, and 4.8%, respectively.
associations with incident major adverse cardiac events
Patients who did not had any lesion in the imaged coronary segment seemed to have 
lower occurrence of MACE (absent 4.1% vs. present 8.3%; HR 0.48, 95% CI 0.15-1.54; 
p=0.22) and lower occurrence of the composite of death or ACS only (absent 1.4% vs. 
present 5.4%; HR 0.25, 95% CI 0.034-1.83; p=0.17), although these associations were not 
statistically significant. The amount of necrotic core in the imaged coronary segment 
was associated with MACE (Supplemental table 3).
After adjustment for clinical characteristics, the presence of TCFA lesions (present 
10.8% vs. absent 5.6%; adjusted HR 1.98, 95% CI 1.09-3.60; p=0.026) and lesions with 
a plaque burden of at least 70% (present 16.2% vs. absent 5.5%; adjusted HR 2.90, 95% 
CI 1.60-5.25; p<0.001) were independently associated with higher occurrence of MACE, 
while the presence of lesions with a minimal luminal area of 4.0 mm² or less was not 
(present 9.4% vs. absent 7.1%; adjusted HR 1.23, 95% CI 0.67-2.26; p=0.50) (Table 3 and 
Supplemental table 4). There was no heterogeneity in the HR estimates between pa-
tients admitted with and without ACS (heterogeneity p=0.31 for TCFA, p=0.58 for plaque 
burden of at least 70% and p=0.65 for minimal luminal area of 4.0 mm² or less). Calcified 
TCFA lesions seemed to carry higher risk than non-calcified TCFA lesions, although the 
Table 2. Patients with major adverse cardiac events
Definite 
culprit 
lesion 
related 
events
Definite 
non-cul-
prit lesion 
related 
events
Indeter-
minate 
events
non-culprit 
lesion related 
and indeter-
minate events 
combined
all
events
Composite of MACE, n 11 27 18 45* 56
Death from any cause, n 1 1 16 17 18
 Definite cardiac or unexplained 
death, n
1 1 6 7 8
Acute coronary syndrome, n 3 9 2 11 14
Myocardial infarction, n 2 3 2 5 7
 Unplanned coronary revascularization, n 7 17 0 17 24
Composite of death or acute coronary 
syndrome, n
4 10 18 28** 32
* Primary endpoint
** Secondary endpoint
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difference was not statistically significant (p=0.32) (Supplemental figure 1). The pres-
ence of TCFA lesions was also significantly associated with the composite of death or 
ACS only (present 7.5% vs. absent 3.0%; adjusted HR 2.51, 95% CI 1.15-5.49; p=0.021).
Risk for occurrence of MACE was further increased if the TCFA lesions had a minimal 
luminal area of 4.0 mm² or less, had a plaque burden of at least 70%, or a combination 
of these three characteristics (Figure 3 and Supplemental figure 2). TCFA lesions with a 
plaque burden of at least 70% were associated with higher MACE rate both in the first 6 
months (p=0.011) and after 6 months (p<0.001) of follow-up, while smaller TCFA lesions 
were only associated with higher MACE rate after 6 months (p=0.033) (Figure 4).
DIsCussIOn
This study investigated the prognostic value of in-vivo high risk plaque detection by 
IVUS for the occurrence of MACE in patients undergoing coronary angiography. In line 
with previous studies, we found that the presence of a TCFA lesion as assessed by IVUS in 
a non-culprit coronary artery was independently predictive for occurrence of MACE that 
was not related to the index procedure.(10, 14) The event rate was even further increased 
when patients had a TCFA lesion with a minimal luminal area of 4.0 mm² or less, a plaque 
figure 3. Cumulative Kaplan-Meier incidence estimates of major adverse cardiac events
Percentages are 1-year cumulative Kaplan-Meier incidence estimates. Hazard ratios are estimated using 
univariate Cox proportional hazards regression analysis. P values are obtained with log-rank test.
MLA, minimal luminal area; PB, plaque burden; TCFA, thin-cap fibroatheroma.
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burden of at least 70%, or a combination thereof. Our study is the first to demonstrate 
that the presence of such vulnerable coronary lesions as assessed in-vivo by IVUS are 
significantly associated with the occurrence of acute cardiac events (composite of death 
or ACS only) that were not related to the index procedure. Furthermore, we found that 
patients with a large TCFA lesion (with a plaque burden of at least 70%) were at higher 
risk than patients with a small TCFA lesion. The presence of a small TCFA lesion was only 
predictive for clinical events occurring on the longer term (after 6 months).
Although the PROSPECT and the Virtual histology Intravascular ultrasound in Vulner-
able Atherosclerosis (VIVA) studies have previously reported on the prognostic value of 
vulnerable plaque detection by IVUS, there are some limitations to the conclusion of 
these studies.(10, 14) First, the PROSPECT study only enrolled ACS patients. Therefore, 
the conclusions of this study cannot be directly extrapolated to patients with stable 
angina. In contrast, our study presents a patient population that underwent coronary 
angiography for ACS or stable angina and that may better reflect the “real world” clinical 
practice. Second, the vast majority of events in the PROSPECT study consisted of rehos-
pitalizations for unstable or progressive angina (69 out of the 74 patients with primary 
composite endpoint), while the majority of events in the VIVA study consisted of coro-
nary revascularizations (14 out of the 16 patients with primary composite endpoint). 
Our study demonstrated that vulnerable coronary lesions as assessed in-vivo by IVUS are 
significantly associated with the occurrence of acute cardiac events (composite of death 
figure 4. associations with of short-term and long-term major adverse cardiac events
P values are obtained with log-rank test. Overall P value 0-6 months is 0.009; overall P value 6-12 months 
is 0.002.
PB, plaque burden; TCFA, thin-cap fibroatheroma.
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or ACS only) that were not related to the index procedure. Finally, an important differ-
ence is that IVUS was performed in three coronary vessels in the PROSPECT and VIVA 
studies. Our study demonstrated that IVUS in only one non-culprit vessel is sufficient for 
prognostication. This finding is relevant for the use of IVUS in daily clinical practice, since 
IVUS acquisition and analysis of three vessels is more time consuming and may increase 
risk for complications.
Previous studies have demonstrated that coronary atherosclerotic plaque burden as 
assessed with coronary computed tomography angiography or IVUS is associated with 
progression of the lesion and with incident clinical events during follow-up.(15-17) 
Similarly, the PROSPECT and the VIVA studies have shown that lesions with a plaque 
burden of at least 70% were strongly associated with their primary endpoint.(10, 14) In 
the Prediction of Progression of Coronary Artery Disease and Clinical Outcome Using 
Vascular Profiling of Shear Stress and Wall Morphology (PREDICTION) study, large plaque 
burden and low local endothelial shear stress were also independently associated with 
progression of the lesion and narrowing of the lumen.(18) In accordance with these 
observations, we found that patients with a coronary lesion that had a plaque burden 
of at least 70% were at higher risk for MACE. However, the presence of a lesion with 
a plaque burden of at least 70% was not significantly predictive for the composite of 
death or ACS only. These findings suggest that lesions with a high plaque burden are 
at high risk to cause a flow-limiting stenosis, requiring coronary revascularizations and 
rehospitalizations for progressive angina.
TCFA is the most common pathological substrate of ACS and has been found to be 
associated with incident cardiac events.(19) In the PROSPECT study, non-culprit lesions 
associated with recurrent events (mainly driven by rehospitalizations) were more likely 
to be classified as TCFA on the basis of radiofrequency IVUS (adjusted HR 3.35, 95% CI, 
1.77-6.36; p<0.001).(10) In the VIVA study, presence of a non-calcified TCFA lesion was 
the only factor that was associated with MACE, which was mainly driven by coronary re-
vascularizations (unadjusted HR 1.79; 95% CI 1.20-2.66, p=0.004).(14) Likewise, we found 
that the presence of TCFA lesions as assessed with IVUS was independently predictive 
for MACE (adjusted HR 1.98, 95% CI 1.09-3.60; p=0.026). Furthermore, the predictive 
value of TCFA lesions for occurrence of acute cardiac events (composite of death or ACS 
only) was even stronger (adjusted HR 2.51, 95% CI 1.15-5.49; p=0.021). These findings 
emphasize the biological importance of TCFA for plaque rupture.
We have also found that patients with a large TCFA lesion (with a plaque burden of 
at least 70%) were at higher risk than patients with a small TCFA lesion. Furthermore, 
large TCFA lesions were associated with higher MACE rate within and after 6 months of 
follow-up, while smaller TCFA lesions were only associated with higher MACE rate after 6 
months. Based on these observations, it can be hypothesized that large TCFA lesions are 
more vulnerable and more prone to rupture, while small TCFA lesions may grow in time 
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and may become more vulnerable in the future. In line with our findings, two previous 
studies have demonstrated that the majority of the untreated non-culprit TCFA lesions 
retain their TCFA morphology during follow-up (6 to 13 months), and may be accompa-
nied by a decrease in minimal luminal area and an increase in necrotic core.(20-21) An 
other small study of patients with a lower risk profile, however, has demonstrated that 
the majority of the TCFA lesions were healed after 1 year.(22)
Different MACE definitions have been used in the above mentioned studies (death, 
ACS and unplanned revascularization in our study; cardiovascular death, cardiac arrest, 
myocardial infarction and rehospitalization due to unstable or progressive angina in 
the PROSPECT study; death, myocardial infarction, and unplanned revascularization in 
the VIVA study).(10, 14) Therefore, MACE rates of these studies cannot be directly com-
pared. Nevertheless, the incidence of MACE seemed to be relatively high in our study 
population. For example, 18 deaths occurred in 581 patients within 1 year in our study 
compared to 2 deaths in 170 patients within 625 days in the VIVA, 31 deaths in 697 
patients within 3.4 years in the PROSPECT and 4 deaths in 506 patients within 9 months 
in the PREDICTION study.(10, 14, 18) However, the MACE rate in our study was consistent 
with that of previous “all-comer” registries in our hospital, which further emphasizes that 
our study population may better reflect the “real world” clinical practice.(23-24)
Some limitations of this study need to be acknowledged. Firstly, this is a prospective 
observational cohort study. Although we aimed to include a patient population that 
reflects clinical practice, those patients with any of the exclusion criteria could not be 
included in this study.(11) Secondly, the spatial resolution of IVUS virtual histology 
(150µm) is insufficient to exactly replicate histopathologic definitions of a thin fibrous 
cap (<65µm).(25) Therefore IVUS virtual histology tends to over-estimate the number of 
TCFA lesions. Nevertheless, the presence of IVUS virtual histology detected TCFA lesions 
has prognostic information and is therefore clinically relevant. Thirdly, the relatively 
small number of endpoints did not allow us to evaluate whether adding IVUS imag-
ing to a prognostic model with conventional risk factors would result in improved risk 
prediction. Finally, repeat intracoronary imaging with IVUS virtual histology was not 
performed. Therefore, the dynamic nature of coronary artery lesion morphology could 
not be investigated. Large, future studies (e.g. IBIS-3, www.trialregister.nl identifier 
NTR2872) may provide useful data in this respect.(26)
In conclusion, IVUS virtual histology appeared to be a useful tool for in-vivo detection 
of high risk coronary lesions. In patients undergoing coronary angiography, the pres-
ence of IVUS virtual histology-derived TCFA lesions in a non-culprit coronary artery is 
strongly and independently predictive for occurrence of MACE, particularly of death and 
ACS. TCFA lesions with a large plaque burden are of higher risk than small TCFA lesions, 
especially on the short-term.
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supplemental figure 1. Cumulative Kaplan-Meier event curves stratified by presence of thin-cap 
fibroatheroma lesions
P value is obtained with log-rank test.
ACS indicates acute coronary syndrome; TCFA, thin-cap fibroatheroma.
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supplemental figure 2. Cumulative Kaplan-Meier event curves stratified by presence of thin-cap 
fibroatheroma lesions in combination with other high-risk lesions types.
P values are obtained with log-rank test.
ACS indicates acute coronary syndrome; MLA, minimal luminal area; PB, plaque burden; TCFA, thin-cap 
fibroatheroma.
IVUS and one-year cardiovascular outcome 197
C
h
a
p
te
r
 1
1
supplemental table 1. lesion types classified with intravascular ultrasound virtual histology
n = 724 lesions
1. Adaptive intimal thickening, n (%) 0 (0.0)
2. Pathological intimal thickening, n (%) 39 (5.4)
3. Fibrotic plaque, n (%) 122 (16.9)
4. Fibrocalcific plaque, n (%) 112 (15.5)
5. Fibroatheroma, n (%) 58 (8.0)
6. Calcified fibroatheroma, n (%) 122 (16.9)
7. Thin-cap fibroatheroma, n (%) 128 (17.7)
8. Calcified thin-cap fibroatheroma, n (%) 143 (19.8)
supplemental table 2. Medication use at discharge
n = 581 patients
Aspirin, n (%) 556 (95.7)
Thienopyridine, n (%) 543 (93.5)
Statin, n (%) 515 (88.6)
Beta blocker, n (%) 441 (75.9)
ACE inhibitor or ARB, n (%) 388 (66.8)
Presented medication use was at time of discharge from our hospital. Patients may be discharged to a 
regional hospital for further treatment.
ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blocker.
supplemental table 3. association between necrotic core in imaged coronary segment and non-
culprit lesion related and indeterminate major adverse cardiac events
unadjusted HR (95%CI) P value
Necrotic core percentage 1.14 (0.80-1.64)* 0.48
Necrotic core volume 1.65 (1.09-2.51)** 0.018
* Unadjusted hazard ratio per 10% increase in necrotic core.
** Unadjusted hazard ratio per standard deviation increase in ln-transformed necrotic core volume.
198 Chapter 11
su
pp
le
m
en
ta
l t
ab
le
 4
. a
ss
oc
ia
ti
on
s 
w
it
h 
no
n-
cu
lp
ri
t l
es
io
n 
re
la
te
d 
an
d 
in
de
te
rm
in
at
e 
m
aj
or
 a
dv
er
se
 c
ar
di
ac
 e
ve
nt
s
u
na
dj
us
te
d 
m
od
el
M
ul
ti
va
ri
ab
le
 m
od
el
 1
M
ul
ti
va
ri
ab
le
 m
od
el
 2
fu
ll 
m
od
el
H
R 
(9
5%
 C
I)
P
H
R 
(9
5%
 C
I)
P
H
R 
(9
5%
 C
I)
P
H
R 
(9
5%
 C
I)
P
M
aj
or
 a
dv
er
se
 ca
rd
ia
c 
ev
en
ts
 (p
ri
m
ar
y 
en
dp
oi
nt
)
TC
FA
1.
96
 (1
.0
8-
3.
53
)
0.
02
6
1.
97
 (1
.0
9-
3.
57
)
0.
02
4
2.
00
 (1
.1
0-
3.
62
)
0.
02
2
1.
98
 (1
.0
9-
3.
60
)
0.
02
6
 
Ag
e
1.
04
 (1
.0
2-
1.
07
)
0.
00
2
1.
04
 (1
.0
1-
1.
07
)
0.
00
3
1.
04
 (1
.0
1-
1.
07
)
0.
00
3
 
Se
x
1.
15
 (0
.5
8-
2.
27
)
0.
70
1.
13
 (0
.5
7-
2.
24
)
0.
73
1.
10
 (0
.5
5-
2.
21
)
0.
78
 
In
di
ca
tio
n
1.
16
 (0
.6
4-
2.
09
)
0.
63
0.
98
 (0
.5
2-
1.
84
)
0.
95
 
D
ia
be
te
s
1.
63
 (0
.8
3-
3.
19
)
0.
16
 
H
yp
er
te
ns
io
n
0.
93
 (0
.5
0-
1.
72
)
0.
81
 
Pr
io
r P
CI
1.
54
 (0
.8
2-
2.
89
)
0.
18
PB
 ≥
70
%
3.
15
 (1
.7
5-
5.
68
)
<0
.0
01
2.
83
 (1
.5
7-
5.
13
)
0.
00
1
2.
83
 (1
.5
6-
5.
12
)
0.
00
1
2.
90
 (1
.6
0-
5.
25
)
<0
.0
01
 
Ag
e
1.
04
 (1
.0
1-
1.
07
)
0.
00
8
1.
04
 (1
.0
1-
1.
07
)
0.
00
8
1.
04
 (1
.0
1-
1.
07
)
0.
00
9
 
Se
x
1.
10
 (0
.5
5-
2.
19
)
0.
79
1.
09
 (0
.5
5-
2.
18
)
0.
80
1.
07
 (0
.5
4-
2.
14
)
0.
85
 
In
di
ca
tio
n
1.
05
 (0
.5
8-
1.
90
)
0.
86
0.
84
 (0
.4
4-
1.
60
)
0.
60
 
D
ia
be
te
s
1.
63
 (0
.8
3-
3.
18
)
0.
16
 
H
yp
er
te
ns
io
n
0.
99
 (0
.5
4-
1.
82
)
0.
98
 
Pr
io
r P
CI
1.
67
 (0
.8
8-
3.
16
)
0.
12
M
LA
 ≤
4.
0m
m
²
1.
36
 (0
.7
4-
2.
48
)
0.
32
1.
24
 (0
.6
8-
2.
28
)
0.
48
1.
24
 (0
.6
8-
2.
28
)
0.
48
1.
23
 (0
.6
7-
2.
26
)
0.
50
 
Ag
e
1.
04
 (1
.0
1-
1.
07
)
0.
00
3
1.
04
 (1
.0
1-
1.
07
)
0.
00
3
1.
04
 (1
.0
1-
1.
07
)
0.
00
4
 
Se
x
1.
18
 (0
.5
9-
2.
34
)
0.
64
1.
17
 (0
.5
9-
2.
33
)
0.
66
1.
14
 (0
.5
7-
2.
30
)
0.
71
 
In
di
ca
tio
n
1.
07
 (0
.5
9-
1.
94
)
0.
82
0.
89
 (0
.4
7-
1.
67
)
0.
71
 
D
ia
be
te
s
1.
64
 (0
.8
4-
3.
20
)
0.
15
 
H
yp
er
te
ns
io
n
1.
00
 (0
.5
4-
1.
84
)
0.
99
 
Pr
io
r P
CI
1.
57
 (0
.8
3-
2.
96
)
0.
17
IVUS and one-year cardiovascular outcome 199
C
h
a
p
te
r
 1
1
su
pp
le
m
en
ta
l t
ab
le
 4
 (c
on
ti
nu
ed
) u
na
dj
us
te
d 
m
od
el
M
ul
ti
va
ri
ab
le
 m
od
el
 1
M
ul
ti
va
ri
ab
le
 m
od
el
 2
fu
ll 
m
od
el
H
R 
(9
5%
 C
I)
P
H
R 
(9
5%
 C
I)
P
H
R 
(9
5%
 C
I)
P
H
R 
(9
5%
 C
I)
P
Co
m
po
si
te
 o
f d
ea
th
 o
r a
cu
te
 co
ro
na
ry
 sy
nd
ro
m
e 
(s
ec
on
da
ry
 e
nd
po
in
t)
TC
FA
2.
56
 (1
.1
8-
5.
54
)
0.
01
7
2.
60
 (1
.2
0-
5.
64
)
0.
01
5
2.
54
 (1
.1
7-
5.
51
)
0.
01
9
2.
51
 (1
.1
5-
5.
49
)
0.
02
1
 
Ag
e
1.
05
 (1
.0
1-
1.
08
)
0.
00
8
1.
05
 (1
.0
1-
1.
08
)
0.
00
7
1.
05
 (1
.0
2-
1.
09
)
0.
00
5
 
Se
x
0.
77
 (0
.3
5-
1.
72
)
0.
53
0.
80
 (0
.3
6-
1.
79
)
0.
58
0.
75
 (0
.3
3-
1.
69
)
0.
49
 
In
di
ca
tio
n
0.
74
 (0
.3
4-
1.
59
)
0.
44
0.
58
 (0
.2
6-
1.
32
)
0.
19
 
D
ia
be
te
s
1.
34
 (0
.5
3-
3.
37
)
0.
54
 
H
yp
er
te
ns
io
n
0.
75
 (0
.3
4-
1.
64
)
0.
47
 
Pr
io
r P
CI
2.
29
 (1
.0
4-
5.
05
)
0.
04
PB
 ≥
70
%
2.
11
 (0
.9
7-
4.
56
)
0.
05
9
1.
90
 (0
.8
7-
4.
15
)
0.
11
1.
92
 (0
.8
8-
4.
20
)
0.
10
2.
01
 (0
.9
2-
4.
39
)
0.
07
9
 
Ag
e
1.
04
 (1
.0
1-
1.
08
)
0.
01
5
1.
05
 (1
.0
1-
1.
08
)
0.
01
1
1.
05
 (1
.0
1-
1.
09
)
0.
00
7
 
Se
x
0.
77
 (0
.3
4-
1.
72
)
0.
52
0.
81
 (0
.3
6-
1.
82
)
0.
61
0.
75
 (0
.3
3-
1.
69
)
0.
48
 
In
di
ca
tio
n
0.
67
 (0
.3
1-
1.
44
)
0.
30
0.
48
 (0
.2
1-
1.
10
)
0.
08
4
 
D
ia
be
te
s
1.
32
 (0
.5
3-
3.
30
)
0.
56
 
H
yp
er
te
ns
io
n
0.
80
 (0
.3
7-
1.
72
)
0.
57
 
Pr
io
r P
CI
2.
55
 (1
.1
4-
5.
74
)
0.
02
3
M
LA
 ≤
4.
0m
m
²
1.
23
 (0
.5
7-
2.
67
)
0.
60
1.
12
 (0
.5
2-
2.
43
)
0.
78
1.
13
 (0
.5
2-
2.
45
)
0.
76
1.
14
 (0
.5
3-
2.
49
)
0.
73
 
Ag
e
1.
05
 (1
.0
1-
1.
08
)
0.
01
0
1.
05
 (1
.0
1-
1.
09
)
0.
00
7
1.
05
 (1
.0
2-
1.
09
)
0.
00
5
 
Se
x
0.
81
 (0
.3
6-
1.
80
)
0.
60
0.
85
 (0
.3
8-
1.
91
)
0.
70
0.
78
 (0
.3
4-
1.
77
)
0.
55
 
In
di
ca
tio
n
0.
67
 (0
.3
1-
1.
45
)
0.
31
0.
50
 (0
.2
2-
1.
14
)
0.
09
8
 
D
ia
be
te
s
1.
31
 (0
.5
2-
3.
28
)
0.
57
 
H
yp
er
te
ns
io
n
0.
81
 (0
.3
7-
1.
75
)
0.
59
 
Pr
io
r P
CI
2.
46
 (1
.1
0-
5.
51
)
0.
02
9
H
R 
in
di
ca
te
s 
ha
za
rd
 ra
tio
; M
LA
, m
in
im
al
 lu
m
in
al
 a
re
a;
 P
B,
 p
la
qu
e 
bu
rd
en
, P
CI
, p
er
cu
ta
ne
ou
s 
co
ro
na
ry
 in
te
rv
en
tio
n;
 T
CF
A
, t
hi
n-
ca
p 
fib
ro
at
he
ro
m
a.
Co
r
o
n
a
r
y 
vu
ln
er
a
b
ility
12
PROGNOSTIC VALUE 
OF INTRAVASCULAR 
ULTRASOUND IN 
PATIENTS WITH 
CORONARY ARTERY 
DISEASE
AUTHORS
Anne-Sophie Schuurman
Maxime M Vroegindewey
Isabella Kardys
Rohit M Oemrawsingh
Hector M Garcia-Garcia
Robert-Jan M van Geuns
Evelyn Regar
Nicolas M van Mieghem
Jurgen MR Ligthart
Patrick W Serruys
Eric Boersma
K Martijn Akkerhuis
J Am Coll Cardiol 2018 Oct 23; 72(17): 2003-2011 
12
PROGNOSTIC VALUE 
OF INTRAVASCULAR 
ULTRASOUND IN 
PATIENTS WITH 
CORONARY ARTERY 
DISEASE
AUTHORS
Anne-Sophie Schuurman
Maxime M Vroegindewey
Isabella Kardys
Rohit M Oemrawsingh
Hector M Garcia-Garcia
Robert-Jan M van Geuns
Evelyn Regar
Nicolas M van Mieghem
Jurgen MR Ligthart
Patrick W Serruys
Eric Boersma
K Martijn Akkerhuis
J Am Coll Cardiol 2018 Oct 23; 72(17): 2003-2011 
202 Chapter 12
absTRaCT
background: Intravascular ultrasound (IVUS) and radiofrequency (RF-)IVUS have shown 
to be able to detect high-risk coronary plaque characteristics.
Objectives: We studied the long-term prognostic value of (RF-)IVUS-derived plaque 
characteristics in patients with coronary artery disease (CAD) undergoing coronary 
angiography.
Methods: During 2008-2011, (RF-)IVUS was performed in one non-stenotic segment of a 
non-culprit coronary artery in 581 patients undergoing coronary angiography for acute 
coronary syndrome (ACS) or stable angina. The predefined primary endpoint was MACE, 
defined as the composite of all-cause death, non-fatal ACS or unplanned revasculariza-
tion. Hazard ratios (HR) were adjusted for age, sex and clinical risk factors.
Results: During a median follow-up of 4.7 years, 152 patients (26.2%) had MACE. The 
presence of a lesion with a minimal luminal area ≤4.0mm² was independently associ-
ated with MACE (HR:1.49, 95%CI:1.07-2.08, p=0.020), whereas the presence of a thin-
cap fibroatheroma lesion or a lesion with a plaque burden ≥70% on their own were 
not. Results were comparable when the composite endpoint included cardiac death 
instead of all-cause death. The presence of a lesion with a plaque burden of ≥70% was 
independently associated with the composite endpoint of cardiac death, nonfatal ACS 
or unplanned revascularization after exclusion of culprit-lesion related events (HR:1.66, 
95%CI:1.06-2.58, p=0.026). Likewise, each 10 units increase in segmental plaque burden 
was independently associated with a 26% increase in risk of this composite endpoint 
(HR:1.26 per 10 units increase, 95%CI:1.03-1.52, p=0.022).
Conclusions: IVUS-derived small luminal area and large plaque burden, and not RF-
IVUS-derived compositional plaque features on their own, predict adverse cardiovascu-
lar outcome during long-term follow-up in patients with CAD.
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InTRODuCTIOn
Patients with coronary artery disease (CAD) are at increased risk of recurrent adverse 
cardiovascular events, such as acute coronary syndromes (ACS).(1,2) Whereas coronary 
angiography (CAG) only yields a two-dimensional silhouette of the lumen,(3) greyscale 
intravascular ultrasound (IVUS) and radiofrequency (RF-)IVUS have shown to be able 
to identify high-risk coronary plaque characteristics within the coronary artery wall.
(4-7) Therefore, (RF-)IVUS may be useful to identify patients at increased risk of future 
adverse cardiovascular events.(6-8) Autopsy studies suggest that an ACS is often caused 
by rupture or fissure of a thin-cap fibroatheroma (TCFA), a vulnerable coronary plaque 
containing a large lipid-rich necrotic core overlaid by a thin inflamed fibrous cap.(9-12) 
Identification of this vulnerable coronary plaque phenotype by invasive imaging may 
therefore improve risk stratification and management of CAD patients.
To date, a few studies have investigated the prognostic value of (RF-)IVUS for adverse 
cardiovascular outcome.(13,14) The PROSPECT (Providing Regional Observations to 
Study Predictors of Events in the Coronary Tree) study demonstrated that (RF-)IVUS-
derived high-risk plaque characteristics in the three major coronary arteries predict 
adverse cardiac events in patients admitted with ACS during long-term follow-up.(13) 
However, patients with stable angina pectoris (SAP) were not included in PROSPECT and 
the number of endpoint events in that study was primarily driven by rehospitalizations. 
Our ATHEROREMO-IVUS (European Collaborative Project on Inflammation and Vascular 
Wall Remodeling in Atherosclerosis – Intravascular Ultrasound) study demonstrated that 
high-risk plaque characteristics, as derived by (RF-)IVUS in one non-stenotic segment 
of a non-culprit coronary artery were predictive of adverse cardiovascular events in a 
broad spectrum of patients with CAD, including SAP, at 1-year follow-up.(15) We now 
report the long-term (median 4.7 years) follow-up data.
MeTHODs
study design and population
The design of the ATHEROREMO-IVUS study has been described in detail elsewhere.
(15,16) Briefly, between 2008 and 2011, 581 patients undergoing diagnostic CAG or 
percutaneous coronary intervention (PCI) for ACS or SAP underwent (RF-)IVUS imaging 
of a non-culprit coronary artery in the Erasmus MC, Rotterdam, The Netherlands.(15,16) 
Baseline (RF-)IVUS images were analyzed off-line and were not used for patient care. 
Thereafter, patients were followed-up on adverse cardiovascular outcome.
The ATHEROREMO-IVUS study was approved by the medical ethics committee of 
the Erasmus MC and was performed in accordance with the declaration of Helsinki. All 
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patients provided written informed consent which included approval for long-term 
follow-up. The ATHEROREMO-IVUS study was registered in ClinicalTrialsgov.org, number 
NCT01789411.
Intravascular ultrasound
Subsequent to the standard index CAG, (RF-)IVUS imaging was performed in a non-
stenotic segment of a non-culprit coronary artery. The target segment in this non-culprit 
coronary artery was required to be at least 40 mm in length and without significant 
luminal narrowing (<50% stenosis) as assessed by on-line angiography. The order of 
preference for selection of the non-culprit vessel was; (i) left anterior descending artery, 
(ii) right coronary artery, (iii) left circumflex artery.(15,16) IVUS images were acquired by 
the Volcano s5/s5i Imaging system, including a Volcano Eagle Eye Gold IVUS catheter 
(20 MHz) that was automatically pulled back at a standard speed of 0.5 mm/s (Volcano 
Corp., San Diego, CA, USA). Greyscale- and RF-IVUS data were analyzed off-line by an in-
dependent core laboratory (Cardialysis, Rotterdam, The Netherlands) using the pcVH 2.1 
and qVH software (Volcano Corp., San Diego, CA, USA). The core laboratory was blinded 
to all other patient characteristics and outcome data.
Greyscale IVUS measurements included segmental plaque volume and plaque bur-
den. The external elastic membrane and luminal borders were contoured for each frame 
(median interslice distance, 0.40 mm). Segmental plaque burden was defined as the 
plaque and media cross-sectional area divided by the external elastic membrane cross-
sectional area. A coronary lesion was defined as a segment with a plaque burden of 
more than 40% in at least 3 consecutive frames. Using RF-IVUS analyses, compositional 
features of coronary lesions were classified as fibrous, fibro-fatty, necrotic core or dense 
calcium.(5,15,16) Confluent necrotic core or dense calcium, or the contact of necrotic 
core with the lumen, were assessed by visual examination performed independently by 
three investigators blinded to outcome data. Coronary lesions were further classified 
into 8 different lesion types.(7,15,16) The mentioned criteria should be present in three 
consecutive frames for a lesion to be considered of a particular category. Three lesions, 
as identified by (RF-)IVUS, were considered as lesions associated with a high risk for 
subsequent adverse cardiac events; 1) TCFA lesion, defined as a lesion with the presence 
of >10% confluent necrotic core in direct contact with the lumen; 2) lesion with a plaque 
burden ≥70%; 3) lesion with a minimal luminal area ≤4.0mm².(15)
follow-up
Follow-up was reported by January 2015. Vital status of the patients was obtained from 
municipal civil registries. Subsequently, as a first screening method, follow-up question-
naires were sent to all living patients for identifying possible adverse events. Thereafter, 
hospital discharge letters were obtained if any hospitalization or possible event was re-
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ported. In patients who did not return the questionnaire, the local hospital records were 
investigated for possible events. Cause of death was obtained from hospital records, 
autopsy reports or general practitioner notes.
study endpoints
The predefined primary endpoint consisted of major adverse cardiovascular events 
(MACE), defined as the composite of all-cause death, non-fatal ACS, or unplanned revas-
cularization during long-term follow-up. In accordance with our previous studies on the 
prognostic value of (RF-)IVUS and near-infrared spectroscopy (NIRS) in this study popu-
lation, we also performed a predefined analysis on the composite endpoint of cardiac 
death, non-fatal ACS, or unplanned revascularization. This analysis was performed based 
on the pathophysiological concept that (RF-)IVUS-derived plaque characteristics would 
hypothetically be more likely associated with (atherosclerotic-driven) cardiovascular 
events and not with definite non-cardiac events (such as death because of malignancy). 
Similarly, an additional analysis was performed on this endpoint after exclusion of defi-
nite culprit lesion-related events. This exploratory analysis aimed to assess the question 
as to whether the atherosclerotic burden, as assessed in a single, non-culprit coronary 
artery segment, would reflect vulnerability of the entire coronary tree.
In accordance with the guidelines of the European Society of Cardiology, non-fatal 
ACS was defined as the clinical diagnosis of ST-segment Elevation Myocardial Infarction 
(STEMI), non-STEMI, or unstable angina.(17,18) Unplanned coronary revascularization 
was defined as urgent revascularization for ACS or unplanned (i.e. not part of pre-
planned multi-stage PCI) elective revascularization for progressive angina pectoris. 
Cardiac death was defined as any death due to proximate cardiac cause, unwitnessed 
death or death of unknown cause.
Based on original source data of available coronary angiography and hospital records 
at the time of the event, the clinical event committee adjudicated (blinded to IVUS data) 
whether the event was related to the coronary site that had been treated during the 
index procedure (culprit lesion-related event) or as related to a coronary site that had 
not been treated during the index procedure (non-culprit lesion-related event). Events 
that were related to both the culprit lesion and a non-culprit site (e.g. revascularization 
of multiple vessels with CABG) were classified into both categories. When information 
was not sufficient to classify an event as either culprit lesion related or non-culprit lesion 
related, the event was classified as indeterminate.(15)
statistical analysis
Normally-distributed continuous variables were reported as means and standard devia-
tions. Non-normally-distributed variables were reported as medians and interquartile 
ranges (IQR). Categorical variables were reported as numbers and percentages.
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Cumulative events rates were estimated by the Kaplan-Meier method and differences 
between groups were evaluated by the Log-rank test. Patients that were lost to follow-
up were censored at the date of last contact. In case a patient had multiple events, the 
first event was counted for the composite endpoint.
The associations between (RF-)IVUS characteristics and study endpoints were further 
analyzed by Cox proportional hazard regression analysis. We applied multivariable Cox 
regression, with adjustment for age, sex, diabetes mellitus, hypertension, dyslipidemia, 
indication for CAG (ACS or SAP), history of myocardial infarction, history of PCI, history 
of CABG, history of peripheral artery disease and PCI performed at index procedure. 
These potential confounders were chosen based on clinical relevance or their significant 
association with MACE in univariable Cox regression analysis. Hazard ratios (HRs) were 
reported with 95% confidence intervals (95% CIs).
In case the composite endpoint was defined with exclusion of culprit lesion-related 
events, the occurrence of a culprit lesion-related event as a first event during follow-up 
was not counted and the patient was not censored as this patient is considered to be still 
at risk of a non-culprit lesion-related or indeterminate event during further follow-up. 
When the composite endpoint was based on non-culprit lesion-related or indeterminate 
events, patients were only censored in case a non-culprit lesion-related or indeterminate 
event occurred, if they were lost-to-follow-up or if they died.
All statistical tests were two-tailed and p-values <0.05 were considered statistically 
significant. Statistical analyses were performed using IBM SPSS statistics version 21.0 
(IBM Corp., Armonk, New York).
ResulTs
baseline characteristics
Mean age of the patients was 61.6 ± 11.3 years, 75.6% were men and 54.7% presented 
with an ACS (Table 1). Median segmental plaque burden was 39.1 (IQR: 30.0-46.4)%, and 
plaque volume was 222.7 (IQR: 136.1-326.6)mm³. On the basis of (RF-)IVUS, 724 lesions 
were identified in 508 (87.4%) patients that had at least one lesion in the imaged seg-
ment, including 127 (17.5%) lesions with a plaque burden ≥70% in 124 (21.3%) patients, 
206 (28.5%) lesions with a minimal luminal area ≤4.0 mm² in 182 (31.3%) patients and 
74 (10.2%) lesions with both plaque characteristics in 74 (12.7%) patients. On the basis 
of RF-IVUS, 271 (37.4%) TCFA lesions were identified in 242 (41.7%) patients, including 
71 (9.8%) TCFA lesions with a plaque burden ≥70% in 69 patients (11.9%), 61 (8.4%) TCFA 
lesions with a minimal luminal area ≤4.0 mm² in 61 (10.5%) patients and 35 (4.8%) TCFA 
lesions with both plaque characteristics in 35 (6.0%) patients.
Prognostic value of intravascular ultrasound in patients with coronary artery disease 207
C
h
a
p
te
r
 1
2
Table 1. baseline characteristics
n = 581 patients
Clinical characteristics
Age, years 61.6 ± 11.3
Men, n (%) 439 (75.6)
Diabetes Mellitus, n (%) 99 (17.0)
Hypertension, n (%) 300 (51.6)
Dyslipidemia, n (%) 321 (55.2)
Current smoking, n (%) 169 (29.1)
Positive family history, n (%) 301 (51.8)
Previous MI, n (%) 184 (31.7)
Previous PCI, n (%) 186 (32.0)
Previous CABG, n (%) 18 (3.1)
Previous CVA, n (%) 26 (4.5)
History of peripheral artery disease, n (%) 36 (6.2)
History of renal impairment, n (%) 32 (5.5)
History of heart failure, n (%) 19 (3.3)
Median C-reactive protein, mg/L 2.1 [0.9-5.4]
Procedural characteristics
Indication for coronary angiography
Acute MI, n (%) 167 (28.7)
Unstable angina, n (%) 151 (26.0)
Stable angina, n (%) 254 (43.7)
Other, n (%) 9 (1.5)
PCI performed, n (%) 511 (88.0)
Coronary artery disease
No significant stenosis, n (%) 43 (7.4)
1-vessel disease, n (%) 308 (53.0)
2-vessel disease, n (%) 168 (28.9)
3-vessel disease, n (%) 62 (10.7)
IVus characteristics
Imaged coronary artery
Left anterior descending, n (%) 210 (36.1)
Left circumflex, n (%) 195 (33.6)
Right coronary artery, n (%) 176 (30.3)
Median imaged segment length, mm 44.3 [33.8-55.4]
Median segmental plaque burden, % 39.1 [30.0-46.4]
Median segmental plaque volume, mm³ 222.7 [136.1-326.6]
CABG, coronary artery bypass graft; CVA, cerebrovascular accident; MI, myocardial infarction; PCI, percu-
taneous coronary intervention.
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Incidence of study endpoints
Median follow-up time was 4.7 (IQR: 4.2-5.6) years. Follow-up questionnaires were sent 
to all 528 (90.9%) living patients and were completed by 86%. The predefined composite 
endpoint of all-cause death, non-fatal ACS or unplanned revascularization occurred in 
152 patients (26.2%) (Table 2). A total of 27 events were classified as definite culprit 
lesion-related, 72 as non-culprit lesion-related and 53 as indeterminate event (Table 2). 
The composite endpoint of cardiac death, non-fatal ACS or unplanned revascularization 
occurred in 125 patients (21.5%) (Table 2). The composite endpoint of cardiac death, 
non-fatal ACS or unplanned revascularization after exclusion of definite culprit lesion-
related events occurred in 98 patients (16.9%) (Table 2).
Table 2. Incidence of composite endpoints.
Definite 
ClR 
events
Definite 
non-ClR 
events
Indeterminate 
events
non-ClR and 
indeterminate 
events 
combined
all 
events
Composite of MaCe, n 27 72 53 125 152a
Death from any cause, n 1 11 38 49 50
Cardiac death, n 1 4 20 24 25
Nonfatal ACS, n 13 24 10 34 47
Unplanned revascularization, n 13 37 5 42 55
Composite of cardiac death, 
nonfatal aCs or unplanned 
revascularization, n
27 63 35 98c 125b
a. Composite of MACE; all-cause death, nonfatal ACS or unplanned revascularization.
b. Composite of cardiac death, nonfatal ACS or unplanned revascularization.
c. Non-culprit lesion-related and indeterminate cardiac death, nonfatal ACS or unplanned revasculariza-
tion.
ACS, acute coronary syndrome; CLR, culprit lesion-related; MACE, major adverse cardiovasulcar events.
Numbers refer to the first event counted for the composite endpoint.
association between (Rf-)IVus and MaCe
The presence of a lesion with a minimal luminal area ≤4.0 mm² was significantly and 
independently associated with MACE (cumulative MACE incidence when present: 33.9% 
vs. 22.2% when absent; adjusted HR: 1.49, 95% CI: 1.07-2.08, p=0.020) (Table 3). Fur-
thermore, the presence of a TCFA lesion with a plaque burden ≥70% was significantly 
associated with MACE (cumulative MACE incidence when present: 37.7% vs. 24.6% when 
absent; adjusted HR: 1.73, 95% CI: 1.12-2.66, p=0.013), while the presence of a TCFA le-
sion or a lesion with a plaque burden ≥70% itself was not independently associated 
with MACE (Table 3). After multivariable adjustment, segmental plaque burden and 
plaque volume remained no longer independently associated with MACE (Table 3). Re-
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sults were essentially similar when definite culprit lesion-related events were excluded. 
Cox regression analysis with follow-up duration as time-dependent variable showed 
that both the presence of a TCFA lesion and a lesion with a plaque burden ≥70% were 
strong predictors of MACE for the first year of follow-up, but not beyond 1-year follow-
up. On the contrary, a lesion with a minimal luminal area ≤4.0 mm² itself was not an 
independent predictor in the first year of follow-up (adjusted HR: 1.40, 95% CI: 0.83-2.34, 
p=0.21), but did predict MACE beyond 1-year of follow-up (1-year to 5-year follow-up 
adjusted HR: 1.58, 95% CI: 1.04-2.40, p=0.032). Results remained essentially similar when 
we performed an exploratory multivariable analysis applying the model used for the 
1-year follow-up data (which comprised 6 variables instead of the 11 variables used in 
the model for the current analyses) (Supplemental table 1).
Table 3. associations of (Rf-)IVus and risk of adverse cardiac events at 4.7-years follow-up
unadjusted model
HR (95% CI)
P-value full model
HR (95% CI)
P-value
MaCe
TCFA 1.20 (0.87-1.65) 0.27 1.27 (0.91-1.77) 0.16
PB ≥70% 1.50 (1.05-2.16) 0.028 1.33 (0.92-1.93) 0.13
MLA ≤4.0 mm² 1.57 (1.13-2.17) 0.007 1.49 (1.07-2.08) 0.020
TCFA + PB ≥70% 1.90 (1.25-2.90) 0.003 1.73 (1.12-2.66) 0.013
TCFA + MLA ≤4.0 mm² 1.47 (0.93-2.33) 0.10 1.50 (0.93-2.44) 0.10
TCFA + PB ≥70% + MLA ≤4.0 mm² 1.64 (0.93-2.89) 0.089 1.74 (0.97-3.13) 0.066
PB≥70% + MLA ≤4.0 mm² 1.29 (0.83-2.01) 0.26 1.30 (0.82-2.04) 0.26
Segmental plaque burden, % 1.24 (1.07-1.44) 0.004 1.15 (0.98-1.34) 0.079
Segmental plaque volume, mm³ 1.07 (0.96-1.20) 0.23 1.02 (0.90-1.14) 0.79
Composite endpoint of cardiac death, non-fatal aCs or unplanned revascularization
TCFA 1.04 (0.73-1.49) 0.83 1.12 (0.77-1.61) 0.56
PB ≥70% 1.63 (1.10-2.42) 0.014 1.43 (0.96-2.15) 0.083
MLA ≤4.0 mm² 1.85 (1.30-2.64) 0.001 1.82 (1.26-2.64) 0.001
TCFA + PB ≥70% 1.95 (1.23-3.09) 0.005 1.78 (1.11-2.85) 0.017
TCFA + MLA ≤4.0 mm² 1.74 (1.08-2.81) 0.023 1.86 (1.11-3.10) 0.018
TCFA + PB ≥70% + MLA ≤4.0 mm² 1.84 (1.02-3.34) 0.044 2.09 (1.12-3.89) 0.020
PB≥70% + MLA ≤4.0 mm² 1.45 (0.91-2.32) 0.12 1.51 (0.93-2.45) 0.093
Segmental plaque burden, % 1.28 (1.09-1.50) 0.003 1.17 (0.99-1.39) 0.070
Segmental plaque volume, mm³ 1.06 (0.93-1.20) 0.40 0.98 (0.86-1.12) 0.80
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Table 3 (continued)
unadjusted model
HR (95% CI)
P-value full model
HR (95% CI)
P-value
Composite endpoint of cardiac death, non-fatal aCs or unplanned revascularization exclusive of culprit 
lesion-related events
TCFA 0.99 (0.66-1.48) 0.95 1.07 (0.70-1.62) 0.76
PB ≥70% 2.08 (1.36-3.18) 0.001 1.66 (1.06-2.58) 0.026
MLA ≤4.0 mm² 2.03 (1.37-3.03) <0.001 1.88 (1.24-2.83) 0.003
TCFA + PB ≥70% 2.17 (1.32-3.59) 0.002 1.84 (1.10-3.07) 0.021
TCFA + MLA ≤4.0 mm² 1.64 (0.95-2.84) 0.078 1.75 (0.98-3.13) 0.059
TCFA + PB ≥70% + MLA ≤4.0 mm² 1.97 (1.02-3.79) 0.042 2.03 (1.03-4.02) 0.041
PB≥70% + MLA ≤4.0 mm² 1.77 (1.07-2.92) 0.026 1.73 (1.04-2.90) 0.035
Segmental plaque burden, % 1.41 (1.18-1.69) <0.001 1.26 (1.03-1.52) 0.022
Segmental plaque volume, mm³ 1.13 (0.99-1.30) 0.080 1.03 (0.89-1.20) 0.68
Hazard ratios per 10 and 100 units increase in segmental plaque burden and plaque volume, respectively.
CI, confidence interval; HR, hazard ratio; IVUS, intravascular ultrasound; MACE, major adverse cardiovas-
cular events; MLA, minimal luminal area; PB, plaque burden; RF, radiofrequency; TCFA, thin-cap fibroath-
eroma.
figure 1. association between the absence or presence of a lesion with a minimal luminal area ≤4.0 
mm² and the composite endpoint of cardiac death, non-fatal aCs or unplanned revascularization. 
P-value obtained by the log-rank test.
ACS, acute coronary syndrome; IVUS, intravascular ultrasound
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association between (Rf-)IVus and the composite endpoint of cardiac death, 
non-fatal aCs or unplanned revascularization
The presence of a lesion with a minimal luminal area ≤4.0 mm² was also significantly and 
independently associated with a higher rate of the composite endpoint of cardiac death, 
non-fatal ACS or unplanned revascularization (cumulative incidence of composite end-
point when present: 30.6% vs. 16.9% when absent; adjusted HR: 1.82, 95% CI:1.26-2.64, 
p=0.001) (Figure 1 and Table 3). The same was true for TCFA lesions with a plaque burden 
≥70% or a minimal luminal area ≤4.0 mm² (Table 3). The highest risk, in terms of adjusted 
HRs, was among patients who had a TCFA lesion with both a plaque burden ≥70% and a 
minimal luminal area ≤4.0 mm² (cumulative incidence of composite endpoint when pres-
ent: 34.3% vs. 20.7% when absent; adjusted HR: 2.09, 95% CI: 1.12-3.89, p=0.020) (Table 3).
These associations remained essentially unchanged after exclusion of culprit lesion-
related events (Figure 2 and Table 3). In addition, a significant association was observed 
figure 2. association between (Rf-)IVus derived lesion characteristics and the composite endpoint 
of cardiac death, non-fatal aCs or unplanned revascularization, after exclusion of culprit lesion-
related events. Percentages are cumulative events rates estimated by the Kaplan-Meier method. 
Prevalence (%) in the footer refers to the prevalence of the specific (Rf-)IVus characteristic. P-val-
ues are obtained by the log-rank test. Hazard ratios are estimated by univariate Cox regression 
analyses.
ACS, acute coronary syndrome; MLA, minimal luminal area; PB, plaque burden; TCFA, thin-cap fibroath-
eroma
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for the presence of a lesion with a plaque burden ≥70%, or its combination with a mini-
mal luminal area ≤4.0 mm², as well as for segmental plaque burden with each 10 units 
increase in segmental plaque burden resulting in a 26% increase in risk for occurrence of 
the composite endpoint of cardiac death, non-fatal ACS or unplanned revascularization 
after exclusion of culprit lesion-related events (adjusted HR: 1.26 per 10 units increase, 
95% CI: 1.03-1.52, p=0.022) (Figure 2 and Table 3).
DIsCussIOn
This 4.7-year follow-up of the ATHEROREMO-IVUS study demonstrated that a small 
luminal area and a large plaque burden, but not RF-IVUS-derived compositional plaque 
features on their own, are independent determinants of (non-culprit lesion-related) ad-
verse cardiac events in patients with CAD. The increased risk associated with a minimal 
luminal area ≤4.0 mm² was not observed at 1-year follow-up,(15) whereas the prognostic 
value of plaque burden ≥70% was confirmed although statistical significance was not 
consistently present for all different composite endpoints. In contrast, the independent 
association between a TCFA lesion as an isolated characteristic and adverse outcome at 
1-year did not persist during long-term follow-up. Still, patients with a TCFA lesion with 
a large plaque burden and/or a small luminal area were at increased risk.
In line with the PROSPECT study, we found that a lesion with a large plaque burden, 
small luminal area, or their combination with a TCFA lesion, predicted adverse cardiovas-
cular events in patients with CAD during long-term follow-up. In contrast to the PROS-
PECT and Virtual histology Intravascular ultrasound in Vulnerable Atherosclerosis (VIVA) 
study, we did not find such an independent association for a TCFA lesion on its own.
(13,14) However, the results of our study and the PROSPECT study cannot be directly 
compared since different definitions of study endpoints were used. In addition, PROS-
PECT only included patients admitted with ACS and the study endpoint was primarily 
driven by rehospitalizations.(13) Furthermore, in the VIVA study only univariable regres-
sion analysis was performed due to the small number of endpoints.(14) Importantly, in 
both the PROSPECT and VIVA study, (RF-)IVUS was applied in all three major coronary 
arteries, whereas in our study only one single non-stenotic non-culprit coronary artery 
segment was investigated.(13,14)
We consider several possible explanations for the inconsistent association between 
the presence of a TCFA lesion as an isolated characteristic and the risk of adverse cardiac 
events during short-term versus long-term follow-up. First, controversy exists about 
the ability of RF-IVUS to correctly discern and identify the thin-cap and necrotic core 
as individual components of a TCFA lesion, due to the limitations with respect to spa-
tial resolution.(4,19) Second, the dynamic nature of TCFA lesions over time should be 
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appreciated, since it has been described that particularly (proximal) TCFA lesions with 
a large plaque burden heal less often and might have a greater tendency to rupture.
(20) This may explain our finding that the presence of a TCFA lesion with a large plaque 
burden was associated with an increased risk for adverse cardiac events over 4.7-years 
of follow-up, whereas a TCFA lesion in itself was not. Third, previous studies have demon-
strated that a lesion with a large plaque burden is a consistent and prevalent predictor 
for adverse cardiac outcome. However, whereas the atherosclerotic disease burden has 
been shown as a consistent and strong predictor of adverse cardiovascular events, no 
study has yet demonstrated that a TCFA lesion by itself independently predicts adverse 
cardiovascular outcome after adjustment for plaque burden and other potential con-
founders.(13,14,21,22)
Our current study suggests that a RF-IVUS-derived TFCA lesion only has long-term 
prognostic value if accompanied with other high-risk plaque features. Therefore, this 
study further adds to the discussion as to whether RF-IVUS offers incremental prognostic 
value to greyscale IVUS in terms of identification of high-risk coronary plaque phenotypes 
based on compositional features. In addition, our current study demonstrates for the 
first time that (RF-)IVUS plaque characteristics, as assessed in one non-stenotic segment 
of a non-culprit coronary artery, predicts adverse cardiovascular events in patients with 
CAD during long-term follow-up. A post-hoc analysis did not show heterogeneity in the 
HR estimates in patients with ACS versus SAP. Moreover, the large number of endpoints 
allowed for a separate analysis with exclusion of culprit-lesion related endpoint events, 
with results that remained essentially unchanged. This indicates that (RF-)IVUS-derived 
plaque characteristics, as identified in one non-culprit coronary artery segment, may 
reflect atherosclerotic vulnerability of the entire coronary tree.
Recently, we have demonstrated that the lipid core burden index, as assessed by 
NIRS in a single non-culprit coronary artery segment, predicts adverse cardiovascular 
outcome, independent of clinical characteristics and IVUS-derived segmental plaque 
burden, over 4 years in CAD patients referred for CAG.(23) In this context, a combined 
NIRS-IVUS catheter may improve the (long-term) prognostic value of intravascular imag-
ing in patients with CAD.(24)
limitations
Several study limitations warrant consideration. First, the number of TCFA lesions might 
be overestimated by RF-IVUS because of the limited spatial resolution with respect to the 
identification of the thin-cap of a TCFA lesion. Second, IVUS imaging was not repeated 
during follow-up. Therefore, we could not account for the potential dynamic nature of 
coronary lesions. It should also be noted that this study does not provide insight in how 
the individual lesion correlates to the adverse event. Third, the follow-up questionnaire 
was completed by 86% of the patients. Although for the majority of the remaining 
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patients follow-up information was retrieved from our local hospital records, we cannot 
fully exclude the possibility that loss to follow-up was in part selective. However, our 
study reflects daily clinical practice since patients admitted with both ACS and SAP were 
included. Besides, the current study represents a long-term study investigating the as-
sociation between (RF-)IVUS-derived plaque characteristics and adverse cardiovascular 
outcome during 4.7-years of follow-up in patients with ACS or SAP, which represents the 
longest follow-up reported so far.
Conclusions
This study demonstrates that a small luminal area and a large plaque burden, and 
not RF-IVUS-derived compositional plaque features on their own, as assessed by (RF-)
IVUS in one single non-stenotic segment of a non-culprit coronary artery, predict (non-
culprit lesion-related) adverse cardiovascular outcome during long-term follow-up over 
4.7-years in patients with CAD. In contrast, this study did not show a single isolated 
imaging parameter as derived by RF-IVUS to be of long-term independent prognostic 
value.
PeRsPeCTIVes
Core Clinical Competencies
Competency in Medical Knowledge
Whereas coronary angiography only yields a two-dimensional silhouette of the lu-
men, greyscale intravascular ultrasound (IVUS) and radiofrequency (RF-)IVUS have 
been shown to be able to identify high-risk coronary plaque characteristics within the 
coronary artery wall. Therefore, (RF-)IVUS may be useful to identify patients at increased 
risk of future adverse cardiovascular events. Identification of high-risk coronary plaque 
characteristics by invasive imaging may therefore improve risk stratification and man-
agement of patients with coronary artery disease.
Translational Outlook
Future studies should investigate whether a combined NIRS-IVUS catheter as an inva-
sive imaging tool may improve risk prediction, as well as prevention and treatment of 
patients at increased risk of adverse cardiovascular outcome.
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supplemental table 1. associations of (Rf-)IVus characteristics and risk of MaCe at 4.7-years of 
follow-up using two different models for multivariable adjustment.
1-year follow-up 
data – adjusted 
model with 6 
covariates
HR (95% CI) P-value
5-year follow-up 
data – adjusted 
model with 6 
covariates
HR (95% CI) † P-value
5-year follow-up 
data – adjusted 
model with 11 
covariates
HR (95% CI) ‡ P-value
MaCe
TCFA 1.98 (1.09-3.60) 0.026 1.25 (0.90-1.73) 0.18 1.27 (0.91-1.77) 0.16
PB≥70% 2.90 (1.60-5.25) <0.001 1.42 (0.99-2.05) 0.059 1.33 (0.92-1.93) 0.13
MLA≤4.0mm² 1.23 (0.67-2.26) 0.50 1.51 (1.09-2.09) 0.014 1.49 (1.07-2.08) 0.020
TCFA+PB≥70% – – 1.80 (1.18-2.75) 0.007 1.73 (1.12-2.66) 0.013
TCFA+ MLA≤4.0mm² – – 1.61 (1.01-2.57) 0.046 1.50 (0.93-2.44) 0.10
TCFA+PB≥70%+ 
MLA≤4.0mm²
– – 1.82 (1.02-3.26) 0.043 1.74 (0.97-3.13) 0.066
Segmental plaque 
burden (per 10 units 
increase)
– – 1.17 (1.01-1.36) 0.040 1.15 (0.98-1.34) 0.079
Segmental plaque 
volume (per 100 
units increase)
– – 1.03 (0.92-1.16) 0.63 1.02 (0.90-1.14) 0.79
CI, confidence interval; HR, hazard ratio; IVUS, intravascular ultrasound; MACE, major adverse cardiovas-
cular events; MLA, minimal luminal area; PB, plaque burden; RF, radiofrequency; TCFA, thin-cap fibroath-
eroma.
† Variables entered in the 6-covariate model were age, gender, diabetes mellitus, hypertension, history of 
percutaneous coronary intervention and indication for coronary angiography.
‡ Variables entered in the 11-covariate model were age, gender, diabetes mellitus, hypertension, his-
tory of percutaneous coronary intervention, indication for coronary angiography, dyslipidemia, history of 
myocardial infarction, history of coronary artery bypass grafting, history of peripheral artery disease and 
percutaneous coronary intervention performed at index.
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absTRaCT
Objective: SYNTAX score II (SSII) is a long-term mortality prediction model to guide the 
decision making of the heart-team between coronary artery bypass grafting or percu-
taneous coronary intervention (PCI) in patients with left main or three-vessel coronary 
artery disease. This study aims to investigate the long-term predictive value of SSII for 
all-cause mortality in patients with one- or two-vessel disease undergoing PCI.
Methods: A total of 628 patients (76% men, mean age: 61±10 years) undergoing PCI due 
to stable angina pectoris (43%) or acute coronary syndrome (57%), included between 
January 2008 and June 2013, were eligible for the current study. SSII was calculated us-
ing the original SYNTAX score website (www.syntaxscore.com). Cox regression analysis 
was used to assess the association between continuous SSII and long-term all-cause 
mortality. The area under the receiver-operating characteristic curve was used to assess 
the performance of SSII.
Results: SSII ranged from 6.6 to 58.2 (median: 20.4, interquartile range: 16.1-26.8). In 
multivariable analysis, SSII proved to be an independent significant predictor for 4.5-
year mortality (hazard ratio per point increase: 1.10; 95% confidence interval: 1.07-1.13; 
p<0.001). In terms of discrimination, SSII had a concordance index of 0.77.
Conclusion: In addition to its established value in patients with left main and three-
vessel disease, SSII may also predict long-term mortality in PCI-treated patients with 
one- or two-vessel disease.
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InTRODuCTIOn
The SYNTAX score II (SSII) has been established as a long-term mortality prediction 
model to guide the decision making of the heart-team between coronary artery bypass 
grafting (CABG) or percutaneous coronary intervention (PCI) in patients with complex 
coronary artery disease (CAD).[1] It combines the original anatomical-based SYNTAX 
score, which grades the complexity of CAD in all coronary arteries, with the clinical base-
line variables that have shown to be important predictors of 4-year all-cause mortality 
in the SYNTAX trial.[1]
SSII has been validated in large patient cohorts with left main or three-vessel disease.
[1-3] However, the predictive performance of SSII on long-term mortality in patients 
with less complex CAD is currently unknown.
This study aims to investigate the long-term predictive value of SSII for all-cause 
mortality in patients with one- or two-vessel disease undergoing PCI.
MeTHODs
study design and population
This study combines the populations of The European Collaborative Project on Inflam-
mation and Vascular Wall Remodeling in Atherosclerosis-intravascular ultrasound 
(ATHEROREMO-IVUS) study and the Integrated Biomarker and Imaging Study-3 (IBIS-3).
[4, 5] Study designs and methods of ATHEROREMO-IVUS and IBIS-3 have been described 
in detail elsewhere.[4, 5] Baseline study procedures and inclusion criteria were similar 
and both studies were conducted at the Erasmus Medical Center, Rotterdam, The Neth-
erlands. In brief, patients undergoing diagnostic coronary angiography (CAG) or PCI for 
an acute coronary syndrome (ACS) or stable angina pectoris (SAP) were included. Dur-
ing CAG, invasive imaging was performed in one non-culprit coronary artery segment. 
Subsequently, patients were followed-up on adverse cardiovascular events. Patient care 
was left at the discretion of the physician. During the first year after the index procedure, 
as per protocol, patients included in IBIS-3 received high dose rosuvastatin.
The medical ethics committee of the Erasmus MC approved both the ATHEROREMO-
IVUS and IBIS-3 study. Both studies were performed in accordance with the declaration 
of Helsinki. All patients provided written informed consent for their participation in 
these studies, and compliance with the study protocols, including long-term follow-up. 
The ATHEROREMO-IVUS study is registered in ClinicalTrials.gov, number NCT01789411, 
and the IBIS-3 study is registered in The Netherlands trial register, number NTR2872.
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sYnTaX score II
The anatomical-based SYNTAX score was determined (pre-PCI) for every coronary an-
giogram taken at study entry, by a trained analyst blinded for patient characteristics and 
outcome using the SYNTAX Score Calculator (www.syntaxscore.com). The calculation of 
the anatomical-based SYNTAX score has been described in detail previously.[6] In brief, 
the complete coronary tree is divided in 16 segments and assessed for lesions produc-
ing 50% or more luminal obstruction. Every segment has a pre-specified corresponding 
weighing factor which, in case of a significant lesion, is added to the SYNTAX score by 
the SYNTAX Score Calculator. Moreover, other variables (i.e. calcification or lesion length) 
that reflect the complexity of a patient’s CAD and, thus, the complexity of treatment 
are assessed and taken into account in the SYNTAX score. Eventually, the SYNTAX score 
is composed of these total points summed, and reflects the complexity of a patient’s 
CAD. As previously applied in other all-comers and ST-segment elevation myocardial 
infarction (STEMI) populations, lesions caused by in-stent restenosis were treated as de 
novo lesions.[7-9] Total occlusions were scored as occlusions of unknown duration, as 
the analyst was blinded for all patient information.[10]
Subsequently, data on the baseline variables age, gender, creatinine clearance 
(CRCL), left ventricular ejection fraction (LVEF), peripheral vascular disease and chronic 
obstructive pulmonary disease was collected for the calculation of SSII. We used the 
original SYNTAX Score II Calculator (www.syntaxscore.com) to obtain all SSII values. The 
algorithm of the SSII calculation has been described in detail elsewhere.[1]
study endpoint
The primary endpoint was all-cause mortality. Vital status of the patients was obtained 
from municipal civil registries.
statistical analysis
The distribution of continuous variables was examined for normality with the Kolmogo-
rov-Smirnov test. ANOVA or Kruskal-Wallis test were used for multiple group comparison 
of continuous variables. Categorical variables were compared using the Pearson Chi-
square test.
Data for most of the variables used for the calculation of SSII were complete. However, 
creatinine, required for the calculation of CRCL, was available in 92.8% of the patients. 
LVEF was available in 72.0% of the patients and categorized as good (LVEF≥50%), mod-
erate (LVEF 40-49%) and poor (LVEF<40%).[11] Because LVEF was reported qualitatively, 
a value of 50% was used for category good, 44.5% for category moderate and 35% for 
category poor for the calculation of SSII. Multiple imputation technique was used to 
impute the missing data of creatinine and LVEF. Ten imputed data sets were generated. 
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Analyses were conducted for both the complete dataset as the imputed datasets, which 
showed similar results.
Long-term cumulative incidences of all-cause mortality, categorized by SSII in tertiles, 
were compared with the log-rank test. Cox regression analysis was used to assess the 
association between continuous SSII and long-term all-cause mortality. Patients that 
were lost to follow-up were censored at the date of last contact. Based on existing litera-
ture, variables known to be associated with mortality and not part of the SSII (diabetes 
mellitus, hypertension, smoking, previous PCI and indication for coronary angiography) 
were entered in a multivariable Cox model. Since our study population also includes 
STEMI-patients and the use of SSII has been validated in stable patients, a subgroup 
analysis was performed in patients with SAP only, to compare the results of the total 
study population with the results found in patients with SAP only. In terms of discrimina-
tion, the area under the receiver-operating characteristic (ROC) curve was assessed. All 
statistical test were two-sided with a type I error level of 0.05. Analyses were performed 
with IBM SPSS Statistics version 21.0.
ResulTs
A total of 628 patients (76% men, mean age: 61 ±10 years) undergoing PCI due to SAP 
(43%) or ACS (57%), included between January 2008 and June 2013, were eligible for 
the current study (Table 1). SSII ranged from 6.6 to 58.2 (median: 20.4, IQR: 16.1-26.8). 
All-cause mortality occurred in 44 patients (7.0%) during a median follow-up of 4.5 (IQR: 
3.4-4.9) years. Patients with a high SSII were older, had a higher prevalence of diabetes 
mellitus, hypertension, hypercholesterolemia and COPD, and more frequently had a his-
tory of renal insufficiency or heart failure than patients with a mid or low SSII.
Cumulative incidence of all-cause mortality categorized by SSII in tertiles is shown 
in Figure 1. The long-term cumulative incidence of all-cause mortality of patients with 
a high SSII showed to be significantly higher than for patients with a mid or low SSII. 
No statistically significant difference was found between the cumulative incidence of 
all-cause mortality of patients with a mid versus low SSII value.
In the multivariable Cox model (Table 2), SSII proved to be an independent significant 
predictor for 4.5-year mortality (hazard ratio [HR] per point increase: 1.10; 95% confi-
dence interval [CI]: 1.07-1.13). For SAP patients only, results were similar to the total 
study population (HR: 1.06; 95%CI: 1.07-1.11). In terms of discrimination, SSII had a 
concordance index (c-index) of 0.77 (95%CI: 0.69-0.84) (Figure 2).
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DIsCussIOn
In this study, we validated for the first time the use of SSII for prediction of long-term 
mortality in a large PCI-treated patient population with one- or two-vessel disease. 
Table 1. baseline characteristics
SSII ≤17 17< SSII ≤24 SSII >24
(n = 209) (n = 210) (n = 209) p-value
Clinical characteristics
Age - yrs, ± sd 52.9 ± 7.8 61.5 ± 8.1 69.0 ± 9.2 <0.001
Men, n(%) 204 (97.6) 163 (77.6) 109 (52.2) <0.001
Diabetes mellitus, n(%) 28 (13.4) 40 (19.0) 49 (23.4) 0.051
Hypertension, n(%) 91 (34.5) 112 (53.3) 134 (64.1) <0.001
Hypercholesterolemia, n(%) 96 (45.9) 120 (57.1) 127 (60.8) 0.025
Current smoking, n(%) 88 (42.3) 60 (28.6) 47 (22.5) <0.001
Previous MI, n(%) 55 (26.3) 57 (27.1) 64 (30.6) 0.48
Previous PCI, n(%) 58 (27.8) 65 (31.0) 60 (28.7) 0.74
Previous CVA, n(%) 10 (4.8) 10 (4.8) 18 (8.6) 0.16
History of PAD, n(%) 0 (0.0) 0 (0.0) 46 (22.0) <0.001
History of renal insufficiency, n(%) 6 (2.9) 4 (1.9) 20 (9.6) <0.001
History of heart failure, n(%) 1 (0.5) 2 (1.0) 10 (4.8) 0.003
COPD, n(%) 1 (0.5) 9 (4.3) 23 (11.0) <0.001
Serum creatinine - µmol/L, ± sd 77.3 ± 13.2 74.8 ± 17.3 84.6 ± 28.3 <0.001
Creatinine clearance - ml/min, ± sd 127.8 ± 31.8 111.9 ± 34.3 80.1 ± 27.8 <0.001
LVEF, n (%) <0.001
Good LVEF ≥50% 189 (90.4) 156 (74.2) 136 (65.1)
Moderate LVEF 40-49% 20 (9.6) 54 (25.8) 65 (31.1)
Poor LVEF <40% 0 (0.0) 0 (0.0) 8 (3.8)
Angiographic characteristics
Indication for angiography, n(%) 0.16
Acute MI 77 (36.8) 64 (30.6) 51 (24.4)
Unstable angina 58 (27.8) 57 (27.3) 61 (29.2)
Stable angina 74 (35.4) 99 (47.4) 97 (46.4)
Coronary artery disease, n(%) 0.007
1-vessel disease 146 (69.9) 118 (56.5) 115 (55.0)
2-vessel disease 63 (30.1) 92 (43.5) 94 (45.0)
Median SS [IQR] 5.0 [3.0-9.0] 9.0 [5.0-13.5] 9.0 [5.0-15.0] <0.001
CI: confidence interval; COPD: Chronic obstructive pulmonary disease; CVA: Cerebrovascular accident; 
IQR: inter quartile range; LVEF: left ventricular ejection fraction; MI: Myocardial infarction; PAD: Peripheral 
artery disease; PCI: Percutaneous coronary intervention; sd: standard deviation; SS: SYNTAX score; SSII: 
SYNTAX score II; yrs: years
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Table 2. Prediction of long-term mortality
Total population (n=628) SAP patients only (n=270)
Unadjusted HR 
(95%CI)
p value
Unadjusted HR 
(95%CI)
p value
SSII 1.09 (1.07-1.12) <0.001 SSII 1.05 (1.00-1.10) 0.050
Adjusted HR 
(95%CI)
Adjusted HR 
(95%CI)
SSII 1.10 (1.07-1.13) <0.001 SSII 1.06 (1.07-1.11) 0.037
Smoking 1.01 (0.52-1.98) 0.97 Smoking 1.52 (0.48-4.82) 0.48
Diabetes mellitus 1.60 (0.79-3.24) 0.19 Diabetes mellitus 1.56 (0.52-4.62) 0.43
Hypertension 0.88 (0.46-1.68) 0.70 Hypertension 0.59 (0.21-1.71) 0.33
Previous PCI 1.09 (0.54-2.18) 0.82 Previous PCI 0.59 (0.20-1.75) 0.35
Indication for CAG, SAP 0.59 (0.30-1.15) 0.12
SSII incorporates the anatomical Syntax score, age, gender, creatinine clearance, left ventricular ejection 
fraction, peripheral vascular disease and chronic obstructive pulmonary disease.
CAG: coronary angiography; CI: confidence interval; HR: hazard ratio; PCI: percutaneous coronary inter-
vention; SAP: stable angina pectoris; SSII: Syntax score II
figure 1. Cumulative incidence of all-cause mortality at 4.5 years
SSII is divided in tertiles with cut-off points 17 and 24 to compare the cumulative all-cause mortality pro-
portions between patients with a low, mid or high SSII value.
SSII: Syntax score II
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SSII demonstrated to be an independent predictor for 4.5-year all-cause mortality in 
multivariable analysis. Moreover, in terms of discrimination, SSII had a c-index of 0.77 
which is in line with the internally and externally validated c-indices of 0.73 and 0.72, 
respectively, of SSII in the SYNTAX trial for CABG or PCI-treated patients with left main or 
three-vessel disease.[1] It is also in line with the c-index (0.75) of SSII found in a study of 
patients with left main or three-vessel disease treated with only PCI.[3]
Although other known predictors of all-cause mortality in patients with CAD which 
are not part of SSII, such as diabetes mellitus, hypertension and prior PCI, were entered 
in the multivariable Cox model, SSII demonstrated to be the only significant predictor 
for 4.5-year all-cause mortality. Diabetes mellitus is a well-known predictor for adverse 
outcome in patients treated with PCI.[12] However, our findings imply that SSII incor-
porates enough relevant clinical prognostic variables to predict long-term all-cause 
mortality in patients with one- or two-vessel disease. Recently, the performance of SSII 
has been compared in diabetic patients versus non-diabetic patients with multi-vessel 
or left main disease undergoing PCI.[13] The SSII showed to have a good discriminative 
ability in both patient groups, independent of diabetic status. It may be hypothesized 
that other clinical variables incorporated in the SSII, such as CRCL, sufficiently reflect 
the influence of diabetes mellitus. In this respect, a previous study has demonstrated 
that kidney disease is of greater importance than diabetes mellitus for risk prediction of 
adverse outcome in patients with CAD.[14]
figure 2. sensitivity and specificity of ssII for the long-term prediction of all-cause mortality
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SSII has been developed for individual risk assessment using a continuous scale to 
overcome the limitations of categorized risk scores. Our study validates the use of SSII 
in patients with one- or two-vessel disease, demonstrating a similar discrimination as 
previously reported in left main or three-vessel disease.
limitations
In our study, the calculation of anatomical-based SYNTAX score for SSII included small 
vessels of at least 1.5mm and intermediate stenosis causing luminal obstruction of 
<70%, as instructed by the SYNTAX trial.[6] However, as recently observed in prospective 
registries, intermediate stenosis and small vessels <2.0 mm may not have additive pre-
dictive value for the prognosis of late mortality.[15-17] Hence, SSII calculated when only 
including severe stenosis of >70% in vessels of at least 2 mm, may even more accurately 
predict late mortality than currently observed in our study.
Further, the modest reproducibility of the anatomical-based SYNTAX score has to 
be acknowledged.[18] However, since our study population with one- or two-vessel 
disease had a relatively low angiographic burden, we expected a fair reproducibility 
of the anatomical-based SYNTAX score. To assess the reproducibility, a second experi-
enced analyst repeated the anatomical-based SYNTAX score analysis in a representa-
tive random sample, blinded for patient information and previously scored SXscores. 
Cohen’s kappa was 0.91, which indicated a good interobserver agreement. Furthermore, 
since SSII is used in a continuous manner and incorporates both anatomical as well as 
clinical variables, SSII offers higher accuracy than the original anatomical-based SYNTAX 
score.[3]
In addition, our single-center study needs external validation. As expected, the me-
dian SSII score in our population was lower than in the original SSII report and further 
research is required to investigate the relation between the actual SSII and correspond-
ing event rate in one- or two-vessel disease.
Conclusion
This study validates the predictive performance of SSII in patients with one- or two-
vessel disease indicating that, in addition to its known value in patients with left main 
or three-vessel disease, SSII may also offer accurate risk prediction in patients with less 
complex CAD.
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absTRaCT
The relation between C-reactive protein (CRP) and coronary atherosclerosis is not fully 
understood. This study aims to investigate the associations between high-sensitivity 
CRP, coronary plaque burden and presence of high-risk coronary lesions as measured by 
intravascular ultrasound (IVUS), as well as 1-year cardiovascular outcome. Between 2008 
and 2011, grayscale and virtual histology IVUS imaging of a non-culprit coronary artery 
was performed in 581 patients who underwent coronary angiography for acute coronary 
syndrome (ACS) or stable angina pectoris. Primary endpoint consisted of 1-year major 
adverse cardiac events (MACE), defined as all-cause mortality, ACS or unplanned coro-
nary revascularization. After adjustment for established cardiac risk factors, baseline CRP 
levels were independently associated with higher coronary plaque burden (p=0.002) 
and plaque volume (p=0.002) in the imaged coronary segment. CRP was also inde-
pendently associated with presence of large lesions (plaque burden ≥70%; p=0.030), 
but not with presence of stenotic lesions (minimal luminal area ≤4.0mm²; p=0.62) or 
IVUS virtual histology-derived thin-cap fibroatheroma (VH-TCFA) lesions (p=0.36). Cu-
mulative incidence of 1-year MACE was 9.7%. CRP levels >3mg/L were independently 
associated with a higher incidence of MACE (HR2.17, 95%CI 1.01-4.67, p=0.046) and of 
all-cause mortality and ACS only (HR3.58, 95%CI 1.04-13.0, p=0.043), when compared to 
CRP levels <1mg/L. In conclusion, in patients undergoing coronary angiography, high-
sensitivity CRP is a marker of coronary plaque burden, but is not related to the presence 
of VH-TCFA lesions and stenotic lesions. CRP levels of >3 mg/L are predictive for adverse 
cardiovascular outcome at 1 year.
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InTRODuCTIOn
C-reactive protein (CRP) is a prognostic marker of cardiovascular outcome in patients 
with stable coronary artery disease and patients with acute coronary syndrome (ACS).1-3 
Although CRP has also been postulated to reflect the extent of coronary atherosclerosis 
as well as plaque vulnerability, these relations are not yet fully understood.4 Previous 
studies have only shown weak associations between CRP and the extent of coronary 
artery disease on angiography and the degree of coronary calcification on computed to-
mography.3,5,6 Furthermore, the associations between CRP and the presence of high-risk 
vulnerable plaque morphology has not been investigated yet.7 Grayscale intravascular 
ultrasound (IVUS) imaging of the coronary arteries allows for accurate measurement 
of coronary plaque burden and plaque volume, as well as identification of large or 
stenotic lesions.8-10 Additionally, IVUS virtual histology (IVUS-VH) (i.e. analysis of IVUS 
radiofrequency backscatter), allows tissue characterization and for identification of 
virtual histology-derived thin-cap fibroatheroma (VH-TCFA) lesions.8-13 This study aims to 
investigate the associations between high sensitivity CRP, coronary plaque burden and 
presence of high-risk coronary lesions (i.e. VH-TCFA lesions, lesions with large plaque 
burden, and stenotic lesions) as measured by grayscale and radiofrequency IVUS, as well 
as 1-year cardiovascular outcome.
MeTHODs
The design of The European Collaborative Project on Inflammation and Vascular Wall 
Remodeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study 
has been described in detail elsewhere.9,14 In brief, 581 patients who underwent di-
agnostic coronary angiography or percutaneous coronary intervention (PCI) for ACS 
or stable angina pectoris have been included between 2008 and 2011 in the Erasmus 
MC, Rotterdam, the Netherlands. The ATHEROREMO-IVUS study was approved by the 
medical ethics committee of the Erasmus MC. The study was performed in accordance 
with the criteria described in the declaration of Helsinki. Written informed consent was 
obtained from all included patients. This study is registered in ClinicalTrials.gov, number 
NCT01789411.
Blood samples were drawn from the arterial sheath prior to the coronary angiography 
procedure. The blood samples stored at temperature of −80°C within 2 hours after blood 
collection. CRP was measured in the stored serum samples (n=576) using a immunotur-
bidimetric high sensitivity assay (Roche Diagnostics Ltd., Rotkreuz, Switzerland) on the 
Cobas 8000 modular analyzer platform (Roche Diagnostics Ltd., Rotkreuz, Switzerland). 
The diagnostic range of this assay is 0.3-350 mg/L with a coefficient of variation of 1.3% 
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at a mean value of 2.63 mg/L. In 5 patients, serum samples were not available for CRP 
measurement.
Following the standard coronary angiography procedure, IVUS imaging of the 
most proximal part of a non-culprit coronary artery was performed. Selection of the 
non-culprit vessel was predefined in the study protocol. The order of preference for 
selection of the non-culprit vessel was: 1. left anterior descending (LAD) artery; 2. right 
coronary artery (RCA); 3. left circumflex (LCX) artery. All IVUS data were acquired with 
the Volcano s5/s5i Imaging System (Volcano Corp., San Diego, CA, USA) using a Volcano 
Eagle Eye Gold IVUS catheter (20 MHz). An automatic pullback system was used with a 
standard pull back speed of 0.5 mm per second. The baseline IVUS images were sent to 
an independent core laboratory (Cardialysis BV, Rotterdam, the Netherlands) for offline 
analysis. The core laboratory personnel were blinded for baseline patient characteristics 
and clinical outcomes data. The IVUS grayscale and virtual histology analyses were per-
formed using pcVH 2.1 and qVH (Volcano Corp., San Diego, CA, USA) software.
The external elastic membrane and luminal borders were contoured for each frame 
(median interslice distance, 0.40 mm). Extent and phenotype of the atherosclerotic 
plaque were assessed. Plaque burden was defined as plaque and media cross-sectional 
area divided by external elastic membrane cross-sectional area (Figure 1). A coronary 
lesion was defined as a segment with a plaque burden of more than 40% in at least 3 
consecutive frames. Using IVUS-VH, the composition of the atherosclerotic lesions was 
characterized into 4 different tissue types: fibrous, fibro-fatty, dense calcium and ne-
crotic core.12 Three types of high-risk lesions were identified: 1. VH-TCFA lesion, defined 
as a lesion with presence of >10% confluent necrotic core in direct contact with the 
lumen in at least 3 consecutive frames; 2. lesion with large plaque burden, defined as a 
lesion with a plaque burden of ≥70% in at least 3 consecutive frames; 3. stenotic lesion, 
defined as a lesion with a minimal luminal area of ≤4.0 mm² in at least 3 consecutive 
frames (Figure 1).8-11,13
Clinical follow-up started at inclusion and lasted 1 year. Post-discharge survival status 
was obtained from municipal civil registries. Post-discharge rehospitalizations were pro-
spectively assessed during follow-up. Questionnaires focusing on the occurrence of ma-
jor adverse cardiac events (MACE) were sent to all living patients. Subsequently, hospital 
discharge letters were obtained and treating physicians and institutions were contacted 
for additional information (i.e. discharge letters and coronary angiogram) whenever 
necessary. All events were adjudicated as related to a coronary site that was treated dur-
ing the index procedure (culprit lesion related event) or as related to a coronary site that 
was not treated during the index procedure (non-culprit lesion related event). Events 
that were related to both the culprit lesion and a non-culprit site (e.g. revascularization 
of multiple vessels) were classified into both categories. When information was not suf-
ficient to classify an event as either culprit lesion related or non-culprit lesion related, 
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the event was classified as indeterminate. The endpoints were adjudicated by a clinical 
event committee that had no knowledge of the CRP and IVUS data.
The primary clinical endpoint was MACE, defined as all-cause mortality, ACS or un-
planned coronary revascularization. ACS was defined as the clinical diagnosis of ST seg-
ment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris 
in accordance with the guidelines of the European Society of Cardiology.15 Unplanned 
coronary revascularization was defined as unplanned repeat PCI (either culprit or non-
culprit coronary artery) or coronary artery bypass grafting (CABG). The secondary end-
figure 1. Measurement of plaque burden and identification of high risk lesions with intravascular 
ultrasound
A: Plaque burden is defined as plaque and media cross-sectional area (green) divided by external elastic 
membrane cross-sectional area (contoured in blue). B: Thin-cap fibroatheroma lesion, defined as a lesion 
with presence of >10% confluent necrotic core (red) in direct contact with the lumen. C: Lesion with 
plaque burden of ≥70%. D: Lesion with a minimal luminal area of ≤4.0 mm2.
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point was defined as the composite of all-cause mortality or ACS. Additional analyses 
were performed on non-culprit lesion-related and indeterminate events only (definite 
culprit lesion-related events were excluded in these analyses).
The distributions of the continuous variables, including CRP levels and the IVUS pa-
rameters, were tested for normality by visual examination of the histogram. CRP was not 
normally distributed and was therefore ln-transformed when analyzed as continuous 
variable. CRP levels were also categorized as low (<1 mg/L), average (1-3 mg/L) or high 
(>3 mg/L) according to the recommendations from the Centers for Disease Control and 
Prevention and the American Heart Association.16 Categorical variables are presented as 
numbers and percentages. We examined associations of CRP concentration with plaque 
burden, plaque volume and presence of high-risk coronary lesions. Plaque volume 
was normalized for the imaged segment length (normalized plaque volume = plaque 
volume / imaged segment length * median segment length of study population). To test 
for trends, we used linear regression and logistic regression analyses with continuous 
ln-transformed CRP concentration as independent variable. Z-test for heterogeneity was 
performed to test for differences in effect estimates between patients admitted with 
and without ACS. In multivariable analyses, the variables age, gender, diabetes mellitus, 
hypertension, hypercholesterolemia, smoking, peripheral artery disease, history of PCI, 
statin use at time of hospital admission and indication for coronary angiography were 
considered as potential confounders (specifically: the variables age, gender, diabetes 
mellitus, hypertension, hypercholesterolemia and smoking represent the traditional 
cardiac risk factors; the variables peripheral artery disease and history of PCI represent 
the presence of clinically manifest atherosclerosis; statin use may modulate baseline 
CRP levels; and the different indications for coronary angiography represent different 
patient risk classes) and were therefore entered into the each multivariate model.
Patients lost to follow-up were considered at risk until the date of last contact, at which 
time-point they were censored. Cumulative event rates were estimated according to the 
Kaplan-Meier method. Cox proportional hazards regression analyses were performed 
to evaluate the associations between CRP and study endpoints. The final results are 
presented as crude and adjusted hazard ratios (HR) with 95% confidence interval (95% 
CI). All data were analyzed with SPSS software (SPSS 20.0, IBM corp.,Armonk,NY,USA). 
All statistical tests were two-tailed and p-values <0.05 were considered statistically 
significant.
ResulTs
Mean age of the patients was 61.5 ± 11.3 years, 76% were men, and 55% had ACS (Table 
1). Mean plaque burden in the imaged coronary segment was 38.2% ± 11.5% and mean 
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Table 1. baseline characteristics
Variable
Total
(n=576)
C-reactive protein (mg/l)
P
<1
(n=172)
1-3
(n=185)
>3
(n=219)
Age (years) 61.5 ± 11.3 61.0 ± 10.2 61.3 ± 12.0 62.1 ± 11.6 0.59
Men 435 (75.5%) 140 (81.4%) 143 (77.3%) 152 (69.4%) 0.019
Diabetes mellitus 99 (17.2%) 28 (16.3%) 30 (16.2%) 41 (18.7%) 0.75
Hypertensiona 300 (52.1%) 93 (54.1%) 95 (51.4%) 112 (51.1%) 0.84
Hypercholesterolemiaa 320 (55.6%) 107 (62.2%) 102 (55.1%) 111 (50.7%) 0.082
Smoker 167 (29.0%) 34 (19.8%) 56 (30.3%) 77 (35.2%) 0.003
Positive family historyb 300 (52.1%) 99 (57.6%) 91 (49.2%) 110 (50.2%) 0.20
Previous MI 183 (31.8%) 52 (30.2%) 61 (33.0%) 70 (32.0%) 0.85
Previous coronary intervention 186 (32.3%) 62 (36.0%) 66 (35.7%) 58 (26.5%) 0.065
Previous coronary bypass 18 (3.1%) 5 (2.9%) 8 (4.3%) 5 (2.3%) 0.49
Previous stroke 26 (4.5%) 8 (4.7%) 8 (4.3%) 10 (4.6%) 0.99
Peripheral artery disease 36 (6.2%) 5 (2.9%) 15 (8.1%) 16 (7.3%) 0.091
History of renal insufficiency 32 (5.6%) 12 (7.0%) 9 (4.9%) 11 (5.0%) 0.62
History of heart failure 19 (3.3%) 6 (3.5%) 7 (3.8%) 6 (2.7%) 0.83
High sensitivity CRP (mg/L) 2.1 [0.9-5.4]
Indication for coronary angiography <0.001
ACS 314 (54.5%) 71 (41.3%) 90 (48.6%) 153 (69.9%)
ST-elevation MI 164 (28.5%) 45 (26.2%) 54 (29.2%) 65 (29.7%)
Non-ST-elevation ACS 150 (26.0%) 26 (15.1%) 36 (19.5%) 88 (40.2%)
Stable angina pectoris 262 (45.5%) 101 (58.7%) 95 (51.4%) 66 (30.1%)
Number of narrowed coronary arteries 0.71
None 42 (7.3%) 14 (8.1%) 10 (5.4%) 18 (8.2%)
1 306 (53.1%) 96 (55.8%) 93 (50.3%) 117 (53.4%)
2 167 (29.0%) 46 (26.7%) 61 (33.0%) 60 (27.4%)
3 61 (10.6%) 16 (9.3%) 21 (11.4%) 24 (11.0%)
PCI performed 507 (88.0%) 153 (89.0%) 163 (88.1%) 191 (87.2%)
Imaged coronary artery 0.14
Left anterior descending 207 (35.9%) 49 (28.5%) 74 (40.0%) 84 (38.4%)
Left circumflex 193 (33.5%) 63 (36.6%) 55 (29.7%) 75 (34.2%)
Right coronary artery 176 (30.6%) 60 (34.9%) 56 (30.3%) 60 (27.4%)
Segment length (mm) 44.3
[33.8-55.4]
44.6
[36.4-54.3]
42.9
[32.5-54.6]
44.4
[32.0-56.3]
0.67
Data are presented as mean ± standard deviation or as median [interquartile range].
a Presence of hypertension and hypercholesterolemia were defined as a clinical diagnosis of these condi-
tions as reported by the treating physician in the medical chart.
b Patient-reported positive family history of ischemic heart disease.
ACS, acute coronary syndrome; CRP, C-reactive protein; MI, myocardial infarction; PCI, percutaneous coro-
nary intervention.
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normalized plaque volume was 248 ± 136 mm³. A total of 241 (42%) patients had ≥1 
VH-TCFA lesion, 124 (22%) patients had ≥1 lesion with large plaque burden (plaque 
burden ≥70%) and 181 (31%) patients had ≥1 stenotic lesion (minimal luminal area 
≤4.0 mm²).
Higher CRP levels were associated with higher mean coronary plaque burden (p for 
trend = 0.013) and higher mean normalized plaque volume (p for trend = 0.015) in the 
imaged coronary segment (Figure 2). Higher CRP levels showed a tendency towards an 
association with the presence of lesions with large plaque burden (plaque burden ≥70%; 
p for trend = 0.093), while CRP was not associated with the presence of VH-TCFA lesions 
(p for trend = 0.36) or stenotic lesions (minimal luminal area ≤4.0 mm²; p for trend = 0.62) 
on IVUS (Figure 3). There was no heterogeneity between ACS patients and patients with 
stable angina (heterogeneity on association with plaque burden p=0.45; plaque volume 
figure 2. association of CRP with coronary plaque burden and plaque volume of imaged coronary 
segment
CRP, C-reactive protein.
figure 3. association with presence of high risk coronary lesions
CRP, C-reactive protein; MLA, minimal luminal area; PB, plaque burden; VH-TCFA, virtual histology-derived 
thin-cap fibroatheroma.
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p=0.71; lesions with large plaque burden p=0.21; VH-TCFA lesions p=0.70; stenotic le-
sions p=0.99) (Supplemental table 1). After adjustment for established cardiovascular 
risk factors, statin use, and the indication for coronary angiography, higher CRP levels 
remained significantly associated with higher plaque burden (per SD increase in ln-
transformed CRP: β 1.49, 95% CI 0.55-2.43, p for trend = 0.002), plaque volume (per SD 
increase in ln-transformed CRP: β 0.080, 95% CI 0.030-0.131, p for trend = 0.002) and 
presence of lesions with large plaque burden (plaque burden ≥70%; OR per SD increase 
in CRP 1.27, 95% CI 1.02-1.58, p for trend = 0.030).
Vital status at 1-year follow-up could be acquired for 574 (99.7%) patients. Response 
rate of the questionnaires that were sent to all living patients was 92.4%. After 1 year of 
follow-up, 56 patients had experienced a MACE (Table 2). The cumulative Kaplan-Meier 
incidences of the 30-day, 6-month and 1-year MACE (primary endpoint) were 0.9%, 5.6%, 
and 9.7%, respectively. The cumulative Kaplan-Meier incidences of the 30-day, 6-month 
and 1-year composite of death or ACS were 0.9%, 3.8%, and 5.6%, respectively.
In univariable analysis, higher CRP levels were associated with a higher incidence 
of MACE during follow-up (>3 vs. <1 mg/L: 11.9% vs. 5.8%, HR 2.11, 95%CI 1.02-4.38, 
p=0.044; 1-3 vs <1 mg/L: 10.8% vs. 5.8, HR 1.92, 95%CI 0.90-4.10, p=0.092) (Table 3, Fig-
ure 4). There was no heterogeneity in the hazard ratio estimate between ACS patients 
and patients with stable angina (Supplemental table 2). Higher CRP levels were also 
associated with the composite of death or ACS only (>3 vs <1 mg/L: 8.7% vs. 1.7%, HR 
5.13, 95%CI 1.52-17.3, p=0.009; 1-3 vs <1 mg/L: 5.4% vs. 1.7%, HR 3.14, 95%CI 0.86-11.4, 
p=0.082). After adjustment for established cardiovascular risk factors, statin use and the 
indication for coronary angiography, CRP levels of >3 mg/L remained independently 
Table 2. Incidence of major adverse cardiac events (n=56)
Variable
Definite 
culprit 
lesion 
related 
events
Definite 
non-culprit 
lesion 
related 
events
Indeter-
minate 
events
non-culprit 
lesion related 
and indeter-
minate events 
combined
all
events
Composite of major adverse cardiac events 11 27 18 45b 56a
Death from any cause 1 1 16 17 18
 Definite cardiac or unexplained death 1 1 6 7 8
Acute coronary syndrome 3 9 2 11 14
Myocardial infarction 2 3 2 5 7
Unplanned coronary revascularization 7 17 0 17 24
Composite of death or acute coronary 
syndrome
4 10 18 28b 32b
a Primary endpoint
b Secondary endpoint
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predictive for higher MACE rate (HR 2.17, 95%CI 1.01-4.67, p=0.046) and for the compos-
ite of death or ACS only (HR 3.58, 95%CI 1.04-13.0, p=0.043).
Additional analyses were performed on non-culprit lesion-related and indeterminate 
events only (definite culprit lesion-related events were excluded in these analyses). Al-
though statistical significance disappeared for some associations because of the lower 
statistical power (less events), the estimates of the associations with non-culprit lesion-
related and indeterminate events only were materially the same (Supplemental table 3).
DIsCussIOn
This study investigated the associations of circulating CRP concentration with extent 
of coronary atherosclerosis, the presence of high-risk lesions, and the risk of adverse 
Table 3. Prediction of cardiovascular outcome
Variable
unadjusted
HR (95%CI) P
adjusteda
HR (95%CI) P
MACE
 CRP 1-3 vs <1 mg/L 1.92 (0.90-4.10) 0.092 1.75 (0.80-3.81) 0.16
 CRP >3 vs <1 mg/L 2.11 (1.02-4.38) 0.044 2.17 (1.01-4.67) 0.046
Composite of death or ACS
 CRP 1-3 vs <1 mg/L 3.14 (0.86-11.4) 0.082 2.23 (0.59-8.37) 0.24
 CRP >3 vs <1 mg/L 5.13 (1.52-17.3) 0.009 3.68 (1.04-13.0) 0.043
a Adjusted for age, gender, diabetes mellitus, hypertension, hypercholesterolemia, smoking, peripheral 
artery disease, history of percutaneous coronary intervention, statin use and indication for coronary an-
giography.
ACS, acute coronary syndrome; CRP, C-reactive protein; MACE, major adverse cardiac event.
figure 4. Prediction of cardiovascular outcome
ACS, acute coronary syndrome; CRP, C-reactive protein.
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cardiovascular outcome in patients who underwent coronary angiography for ACS or 
stable angina pectoris. The present study is the first large study that investigated the 
relation between high sensitivity CRP and coronary plaque characteristics using IVUS-
VH. The main findings are that high CRP concentrations were associated with a higher 
coronary plaque burden and the presence of large lesions, but not with presence of 
VH-TCFA and stenotic lesions on grayscale IVUS and IVUS-VH.
Many epidemiologic studies have shown associations between elevated serum CRP 
concentrations and the risk of recurrent cardiovascular events among patients with 
established coronary artery disease, and the incidence of first cardiovascular events 
among individuals with cardiovascular risk factors.16,17 In line with these findings, this 
study demonstrates that baseline CRP levels were predictive of a higher rate of cardio-
vascular events during the first year after coronary angiography in patients with known 
coronary artery disease.
CRP is hypothesized to reflect the extent of underlying atherosclerosis.16,17 However, 
previous studies only found a weak (or even no) association with the extent of coronary 
artery disease on angiography and the degree of coronary artery calcification on com-
puted tomography.3,5,18 IVUS imaging may provide more accurate measures of the extent 
of coronary atherosclerosis. Our results support the hypothesis that serum CRP levels 
reflect the presence and extent of underlying atherosclerosis.
Other studies have suggested that CRP is a marker of plaque instability and plaque rup-
ture.19 This hypothesis was primarily based on the fact that CRP was found to be elevated 
in patients with ACS and that it displayed prognostic value for cardiovascular outcome. 
A population-based study also showed that high serum CRP levels were associated with 
the presence of mixed calcified arterial plaques on coronary computed tomography 
angiography, suggesting an association with plaque vulnerability.20 In contrast, previous 
large studies showed conflicting results regarding to a direct pathogenic role of CRP in 
development of plaque vulnerability.7,21 In the present study, we did not find an associa-
tion between serum CRP and the presence of VH-TCFA lesions. A plausible explanation 
for our finding that CRP is still predictive for coronary events may be that CRP has a role in 
the evolution of stable coronary plaque to unstable plaque.22 Furthermore, a substantial 
part of ACS cases are not attributable to plaque rupture, but to plaque erosion due to en-
dothelial inflammation.23 CRP may have a role in such endothelial inflammation as well.24
Patients with ACS had higher CRP levels than those with stable angina pectoris. Nev-
ertheless, the distribution of CRP of both groups largely overlapped, so that the same 
standard cut-off values for CRP (<1, 1-3 and >3 mg/L) could be used for both groups. 
Although there was no heterogeneity on the associations with plaque characteristics 
and cardiovascular outcome between ACS patients and patients with stable angina 
pectoris, it should be acknowledged that heterogeneity is difficult to detect with the 
relatively small number endpoints in this study.
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Some limitations of this study need to be acknowledged. Firstly, a single non-culprit 
coronary vessel was imaged in this study. High risk lesions (e.g. VH-TCFA lesions and 
stenotic lesions) elsewhere in the coronary tree could not be detected in our study. This 
may have lead to an underestimation of the association between CRP and the presence 
of high risk lesions in the coronary tree. Secondly, the spatial resolution of IVUS-VH 
(150µm) is insufficient to exactly replicate histopathologic definitions of a thin fibrous 
cap (<65µm).25 Therefore, IVUS-VH tends to over-estimate the number of thin-cap fibro-
atheroma lesions. Nevertheless, the presence of VH-TCFA lesions has been shown to 
have prognostic information.8-10 Thirdly, repeat intracoronary imaging with IVUS was not 
performed. Therefore, the dynamic nature of coronary artery lesion morphology could 
not be investigated. Finally, the number of endpoints was relatively small. Consequently, 
we may have lacked statistical power to detect small effect sizes (e.g. in presence of 
VH-TCFA lesions). Furthermore, we were not able to evaluate whether adding CRP to a 
prognostic model with conventional risk factors would result in improved risk prediction 
and discrimination.
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suPPleMenTal Tables
supplemental table 1. associations between C-reactive protein and coronary plaque characteristics 
stratified by patients with acute coronary syndrome and patients with stable coronary artery disease
Total study 
population aCs patients
stable CaD 
patients
P for 
heterogeneity
Plaque burden
β 0.80
(0.17 ; 1.44)
p=0.013
β 1.31
(0.42 ; 2.20)
p=0.004
β 0.81
(−0.13 ; 1.76)
p=0.094
0.45
Normalized plaque volume 
(ln-transformed)
β 0.042
(0.008 ; 0.075)
p=0.014
β 0.047
(0.001 ; 0.094)
p=0.046
β 0.060
(0.009 ; 0.111)
p=0.022
0.71
≥1 VH-TCFA lesion
OR 1.05
(0.94-1.18)
p=0.36
OR 1.01
(0.87-1.18)
p=0.91
OR 1.06
(0.88-1.26)
p=0.55
0.70
≥1 lesion with plaque 
burden ≥70%
OR 1.12
(0.98-1.29)
p=0.093
OR 1.28
(1.05-1.56)
p=0.016
OR 1.07
(0.87-1.30)
p=0.54
0.21
≥1 lesion with minimal 
luminal area ≤4.0 mm²
OR 0.97
(0.86-1.09)
p=0.62
OR 0.99
(0.83-1.17)
p=0.89
OR 0.99
(0.83-1.19)
p=0.92
0.99
Presented results are unadjusted β per standard deviation increase in ln-transformed C-reactive protein 
or unadjusted odds ratio per standard deviation increase in ln-transformed C-reactive protein with 95% 
confidence interval.
ACS, acute coronary syndrome; CAD, coronary artery disease; CRP, C-reactive protein; VH-TCFA, virtual 
histology-derived thin-cap fibroatheroma.
supplemental table 2. associations between C-reactive protein and cardiovascular outcome strati-
fied by patients with acute coronary syndrome and patients with stable coronary artery disease
Total study 
population aCs patients
stable CaD 
patients
P for 
heterogeneity
MACE
 CRP 1-3
 vs <1 mg/L
HR 1.92
(0.90-4.10)
p=0.092
HR 9.10
(1.17-70.5)
p=0.035
HR 1.07
(0.42-2.69)
p=0.89
0.061
 CRP >3
 vs <1 mg/L
HR 2.11
(1.02-4.38)
p=0.044
HR 6.71
(0.88-51.0)
p=0.066
HR 2.15
(0.91-5.10)
p=0.083
0.31
Composite of death or ACS
 CRP 1-3
 vs <1 mg/L
HR 3.14
(0.86-11.4)
p=0.082
HR 5.63
(0.69-45.8)
p=0.11
HR 1.60
(0.27-9.59)
p=0.61
0.37
 CRP >3
 vs <1 mg/L
HR 5.13
(1.52-17.3)
p=0.009
HR 5.73
(0.74-44.0)
p=0.094
HR 5.54
(1.15-26.7)
p=0.033
0.98
Presented results are unadjusted hazard ratios with 95% confidence intervals.
ACS, acute coronary syndrome; CAD, coronary artery disease; CRP, C-reactive protein; MACE, major ad-
verse cardiac events.
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supplemental table 3. association with non-culprit lesion related and indeterminate events only
unadjusted
HR (95%CI) P
adjusted*
HR (95%CI) P
MACE
 CRP 1-3 vs <1 mg/L 1.91 (0.82-4.46) 0.14 1.60 (0.67-3.83) 0.29
 CRP >3 vs <1 mg/L 2.12 (0.94-4.78) 0.071 1.91 (0.81-4.49) 0.14
Composite of death or ACS
 CRP 1-3 vs <1 mg/L 2.50 (0.66-9.43) 0.18 1.74 (0.44-6.85) 0.43
 CRP >3 vs <1 mg/L 4.58 (1.34-15.6) 0.015 3.40 (0.94-12.3) 0.061
Definite culprit lesion-related events were excluded in the current analyses.
* Adjusted for age, gender, diabetes mellitus, hypertension, hypercholesterolemia, smoking, peripheral 
artery disease, history of percutaneous coronary intervention, statin use at time of hospital admission and 
indication for coronary angiography.
ACS, acute coronary syndrome; CRP, C-reactive protein; MACE, major adverse cardiac event.
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absTRaCT
background and aims: To assess the relationship between the extent and phenotype 
of coronary atherosclerosis, as assessed by in-vivo grayscale and radiofrequency intra-
vascular ultrasound (IVUS), and circulating Troponin levels in patients with established 
stable coronary artery disease (CAD).
Methods: In this single-center, cross-sectional analysis, high-sensitivity Troponin T 
(hsTnT) was measured and IVUS was performed in a predefined non-stenotic segment 
of a non-culprit coronary artery in 231 patients with stable CAD undergoing elective 
angiography.
Results: HsTnT was detectable (>3 pg/mL) in 212 patients (92%) and a concentration 
above 14 pg/mL was observed in 19.5%. Normalised segmental plaque volumes were 
positively associated with hsTnT levels (25.0 mm³ increase in segmental plaque volume 
per SD increase in ln-transformed hsTnT, 95%CI: 6.0-44.0, p=0.010). Higher hsTnT levels 
were measured in patients with a virtual histology derived thin-cap fibroatheroma (VH-
TCFA, adj. odds ratio for presence of VH-TCFA = 1.52 per SD increase in ln-transformed 
hsTnT, 95%CI: 1.10-2.11, p=0.011). Patients with a VH-TCFA had a 2-fold increased preva-
lence of hsTnT concentration ≥14 pg/mL (adj. OR 2.35, 95% CI: 1.12-4.91,p=0.024). In 
addition, a 3-fold increased prevalence of hsTnT concentration ≥14 pg/mL was observed 
in patients with a VH-TCFA with a lesional plaque volume higher than the median (adj. 
OR 3.36, 95%CI: 1.44-7.84, p=0.005).
Conclusions: Segmental plaque volume and presence of VH-TCFA lesions are associ-
ated with higher circulating hsTnT concentrations in stable CAD patients. Subclinical 
plaque rupture or erosion and distal embolization may be hypothesized as a potential 
pathophysiological mechanism with respect to Troponin elevation and its relation with 
adverse outcome in this patient population.
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InTRODuCTIOn
Cardiac Troponin is the preferred biochemical marker for diagnostic use in patients with 
a suspected acute coronary syndrome (ACS) [1]. However Troponin elevation also has 
prognostic relevance in patients without chestpain at rest. In ambulatory patients with 
established stable coronary artery disease (CAD) as enrolled in the Heart and Soul study, 
TroponinT (TnT) was detectable in 6% of the study population when using a conven-
tional TnT assay [2]. With the recent introduction of the high-sensitivity Troponin T assay 
(hsTnT), circulating TnT levels could be detected in 81% of the same study population of 
ambulatory patients with stable CAD [3]. In these 984 patients, higher hsTnT levels were, 
amongst others, associated with greater inducible ischemia, worse treadmill exercise ca-
pacity and lower left ventricular ejection fraction. Moreover, hsTnT elevation remained 
independently predictive of cardiovascular mortality, myocardial infarction (MI) and 
heart failure after adjustment for abnormalities in cardiac structure and function [3]. 
Similar associations between hsTnT elevation and increased risk for major adverse car-
diovascular events (MACE) in ambulatory patients with stable CAD were also observed 
in a post-hoc analyses of the PEACE trial [4], the BARI-2D trial [5] and in a study of stable 
CAD patients participating in an in-hospital rehabilitation program[6].
Yet, despite these positive associations between hsTnT and long-term outcome, cur-
rently no data are available on the association between coronary plaque characteristics 
and hsTnT elevation in patients with stable CAD. However, the assessment of such a 
possible relationship is imperative in order to understand the etiology of the Troponin 
elevation, as well as to gain insight into the mechanisms by which Troponin elevation 
exerts its adverse impact on prognosis [7]. Hence, our objective was to assess the rela-
tionship between coronary plaque characteristics and phenotype, as assessed by in-vivo 
grayscale and radiofrequency intravascular ultrasound (IVUS), and Troponin levels in 
patients with established stable CAD.
MeTHODs
study population
The design, detailed inclusion and exclusion criteria and initial results of the prospec-
tive, single-center, observational, European Collaborative Project on Inflammation and 
Vascular Wall Remodeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-
IVUS) study have been described previously [8,9]. The study enrolled 581 patients, but for 
the current analysis 318 ACS patients were omitted, since hsTnT levels in those patients 
are obviously more determined by intracoronary thrombosis due to acute plaque rup-
ture of a culprit vessel and subsequent varying degrees of myocardial necrosis, and to a 
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much lesser extent by the vessel characteristics of a non-culprit vessel, as investigated 
in the ATHEROREMO-IVUS study. All of the patients had stable angina, were ambulatory 
and presented at the discretion of the referring physician for a planned and elective ad-
mission for angiography after consenting at the out-patient clinic. None of the patients 
were admitted for acute chest pain or dynamic ECG changes at rest. Patients with an 
indication for angiography other than stable angina pectoris (SAP, n=9) and those with 
known confounders of Troponin elevation [10] such as history of heart failure (n=13) or 
renal insufficiency (n=19, nine of whom had concomitant heart failure) were omitted.
The ATHEROREMO-IVUS study was approved by the medical ethics committee of 
the Erasmus MC. The study was performed in accordance with the criteria described in 
the declaration of Helsinki. Written informed consent was obtained from all included 
patients. ATHEROREMO-IVUS is registered in ClinicalTrials.gov, number NCT01789411.
High-sensitivity Troponin T
Blood samples were drawn from the 6 French arterial sheath prior to catheter insertion. 
TnT was measured with both a conventional fourth generation assay and a high-sensi-
tivity assay on the Cobas 8000 modular analyzer platform (Roche Diagnostics GmbH, 
Mannheim, Germany). The diagnostic range of the high-sensitivity assay is 3–10.000 pg/
mL with a coefficient of variation of 9% at the 99th percentile value of 14 pg/mL [11]. 
Laboratory personnel were blinded for baseline patient characteristics and IVUS data.
Intracoronary ultrasound imaging
Subsequent to the standard angiography and PCI (when applicable), IVUS of a non-
culprit coronary artery was performed with the Volcano s5/s5i Imaging System (Volcano 
Corp., San Diego, CA, USA)[9]. The IVUS target segment of the non-culprit coronary 
artery was required to be at least 40 mm in length and without significant luminal nar-
rowing (< 50% stenosis) as assessed by on-line angiography. Selection of the non-culprit 
vessel was predefined in the study protocol. The IVUS images were analyzed off-line 
by an independent core laboratory (Cardialysis BV, Rotterdam, the Netherlands). The 
core laboratory personnel were blinded for baseline patient characteristics and TnT and 
hsTnT levels.
Plaque burden was defined as plaque and media cross-sectional area divided by 
external elastic membrane cross-sectional area X 100. A coronary lesion was defined as 
a segment with a plaque burden of more than 40% in at least 3 consecutive frames. The 
composition of the atherosclerotic lesions was characterized into 4 different tissue types 
with the use of IVUS virtual histology (IVUS-VH): fibrous, fibro-fatty, dense calcium and 
necrotic core. Three types of high-risk lesions were identified: 1. Virtual histology-based 
thin-cap fibroatheroma (VH-TCFA) lesion, defined as a lesion with presence of >10% 
confluent necrotic core in direct contact with the lumen; 2. lesion with large plaque 
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burden, defined as a lesion with a plaque burden of ≥70%; 3. stenotic lesion, defined as a 
lesion with a minimal luminal area of ≤4.0 mm² [12,13]. VH-TCFAs were further classified 
as having a high lesional plaque volume in case the plaque volume of that particular 
VH-TCFA was above the median plaque volume of all lesions classified as VH-TCFA.
statistical analysis
Normally distributed continuous variables are presented as mean ± standard deviation 
(SD). Non-normally distributed continuous variables are presented as median and inter-
quartile range (IQR). Categorical variables are presented in numbers and percentages. 
Linear regression was used to evaluate the association between segmental plaque vol-
ume, plaque burden, plaque tissue types and natural logarithm(ln)-transformed hsTnT 
concentration (ln-transformation was performed in order to maintain homogeneity of 
variance and normality of the (error) distribution). Segmental plaque and vessel volume 
were normalised for the imaged segment length (normalised plaque volume = plaque 
volume / imaged segment length * median segment length of study population). 
Logistic regression was used to examine the association between hsTnT concentration 
and presence of high-risk coronary lesions (as dependent). Determinants of a hsTnT con-
centration above the clinically used 99th percentile in an apparently healthy reference 
population of 14 pg/mL [11], were also assessed with logistic regression. Multivariable 
analyses accounted for confounding by age, gender, hypercholesterolemia, diabetes, 
glomerular filtration rate, hypertension, smoking status, family history of CAD, history of 
MI, prior PCI, prior coronary artery bypass grafting (CABG), stroke and peripheral artery 
disease (PAD). Crude and adjusted odds ratios (OR) are presented with 95% confidence 
intervals. When necessary to assure parsimony of the logistic regression models, adjust-
ment according to a propensity score (using the same confouders as mentioned above) 
was used [14,15]. All statistical tests were two-sided with a type I error level of 0.05. 
Analyses were performed with IBM SPSS statistics version 21.0.
ResulTs
Between October 24, 2008 and January 28, 2011, a total of 231 patients with stable 
angina pectoris were enrolled prior to coronary angiography. Mean age was 63.6 ± 9.9 
years. Men constituted 77% of the study population. A PCI was performed in 85% of the 
patients during the index coronary angiography (Table 1).
Troponin T was detectable in 5.8% of the study patients by the conventional TnT assay 
(>0.01 ug/L). In contrast, the hsTnT assay enabled detection (>3 pg/mL) in 212 patients 
(92%) and concentrations above the commonly used 99th percentile of a healthy refer-
ence population of 14 pg/mL were observed in 45 (19.5%) of our patients with manifest 
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Table 1. baseline characteristics
Patient characteristics, N (%) n=231
Age (years±SD) 63.6 ± 9.9
Male 177 (76.6)
Diabetes Mellitus 48 (20.8)
Hypertension 141 (61.0)
Hypercholesterolemia 162 (70.1)
Smoking 42 (18.2)
Positive family history of CAD 137 (59.3)
Previous MI 93 (40.3)
Previous PCI 116 (50.2)
Previous CABG 7 (3.0)
Previous stroke 13 (5.6)
Peripheral artery disease 19 (8.2)
Glomerular Filtration Rate (ml/min, median[IQR]) 101.5 [80.2 – 123.0]
Out-patient clinic medication prior to angiography
Aspirin 218 (94.4)
Beta-blockers 181 (78.4)
ACE-inhibitors 139 (60.2)
Calcium antagonists 63 (27.3)
Oral nitrates 82 (35.5)
Statin 209 (90.5)
High-sensitivity Troponin T levels (pg/ml)
Median [IQR] 7.3 [4.9 - 12.1]
Mean 11.0
Standard deviation 15.5
Range 3.00 – 192.70
99th percentile 88.7
Procedural characteristics
Extent of coronary artery disease
No significant stenosis 22 (9.5)
1-vessel disease 116 (50.2)
2-vessel disease 70 (30.3)
3-vessel disease 23 (10.0)
PCI / stent implantation 196 (84.8)
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stable CAD. The 99th percentile in our patient population was 88.7 pg/mL (Table 1 and 
Figure 1).
Clinical determinants of high-sensitivity Troponin T concentration
Age was the only determinant of hsTnT concentration (adjusted (adj.) p<0.001) (Figure 
2). There was no association with hsTnT concentration and other baseline clinical vari-
ables, such as male gender (adj. p=0.39), hypercholesterolemia (adj. p=0.28), diabetes 
(adj. p=0.96), glomerular filtration rate (adj. p=0.08), hypertension (adj. p=0.64), smok-
ing status (adj. p=0.37), family history (adj. p=0.60), history of MI (adj. p=0.57), PCI (adj. 
p=0.60), CABG (adj. p=0.46), stroke (adj. p=0.61), or PAD (adj. p=0.28), and the number 
of diseased coronary vessels on angiography (adj. p=0.71).
Table 1 (continued)
IVUS segment characteristics
Imaged coronary artery
Left anterior descending 76 (33.9)
Left circumflex 76 (32.9)
Right coronary artery 79 (34.2)
Segment length, mm [IQR] 43.8 [33.9 - 56.0]
MI= myocardial infarction; PCI= percutaneous coronary intervention; CABG= coronary artery bypass graft
figure 1. Distribution of high-sensitivity Troponin T values in patients with stable coronary artery 
disease.
High-sensitivity Troponin T was measured in 231 patients with stable coronary artery disease, undergoing 
an elective CAG. Blood samples were drawn prior to catheterisation and/or PCI. Troponin concentrations 
were undetectably low in 19 patients (8.2%). The datapoints of three patients with concentrations of 82, 
91 and 192 pg/ml respectively are not shown in this histogram.
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High-sensitivity Troponin T in association with segmental plaque 
characteristics.
The median segment length, as imaged with IVUS, was 43.8 mm (Table1). Normalised 
segmental plaque volumes were positively associated with hsTnT levels (adjusted β= 
25.0 mm³ increase in segmental plaque volume per SD increase in natural log-trans-
formed hsTnT, 95% CI: 6.0-44.0, p=0.010) (Table 2, Figure 3 A). There was no significant 
association between segmental plaque burden and hsTnT (adjusted β= 0.92% increase 
in plaque burden per SD increase in natural log-transformed hsTnT, 95% CI: −0.61-2.44, 
p=0.24). However normalised segmental vessel volumes were positively associated with 
hsTnT levels (adjusted β= 56.2 mm³ increase in segmental vessel volume per SD increase 
in natural log-transformed hsTnT, 95% CI: 21.9-90.5, p=0.001).
High-sensitivity Troponin T concentrations were not associated with the segmental 
plaque distribution of the four tissue types as assessed by IVUS virtual histology; fibrous 
(adj. p=0.81), fibro-fatty (adj. p=0.66), dense calcium (adj. p=0.37) and necrotic core (adj. 
p=0.80).
figure 2. age in relation to high-sensitivity Troponin T concentration.
The study population was divided in age tertiles of 77 patients each. Multivariable analyses accounted 
for confounding by age, gender, hypercholesterolemia, diabetes, glomerular filtration rate, hypertension, 
smoking status, family history of CAD, history of MI, prior PCI, prior coronary artery bypass grafting, prior 
stroke and peripheral artery disease. The histograms display the mean hsTnT concentration plus the stan-
dard error of the mean.
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High-sensitivity Troponin T in association with lesion characteristics and 
morphology.
With respect to lesion morphology, a VH-TCFA was observed in 86 (37%) patients (Table 2 
and Supplementary appendix Figure 4). Higher hsTnT levels were measured in patients 
with the presence of a VH-TCFA (adj. OR for presence of VH-TCFA= 1.52 per SD increase in 
natural log-transformed hsTnT, 95% CI: 1.10-2.11, p=0.011) (Figure 3B).
In patients with hsTnT concentrations ≥ 14 pg/mL, a VH-TCFA was observed in 49%. 
Hence, patients with a VH-TCFA had a 2-fold increased prevalence of hsTnT concentra-
tion ≥ 14 pg/mL (adj. OR 2.35, 95% CI: 1.12-4.91, p=0.024) (Table2). In addition, a 3-fold 
increased prevalence of hsTnT concentration ≥ 14 pg/mL was observed in patients with 
a VH-TCFA with a high lesional plaque volume, i.e. a lesional plaque volume above the 
Table 2. High-sensitivity Troponin T concentration in relation to plaque characteristics in a non-
culprit coronary artery in patients with stable coronary artery disease
Total study 
population
hsTnT < 14 pg/ml
(N= 186)
hsTnT ≥ 14 pg/ml
(N=45)
adjusted 
P-value
SEGMENTAL PLAQUE 
CHARACTERISTICS
Median [IQR]
Normalised vessel volume 
(mm³)
563.9 [439.2 – 755.0] 545.5 [421.2 – 691.3] 733.6 [494.8 - 917.5] 0.001
Normalised plaque volume 
(mm³)
234.0 [149.9 - 340.6] 215.2 [140.8 - 311.2] 271.1 [192.4 - 413.7] 0.008
Plaque burden (%) 40.4 [32.2 - 47.7] 39.8 [31.9 - 47.1] 43.2 [33.8 - 50.2] 0.41
Plaque composition Median [IQR]
Fibrous (%) 56.3 [49.4 - 63.8] 56.0 [49.5 - 65.1] 56.6 [48.6 – 60.3] 0.49
Fibro-fatty (%) 9.5 [6.3 - 13.4] 9.3 [5.8 - 13.4] 11.2 [8.1 - 14.2] 0.18
Dense calcium (%) 11.0 [5.9 - 16.1] 10.9 [5.7 - 16.1] 11.4 [6.3 - 17.1] 0.79
Necrotic core (%) 21.5 [17.2 - 25.3] 21.5 [16.7 - 25.7] 21.5 [18.4 - 24.9] 0.82
LESION MORPHOLOGY N (%)
VH-TCFA 86 (37.2) 64 (34.4) 22 (48.9) 0.024
VH-TCFA with high lesional 
plaque volume
43 (18.6) 28 (15.1) 15 (33.3) 0.005
MLA ≤ 4.0 mm² 80 (34.6) 67 (36.0) 13 (28.9) 0.66
Plaque burden ≥ 70% 56 (24.2) 41 (22.0) 15 (33.3) 0.064
VH-TCFAs were classified as having a high lesional plaque volume in case the plaque volume of that par-
ticular VH-TCFA was above the median of all lesions classified as VH-TCFA. Multivariable analyses account-
ed for confounding by age, gender, hypercholesterolemia, diabetes, glomerular filtration rate, hyperten-
sion, smoking status, family history of CAD, history of MI, prior PCI, coronary artery bypass grafting, stroke 
and peripheral artery disease (PAD).
HsTnT= high-sensitivity Troponin T; VH-TCFA= Virtual histology-derived Thin-cap fibroatheroma; MLA= 
minimal luminal area
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figure 3. High-sensitivity Troponin T concentration in relation to intravascular ultrasound charac-
teristics.
HsTnT, high-sensitivity Troponin T; PB, plaque burden; MLA, minimal luminal area, VH-TCFA, Virtual histol-
ogy-derived thin-cap fibroatheroma.
Panel A. High-sensitivity Troponin T per tertile of normalised plaque volume for the entire segment (me-
dian length 43.8 mm, IQR: 33.9 - 56.0) as evaluated with grayscale intravascular ultrasonography (IVUS).
Panel B. High-sensitivity Troponin T in relation to the presence of at least one high-risk lesion type per 
patient. Thin-cap fibroatheroma (TCFA) was assessed by means of radiofrequency IVUS.VH-TCFAs were 
classified as having a high lesional plaque volume in case the plaque volume of that particular VH-TCFA 
was above the median plaque volume of all lesions classified as VH-TCFA.
For both figures, multivariable analyses accounted for confounding by age, gender, hypercholesterol-
emia, diabetes, glomerular filtration rate, hypertension, smoking status, family history of CAD, history of 
MI, prior PCI, coronary artery bypass grafting, stroke and peripheral artery disease. The histograms display 
the mean hsTnT concentration plus the standard error of the mean.
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median of all lesions classified as VH-TCFA (adj. OR 3.36, 95% CI: 1.44-7.84, p=0.005) 
(Table 2). Patients with a VH-TCFA with a high lesional plaque volume also had higher 
hsTnT levels than patients with a VH-TCFA without a high lesional plaque volume (16.8 
pg/mL versus 9.4 pg/mL, p=0.03).
The relationship between lesions with a plaque burden ≥ 70% and hsTnT was not 
statistically significant (adj. OR= 1.37 per SD increase in natural log-transformed hsTnT, 
95% CI: 0.99-1.90, p=0.059) (Table 2 and Figure3B). No association was found between 
stenotic lesions with a MLA ≤ 4.0 mm² and hsTnT (adj. OR= 0.83 per SD increase in natural 
log-transformed hsTnT, 95% CI: 0.60-1.15, p=0.26).
DIsCussIOn
This cross-sectional study is the first to demonstrate an association between elevated 
circulating Troponin levels and the extent of coronary atherosclerosis and high-risk 
plaque phenotype, as assessed with intracoronary IVUS in a non-culprit coronary artery 
in a broad population of stable CAD patients referred for elective coronary angiography, 
as seen in everyday routine clinical practice.
In contrast to the conventional TnT assay, the hsTnT assay has enabled detection of 
circulating TnT in the majority of patients with stable CAD. Our finding that serum TnT 
levels were detectable in only 5.8% of our stable CAD patients with the conventional 
fourth generation TnT assay, versus detection in 92% when using the hsTnT assay, cor-
responds to the results found in the Heart and Soul study [3]. This expansion of serum 
TnT detection has led to more elaborate risk prediction for the occurrence of MACE, 
as previously demonstrated [3,4,6,16]. In a post-hoc analysis of the relatively low-risk, 
stable CAD population of the PEACE trial, a graded increase in the cumulative incidence 
of cardiovascular death (adjusted hazard ratio (HR) per unit increase in the natural 
logarithm of the hsTnT level 2.09; 95% confidence interval [CI], 1.60 to 2.74) and of heart 
failure (adjusted HR 2.20; 95% CI, 1.66 to 2.90) was seen in 3679 patients with stable CAD 
and preserved left ventricular function [4]. Similarly hsTnT was an independent predictor 
of death from cardiovascular causes, myocardial infarction, or stroke in patients who 
had both type 2 diabetes and stable ischemic heart disease in a post-hoc analysis of 
the BARI-2D trial [5]. In addition, several prospective, intracoronary imaging studies, 
primarily conducted in ACS-patients, have reported an increased risk of repeat MACE 
in the presence of TCFA as identified by IVUS-VH [17,18]. The presence of a VH-TCFA was 
associated with a 3-fold increased risk of cardiovascular mortality, cardiac arrest, MI, or 
rehospitalization due to unstable or progressive angina during 3.4 year follow-up of ACS 
patients enrolled in the PROSPECT study [17]. More recently, similar conclusions were 
drawn with respect to the complete ATHEROREMO-IVUS study population comprising 
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both stable CAD and ACS patients [9]. The presence of a VH-TCFA, in a single target 
segment without significant luminal narrowing in a non-culprit coronary artery, was 
independently associated with the composite of death and non-fatal ACS (7.5% vs. 3.0%; 
adjusted HR 2.51, 95% CI 1.15-5.49) during 1-year follow-up [9].
Thus, both TnT elevation and high-risk intracoronary lesion phenotypes as assessed by 
radiofrequency IVUS are recognized as independent predictors of adverse cardiovascu-
lar outcome. Yet, to our best knowledge, this is the first study to describe the crosslink 
between TnT elevation and the extent and phenotype of coronary atherosclerosis as 
assessed by IVUS in a non-culprit coronary artery in a population of patients with stable 
CAD.
Despite the increasing body of evidence showing adverse outcome in case of Tropo-
nin elevation in ambulatory non-ACS patients, only few reports have actually provided 
insight into a possible mechanistic explanation for the Troponin elevation from the 
perspective of coronary pathophysiology. A greater insight into the pathophysiological 
mechanisms of Troponin elevation may also increase our understanding of how Tropo-
nin elevation is linked to adverse outcome in this patient population. In two studies 
evaluating cardiac computed tomography, one in patients with stable CAD and another 
in patients with acute chest pain presenting at the emergency department, hsTnT levels 
were not associated with stenosis severity, but were associated with the extent of coro-
nary plaque volume, which might support the hypothesis that chronic, clinically silent 
rupture or erosion of non-calcified plaques with subsequent microembolisation may be 
a potential source of myocardial injury and Troponin release [19,20]. However, given the 
current state-of-the-art, cardiac computed tomography does not allow for such extensive 
plaque phenotyping as grayscale and radiofrequency IVUS. Therefore, our data showing 
that VH-TCFAs are associated with Troponin release are essential for the line of reasoning 
and hypothesis that microembolisation resulting from silent plaque rupture or erosion 
might be a possible mechanistic explanation for the elevated Troponin levels in these 
patients. Indeed, autopsy studies have described TCFAs to be the plaques that are most 
prone to superficial erosion or rupture, consequently leading to thrombus formation 
and distal (micro)embolisation [21]. Such plaque erosion or rupture has shown to be the 
major cause of (fatal) acute MI, but not every plaque erosion or rupture invariably leads 
to sufficient thrombotic occlusion in order to provoke symptoms of angina. It has been 
suggested that, at any given time, approximately 15% of patients with stable CAD have 
ongoing atherothrombotic plaque events compared to an annual incidence of acute MI 
of approximately 5% [22]. Against this background, hsTnT may serve as a biomarker for 
subclinical plaque rupture or erosion leading to atherothrombosis, distal embolisation 
and continuous low grade myocardial ischemia and cardiomyocyte necrosis, even in 
presumably asymptomatic patients with stable CAD.
High-sensitivity troponin T in relation to coronary plaque characteristics in patients with stable coronary artery disease 261
C
h
a
p
te
r
 1
5
Similarly, the association between the presence of VH-TCFA and serum TnT elevation 
as found in the current population might also be extended in order to hypothesize on 
the observation of subtle TnT elevation in the general population and the associated 
increased risk of MACE. In the Dallas Heart Study, a multi-ethnic, population-based co-
hort study of individuals aged 30 to 65 years, the prevalence of TnT levels above 3.0 pg/
mL was 25.0% [16]. Interestingly, a graded increase in both cardiovascular and all-cause 
mortality was seen across quintiles of TnT elevation in the entire study cohort, but also 
in the subgroup analysis of 3222 patients without cardiovascular or chronic kidney dis-
ease. A five-fold increased risk for cardiovascular mortality was observed in case of hsTnT 
levels ≥ 14 pg/mL. Understandably, the Dallas Heart study did not collect intracoronary 
IVUS data. Although speculative, an increased prevalence of rupture-prone, high-risk 
lesion types, such as TCFAs, might underlie the observation that participants without 
symptoms of angina, i.e. without a fixed and significant coronary luminal narrowing, did 
have both TnT elevation and a subsequent increased risk of cardiovascular mortality.
Another important finding of our study was the association between segmental 
plaque volume and Troponin concentration. Similar observations were previously found 
in cardiac computed tomography studies [19,20]. More recently, a post-hoc analysis of 
the SATURN trial has demonstrated that a large plaque volume as assessed with grayscale 
IVUS, in a non-culprit segment without significant stenosis, is associated with increased 
risk of MACE [23]. Hence, segmental plaque volume of a non-culprit coronary artery, as 
assessed in ATHEROREMO-IVUS, may have prognostic importance. Segmental plaque 
volume may not only be linked to Troponin concentration, but also to TCFA and plaque 
rupture, since the majority of large stable plaques have evidence of previously healed 
plaque rupture with incorporation of old thrombus into the atheroma [21,22,24,25].
Troponin was not related to segmental plaque burden (p=0.24). Levels seemed higher 
in patients with a lesion with plaque burden ≥ 70%, but the difference with patients 
with smaller plaque burden did not reach statistical significance (p=0.061). This may 
be due to the fact that plaque burden is not a direct measure of three dimensional 
plaque volume, but rather a two dimensional measure that also accounts for arterial 
wall remodeling. The fact that both normalized plaque and vessel volume were highly 
associated with troponin levels may be seen as a confirmation of positive remodeling 
in our dataset. Outward remodeling explains why presence of large segmental plaque 
volumes do not necessarily relate to focal lesional stenoses. The observation that ste-
nosis severity, i.e. a MLA ≤ 4.0 mm², was not related to hsTnT concentration in our study 
may be regarded as a reconfirmation of the earlier mentioned cardiac computed to-
mography studies [19,20,26]. Similarly, coronary artery calciumscore was not associated 
with hsTnT concentration after multivariate adjustment in the in the Dallas Heart Study 
[16]. Such observations may indirectly support the hypothesis that not ischemia due to 
luminal narrowing, but rather plaque rupture, microembolisation and microcirculatory 
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dysfunction is the pathophysiological mechanism behind the increased circulating TnT 
levels [27]. On the other hand, it has to be emphasized that 84.8% of the patients in our 
analysis underwent a PCI and therefore had significant luminal stenosis in the culprit 
vessel. Our protocol was based on non-culprit, single vessel imaging. Since the culprit 
vessels were not imaged, all of our associations only apply to the angiographically 
non-stenotic non-culprit segments and no formal conclusions can be drawn on stenosis 
severity elsewhere in the coronary circulation and Troponin elevation.
Our study has several strengths. Our data were prospectively obtained and, due to 
the broad inclusion criteria of ATHEROREMO-IVUS, its conclusions seem applicable to 
a broad range of patients with stable CAD. Of great importance is that IVUS evaluation 
was performed in an independent, dedicated core lab with personnel blinded for pa-
tient and TnT data. Similarly, Troponin was measured by laboratory personnel blinded 
for baseline patient characteristics and IVUS data.
study limitations
However, there are several limitations to our findings. A possible limitation of our analysis 
might be the sample size, although this study represents the only and therefore largest 
cohort of patients in which the association between intracoronary IVUS plaque charac-
teristics and circulating hsTnT was evaluated, so far. Furthermore, ATHEROREMO-IVUS 
was a single center study by virtue of design. External validation, preferably in a larger 
sample size, is a fundamental prerequisite before final conclusions may be drawn. In our 
study, IVUS imaging took place of a pre-specified single target segment of a non-culprit 
coronary artery of least 40 mm in length and without significant luminal narrowing (< 
50% stenosis) as assessed by on-line angiography. This approach was developed under 
the assumption that such a non-stenotic segment would adequately reflect coronary 
wall pathophysiology of the larger coronary tree. Indeed, in a previous ATHEROREMO-
IVUS report, this assumption was confirmed with respect to the presence of high-risk 
lesion types, such as VH-TCFA, and subsequent increased risk of MACE [9]. In addition, 
the post-hoc analysis of the SATURN trial also emphasized the prognostic importance 
of plaque characteristics of a non-stenotic, non-culprit target segment [23]. Ideally, a 
confirmatory replication of our association between segmental plaque volume, pres-
ence of (VH-)TCFA and TnT elevation should take place in a study enrolling patients 
with stable CAD for three-vessel and left main IVUS assessment, since such an approach 
would more precisely characterize the total coronary atherosclerosis burden. IVUS-VH 
has been validated in vitro [28]. Sensitivities and specificities for the detection of various 
plaque components ranged from 72-99%, thus leaving room for misclassification [28]. 
Furthermore, its ability to detect plaque erosion, rupture and thrombus is limited given 
the current spatial resolution.
High-sensitivity troponin T in relation to coronary plaque characteristics in patients with stable coronary artery disease 263
C
h
a
p
te
r
 1
5
In conclusion, plaque volume and presence of VH-TCFAs, as assessed with intracoro-
nary IVUS in a non-culprit coronary artery segment, are associated with higher circulat-
ing Troponin concentrations in a broad population of patients with stable CAD. Our data 
are based on associations and cannot provide final conclusions on the exact etiology of 
Troponin elevation. However our findings may generate the hypothesis that subclinical 
plaque rupture or erosion of vulnerable plaques and subsequent intracoronary throm-
bosis and distal embolization may be the potential mechanism of action with respect to 
Troponin elevation and its relation with adverse outcome.
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OnlIne suPPleMenT
figure 4. Thin-cap fibroatheroma as classified by radiofrequency intravascular ultrasonography
This lesion (here only represented by one frame) in the proximal right coronary artery of a 76-year old 
ATHEROREMO-patient was classified as virtual histology thin-cap fibroatheroma. It demonstrated a large 
plaque volume (298 mm³) and plaque burden(61%), nevertheless without luminal narrowing (luminal 
area of 9.0 mm²) The high-sensitivity Troponin T concentration in this patient was 14 pg/mL.
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absTRaCT
background and aims: Experimental studies have suggested that proprotein conver-
tase substilisin/kexin type 9 (PCSK9) might directly promote inflammatory processes 
contributing to atherosclerosis by mechanisms independent of low-density lipoprotein 
(LDL) cholesterol levels. This study aims to investigate the association between serum 
PCSK9 levels and the fraction and amount of necrotic core tissue in coronary atheroscle-
rotic plaque as assessed by intravascular ultrasound virtual histology (IVUS-VH) imaging.
Methods: Between 2008 and 2011, IVUS-VH imaging of a non-culprit coronary artery 
was performed in 581 patients who underwent coronary angiography for acute coro-
nary syndrome (ACS) or stable angina. PCSK9 concentrations were measured in serum 
samples that were drawn prior to coronary angiography. None of the patients received 
PCSK9 inhibitors.
Results: After adjustment for established cardiac risk factors, statin use and serum LDL 
cholesterol, serum PCSK9 levels were linearly associated with the fraction of plaque 
consisting of necrotic core tissue (β=1.24 percent increase per 100μg/L increase in 
PCKS9, 95%CI 0.55-1.94, p=0.001) and with the absolute volume of necrotic core tissue 
(β=0.09, 95%CI 0.01-0.18, p=0.033), but were not significantly associated with plaque 
burden (p=0.11), plaque volume (p=0.22) or the presence of IVUS-VH-derived thin-cap 
fibroatheroma lesions (p=1.0).
Conclusion: Serum PCSK9 levels were linearly associated with the fraction and amount 
of necrotic core tissue in coronary atherosclerosis, independently of serum LDL choles-
terol levels and statin use. Therefore, PCSK9 may be an interesting therapeutic target for 
the treatment of atherosclerotic disease beyond LDL cholesterol regulation.
Key words: PCSK9, atherosclerosis, inflammation, intravascular ultrasound, prognosis
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InTRODuCTIOn
Proprotein convertase substilisin/kexin type 9 (PCSK9) has an important role in the deg-
radation of low-density lipoprotein (LDL) receptors, resulting in increased serum LDL 
cholesterol concentrations.1,2 Novel drugs targeting PCSK9 are currently being investi-
gated in large phase II and phase III clinical trials.2-9 Most of these trials investigate the 
effects of PCSK9 inhibition on LDL cholesterol reduction. However, recent experimental 
studies have also demonstrated that PCSK9 might directly promote inflammation, apop-
totic cell death and endothelial dysfunction in atherosclerosis by mechanisms that are 
independent of its effect on the LDL receptor.2,10-12 Therefore, it has been hypothesized 
that PCSK9 contributes directly to the progression of atherosclerotic disease, beyond its 
indirect role in cholesterol homeostasis.2
Intravascular ultrasound virtual histology (IVUS-VH) is an in-vivo imaging technique 
that analyzes radiofrequency backscatter.13 IVUS-VH imaging allows for accurate mea-
surement of the extent of coronary atherosclerosis and of the type of plaque tissue, 
including necrotic core tissue which is considered to be a result of continuous inflamma-
tion.13-17 Previous studies have demonstrated that the amount of necrotic core tissue on 
IVUS-VH is predictive of cardiovascular outcome.14-16 This study aims to investigate the 
association between serum PCSK9 levels and the fraction and amount of necrotic core 
tissue in coronary atherosclerotic plaque as assessed by IVUS-VH imaging.
MeTHODs
study population
The design of The European Collaborative Project on Inflammation and Vascular Wall 
Remodeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study 
has been described in detail elsewhere (ClinicalTrials.gov NCT01789411).14,18 In brief, 581 
patients who underwent diagnostic coronary angiography or percutaneous coronary 
intervention (PCI) for acute coronary syndrome (ACS) or stable angina pectoris were 
included. None of the patients were treated with drugs targeting PCSK9 during the 
study period. This study was approved by the medical ethics committee of Erasmus MC. 
Written informed consent was obtained from all included patients.
serum proprotein convertase substilisin/kexin type 9
Blood samples were drawn from the arterial sheath prior to coronary angiography, and 
were stored at a temperature of −80°C within 2 hours after blood collection. PCSK9 
concentrations were measured in the stored serum samples (n=576) using an enzyme-
linked immunosorbent assay (Human PCSK9 Quantikine ELISA, R&D Systems Inc., Min-
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neapolis, MN, USA). The minimum detectable concentration of this assay was 0.096 μg/L 
with a coefficient of variation of 4.1% at a mean value of 27.9 μg/L. In 5 patients, serum 
samples were not available for PCSK9 measurement.
Coronary intravascular ultrasound imaging
Following the standard coronary angiography procedure, IVUS-VH imaging of the most 
proximal part of a non-culprit coronary artery was performed. Offline analysis of the 
IVUS-VH images was performed by an independent core laboratory (Cardialysis bv, 
Rotterdam, the Netherlands) that was blinded for patient characteristics, PCSK9 levels 
and clinical outcome data. Extent and phenotype of the atherosclerotic plaque were 
assessed (Figure 1). Plaque burden was defined as the plaque and media cross-sectional 
area divided by the external elastic membrane cross-sectional area. Plaque volume was 
adjusted for the imaged segment length (adjusted plaque volume = plaque volume / 
imaged segment length * median segment length in study population). The composi-
tion of atherosclerotic plaque was characterized into 4 different tissue types: fibrous, 
fibro-fatty, dense calcium and necrotic core (Figure 1).13 The fraction of coronary ath-
erosclerosis consisting of necrotic core tissue was a priori defined as primary outcome 
measure. A coronary lesion was defined as a segment with a plaque burden of more 
than 40% in at least 3 consecutive frames. An IVUS-VH-derived TCFA lesion was defined 
as a lesion with presence of >10% confluent necrotic core in direct contact with the 
lumen in at least three consecutive frames.14-16,18-20
statistical analysis
The distributions of the continuous variables, including PCSK9 levels and the IVUS-VH 
parameters, were assessed for normality by visual examination of the histogram. The 
non-normally distributed variables (i.e. plaque volume and necrotic core volume) were 
root-transformed. Linear regression analyses were performed to evaluate the asso-
ciations of serum PCSK9 levels with 1. plaque burden; 2. plaque volume; 3. fraction of 
plaque consisting of necrotic core tissue; and 4. necrotic core volume. The results are 
presented as β with 95% confidence interval (95% CI). Logistic regression analyses were 
performed to evaluate the association between serum PCSK9 levels and the presence of 
IVUS-VH-derived TCFA lesions. The results are presented as odds ratios (OR) with 95% CI. 
First, all analyses were performed univariably. In subsequent multivariate analyses, the 
variables age, gender, diabetes mellitus, hypertension, hypercholesterolemia, smoking, 
indication for coronary angiography (ACS or stable CAD) and statin use at time of hospi-
tal admission were a priori defined as potential confounders. Hereafter, baseline serum 
LDL cholesterol levels was additionally entered into the model to evaluate whether the 
associations between PCSK9 and coronary plaque characteristics were independent of 
serum LDL cholesterol levels. Additionally, stratified analyses were performed to evaluate 
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whether the observed associations between PCSK9 and coronary plaque characteristics 
in the total study population were applicable for all patient subgroups (including statin 
users and non-statin users, as well as patients with low and high LDL cholesterol). All 
data were analyzed with SPSS software (SPSS 20.0, IBM corp., Armonk, NY, USA). All sta-
tistical tests were two-tailed and p-values <0.05 were considered statistically significant
figure 1. Intravascular ultrasound virtual histology imaging
Intravascular ultrasound virtual histology imaging was used to characterize atherosclerotic plaques into 
4 different tissue types: fibrous (dark green), fibro-fatty (light green), dense calcium (white) and necrotic 
core (red).
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ResulTs
Patient characteristics
The patient characteristics are described in Table 1. Median serum PCSK9 level was 
270 μg/L and ranged from 91 to 804 μg/L [interquartile range 217-336]. PCSK9 levels 
were higher in patients with hypertension (median 283 [227-347] versus 255 [215-335] 
μg/L, p=0.005), hypercholesterolemia (median 281 [228-350} versus 255 [210-328] μg/L, 
p=0.001), and statin use at time of hospital admission (median 280 [221-342] versus 253 
[208-323] μg/L, p=0004). PCSK9 levels did not differ between patients admitted with 
ACS and patients with stable CAD (p=0.19). The median length of the imaged coronary 
segment was 44.3 [33.8-55.5] mm. Mean plaque burden in the imaged coronary seg-
ment was 38.2 ± 11.5 percent and median plaque volume was 222 [147-326] mm³. Mean 
fraction of plaque that consisted of necrotic core was 21.4 ± 8.0 percent and median 
necrotic core volume was 21.1 [8.6-41.6] mm³. A total of 241 (42%) patients had at least 
one IVUS-VH-derived TCFA lesion.
association between PCsK9 level and coronary plaque characteristics
In univariate analysis, higher serum PCSK9 levels were linearly associated with a higher 
necrotic core fraction (β = 1.31 percent increase in necrotic core per 100 μg/L increase 
Table 1. baseline characteristics
n = 576 patients
Patient characteristics
Age, years 61.5 ± 11.3
Men, n (%) 435 (75.5)
Diabetes Mellitus, n (%) 99 (17.2)
Hypertension, n (%) 300 (52.1)
Hypercholesterolemia, n (%) 320 (55.6)
Current smoking, n (%) 167 (29.0)
Positive family history, n (%) 300 (52.1)
Previous MI, n (%) 183 (31.8)
Previous PCI, n (%) 186 (32.3)
Previous CABG, n (%) 18 (3.1)
Previous stroke, n (%) 26 (4.5)
History of peripheral artery disease, n (%) 36 (6.2)
History of renal insufficiency, n (%) 32 (5.6)
History of heart failure, n (%) 19 (3.3)
Serum LDL cholesterol, mmol/L 2.72 [2.12-3.54]
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Table 1.  (continued)
Serum PCSK9, μg/L 270 [217-336]
Statin use at time of hospital admission, n (%) 359 (62.3)
Procedural characteristics
Indication for coronary angiography
ACS, n (%) 314 (54.5)
ST-elevation MI 164 (28.5)
Non-ST-elevation ACS 150 (26.0)
Stable coronary artery disease, n (%) 262 (45.5)
Number of diseased coronary vessels *
No significant stenosis, n (%) 42 (7.3)
1-vessel disease, n (%) 306 (53.1)
2-vessel disease, n (%) 167 (29.0)
3-vessel disease, n (%) 61 (10.6)
PCI performed, n (%) 507 (88.0)
IVUS-VH imaging
Imaged coronary artery
Left anterior descending, n (%) 207 (35.9)
Left circumflex, n (%) 193 (33.5)
Right coronary artery, n (%) 176 (30.6)
Segment length, mm 44.3 [33.8-55.5]
Plaque burden, % 38.2 ± 11.5
Plaque volume †, mm³ 222 [147-326]
Fibrous tissue fraction, % 57.8 ± 11.6
Fibro-fatty tissue fraction, % 8.9 [5.7-12.6]
Dense calcium fraction, % 9.3 [5.1-15.1]
Necrotic core fraction, % 21.4 ± 8.0
Fibrous tissue volume †, mm³ 56.2 [26.9-95.9]
Fibro-fatty volume †, mm³ 7.7 [3.4-17.2]
Dense calcium volume †, mm³ 8.9 [2.9-20.7]
Necrotic core volume †, mm³ 21.1 [8.6-41.6]
≥1 IVUS-VH-derived TCFA lesion, n (%) 241 (41.8)
Data are presented as mean ± standard deviation or as median [interquartile range].
* A significant stenosis was defined as a stenosis ≥50% of vessel diameter by visual assessment on the 
coronary angiogram.
† Adjusted for imaged segment length.
ACS = acute coronary syndrome; CABG = coronary artery bypass grafting; IVUS-VH = intravascular ultra-
sound virtual histology; LDL = low-density lipoprotein; MI = myocardial infarction; PCI = percutaneous 
coronary intervention; PCSK9 = proprotein convertase substilisin/kexin type 9; TCFA = thin-cap fibroath-
eroma.
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in PCSK9, 95% CI 0.63;1.99, p<0.001) and tended to be associated with a higher abso-
lute necrotic core volume (β = 0.08, 95%CI −0.01;0.16, p=0.075) (Table 2 and Figure 2). 
Furthermore, PCSK9 levels were inversely associated with fractions of fibrous tissue (β = 
−1.45, 95%CI −2.43;−0.47, p=0.004) and fibro-fatty tissue (β = −0.83, 95%CI −1.36;−0.30, 
p=0.002), and positively associated with dense calcium fraction (β 0.97, 95%CI 0.32;1.62, 
p=0.004) (Supplemental Figure 1). PCSK9 levels were not associated with overall 
plaque burden (β = 0.62, 95%CI −0.36;1.59, p=0.22), plaque volume (β = 0.03, 95%CI 
−0.06;0.12, p=0.48) or the presence of IVUS-VH-derived TCFA lesions (OR 1.01, 95%CI 
0.85-1.20, p=0.93). After adjustment in multivariate analysis, PCSK9 levels remained 
significantly associated with both necrotic core fraction (β = 1.22 percent increase in 
necrotic core per 100 μg/L increase in PCSK9, 95% CI 0.52-1.91, p<0.001) and absolute 
necrotic core volume (β = 0.09, 95%CI 0.01;0.18, p=0.036). These associations did not 
Table 2. association between serum PCsK9 level and coronary plaque characteristics
unadjusted P-value
adjusted for
cardiac risk 
factors + aCs 
or stable 
CaD +
statin use * P-value
adjusted for
cardiac risk 
factors + aCs 
or stable CaD 
+ statin use +
serum lDl * P-value
Plaque burden † β 0.62 
(−0.36;1.59)
0.22 β 0.77 
(−0.19;1.73)
0.12 β 0.78 
(−0.19;1.74)
0.11
Plaque volume ‡ β 0.03 
(−0.06;0.12)
0.48 β 0.05 
(−0.03;0.14)
0.22 β 0.05 
(−0.03;0.14)
0.22
Necrotic core fraction § β 1.31 
(0.63;1.99)
<0.001 β 1.22 
(0.52;1.91)
0.001 β 1.24 
(0.55;1.94)
0.001
Necrotic core volume || β 0.08 
(−0.01;0.16)
0.075 β 0.09 
(0.01;0.18)
0.036 β 0.09 
(0.01;0.18)
0.033
≥1 IVUS-VH-derived TCFA 
lesion
OR 1.01 (0.85-
1.20)
0.93 OR 1.00 (0.84-
1.20)
0.99 OR 1.00 (0.84-
1.20)
1.0
* Cardiac risk factors include: age, gender, diabetes mellitus, hypertension, hypercholesterolemia, smok-
ing. Statin use was registered at the time of hospital admission.
† β (95% confidence interval) is increase in plaque burden (%) per 100 μg/L increase in PCKS9.
‡ β (95% confidence interval) is increase in standard deviations of square root transformed plaque vol-
ume (mm³) per 100 μg/L increase in PCKS9. Plaque volume is adjusted for imaged segment length.
§ β (95% confidence interval) is increase in necrotic core fraction (%) per 100 μg/L increase in PCKS9.
|| β (95% confidence interval) is increase in standard deviations of square root transformed necrotic core 
volume (mm³) per 100 μg/L increase in PCKS9. Necrotic core volume is adjusted for imaged segment 
length.
ACS = acute coronary syndrome; CAD = coronary artery disease; IVUS-VH = intravascular ultrasound vir-
tual histology; LDL = low-density lipoprotein; PCSK9 = proprotein convertase substilisin/kexin type 9; 
TCFA = thin-cap fibroatheroma.
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change materially after additional adjustment for serum LDL cholesterol levels (Table 2). 
The full univariate and multivariate predictors of necrotic core fraction are presented in 
Supplemental Table 1. Subgroup analysis showed that the positive association between 
serum PCSK9 levels and necrotic core fraction was present in all patient subgroups, 
including statin users and non-statin users as well as patients with low and high LDL 
cholesterol. (Figure 3). There was no significant heterogeneity in the β estimate between 
the evaluated patient subgroups.
PCsK9 level and cardiovascular outcome
Although this study was not primarily designed to investigate the association between 
serum PCSK9 levels and cardiovascular outcome, 1-year follow-up was available for 
(99.7%) of patients. A total of 28 patients died or had an ACS (definite culprit lesion-
related events were not counted). Serum PCSK9 levels were significantly associated 
with the composite of death or ACS when PCSK9 was analyzed as a categorical variable 
(event rate 3.1% in patients with PCSK9 below median versus event rate 6.6% in patients 
with PCSK9 above median, p=0.049) (Supplemental Figure 2).
figure 2. association between serum PCsK9 level and fraction of coronary plaque that consists of 
necrotic core tissue
PCSK9, proprotein convertase substilisin/kexin type 9.
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DIsCussIOn
This study investigated the association of serum PCSK9 levels with the fraction and 
amount of necrotic core tissue in coronary atherosclerotic plaque as assessed by IVUS-
VH imaging in patients with established CAD undergoing coronary angiography. The 
main finding was that higher serum PCSK9 levels were linearly associated with a higher 
necrotic core fraction in coronary atherosclerosis. This association was independent of 
serum LDL cholesterol levels and statin use, and was observed in all patient subgroups, 
including statin users and non-statin users as well as patients with low and high LDL cho-
figure 3. association between PCsK9 level and necrotic core fraction stratified by patient sub-
groups
β (95% confidence interval) is increase in necrotic core fraction (%) per 100 μg/L increase in PCKS9. Red 
dotted line indicates the β estimate in the total study population.
ACS, acute coronary syndrome; CAD, coronary artery disease; LDL, low-density lipoprotein.
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lesterol. To the best of our knowledge, this is, as yet, the first study that has investigated 
the relation between serum PCSK9 levels and atherosclerotic plaque characteristics.
Serum PCSK9 levels vary between individuals.21 The median PCSK9 level in our patient 
population with established CAD (270 μg/L) was higher than that in healthy individuals 
in previously published studies, for example in the Justification for the Use of Statins in 
Primary Prevention: An Intervention Trial Evaluating Rosuvastatin trial (JUPITER) trial (71 
μg/L).21 Currently, PCSK9 is mostly known for its role in the regulation of cholesterol ho-
meostasis.2 It enhances the degradation of hepatic LDL receptors, resulting in an increase 
in LDL cholesterol levels.2 Gain-of-function mutations in the PCSK9 gene are linked to 
familiar hypercholesterolemia, while loss-of-function mutations of the PCSK9 gene 
are linked to low LDL cholesterol levels and low cardiovascular risk, without currently 
known adverse effects on health.22-25 Furthermore, statin treatment is known to increase 
PCSK9 levels by a negative feedback mechanism in response to lower cholesterol levels, 
making it even more interesting to investigate the effects of new PCSK9 inhibiting drugs 
on top of statin treatment.21,26-28 Recent phase II clinical trials have reported promising 
results on serum LDL cholesterol levels by administration of monoclonal antibodies 
against PCSK9.3-9
Although a previous study did not find a significant association between serum PCSK9 
levels and carotid intima-media thickness in healthy men,29 other studies have suggested 
that PCSK9 may have a direct role in inflammatory processes contributing to athero-
sclerotic disease by mechanisms that are independent of LDL cholesterol levels.2 Recent 
experimental studies have shown that PCSK9 is expressed in human atherosclerotic 
plaques.30 PCSK9 enhances the expression of pro-inflammatory genes through activation 
of nuclear factor kappa beta (Nf-κB).10 Inhibition of PCSK9 has been shown to suppress 
this pro-inflammatory pathway.10 Furthermore, PCSK9 also targets apolipoprotein E 
receptor 2, which is a family member of the LDL receptor.11 Degradation of apolipopro-
tein E receptor 2 is accompanied with loss of its known anti-inflammatory function.11,31 
Finally, PCSK9 is also associated with increased oxidized LDL-induced apoptosis of hu-
man endothelial cells, which may lead to endothelial dysfunction.12 Inhibition of PCSK9 
has been shown to suppress such endothelial apoptosis.12 Our finding that serum PCSK9 
levels were linearly associated with the amount of necrotic core by IVUS-VH imaging, 
independently of serum LDL cholesterol levels and in all patient subgroups (including 
statin users and non-statin users as well as patients with low and high LDL cholesterol), 
supports the hypothesis that PCSK9 has a direct role in plaque inflammation.
Although this study was not primarily designed to investigate the association 
between serum PCSK9 levels and cardiovascular outcome, a significant association 
between PCSK9 (below vs. above median level) and 1-year death or ACS was present. 
Previous studies have demonstrated that the presence of IVUS-VH-derived TCFA lesions 
and the amount of IVUS-VH-derived necrotic core tissue in coronary atherosclerosis are 
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both independent predictors of adverse coronary events.14-16 Rupture of a TCFA lesion is 
believed to be a major cause of ACS.32 Although we did not find an association between 
PCSK9 and the presence of IVUS-VH-derived TCFA lesions, we did find an association 
with its precursor, namely necrotic core. Plaque erosion due to chronic inflammation is 
another major cause of ACS.33 It may be possible that PCSK9 has a role in plaque erosion 
through its involvement in the pro-inflammatory pathways and endothelial apoptosis 
as described above. The exact mechanism underlying the relation between PCSK9, 
the amount of necrotic core tissue and cardiovascular outcome (beyond its role in LDL 
cholesterol homeostasis) requires further elucidation in future research.
Some limitations of this study need to be acknowledged. Firstly, a single non-culprit 
coronary vessel was imaged in this study. This approach was eventually chosen to test 
the hypothesis that the phenotype of a non-culprit artery segment may indicate the 
patient’s systemic atherosclerotic disease burden.18 This hypothesis is supported by our 
previous finding that IVUS-VH imaging in only one non-culprit vessel appeared relevant 
for prognostication.14 However, necrotic core-rich plaques (e.g. TCFA lesions) elsewhere 
in the coronary tree (including the culprit lesion) were not assessed in our study. This 
may have lead to an underestimation of the association between PCSK9 and necrotic 
core-rich plaques in the coronary tree. Secondly, repeated intracoronary imaging with 
IVUS-VH was not performed. Therefore, the association between PCSK9 and actual pro-
gression of necrotic core tissue and atherosclerotic plaque could not be investigated. 
Finally, this study was not primarily designed to investigate the association between 
PCSK9 and clinical outcome, and the number of clinical endpoints was relatively small.
COnClusIOns
In patients with established CAD, the range in serum PCSK9 levels is wide. Higher PCSK9 
levels were linearly associated with a higher fraction and amount of IVUS-VH-derived 
necrotic core tissue in coronary atherosclerotic plaque. These associations were inde-
pendent of serum LDL cholesterol levels and were observed in all patient subgroups, 
including statin users and non-statin users, as well as patients with low and high LDL cho-
lesterol. Our results support the hypothesis that PCSK9 is directly involved in promoting 
inflammatory processes contributing to atherosclerosis by mechanisms independent of 
LDL cholesterol levels. Therefore, PCSK9 may be an interesting therapeutic target for 
the treatment of atherosclerotic disease beyond LDL cholesterol regulation (i.e. on top 
of statin treatment). Further research is warranted to investigate the effects of PCSK9 
inhibiting therapies on the composition of atherosclerosis and on clinical outcome.
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suPPleMenTal MaTeRIal
supplemental Table 1. Predictors of necrotic core fraction
unadjusted P-value adjusted* P-value
Age β -0.02 (-0.07;0.04) 0.62 β -0.02 (-0.08;0.05) 0.61
Gender (man) β -0.73 (-2.3;0.79) 0.35 β -0.46 (-2.04;1.12) 0.57
Diabetes mellitus β -0.86 (-2.60;0.89) 0.34 β -0.61 (-2.42;1.20) 0.51
Hypertension β 0.60 (-0.72;1.91) 0.37 β 0.57 (-0.91;2.05) 0.45
Hypercholesterolemia β 0.26 (-1.06;1.58) 0.70 β -0.28 (-1.87;1.31) 0.73
Smoking β -0.25 (-1.70;1.20) 0.73 β -0.64 (-2.23;0.95) 0.43
ACS (vs stable CAD) β -0.65 (-1.96;0.67) 0.34 β -0.95 (-2.40;0.50) 0.20
LDL cholesterol β 0.28 (-0.33;0.90) 0.36 β 0.56 (-0.17-1.28) 0.13
Statin use β 0.99 (-0.37;2.34) 0.15 β 1.71 (-0.02;3.44) 0.052
PCSK9† β 1.31 (0.63;1.99) <0.001 β 1.24 (0.55;1.94) <0.001
* Full model includes: age, gender, diabetes mellitus, hypertension, hypercholesterolemia, smoking, clini-
cal presentation (ACS or stable CAD), LDL cholesterol, statin use (registered at the time of hospital admis-
sion) and PCSK9.
† β (95% confidence interval) is increase in necrotic core fraction (%) per 100 μg/L increase in PCKS9.
ACS = acute coronary syndrome; CAD = coronary artery disease; LDL = low-density 9 = proprotein con-
vertase substilisin/kexin type 9.
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supplemental figure 1. association between serum PCsK9 and plaque composition
PCSK9 = proprotein convertase substilisin/kexin type 9.
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supplemental figure 2. association of PCsK9 level with clinical outcome
Definite culprit lesion-related events were not counted as endpoint.
ACS = acute coronary syndrome.
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absTRaCT
Objective: To investigate relations of several circulating chemokines with extent and 
phenotype of coronary atherosclerosis and with 1-year clinical outcome.
Methods: Intravascular ultrasound virtual histology imaging of a coronary artery was 
performed in 581 patients. MCP-1, MIP-1α, MIP-1β and RANTES were measured in plasma.
Results: Higher MCP-1, MIP-1α and lower RANTES were associated with coronary plaque 
burden. Higher MCP-1, MIP-1α and lower RANTES were associated with the presence 
of IVUS-VH-derived thin-cap fibroatheroma lesions. RANTES was associated with major 
adverse cardiac events.
Conclusions: RANTES is a promising biomarker that is inversely associated with coro-
nary plaque burden and vulnerability, as well as with death and ACS.
Chemokines, coronary atherosclerosis and outcome 291
C
h
a
p
te
r
 1
7
InTRODuCTIOn
Inflammation has been recognized as an important contributing factor in all phases 
of atherosclerosis.1-3 In particular, inflammation is believed to play a crucial role in the 
development and rupture of vulnerable plaques, resulting in major cardiovascular prob-
lems such as myocardial infarction and stroke.1-3 Circulating inflammatory biomarkers 
may potentially improve prognostication of patients with atherosclerotic cardiovascular 
disease.4
Chemokines are involved in the recruitment of various leukocytes, such as monocytes, 
macrophages and T lymphocytes, into the atherosclerotic plaque.5,6 Monocyte chemoat-
tractant protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), MIP-1β and 
regulated upon activation normal T cell expressed and secreted (RANTES) are typical 
C-C motif chemokines that have been studied extensively.5,6 Several studies have shown 
that these chemokines have an important role throughout the entire atherosclerotic 
process from atherogenesis to plaque destabilization.5,6 However, their clinical utility as 
biomarker remains unclear.5,6 Furthermore, prospective data on associations of these 
biomarkers with in-vivo measurements of extensiveness, phenotype and vulnerability of 
coronary atherosclerosis is currently lacking. This study aims to evaluate the usefulness 
of MCP-1, MIP-1α, MIP-1β and RANTES by investigating their relations with intravascular 
ultrasound virtual histology (IVUS-VH)-derived measures of coronary plaque burden, 
quantity of necrotic core, and presence of thin-cap fibroatheroma lesions (TCFA), and by 
investigating their prognostic value for major adverse cardiac events.
MeTHODs
study population
The design of The European Collaborative Project on Inflammation and Vascular Wall Re-
modeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study has 
been described in detail elsewhere.7,8 In brief, 581 patients who underwent diagnostic 
coronary angiography or percutaneous coronary intervention (PCI) for acute coronary 
syndrome (ACS) or stable angina pectoris (SAP) have been included between 2008 and 
2011 in the Erasmus MC, Rotterdam, the Netherlands. The ATHEROREMO-IVUS study was 
approved by the medical ethics committee of the Erasmus MC. The study was performed 
in accordance with the criteria described in the declaration of Helsinki. Written informed 
consent was obtained from all included patients. This study is registered in ClinicalTrials.
gov, number NCT01789411.
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Data collection
Baseline characteristics of all patients were collected prospectively by trained research 
physicians. These physicians reviewed the medical charts of the patients at the time of 
inclusion in the study, and extracted variables regarding demographics, medical history, 
cardiovascular risk factors and procedural characteristics. Medical history and cardio-
vascular risk factors are a routine part of clinical patient assessment at the department 
of Cardiology. Thus, presence of diabetes mellitus, hypertension, hypercholesterolemia, 
history of renal insufficiency and history of heart failure were defined as a clinical di-
agnosis of these conditions as reported by the treating physician in the medical chart. 
Smoking was defined as current smoking, reported by the patient. Procedural character-
istics were prospectively extracted from the catheterization report.
biomarkers
Blood samples were drawn from the arterial sheath prior to the diagnostic coronary 
angiography or PCI procedure. The blood samples were transported to the clinical labo-
ratory of Erasmus MC for further processing and storage at temperature of −80°C within 
2 hours after blood collection. MCP-1, MIP-1α, MIP-1β and RANTES were measured in the 
stored EDTA-plasma samples (n=570) using a validated multiplex assay (Custom Human 
Map, Myriad RBM, Austin, Texas, USA).
Intravascular ultrasound
Following the standard coronary angiography or PCI procedure, IVUS data were acquired 
in a non-culprit coronary vessel. Selection of the non-culprit vessel was predefined in 
the study protocol. The order of preference for selection of the non-culprit vessel was: 
1. left anterior descending (LAD) artery; 2. right coronary artery (RCA); 3. left circumflex 
(LCX) artery. All IVUS data were acquired with the Volcano s5/s5i Imaging System (Vol-
cano Corp., San Diego, CA, USA) using a Volcano Eagle Eye Gold IVUS catheter (20 MHz). 
An automatic pullback system was used with a standard pull back speed of 0.5 mm 
per second. The IVUS images were analyzed offline by an independent core laboratory 
(Cardialysis BV, Rotterdam, the Netherlands) that had no knowledge of clinical data. The 
IVUS gray-scale and IVUS radiofrequency analyses, also known as IVUS virtual histology, 
were performed using pcVH 2.1 and qVH (Volcano Corp., San Diego, CA, USA) software. 
The external elastic membrane and luminal borders were contoured for each frame (me-
dian interslice distance, 0.40 mm). Extent and phenotype of the atherosclerotic plaque 
were assessed. Plaque burden was defined as plaque and media cross-sectional area 
divided by external elastic membrane cross-sectional area and is presented as a percent-
age. The composition of the atherosclerotic plaque was characterized into 4 different 
tissue types: fibrous, fibro-fatty, dense calcium and necrotic core.9 A coronary lesion was 
defined as a segment with a plaque burden of more than 40% in at least 3 consecutive 
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frames. A thin-cap fibroatheroma (TCFA) lesion on IVUS-VH was defined as a lesion with 
presence of >10% confluent necrotic core in direct contact with the lumen (Figure 1).10,11 
TCFA lesions with a plaque burden of at least 70% were classified as large TCFA lesions.
study endpoints
In this study, follow-up started at inclusion and lasted up to 1 year. Post-discharge 
survival status was obtained from municipal civil registries. Post-discharge rehospital-
izations were prospectively assessed during follow-up. Questionnaires focusing on the 
occurrence of major adverse cardiac events (MACE) were sent to all living patients. Treat-
ing physicians and institutions were contacted for additional information whenever 
necessary. ACS was defined as the clinical diagnosis of ST segment elevation myocardial 
figure 1. Thin-cap fibroatheroma lesion on intravascular ultrasound virtual histology
Thin-cap fibroatheroma lesion on intravascular ultrasound virtual histology is defined as a lesion with 
presence of >10% confluent necrotic core (red) in direct contact with the lumen. White indicates dense 
calcium, light green indicates fibrofatty tissue, dark green indicates fibrous tissue.
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infarction (STEMI), non-STEMI or unstable angina pectoris in accordance with the guide-
lines of the European Society of Cardiology.12-14 Unplanned coronary revascularization 
was defined as unplanned repeat PCI or coronary artery bypass grafting (CABG). All 
events were adjudicated as related to a coronary site that was treated during the index 
procedure (culprit lesion related event) or as related to the coronary site that was not 
treated during the index procedure (non-culprit lesion related event). Events that were 
related to both the culprit lesion and a non-culprit site (e.g. revascularization of multiple 
vessels with CABG) were classified into both categories. When information was not suf-
ficient to classify an event as either culprit lesion related or non-culprit lesion related, 
the event was classified as indeterminate.
The primary endpoint was MACE, defined as non-culprit lesion related or indetermi-
nate all-cause mortality, ACS or unplanned coronary revascularization. The secondary 
endpoint was defined as the composite of non-culprit lesion related or indeterminate 
all-cause mortality or ACS. Definite culprit lesion related events were excluded from 
the primary and secondary endpoints, because the pathophysiology of culprit lesions 
related events (e.g. in-stent restenosis or in-stent thrombosis) differs from our primary 
research focus on spontaneous plaque rupture leading to unanticipated, spontane-
ous MACE. The endpoints were adjudicated by a clinical event committee that had no 
knowledge of biomarkers and IVUS data.
statistical analysis
The distributions of the continuous variables, including biomarker levels and the IVUS 
parameters, were tested for normality by visual examination of the histogram. Normally 
distributed continuous variables are presented as mean ± standard deviation (SD), while 
non-normally distributed continuous variables are presented as median and interquar-
tile range (IQR). MCP-1, MIP-1α, MIP-1β and RANTES concentrations were not normally 
distributed and were therefore ln-tranformed for further analysis. Categorical variables 
are presented in percentages. We examined associations of biomarker concentrations 
with plaque burden and necrotic core fraction in the imaged coronary segment. Spe-
cifically, we calculated means of plaque burden and necrotic core fraction according to 
tertiles of biomarker concentration. To test for trends, we used linear regression analyses 
with continuous ln-transformed biomarker concentrations as the independent variable. 
The final results are presented as β (per SD increase in ln-transformed biomarker con-
centration) with 95% confidence interval (95% CI). Furthermore, we have examined the 
relation between biomarker concentrations and the presence of IVUS-VH derived TCFA 
lesions using logistic regression analyses with continuous ln-tranformed biomarker 
concentration as the independent variable. The final results are presented as odds ratio 
(OR) per SD increase in ln-transformed biomarker concentration with 95% CI.
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Patients lost to follow-up were considered at risk until the date of last contact, at 
which time-point they were censored. Cumulative event rates were estimated according 
to the Kaplan-Meier method. Cumulative Kaplan-Meier event curves were compared by 
log-rank test. Cox proportional hazards regression analyses were performed to evaluate 
the relationship between biomarker concentration and clinical endpoints. Biomarkers 
that were significantly associated with occurrence of MACE in univariable analysis were 
further evaluated in multivariable analyses. The variables age, gender, diabetes mellitus, 
hypertension, hypercholesterolemia, smoking, statin use, history of MI and indication for 
coronary angiography were considered as potential confounders and were entered into 
the full model. These covariates were a priori chosen, taking into account the number of 
events available. Subsequently, C-reactive protein (CRP) was also entered into the model 
to evaluate whether the associations between biomarkers and MACE were independent 
of CRP concentration. The final results are presented as hazard ratio (HR) per SD increase 
in ln-transformed biomarker concentration with 95% CI.
All statistical analyses were primarily performed in the overall study population. 
Heterogeneity in effect estimates between patients with ACS and patients with stable 
angina were examined using the Z-test for heterogeneity. If there was no heterogeneity, 
conclusions were based on the effect estimates belonging to the total study population. 
If there was significant heterogeneity between patients admitted with and without ACS, 
conclusions were based on effect estimates of the separate groups.
All data were analyzed with SPSS software (SPSS 20.0, IBM corp., Armonk, NY, USA). 
All statistical tests were two-tailed and p-values <0.05 were considered statistically 
significant.
ResulTs
baseline characteristics
Mean age of the patients was 61.5 ± 11.4 years, 75.4% were men and 17.4% had diabetes 
mellitus (Table 1). Coronary angiography or PCI was performed for various indications: 
159 (27.9%) patients had an acute myocardial infarction, 150 (26.3%) patients had 
unstable angina pectoris and 261 (45.8%) patients had stable angina pectoris. Some 
patients had biomarker concentrations beneath the lowest detection limit of the assay, 
which especially pertains to MIP-1α (measurable in 84% of patients). The median length 
of the imaged coronary segment was 44.1 [33.7-55.4] mm. On basis of radiofrequency 
IVUS, a total of 239 (41.9%) patients had at least 1 IVUS-VH-derived TCFA, including 69 
(12.1%) patients with at least 1 IVUS-VH-derived TCFA with a plaque burden ≥70%.
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Table 1. baseline characteristics
Total
(n=570)
aCs
patients
(n=309)
saP
patients
(n=261)
Patient characteristics
Age, years 61.5 ± 11.4 59.7 ± 11.9 63.6 ± 10.3
Men, n (%) 430 (75.4) 227 (73.5) 203 (77.8)
Diabetes mellitus, n (%) 99 (17.4) 40 (12.9) 59 (22.6)
Hypertension. n (%) 295 (51.8) 134 (43.4) 161 (61.7)
Hypercholesterolemia, n (%) 317 (55.6) 137 (44.3) 180 (69.0)
Smoking, n (%) 164 (28.8) 115 (37.2) 49 (18.8)
Positive family history, n (%) 293 (51.4) 140 (45.3) 153 (58.6)
Previous MI, n (%) 184 (32.3) 80 (25.9) 104 (39.8)
Previous PCI, n (%) 185 (32.5) 57 (18.4) 128 (49.0)
Previous CABG, n (%) 18 (3.2) 7 (2.3) 11 (4.2)
Previous stroke, n (%) 23 (4.0) 10 (3.2) 13 (5.0)
Peripheral artery disease, n (%) 36 (6.3) 12 (3.9) 24 (9.2)
History of renal insufficiency, n (%) 32 (5.6) 13 (4.2) 19 (7.3)
History of heart failure, n (%) 19 (3.3) 6 (1.9) 13 (5.0)
C-reactive protein, mg/L 2.1 [0.8-5.3] 2.8 [1.1-7.0] 1.5 [0.6-3.1]
Statin use, n (%) 359 (63.0) 146 (47.2) 213 (81.6)
Procedural characteristics
Indication for catheterization
Acute coronary syndrome, n (%) 309 (54.2) 309 (100) 0 (0)
Myocardial infarction, n (%) 159 (27.9) 159 (51.5) 0 (0)
Unstable angina pectoris, n (%) 150 (26.3) 150 (48.5 0 (0)
Stable angina pectoris, n (%) 261 (45.8) 0 (0) 261 (100)
Coronary artery disease
No significant stenosis, n (%) 42 (7.4) 18 (5.8) 24 (9.2)
1-vessel disease, n (%) 301 (52.8) 168 (54.4) 133 (51.0)
2-vessel disease, n (%) 166 (29.1) 88 (28.5) 78 (29.9)
3-vessel disease, n (%) 61 (10.7) 35 (11.3) 26 (10.0)
PCI performed, n (%) 501 (87.9) 287 (92.9) 214 (82.0%)
Serum biomarker concentrations
MCP-1, pg/ml * 91 [70-122] 92 [70-133] 88 [71-111]
MIP-1α, pg/ml † 16.0 [12.0-21.9] 15.0 [12.0-21.9] 17.0 [12.0-21.9]
MIP-1β, pg/ml * 123 [92-165] 130 [95-179] 114 [89-146]
RANTES, ng/ml ‡ 11.0 [6.4-19.0] 14.0 [7.6-23.0] 9.1 [5.0-14.3]
IVUS segment characteristics
Imaged coronary artery
Left anterior descending, n (%) 204 (35.8) 117 (37.9) 87 (33.3)
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associations with coronary atherosclerosis
In patients who were admitted with stable angina pectoris, higher plasma MCP-1 
concentrations were associated with higher coronary plaque burden (per SD increase 
of ln-transformed MCP-1: β=2.56, 95% CI 0.91-4.21, p=0.002) and a higher fraction of 
plaque consisting of necrotic core (per SD increase of ln-transformed MCP-1: β=1.14, 
95% CI 0.02-2.25, p=0.045) (Table 2). Higher MCP-1 concentrations also seemed to be 
associated with the presence of IVUS-VH derived TCFA lesions (OR per SD increase in 
ln-transformed MCP-1 1.90, 95% CI 1.00-3.61, p=0.052) in patients who were admitted 
with stable angina pectoris (Table 3).
Higher MIP-1α concentrations were associated with higher plaque burden (per SD in-
crease of ln-transformed MIP-1α: β=1.66, 95% CI 0.72-2.61, p=0.001), higher necrotic core 
fraction (per SD increase of ln-transformed MIP-1α: β=0.89, 95% CI 0.23-1.55, p=0.008) 
and with the presence of IVUS-VH derived TCFA lesions with plaque burden ≥70% (OR 
per SD increase in ln-transformed MIP-1α 1.75, 95% CI 1.09-2.81, p=0.021) in the total 
study population.
In patients who were admitted with ACS, lower RANTES concentrations were associ-
ated with higher plaque burden (per SD increase of ln-transformed RANTES: β=−1.57, 
95% CI −2.94;−0.20, p=0.025) (Figure 2). Furthermore, lower RANTES concentrations also 
seemed to be associated with the presence of IVUS-VH derived TCFA lesions with plaque 
burden ≥70% in the overall patient population (OR per SD increase in ln-transformed 
RANTES 0.76, 95% CI 0.57-1.02, p=0.067).
Table 1 (continued)
Total
(n=570)
aCs
patients
(n=309)
saP
patients
(n=261)
Left circumflex, n (%) 190 (33.3) 107 (34.6) 83 (31.8)
Right coronary artery, n (%) 176 (30.9) 85 (27.5) 91 (34.9)
Segment length, mm 44.1 [33.7-55.4] 43.9 [32.9- 54.1] 44.8 [34.2-57.2]
At least 1 TCFA 239 (41.9) 140 (45.3) 99 (37.9)
At least 1 TCFA with PB≥70% 69 (12.1) 32 (10.4) 37 (14.2)
* Measurable in >99% of patients; below limit of detection in <1% of patients.
† Measurable in 84% of patients; below limit of detection in 16% of patients.
‡ Measurable in all patients.
ACS indicates acute coronary syndrome; CABG, coronary artery bypass grafting; MCP-1, monocyte che-
moattractant protein-1; MI, myocardial infarction; MIP-1α, macrophage inflammatory protein-1α; MIP-
1β, macrophage inflammatory protein-1β; PB, plaque burden; PCI, percutaneous coronary intervention; 
RANTES, Regulated upon Activation Normal T cell Expressed and Secreted; SAP, stable angina pectoris; 
TCFA, thin-cap fibroatheroma.
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Major adverse cardiac events
Vital status was acquired for 569 (99.8%) patients. Response rate of the questionnaires 
that were sent to all living patients was 92.3%. After 1 year of follow-up, 56 patients had 
at least 1 event (Supplemental table 1). A total of 11 patients had a definite culprit lesion 
related event, while 27 patients had a definite non-culprit lesion related event. Another 
18 patients had an event that could not be judged to be either culprit lesion related 
or non-culprit lesion related and were therefore classified as having an indeterminate 
event. The cumulative Kaplan-Meier incidences of the 30-day, 6-month and 1-year com-
posite of non-culprit lesion related or indeterminate death, ACS or unplanned coronary 
revascularization were 0.7%, 4.7%, and 7.9%, respectively. The cumulative Kaplan-Meier 
incidences of the 30-day, 6-month and 1-year composite of non-culprit lesion related or 
indeterminate death or ACS were 0.7%, 3.2%, and 4.9%, respectively.
associations with non-culprit lesion related and indeterminate events
In univariable analysis, RANTES (HR per SD increase of ln-transformed RANTES 0.67, 
95% CI 0.50-0.89, p=0.005) was associated with occurrence of the primary endpoint of 
non-culprit lesion related and indeterminate MACE during follow-up (Table 4, Figure 
2). There was no heterogeneity in the hazard ratio estimate between ACS patients and 
patients with stable angina (heterogeneity p=0.39). RANTES (HR per SD increase of ln-
transformed RANTES 0.64, 95% CI 0.45-0.91, p=0.013) was also significantly associated 
Table 3. associations with presence of intravascular ultrasound virtual histology-derived thin-cap 
fibroatheroma lesions
Total study population 
(n=570) aCs patients (n=309) saP patients (n=261)
Hetero-
geneity
OR (95% CI) P OR (95% CI) P OR (95% CI) P P
Presence of at least 1 thin-cap fibroatheroma
MCP-1 1.03 (0.74-1.45) 0.85 0.77 (0.51-1.17) 0.22 1.90 (1.00-3.61) 0.052 0.022
MIP-1α 0.87 (0.63-1.21) 0.42 0.94 (0.61-1.42) 0.75 0.83 (0.49-1.39) 0.47 0.72
MIP-1β 1.16 (0.85-1.60) 0.36 1.18 (0.79-1.76) 0.42 0.97 (0.55-1.70) 0.91 0.69
RANTES 0.97 (0.80-1.18) 0.75 0.87 (0.66-1.15) 0.33 0.98 (0.72-1.33) 0.90 0.57
Presence of at least 1 thin-cap fibroatheroma with plaque burden ≥70%
MCP-1 1.23 (0.75-2.04) 0.41 0.94 (0.48-1.83) 0.86 2.16 (0.95-4.93) 0.067 0.12
MIP-1α 1.75 (1.09-2.81) 0.021 2.15 (1.13-4.09) 0.020 1.29 (0.63-2.66) 0.49 0.30
MIP-1β 0.89 (0.54-1.47) 0.66 0.91 (0.47-1.78) 0.79 1.01 (0.46-2.20) 0.98 0.85
RANTES 0.76 (0.57-1.02) 0.067 0.73 (0.47-1.15) 0.17 0.84 (0.55-1.28) 0.41 0.67
Odds ratios are per standard deviation increase in ln-transformed biomarker concentration.
ACS indicates acute coronary syndrome; MCP-1, monocyte chemoattractant protein-1; MIP-1α, macro-
phage inflammatory protein-1α; MIP-1β, macrophage inflammatory protein-1β; RANTES, Regulated upon 
Activation Normal T cell Expressed and Secreted; SAP, stable angina pectoris.
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with the composite of non-culprit lesion related and indeterminate death or ACS only. 
After adjustment for conventional cardiovascular risk factors in multivariable analysis, 
RANTES remained independently predictive for non-culprit lesion related and inde-
figure 2. associations of circulating RanTes concentrations with coronary atherosclerosis and 
clinical outcome
A. Association with intravascular ultrasound-derived measures of coronary plaque burden in patients 
admitted with acute coronary syndrome.
B. Association with presence of thin-cap fibroatheroma lesions with plaque burden ≥70% as assessed by 
intravascular ultrasound virtual histolgy.
C. Association with occurrence of non-culprit lesion related and indeterminate death, acute coronary 
syndrome or coronary revascularization. The lowest RANTES tertile was associated with the highest event 
rate (lowest tertile vs. middle tertile p=0.006; lowest tertile vs. highest tertile p=0.042; middle tertile vs. 
highest tertile p=0.50; logrank p for trend=0.026).
D. Association with occurrence of non-culprit lesion related and indeterminate death or acute coronary 
syndrome. The lowest RANTES tertile was associated with the highest event rate (lowest tertile vs. middle 
tertile p=0.004; lowest tertile vs. highest tertile p=0.039; middle tertile vs. highest tertile p=0.86; logrank 
p for trend=0.019).
ACS indicates acute coronary syndrome; PB, plaque burden; RANTES, Regulated upon Activation Normal 
T cell Expressed and Secreted; TCFA, thin-cap fibroatheroma.
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p=0.016) and for non-culprit lesion related and indeterminate death or ACS only (HR 
per SD increase of ln-transformed RANTES 0.60, 95% CI 0.41-0.88, p=0.010) (Table 5). 
RANTES also remained independently associated with MACE (HR per SD increase of ln-
transformed RANTES 0.69, 95% CI 0.51-0.93, p=0.014) and the composite of death or ACS 
Table 4. associations with non-culprit lesion related and indeterminate major adverse cardiac 
events
Total study population
(n=570)
aCs patients
(n=309)
saP patients
(n=261)
Hetero-
geneity
HR (95% CI) P HR (95% CI) P HR (95% CI) P P
Major adverse cardiac events (primary endpoint)
MCP-1 0.87 (0.64-1.18) 0.37 0.81 (0.55-1.20) 0.29 1.00 (0.61-1.65) 1.00 0.51
MIP-1α 1.13 (0.85-1.49) 0.40 1.16 (0.82-1.66) 0.40 1.06 (0.69-1.64) 0.80 0.74
MIP-1β 1.00 (0.74-1.34) 0.99 1.15 (0.82-1.62) 0.42 0.82 (0.50-1.34) 0.42 0.26
RANTES 0.67 (0.50-0.89) 0.005 0.77 (0.50-1.18) 0.23 0.59 (0.40-0.88) 0.009 0.39
Composite of death or acute coronary syndrome (secondary endpoint)
MCP-1 0.73 (0.48-1.09) 0.12 0.74 (0.47-1.16) 0.19 0.69 (0.31-1.53) 0.36 0.88
MIP-1α 1.11 (0.77-1.58) 0.58 1.12 (0.73-1.70) 0.61 1.11 (0.59-2.09) 0.74 0.99
MIP-1β 1.11 (0.78-1.57) 0.57 1.34 (0.98-1.84) 0.071 0.48 (0.24-0.98) 0.043 0.010
RANTES 0.64 (0.45-0.91) 0.013 0.58 (0.36-0.94) 0.028 0.62 (0.35-1.10) 0.10 0.86
Hazard ratios are per standard deviation increase in ln-transformed biomarker concentration.
MCP-1, monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory protein-1α; MIP-1β, 
macrophage inflammatory protein-1β; RANTES, Regulated upon Activation Normal T cell Expressed and 
Secreted; SAP, stable angina pectoris.
Table 5. Multivariable analysis on non-culprit lesion related and indeterminate major adverse car-
diac events
adjusted for
age and gender
adjusted for
age, gender and 
indication for 
angiography
adjusted for 
conventional risk 
factors and indication 
for angiography*
adjusted for 
conventional risk 
factors, indication for 
angiography and CRP*
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Major adverse cardiac events (primary endpoint)
RANTES
0.72
(0.54-0.96)
0.024
0.71
(0.53-0.95)
0.023
0.69
(0.52-0.93)
0.016
0.69
(0.51-0.93)
0.014
Composite of death or acute coronary syndrome (secondary endpoint)
RANTES
0.69
(0.48-0.99)
0.046
0.64
(0.44-0.93)
0.021
0.60
(0.41-0.88)
0.010
0.59
(0.40-0.88)
0.010
Hazard ratios are per standard deviation increase in ln-transformed biomarker concentration.
* Conventional risk factors include: age, gender, diabetes mellitus, hypertension, hypercholesterolemia, 
smoking, statin use and history of myocardial infarction.
CRP indicates C-reactive protein; RANTES, Regulated upon Activation Normal T cell Expressed and Se-
creted.
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only (HR per SD increase of ln-transformed RANTES 0.59, 95% CI 0.40-0.88, p=0.010) after 
additional adjustment for baseline CRP levels. Subgroup analysis showed that the in-
verse association between RANTES level and MACE was present in all patient subgroups 
(Figure 3). There was no significant heterogeneity in the hazard ratio estimate between 
the evaluated patient subgroups.
DIsCussIOn
This study investigated the relations of circulating chemokine concentrations with 
extensiveness of coronary atherosclerosis, amount of necrotic core, the presence of 
figure 3. association between RanTes level and major adverse cardiac events stratified by patient 
subgroups
Hazard ratios (95% confidence intervals) are per standard deviation increase in ln-transformed RANTES 
concentration. Dotted line indicates the hazard ratio estimate in the total study population.
ACS indicates acute coronary syndrome; CAD, coronary artery disease; HR, hazard ratio; MI, myocardial 
infarction; RANTES, Regulated upon Activation Normal T cell Expressed and Secreted.
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IVUS-VH derived TCFA lesions and occurrence of future major adverse cardiac events in 
patients who underwent coronary angiography for ACS or stable angina pectoris. To our 
best knowledge, this is the first study that correlates circulating chemokines with in-vivo 
measurements of coronary atherosclerosis using IVUS-VH. Higher plasma MCP-1, MIP-
1α, and lower RANTES concentrations were all associated with higher coronary plaque 
burden and more advanced plaque phenotypes as determined by IVUS-VH (Figure 4). 
However, only RANTES was found to be independently predictive for the occurrence of 
MACE, particularly of death and ACS.
Chemokines are small cytokines that have the ability to induce directed chemotaxis 
of nearby leukocytes. MCP-1, MIP-1α, MIP-1β and RANTES belong to the C-C motif che-
mokine ligand (CCL) family and are also known as CCL2, CCL3, CCL4 and CCL5, respec-
tively.5,6 Pathologic studies have shown that these chemokines are highly expressed 
in atherosclerotic plaques.15-17 Animal studies have shown that these chemokines are 
actively involved in atherogenesis and plaque destabilization.5,6 Furthermore, several 
epidemiological studies have indicated that serum or plasma levels of MCP-1, MIP-1α, 
MIP-1β and RANTES may predict future cardiac events.5 However, their clinical utility as 
biomarker for cardiovascular risk stratification remains unclear.5,6 We sought to further 
elucidate the correlations of circulating chemokine concentrations with in-vivo mea-
surements of extensiveness, phenotype and vulnerability of coronary atherosclerosis by 
using IVUS-VH.
Grey-scale IVUS allows for in-vivo measurements of coronary plaque burden. Addi-
tionally, radiofrequency IVUS allows for differentiation of the composition of the athero-
figure 4. Circulating chemokine concentrations as biomarkers for phenotype of coronary athero-
sclerosis and risk of plaque rupture
Hypothesized model based on findings in this study. Plasma MCP-1, MIP-1α and RANTES concentrations 
were all associated with coronary plaque burden and different plaque phenotypes. RANTES was associ-
ated with major adverse cardiac events that were most probably caused by plaque rupture.
* Only for patients with stable angina pectoris.
↑ indicates higher biomarker concentrations.
↓ indicates lower biomarker concentrations.
MCP-1 indicates monocyte chemoattractant protein-1; MIP-1α, macrophage inflammatory protein-1α; 
RANTES, Regulated upon Activation Normal T cell Expressed and Secreted; TCFA, thin-cap fibroatheroma.
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sclerotic plaque and is therefore also known as IVUS-VH.10 Necrotic core is often found in 
the more advanced and rupture-prone plaques.18 The Providing Regional Observations 
to Study Predictors of Events in the Coronary Tree (PROSPECT) study has demonstrated 
that TCFA lesions as determined by IVUS-VH are associated with MACE.19 The strong and 
independent associations (adjusted hazard ratios ranging from 1.79 to 3.35) of IVUS-VH-
derived TCFA with MACE emphasize its biological importance.18-20 However, there are 
several reasons why IVUS is currently not suitable for use as diagnostic and prognostic 
tool in the overall population of patients with coronary artery disease.19 Its invasiveness 
is probably the most important limitation in this respect. Therefore, circulating biomark-
ers may have an important role in cardiovascular risk assessment.
In our study, lower plasma RANTES concentrations were independently associated 
with adverse outcomes during 1 year of follow-up. The association was independent of 
CRP. Its association with acute cardiac events (death or ACS; HR 0.59) seemed to be even 
stronger than with all major adverse cardiac events (death, ACS or unplanned coronary 
revascularization; HR 0.69). This may indicate that RANTES is especially predictive for 
plaque rupture rather than plaque growth. Our finding that low serum RANTES concen-
trations, rather than high, are associated with adverse coronary events may seem coun-
terintuitive, since animal studies have shown that RANTES and its receptor are actively 
involved in atherogenesis and that RANTES was found to be highly expressed within 
atheromous lesions.6,21 However, the inverse associations of RANTES may be explained 
by increased deposition of RANTES on the vascular endothelium, resulting in lower 
free circulating serum concentrations.22,23 The inverse associations of RANTES are also 
consistent with observations from previous studies. A large case-control study reported 
that serum RANTES levels were lower in coronary heart disease patients compared with 
age- and gender-matched controls.22 Another study reported that low plasma RANTES 
levels were independently associated with cardiac mortality in 389 male patients who 
underwent coronary angiography.23 Such an association was not found in a population-
based case-cohort study that included 363 individuals with incident coronary events 
and 1908 non-cases.24
We found that higher plasma MCP-1 concentrations were associated with higher 
coronary plaque burden in patients who were admitted with stable angina pectoris. 
These findings are in line with a previous study that measured MCP-1 concentrations 
in blood from the coronary sinus and found that these levels were associated with the 
extent of coronary atherosclerosis as assessed on the coronary angiogram.25 Although 
we observed that high MCP-1 concentrations were associated with a more advanced 
plaque phenotype (i.e. higher necrotic core fraction) and with the presence of IVUS-VH 
derived TCFA lesions, MCP-1 was not predictive for future events. Previous epidemiologi-
cal studies have shown that the ability of MCP-1 to predict subclinical coronary artery 
disease is somewhat disappointing, but that MCP-1 may have some value in predicting 
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cardiovascular events in patients with overt coronary artery disease.5 For example, a 
previous study found that MCP-1 was independently associated with the composite of 
death or myocardial infarction in a large cohort of 4244 patients with ACS.26 This study 
also demonstrated that high MCP-1 values at 4 months after the initial ACS were still 
predictive for long-term mortality afterwards. A major difference with our study is that 
both culprit lesion related and non-culprit lesion related events were included in their 
study endpoints, while definite culprit lesion related events were excluded from our 
study endpoints. Furthermore, we may have lacked statistical power to detect the previ-
ously reported association.
MIP-1α has been studied less extensively. We found that MIP-1α was associated with 
coronary plaque burden, necrotic core fraction and with the presence of large TCFA 
lesions on IVUS-VH. However, we did not observe a correlation between MIP-1α con-
centration and occurrence of MACE. Another study, however, found that MIP-1α was 
predictive for recurrent ACS in a relatively small cohort of 54 patients with unstable 
angina pectoris.27 Further research is required to elucidate the role of MIP-1α in patients 
with coronary artery disease.
COnClusIOns
Higher circulating MCP-1, MIP-1α, and lower RANTES concentrations were associated 
with a higher extent, a more advanced phenotype and a higher vulnerability of coronary 
atherosclerosis. Such associations were not present for MIP-1β. In addition, RANTES was 
independently associated with occurrence of MACE, particularly of death and ACS. Its 
prognostic value was similar in patients with and without ACS. Its inverse associations 
are consistent with observations from previous studies and may be explained by in-
creased deposition of RANTES on the endothelium, resulting in lower free circulating 
concentrations. The findings in this study demonstrate that RANTES may be a useful 
biomarker for assessment of cardiovascular risk. Further research on the incremental 
prognostic value of RANTES over established clinical covariates in large, prospective 
studies is warranted.
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suPPleMenTal Tables
supplemental table 1. Patients with major adverse cardiac events
Culprit 
lesion 
related 
events
non-
culprit 
lesion 
related 
events
Indetermi-
nate events
non-culprit 
lesion 
related and 
indetermi-
nate events 
combined
all
events
Composite of major adverse cardiac 
events, n
11 27 18 45 56
Death from any cause, n 1 1 16 17 18
Definite cardiac or unexplained 
sudden death, n
1 1 6 7 8
Acute coronary syndrome, n 3 9 2 11 14
Myocardial infarction, n 2 3 2 5 7
Elective coronary revascularization, n 7 17 0 17 24
Composite of death or acute coronary 
syndrome, n
4 10 18 28 32
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absTRaCT
Objective: We investigated whether concentrations of TNF-α, TNF-β, TNF-receptor 2, 
interferon-γ, IL-6, IL-8, IL-10 and IL-18 are associated with cardiovascular outcome, as 
well as extent and composition of coronary atherosclerosis determined by grayscale and 
virtual histology (VH)-intravascular ultrasound (IVUS).
Methods: Between 2008-2011, IVUS(-VH) imaging of a non-culprit coronary artery was 
performed in 581 patients (stable angina pectoris (SAP), n=261; acute coronary syn-
drome (ACS), n=309) undergoing coronary angiography from the ATHEROREMO-IVUS 
study. Coronary plaque burden and VH-derived thin-cap fibroatheroma (TCFA) lesions 
were assessed. Major adverse cardiac events (MACE: all-cause mortality, ACS, unplanned 
coronary revascularization) were registered during 1-year follow-up. We applied linear 
and logistic regression.
Results: TNF-α levels were positively associated with plaque burden (beta (β) [95%CI]: 
4.45 [0.99-7.91], for highest vs lowest TNF-α tertile) and presence of VH-TCFA lesions 
(odds ratio (OR) [95%CI] 2.30 (1.17-4.52), highest vs lowest TNF-α tertile) in SAP patients. 
Overall, an inverse association was found between IL-10 concentration and plaque bur-
den (β [95%CI]: −1.52 [−2.49 – −0.55], per Ln(pg/mL) IL-10) as well as IL-10 and VH-TCFA 
lesions with plaque burden ≥70% (OR: 0.31 [0.12-0.80],highest vs lowest IL-10 tertile). 
These effects did not reach statistical significance in the separate SAP and ACS groups. 
Fifty-six (9.8%) patients had MACE. No statistically significant associations were present 
between biomarkers and MACE.
Conclusion: Higher circulating TNF-α was associated with higher plaque burden and 
VH-TCFA lesions in SAP patients. Lower circulating IL-10 was associated with higher 
plaque burden and large VH-TCFA lesions. These in-vivo findings suggest a role for these 
cytokines in extent and vulnerability of atherosclerosis.
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InTRODuCTIOn
Inflammation is known to play a major role in atherosclerosis[1-3].The development of 
atherosclerosis includes, among others, expression of adhesion molecules by inflamed 
endothelium, migration of leukocytes into the intima, uptake of modified lipoprotein 
particles, and formation of lipid-laden macrophages[4]. During the evolution of ath-
erosclerotic lesions, T-lymphocytes join the macrophages in the intima[4]. This T-cell 
infiltrate produces proinflammatory cytokines (including tumor necrosis factors (TNFs), 
interferons (IFNs), and interleukins (ILs)), but may also stimulate a T helper cell type 2 
(Th2) response which can promote anti-inflammatory actions (and cytokines such as 
IL-10 and transforming growth factor β) [2, 5]. This dual role of cytokines is believed to 
control the subsequent development and destabilization of arherosclerotic plaques in 
coronary (among other) arteries[6], potentially leading to plaque rupture or erosion and 
ultimately resulting in adverse clinical events such as myocardial infarction or sudden 
cardiac death [7].
While previous research has provided ample insights into the signalling cascades 
of cytokines and their roles in the pathogenesis of atherosclerosis, studies on the as-
sociations of cytokines with in-vivo determined extent and particularly composition 
of coronary atherosclerosis are currently scarce. Cytokines are located both inside the 
affected vessel walls and in the circulation [8]. We hypothesize that circulating cytokines 
are associated with in-vivo measures of plaque burden and features of plaque vulner-
ability, and consequently may be useful for clinical risk stratification with regard to 
cardiovascular outcome.
The aim of this study is to examine the associations of the cytokines TNF-α, TNF-β, 
interferon γ (IFNγ), IL-6, IL-8, IL-10 and IL-18 and of circulating TNF receptor 2 (TNF R2) 
with the extent and composition of coronary atherosclerosis as determined in-vivo by 
intravascular ultrasound (IVUS) and IVUS-virtual histology (IVUS-VH), in a non-culprit 
vessel in patients undergoing coronary angiography. Furthermore, the prognostic value 
of the cytokines for major adverse cardiac events (MACE) in these patients is studied.
MeTHODs
study population
The design of The European Collaborative Project on Inflammation and Vascular Wall Re-
modeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study has 
been described elsewhere[9]. In brief, 581 patients who underwent diagnostic coronary 
angiography or percutaneous coronary intervention (PCI) for acute coronary syndrome 
(ACS; n=309) or stable angina pectoris (SAP; n=261) have been included from November 
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2008 to January 2011 in the Erasmus MC, Rotterdam, the Netherlands. Intravascular 
ultrasound (IVUS) of a non-culprit coronary artery was performed subsequent to angi-
ography. The ATHEROREMO-IVUS study has been approved by the human research eth-
ics committee of Erasmus MC, Rotterdam, the Netherlands. Written informed consent 
was obtained from all included patients and the study protocol conforms to the ethical 
guidelines of the Declaration of Helsinki.
biomarkers
Blood samples were drawn from the arterial sheath prior to the diagnostic coronary 
angiography or PCI procedure, and were available in 570 patients for the current study. 
The blood samples were transported to the clinical laboratory of Erasmus MC for further 
processing and storage at a temperature of −80°C within two hours after blood collection.
C-reactive protein (CRP) was measured in serum samples using a immunoturbidimet-
ric high sensitivity assay (Roche Diagnostics Ltd., Rotkreuz, Switzerland) on the Cobas 
8000 modular analyzer platform (Roche Diagnostics Ltd., Rotkreuz, Switzerland). These 
analyses were performed in the clinical laboratory of Erasmus MC.
Frozen EDTA-plasma samples were transported under controlled conditions (at a 
temperature of −80°C) to Myriad RBM, Austin, Texas, USA, where the concentrations of 
TNF-α, TNF-β, TNF R2, INFγ, IL-6, IL-8, IL-10 and IL-18 were determined using a validated 
multiplex assay (Custom Human Map, Myriad RBM, Austin, Texas, USA). While TNF-α, TNF 
R2, IL-6, and IL-8 were determined in the full cohort of 570 patients, TNF-β, INFγ, IL-10 and 
IL-18, were determined in a random subset of 473 patients. This difference in numbers 
resulted from batch-wise handling of the samples in combination with an update of the 
composition of the multiplex assay by the manufacturer in-between two batches. None 
of the biomarker laboratories had knowledge of clinical or intracoronary imaging data.
Intravascular ultrasound
Following the standard coronary angiography or PCI procedure, IVUS data were acquired 
in a non-culprit, non-treated, coronary vessel, without significant luminal narrowing. The 
order of preference for selection of the non-culprit vessel was: 1. Left anterior descend-
ing (LAD) artery; 2. Right coronary artery (RCA); 3. Left circumflex (LCX) artery. All IVUS 
data were acquired with the Volcano s5/s5i Imaging System (Volcano Corp., San Diego, 
CA, USA) using a Volcano Eagle Eye Gold IVUS catheter (20 MHz). An automatic pullback 
system was used with a standard pull back speed of 0.5 mm per second. The IVUS images 
were analyzed offline by an independent core laboratory (Cardialysis BV, Rotterdam, the 
Netherlands) that had no knowledge of clinical or biomarker data. The IVUS gray-scale 
and IVUS radiofrequency analyses, also known as IVUS virtual histology (IVUS-VH), were 
performed using pcVH 2.1 and qVH (Volcano Corp., San Diego, CA, USA) software. The 
external elastic membrane and luminal borders were contoured for each frame (median 
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interslice distance, 0.40 mm). Extent and phenotype of the atherosclerotic plaque were 
assessed.
Plaque burden was defined as the plaque and media cross-sectional area divided by 
the external elastic membrane cross-sectional area and is presented as a percentage. A 
coronary lesion was defined as a segment with a plaque burden of 40% in at least three 
consecutive frames[9]. Using IVUS-VH, the composition of the atherosclerotic plaque 
was characterized into 4 different types: fibrous, fibro-fatty, dense calcium and necrotic 
core [10]. A VH-IVUS-derived thin-cap fibroatheroma (TCFA) lesion was defined as a le-
sion with presence of > 10% confluent necrotic core in direct contact with the lumen[11].
Clinical study endpoints
In this study, follow-up lasted up to 1 year post angiography. Post-discharge survival 
status was obtained from municipal civil registries. Post-discharge rehospitalizations 
were prospectively assessed. Questionnaires focusing on the occurrence of major 
adverse cardiac events (MACE) were sent to all living patients. Subsequently, hospital 
discharge letters were obtained and treating physicians and institutions were contacted 
for additional information whenever necessary. ACS was defined as the clinical diagno-
sis of ST segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina 
pectoris in accordance with the guidelines of the European Society of Cardiology.[12-14] 
Unplanned coronary revascularization was defined as unplanned repeat PCI or coronary 
artery bypass grafting (CABG). The primary endpoint was MACE, defined as all-cause 
mortality, ACS or unplanned coronary revascularization. The endpoints were adjudicated 
by a clinical event committee that had no knowledge of biomarkers and IVUS data.
statistical analysis
Categorical variables are presented in percentages. The distributions of continuous vari-
ables, including biomarker levels and IVUS parameters, were examined for normality by 
visual inspection of the histogram and calculation of the skewness coefficient. Normally 
distributed continuous variables are presented as mean ± standard deviation (SD), while 
non-normally distributed continuous variables are presented as median and interquar-
tile range (IQR). For reasons of uniformity, all biomarkers are presented as median (IQR).
In further analyses, biomarker concentrations were examined both as continuous and 
as categorical variables (the latter by dividing the variables into tertiles). Biomarkers 
with a non-normal distribution were ln-transformed. Biomarkers in which the concen-
trations were too low to detect in more than 20% of the patients, were not examined as 
continuous variables. They were examined as tertiles, or else as dichotomous variables 
(measurable vs not measurable).
To take into account possible effect modification by indication for coronary angi-
ography, we performed all analyses separately in patients with SAP and patients with 
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ACS. We also present the results for the full cohort, in order to evaluate the effect of 
higher statistical power in those cases where associations were present in both groups 
of patients.
First, we examined associations of biomarker concentrations with the extent of ath-
erosclerosis according to IVUS. We applied linear regression analyses with biomarker 
concentrations as the independent variable (ln-transformed or categorized when ap-
propriate) and segmental plaque burden in the imaged coronary segment as the depen-
dent variable. The results are presented as βs (per unit increase in ln-transformed bio-
marker concentration or per category of biomarker concentration) with 95% confidence 
intervals (95% CI). Subsequently, we examined the associations between biomarker 
concentrations and composition of atherosclerosis, specifically the presence of VH-TCFA 
lesions as well as VH-TCFA lesions with plaque burden ≥ 70%. We used logistic regression 
analyses with biomarker concentrations as the independent variable (ln-transformed 
or categorized when appropriate). The results are presented as odds ratios (ORs) per 
unit increase in ln-transformed biomarker concentration or per category of biomarker 
concentration, with 95% CIs.
Moreover, we examined associations of biomarker concentrations with MACE dur-
ing 1 year follow-up. Patients lost to follow-up were considered at risk until the date 
of last contact, at which time-point they were censored. We used Cox proportional 
hazard regression analyses with biomarker concentration as the independent variable 
(ln-transformed or categorized when appropriate). The results are presented as hazard 
ratios (HRs) per unit increase in ln-transformed biomarker concentration or per category 
of biomarker concentration, with 95% CIs.
First, all above-described analyses were performed univariably. Subsequently, we 
adjusted for age, gender, indication for coronary angiography, diabetes, hypertension 
and CRP.
All data were analyzed with SPSS software (IBM SPSS Statistics for Windows, Version 
21.0. Armonk, NY, USA). All statistical tests were two-tailed and p-values <0.05 were 
considered statistically significant.
ResulTs
baseline characteristics
Baseline characteristics are summarized in Table 1. Mean age was 61.5 ± 11.4 years and 
75.4% were men. Coronary angiography or PCI was performed for several indications: 
159 (27.9%) patients had an acute myocardial infarction, 150 (26.3%) patients had 
unstable angina pectoris and 261 (45.8%) had SAP. The median length of the imaged 
coronary segment was 44.1 [33.7-55.4] mm. Based on IVUS-VH, a total of 239 (41.9%) 
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Table 1. baseline characteristics.
Total
(n=570)
aCs patients
(n=309)
saP patients
(n=261)
Patient characteristics
Age, years (mean±SD) 61.5 ± 11.4 59.7 ± 11.9 63.6 ± 10.3
Men, n(%) 430 (75.4) 227 (73.5) 203 (77.8)
Diabetes Mellitus, n(%) 99 (17.4) 40 (12.9) 59 (22.6)
Hypertension, n (%) 295 (51.8) 134 (43.4) 161 (61.7)
Hypercholesterolemia, n(%) 317 (55.6) 137 (44.3) 180 (69.0)
Smoking, n (%) 164 (28.8) 115 (37.2) 49 (18.8)
Positive family history, n (%) 293 (51.5) 140 (45.5) 153 (58.6)
Previous MI, n (%) 184 (32.3) 80 (25.9) 104 (39.8)
Previous PCI, n (%) 185 (32.5) 57 (18.4) 128 (49.0)
Previous CABG, n (%) 18 (3.2) 7 (2.3) 11 (4.2)
Previous stroke, n (%) 23 (4.0) 10 (3.2) 13 (5.0)
Peripheral artery disease, n (%) 36 (6.3) 12 (3.9) 24 (9.2)
History of renal insufficiency, n (%) 32 (5.6) 13 (4.2) 19 (7.3)
History of heart failure, n (%) 19 (3.3) 6 (1.9) 13 (5.0)
Procedural characteristics
Indication for coronary angiography
Acute coronary syndrome, n (%) 309 (54.2) 309 (100) 0 (0)
Myocardial infarction, n (%) 159 (27.9) 159 (51.5) 0 (0)
Unstable angina pectoris, n(%) 150 (26.3) 150 (48.5) 0 (0)
Stable angina pectoris, n (%) 261 (45.8) 0 (0) 261 (100)
Coronary artery disease
No significant stenosis, n (%) 42 (7.4) 18 (5.8) 24 (9.2)
1-vessel disease, n (%) 301 (52.8) 168 (54.4) 133 (51.0)
2-vessel disease, n (%) 166 (29.1) 88 (28.5) 78 (29.9)
3-vessel disease, n (%) 61 (10.7) 35 (11.3) 26 (10.0)
PCI performed, n (%) 501 (87.9) 287 (92.9) 214 (82.0)
IVus characteristics
Segment length (mm), median (IQR) 44.1 (33.7-55.4) 43.9 (32.9-54.1) 44.8 (34.2-57.2)
Plaque burden (%), median (IQR) 39.2 (30.0-46.4) 37.2 (28.0-45.5) 40.2 (31.8-47.8)
Presence of VH-TCFA, n(%) 239 (41.9) 140 (45.3) 99 (37.9)
Presence of VH-TCFA with PB ≥ 70%, n(%) 69 (12.1) 32 (10.4) 37 (14.2)
serum biomarker concentrations
C-reactive protein (mg/L), median (IQR) 2.1 [0.8-5.3] 2.8 [1.1-7.0] 1.5 [0.6-3.1]
Tumor Necrosis Factor α (pg/mL) median (IQR)+ 2.0 [1.4-2.9] 1.8 [1.4-2.6] 2.0 [1.4-3.3]
Tumor Necrosis Factor β (pg/mL) median (IQR)†§ 35.0 [18.0-116.0] 20.5 [16.5-44.3] 36.5 [27.0-152.8]
Tumor necrosis factor receptor 2 (ng/mL) 
median (IQR)#
4.5 [3.6-5.7] 4.4 [3.5-5.8] 4.5 [3.7-5.6]
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patients had at least 1 TCFA lesion, including 69 (12.1%) patients with at least 1 TCFA 
lesion with a plaque burden ≥ 70%. Concentrations of INFγ, TNF R2, IL-8, IL-10 and IL-18 
were not normally distributed; these biomarkers were therefore ln-tranformed for fur-
ther analyses. TNF-α, TNF-β and IL-6 were too low to detect in a large part of the patients, 
and thus were not examined as continuous variables in the statistical models. TNF-α was 
too low to detect in 24%, and hence was categorized into tertiles for further analyses. 
TNF-β and IL-6 were too low to detect in 92% and 62% of the patients, respectively, and 
these markers were dichotomized into measurable versus not measurable for further 
analyses. IL-10 concentrations could be measured in 99%. TNF R2, IL-8, IL-18 and IFNγ 
were measurable in all patients.
biomarkers and extent of atherosclerosis
The results of the analyses for plaque burden of the entire measured segment are shown 
in Figure 1 and supplemental tables 1a,b and c. Higher TNF-α was associated with higher 
coronary plaque burden in patients with SAP (β [95%CI]: 4.45 [0.99-7.91], for the highest 
vs the lowest tertile of TNF-α). Such an effect could not be demonstrated in patients with 
ACS.
Furthermore, lower IL-10 concentrations were associated with higher coronary plaque 
burden in the full cohort (β [95%CI]: −3.88 [−6.00 – −1.76], for the highest vs the lowest 
tertile of IL-10). This effect was driven by both the SAP patients and the ACS patients. 
Although effect estimates for the highest tertile of IL-10 were similar in both groups 
(SAP: −2.95 [−6.23-0.33], ACS: −3.42 [−6.57 – −0.27], in the SAP patients the estimates, as 
well as the linear trend, did not reach statistical significance.
After multivariable adjustment, associations remained essentially the same for both 
TNF-α and IL-10.
Table 1. (continued)
Total
(n=570)
aCs patients
(n=309)
saP patients
(n=261)
Interferon γ (pg/mL) median (IQR)* § 5.1 [3.9-7.3] 4.8 [3.8-6.6] 5.7 [4.2-8.2]
Interleukin-6 (pg/mL) median (IQR)− 3.5 [2.2-5.8] 3.7 [2.5-6.8] 2.5 [2.1-4.1]
Interleukin-8 (pg/mL) median (IQR)# § 8.9 [6.8-12.0] 9.9 [7.1-12.6] 8.3 [6.5-10.3]
Interleukin-10 (pg/mL) median (IQR)# § 5.2 [3.6-9.4] 6.9 [4.1-15.0] 4.4 [3.0-6.0]
Interleukin-18 (pg/mL) median (IQR)* 171.0 [132.3-215.0] 173.0 [133.0-216.3] 169.5 [130.5-211.3]
*Measurable in all patients
#Measurable in >99% of patients, too low to detect in <1%
+Measurable in 76% of patients, too low to detect in 24%
− Measurable in 38% of patients, too low to detect in 62%
†Measurable in 8% of patients, too low to detect in 92%
§ TNFβ, IFNγ, IL-10 and IL-18: total n= 473, ACS n=309, SAP n= 261
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biomarkers and composition of atherosclerosis
The results of the analyses for VH-TCFA lesions are displayed in Figure 2 and supplemental 
tables 2a, b and c. High TNF-α was positively associated with presence of VH-TCFA lesions 
in patients with SAP (OR[95%CI]: 2.30 [1.17-4.52] for the highest vs the lowest tertile of 
TNF-α). Such an effect was absent in patients with ACS. Furthermore, higher IL-8 seemed 
to confer lower risk of VH-TCFA in ACS patients; however, this effect was mainly driven by 
tertile 2. No associations were present between any of the other biomarkers and VH-TCFA.
Higher TNF-α was positively associated with presence of VH-TCFA lesions with a plaque 
burden ≥ 70% in the full cohort (OR[95%CI]: 2.85 [1.28-6.31] for the highest vs the lowest 
tertile of TNF-α) (table 4). This effect was driven by both patients with SAP and patients 
with ACS. Although the effect estimate reached statistical significance in the full cohort, 
this was not the case in the SAP and ACS groups. Nevertheless, the effect estimates for 
the highest tertile of TNF-α were similar in magnitude in both groups (SAP: 3.44 [0.89-
13.29], ACS: 2.39 [0.89-6.45]. Higher IL-10 displayed an inverse association with presence 
of VH-TCFA lesions with a plaque burden ≥ 70% in the full cohort (OR[95%CI]: 0.31 
[0.12-0.80] for the highest vs the lowest tertile of IL-10, p for trend=0.037). Again, effect 
estimates did not reach statistical significance in these separate groups.
After multivariable adjustment, associations remained essentially the same.
figure 1. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with segment plaque 
burden in all patients, patients with stable aP and patients with aCs.
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figure 2. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with presence of VH-
TCfa in all patients, patients with stable aP and patients with aCs.
figure 3. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with presence of VH-
TCfa with plaque burden ≥ 70% in all patients, patients with stable aP and patients with aCs.
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biomarkers and MaCe
Vital status was acquired for 569 (99.8%) patients. Response rate of the questionnaires 
that were sent to all living patients was 92.3%. After 1 year of follow-up, 56 patients 
reached the composite endpoint. Hazard ratios for the occurrence of MACE are shown 
in Figure 4 and supplemental tables 4a, b and c. Higher TNF R2 was associated with 
MACE in SAP patients (OR[95%CI]: 2.99 [1.10-8.13], per Ln (ng/mL) TNF R2) on univari-
able analysis; after multivariable adjustment, this association lost statistical significance. 
No significant associations could be demonstrated between any of the other biomarkers 
and MACE. Additional analysis of the composite of all-cause mortality or ACS (secondary 
endpoint) did not result in significant associations either.
DIsCussIOn
This study examined whether circulating cytokine concentrations are associated with 
extent and composition of coronary atherosclerosis, as determined by IVUS and IVUS-VH 
in a non-culprit vessel, in patients with SAP or ACS undergoing coronary angiography. 
We also investigated whether these cytokines have prognostic value for cardiovascular 
figure 4. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with occurrence of 
MaCe in all patients, patients with stable aP and patients with aCs.
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outcome. In patients with SAP, higher concentrations of TNF-α were associated with 
higher coronary plaque burden and with presence of VH-TCFA lesions, and displayed a 
tendency towards a positive association with presence of VH-TCFA lesion with a plaque 
burden ≥ 70%. Overall, higher concentrations of IL-10 were inversely associated with 
coronary plaque burden and with presence of VH-TCFA with a plaque burden ≥ 70%. 
These effects of IL-10 did not reach statistical significance in the separate groups. No 
associations were found between any of the studied cytokines and the occurrence of 
MACE.
Inflammation is known to play a major role in atherosclerosis. In a previous study in 
the current patient population, we have demonstrated an association between CRP 
and IVUS characteristics as well as incidence of MACE[15]. TNF-α is a proinflammatory 
cytokine that is secreted from activated innate immunity cells and is capable of inducing 
a cascade with a broad range of effects, including immunological activation, apoptosis, 
and procoagulative and antifibrinolytic actions, all of which can have an effect on the 
course of atherosclerosis [5, 16]. Experimental studies on the role of TNF-α in plaque 
development and stability in mice have rendered inconsistent results, some finding 
anti-atherogenic effects and others finding pro-atherogenic effects [5]. This discrepancy 
in results may be due to differences in underlying mechanisms of atherogenesis in dif-
ferent types of mouse models. A recent study [17] in human saphenous vein organ cul-
ture, to which a combination of TNF-α and LDL was applied, demonstrated phenotypic 
changes characteristic of the initial development of atherosclerotic plaques. Clinical 
studies on the role of TNF-α in cardiovascular disease have also rendered inconsistent 
results. A prior study found an increase of serum TNF-α in patients with MI and unstable 
angina pectoris compared to healthy subjects[18]. Ridker et al. [19] found that plasma 
concentrations of TNF-α are persistently elevated among post-MI patients at increased 
risk for recurrent coronary events. [20]. Furthermore, Naranjo et al. [21] found that TNF-α 
therapy was associated with a lower incidence of cardiovascular events in patients with 
rheumatoid arthritis, who are known to be at high cardiovascular risk. On the other hand, 
Cherneva et al. [22] and Sukhija et al. [23] examined the prognostic abilities of TNF-α in 
patients with known coronary artery disease, but did not find any associations between 
TNF-α and patient outcome. In the current study, we found that higher TNF-α level are 
associated with both extent of atherosclerosis and with plaque vulnerability in patients 
with SAP, which is in line with the presumed proinflammatory nature of this cytokine. 
On the other hand, we have recently demonstrated in the same study population [24] 
that presence of lesions with a high plaque burden, and presence of VH-TCFA lesions, 
are both independently associated with a higher MACE rate. However, higher TNF-α was 
not associated with the occurrence of MACE. Altogether, these findings imply that the 
deleterious effect of TNF-α does not translate into a higher MACE rate in the current 
study population. Possible explanations may include the fact that the magnitude of the 
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effect of TNF-α is small in the context of this multifactorial disease, or that the current 
study lacks statistical power to expose such an effect.
IL-10 is an anti-inflammatory cytokine that is produced by macrophages and lym-
phocytes [6]. This cytokine is capable of inhibiting many cellular processes that may 
play an important role in atherosclerotic lesion development and in the modulation 
of plaque composition [6, 25]. Mallat et al. [25] investigated atherosclerotic lesions in 
IL-10 deficient mice and showed increased infiltration of inflammatory cells, increased 
production of INF-γ, and decreased collagen content, which resulted in development of 
atheromatous lesions with signs of increased vulnerability. Several clinical studies have 
been performed on IL-10 and cardiovascular disease. Heeschen et al. [26] demonstrated 
that a reduced serum IL-10 level in patients with ACS is indicative of a poor prognosis. 
Most subsequent studies on the association of elevated circulating IL-10 levels with 
cardiovascular outcome have demonstrated positive associations with better prognosis 
[27-31]. In line with this, we found an inverse association between IL-10 and coronary 
plaque burden as well as between IL-10 and presence of large, vulnerable plaques (i.e., 
VH-TCFA lesions with a plaque burden ≥ 70%) in the overall study population. How-
ever, we did not find an association of IL-10 with presence of TCFA lesions in general. 
These results suggest that IL-10 may in particular be associated with lower extent of 
coronary atherosclerosis and slower growth of VH-TCFAs. In any case, these findings 
further support the hypothesis of a protective role of IL-10 in atherosclerosis. In a recent 
study performed in the same population[24], we have demonstrated that lesions with 
a high plaque burden, as well as VH-TCFA lesions with a plaque burden of ≥70%, are 
both independently associated with a higher MACE rate. While an inverse association 
was present of IL-10 with both plaque burden and with presence of VH-TCFA lesions 
with plaque burden >70% in the current study, an inverse association between IL-10 and 
MACE could not be demonstrated. Taken together, these results imply that the potential 
advantageous effect of IL-10 on plaque burden and large TCFA does not translate into a 
lower MACE rate. Again, the magnitude of the effect of IL-10 may be small, or statistical 
power may be insufficient to demonstrate the effect.
Since no associations could be demonstrated between the individual cytokines and 
MACE, clinical usefulness of this study may be debated. Nevertheless, we believe that 
our findings are informative, because they provide additional insights into the complex 
pathophysiologic relation between cytokines and cardiovascular disease. Moreover, we 
did not find any associations between several cytokines we examined and the extent 
or composition of atherosclerosis. Analysis of some of the biomarkers (TNF-β and IL-6) 
was complicated by the fact that over 50% of the measurements were too low to detect. 
Cytokine assays are generally known to display limitations in terms of % detectability 
[32, 33]. This makes clinical investigations into the pathophysiological role and the prog-
nostic value of these biomarkers challenging. In line with this, few clinical studies have 
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been performed on circulating TNF-β. Furthermore, IL-6 is known to have large circadian 
variations, and a relatively short half-life of less than 6 hours [34] which also makes this 
marker difficult to investigate. Clinical studies on circulating TNFR2, INFγ, and IL-8 in pa-
tients with coronary artery disease are also limited in number. IL-18 has been examined 
more often, and has been suggested to be associated with the presence and severity of 
coronary atherosclerosis [35, 36]. In the present study, we could not demonstrate such 
an association.
Some aspects of this study warrant consideration. Our study population consisted of 
patients with SAP as well as patients with ACS. The group of patients with ACS is likely 
to be more heterogeneous, which may have influenced the findings. To account for this, 
we have performed the analyses separately in both groups. Furthermore, VH-IVUS imag-
ing took place of a prespecified single target segment of a single non-culprit coronary 
artery, based on the assumption that such a non-stenotic segment adequately reflects 
coronary wall pathophysiology of the larger coronary tree. Although this assumption 
may be debated, previous studies evaluating IVUS have demonstrated that the coronary 
wall of comparable non-culprit, non-stenotic segments of a single vessel does reflect 
coronary disease burden at large and is associated with subsequent cardiovascular out-
come [24, 37, 38]. Moreover, it is important to note that IVUS is formally not capable of 
detecting the most rupture prone of all plaque phenotypes, the TCFA [39, 40], because 
the spatial resolution of IVUS is insufficient for thin cap detection (23, 24). Nonetheless, a 
concept of VH-IVUS derived TCFA has been postulated for plaques with a plaque burden 
≥ 40% and a confluent necrotic core ≥ 10% in direct contact with the lumen in at least 
three VH-IVUS frames (13, 23). Notably, we have recently demonstrated that such VH-
IVUS derived TCFA lesions are strongly and independently predictive of the occurrence 
of major adverse cardiac events within the current study population [24].
In conclusion, in patients undergoing coronary angiography, higher circulating TNF-α 
was associated with higher plaque burden and with presence of VH-TCFA lesions in 
patients with SAP. Overall, lower circulating IL-10 was associated with higher plaque 
burden and with presence of VH-TCFA lesions with a plaque burden ≥ 70%. The latter 
effects did not reach statistical significance in the separate SAP and ACS groups. These 
cytokines were not associated with occurrence of MACE. These in-vivo findings illustrate 
that TNF-α and IL-10 appear to play a role in both extent and vulnerability of coronary 
atherosclerosis, which is in line with experimental studies. However, their clinical value 
in terms of risk stratification warrants further investigation.
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suPPleMenTal Tables
supplemental table 1a. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with 
segment plaque burden in all patients.
segment plaque burden
 unadjusted model
 
Multivariable model*
beta (95%CI) P beta (95%CI) P
TNFalpha (tertiles)
 Tertile 1 reference reference
 Tertile 2 2.39 (−0.10-4.88) 0.060 1.94 (−0.52-4.39) 0.12
 Tertile 3 3.67 (1.10-6.23) 0.005 3.13 (0.63-5.62) 0.014
TNFbeta
 not measurable reference reference
 measurable −0.88 (−4.78-3.03) 0.66 −1.39 (−5.25- −2.47) 0.48
TNFR2 (tertiles)
 Tertile 1 reference reference
 Tertile 2 1.34 (−0.96-3.64) 0.25 −0.56 (−2.89-1.76) 0.63
 Tertile 3 0.48 (−1.92-2.88) 0.69 −1.73 (−4.29-0.82) 0.18
Ln (TNFR2) 0.61 (−1.98-3.20) 0.65 −2.43 (−5.15-0.29) 0.080
Interferon γ (tertiles)
 Tertile 1 reference reference
 Tertile 2 1.29 (−1.02-3.61) 0.27 0.41 (−1.86-2.67) 0.73
 Tertile 3 2.24 (−0.05-4.53) 0.055 0.51 (−1.98-2.99) 0.69
Ln (Interferon γ) 1.61 (−0.15-3.37) 0.072 0.11 (−1.71-1.92) 0.91
IL-6
 not measurable reference reference
 measurable −1.40 (−3.36-0.56) 0.16 −0.70 (−2.74-1.35) 0.50
IL-8 (tertiles)
 Tertile 1 reference reference
 Tertile 2 −0.96 (−3.29-1.36) 0.42 −0.78 (−3.06-1.49) 0.50
 Tertile 3 −0.89 (−3.27-1.50) 0.46 −1.63 (−4.08-0.82) 0.19
Ln (IL8) −0.07 (−2.22-2.09) 0.95 −0.54 (−2.70-1.62) 0.63
IL-10 (tertiles)
 Tertile 1 reference reference
 Tertile 2 0.37 (−2.00-2.73) 0.76 0.63 (−1.73-3.00) 0.60
 Tertile 3 −3.88 (−6.00- −1.76) <0.001 −3.27 (−5.55- −0.99) 0.005
Ln (IL10) −1.52 (−2.49- −0.55) 0.002 −1.25 (−2.26- −0.24) 0.016
IL-18 (tertiles)
 Tertile 1 reference reference
 Tertile 2 0.77 (−1.52-3.06) 0.51 1.04 (−1.24-3.33) 0.37
 Tertile 3 −0.14 (−2.50-2.21) 0.91 0.14 (−2.15-2.42) 0.91
Ln (IL18) −0.84 (−3.17-1.48) 0.48 −0.53 (−2.80-1.74) 0.65
*adjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP
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supplemental table 1b. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with 
segment plaque burden in patients with stable aP.
segment plaque burden
 unadjusted model
 
Multivariable model*
beta (95%CI) P beta (95%CI) P
TNFalpha (tertiles)
 Tertile 1 reference reference
 Tertile 2 0.86 (−2.58-4.30) 0.62 0.33 (−3.09-3.74) 0.85
 Tertile 3 4.45 (0.99-7.91) 0.012 4.64 (1.11-8.16) 0.010
TNFbeta
 not measurable reference reference
 measurable −1.94 (−6.61-2.73) 0.41 −1.63 (−6.27-3.00) 0.49
TNFR2 (tertiles)
 Tertile 1 reference reference
 Tertile 2 1.54 (−1.71-4.80) 0.35 −0.16 (−3.49-3.18) 0.93
 Tertile 3 2.26 (−1.22-5.73) 0.20 0.40 (−3.48-4.29) 0.84
Ln (TNFR2) 2.90 (−0.94-6.74) 0.14 0.64 (−3.54-4.82) 0.76
Interferon γ (tertiles)
 Tertile 1 reference reference
 Tertile 2 3.08 (−0.31-6.47) 0.075 2.57 (−0.92-6.05) 0.15
 Tertile 3 1.60 (−1.79-4.99) 0.35 0.40 (−3.22-4.02) 0.83
Ln (Interferon γ) 1.39 (−1.01-3.80) 0.26 0.44 (−2.07-2.95) 0.73
IL-6
 not measurable reference reference
 measurable 0.44 (−2.68-3.57) 0.78 0.47 (−2.76-3.70) 0.78
IL-8 (tertiles)
 Tertile 1 reference reference
 Tertile 2 0.56 (−2.50-3.63) 0.72 0.17 (−2.90-3.23) 0.91
 Tertile 3 0.57 (−3.04-4.17) 0.76 −0.18 (−3.87-3.50) 0.92
Ln (IL8) 2.03 (−1.11-5.16) 0.21 1.10 (−2.08-4.28) 0.50
IL-10 (tertiles)
 Tertile 1 reference reference
 Tertile 2 0.28 (−2.76-3.32) 0.86 0.34 (−2.65-3.33) 0.82
 Tertile 3 −2.95 (−6.23-0.33) 0.078 −3.30 (−6.64-0.04) 0.053
Ln (IL10) −1.03 (−3.02-0.95) 0.31 −1.34 (−3.34-0.66) 0.19
IL-18 (tertiles)
 Tertile 1 reference reference
 Tertile 2 0.07 (−3.33-3.47) 0.97 −0.34 (−3.71-3.02) 0.84
 Tertile 3 0.99 (−2.30-4.29) 0.55 0.11 (−3.24-3.47) 0.95
Ln (IL18) 1.72 (−1.83-5.28) 0.34 0.99 (−2.57-4.56) 0.58
*adjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP
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supplemental table 1c. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with 
segment plaque burden in patients with aCs.
segment plaque burden
 unadjusted model
 
Multivariable model*
beta (95%CI) P beta (95%CI) P
TNFalpha (tertiles)
 Tertile 1 reference reference
 Tertile 2 3.76 (0.17-7.35) 0.040 2.98 (−0.65-6.61) 0.11
 Tertile 3 2.10 (−1.63-5.84) 0.27 1.79 (−1.83-5.41) 0.33
TNFbeta
 not measurable reference reference
 measurable −0.62 (−7.48-6.24) 0.86 −1.08 (−7.98-5.82) 0.76
TNFR2 (tertiles)
 Tertile 1 reference reference
 Tertile 2 1.01 (−2.26-4.27) 0.54 −1.19 (−4.48-2.10) 0.48
 Tertile 3 −1.19 (−4.47-2.09) 0.48 −3.37 (−6.86-0.13) 0.059
Ln (TNFR2) −1.18 (−4.67-2.30) 0.51 −4.53 (−8.17- −0.89) 0.015
Interferon γ (tertiles)
 Tertile 1 reference reference
 Tertile 2 −0.37 (−3.47-2.74) 0.82 −0.96 (−4.01-2.08) 0.53
 Tertile 3 2.40 (−0.87-5.67) 0.15 0.58 (−2.89-4.05) 0.74
Ln (Interferon γ) 1.09 (−1.51-3.70) 0.41 −0.22 (−2.89-2.46) 0.87
IL-6
 not measurable reference reference
 measurable −1.58 (−4.22-1.07) 0.24 −1.49 (−4.18-1.20) 0.28
IL-8 (tertiles)
 Tertile 1 reference reference
 Tertile 2 −2.44 (−5.96-1.07) 0.17 −2.25 (−5.71-1.22) 0.20
 Tertile 3 −1.27 (−4.58-2.03) 0.45 −2.77 (−6.12-0.59) 0.11
Ln (IL8) −0.99 (−3.99-2.02) 0.52 −2.02 (−5.02-0.97) 0.19
IL-10 (tertiles)
 Tertile 1 reference reference
 Tertile 2 0.81 (−3.01-4.63) 0.68 1.31 (−2.65-5.28) 0.51
 Tertile 3 −3.42 (−6.57- −0.27) 0.034 −3.12 (−6.24-0.01) 0.051
Ln (IL10) −1.30 (−2.52- −0.08) 0.038 −1.27 (−2.48- −0.05) 0.041
IL-18 (tertiles)
 Tertile 1 reference reference
 Tertile 2 1.40 (−1.72-4.52) 0.38 2.11 (−1.14-5.35) 0.20
 Tertile 3 −0.93 (−4.23-2.37) 0.58 0.07 (−3.21-3.34) 0.97
Ln (IL18) −2.30 (−5.35-0.75) 0.14 −1.52 (−4.55-1.51) 0.32
*adjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP
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supplemental table 2a. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with 
presence of VH-TCfa in all patients.
VH-TCfa
unadjusted model Multivariable model *
OR (95%CI) P OR (95%CI) P
TNFalpha (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 1.13 (0.69-1.84) 0.63 1.12 (0.68-1.83) 0.67
 Tertile 3 1.76 (1.10-2.81) 0.018 1.82 (1.13-2.93) 0.014
TNFbeta
 not measurable  1 (reference)   1 (reference)  
 measurable 0.59 (0.29-1.23) 0.16 0.70 (0.33-1.47) 0.34
TNFR2 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.69 (0.46-1.04) 0.079 0.68 (0.44-1.04) 0.078
 Tertile 3 0.85 (0.57-1.28) 0.45 0.84 (0.54-1.30) 0.43
LN (TNFR2) 0.87 (0.55-1.37) 0.55 0.85 (0.52-1.40) 0.52
Interferon γ (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 1.17 (0.75-1.84) 0.50 1.21 (0.76-1.91) 0.42
 Tertile 3 1.12 (0.72-1.76) 0.62 1.22 (0.75-1.97) 0.43
LN (Interferon γ) 1.08 (0.76-1.52) 0.68 1.15 (0.79-1.66) 0.47
IL-6
 not measurable  1 (reference)   1 (reference)  
 measurable 0.98 (0.69-1.38) 0.90 0.97 (0.67-1.41) 0.87
IL-8 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.70 (0.46-1.05) 0.085 0.69 (0.46-1.06) 0.089
 Tertile 3 0.81 (0.54-1.22) 0.81 0.77 (0.50-1.18) 0.23
LN (IL8) 0.91 (0.62-1.33) 0.63 0.87 (0.59-1.30) 0.50
IL-10 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.95 (0.60-1.51) 0.84 0.95 (0.59-1.52) 0.83
 Tertile 3 1.24 (0.80-1.95) 0.34 1.21 (0.75-1.94) 0.44
LN (IL10) 1.15 (0.95-1.39) 0.16 1.13 (0.92-1.39) 0.25
IL-18 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.87 (0.55-1.36) 0.54 0.90 (0.57-1.43) 0.66
 Tertile 3 0.77 (0.49-1.21) 0.25 0.76 (0.48-1.20) 0.24
LN (IL18) 0.90 (0.57-1.42) 0.64 0.91 (0.57-1.44) 0.67
*adjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP
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supplemental table 2b. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with 
presence of VH-TCfa in patients with stable aP.
VH-TCfa
unadjusted model Multivariable model *
OR (95%CI) P OR (95%CI) P
TNFalpha (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 1.23 (0.59-2.56) 0.58 1.27 (0.60-2.66) 0.53
 Tertile 3 2.30 (1.17-4.52) 0.015 2.31 (1.16-4.59) 0.017
TNFbeta
 not measurable  1 (reference)   1 (reference)  
 measurable 0.52 (0.20-1.35) 0.18 0.52 (0.20-1.37) 0.19
TNFR2 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.69 (0.37-1.30) 0.25 0.67 (0.35-1.29) 0.23
 Tertile 3 1.21 (0.65-2.24) 0.55 1.14 (0.58-2.23) 0.71
LN (TNFR2) 1.44 (0.70-2.94) 0.32 1.38 (0.62-3.04) 0.43
Interferon γ (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 1.02 (0.49-2.15) 0.95 0.96 (0.45-2.05) 0.91
 Tertile 3 1.24 (0.62-2.48) 0.55 1.19 (0.57-2.50) 0.64
LN (Interferon γ) 1.23 (0.74-2.05) 0.43 1.23 (0.71-2.13) 0.45
IL-6
 not measurable  1 (reference)   1 (reference)  
 measurable 1.03 (0.58-1.84) 0.92 0.95 (0.51-1.76) 0.87
IL-8 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 1.23 (0.69-2.20) 0.48 1.27 (0.70-2.29) 0.44
 Tertile 3 1.00 (0.52-1.92) 1.00 0.95 (0.48-1.85) 0.87
LN (IL8) 1.15 (0.64-2.05) 0.64 1.08 (0.59-1.97) 0.81
IL-10 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 1.19 (0.64-2.22) 0.58 1.22 (0.65-2.30) 0.54
 Tertile 3 1.10 (0.51-2.40) 0.81 1.06 (0.47-2.36) 0.90
LN (IL10) 1.41 (0.93-2.15) 0.11 1.39 (0.90-2.14) 0.14
IL-18 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.91 (0.46-1.79) 0.78 0.88 (0.44-1.76) 0.72
 Tertile 3 0.91 (0.46-1.81) 0.78 0.82 (0.41-1.68) 0.60
LN (IL18) 1.01 (0.48-2.13) 0.99 0.95 (0.44-2.04) 0.89
*adjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP
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supplemental table 2c. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with 
presence of VH-TCfa in patients with aCs.
VH-TCfa
unadjusted model Multivariable model *
OR (95%CI) P OR (95%CI) P
TNFalpha (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 1.05 (0.54-2.03) 0.89 0.89 (0.45-1.78) 0.74
 Tertile 3 1.35 (0.70-2.64) 0.37 1.43 (0.72-2.84) 0.31
TNFbeta
 not measurable  1 (reference)   1 (reference)  
 measurable 0.86 (0.27-2.76) 0.80 0.98 (0.29-3.34) 0.98
TNFR2 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.72 (0.42-1.25) 0.25 0.69 (0.39-1.22) 0.20
 Tertile 3 0.66 (0.38-1.14) 0.14 0.62 (0.34-1.12) 0.11
LN (TNFR2) 0.63 (0.34-1.14) 0.13 0.59 (0.30-1.15) 0.12
Interferon γ (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 1.35 (0.76-2.41) 0.30 1.38 (0.77-2.49) 0.28
 Tertile 3 1.13 (0.61-2.10) 0.69 1.15 (0.60-2.21) 0.68
LN (Interferon γ) 1.06 (0.65-1.73) 0.83 1.05 (0.63-1.76) 0.86
IL-6
 not measurable  1 (reference)   1 (reference)  
 measurable 0.83 (0.53-1.30) 0.42 0.96 (0.59-1.55) 0.86
IL-8 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.37 (0.20-0.67) 0.001 0.40 (0.21-0.74) 0.004
 Tertile 3 0.55 (0.32-0.95) 0.033 0.60 (0.33-1.08) 0.086
LN (IL8) 0.70 (0.42-1.17) 0.17 0.76 (0.44-1.30) 0.31
IL-10 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.69 (0.35-1.37) 0.29 0.76 (0.37-1.54) 0.44
 Tertile 3 1.03 (0.56-1.90) 0.93 1.14 (0.61-2.14) 0.68
LN (IL10) 1.02 (0.81-1.28) 0.90 1.03 (0.82-1.31) 0.79
IL-18 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.83 (0.45-1.52) 0.55 0.90 (0.48-1.69) 0.75
 Tertile 3 0.66 (0.36-1.21) 0.18 0.65 (0.35-1.21) 0.17
LN (IL18) 0.82 (0.46-1.46) 0.50 0.82 (0.46-1.49) 0.52
*adjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP
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supplemental table 3a. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with 
presence of VH-TCfa with plaque burden ≥ 70% in all patients.
VH-TCfa≥ 70% Pb
unadjusted model Multivariable model*
OR (95%CI) P OR (95%CI) P
TNFalpha (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 2.10 (0.91-4.85) 0.083 2.11 (0.91-4.93) 0.084
 Tertile 3 2.85 (1.28-6.31) 0.01 2.78 (1.24-6.23) 0.013
TNFbeta
 not measurable 1 (reference) 1 (reference)
 measurable 0.41 (0.10-1.75) 0.23 0.41 (0.10-1.78) 0.24
TNFR2 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.78 (0.43-1.43) 0.42 0.67 (0.36-1.25) 0.20
 Tertile 3 0.66 (0.35-1.23) 0.19 0.52 (0.26-1.04) 0.064
LN (TNFR2) 0.65 (0.32-1.30) 0.22 0.50 (0.23-1.09) 0.081
Interferon γ (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.89 (0.39-2.06) 0.79 0.78 (0.34-1.83) 0.57
 Tertile 3 1.31 (0.61-2.82) 0.49 0.93 (0.41-2.14) 0.87
LN (Interferon γ) 1.21 (0.66-2.21) 0.54 0.93 (0.48-1.80) 0.83
IL-6
 not measurable 1 (reference) 1 (reference)
 measurable 0.65 (0.37-1.12) 0.12 0.75 (0.42-1.36) 0.35
IL-8 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.61 (0.33-1.14) 0.12 0.63 (0.34-1.18) 0.15
 Tertile 3 0.62 (0.34-1.14) 0.12 0.64 (0.34-1.22) 0.17
LN (IL8) 0.57 (0.32-1.02) 0.059 0.57 (0.31-1.05) 0.069
IL-10 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.92 (0.45-1.87) 0.81 0.97 (0.47-2.02) 0.94
 Tertile 3 0.31 (0.12-0.80) 0.016 0.36 (0.13-0.97) 0.043
LN (IL10) 0.64 (0.42-0.97) 0.037 0.69 (0.44-1.08) 0.10
IL-18 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 1.07 (0.51-2.24) 0.87 1.09 (0.51-2.32) 0.82
 Tertile 3 0.58 (0.24-1.36) 0.21 0.59 (0.25-1.40) 0.23
LN (IL18) 0.49 (0.23-1.08) 0.077 0.51 (0.22-1.14) 0.10
*adjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP
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supplemental table 3b. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with 
presence of VH-TCfa with plaque burden ≥ 70% in patients with stable aP.
VH-TCfa≥ 70% Pb
unadjusted model Multivariable model*
OR (95%CI) P OR (95%CI) P
TNFalpha (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 2.00 (0.69-5.79) 0.20 2.11 (0.72-6.18) 0.17
 Tertile 3 2.39 (0.89-6.45) 0.086 2.48 (0.90-6.79) 0.078
TNFbeta
 not measurable 1 (reference) 1 (reference)
 measurable 0.24 (0.03-1.85) 0.17 0.24 (0.03-1.86) 0.17
TNFR2 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.64 (0.27-1.50) 0.30 0.63 (0.26-1.53) 0.31
 Tertile 3 0.72 (0.31-1.67) 0.45 0.71 (0.28-1.77) 0.46
LN (TNFR2) 0.79 (0.29-2.15) 0.65 0.81 (0.27-2.42) 0.70
Interferon γ (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.69 (0.22-2.19) 0.53 0.64 (0.20-2.05) 0.45
 Tertile 3 0.90 (0.32-2.53) 0.85 0.83 (0.28-2.47) 0.73
LN (Interferon γ) 0.96 (0.44-2.09) 0.91 0.90 (0.38-2.12) 0.81
IL-6
 not measurable 1 (reference) 1 (reference)
 measurable 0.96 (0.43-2.17) 0.93 0.99 (0.42-2.33) 0.99
IL-8 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.88 (0.40-1.95) 0.76 0.91 (0.41-2.04) 0.82
 Tertile 3 0.78 (0.31-1.94) 0.59 0.79 (0.31-2.00) 0.62
LN (IL8) 0.85 (0.38-1.94) 0.70 0.87 (0.37-2.01) 0.74
IL-10 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 1.19 (0.50-2.88) 0.69 1.23 (0.50-2.98) 0.66
 Tertile 3 0.75 (0.28-2.03) 0.57 0.74 (0.27-2.05) 0.57
LN (IL10) 0.66 (0.32-1.36) 0.26 0.64 (0.30-1.36) 0.25
IL-18 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.89 (0.32-2.45) 0.82 0.87 (0.31-2.42) 0.79
 Tertile 3 0.68 (0.23-2.01) 0.48 0.63 (0.21-1.93) 0.42
LN (IL18) 0.55 (0.18-1.71) 0.30 0.53 (0.17-1.68) 0.28
*adjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP
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supplemental table 3c. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with 
presence of VH-TCfa with plaque burden ≥ 70% in patients with aCs.
VH-TCfa≥ 70% Pb
unadjusted model Multivariable model*
OR (95%CI) P OR (95%CI) P
TNFalpha (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 2.37 (0.59-9.53) 0.23 2.07 (0.50-8.65) 0.32
 Tertile 3 3.44 (0.89-13.29) 0.073 3.57 (0.90-14.13) 0.070
TNFbeta
 not measurable 1 (reference) 1 (reference)
 measurable 0.78 (0.10-6.25) 0.82 0.86 (0.10-7.15) 0.89
TNFR2 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.92 (0.39-2.17) 0.86 0.66 (0.27-1.66) 0.38
 Tertile 3 0.54 (0.21-1.42) 0.22 0.35 (0.12-1.03) 0.056
LN (TNFR2) 0.51 (0.19-1.39) 0.19 0.30 (0.09-0.97) 0.044
Interferon γ (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 1.04 (0.31-3.54) 0.95 1.02 (0.29-3.56) 0.98
 Tertile 3 1.61 (0.50-5.22) 0.43 1.12 (0.32-3.86) 0.86
LN (Interferon γ) 1.40 (0.53-3.71) 0.50 1.02 (0.37-2.84) 0.97
IL-6
 not measurable 1 (reference) 1 (reference)
 measurable 0.53 (0.25-1.14) 0.10 0.60 (0.27-1.36) 0.22
IL-8 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.37 (0.14-1.01) 0.052 0.38 (0.13-1.07) 0.066
 Tertile 3 0.54 (0.24-1.23) 0.14 0.50 (0.20-1.23) 0.13
LN (IL8) 0.42 (0.18-0.96) 0.039 0.38 (0.16-0.91) 0.029
IL-10 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 0.65 (0.19-2.23) 0.49 0.69 (0.19-2.50) 0.57
 Tertile 3 0.49 (0.15-1.59) 0.24 0.53 (0.16-1.79) 0.31
LN (IL10) 0.69 (0.40-1.20) 0.19 0.71 (0.41-1.23) 0.22
IL-18 (tertiles)
 Tertile 1 1 (reference) 1 (reference)
 Tertile 2 1.33 (0.44-4.02) 0.61 1.37 (0.43-4.42) 0.60
 Tertile 3 0.46 (0.11-1.90) 0.28 0.52 (0.12-2.21) 0.37
LN (IL18) 0.44 (0.14-1.35) 0.15 0.45 (0.13-1.54) 0.20
*adjusted for age, gender, indication for coronary angiography, diabetes, hypertension, and CRP
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supplemental table 4a. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with 
occurrence of MaCe** in all patients.
MaCe
unadjusted model Multivariable model* Multivariable model#
HR (95%CI) P HR (95%CI) P HR (95%CI) P
TNFalpha (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 0.95 (0.48-1.90) 0.89 0.88 (0.44-1.77) 0.73 0.96 (0.48-1.93) 0.91
 Tertile 3 0.82 (0.40-1.65) 0.57 0.76 (0.37-1.54) 0.44 0.74 (0.36-1.51) 0.40
TNFbeta
 not measurable 1 (reference) 1 (reference) 1 (reference)
 measurable 0.53 (0.13-2.19) 0.38 0.51 (0.12-2.08) 0.34 0.54 (0.13-2.23) 0.40
TNFR2 (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 1.06 (0.51-2.19) 0.88 0.88 (0.42-1.86) 0.75 1.01 (0.48-2.09) 0.99
 Tertile 3 1.95 (1.02-3.72) 0.042 1.55 (0.77-3.09) 0.22 1.71 (0.88-3.32) 0.11
LN (TNFR2) 2.34 (1.20-4.55) 0.012 1.92 (0.92-3.99) 0.08 1.81 (0.91-3.57) 0.090
Interferon γ (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 1.52 (0.74-3.10) 0.25 1.38 (0.68-2.84) 0.38 1.47 (0.72-3.01) 0.29
 Tertile 3 1.28 (0.61-2.65) 0.51 0.97 (0.45-2.09) 0.94 1.15 (0.55-2.42) 0.72
LN (Interferon γ) 1.15 (0.67-1.98) 0.62 0.93 (0.52-1.65) 0.79 1.08 (0.63-1.87) 0.78
IL-6
 not measurable 1 (reference) 1 (reference) 1 (reference)
 measurable 0.923 (0.54-1.60) 0.79 1.03 (0.58-1.81) 0.93 0.78 (0.43-1.40) 0.40
IL-8 (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 0.71 (0.36-1.41) 0.33 0.71 (0.36-1.40) 0.32 0.66 (0.33-1.32) 0.24
 Tertile 3 1.00 (0.54-1.86) 1.00 0.95 (0.50-1.80) 0.87 0.83 (0.43-1.58) 0.56
LN (IL8) 1.25 (0.69-2.27) 0.47 1.18 (0.64-2.17) 0.60 1.07 (0.58-1.97) 0.84
IL-10 (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 1.28 (0.66-2.48) 0.47 1.31 (0.67-2.57) 0.43 1.12 (0.57-2.20) 0.75
 Tertile 3 0.77 (0.36-1.62) 0.48 0.83 (0.38-1.81) 0.65 0.74 (0.35-1.57) 0.43
LN (IL10) 0.98 (0.72-1.32) 0.88 1.03 (0.75-1.42) 0.87 0.98 (0.71-1.34) 0.89
IL-18 (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 0.99 (0.49-2.03) 0.98 0.98 (0.48-2.02) 0.96 1.10 (0.53-2.27) 0.81
 Tertile 3 1.14 (0.57-2.28) 0.71 1.18 (0.59-2.36) 0.65 1.18 (0.58-2.37) 0.65
LN (IL18) 1.10 (0.54-2.21) 0.80 1.15 (0.56-2.36) 0.71 1.05 (0.53-2.06) 0.89
** MACE = major adverse cardiac events: all-cause mortality, acute coronary syndrome or unplanned 
coronary revascularization during 1-year follow-up (n=56)
*adjusted for age, gender and indication for coronary angiography
#additionally adjusted for diabetes mellitus, hypertension and CRP
Two separate models were constructed for adjustment because of limited number of endpoints.
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supplemental table 4b. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with 
occurrence of MaCe** in patients with stable aP.
MaCe
unadjusted model Multivariable model* Multivariable model#
HR (95%CI) P HR (95%CI) P HR (95%CI) P
TNFalpha (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 1.44 (0.55-3.78) 0.46 1.40 (0.53-3.70) 0.50 1.45 (0.55-3.83) 0.46
 Tertile 3 0.96 (0.36-2.57) 0.93 0.95 (0.35-2.55) 0.91 0.81 (0.29-2.24) 0.68
TNFbeta
 not measurable 1 (reference) 1 (reference) 1 (reference)
 measurable 0.33 (0.05-2.46) 0.28 0.35 (0.05-2.55) 0.30 0.34 (0.05-2.47) 0.28
TNFR2 (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 1.15 (0.40-3.33) 0.79 1.09 (0.37-3.18) 0.88 1.08 (0.37-3.11) 0.89
 Tertile 3 2.45 (0.96-6.25) 0.062 2.38 (0.88-6.46) 0.087 2.07 (0.78-5.44) 0.14
LN (TNFR2) 2.99 (1.10-8.13) 0.031 2.80 (0.97-8.07) 0.057 2.29 (0.80-6.53) 0.12
Interferon γ (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 0.97 (0.33-2.89) 0.96 0.93 (0.31-2.76) 0.89 0.94 (0.31-2.82) 0.91
 Tertile 3 1.29 (0.48-3.44) 0.61 1.13 (0.41-3.15) 0.82 1.17 (0.43-3.16) 0.76
LN (Interferon γ) 1.41 (0.68-2.91) 0.36 1.26 (0.59-2.69) 0.56 1.30 (0.62-2.71) 0.49
IL-6
 not measurable 1 (reference) 1 (reference) 1 (reference)
 measurable 1.13 (0.51-2.55) 0.76 1.19 (0.53-2.68) 0.67 0.87 (0.36-2.10) 0.76
IL-8 (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 0.25 (0.08-0.75) 0.014 0.25 (0.08-0.74) 0.012 0.23 (0.07-0.69) 0.009
 Tertile 3 0.89 (0.39-2.01) 0.78 0.87 (0.38-1.96) 0.73 0.71 (0.30-1.68) 0.44
LN (IL8) 1.03 (0.44-2.41) 0.94 0.98 (0.42-2.28) 0.95 0.81 (0.34-1.97) 0.65
IL-10 (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 1.09 (0.47-2.53) 0.83 1.11 (0.48-2.57) 0.81 1.08 (0.47-2.51) 0.85
 Tertile 3 0.62 (0.18-2.21) 0.47 0.60 (0.17-2.12) 0.42 0.50 (0.13-1.90) 0.31
LN (IL10) 1.28 (0.73-2.27) 0.39 1.26 (0.71-2.22) 0.43 1.17 (0.65-2.14) 0.60
IL-18 (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 1.33 (0.50-3.57) 0.57 1.32 (0.49-3.55) 0.58 1.20 (0.44-3.27) 0.72
 Tertile 3 1.39 (0.52-3.74) 0.51 1.32 (0.49-3.55) 0.58 1.15 (0.42-3.18) 0.78
LN (IL18) 1.78 (0.61-5.19) 0.29 1.70 (0.58-5.02) 0.33 1.49 (0.50-4.44) 0.48
** MACE = major adverse cardiac events: all-cause mortality, acute coronary syndrome or unplanned 
coronary revascularization during 1-year follow-up (n=56)
*adjusted for age, gender and indication for coronary angiography
# additionally adjusted for diabetes mellitus, hypertension and CRP
Two separate models were constructed for adjustment because of limited number of endpoints.
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supplemental table 4c. association of Tnf-α, Tnf-β, Tnf R2, Infγ, Il-6, Il-8, Il-10 and Il-18 with 
occurrence of MaCe** in patients with aCs.
MaCe
unadjusted model Multivariable model* Multivariable model#
HR (95%CI) P HR (95%CI) P HR (95%CI) P
TNFalpha (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 0.61 (0.22-1.72) 0.35 0.55 (0.20-1.55) 0.26 0.64 (0.22-1.83) 0.40
 Tertile 3 0.69 (0.25-1.94) 0.48 0.61 (0.22-1.73) 0.35 0.62 (0.22-1.79) 0.38
TNFbeta
 not measurable 1 (reference) 1 (reference) 1 (reference)
 measurable 0.95 (0.13-7.02) 0.96 0.96 (0.13-7.09) 0.97 1.01 (0.14-7.52) 0.99
TNFR2 (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 0.97 (0.35-2.66) 0.95 0.74 (0.26-2.10) 0.57 0.93 (0.33-2.59) 0.89
 Tertile 3 1.51 (0.61-3.76) 0.37 1.01 (0.37-2.72) 0.99 1.27 (0.49-3.31) 0.63
LN (TNFR2) 1.95 (0.77-4.96) 0.16 1.39 (0.48-4.00) 0.54 1.41 (0.53-3.74) 0.49
Interferon γ (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 2.06 (0.80-5.32) 0.13 1.92 (0.74-4.97) 0.18 1.90 (0.73-4.94) 0.19
 Tertile 3 0.88 (0.26-3.00) 0.83 0.68 (0.19-2.37) 0.54 0.77 (0.22-2.73) 0.69
LN (Interferon γ) 0.80 (0.35-1.83) 0.60 0.65 (0.28-1.51) 0.32 0.75 (0.32-1.78) 0.52
IL-6
 not measurable 1 (reference) 1 (reference) 1 (reference)
 measurable 0.91 (0.42-1.97) 0.82 0.91 (0.42-1.97) 0.81 0.73 (0.32-1.70) 0.47
IL-8 (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 2.49 (0.78-7.94) 0.12 2.36 (0.74-7.58) 0.15 2.37 (0.74-7.59) 0.15
 Tertile 3 1.94 (0.62-6.09) 0.26 1.48 (0.46-4.80) 0.51 1.56 (0.48-5.07) 0.46
LN (IL8) 1.70 (0.71-4.06) 0.23 1.38 (0.56-3.41) 0.49 1.43 (0.58-3.51) 0.43
IL-10 (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 1.88 (0.58-6.11) 0.29 1.81 (0.55-5.97) 0.33 1.51 (0.45-5.04) 0.51
 Tertile 3 1.20 (0.37-3.89) 0.76 1.20 (0.37-3.90) 0.77 1.10 (0.34-3.60) 0.88
LN (IL10) 0.95 (0.63-1.42) 0.80 0.96 (0.64-1.43) 0.84 0.95 (0.63-1.44) 0.81
IL-18 (tertiles)
 Tertile 1 1 (reference) 1 (reference) 1 (reference)
 Tertile 2 0.72 (0.25-2.08) 0.55 0.67 (0.23-1.96) 0.47 0.94 (0.31-2.81) 0.91
 Tertile 3 0.95 (0.36-2.54) 0.92 1.04 (0.39-2.77) 0.94 1.09 (0.40-2.96) 0.87
LN (IL18) 0.77 (0.29-2.00) 0.58 0.82 (0.30-2.23) 0.70 0.76 (0.31-1.89) 0.56
** MACE = major adverse cardiac events: all-cause mortality, acute coronary syndrome or unplanned 
coronary revascularization during 1-year follow-up (n=56)
*adjusted for age, gender and indication for coronary angiography
#additionally adjusted for diabetes mellitus, hypertension and CRP
Two separate models were constructed for adjustment because of limited number of endpoints.
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absTRaCT
Objective: High VWF plasma levels are associated with an increased risk of coronary 
artery disease. It has been suggested that the increase of VWF levels is partly due to 
endothelial dysfunction and atherosclerosis. Our aim was to investigate the association 
between coronary plaque burden, the presence of high-risk coronary lesions as mea-
sured by intravascular ultrasound virtual histology (IVUS-VH) and VWF levels. In addition, 
we studied the association between VWF levels and 1-year cardiovascular outcome.
Methods: Between 2008 and 2011, IVUS-VH imaging of a non-culprit coronary artery 
was performed in 581 patients undergoing coronary angiography for acute coronary 
syndrome (ACS) (n= 318) or stable angina pectoris (SAP) (n= 263). Arterial blood was 
sampled prior to the coronary angiography. VWF antigen (VWF:Ag) levels were mea-
sured using ELISA (n= 577).
Results: Patients with ACS had significantly higher VWF:Ag levels than SAP patients 
(median 1.73 IU/ml [IQR 1.27-2.31] vs. 1.26 IU/ml [0.93-1.63], p<0.001). High coronary 
plaque burden was associated with higher VWF:Ag levels (β= 0.12, p=0.027) in SAP 
patients, but not in ACS patients. In ACS patients, VWF:Ag levels were associated with 
1-year MACE (HR 4.14 per SD increase of lnVWF:Ag, 95% CI 1.47-11.6), whereas in SAP 
patients VWF:Ag levels predicted 1-year all-cause death and hospitalisation for ACS (HR 
7.07 95% CI 1.40-35.6).
Conclusions: Coronary plaque burden was associated with VWF:Ag levels in SAP pa-
tients undergoing coronary angiography. In ACS and SAP patients, high VWF levels are 
predictive of adverse cardiovascular outcome and death during 1-year follow-up.
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InTRODuCTIOn
Von Willebrand Factor (VWF) is a multimeric protein that plays a crucial role in primary 
hemostasis by mediating platelet adhesion and aggregation (1). VWF is produced by 
endothelial cells and megakaryocytes and stored in Weibel-Palade bodies in the endo-
thelium and alpha-granules of platelets. VWF plasma levels are increased at moments of 
endothelial damage and are a marker of endothelial dysfunction (2).
It is well known that high VWF levels are associated with an increased risk of coro-
nary heart disease and ischemic stroke in the general population (3-8). However, the 
underlying mechanisms of this association are still unclear. As high VWF levels are seen 
in situations with endothelial dysfunction, which is an important early process in athero-
sclerosis development, it has previously been suggested that VWF has a pathogenic role 
in atherosclerosis. This hypothesis is supported by results from animal studies (9-11). 
However, studies in patients with type 3 von Willebrand disease, characterized by a total 
deficiency of VWF in the circulation, revealed no reduction in atherosclerotic lesions 
(12-14). The role of VWF in the development of atherosclerosis in humans is therefore 
still unresolved. In a recent study, we observed a strong association between the extent 
of atherosclerosis, measured by the calcification volume in the aortic arch and carotid 
arteries, and VWF levels in ischemic stroke patients (15). Because VWF also plays a pivotal 
role in platelet aggregation and thrombus formation, these high VWF levels may further 
increase the risk of coronary events in patients with high risk atherosclerotic lesions.
Intravascular ultrasound (IVUS) can accurately quantify coronary atherosclerosis (16, 
17). A previous study in 697 patients with an acute coronary syndrome at inclusion 
showed that half of the incident recurrent cardiovascular events occurred in patients 
with non-culprit lesions present at baseline, assessed by IVUS imaging (18). High-risk 
coronary lesions that are predictive for events include lesions with a plaque burden of 
at least 70%, a minimal luminal area of 4.0 mm² or less or the presence of IVUS virtual 
histology (VH)-derived thin-cap fibroatheroma lesions (VH-TCFA) (18).
In order to gain further insight into the relationship between VWF levels and cardio-
vascular outcome, the aim of the present study was to investigate the associations of 
coronary plaque burden, and the presence of high-risk coronary lesions as assessed 
by virtual histology intravascular ultrasound (VH-IVUS) with VWF levels, as well as to 
investigate the association of VWF with 1-year cardiovascular outcome in patients with 
coronary artery disease (CAD).
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MeTHODs
study population
The design of The European Collaborative Project on Inflammation and Vascular Wall 
Remodeling in Atherosclerosis – Intravascular Ultrasound (ATHEROREMO-IVUS) study 
has been described in detail elsewhere (19). In brief, 581 patients who underwent diag-
nostic coronary angiography or percutaneous coronary intervention (PCI) for an acute 
coronary syndrome (ACS) or stable angina pectoris (SAP) have been included between 
2008 and 2011 in the Erasmus MC, Rotterdam, the Netherlands.
The ATHEROREMO-IVUS study was approved by the medical ethics committee of 
the Erasmus MC. The study was performed in accordance with the criteria described in 
the declaration of Helsinki. Written informed consent was obtained from all included 
patients. This study is registered in ClinicalTrials.gov, number NCT01789411.
Von Willebrand factor measurement
Blood samples were drawn from the arterial sheath prior to the coronary angiography 
procedure. The blood samples were transported to the clinical laboratory of the Erasmus 
MC for further processing and storage at temperature of −80°C within 2 hours after 
blood collection. VWF antigen (VWF:Ag) levels were determined (N=577) using citrate 
blood with an in-house ELISA using rabbit anti-human VWF antibodies (DakoCytoma-
tion, Glostrop, Denmark) for catching and tagging. Reference standard plasma was 
calibrated against the international standard (Cryocheck Reference, Kordia, Leiden, The 
Netherlands) and was used as a calibrator. The intra- and inter-assay coefficients of varia-
tion were 2.6% and 4.7%.
Intracoronary ultrasound imaging
Following the standard coronary angiography procedure, IVUS imaging of a non-culprit 
coronary artery was performed. Selection of the non-culprit vessel was predefined in the 
study protocol. The order of preference for selection of the non-culprit vessel was: 1. left an-
terior descending (LAD) artery; 2. right coronary artery (RCA); 3. left circumflex (LCX) artery. 
All IVUS data were acquired with the Volcano s5/s5i Imaging System (Volcano Corp., San 
Diego, CA, USA) using a Volcano Eagle Eye Gold IVUS catheter (20 MHz). An automatic pull-
back system was used with a standard pull back speed of 0.5 mm per second. The baseline 
IVUS images were sent to an independent core laboratory (Cardialysis BV, Rotterdam, the 
Netherlands) for offline analysis. The core laboratory personnel were blinded for baseline 
patient characteristics and clinical outcome data. The IVUS virtual histology analyses were 
performed using pcVH 2.1 and qVH (Volcano Corp., San Diego, CA, USA) software.
The external elastic membrane and luminal borders were contoured for each frame 
(median interslice distance, 0.40 mm). Extent and phenotype of the atherosclerotic 
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plaque were assessed. Plaque burden was defined as plaque and media cross-sectional 
area divided by external elastic membrane cross-sectional area (Figure 1). A coronary 
lesion was defined as a segment with a plaque burden of more than 40% in at least 3 
consecutive frames. Three types of high-risk lesions were identified: 1. Virtual histology-
derived thin-cap fibroatheroma (VH-TCFA) lesion, defined as a lesion with presence 
of >10% confluent necrotic core in direct contact with the lumen; 2. lesion with large 
plaque burden, defined as a lesion with a plaque burden of ≥70%; 3. stenotic lesion, 
defined as a lesion with a minimal luminal area of ≤4.0 mm² (Figure 1) (18, 20-22).
figure 1. Measurement of plaque burden and identification of high risk lesions with intravascular 
ultrasound virtual histology
A: Plaque burden is defined as plaque and media cross-sectional area (green) divided by external elastic 
membrane cross-sectional area (contoured in blue). B: Thin-cap fibroatheroma lesion, defined as a lesion 
with presence of >10% confluent necrotic core (red) in direct contact with the lumen. White indicates 
dence calcium, light green indicates fibrofatty tissue, and dark green indicates fibrous tissue. C: Lesion 
with plaque burden of ≥70%. D: Lesion with a minimal luminal area of ≤4.0 mm2.
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Clinical endpoints
Clinical follow-up started at inclusion and lasted 1 year. Post-discharge survival status 
was obtained from municipal civil registries. Post-discharge rehospitalizations were 
prospectively assessed during follow-up. Questionnaires focusing on the occurrence 
of major adverse cardiac events (MACE) were sent to all living patients. Subsequently, 
hospital discharge letters were obtained and treating physicians and institutions were 
contracted for additional information whenever necessary.
The primary endpoint was MACE, defined as all-cause mortality, ACS or unplanned 
coronary revascularization. ACS was defined as the clinical diagnosis of ST segment 
elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris in ac-
cordance with the guidelines of the European Society of Cardiology (23). Unplanned 
coronary revascularization was defined as unplanned repeat PCI (either culprit or 
non-culprit coronary artery) or coronary artery bypass grafting (CABG). The secondary 
endpoint was defined as the composite of all-cause mortality or ACS. The endpoints 
were adjudicated by a clinical event committee that had no knowledge of the VWF:Ag 
levels and IVUS data.
statistical analysis
The distributions of the continuous variables, including VWF levels and the IVUS pa-
rameters, were tested for normality by visual examination of the histogram. Normally 
distributed continuous variables are presented as mean ± standard deviation (SD). Non-
normally distributed continuous variables are presented as median and interquartile 
range (IQR). VWF levels were not normally distributed and were therefore natural 
logarithmically (ln) transformed (lnVWF:Ag), where after a normal distribution was ac-
quired. Categorical variables are presented as numbers and percentages. We examined 
associations of plaque burden and presence of high-risk coronary lesions with VWF:Ag 
levels. VWF:Ag levels and plaque burden were divided into tertiles. To test for linear as-
sociation, we used linear regression analyses with continuous ln-transformed VWF:Ag 
level as dependent variable. In multivariable analyses, the covariates age, gender, dia-
betes mellitus, hypertension, hypercholesterolemia, smoking and history of myocardial 
infarction were considered as established cardiovascular risk factors and as potential 
confounders, and were therefore entered into the full model.
Patients lost to follow-up were considered at risk until the date of last contact, at which 
time-point they were censored. Cumulative event rates were estimated according to the 
Kaplan-Meier method. Cox proportional hazards regression analyses were performed to 
evaluate the associations between VWF:Ag levels and study endpoints. Analyses were 
adjusted for age, gender and plaque burden. The final results are presented as crude and 
adjusted hazard ratios (HR) with 95% confidence interval (95% CI).
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We a priori expected that there might be heterogeneity in effect estimates between 
patients with ACS and patients with stable angina pectoris, since VWF:Ag levels are 
known to be elevated in the acute phase of an ACS (24, 25). Therefore, all statistical 
analyses were performed separately for patients with ACS and patients with stable 
angina pectoris at inclusion. Data were analyzed with SPSS software (SPSS 20.0, IBM 
corp., Armonk, NY, USA). All statistical tests were two-tailed and p-values <0.05 were 
considered statistically significant.
ResulTs
In total 577 patients were included, 315 had an ACS and 262 had a SAP. Patients had a 
mean age of 61.5 years and 75% were men (Table 1). Over half of the patients had single 
vessel disease. SAP patients had a higher prevalence of cardiovascular risk factors than 
ACS patients. ACS patients were more likely to smoke. ACS patients had significantly 
higher VWF:Ag levels than patients with SAP (median 1.73 IU/ml [IQR 1.27-2.31] vs. 1.26 
IU/ml [0.93-1.63], p<0.001) (Table 1).
Plaque burden was significantly higher in SAP patients than in ACS patients (39.7 ± 
11.0% vs. 36.9 ± 11.8%, p = 0.005). In SAP patients, higher plaque burden was associ-
ated with higher VWF:Ag levels (P for trend 0.015) (Figure 2). Also after adjustment for 
figure 2. Coronary plaque burden of imaged coronary segment in relation to Von Willebrand fac-
tor levels
Mean ± standard error VWF:Ag levels per tertile coronary plaque burden.
ACS = acute coronary syndrome; SAP = stable angina pectoris; VWF:Ag = von Willebrand Factor antigen.
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established cardiovascular risk factors in multivariable analysis, higher plaque burden 
remained associated with higher VWF:Ag levels (p = 0.027) in patients admitted with 
SAP. In ACS patients, the coronary plaque burden was not associated with VWF:Ag levels 
(P for trend 0.84). VWF:Ag levels were not significantly different between patients with 
and without high risk coronary lesions in both ACS and SAP patients (Figure 3).
Table 1. baseline characteristics
aCs patients
(n=315)
saP patients
(n=262)
Patient characteristics
Age, years 59.7 ± 11.8 63.6 ± 10.2
Men, n (%) 232 (73.7) 203 (77.5)
Diabetes mellitus, n (%) 40 (12.7) 59 (22.5)
Hypertension, n (%) 138 (43.8) 161 (61.5)
Hypercholesterolemia, n (%) 139 (44.1) 180 (68.7)
Smoking, n (%) 117 (37.1) 50 (19.1)
Positive family history, n (%) 145 (46.0) 155 (59.2)
Previous MI, n (%) 80 (25.4) 104 (39.7)
Previous PCI, n (%) 57 (18.1) 128 (48.9)
Previous CABG, n (%) 7 (2.2) 11 (4.2)
Previous stroke, n (%) 11 (3.5) 15 (5.7)
Peripheral artery disease, n (%) 12 (3.8) 24 (9.2)
History of renal insufficiency, n (%) 13 (4.1) 19 (7.3)
History of heart failure, n (%) 6 (1.9) 13 (5.0)
Von Willebrand Factor, IU/mL 1.73 [1.27-2.31] 1.26 [0.93-1.63]
Procedural characteristics
Coronary artery disease
 No significant stenosis, n (%) 18 (5.7) 25 (9.5)
 1-vessel disease, n (%) 174 (55.2) 133 (50.8)
 2-vessel disease, n (%) 88 (27.9) 78 (29.8)
 3-vessel disease, n (%) 35 (11.1) 26 (9.9)
PCI performed, n (%) 293 (93.0) 214 (81.7)
IVUS segment characteristics
Imaged coronary artery
 Left anterior descending, n (%) 120 (38.1) 88 (33.6)
 Left circumflex, n (%) 110 (34.9) 84 (32.1)
 Right coronary artery, n (%) 85 (27.0) 90 (34.4)
Segment length, mm 44.1 [33.0-54.3] 44.3 [34.3-57.2]
Data are presented as mean ± standard deviation or as median [interquartile range].
ACS = acute coronary syndrome; CABG = coronary artery bypass grafting; MI = myocardial infarction; PCI 
= percutaneous coronary intervention; SAP = stable angina pectoris.
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For 575 (99.7%) patients the vital status at 1-year follow-up could be acquired, and the 
response rate to the questionnaires that were sent to all living patients was 93.4%. After 
1 year of follow-up, 55 patients (9.6%) had experienced a MACE (Table 2). The cumulative 
Kaplan-Meier incidences of the 1-year MACE was 8.3% for patients with ACS, and 11.1% 
for patients with SAP. The risk of all-cause death and ACS was significantly associated 
figure 3. High risk coronary lesions in relation to Von Willebrand factor levels
Mean ± standard error VWF:Ag levels between high-risk coronary lesions present or absent.
ACS = acute coronary syndrome; MLA = minimal luminal area; PB = plaque burden; SAP = stable angina 
pectoris; TCFA = thin-cap fibroatheroma; VWF:Ag = von Willebrand Factor antigen.
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with higher VWF:Ag levels in both ACS patients (HR 7.45, 95% CI 2.15-25.9, P=0.002) and 
patients with SAP (HR 7.07 95% CI 1.40-35.6, P=0.018). Additional adjustment for plaque 
burden did not affect the risk estimate for all-cause death and ACS in ACS patients (HR 
4.13 95% CI 1.47-11.6), while the risk in SAP patients was slightly lower (HR 4.05 95% CI 
0.88-18.7). Higher VWF:Ag levels were also significantly associated with a higher inci-
dence of MACE in ACS patients (HR 4.14, 95% CI 1.47–11.6, P=0.007), but not in patients 
with SAP (HR 1.31, 95% CI 0.52-3.29, p=0.57) (Table 3, Figure 4). Additional adjustment 
for plaque burden did not change the results.
Table 3. associations between von Willebrand factor level and cardiovascular outcome
aCs patients saP patients
HR (95%CI)* P HR (95%CI)* P
MACE
 Unadjusted 4.28 (1.61-11.4) 0.004 1.39 (0.56-3.42) 0.48
 Adjusted for age and gender 4.14 (1.47-11.6) 0.007 1.31 (0.52-3.29) 0.57
 Adjusted for age, gender and plaque burden 4.13 (1.47-11.6) 0.007 1.08 (0.43-2.70) 0.87
Composite of death or ACS
 Unadjusted 7.15 (2.21-23.1) 0.001 7.62 (1.58-36.8) 0.011
 Adjusted for age and gender 7.45 (2.15-25.9) 0.002 7.07 (1.40-35.6) 0.018
 Adjusted for age, gender and plaque burden 7.65 (2.16-27.2) 0.002 4.05 (0.88-18.7) 0.073
* Hazard ratio per SD increase in ln-transformed Von Willebrand Factor level.
ACS = acute coronary syndrome; MACE = major adverse cardiac event; SAP = stable angina pectoris.
DIsCussIOn
This is the first study that has investigated the association between invasive measured 
coronary atherosclerosis by VH-IVUS and VWF:Ag levels. We have shown that patients 
with an ACS have significantly higher VWF levels than patients with SAP. In patients with 
Table 2. number of patients with incident major adverse cardiac events
number of patients
aCs patients
(n=315)
saP patients
(n=262)
Composite of major adverse cardiac events 26 29
Death from any cause 13 4
Definite cardiac or unexplained sudden death 6 2
Acute coronary syndrome 7 7
Myocardial infarction 4 3
Unplanned coronary revascularization 6 18
Composite of death or acute coronary syndrome 20 11
ACS = acute coronary syndrome; SAP = stable angina pectoris.
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SAP, coronary plaque burden was positively associated with VWF:Ag levels. In addition, 
high VWF:Ag levels were associated with death and ACS at 12 months follow up and this 
was also observed for all MACE in patients with ACS.
The exact pathophysiologic role of VWF in cardiovascular disease has not been elucidat-
ed yet. First, it has been hypothesized that VWF may play a causal role in the development 
of atherosclerosis, thereby increasing the risk of CAD. This was suggested by animal stud-
ies with VWF deficient mice, which showed less development of atherosclerosis (9-11). 
However, human studies, for instance in patients with type 3 von Willebrand disease who 
have a complete deficiency of VWF, could not confirm these findings (12, 14). However, 
these patients may incidentally receive VWF concentrates and some use prophylaxis at 
regular basis and are therefore not completely VWF deficient. It is now suggested that the 
association between atherosclerosis and VWF is mainly driven by the fact that VWF is a 
marker of endothelial damage, which is also observed in atherosclerosis (26, 27).
In this study we found that patients with ACS had significantly higher VWF:Ag levels 
compared with SAP patients, which is in line with a previous study (24). The finding that 
figure 4. Von Willebrand factor and cardiovascular outcome
Kaplan-Meier curve for the cumulative event-free survival of MACE or death and hospitalization for ACS 
per VWF:Ag above and below the median (1.45 IU/ml).
ACS = acute coronary syndrome; SAP = stable angina pectoris.
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plaque burden was associated with VWF:Ag levels in SAP patients confirms our previous 
findings that VWF is associated with the extent of atherosclerosis. In our previous study 
in ischemic stroke patients, we observed that a higher calcification volume in the aortic 
arch and carotid arteries was associated with higher VWF:Ag levels (15). The fact that 
there was no association between plaque burden and VWF:Ag levels in ACS patients 
might be explained by the strongly increased VWF:Ag levels in these patients due to an 
acute phase response, which is well known for VWF (2, 25).
We observed no association between several types of high-risk coronary lesions, 
including thin-cap fibroatheroma lesions, lesions with plaque burden ≥70% or lesions 
with a minimal luminal area ≤4.0mm² and VWF:Ag levels. High risk lesions are precur-
sors of plaque rupture and may thereby account for the occurrence of coronary thrombi 
(18, 22, 28). Our results suggest that although VWF is associated with the extent of 
atherosclerosis, it is not associated with the phenotypic more vulnerable atherosclerotic 
lesions and might be more involved in stable atherosclerosis. However, a previous mice 
study showed, by molecular imaging, that activated VWF was found in atherosclerotic 
disease with high risk features (29). This difference might be explained by the VWF mea-
surement, as only locally activated VWF was measured in the mice study and in our 
study we measured circulating VWF:Ag plasma levels. In addition, a difference in the 
pathophysiologic mechanism of destabilising the plaque between mice and human 
could also influence the results (30-33).
Our data on the association between VWF:Ag levels and MACE in ACS patients 
strengthens findings of previous studies suggesting that VWF has a predictive role in 
cardiovascular outcome (34-39). These results were not affected by additional adjust-
ment for plaque burden, suggesting a role for VWF in cardiovascular outcome. In SAP 
patients, we found an association between high VWF levels and risk of death or ACS. 
After additional adjustment for plaque burden the association was not significant any-
more in SAP patients, which may be explained by the small sample size, resulting in 
reduced power. These data suggest that the high VWF levels observed in ACS patients, 
the most severe CAD patients, at inclusion predict MACE at follow-up. However, in the 
definition of MACE unplanned revascularisation was included which may be considered 
as a weaker end-point and could therefore have influenced the adverse outcome risk 
(40). Overall these data supports the role for VWF in the prognosis of patients with a 
CAD, independent of plaque burden.
There are some limitations of this study. First, blood was sampled in the acute phase 
at the moment of the coronary angiography. This may explain the higher VWF:Ag levels 
in ACS patients compared with SAP patients. Therefore, this could have influenced our 
results. However, we separated the ACS and SAP patients for all analyses. Secondly, a 
single non-culprit coronary vessel was imaged in this study. This may have led to an un-
derestimation of the association between the presence of high risk lesions in the overall 
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coronary tree and VWF:Ag levels. However, a previous study have shown that culprit and 
non-culprit lesions were equally related to MACE (18). In addition, the spatial resolution 
of IVUS-VH (150 µm) is insufficient to exactly replicate histopathologic definitions of a 
thin fibrous cap (<65 µm) (41). Therefore, IVUS-VH tends to overestimate the number of 
thin-cap fibroatheroma lesions. Nevertheless, the presence of VH-TCFA lesions has been 
shown to carry prognostic information (18, 22). Finally, due to the cross-sectional design 
our data are not able to distinguish whether VWF is causal or a marker of atherosclerosis.
In conclusion, the extent of coronary atherosclerosis is associated with VWF:Ag levels 
in SAP patients undergoing coronary angiography, but not in ACS patients which might 
be explained by the acute phase response. High VWF:Ag levels have a predictive role 
for adverse cardiovascular outcome, and also for MACE in ACS patients, independent of 
plaque burden.
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absTRaCT
background: Conflicting results exist regarding the association between a common 
Haptoglobin (Hp) polymorphism and risk of coronary artery disease. We investigated 
the association of three functionally different anti-oxidant and anti-inflammatory Hp 
phenotypes (Hp1-1, Hp2-1, Hp2-2) with invasively measured degree and composition of 
coronary atherosclerosis as determined by intravascular ultrasound (-virtual histology) 
(IVUS(-VH)) as well as near-infrared spectroscopy (NIRS).
Methods: Non-culprit coronary artery segments of 581 patients with acute coronary 
syndrome (ACS) or stable angina pectoris were imaged with IVUS(-VH). In 203 patients, 
the segments were also imaged with NIRS. Pre-procedural blood samples were drawn 
for Hp phenotyping. Degree (segment plaque volume, segment plaque burden (PB); 
presence of lesions with PB ≥ 70%) and composition (segment fractions of fibrous, 
fibrofatty, dense calcium, and necrotic core tissue; presence of IVUS-VH derived thin-cap 
fibroatheroma lesions) of coronary atherosclerosis were measured.
Results: No differences were present between the three Hp phenotypes with regard to 
degree and composition of coronary atherosclerosis in the full cohort. However, ACS 
patients with a Hp2-1 or Hp2-2 phenotype had a higher segment PB percentage (β[95% 
CI]: 3.88[0.31–7.44], p = 0.033), increased prevalence of lesions with PB ≥ 70% (OR[95% 
CI]: 3.61[1.06–12.30], p = 0.040), and a tendency towards a higher segment plaque vol-
ume (β[95% CI]: 1.29[−0.04–2.62], p = 0.056) in multivariable analyses.
Conclusions: Although in the full cohort no associations could be demonstrated be-
tween Hp phenotypes and plaque characteristics, a significant association was present 
between phenotypes resulting from a genotype containing a Hp2 allele (Hp2-1 or Hp2-
2) and a higher degree of atherosclerosis in patients with ACS.
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1. InTRODuCTIOn
Circulating haptoglobin (Hp) is hypothesized to influence atherosclerosis through its 
anti-oxidant and immunomodulatory properties. Specifically, it prevents hemoglobin-
driven oxidative reactions in response to intraplaque hemorrhage, and stimulates a 
variety of pro- and anti-inflammatory cytokines [1,2]. The Hp gene carries a common 
polymorphism with two alleles (Hp1 and Hp2), resulting in three functionally-different 
phenotypes, each characterized by a unique protein structure: Hp1-1 (wildtype geno-
type; dimer), Hp2-1 (heterozygous variant; linear polymer) and Hp2-2 (homozygous 
variant; cyclic polymer) [2]. The homozygous variant Hp2-2 produces a dysfunctional 
protein with the lowest anti-oxidant and anti-inflammatory properties as compared to 
the proteins encoded by Hp2-1 or Hp1-1 [1,2].
Although the molecular functions of these proteins in the vascular wall have been well 
investigated and seem to be clear, clinical studies on the association of Hp phenotypes 
with coronary events have rendered conflicting results [3,4]. In order to further increase 
understanding of the pathophysiological relation between Hp phenotypes and coro-
nary atherosclerosis, imaging studies using coronary angiography and CT angiography 
have been performed. However, these have not been able to further elucidate potential 
mechanisms [5,6]. The imaging techniques used in these studies only enable evaluation 
of the lumen of the coronary artery. Conversely, radiofrequency intravascular ultrasound 
(IVUS) and near-infrared spectroscopy (NIRS) enable evaluation and quantification of the 
arterial wall itself. However, studies on Hp phenotype and invasively-measured coronary 
atherosclerotic plaque characteristics by IVUS or NIRS are currently lacking.
In the current study, we investigated the relation between Hp phenotype and in-vivo 
measurements of degree and composition of coronary atherosclerosis by IVUS and NIRS 
in 581 patients undergoing coronary angiography. Herewith, we aimed to provide ad-
ditional insights into the pathophysiology concerning Hp and coronary atherosclerosis.
2. MeTHODs
The rationale and design of the ATHEROREMO-IVUS study and its ATHEROREMO-NIRS 
substudy have been described in detail elsewhere [7–9]. These studies were approved 
by the medical ethics committee of the Erasmus MC and performed in accordance with 
the declaration of Helsinki. All included patients provided written informed consent.
In brief, 581 patients with an indication for coronary angiography due to stable angina 
pectoris (SAP) or acute coronary syndrome (ACS) underwent IVUS imaging of a nonste-
notic segment of at least 40 mm in length in a predefined non-culprit coronary artery 
with the Volcano™ s5/s5i Imaging System (Volcano Corp., San Diego, USA), using the 
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Volcano™ Eagle Eye Gold IVUS catheter (20MHz) [7]. The order of preference for selection 
of the non-culprit coronary artery segment was: 1. Left anterior descending artery; 2. 
Right coronary artery; and 3. Left circumflex artery. An automatic pullback system was 
used with a standard pull back speed of 0.5mm per second. Both IVUS grayscale and 
virtual histology (IVUS-VH) analyses were performed using pcVH 2.1 and qVH (Volcano 
Corp., San Diego, USA) software. The external elastic membrane and luminal borders 
were contoured for each frame (median interslice distance, 0.40mm). The degree and 
composition of each atherosclerotic plaque were assessed. Plaque volume (mm³) was 
defined as the total volume of the external elastic membrane occupied by atheroma 
and normalized for the length of the imaged segment. Plaque burden (%) was defined 
as plaque and media cross-sectional area divided by external elastic membrane cross-
sectional area and is presented as a percentage. Atherosclerotic plaque composition 
was characterized into fibrous (FI), fibro-fatty (FF), dense calcium (DC) and necrotic core 
(NC) tissue and expressed as percentages of total plaque volume. Three types of high-
risk lesions were identified: 1. Virtual Histology-IVUS derived thin-cap fibroatheroma 
(VH-TCFA) lesions (presence of N10% confluent necrotic core in direct contact with the 
lumen); 2. Lesions with plaque burden ≥70%; and 3. Lesions with a minimal luminal 
area ≤4.0mm². Hp phenotypes were successfully determined in 574 of the patients who 
underwent IVUS(-VH) imaging (Fig. 1). NIRS (InfraReDx, Burlington, Massachusetts, USA) 
of the same segment was performed in a subset of 191 patients, as well as 12 addi-
tional patients that only underwent NIRS, not IVUS [7,9] (Fig. 1). The U.S. Food and Drug 
ultrasound (IVUS) and near-infrared spectroscopy (NIRS) enable evalu-
ation and quantiﬁcation of the arterial wall itself. However, studies on
Hp phenotype and invasively-measured coronary atherosclerotic
plaque characteristics by IVUS or NIRS are currently lacking.
In the current study,we investigated the relation betweenHppheno-
type and in-vivo measurements of degree and composition of coronary
atherosclerosis by IVUS and NIRS in 581 patients undergoing coronary
angiography. Herewith, we aimed to provide additional insights into
the pathophysiology concerning Hp and coronary atherosclerosis.
2. Methods
The rationale and design of theATHEROREMO-IVUS study and its ATHEROREMO-NIRS
substudy have been described in detail elsew ere [7–9]. These studies were approved by
the medical ethics committee of the Erasmus MC and performed in accordance with the
declaration of Helsinki. All included patients provided written informed consent.
In brief, 581 patientswith an indication for coronary angiography due to stable angina
pectoris (SAP) or acute coronary syndrome (ACS) underwent IVUS imaging of a non-
stenotic segment of at least 40 mm in length in a predeﬁned non-culprit coronary artery
with the Volcano™ s5/s5i Imaging System (Volcano Corp., San Diego, USA), using the
Volcano™ Eagle EyeGold IVUS catheter (20MHz) [7]. The order of preference for selection
of thenon-culprit coronary artery segmentwas: 1. Left anterior descending artery; 2. Right
coronary artery; a d 3. Left circumﬂex artery. An automatic pullback system was used
with a standard pull back speed of 0.5mmper second. Both IVUS grayscale and virtual his-
tology (IVUS-VH) analyses were performed using pcVH 2.1 and qVH (Volcano Corp., San
Diego,USA) software. The external elasticmembrane and luminal borderswere contoured
for each frame (median interslice distance, 0.40mm). The degree and composition of each
atherosclerotic plaque were assessed. Plaque volume (mm3) was deﬁned as the total vol-
ume of the external elastic membrane occupied by atheroma and normalized for the
length of the imaged segment. Plaque burden (%) was eﬁned as plaque and media
cross-sectional area divided by external elastic membrane cross-sectional area and is pre-
sented as a percentage. Atherosclerotic plaque compositionwas characterized into ﬁbrous
(FI), ﬁbro-fatty (FF), dense calcium (DC) and necrotic core (NC) tissue and expressed as
percentages of total plaque volume. Three types of high-risk lesionswere identiﬁed: 1. Vir-
tual Histology-IVUS derived thin-cap ﬁbroatheroma (VH-TCFA) lesions (presence of N10%
conﬂuent necrotic core in direct contact with the lumen); 2. Lesions with plaque burden
≥70%; and 3. Lesionswith aminimal luminal area ≤4.0mm2. Hp phenotypeswere success-
fully determined in 574 of the patients who underwent IVUS(-VH) imaging (Fig. 1). NIRS
(InfraReDx, Burlington,Massachusetts, USA)of the same segmentwasperformed in a sub-
set of 191 patients, as well as 12 additional patients that only underwent NIRS, not IVUS
[7,9] (Fig. 1). Th U.S. Food and Dru Administration- pproved NIRS system, as used in
this study, consisted of a 3.2-F rapid exchange catheter, a pullback and rotation device.
Image acquisition was performed by a motorized catheter pullback at a speed of 0.5 mm
per second and 240 rotations per minute. The Lipid Core Burden Index (LCBI) score was
measured and represents the amount of lipid core in the imaged segment on a 0-to-
1000 scale, as d scribed previously [9]. Both IVUS and NIRS images were analyzed off-
line by an independent core laboratory (Cardialysis BV, Rotterdam, the Netherlands), by
personnel blinded for baseline patient characteristics and Hp phenotypes. Two-hundred
of the 203 patients who underwent NIRS imaging, were successfully phenotyped,
resulting in a total of 585 successfully phenotyped and imaged patients for the current in-
vestigation (Fig. 1).
EDTA plasma samples were drawn from the arterial sheath prior to coronary angiog-
raphy and transported to the clinical laboratory of the Erasmus MC for further processing
and storage at a temperature of−80 °Cwithin 2 h after blood collection. After completion
of the cohort, all frozen EDTA-plasma samples were transported under controlled
conditions (at a temperature of−80 °C) to the Laboratory of Experimental Cardiology,
University Medical Cent r Utrecht, Utrecht, The Netherlands, where Hp phenotypes
were differentiated through western blotting.
The primary endpoint consisted of major adverse cardiovascular events (MACE), and
was deﬁned as a composite of all-cause mortality, ACS, and unplanned coronary revascu-
larization. The secondary endpoint consisted of the composite of all-cause mortality and
ACS. ACS was deﬁned as the clinical diagnosis of (non-)ST-segment elevation myocardial
infarction or unstable angina pectoris [10,11]. Unplanned coronary revascularization was
deﬁned as any repeat PCI or coronary artery bypass grafting that was not foreseen at the
index procedure. Follow-up data were collected during 1 year. Vital status was obtained
from municipal civil registries and que tionnaires were sent focusing on the occurrence
of MACE to all living patients (response rate of 92.3%). Upon patients' approval, additional
information was obtained from hospital discharge letters and treating physicians
whenever necessary. Endpoints were adjudicated based on original source data by a
clinical events committee.
Variables with a non-normal distribution were transformed by using either the
natural logarithm (ln) or square root for further analyses. Univariate analyses were
performed by ANOVA or Student's t-test for continuous variables and Chi-squared
test for categorical variables, comparing the phenotypes. Multivariate linear and lo-
gistic regression analyses were performed with Hp phenotype as the independent
variable and with adjustment for the potential confounders age, gender, smoking,
diabetes mellitus, hypertension, dyslipidemia and previous myocardial infarction.
Interaction terms were used to test for effect modiﬁcation by indication for angiogra-
phy (ACS versus SAP). Subsequently, analyses were stratiﬁed on indication. Since ACS
subgroup analysis showed (VH-)IVUS values of similar magnitude in the Hp2-1 and
Hp2-2 groups, a post-hoc analysis was performed comparing ACS patients with
wildtype Hp1-1 versus a pooled group with the variant phenotypes Hp2-1 and
Hp2-2. Furthermore, a subgroup analysis was performed in diabetic patients (n =
99). Finally, the association between Hp phenotype and clinical endpoints after
1 year of follow-up was examined with Cox proportional hazard regression analyses.
All data were analyzed with SPSS software (IBM SPSS Statistics forWindows, Version
23, Armonk, NY, USA). All statistical tests were two-tailed and p-values b 0.05 were con-
sidered statistically signiﬁcant.
Fig. 1. Flowchart patient inclusion in theATHEROREMO-IVUS study, ATHEROREMO-NIRS substudy andATHEROREMOHaptoglobin phenotype substudy. ACS=acute coronary syndrome;
Hp = haptoglobin; IVUS(-VH) = intravascular ultrasound(-virtual histology); NIRS = near-infrared spectroscopy.
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fig. 1. flowchart patient inclusion in the aTHeROReMO-IVus study, aTHeROReMO-nIRs substudy 
and aTHeROReMO Haptoglobin phenotype substudy.
ACS=acute coronary syndrome; Hp = haptoglobin; IVUS(-VH) = intravascular ultrasound(-virtual histol-
ogy); NIRS = near-infrared spectroscopy.
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Administration-approved NIRS system, as used in this study, consisted of a 3.2-F rapid 
exchange catheter, a pullback and rotation device. Image acquisition was performed 
by a motorized catheter pullback at a speed of 0.5 mm per second and 240 rotations 
per minute. The Lipid Core Burden Index (LCBI) score was measured and represents the 
amount of lipid core in the imaged segment on a 0-to-1000 scale, as described previously 
[9]. Both IVUS and NIRS images were analyzed offline by an independent core laboratory 
(Cardialysis BV, Rotterdam, the Netherlands), by personnel blinded for baseline patient 
characteristics and Hp phenotypes. Two-hundred of the 203 patients who underwent 
NIRS imaging, were successfully phenotyped, resulting in a total of 585 successfully 
phenotyped and imaged patients for the current investigation (Fig. 1).
EDTA plasma samples were drawn from the arterial sheath prior to coronary angiogra-
phy and transported to the clinical laboratory of the Erasmus MC for further processing 
and storage at a temperature of −80°C within 2 h after blood collection. After comple-
tion of the cohort, all frozen EDTA-plasma samples were transported under controlled 
conditions (at a temperature of −80°C) to the Laboratory of Experimental Cardiology, 
University Medical Center Utrecht, Utrecht, The Netherlands, where Hp phenotypes 
were differentiated through western blotting.
The primary endpoint consisted of major adverse cardiovascular events (MACE), and 
was defined as a composite of all-cause mortality, ACS, and unplanned coronary revascu-
larization. The secondary endpoint consisted of the composite of all-cause mortality and 
ACS. ACS was defined as the clinical diagnosis of (non-)ST-segment elevation myocardial 
infarction or unstable angina pectoris [10,11]. Unplanned coronary revascularization 
was defined as any repeat PCI or coronary artery bypass grafting that was not foreseen 
at the index procedure. Follow-up data were collected during 1 year. Vital status was 
obtained from municipal civil registries and questionnaires were sent focusing on the 
occurrence of MACE to all living patients (response rate of 92.3%). Upon patients’ ap-
proval, additional information was obtained from hospital discharge letters and treating 
physicians whenever necessary. Endpoints were adjudicated based on original source 
data by a clinical events committee.
Variables with a non-normal distribution were transformed by using either the natural 
logarithm (ln) or square root for further analyses. Univariate analyses were performed by 
ANOVA or Student’s t-test for continuous variables and Chi-squared test for categorical 
variables, comparing the phenotypes. Multivariate linear and logistic regression analyses 
were performed with Hp phenotype as the independent variable and with adjustment 
for the potential confounders age, gender, smoking, diabetes mellitus, hypertension, 
dyslipidemia and previous myocardial infarction. Interaction terms were used to test 
for effect modification by indication for angiography (ACS versus SAP). Subsequently, 
analyses were stratified on indication. Since ACS subgroup analysis showed (VH-)IVUS 
values of similar magnitude in the Hp2-1 and Hp2-2 groups, a post-hoc analysis was 
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performed comparing ACS patients with wildtype Hp1-1 versus a pooled group with the 
variant phenotypes Hp2-1 and Hp2-2. Furthermore, a subgroup analysis was performed 
in diabetic patients (n = 99). Finally, the association between Hp phenotype and clinical 
endpoints after 1 year of follow-up was examined with Cox proportional hazard regres-
sion analyses.
All data were analyzed with SPSS software (IBMSPSS Statistics for Windows, Version 23, 
Armonk, NY, USA). All statistical tests were two-tailed and p-values < 0.05 were consid-
ered statistically significant.
3. ResulTs
3.1. baseline characteristics
Baseline clinical and procedural characteristics of the 3 phenotype groups are presented 
in Table 1. Prevalence of phenotype Hp1-1, Hp2- 1 and Hp2-2 was 16.1% (n = 94), 45.5% 
(n = 266), and 38.5% (n = 225), respectively, and this distribution was in Hardy–Weinberg 
equilibrium (p = 0.67). Mean age ± standard deviation was 61.9 ± 12.6, 62.4 ± 10.7 and 
60.0 ± 11.4 years, respectively (p = 0.07). Except for history of myocardial infarction, 
there were no differences in clinical or procedural characteristics across the various 
phenotypes. As expected, circulating plasma haptoglobin concentration was lowest for 
Hp1-1 and highest for Hp2-2 (p=<0.001, Table 1).
3.2. Degree and composition of coronary atherosclerosis
No differences could be demonstrated between the different phenotypes with regard 
to the degree and composition of atherosclerosis as assessed by IVUS-VH or NIRS (Table 
2). The same could be concluded for the subgroup analysis of diabetic patients (n=99, 
data not shown).
Significant interactions were present between Hp phenotype and indication for 
angiography (ACS versus SAP) for the association with plaque volume, plaque burden, 
FI tissue percentage and lesions with PB ≥ 70% (p-values for interaction all <0.05 in 
uni- and multivariate analysis). In line with this, in ACS patients, phenotypes resulting 
from a genotype containing a Hp2 allele (Hp2-1 or Hp2-2) were significantly associated 
with a higher plaque volume (p=0.031) in univariate analysis and tended to be associ-
ated with a higher plaque volume in multivariate analysis (β [95% CI]: 1.29 [−0.04–2.62]
mm3 increase in (square root transformed) plaque volume for having Hp2-1 or Hp2-
2 as compared to Hp1-1, p = 0.056) (Table 3, Fig. 2). Moreover, in ACS patients these 
phenotypes were independently associated with a larger plaque burden (β [95% CI]: 
3.88 [0.31–7.44]% increase in PB for having Hp2-1 or Hp2-2 as compared to Hp1-1, p 
= 0.033) (Table 3, Fig. 3), as well as an increased prevalence of lesions with PB ≥ 70% 
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(OR[95% CI]: 3.61 [1.06–12.30], p = 0.040) (Table 3, Fig. 4). With respect to atherosclerotic 
plaque composition, no associations were present with the various VH-tissue types, LCBI 
or VH-TCFA lesions in ACS patients (Table 3).
Table 1. baseline clinical and procedural characteristics of the haptoglobin phenotype groups in 
the full cohort (n= 585).
Clinical characteristics
Haptoglobin 1-1
(n = 94)
Haptoglobin 1-2
(n = 266)
Haptoglobin 2-2
(n = 225)
P-valuea
Age, years 61.9 ± 12.6 62.4 ± 10.7 60.0 ± 11.4 0.07
Male gender, n (%) 69 (73.4) 200 (75.2) 173 (76.9) 0.79
Diabetes mellitus, n (%) 11 (11.7) 46 (17.3) 43 (19.1) 0.28
Hypertension, n (%) 48 (51.1) 138 (51.9) 118 (52.7) 0.96
Dyslipidemia, n (%) 45 (47.9) 154 (57.9) 126 (56.3) 0.24
Smoking, n (%) 25 (26.6) 83 (31.2) 63 (28.0) 0.61
Positive family history, n (%) 58 (61.7) 139 (52.3) 110 (49.1) 0.12
Peripheral artery disease, n (%) 4 (4.3) 18 (6.8) 14 (6.2) 0.68
Previous myocardial infarction, 
n (%)
24 (25.5) 98 (36.8) 64 (28.4) 0.050
Previous PCI, n (%) 26 (27.7) 91 (34.2) 73 (32.4) 0.51
Previous CABG, n (%) 3 (3.2) 9 (3.4) 7 (3.1) 0.99
Previous stroke, n(%) 3 (3.2) 12 (4.5) 10 (4.4) 0.85
History of renal insufficiency, 
n (%)
4 (4.3) 21 (7.9) 8 (3.6) 0.10
Haptoglobin level, mg/ml 0.79 [0.58–0.99] 1.53 [1.10–2.20] 1.60 [1.10–2.30] <0.001
Procedural characteristics
Indication for coronary 
angiography
Acute coronary syndrome, n (%) 49 (52.1) 144 (54.1) 127 (56.4) 0.76
Stable angina pectoris, n (%) 45 (47.9) 122 (45.9) 98 (43.6) 0.76
Coronary artery disease
No significant stenosis, n (%) 4 (4.3) 17 (6.4) 22 (9.8) 0.16
1-vessel disease, n (%) 57 (60.6) 138 (51.9) 117 (52.0) 0.30
2-vessel disease, n (%) 26 (27.7) 82 (30.8) 60 (26.7) 0.58
3-vessel disease, n (%) 7 (7.4) 29 (10.9) 26 (11.6) 0.54
PCI performed 86 (91.5) 233 (87.6) 195 (86.7) 0.48
Continuous variables are presented as mean ± SD or median [interquartile range], depending on their 
distribution. Categorical variables are presented as n (%).
PCI= percutaneous coronary intervention; CABG= coronary artery bypass graft surgery.
a P-values obtained by ANOVA for the continuous variables and Chi-squared test for the categorical variables.
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3.3. Clinical endpoints
With regard to clinical outcome, associations between Hp phenotype and 1-year car-
diovascular outcome could not be demonstrated, both in the full cohort and in the ACS 
and diabetes subgroups. In particular, the Hp phenotypes were not associated with the 
occurrence of MACE (primary composite endpoint) on multivariate analysis: HR[95% CI] 
0.88 [0.52–1.49] for Hp2-1 and 0.97 [0.57–1.67] for Hp2-2 in the full cohort; HR[95% CI] 
0.77 [0.38–1.56] for Hp2-1 and 0.70 [0.33– 1.49] for Hp2-2 in the ACS subgroup; HR [95% 
CI] 0.91 [0.30–2.82] for Hp2-1 and 0.94 [0.30–3.02] for Hp2-2 in the diabetic subgroup.
Table 2. nIRs and (VH-)IVus segment and lesion characteristics of the Haptoglobin phenotype 
groups in the full cohort (n = 585).
Haptoglobin 1-1
(n = 94)
Haptoglobin 1-2
(n = 266)
Haptoglobin 2-2
(n = 225)
P-valuec
Segment plaque characteristicsa
Degree of atherosclerosis
Plaque volume, mm³ 240.7 [118.5–
313.4]
235.1 [150.8–
332.9]
216.0 [147.6–
323.3]
0.94
Plaque burden, % 37.4 ± 12.1 38.3 ± 11.6 38.4 ± 11.1 0.80
Plaque composition
Fibrous percentage 57.6 ± 12.0 57.4 ± 11.4 58.2 ± 11.7 0.74
Fibro-fatty percentage 9.1 [5.9–12.4] 9.2 [5.9–13.3] 8.4 [5.3–11.9] 0.19
Necrotic core percentage 21.7 ± 8.1 21.0 ± 8.3 21.8 ± 7.7 0.57
Dense calcium percentage 9.5 [5.3–14.4] 9.5 [5.4–15.3] 9.1 [4.9–15.1] 0.92
Lipid Core Burden Index 
(LCBI)b
47.5 [9.0–93.5] 40.5 [16.0–85.8] 40.0 [13.3–80.8] 0.82
Lesion plaque characteristicsa
Degree of atherosclerosis
≥1 Lesion with PB ≥70%, n (%) 18 (20.2) 54 (20.5) 51 (23.2) 0.74
≥1 Lesion with MLA ≤4.0 
mm², n (%)
29 (32.6) 83 (31.7) 68 (30.9) 0.96
Plaque composition
≥1 TCFA, n (%) 43 (48.3) 106 (40.3) 91 (41.2) 0.40
Continuous variables are presented as mean ± SD or median [interquartile range], depending on their 
distribution. Categorical variables are presented as n (%).
PB= plaque burden; MLA = minimal lumen area; and TCFA = thin-cap fibroatheroma.
a IVUS(-VH) imaging was performed in 574 patients.
b NIRS imaging was performed in a subset of 200 patients.
c P-values obtained by ANOVA for the continuous variables and Chi-squared test for the categorical 
 variables.
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PB ≥ 70% (p-values for interaction all b0.05 in uni- and multivariate
analysis). In line with this, in ACS patients, phenotypes resulting from
a genotype containing a Hp2 allele (Hp2-1 or Hp2-2) were signiﬁcantly
associated with a higher plaque volume (p= 0.031) in univariate anal-
ysis and tended to be associated with a higher plaque volume in multi-
variate analysis (β [95% CI]: 1.29 [−0.04–2.62]mm3 increase in (square
root transformed) plaque volume for having Hp2-1 or Hp2-2 as
compared to Hp1-1, p = 0.056) (Table 3, Fig. 2). Moreover, in ACS
patients these phenotypes were independently associated with a larger
plaque burden (β [95% CI]: 3.88 [0.31–7.44]% increase in PB for having
Hp2-1 or Hp2-2 as compared to Hp1-1, p = 0.033) (Table 3, Fig. 3), as
well as an increased prevalence of lesions with PB ≥ 70% (OR[95% CI]:
3.61 [1.06–12.30], p = 0.040) (Table 3, Fig. 4). With respect to athero-
sclerotic plaque composition, no associations were present with the
various VH-tissue types, LCBI or VH-TCFA lesions in ACS patients
(Table 3).
Table 3
NIRS and (VH)-IVUS segment and lesion characteristics of the haptoglobin phenotype groups in patients with ACS (n = 320).
Haptoglobin 1-1
(n = 49)
Haptoglobin 2-1 or 2-2
(n = 271) P-valuec β [95% CI] P-valued
Haptoglobin level, mg/ml 0.84 [0.63–1.10] 1.60 [1.10–2.50] b0.001 0.65 [0.45–0.85] b0.001
Segment plaque characteristicsa
Degree of atherosclerosis
Plaque volume, mm3 173.5 [107.3–303.1] 215.5 [141.2–304.2] 0.031 1.29 [−0.04–2.62] 0.056
Plaque burden, % 32.9 ± 10.6 37.6 ± 11.8 0.014 3.88 [0.31–7.44] 0.033
Plaque composition
Fibrous percentage 61.4 ± 11.2 58.5 ± 12.0 0.13 −2.99 [−6.80–0.83] 0.12
Fibro-fatty percentage 8.6 [4.6–12.0] 8.6 [5.5–12.0] 0.35 0.18 [−0.14–0.51] 0.26
Necrotic core percentage 21.2 ± 8.3 21.8 ± 8.6 0.68 0.43 [−2.37–3.22] 0.76
Dense calcium percentage 6.7 [4.9–11.3] 8.3 [4.9–13.8] 0.28 0.21 [−0.17–0.58] 0.28
Lipid Core Burden Index (LCBI)b 48.0 [6.0–91.0] 44.5 [16.0–88.0] 0.53 0.03 [−0.71–0.77] 0.93
Lesion plaque characteristicsa P-valuec OR [95% CI] P-valued
Degree of atherosclerosis
≥1 Lesion with PB ≥ 70%, n (%) 3 (6.7) 56 (21.0) 0.023 3.61 [1.06–12.30] 0.040
≥1 Lesion with MLA ≤4.0 mm2, n (%) 11 (24.4) 80 (30.1) 0.44 1.30 [0.61–2.7 0.51
Plaque composition
≥1 TCFA, n (%) 22 (48.9) 119 (44.6) 0.59 0.78 [0.41–1.51] 0.46
Continuous variables are presented as mean ± SD or median [interquartile range], depending on the distribution. Categorical variables are presented as n (%).
Beta (β) indicates the increase or decrease (minus sign) in each (transformed) imaging segment parameter for the Haptoglobin 2-1 or 2-2 ACS patients as compared to
Haptoglobin 1-1 ACS patients.
Odds ratio (OR) increase in each lesion parameter for the Haptoglobin 2-1 or 2-2 ACS patients as compared to Haptoglobin 1-1 ACS patients.
a IVUS-VH imaging was performed in 313 ACS patients.
b NIRS imaging was performed in a subset of 93 ACS patients.
c P-values (univariate) obtained by the independent Student's two-sample t-test for the continuous variables and Chi-squared test for the categorical variables.
d P-values (multivariate) obtained by linear regression analyses for continuous variables and logistic regression analyses for categorical variables with Haptoglobin 1-1 as the reference
category. Models adjusted for age, gender, smoking, diabetes mellitus, hypertension, dyslipidemia and previous myocardial infarction.
Fig. 2. Segment plaque volume in the haptoglobin phenotypes within the full cohort and
within the ACS subgroup. * P-value for difference in segment plaque volume between
Hp2-1 or Hp2-2 as compared to Hp1-1 within the ACS subgroup. Adjusted for age,
gender, smoking, diabetes mellitus, hypertension, dyslipidemia and previous myocardial
infarction. ACS = acute coronary syndrome; and Hp = haptoglobin.
Fig. 3. Segment plaque burden in the haptoglobin phenotypes within the full cohort and
ACS subgroup. *P-value for difference in segment plaque burden between Hp2-1 or
Hp2-2 as compared to Hp1-1 within the ACS subgroup. Adjusted for age, gender,
smoking, diabetes mellitus, hypertension, dyslipidemia and previous myocardial
infarction. ACS = acute coronary syndrome; Hp = haptoglobin.
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fig. 2. segment plaque volume in the haptoglobin phen types wit in the full cohort and within 
the aCs subgroup.
* P-value for difference in segment plaque volume between Hp2-1 or Hp2-2 as compared to Hp1-1 within 
the ACS subgroup. Adjusted for age, gender, smoking, diabetes mellitus, hypertension, dyslipidemia and 
previous myocardial infarction. ACS = acute coronary syndrome; and Hp = haptoglobin.
PB ≥ 70% (p-values for interaction all b0.05 in uni- and multivariate
analysis). In line with this, in ACS patients, phenotypes resulting from
a genotype containing a Hp2 allele (Hp2-1 or Hp2-2) were signiﬁcantly
associated with a higher plaque volume (p= 0.031) in univariate anal-
ysis and tended to be associated with a higher plaque volume in multi-
variate analysis (β [95% CI]: 1.29 [−0.04–2.62]mm3 increase in (square
root transformed) plaque volume for having Hp2-1 or Hp2-2 as
compared to Hp1-1, p = 0.056) (Table 3, Fig. 2). Moreover, in ACS
patients these phenotypes were independently associated with a larger
plaque burden (β [95% CI]: 3.88 [0.31–7.44]% increase in PB for having
Hp2-1 or Hp2-2 as compared to Hp1-1, p = 0.033) (Table 3, Fig. 3), as
well as an increased prevalence of lesions with PB ≥ 70% (OR[95% CI]:
3.61 [1.06–12.30], p = 0.040) (Ta le 3, Fig. 4). W th respect to athe o-
sclerotic plaque compositio , no association w re present with the
various VH-tissue types, LCBI or VH-TCFA lesions in ACS patients
(Table 3).
Table 3
NIRS and (VH)-IVUS segment and lesion characteristics of the haptoglobin phenotype groups in patients with ACS (n = 320).
Haptoglobin 1-1
(n = 49)
Haptoglobin 2-1 or 2-2
(n = 271) P-valuec β [95% CI] P-valued
Haptoglobin level, mg/ml 0.84 [0.63–1.10] 1.60 [1.10–2.50] b0.001 0.65 [0.45–0.85] b0.001
Segment plaque characteristicsa
Degree of atherosclerosis
Plaque volume, mm3 173.5 [107.3–303.1] 215.5 [141.2–304.2] 0.031 1.29 [−0.04–2.62] 0.056
Plaque burden, % 32.9 ± 10.6 37.6 ± 11.8 0.014 3.88 [0.31–7.44] 0.033
Plaque composition
Fibrous percentage 61.4 ± 11.2 58.5 ± 12.0 0.13 −2.99 [−6.80–0.83] 0.12
Fibro-fatty percentage 8.6 [4.6–12.0] 8.6 [5.5–12.0] 0.35 0.18 [−0.14–0.51] 0.26
Necrotic core percentage 21.2 ± 8.3 21.8 ± 8.6 0.68 0.43 [−2.37–3.22] 0.76
Dense calcium percentage 6.7 [4.9–11.3] 8.3 [4.9–13.8] 0.28 0.21 [−0.17–0.58] 0.28
Lipid Core Burden Index (LCBI)b 48.0 [6.0–91.0] 44.5 [16.0–88.0] 0.53 0.03 [−0.71–0.77] 0.93
Lesion plaque characteristicsa P-valuec OR [95% CI] P-valued
Degree of atherosclerosis
≥1 Lesion with PB ≥ 70%, n (%) 3 (6.7) 56 (21.0) 0.023 3.61 [1.06–12.30] 0.040
≥1 Lesion with MLA ≤4.0 mm2, n (%) 11 (24.4) 80 (30.1) 0.44 1.30 [0.61–2.7 0.51
Plaque composition
≥1 TCFA, n (%) 22 (48.9) 119 (44.6) 0.59 0.78 [0.41–1.51] 0.46
Continuous variables are presented as mean ± SD or median [interquartile range], depending on the distribution. Categorical variables are presented as n (%).
Beta (β) indicates the increase or decrease (minus sign) in each (transformed) imaging segment parameter for the Haptoglobin 2-1 or 2-2 ACS patients as compared to
Haptoglobin 1-1 ACS patients.
Odds ratio (OR) increase in each lesion parameter for the Haptoglobin 2-1 or 2-2 ACS patients as compared to Haptoglobin 1-1 ACS patients.
a IVUS-VH imaging was performed in 313 ACS patients.
b NIRS imaging was performed in a subset of 93 ACS patients.
c P-values (univariate) obtained by the independent Student's two-sample t-test for the continuous variables and Chi-squared test for the categorical variables.
d P-values (multivariate) obtained by linear regression analyses for continuous variables and logistic regression analyses for categorical variables with Haptoglobin 1-1 as the reference
category. Models adjusted for age, gender, smoking, diabetes mellitus, hypertension, dyslipidemia and previous myocardial infarction.
Fig. 2. Segment plaque volume in the haptoglobin phenotypes within the full cohort and
within the ACS subgroup. * P-value for difference in segment plaque volume between
Hp2-1 or Hp2-2 as compared to Hp1-1 within the ACS subgroup. Adjusted for age,
gender, smoking, diabetes mellitus, hypertension, dyslipidemia and previous myocardial
infarction. ACS = acute coronary syndrome; and Hp = haptoglobin.
Fig. 3. Segment plaque burden in the haptoglobin phenotypes within the full cohort and
ACS subgroup. *P-value for difference in segment plaque burden between Hp2-1 or
Hp2-2 as compared to Hp1-1 within the ACS subgroup. Adjusted for age, gender,
smoking, diabetes mellitus, hypertension, dyslipidemia and previous myocardial
infarction. ACS = acute coronary syndrome; Hp = haptoglobin.
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fig. 3. segment plaque burden in the hap oglobin phenoty s within the full cohort and aCs 
 subgroup.
*P-value for difference i  segment plaq e burde  between Hp2-1 or Hp2-2 as c mpared to Hp1-1 within 
the ACS subgroup. Adjusted for age, gender, smoking, diabetes mellitus, hypertension, dyslipidemia and 
previous myocardial infarction. ACS = acute coronary syndrome; Hp= haptoglobin.
368 Chapter 20
Table 3. nIRs and (VH)-IVus segment and lesion characteristics of the haptoglobin phenotype 
groups in patients with aCs (n = 320).
Haptoglobin 1-1
(n = 49)
Haptoglobin 2-1 or 2-2
(n = 271)
P-valuec β [95% CI] P-valued
Haptoglobin level, 
mg/ml
0.84 [0.63–1.10] 1.60 [1.10–2.50] <0.001 0.65 [0.45–0.85] <0.001
Segment plaque characteristicsa
Degree of 
atherosclerosis
Plaque volume, mm³ 173.5 [107.3–303.1] 215.5 [141.2–304.2] 0.031 1.29 [−0.04–2.62] 0.056
Plaque burden, % 32.9 ± 10.6 37.6 ± 11.8 0.014 3.88 [0.31–7.44] 0.033
Plaque composition
Fibrous percentage 61.4 ± 11.2 58.5 ± 12.0 0.13 −2.99 [−6.80–0.83] 0.12
Fibro-fatty percentage 8.6 [4.6–12.0] 8.6 [5.5–12.0] 0.35 0.18 [−0.14–0.51] 0.26
Necrotic core 
percentage
21.2 ± 8.3 21.8 ± 8.6 0.68 0.43 [−2.37–3.22] 0.76
Dense calcium 
percentage
6.7 [4.9–11.3] 8.3 [4.9–13.8] 0.28 0.21 [−0.17–0.58] 0.28
Lipid Core Burden Index 
(LCBI)b
48.0 [6.0–91.0] 44.5 [16.0–88.0] 0.53 0.03 [−0.71–0.77] 0.93
Lesion plaque characteristicsa P-valuec OR [95% CI] P-valued
Degree of 
atherosclerosis
≥1 Lesion with PB ≥ 
70%, n (%)
3 (6.7) 56 (21.0) 0.023 3.61 [1.06–12.30] 0.040
≥1 Lesion with MLA 
≤4.0 mm², n (%)
11 (24.4) 80 (30.1) 0.44 1.30 [0.61–2.7 0.51
Plaque composition
≥1 TCFA, n (%) 22 (48.9) 119 (44.6) 0.59 0.78 [0.41–1.51] 0.46
Continuous variables are presented as mean ± SD or median [interquartile range], depending on the 
distribution. Categorical variables are presented as n (%).
Beta (β) indicates the increase or decrease (minus sign) in each (transformed) imaging segment param-
eter for the Haptoglobin 2-1 or 2-2 ACS patients as compared to Haptoglobin 1-1 ACS patients.
Odds ratio (OR) increase in each lesion parameter for the Haptoglobin 2-1 or 2-2 ACS patients as com-
pared to Haptoglobin 1-1 ACS patients.
a IVUS-VH imaging was performed in 313 ACS patients.
b NIRS imaging was performed in a subset of 93 ACS patients.
c P-values (univariate) obtained by the independent Student’s two-sample t-test for the continuous vari-
ables and Chi-squared test for the categorical variables.
d P-values (multivariate) obtained by linear regression analyses for continuous variables and logistic re-
gression analyses for categorical variableswith Haptoglobin 1-1 as the reference category. Models ad-
justed for age, gender, smoking, diabetes mellitus, hypertension, dyslipidemia and previous myocardial 
infarction.
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4. DIsCussIOn
To our knowledge, this is the first study that investigated the relation between Hp 
phenotypes and coronary plaque characteristics as assessed with IVUS-VH and NIRS 
in patients with CAD. Although no associations could be demonstrated between Hp 
phenotypes and coronary plaque characteristics in the full cohort, in ACS patients phe-
notypes Hp2-1 and Hp2-2 were significantly associated with a higher degree of coronary 
atherosclerosis as expressed by higher segment plaque burden and higher prevalence 
of lesions with PB ≥ 70%, as compared to Hp1-1.
Existing imaging studies on Hp phenotype and atherosclerosis as assessed with either 
coronary angiography or CT angiography are limited in number and were mainly per-
formed in specifically defined study populations, such as patients with diabetes mellitus 
[5,6,12,13]. Overall, these studies did not find any associations between Hp phenotype 
and coronary atherosclerosis [5,6,12,13]. The interaction between Hp phenotype and 
acute versus stable clinical presentation of CAD has not been investigated earlier. A 
potential, biologically plausible explanation for this interaction could be that patients 
who ultimately experience ACS represent a subgroup that exhibits an increased pro-
inflammatory [14] and oxidative state [15–17] as compared to SAP patients. In these 
patients, elevated oxidative stress may not only be present systemically [15,16] but also 
3.3. Clinical endpoints
With regard to clinical outcome, associations between Hp pheno-
type and 1-year cardiovascular outcome could not be demonstrated,
both in the full cohort and in the ACS and diabetes subgroups. In partic-
ular, the Hp phenotypes were not associated with the occurrence of
MACE (primary composite endpoint) on multivariate analysis: HR[95%
CI] 0.88 [0.52–1.49] for Hp2-1 and 0.97 [0.57–1.67] for Hp2-2 in the
full cohort; HR[95% CI] 0.77 [0.38–1.56] for Hp2-1 and 0.70 [0.33–
1.49] for Hp2-2 in the ACS subgroup; HR [95% CI] 0.91 [0.30–2.82] for
Hp2-1 a d 0.94 [0.30–3.02] for Hp2-2 in the diabetic subgroup.
4. Discussion
To our knowledge, this is the ﬁrst study that investigated the relation
betweenHpphe oty es and c ronary plaque characteristics as assessed
with IVUS-VH and NIRS in patients with CAD. Although no associations
could be demonstrated between Hp phenotypes and coronary plaque
characteristics in the full cohort, in ACS patients phenotypes Hp2-1
and Hp2-2 were signiﬁcantly associated with a higher degree of coro-
nary atherosclerosis as expressed by higher segment plaque burden
and higher prevalence of lesions with PB ≥ 70%, as compared to Hp1-1.
Existing imaging studies on Hp phenotype and atherosclerosis as
assessedwith either coronary angiography or CT angiography are limit-
ed in number and were mainly performed in speciﬁcally deﬁned study
populations, such as patients with diabetesmellitus [5,6,12,13]. Overall,
these studies did not ﬁnd any associations between Hp phenotype and
coronary atherosclerosis [5,6,12,13]. The interaction between Hp phe-
notype and acute versus stable clinical presentation of CAD has not
been investigated earlier. A potential, biologically plausible explanation
for this interaction could be that patients who ultimately experience
ACS represent a subgroup that exhibits an increased pro-inﬂammatory
[14] and oxidative state [15–17] as compared to SAP patients. In these
patients, elevated oxidative stress may not only be present systemically
[15,16] but also locally at the level of the atherosclerotic plaque, as part
of the pathogenesis and evolution towards an ACS. The latter results,
among others, from intraplaque hemorrhage, which occurs more often
in ACS than in SAP patients, and gives rise to a local release of hemoglo-
bin (iron) into the atherosclerotic plaque [18]. Such a state leads, among
several other reactions, to local generation of reactive oxygen species
and consequently lipid peroxidation [15], which eventually may con-
tribute to accelerated atherosclerotic plaque growth [15,19] in these pa-
tients. This processmay be further enhanced inHp2 phenotypes (Hp2-1
and Hp2-2) due to their reduced anti-oxidant and anti-inﬂammatory
properties as compared to Hp1-1 [1,2]. A previous study in mice sup-
ports this hypothesis by demonstrating increased iron, lipid peroxida-
tion and macrophage accumulation in Hp2-2 atherosclerotic plaques
as compared with Hp1-1 plaques [20]. This was conﬁrmed in humans
by autopsy studies that have demonstrated more advanced atheroscle-
rotic plaques in Hp2-2 compared to Hp1-1 individuals [21]. In contrast
to Hp1-1 proteins, the Hp2-1 and Hp 2-2 proteins have low afﬁnity for
both hemoglobin and the macrophage CD163 scavenger receptor in
order to clear hemoglobin (iron) from the atherosclerotic plaque and
prevent its harmful intraplaque oxidative reactions [2,22]. Altogether,
these studies indicate that oxidative stressmight strongly be implicated
in the atherosclerotic process with a critical role for Hp proteins in its
further development.
In a previous study within the same cohort, we could not demon-
strate an association between plasma Hp concentration and (VH-)IVUS
plaque characteristics or clinical events [8]. Although the biological func-
tion of Hp in the vascular wall might not directly depend on its plasma
concentrations, but rather on its protein structure, there is a direct cor-
relation of Hp phenotype with Hp plasma concentrations. Speciﬁcally,
Hp concentration is higher in Hp2-2 than in Hp1-1 individuals, because
of the weaker binding of Hp2-2 proteins to hemoglobin and the macro-
phage CD163 receptor [22]. Thus, since Hp concentrations may at least
in part be phenotype-dependent, these negative results seem consistent
with our current ﬁndings.
Epidemiologic studies investigating the association between Hp
phenotype and incidence of CAD in the general population are limited
in number and have yielded contradicting results. While De Baquer
et al. found that Hp1-1 individuals were at higher risk of CAD mortality
as compared to the other Hp phenotypes [3], the Framingham Heart
Offspring Study (n=3273) could not demonstrate any relationship be-
tween Hp phenotype and CAD prevalence in the overall study popula-
tion [4].
The majority of clinical studies concerning Hp phenotypes has
focused on diabetic individuals, since strong evidence exists that Hp
phenotyp and diabetic state signiﬁcantly interact with regard to prev-
alence of CAD. It has been demonstrated that Hp2-2 individuals with di-
abetes have a higher risk of adverse cardiovascular outcomes as
compared to the other phenotypes [4,23–27], which is thought to be
caused by the decreased anti-oxidant capabilities of the Hp2-2 protein
in conjunction with an exceptionally high level of oxidative stress in di-
abetes [28,29]. However, some other studies could not conﬁrm these
ﬁndings [30], or even rendered contradictory results [4]. We also
could not demonstrate any associations with in-vivo coronary plaque
characteristics or 1-year clinical outcome in diabetic patients. Our ﬁnd-
ings are in agreementwith a study in type 2 diabetic patients, that could
not demonstrate an association between Hp genotype and coronary ar-
tery calciﬁcation (CAC) as a reﬂection of total coronary atherosclerotic
burden [5]. On the other hand, a larger case-control study on type 1 di-
abetic patients found that the Hp2-2 genotype was a predictor of CAC
progression. The limited number of diabetic participants (n = 99) in
our cohort may have contributed to the lack of such an association in
our study.
Our study has several limitations that warrant acknowledgement.
Firstly, our ﬁndings in the ACS subgroup should be considered as
hypothesis-generating, because the comparison of Hp2-2 and Hp2-1
on the one hand with Hp1-1 on the other hand in the ACS patients
was a post-hoc analysis. Nevertheless, the interaction terms between
Hp phenotypes and indication for catheterization were highly signiﬁ-
cant in multivariate analyses. Secondly, IVUS(-VH) imaging took place
Fig. 4. Presence of large lesions in the haptoglobin phenotypes within the full cohort and
ACS subgroup. *P-value for difference in the presence of large lesions between Hp2-1 or
Hp2-2 as compared to Hp1-1 within the ACS subgroup. Adjusted for age, gender,
smoking, diabetes mellitus, hypertension, dyslipidemia and previous myocardial
infarction. ACS = acute coronary syndrome; Hp = haptoglobin.
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fig. 4. Presence of large l sions in the haptoglobin phenot es within the full cohort and aCs sub-
group.
*P-value for difference in the presence of large lesions between Hp2-1 or Hp2-2 as compared to Hp1-1 
within the ACS subgroup. Adjusted f r age, gend r, smoking, diabetes mellitus, hypertension, dyslipid-
emia and previous myocardial infarction. ACS = acute coronary syndrome; Hp= haptoglobin.
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locally at the level of the atherosclerotic plaque, as part of the pathogenesis and evolu-
tion towards an ACS. The latter results, among others, from intraplaque hemorrhage, 
which occurs more often in ACS than in SAP patients, and gives rise to a local release 
of hemoglobin (iron) into the atherosclerotic plaque [18]. Such a state leads, among 
several other reactions, to local generation of reactive oxygen species and consequently 
lipid peroxidation [15], which eventually may contribute to accelerated atherosclerotic 
plaque growth [15,19] in these patients. This process may be further enhanced in Hp2 
phenotypes (Hp2-1 and Hp2-2) due to their reduced anti-oxidant and anti-inflammatory 
properties as compared to Hp1-1 [1,2]. A previous study in mice supports this hypothesis 
by demonstrating increased iron, lipid peroxidation and macrophage accumulation in 
Hp2-2 atherosclerotic plaques as compared with Hp1-1 plaques [20]. This was confirmed 
in humans by autopsy studies that have demonstrated more advanced atherosclerotic 
plaques in Hp2-2 compared to Hp1-1 individuals [21]. In contrast to Hp1-1 proteins, the 
Hp2-1 and Hp 2-2 proteins have low affinity for both hemoglobin and the macrophage 
CD163 scavenger receptor in order to clear hemoglobin (iron) from the atherosclerotic 
plaque and prevent its harmful intraplaque oxidative reactions [2,22]. Altogether, these 
studies indicate that oxidative stress might strongly be implicated in the atherosclerotic 
process with a critical role for Hp proteins in its further development.
In a previous study within the same cohort, we could not demonstrate an associa-
tion between plasma Hp concentration and (VH-)IVUS plaque characteristics or clinical 
events [8]. Although the biological function of Hp in the vascular wall might not directly 
depend on its plasma concentrations, but rather on its protein structure, there is a direct 
correlation of Hp phenotype with Hp plasma concentrations. Specifically, Hp concen-
tration is higher in Hp2-2 than in Hp1-1 individuals, because of the weaker binding of 
Hp2-2 proteins to hemoglobin and the macrophage CD163 receptor [22]. Thus, since 
Hp concentrations may at least in part be phenotype-dependent, these negative results 
seem consistent with our current findings.
Epidemiologic studies investigating the association between Hp phenotype and 
incidence of CAD in the general population are limited in number and have yielded 
contradicting results. While De Baquer et al. found that Hp1-1 individuals were at higher 
risk of CAD mortality as compared to the other Hp phenotypes [3], the Framingham 
Heart Offspring Study (n=3273) could not demonstrate any relationship between Hp 
phenotype and CAD prevalence in the overall study population [4].
The majority of clinical studies concerning Hp phenotypes has focused on diabetic 
individuals, since strong evidence exists that Hp phenotype and diabetic state signifi-
cantly interact with regard to prevalence of CAD. It has been demonstrated that Hp2-2 
individuals with diabetes have a higher risk of adverse cardiovascular outcomes as 
compared to the other phenotypes [4,23–27], which is thought to be caused by the de-
creased anti-oxidant capabilities of the Hp2-2 protein in conjunction with an exception-
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ally high level of oxidative stress in diabetes [28,29]. However, some other studies could 
not confirm these findings [30], or even rendered contradictory results [4]. We also could 
not demonstrate any associations with in-vivo coronary plaque characteristics or 1-year 
clinical outcome in diabetic patients. Our findings are in agreement with a study in type 
2 diabetic patients, that could not demonstrate an association between Hp genotype 
and coronary artery calcification (CAC) as a reflection of total coronary atherosclerotic 
burden [5]. On the other hand, a larger case-control study on type 1 diabetic patients 
found that the Hp2-2 genotype was a predictor of CAC progression. The limited number 
of diabetic participants (n = 99) in our cohort may have contributed to the lack of such 
an association in our study.
Our study has several limitations that warrant acknowledgement. Firstly, our findings 
in the ACS subgroup should be considered as hypothesis-generating, because the com-
parison of Hp2-2 and Hp2-1 on the one hand with Hp1-1 on the other hand in the ACS 
patients was a post-hoc analysis. Nevertheless, the interaction terms between Hp pheno-
types and indication for catheterization were highly significant in multivariate analyses. 
Secondly, IVUS(-VH) imaging took place of a non-culprit coronary artery segment only. 
However, this approach was developed under the hypothesis that such a non-culprit 
target segment adequately reflects coronary wall pathophysiology of the larger coronary 
tree, and this hypothesis has been confirmed by several studies [31,32]. Finally, this study 
was not primarily designed to investigate the association between Hp phenotypes and 
atherosclerosis and clinical outcome in diabetic patients. A small number of diabetic pa-
tients in this study may have contributed to the lack of significant associations between 
Hp phenotypes and degree and composition of atherosclerosis in this subgroup.
In conclusion, in patients undergoing coronary angiography, no associations were 
present between Hp phenotypes and invasively measured coronary atherosclerotic 
plaque characteristics by IVUS and NIRS. However, patients with Hp2-1 or Hp2-2 present-
ing with ACS had a significantly higher degree of coronary atherosclerosis as compared 
to Hp1-1. Thus, genetic differences in the endogenous antioxidant status, as reflected 
by the haptoglobin phenotype, may be of considerable importance in patients suffer-
ing from CAD. Our hypothesis-generating findings should be confirmed by other, large 
studies in order to identify patient groups that might benefit from risk stratification by 
Hp phenotyping in the future.
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absTRaCT
Objectives: We compared the incidence of late increase in hs-cTnI between ACS and 
non-ACS patients treated with standard of care with or without darapladib.
Methods: A total of 323 (161 ACS and 162 non-ACS patients) were included. High sensi-
tivity troponin I was measured at baseline and at 4, 13, 26 and 52 weeks.
Results: ACS patients had statistically higher hs-cTnI values during longer term follow-
up at which these patients were no longer in the acute setting of myocardial ischemia, 
but were regarded to have stable CAD (mean hsTnI value in ACS patients: 1.180 versus 
0.886 ng/L in non-ACS patients, p = 0.02). Multivariate logistic regression revealed three 
predictors of any 2-fold increase in hs-cTnI levels compared to the previous visit when 
interactions were not considered. Treatment with darapladib (adjusted OR 0.53; 95% 
CI: 0.30-0.92) and initial presentation with ACS (adjusted OR 0.42; 95% CI: 0.23-0.77) 
were associated with less frequent occurrence of a 2-fold increase in hs-cTnI levels. In 
contrast, diabetes was associated with a higher incidence of 2-fold increases in hs-cTnI 
levels (adjusted OR 2.20; 95% CI: 1.04-4.64). Logistic regression to predict any 2-fold in-
crease in hs-cTnI by ACS status showed that in the ACS group, treatment with darapladib 
decreased the risk of elevation of hs-cTnI (OR 0.219; 95% CI: 0.087, 0.553, p = 0.0013).
Conclusion: In patients with ACS, treatment with darapladib is associated with less 
increase in cardiac troponin I compared to standard of care alone. This beneficial effect 
may be associated with darapladib’s capability of reducing necrotic core in coronary 
plaques.
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1. InTRODuCTIOn
Myocardial damage after either temporal or permanent suppression of the coronary 
blood flow has been reported to be prognostically relevant for patients. [1] Early detec-
tion of myocardial damage is highly encouraged to better assess risk of a new clinical 
event. Several markers of myocardial damage have been described (i.e creatinine kinase 
and cardiac troponin – cTn) as means of diagnosis of myocardial infarction [2]. Eleva-
tions of serum cardiac troponin levels above the detection limit have been associated 
with increased mortality and recurrent ischemic events in patients with acute coronary 
syndrome (ACS) and also in subjects without clinical evidence of cardiovascular disease 
[3-5]. As a consequence, the possibility that circulating troponin levels below the con-
ventional detection limits might lead to further risk stratification for adverse cardiovas-
cular outcome, led to the development of so-called high-sensitivity troponin (hs-cTn) 
assays. A post-hoc analysis of the PEACE trial demonstrated that, in patients with stable 
coronary artery disease (CAD), cardiac troponin T concentrations as measured with a 
highly sensitive assay were significantly associated with increased incidence of cardio-
vascular mortality and heart failure after adjustment for other independent prognostic 
indicators [6].
In addition, the serial assessment of c-Tn could also be a prognostically relevant 
marker of late events and its late suppression could become a therapeutical target.
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a circulating enzyme bound 
predominantly to apoB-containing lipoproteins, and highly expressed in the necrotic 
core of atherosclerotic lesions [7,8]. Lp-PLA2 rapidly degrades oxidatively modified 
phospholipids in LDL-c leading to formation of proinflammatory and cytotoxic products 
[9–11]. Because enhanced cell death and impaired clearance of apoptotic bodies are 
thought to be key mechanisms for necrotic core expansion [12], Lp-PLA2 inhibition may 
favorably affect rupture-prone lesions.
Darapladib (GlaxoSmithKline, Philadelphia PA) which is a Lp- PLA2 inhibitor has been 
studied in the Integrated Biomarkers and Imaging Study-2 trial (NCT00268996) [13]. One 
of the key findings was that Lp-PLA2 inhibition with darapladib interferes with necrotic 
core expansion.
The primary objective of this exploratory post-hoc analysis is to compare hs troponin 
I levels between darapladib and placebo subjects in the IBIS 2 study, and to describe 
the differences in patterns of troponin levels between patients presenting with ACS 
and those presenting with non-ACS as measured longitudinally with a high sensitivity 
immunoassay during one-year follow-up.
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2. MeTHODs
2.1. study design
The Integrated Biomarkers and Imaging Study-2 trial has been published elsewhere 
[13]. Briefly, it was an international, multicenter, randomized, double blind, placebo-
controlled study in patients with confirmed CHD. Institutional review boards at each 
center approved the protocol, and patients provided written informed consent.
2.2. Patient population
Patients 18 years of age or older undergoing cardiac catheterization for acute coronary 
syndrome (ACS) or non-ACS were eligible.
In the protocol, ACS is defined as: patients with enzymatic evidence of myocardial 
necrosis [chest pain or chest pain equivalent lasting greater than or equal to 20 min 
within past 72 h with elevated pre-catheterization levels of troponin I or T (i.e. >99th 
percentile of reference control group)]. Non-ACS is defined as: patients with coronary 
heart disease other than troponin-positive acute coronary syndrome.
Randomization allocated patients into darapladib vs. placebo groups and was strati-
fied according to ACS status and center. Key exclusion criteria were planned surgical 
revascularization, stroke in the past 6 months, chronic hepatic disorder or abnormal 
ALT, bilirubin (ALT >2.5 or bilirubin >1.5 upper limit of normal), serum creatinine >2.0 
mg/dL, blood pressure >160/100 mm Hg, poorly controlled diabetes mellitus (HbA1c 
>10%), severe heart failure or left ventricular ejection fraction <30%, and current life-
threatening condition. Patients were ineligible if angiography demonstrated left main 
coronary stenosis >50% or coronary anatomy was inappropriate for IVUS.
2.3. IVus imaging
The ECG-gated IVUS-RF acquisition was performed using EagleEye catheter (20 MHz) at 
pullback speed of 0.5 mm/s as described. The quantitative IVUS analysis was performed 
by the Core Imaging Laboratory (Cardialysis, Rotterdam, The Netherlands) using custom-
ized software (pcVH 2.1, Volcano Therapeutics). After selection of the region of interest in 
the nonculprit vessel, vessel and lumen area data were obtained for every cross-section 
throughout the region of interest by semiautomatic planimetry of the leading edges of 
the luminal and external elastic membrane borders. Necrotic core was identified with 
autoregressive classification system that showed sensitivity and specificity of 92% and 
97% for detection of necrotic core, respectively. The intra- and interobserver variability 
of necrotic core measurements: the mean absolute difference for necrotic core area was 
0.01 mm² (SD 0.06) for the intraobserver and 0.02 mm² (SD 0.08) for the interobserver 
variability, respectively.
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2.4. biomarkers
Plasma samples were drawn at baseline (prior to the cardiac catheterization), weeks 4, 
13, 26, 52 and at the follow-up visit. Cardiac troponin I was measured using the ultrasen-
sitive Singulex Erenna System (Singulex Inc., Berkeley, CA, USA) which is an ultrasensitive 
flow-based immunoassay that uses single-molecule counting [14]. It has been standard-
ized to National Institute of Standards and Technology Material and validated with a 
lower limit of detection of 0.0002 ng/mL (0.20 ng/L). The inter-assay coefficient of varia-
tion (CV) is 10% at 0.91 ng/L, and the 99th percentile in a healthy control population is 
9 ng/L [15].
2.5. statistical analysis
Baseline characteristics are reported as mean values (+/– standard deviation) for con-
tinuous variables, whereas discrete variables are presented in terms of frequencies and 
percentages.
Summary statistics were calculated for the natural log of the area under the curve 
(AUC) high sensitive troponin I, weighted by day, excluding baseline and week 4 (thus 
from week 13 to week 52). Treatment group comparisons were based on the general 
linear model with terms for treatment group and ACS status. Pearson correlations be-
tween the change from baseline to week 52 in necrotic core volume and the weighted 
area under the curve of hs troponin (excluding the baseline and week 4 visits) were 
calculated.
The proportions of subjects with 2-,3- and 4- fold increases in hs-cTnI from the previ-
ous visit were examined by treatment group and ACS status. These proportions were 
examined excluding the baseline value and the week 4 hs-cTnI values because ACS 
subjects would be expected to have high hs-cTnI at entry into the study. Thus, solely the 
late increase/suppression (>13 weeks) was explored.
Logistic regression modeling was performed to predict any 2- fold increase in hs-cTnI 
from the previous visit. The following terms were included in the model: treatment group, 
ACS status, treatment group by ACS status interaction, age, smoking status, presence 
of a stent at baseline, previous MI, hypertension, HDL <1.03, LDL <1.81 mmol/L, and 
diabetes. In this model, only treatment group, ACS status, and the treatment group by 
ACS status interaction were significant at the 5% level. Due to the significant interaction 
between treatment group and ACS status, odds ratios for treatment group are presented 
within ACS status.
All statistical tests were two-sided with a type I error level of 0.05. Analyses were 
performed with SAS version 9.1.
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3. ResulTs
A total of 323 patients constituted the Intent-to-Treat population (patients who took at 
least 1 dose), 161 patients had an acute coronary syndrome (ACS) and 162 had a non-
ACS. At baseline, 252 patients had at least one stenting procedure in a non-study vessel. 
Table 1 contains the baseline characteristics of patients in the ITT population.
Table 1. baseline characteristics
Clinical characteristics
Placebo
(n = 151)
Darapladib
(n = 172)
Age (y) 57.3 ± 10.9 59.4 ± 9.8
Males (n, %) 126 (83) 140 (81)
Body-mass index (kg/m²) 27.8 ± 3.8 27.5 ± 4.0
Diabetes mellitus (n, %) 22 (15) 22 (13)
Hypertension (n, %) 89 (59) 115 (67)
Low HDL cholesterol (<40 mg/dL) (n, %) 40 (26) 45 (26)
Hypercholesterolemia (n, %) 95 (63) 108 (63)
Current smoker (n, %) 57 (38) 64 (37)
Prior medical history (n, %)
Prior myocardial infarction 49 (32) 51 (29)
Prior coronary revascularization 47 (31) 50 (29)
Peripheral artery disease 7 (5) 17 (10)
Prior stroke 3 (2) 4 (2)
Index hospitalization (n, %)
PCI during index hospitalization 122 (81) 130 (76)
ACS 74 (49) 87 (51)
STEMI 35 (23) 40 (23)
Non-STEMI 39 (26) 47 (27)
Cardiovascular medications at randomization (n, %)
Aspirin 138 (91) 149 (87)
Clopidogrel or ticlopidine 122 (81) 136 (79)
Any antiplatelet medication 150 (>99) 170 (99)
ACE inhibitors or ARBs 88 (58) 101 (59)
Beta-blockers 119 (79) 138 (80)
Statins 134 (89) 157 (91)
Laboratory values
Cholesterol (mg/dL)
Total 187.3 ± 47.6 182.3 ± 43.2
LDL 108.2 ± 41.4 103.6 ± 37.4
HDL 46.8 ± 11.2 48.0 ± 12.4
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Higher high sensitivity troponin AUCs were observed in patients presenting with 
an ACS as compared to those without (mean hsTnI values: 3.7 ± 1.8 versus 1.1 ± 0.1.2 
ng/L, p < 0.001), when measurements at all timepoints were taken into account. (Fig. 
1) ACS patients also had statistically higher hs-TnI values during longer term follow-up, 
at which these patients were no longer in the acute setting of myocardial ischemia (>4 
weeks), but were regarded to have stable CAD (mean hsTnI value in ACS patients: 1.180 
versus 0.886 ng/L in non-ACS patients, p < 0.02).
3.1. High-sensitivity troponin I levels over time
When hsTnI measurements at all timepoints were considered, 18% of ACS subjects vs. 
33% of non-ACS subjects had a 2-fold increase in hsTnI levels compared to the previ-
ous sample collection. As mentioned earlier, hsTnI levels are known to be elevated at 
Table 1. (continued)
Clinical characteristics
Placebo
(n = 151)
Darapladib
(n = 172)
Triglycerides (mg/dL)
Median 141 136
IQR 97-202 96-193
hsC-reactive protein (mg/L)
Geometric mean 2.4 2.4
95% CI 1.9, 3.1 1.9, 3.0
Lp-PLA2 activity (µmol/min
-1/L-1)a
Geometric mean 159 160
95% CI 152, 167 153, 167
Blood pressure
Systolic-mm Hg 125.7 ± 16.9 128.0 ± 16.1
Diastolic-mm Hg 75.2 ± 10.1 75.6 ± 9.9
Study vesselb-no. (%)
LAD 44 (36) 56 (39)
LCX 32 (26) 37 (26)
RCA 45 (37) 51 (35)
Diameter stenosisc (%) 28.0 (10.5) 26.6 (10.3)
Mean lumen diameterc (mm) 2.9 ± 0.5 3.0 ± 0.6
Values are presented as mean ± SD unless otherwise specified; to convert to mmol/L multiply values of 
cholesterol by 0.02586 and triglycerides by 0.0113; PCI, percutaneous coronary intervention; ACS, acute 
coronary syndromes.
a Plasma Lp-PLA2 activity was measured by a colorimetric method with an intraassay precision of 1.7% 
and interassay precision of 4.8%.
b Imaging evaluable population: placebo 121 patients; darapladib 146 patients.
c Quantitative coronary angiography: placebo 121 patients; darapladib 144 patients.
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baseline in the ACS patients, followed by a period of normalization (i.e. decrease instead 
of increase). A second model was therefore used to assess whether the lower incidence 
of 2-fold increases in hsTnI levels would persist in the ACS patients when only changes 
between visits from week 13 onwards were evaluated. This also demonstrated that 
2-fold increases in hsTnI levels during follow-up occurred less frequently in ACS patients 
(15% of ACS subjects vs. 26% of non-ACS subjects) (Online Supplement Table 1).
Multivariate logistic regression revealed three predictors of any 2-fold increase in hsTnI 
levels compared to the previous visit. After adjustment for clinically relevant variables, 
treatment with darapladib (adjusted OR 0.53; 95% CI: 0.30-0.92) and initial presentation 
with ACS (adjusted OR 0.42; 95% CI: 0.23-0.77) were associated with less frequent oc-
currence of a 2-fold increase in hsTnI levels. In contrast, diabetes was associated with a 
higher incidence of 2-fold increases in hsTnI levels (adjusted OR 2.20; 95% CI: 1.04-4.64). 
No other clinical baseline characteristic was significantly associated with hsTnI increases, 
either in univariate or multivariate analyses. (Table 2) However, due to the presence of 
a significant treatment by ACS status interaction, a logistic regression model to predict 
any 2-fold increase in troponin by ACS status was performed. In the ACS group, treat-
ment with darapladib reduced the risk of hs-TnI elevation (OR 0.219; 95% CI: 0.087, 0.553, 
p = 0.0013) (Table 3).
No significant correlations were found between change in necrotic core volume and 
the weighted area under the curve of hscTnI in the overall study population or in sub-
groups of ACS-status or treatment allocation (Online Supplement Table 2).
equal in both treatment arms; 2. Apoptosis of cardiomyocytes could
be another explanation for measurable troponin levels in the long
term after index procedure. This phenomenon is speciﬁc for
patients who had an ACS in whom the apoptotic processes persist
for months ft r an AMI. [18]. In humans, circulating Lp-PLA2 is
bound predominantly to LDL. Lp-PLA2 acts on oxidized phospho-
lipids within modiﬁed LDL to generate lysophosphatidylcholine
and oxidized fatty acids. Both products have proinﬂammatory
effects that contribute to the initiation and progression of
atheroma, in larg part, through the recruitment and activation of
monocyte-macrophages. The products of Lp-PLA2 activity can also
induce apoptosis among macrophages. Although the exact mech-
anism has not been yet completely elucidated, monocytes activated
by transient hypoxia protect cardiomyocytes during hypoxia and
re-oxygenation through expression of CD11b receptors [19]. Thus,
this process can be affected by darapladib by preventing the
formation of lysophosphatidylcholine and oxidized fatty acids,
thereby avoiding monocyte apoptosis and therefore protecting
myocytes; 3. Late TnI increase is marked in non-ACS patients
treated with and without arapla ib, and in ACS patients treated
with standard of care, but not in those ACS patients treated with
darapladib. Whether ACS patients receiving darapladib represent
a subset of patients with enhanced reduction in major adverse
cardiovascular events is currently being investigated in the SOLID-
TIMI 52 trial [20]. As mentioned above, a possible explanation is
that ACS patients exhibit a more signiﬁcant inﬂammatory process
post-ACS with activation of monocytes and macrophages, as
compared with non-ACS patients. In such environment darapladib
is hypothesized to pl y amajor role, reducing the apoptosis of these
cells with eventual protection of cardiomyocytes. 4. Asymptomatic
coronary plaque ruptures with subsequent microembolization of
the resulting thrombus may also represent a cause of late increase
in hs-cTnI. It has been reported that patients with ACS have addi-
tional asymptomatic ruptured plaques beyond the culprit lesions,
showing the multifocal nature of the disease [21]. The size of the
necrotic core is one important determinant for the rupture of those
plaques [22]. In the IBIS 2, the progression of the expansion of
necrotic core was halted by darapladib [13]. In this subset of
patients (i.e. ACS), darapladib a so de reases the incidence of a two-
fold increase in high sensitive troponin; 5. Another simpler reason
for the late increase in cTn is the occurrence of thrombotic events in
this population. In this report, the 2-fold increase in hsTnI occurred
in 25% (80/323) of the total population, and of these patients only
27.5% (22/80) had at l ast a MACE event. The raise in high sensitive
troponin was most of the time unrelated to the time of the event
(Online Supplement Table 3).
4.1. Study limitations
This exploratory post-hoc subanalysis has several limitations: 1.
blood samples were not processed at short-termwhich might have
caused increase variability in the assessment of the high sensitivity
troponin I as it has been described [23,24]; 2. this report includes
Fig. 1. High sensitive troponin I levels by visit and acute coronary syndrome (ACS) status.
Table 2
Details of logistic r g ession modeling to predict any 2-fold increase in troponin
from the previous visit full model (no interaction terms).
Parameter Estimate p-value OR (95% CI)
Treatment group
(darapladib vs placebo)
�0.32 0.024 0.526 (0.301, 0.919)
ACS status
(ACS vs non-ACS)
�0.43 0.005 0.420 (0.230, 0.765)
Age 0.005 0.745 1.005 (0.976, 1.034)
Smoker (yes vs no) �0.03 0.857 0.944 (0.502, 1.773)
Stent at baseline (yes vs no) �0.25 0.138 0.609 (0.316, 1.173)
Previous MI (yes vs no) �0.12 0.423 0.780 (0.425, 1.433)
Hypertension (yes vs no) �0.14 0.366 0.763 (0.424, 1.373)
HDL (<1.03 vs >¼1.03) 0.13 0.447 1.305 (0.657, 2.595)
LDL (<1.81 vs >¼1.81) �0.21 0.157 0.663 (0.375, 1.172)
Diabetes (yes vs no) 0.40 0.038 2.200 (1.044, 4.636)
Table 3
Details of logistic regression modeling to predict any 2-fold increase in troponin
from the previous visit model by ACS status.
Parameter Estimate p-value OR (95% CI)
ACS subgroup (n ¼ 159)
Treatment group
(darapladib vs placebo)
�0.7583 0.0013 0.219 (0.087, 0.553)
Non-ACS subgroup (n ¼ 159)
Treatment group
(darapladib vs placebo)
�0.1228 0.4683 0.782 (0.403, 1.519)
H.M. García-García et al. / Atherosclerosis 225 (2012) 142e147 145
fig. 1. High sensitivity troponin I levels by visit and acute coronary syndrome (aCs) status.
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Additionally, examination of the incidence of clinical events in those patients who had 
a 2-fold increase of hs-cTnI from the previous visit (n = 80), showed that 27.5% of these 
patients had at least one MACE (cardiovascular death, MI, stroke, coronary revascular-
ization) event. (Table 4). The timing of the determination of hsTnI and MACE event is 
reported in the Online Supplement Table 3. A 2-fold increase in hs-cTnI was not related 
to the date of the MACE events in the majority of events.
4. DIsCussIOn
In this exploratory post-hoc analysis of the IBIS 2 trial, there was a marked suppression 
of the late elevation (>13 weeks) of high sensitivity troponin I in patients treated with 
darapladib. This was more apparent in patients that had ACS at the time of randomiza-
tion to darapladib, when compared with non-ACS patients.
In a substudy from the FRISC-II trial(5), persistent minute elevation (levels >0.01 µg/L) 
of cTnI, predicted mortality during long-term follow-up. In our study, an association with 
mortality cannot be done due to the nature of the IBIS study (i.e. imaging vs. outcome 
trial). Nevertheless, it is expected that treatment with darapladib may have an effect 
Table 2. Details of logistic regression modeling to predict any 2-fold increase in troponin from the 
previous visit full model (no interaction terms).
Estimate p-value OR (95% CI)
Treatment group (darapladib vs placebo) −0.32 0.024 0.526 (0.301, 0.919)
ACS status (ACS vs non-ACS) −0.43 0.005 0.420 (0.230, 0.765)
Age 0.005 0.745 1.005 (0.976, 1.034)
Smoker (yes vs no) −0.03 0.857 0.944 (0.502, 1.773)
Stent at baseline (yes vs no) −0.25 0.138 0.609 (0.316, 1.173)
Previous MI (yes vs no) −0.12 0.423 0.780 (0.425, 1.433)
Hypertension (yes vs no) −0.14 0.366 0.763 (0.424, 1.373)
HDL (<1.03 vs >=1.03) 0.13 0.447 1.305 (0.657, 2.595)
LDL (<1.81 vs >=1.81) −0.21 0.157 0.663 (0.375, 1.172)
Diabetes (yes vs no) 0.40 0.038 2.200 (1.044, 4.636)
Table 3. Details of logistic regression modeling to predict any 2-fold increase in troponin from the 
previous visit model by aCs status.
Estimate p-value OR (95% CI)
ACS subgroup (n = 159)
Treatment group (darapladib vs placebo) −0.7583 0.0013 0.219 (0.087, 0.553)
Non-ACS subgroup (n = 159)
Treatment group (darapladib vs placebo) −0.1228 0.4683 0.782 (0.403, 1.519)
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on clinical outcomes not only by preventing late elevations of troponin (this report), 
but also for halting progression of necrotic core assessed by IVUS-virtual histology [13]. 
One can hypothesize that the late elevation of cardiac TnI is caused by several factors: 
1. increased demand ischemia due to volume and pressure overload that can occur in 
patients with high prevalence of co-morbidities (congestive heart failure, left ventricular 
hypertrophy, diabetes mellitus, and chronic kidney disease) [16,17]. In the context of a 
randomized control trial such as IBIS 2, the distribution of these diseases is expected 
to be equal in both treatment arms; 2. Apoptosis of cardiomyocytes could be another 
explanation for measurable troponin levels in the long term after index procedure. 
This phenomenon is specific for patients who had an ACS in whom the apoptotic pro-
cesses persist for months after an AMI. [18]. In humans, circulating Lp-PLA2 is bound 
predominantly to LDL. Lp-PLA2 acts on oxidized phospholipids within modified LDL 
to generate lysophosphatidylcholine and oxidized fatty acids. Both products have 
proinflammatory effects that contribute to the initiation and progression of atheroma, 
in large part, through the recruitment and activation of monocyte-macrophages. The 
products of Lp-PLA2 activity can also induce apoptosis among macrophages. Although 
the exact mechanism has not been yet completely elucidated, monocytes activated by 
transient hypoxia protect cardiomyocytes during hypoxia and re-oxygenation through 
expression of CD11b receptors [19]. Thus, this process can be affected by darapladib by 
preventing the formation of lysophosphatidylcholine and oxidized fatty acids, thereby 
avoiding monocyte apoptosis and therefore protecting myocytes; 3. Late TnI increase is 
marked in non-ACS patients treated with and without darapladib, and in ACS patients 
treated with standard of care, but not in those ACS patients treated with darapladib. 
Whether ACS patients receiving darapladib represent a subset of patients with enhanced 
Table 4. summary of subjects with a MaCe event and a two-fold increase in 
troponin in IbIs-2.
Subjects with MACE 58/323 (18%)
Death 0
Myocardial infarction 11
Stroke 2
Coronary revascularization 57
Subjects with 2 MACE 13
Subjects with a two-fold increase in troponin from the previous visit 80/323 (25%)
Subjects with a two-fold increase in troponin from the previous visit:
And a MACE eventa 22/80 (27.5%)
And no MACE event 58/80 (72.5%)
Note: MACE includes death, myocardial infarction, stroke, and coronary revascularization.
a Includes subjects with both a MACE and a two-fold troponin increase at any time. Troponin increase may 
have been before or after MACE.
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reduction in major adverse cardiovascular events is currently being investigated in the 
SOLID-TIMI 52 trial [20]. As mentioned above, a possible explanation is that ACS patients 
exhibit a more significant inflammatory process post-ACS with activation of monocytes 
and macrophages, as compared with non-ACS patients. In such environment darapladib 
is hypothesized to play a major role, reducing the apoptosis of these cells with eventual 
protection of cardiomyocytes. 4. Asymptomatic coronary plaque ruptures with subse-
quent microembolization of the resulting thrombus may also represent a cause of late 
increase in hs-cTnI. It has been reported that patients with ACS have additional asymp-
tomatic ruptured plaques beyond the culprit lesions, showing the multifocal nature 
of the disease [21]. The size of the necrotic core is one important determinant for the 
rupture of those plaques [22]. In the IBIS 2, the progression of the expansion of necrotic 
core was halted by darapladib [13]. In this subset of patients (i.e. ACS), darapladib also 
decreases the incidence of a two-fold increase in high sensitive troponin; 5. Another 
simpler reason for the late increase in cTn is the occurrence of thrombotic events in this 
population. In this report, the 2-fold increase in hsTnI occurred in 25% (80/323) of the 
total population, and of these patients only 27.5% (22/80) had at least a MACE event. The 
raise in high sensitive troponin was most of the time unrelated to the time of the event 
(Online Supplement Table 3).
4.1. study limitations
This exploratory post-hoc subanalysis has several limitations: 1. blood samples were not 
processed at short-term which might have caused increase variability in the assessment 
of the high sensitivity troponin I as it has been described [23,24]; 2. this report includes 
the total population included in IBIS 2 study but the sample size is too small to investi-
gate a potential relationship between elevations in high sensitivity troponin and clinical 
events and; 3. likewise, the observations regarding the effect of darapladib on levels of 
high sensitive troponin are hypothesis-generating and require further exploration.
5. COnClusIOns
In patients with acute coronary syndrome, addition of darapladib to standard of care 
therapy is associated with a lower incidence of a two-fold increase in cardiac troponin 
I over time when compared to standard of care alone. This beneficial effect may be as-
sociated with darapladib’s capability of reducing necrotic core in coronary plaques, and 
thus warrants further study.
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aPPenDIX
Core Laboratories: imaging (Cardialysis, Rotterdam, The Netherlands).
Participating Centers (number of patients enrolled): Austria: Hanusch Krankenhaus, 
Georg Gaul [6]. Belgium: Centre Hospitalier Universitaire Sart-Tilman, Victor Legrand 
[10]; ZNA Campus Middelheim, Stefan Verheye (25); Cardiovascular Center, Aalst, Wil-
liam Wijns [14]. Czech Republic: V_seobecná Fakultní Nemocnice, Michael Aschermann 
[23]. Denmark: Skejby University Hospital, Hans Erik Bøtker [18]. Germany: West German 
Heart Center, Raimund Erbel [7]; Kerckhoff Klinik, Christian Hamm [7]; Universitätsklini-
kum Heidelberg, Stefan Hardt, Helmut Kücherer (1); Universitätsklinikum München, 
Volker Klauss [14], Universitätsklinikum Ulm, Wolfgang Koenig [9]; Segeberger Kliniken, 
Gert Richardt [3]. The Netherlands: Medisch Spectrum Twente, Clemens von Birgelen 
[14]; Medisch Centrum Leeuwarden, Adrianus Johannes van Boven [12]; Catharina 
Hospital and Catherine R&D, Herman Rolf Michels [14], Erasmus Medical Center, Patrick 
Serruys [20]; Medisch Centrum Rijnmond Zuid, Pieter Smits [11]. Norway: Haukeland 
Sykehus, Oyvind Bleie [20]. Poland: Upper Silesian Heart Center, Pawel Buszman (40); 
Szpital Uniwersytecki, Dariusz Dudek [19]. Spain: Hospital Marques de Valdecilla, Thierry 
Colman [9]; Hospital Clinico San Carlos, Carlos Macaya [9]. Switzerland: Kantonsspital 
Luzern, Paul Erne (25).
appendix a. supplementary data
Supplementary data related to this article can be found online at http://dx.doi.
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Table 1. summary of subjects with an increase in high sensitive troponin from the previous visit at 
weeks 26, 52 by acute coronary syndrome (aCs) status
Placebo Darapladib Total
aCs 71 83 154
2-fold 17 24% 6 7% 23 15%
3-fold 11 15% 3 4% 14 9%
4-fold 6 8% 3 4% 9 6%
non-aCs 73 80 153
2-fold 20 27% 20 25% 40 26%
3-fold 7 10% 15 19% 22 14%
4-fold 6 8% 8 10% 14 9%
Table 2. Correlation between the Change from baseline to Week 52 in necrotic Core Volume and 
Weighted area under the Curve of hs Troponin (excluding the baseline and Week 4 Visits)
n Pearson Correlation
Overall 239 0.109 (p=0.09)
Placebo Treatment Group 110 0.115 (p=0.23)
Darapladib Treatment Group 129 0.133 (p=0.13)
aCs 118 0.172 (p=0.06)
Placebo Treatment Group 56 0.182 (p=0.18)
Darapladib Treatment Group 62 0.249 (p=0.05)
non-aCs 121 −0.048 (p=0.60)
Placebo Treatment Group 54 −0.071 (p=0.60)
Darapladib Treatment Group 67 −0.131 (p=0.29)
ACS, acute coronary syndrome; hs, high sensitive
Table 3. summary of subjects with a MaCe event and a two-fold increase in Troponin in IbIs-2
subjects with MaCe and two-fold increase in troponin 22
Time from first MaCe to two-fold increase in troponin:
 Increase prior to MaCe
  >=100 days prior 4
  >50 to <100 days prior 2
... 1 day prior 1
Two-fold increase followed first MaCe or same day as MaCe
 Same day as MACE 3
 <=10 days after MACE 2
 >10-<30 days after MACE 7
… >100 days after MACE 3
Note: MACE includes death, myocardial infarction, stroke, and coronary revascularization
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absTRaCT
aims: Statins are highly effective in reducing major adverse clinical events, but the direct 
effects on coronary plaque composition remain debatable. Our aim was to mechanisti-
cally evaluate the treatment effect of high-intensity statin therapy on compositional 
coronary plaque changes.
Methods and results: The third Integrated Biomarker and Imaging Study (IBIS-3) was 
a prospective, investigator-initiated, single-center study. Serial radiofrequency intra-
vascular ultrasound (RF-IVUS) measurements of a predefined non-stenotic segment 
in a non-culprit coronary artery were performed to evaluate the effect of rosuvastatin 
(intended dose: 40 mg daily) on necrotic core (NC) volume in patients with stable angina 
or acute coronary syndrome. Changes in lipid core burden index (LCBI) were evaluated 
through serial near-infrared spectroscopy (NIRS) imaging in a subset.
Serial RF-IVUS (and NIRS) data of a median segment of 41 (interquartile range: 32 to 49) 
mm were complete in 164 (103) patients. Follow-up measurements were performed at 6 
and 12 months in 30 (26) and 134 (77) patients, respectively. Mean levels of low-density 
lipoprotein cholesterol decreased by 30%, from 2.49 mmol/l to 1.73 mmol/l at the end 
of follow-up. High-dose rosuvastatin therapy resulted in a non-significant (P=0.074) 
change of −1.4 mm³ (95% confidence interval [CI]: −3.0 to 0.1) in NC volume during 
follow-up. The change in NC percentage of total plaque volume was −1.4% (95% CI:−2.4 
to −0.4; P=0.006). A neutral effect was also observed on LCBI. Indications of significant 
regression of NC volume and LCBI in the highest baseline quartiles were observed, which 
should be cautiously regarded as hypothesis generating.
Conclusion: High-intensity rosuvastatin therapy during 1 year resulted in a neutral ef-
fect on NC and LCBI within non-stenotic, non-culprit coronary segments with a relatively 
low atheroma burden.
Keywords: Atherosclerosis, Statin, Radiofrequency Intravascular Ultrasonography, 
Near-Infrared Spectroscopy
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InTRODuCTIOn
The presence of coronary plaque phenotypes with large necrotic core (NC) volumes is 
associated with a high incidence of major adverse cardiac events.(1-3) In the second 
Integrated Biomarker and Imaging Study (IBIS-2), the lipoprotein-associated phospholi-
pase A2 (Lp-PLA2) inhibitor darapladip – added to statins – halted coronary NC volume 
progression.(4) We now report IBIS-3, evaluating high-dose rosuvastatin to reduce 
coronary NC volume, assessed by radiofrequency intravascular ultrasound (RF-IVUS), 
and intracoronary cholesterol accumulation, assessed by near-infrared spectroscopy 
(NIRS).(5)
MeTHODs
The IBIS-3 study details have been published elsewhere.(5) Briefly, patients undergoing 
coronary angiography (CAG) or percutaneous coronary intervention (PCI) were treated 
with high-dose (40 mg daily) rosuvastatin for 12 months. Near completion of the study, 
the protocol was amended to enable a treatment duration of 6 months.
IBIS-3 was approved by the Medical Ethics Committee of the Erasmus MC. Written 
informed consent was obtained from all participants.
Subsequent to the index CAG/PCI, RF-IVUS was performed in a non-culprit coronary 
segment with the Volcano Corporation Eagle-Eye catheter, and NIRS with the InfraReDx 
system, at a pullback speed of 0.5 mm/sec. Initially, the NIRS system was non-CE marked 
and several patients refused to provide consent for its use. Intracoronary imaging was 
repeated at the end of the scheduled rosuvastatin treatment period. RF-IVUS and NIRS 
images were analyzed offline by an independent core laboratory (Cardialysis, Rotterdam, 
The Netherlands).
The primary endpoint was the change in NC volume. Secondary endpoints included 
the change in NC percentage, and the change in NIRS-derived lipid core burden index 
(LCBI) for the entire region of interest (ROI), and the 10- and 4 mm segments with the 
highest LCBI, the LCBImax10mm and LCBImax4mm, respectively.
We aimed to enroll 300 patients. Assuming an attrition rate of 15%, the sample size was 
determined at 350 patients.(5) The actual attrition rate appeared to be approximately 
30% (Figure 1). We therefore decided to terminate patient enrollment in June 2013.
The study design paper specified that treatment effects be tested with paired Stu-
dent’s t-tests.(5) However, because study endpoints had non-normal distributions, 
we decided to perform non-parametric statistics instead. Furthermore, we decided to 
square our data analysis methods with IBIS-4 study, including the use of linear mixed 
models and regression.(6) We report changes in serum cholesterol levels and study end-
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points as follow-up minus baseline values, and negative values indicate a decrease over 
time. All statistical tests were two-sided, and a P-value <0.05 was considered statistically 
significant.
ResulTs
Serial RF-IVUS was available in 164 patients, including 103 with serial NIRS (Figure 1). 
Table 1 shows baseline characteristics. Rosuvastatin was taken during a median of 372 
(interquartile range: 357 to 395) days, with 90.9% of the patients being titrated to the 
maximum dose. At the time of the recatheterization, 92% of patients were on rosuva-
statin 20-40 mg (online Table 1).
Mean LDL-C decreased by 30%, from 2.49 to 1.73 mmol/l, and HDL-C increased by 
11%, from 1.11 to 1.23 mmol/l (Table 2; online Figure 1).
NC volume changed with −1.4 mm³ (95% confidence interval [CI]: −3.0 to 0.1; Table 
2; Figure 2). NC percentage of total plaque volume changed with −1.4% (95% CI:−2.4 
to −0.4). The latter finding should be interpreted in conjunction with a modest, but 
significant rise in percent atheroma volume (PAV). The change in serum LDL-C levels was 
not associated with the change in coronary plaque characteristics (online Table 2; online 
Figure 2). Regression of NC volume was observed in patients within the highest baseline 
quartile (online Table 3; Figure 2).
Within the 103 patients with repeat NIRS, changes in LCBI were non-significant (Table 
2; Figure 3). LCBI regression might be pronounced in the highest baseline quartile 
(online Table 3; Figure 3). There was no correlation between LDL-C change and LCBI 
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EuroIntervention 2
0
16
;1
2
:73
4
-73
9
Effect of rosuvastatin on coronary plaque composition
Abbreviations
ACS acute coronary syndrome
CAG coronary angiography
IBIS Integrated Biomarker and Imaging Study
LCBI lipid core burden index
LDL-c low-density lipoprotein cholesterol
NC necrotic core
NIRS near-infrared spectroscopy
PCI percutaneous coronary intervention
RF-IVUS radiofrequency intravascular ultrasonography
SAP stable angina pectoris
Introduction
The presence of coronary plaque phenotypes with large necrotic 
core (NC) volumes is associated with a high incidence of major 
adverse cardiac events1-3. In the second Integrated Biomarker and 
Imaging Study (IBIS-2), the lipoprotein-associated phospholipase 
A2 (Lp-PLA2) inhibitor darapladib – added to statins – halted 
coronary NC volume progression4. We now report IBIS-3, which 
evaluated high-dose rosuvastatin to reduce coronary NC volume, 
assessed by radiofrequency intravascular ultrasound (RF-IVUS), 
and intracoronary cholesterol accumulation, assessed by near-
infrared spectroscopy (NIRS)5.
Methods
The IBIS-3 study details have been published elsewhere5. Briefly, 
patients undergoing coronary angiography (CAG) or percutane-
ous coronary intervention (PCI) were treated with a high dose 
(40 mg daily) of rosuvastatin for 12 months. Near the completion 
of the study, the protocol was amended to enable a treatment dura-
tion of six months. IBIS-3 was approved by the Medical Ethics 
Committee of the Erasmus MC. Written informed consent was 
obtained from all participants.
Subsequent to the index CAG/PCI, RF-IVUS was performed 
in a non-culprit coronary segment with the Eagle Eye® cath-
eter (Volcano Corp., San Diego, CA, USA) and NIRS with the 
Infraredx system (Infraredx, Burlington, MA, USA), at a pullback 
speed of 0.5 mm/sec. Initially, the NIRS system was non-CE-
marked and several patients refused to provide consent for its use. 
Intracoronary imaging was repeated at the end of the scheduled 
rosuvastatin treatment period. RF-IVUS and NIRS images were 
analysed offline by an independent core laboratory (Cardialysis, 
Rotterdam, The Netherlands).
The primary endpoint was the change in NC volume. 
Secondary endpoints included the change in NC percentage, and 
the change in NIRS-derived lipid core burden index (LCBI) for 
the entire region of interest (ROI), and the 10 mm and 4 mm seg-
ments with the highest LCBI, the LCBImax10 mm and LCBImax4 mm, 
respectively.
We aimed to enrol 300 patients. Assuming an attrition rate of 
15%, the sample size was determined at 350 patients5. The actual 
attrition rate appeared to be approximately 30% (Figure 1). We 
therefore decided to terminate patient enrolment in June 2013.
eligible patients who started rosuvastatin treatment
premature termination of rosuvastatin treatment
withdraw consent for repeat catheterisation
follow-up IVUS
non-matching baseline/follow-up segments
IBIS-3 core: matching baseline and follow-up IVUS
matching baseline and follow-up NIRS
NIRS not available
241
175
164
103
61
11
37
29
Figure 1. Study flow chart describing inclusion, attrition and the 
final IBIS-3 core of 164 patients with matching baseline and 
follow-up RF-IVUS. IVUS: radiofrequency intravascular ultrasound; 
NIRS: near-infrared spectroscopy.
STATISTICAL ANALYSIS
The study design paper specified that treatment effects would be 
tested with paired Student’s t-tests5. However, because the study 
endpoints had non-normal distributions, we decided to perform 
non-parametric statistics instead. Furthermore, we decided to 
square our data analysis methods with the IBIS-4 study, includ-
ing the use of linear mixed models and regression6. We report 
changes in serum cholesterol levels and study endpoints as follow-
up minus baseline values, and negative values indicate a decrease 
over time. All statistical tests were two-sided, and a p-value <0.05 
was consider d statistically significant.
Results
Serial RF-IVUS was available in 164 patients, including 103 
with serial NIRS (Figure 1). Table 1 shows baseline characteris-
tics. Rosuvastatin was taken during a median of 372 (interquartile 
range: 357 to 395) days, with 90.9% of the patients being titrated 
to the maximum dose. At the time of the recatheterisation, 92% of 
patients were on rosuvastatin 20-40 mg (Online Table 1).
Mean LDL-c decreased by 30%, from 2.49 to 1.73 mmol/l, and 
HDL-c increased by 11%, from 1.11 to 1.23 mmol/l (Table 2, 
Online Figure 1).
A change of –1.4 mm3 (95% confidence interval [CI]: –3.0 to 
0.1) n NC volum  was observed (T ble 2, Figure 2). The change 
in NC percentage of total plaque volume was –1.4% (95% CI: 
–2.4 to –0.4). The latter finding should be interpreted in conjunc-
tion with a modest, but significant rise in percent atheroma volume 
(PAV). The change in serum LDL-c levels did not correlate with the 
change in coronary plaque characteristics (Online Table 2, Online 
Figure 2). Regression of NC volume was observed in patients 
within the highest baseline quartile (Online Table 3, Figure 2).
Within the 103 patients with repeat NIRS, changes in LCBI 
were non-significant (Table 2, Figure 3). LCBI regression might 
figure 1. study flowchart describing inclusion, attrition and the final IbIs-3 core of 164 patients 
with matching baseline and follow-up Rf-IVus. IVus: radiofrequency intravascular ultrasound.
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Table 1. baseline characteristics.
IBIS-3 core: patients with 
completed treatment phase 
and matching baseline and 
follow-up RF-IVUS
(N=164)
Patients without 
matching follow-up 
RF-IVUS*
(N=77)
p-value
Age, years 60.4 (55.3, 65.9) 57.5 (51.6, 66.0) 0.22
Male 84.1 79.2 0.35
Diabetes mellitus 20.7 20.8 0.99
Hypertension 64.2 54.6 0.15
Hypercholesterolaemia 63.6 61.8 0.80
LDL-c, mmol/l 2.41 (1.89, 3.00) 2.69 (1.99, 3.50) 0.030
HDL-c, mmol/l 1.09 (0.91, 1.30) 1.01 (0.91, 1.30) 0.43
Total cholesterol, mmol/l 3.99 (3.29, 4.61) 4.48 (3.60, 5.21) 0.024
Statin use¶ 95.1 92.2 0.37
Current smoker 28.0 37.7 0.13
Positive family history 54.6 64.5 0.15
Previous MI 29.9 33.8 0.54
Previous PCI 36.0 40.3 0.52
Previous CABG 0.6 0 1.0
Previous stroke 9.1 13.0 0.36
Peripheral artery disease 4.3 13.0 0.014
History of renal insufficiency 3.7 6.5 0.33
History of heart failure 1.2 1.3 0.96
Indication for coronary angiography 0.009
STEMI 14.7 31.6
NSTE ACS 26.8 22.4
Stable angina 58.5 46.1
Extent of coronary artery disease 0.97
No significant stenosis 3.7 3.9
1-vessel disease 51.2 49.4
2-vessel disease 39.0 39.0
3-vessel disease 6.1 7.8
PCI performed 89.0 87.0 0.65
Continuous data are presented as median (25th, 75th percentile) values. Categorical data are presented 
as percentages. *39 patients with premature termination of rosuvastatin treatment, 27 with withdrawal 
of consent for repeat catheterisation. An additional seven patients did complete the treatment phase and 
underwent repeat catheterisation, but had non-matching baseline/follow-up segments. ¶ 12 (63%) of the 19 
statin naïve patients had no history of vascular disease, as compared to 51% of statin users. CABG: coronary 
artery bypass grafting; HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol; 
MI: myocardial infarction; NSTE ACS: non-ST-elevation acute coronary syndromes; PCI: percutaneous coronary 
intervention; RF-IVUS: radiofrequency intravascular ultrasound; STEMI: ST-elevation myocardial infarction
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change (online Table 2; online Figure 2). LCBI change was similar in statin-naïve patients 
and previous statin users.
All effects were similar in patients with repeat imaging at 6 and 12 months (online 
Tables 4-6).
DIsCussIOn
High-intensity rosuvastatin therapy resulted in a neutral effect on NC and LCBI within 
non-stenotic coronary segments with a relatively low baseline atheroma burden. IBIS-
2 showed a stabilization of NC volume by darapladib, with 91% of patients on statin 
therapy.(4) IBIS-3 suggests that NC stabilization might be possible with a potent statin 
alone.
Our findings concur with a meta-analysis of 17 studies involving 2171 patients on at 
least six different statins, which showed that longer-duration and higher-intensity statin 
therapy may result in plaque volume regression, but not in a significant NC reduction.
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Effect of rosuvastatin on coronary plaque composition
Table 2. Baseline and follow-up serum cholesterol and intracoronary imaging endpoints.
Baseline Follow-up Change
mean (SD) median (IQR) mean (SD) median (IQR) mean (95% CI) p-value*
LDL-c, mmol/l 2.49 (0.85) 2.36 (1.92, 2.99) 1.73 (0.71) 1.60 (1.26, 2.01) –0.76 (–0.91, –0.61) <0.001
HDL-c mmol/l 1.11 (0.31) 1.07 (0.90, 1.29) 1.23 (0.37) 1.18 (0.97, 1.46) 0.12 (0.08, 0.16) <0.001
Total cholesterol, mmol/l 4.11 (0.93) 4.0 (3.3, 4.6) 3.34 (0.87) 3.3 (2.7, 3.8) –0.77 (–0.93, –0.61) <0.001
External elastic membrane 
volume, mm3 579.6 (278.0) 520.8 (376.6, 724.9) 577.0 (273.4) 518.3 (378.1, 715.6) –2.7 (–9.4, 4.0) 0.42
Lumen volume, mm3 335.4 (149.7) 314.8 (227.6, 409.1) 329.2 (145.8) 309.4 (225.5, 403.4) –6.6 (–12.0, –1.2) 0.015
Atheroma volume, mm3 243.9 (151.3) 204.0 (142.7, 304.8) 247.8 (148.6) 210.9 (145.4, 301.8) 3.9 (–0.2, 8.0) 0.064
Percent atheroma volume, % 40.7 (10.2) 41.5 (32.9, 48.8) 41.6 (9.7) 41.5 (33.8, 49.8) 1.0 (0.4, 1.5) 0.001
NC volume, mm3 29.1 (31.9) 17.8 (7.3, 38.0) 27.7 (31.2) 19.2 (6.2, 35.1) –1.4 (–3.0, 0.1) 0.074
DC volume, mm3 13.0 (15.9) 7.9 (2.3, 17.4) 13.4 (16.9) 8.2 (2.2, 17.2) 0.4 (–0.4, 1.2) 0.31
FI volume, mm3 71.1 (63.9) 51.3 (31.1, 93.4) 70.8 (61.8) 52.8 (30.6, 94.6) –0.3 (–2.7, 2.2) 0.83
FF volume, mm3 13.7 (14.6) 9.0 (3.9, 18.8) 15.7 (15.3) 10.9 (5.4, 22.1) 2.0 (0.6, 3.4) 0.005
NC percentage, % 20.2 (8.2) 20.0 (15.2, 25.0) 18.9 (7.3) 19.5 (14.6, 24.0) –1.4 (–2.4, –0.4) 0.006
DC percentage, % 9.0 (5.6) 8.4 (4.6, 12.7) 9.1 (5.9) 8.4 (4.4, 13.1) 0.0 (–0.6, 0.7) 0.85
FI percentage, % 60.0 (11.0) 60.5 (52.6, 66.8) 58.7 (11.0) 60.7 (50.6, 66.2) –1.2 (–2.6, 0.2) 0.076
FF percentage, % 10.7 (5.2) 9.9 (7.5, 13.7) 13.2 (9.9) 11.8 (8.5, 15.6) 2.6 (1.1, 4.1) 0.001
LCBI, full region of interest 44.9 (51.1) 33.0 (6.0, 67.0) 46.1 (43.2) 35.0 (8.0, 72.0) 1.2 (–8.5, 11.0) 0.80
LCBImax10mm 127.8 (121.7) 107.0 (25.0, 197.0) 130.5 (114.0) 109.0 (30.0, 194.0) 2.7 (–16.9, 22.2) 0.79
LCBImax4mm 201.9 (163.8) 182.5 (60.0, 319.0) 206.8 (154.5) 192.0 (72.0, 323.0) 4.9 (–21.7, 31.4) 0.72
*based on linear mixed models (patient as random intercept) to test if change is different from 0. CI: confidence interval; DC: dense calcium 
tissue; FF: fibro-fatty tissue; FI: fibrous tissue; HDL-c: high-density lipoprotein cholesterol; IQR: interquartile range; LCBI: lipid core burden 
index; LDL-c: low-density lipoprotein cholesterol; NC: necrotic core tissue; SD: standard deviation
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Figure 2. Necrotic core volume and percentage at baseline and follow-up. High-intensity rosuvastatin therapy led to a neutral effect on NC 
volume (A) and a significant decrease in NC percentage (B). The highest reductions were observed in those patients with relatively high 
necrotic core burden at baseline. Panel C depicts the change of NC volume under high-intensity rosuvastatin therapy against the baseline NC 
volume. Panel D illustrates the same for NC percentage. NC: necrotic core
figure 2. necrotic core volume and percentage at baseline and f llow-up.
High-intensity rosuv tatin therapy led to a n utral eff ct on NC volum  (A) and a significant decrease in 
NC percentage (B). The highest reductions were observed in those patients with a relatively high necrotic 
core burden at baseline. Panel C depicts the change of NC under high-intensity rosuvstatine therapy 
against the baseline NC volume. Panel D illustrates the same for NC percentage.
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(7) Lack of change in NC burden after high-intensity statin therapy was also observed in 
SATURN (8) and in IBIS-4, which studied STEMI patients.(6)
The YELLOW trial demonstrated a significant LCBI reduction in 44 patients after 6-8 
weeks of high-intensity rosuvastatin therapy.(9) In the comparator group of 43 patients, 
who were kept on their ‘regular’ statin, LCBI remained unchanged. However, YELLOW 
evaluated the effect of rosuvastatin on untreated obstructive coronary lesions with a 
fractional flow reserve < 0.8. In contrast, we studied non-flow-limiting coronary seg-
ments with a low median LCBI of 33 (versus 95-132 in YELLOW). As a consequence, high-
intensity statin therapy in IBIS-3 only had a limited substrate with respect to regression 
of LCBI. Still, our observation of a significant LCBI reduction in patients with high baseline 
values might be relevant, since they are at increased risk of adverse cardiac events.(10)
The fact that changes in NC and LCBI were not correlated to changes in serum LDL-C 
levels may support the abundance of data on the pleiotropic effects of statins that are 
not directly related to serum lipid levels.(11) We only studied the effect of rosuvastatin 
on plaque composition in relation to its effect on LDL-C. However, recent studies sug-
gest that LDL-C will not be atherogenic until it becomes oxidized in the arterial wall.(11)
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of IBIS-3 was still high enough (90%) to declare the anticipated 
2.5 mm3 NC reduction statistically significant, but too small (50%) 
with regard to the observed effect.
Conclusion
The IBIS-3 study, a prospective, mechanistic, single-arm, open-
label study designed to evaluate the treatment effect of high-inten-
sity rosuvastatin therapy, demonstrated a neutral effect on NC 
volum  in a non-culprit coronary artery segment without signifi-
cant luminal narrowing. Indications of regression of NC percent-
age and NC volume and LCBI in the highest baseline quartiles 
should only be cautiously regarded as hypothesis-generating.
Impact on daily practice
IBIS-3 was designed to elucidate the already proven effective-
ness of rosuvastatin therapy on cholesterol and clinical event 
reduction from a mechanistic approach by evaluating its effects 
on relevant coronary plaque components. As such it indicates 
that a high-intensity statin alone could halt necrotic (or lipid) 
core progression. Future studies might focus on the question 
whether regression is possible in lesions with a h gher baseline 
atheroma burden.
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Figure 3. LCBI at baseline and follow-up. The effect of high-intensity rosuvastatin therapy on LCBI of the full region of interest (A) and the 
LCBImax4mm (B). Panels C and D indicate that the degree of LCBI regression might be dependent on the baseline LCBI. LCBI: lipid core burden 
index; LCBImax4mm: the 4 mm segment with the highest LCBI
figure 3. lCbI at baseline and follow-up.
The effect of high-intensity rosuvastatin therapy on LCBI of the full region of interest (A) and the LCBImax4mm 
(B). Panels C and D indicate that the degree of LCBI regression might be dependent on the baseline LCBI. 
LCBI: lipid core burden index; LCBImax4mm: the 4 mm segment with the highest LCBI.
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IBIS-3 was an uncontrolled, observational study, similar to IBIS-4 and ASTEROID.(6,12) 
A disadvantage of such approach is that true treatment effects cannot be distinguished 
from ‘regression to the mean’. In our study, the most pronounced regression of plaque 
components occurred within the highest baseline quartiles, which might be an expected 
and logical consequence of a real treatment effect. On the other hand, the simultaneous 
increase in most plaque parameters that was observed in the lowest baseline quartiles 
is suggestive for at least a component of regression to the mean.
IBIS-3 was designed to be embedded in our routine clinical practice, which we consider 
important for external validity. Consequently, however, the IBIS-3 patients were some-
what older and had more comorbidities than observed in similar studies with repeat 
imaging,(12,13) which may explain their higher than expected drop-out rate. We en-
rolled 164 of 300 planned patients with repeat IVUS. The observed 1.4 mm³ NC reduction 
was smaller than anticipated, but the standard deviation was also smaller (10.0 versus 
13.9 mm³). Consequently, the power of IBIS-3 was still high enough (90%) to declare 
the anticipated 2.5 mm³ NC reduction statistically significant, but too small (50%) with 
regard to the observed effect.
Conclusion
The IBIS-3 study, a prospective, mechanistic, single-arm, open-label study designed to 
evaluate the treatment effect of high-intensity rosuvastatin therapy, demonstrated a 
neutral effect on NC volume in a non-culprit coronary artery segment without signifi-
cant luminal narrowing. Indications of regression of NC percentage and NC volume and 
LCBI in the highest baseline quartiles should only be cautiously regarded as hypothesis 
generating.
funDInG
IBIS-3 was sponsored by AstraZeneca (Wilmington, Delaware, USA), by InfraredX (Bur-
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suPPleMenTal DaTa
Online Table 1. Rosuvastatin treatment.
Days to start treatment 23 (18, 31)
Starting dose, mg 5 0.6
10 84.2
20 14.6
40 0.6
Maximum dose, mg 20 9.1
40 90.9
Days to maximum dose 52 (45, 62)
Total duration of rosuvastatin use, days 372 (357, 395)
Dose at day of repeat catheterisation, mg rosuvastatin discontinuation 4.9
5 0.6
10 2.4
20 24.4
40 67.7
Continuous data are presented as median (25th, 75th percentile) values. Categorical data are presented 
as percentages.
Online Table 2. study endpoints by quartiles of lDl cholesterol change.
Study endpoint ∆ LDL-c<−1.33 −1.33≤∆ LDL-c
<−0.68
−0.68≤∆ LDL-c
<−0.24
−0.24≤∆ LDL-c p-value
for
trend*
Atheroma volume, 
mm³
7.51 (−1.82, 16.8) 1.50 (−6.58, 9.58) −1.77 (−9.92, 6.39) 10.5 (1.98, 19.0) 0.15
Percent atheroma 
volume, %
1.40 (0.20, 2.60) 0.51 (−0.59, 1.61) 1.07 (−0.04, 2.17) 1.23 (0.04, 2.43) 0.38
NC volume, mm³ −0.04 (−2.21, 2.14) −1.58 (−4.02, 0.87) −1.77 (−4.11, 0.58) −1.50 (−6.59, 3.59) 0.71
NC percentage, % 0.53 (−1.45, 2.50) −0.94 (−2.02, 0.15) −1.89 (−3.34, −0.44) −2.83 (−5.75, 0.08) 0.018
LCBI, full region of 
interest
−13.5 (−27.0, −0.06) 15.4 (−1.10, 31.9) 7.29 (−10.7, 25.3) −4.0 (−33.7, 25.6) 0.24
LCBImax4mm −28.2 (−71.2, 14.7) 46.3 (0.58, 91.9) 9.29 (−52.5, 71.1) 0.04 (−63.7, 63.8) 0.33
*based on a linear trend test across the four quartiles of ∆ LDL-c in a linear regression model, with adjust-
ment for age, sex, diabetes, smoking, previous use of statins, and time to recatheterisation. LCBI: lipid core 
burden index; LCBImax4mm: 4 mm segment with the highest LCBI; ∆ LDL-c: change in low-density lipopro-
tein cholesterol (follow-up – baseline); the 25th, 50th and 75th percentile of the ∆ LDL-c distribution were 
−51, −26 and −9 mg/dl, respectively; NC: necrotic core
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Online Table 3. study endpoints by quartiles of baseline values.
Study endpoint 25th, 50th, 75th 
percentiles of 
baseline values
Mean change (95% CI) p-value 
for 
trend¶
Baseline Q1 Baseline Q2 Baseline Q3 Baseline Q4
LDL-c, mmol/l 1.92, 2.36, 2.99 −0.24 (−0.43, 
−0.06)
−0.37 (−0.60, 
−0.14)
−0.62 (−0.87, 
−0.37)
−1.82 (−2.06, 
−1.57)
<0.001
Atheroma volume, 
mm³
143, 204, 305 11.0 (5.83, 
16.3)
4.00 (−3.79, 
11.8)
2.01 (−3.75, 
7.77)
−1.57 (−14.5, 
11.4)
0.19
Percent atheroma 
volume*, %
32.9, 41.5, 48.8 2.35 (1.28, 
3.42)
1.69 (0.58, 
2.79)
0.19 (−0.84, 
1.23)
−0.44 (−1.58, 
0.70)
0.001
NC volume, mm³ 7.3, 17.8, 38.0 0.54 (−0.35, 
1.42)
−0.15 (−1.97, 
1.66)
1.44 (−1.15, 
4.03)
−7.45 (−12.4, 
−2.46)
<0.001
NC percentage, % 15.2, 20.0, 25.0 1.67 (−0.32, 
3.67)
−0.08 (−1.48, 
1.32)
−2.38 (−4.20, 
−0.57)
−4.61 (−6.69, 
−2.51)
<0.001
LCBI, full region of 
interest
6, 33, 67 19.3 (7.7, 
30.9)
16.3 (4.4, 
28.2)
1.81 (−12.6, 
16.2)
−31.7 (−61.7, 
−1.7)
0.001
LCBImax4mm 60, 183, 319 83.6 (40.6, 
126.6)
46.6 (0.2, 
93.0)
−26.1 (−76.0, 
23.7)
−82.7 
(−138.7, 
−26.7)
<0.001
¶ based on a linear trend test across the four quartiles in a linear regression model, with adjustment for 
age, sex, diabetes, smoking, previous use of statins, and time to recatheterisation. * None of the inter-
rogated segments represented a percent atheroma volume ≥70%. CI: confidence interval; LCBI: lipid core 
burden index; LCBImax4mm: 4 mm segment with the highest LCBI; LDL-c: low-density lipoprotein cholesterol; 
NC: necrotic core
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Online Table 4. serial cholesterol measurements.
Baseline Follow-up Change
mean (SD) median 
(IQR)
mean (SD) median (IQR) mean (95% CI) p-value¶ p-value‡
Patients with follow-up IVus at 6 months (n=30)
LDL-c, mmol/l 2.34 (0.75) 2.28 (1.92, 
2.92)
1.67 (0.56) 1.70 (1.31, 
1.88)
−0.76 (−1.00, 
−0.52)
<0.001 0.98
HDL-c, mmol/l 1.11 (0.31) 1.09 (0.86, 
1.31)
1.21 (0.39) 1.13 (0.92, 
1.58)
0.10 (0.04, 0.16) 0.004 0.52
Total cholesterol, 
mmol/l
3.89 (0.89) 3.7 (3.2, 
4.5)
3.21 (0.73) 3.3 (2.8, 3.6) −0.67 (−0.94, 
−0.40)
<0.001 0.47
Patients with follow-up IVus at 12 months (n=134) *
LDL-c, mmol/l 2.51 (0.87) 2.37 (1.91, 
3.00)
1.74 (0.74) 1.59 (1.22, 
2.02)
−0.77 (−0.94, 
−0.60)
<0.001
HDL-c, mmol/l 1.11 (0.31) 1.07 (0.91, 
1.28)
1.24 (0.37) 1.19 (0.98, 
1.44)
0.13 (0.08, 0.18) <0.001
Total cholesterol, 
mmol/l
4.16 (0.93) 4.0 (3.5, 
4.6)
3.36 (0.89) 3.2 (2.7, 3.8) −0.80 (−0.99, 
0.61)
<0.001
all patients (n=164) *
LDL-c, mmol/l 2.49 (0.85) 2.36 (1.92, 
2.99)
1.73 (0.71) 1.60 (1.26, 
2.01)
−0.76 (−0.91, 
−0.61)
<0.001
HDL-c, mmol/l 1.11 (0.31) 1.07 (0.90, 
1.29)
1.23 (0.37) 1.18 (0.97, 
1.46)
0.12 (0.08, 0.16) <0.001
Total cholesterol, 
mmol/l
4.11 (0.93) 4.0 (3.3, 
4.6)
3.34 (0.87) 3.3 (2.7, 3.8) −0.77 (−0.93, 
−0.61)
<0.001
* Six patients had missing baseline and/or follow-up measurements. ¶ based on linear mixed models (patient 
as random intercept) to test if change is different from 0. ‡based on two-sample Student’s t-tests (equal 
variances not assumed) for the difference in change between patients with 6 versus 12 months of follow-up. 
CI: confidence interval; HDL-c: high-density lipoprotein cholesterol; IQR: interquartile range; LDL-c: low-density 
lipoprotein cholesterol; SD: standard deviation
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Online Table 6. Serial near-infrared spectroscopy measurements.
Baseline Follow-up Change
mean (SD) median (IQR) mean (SD) median (IQR) mean (95% CI) p-value¶ p-value‡
Patients with follow-up NIRS at 6 months (n=26)
LCBI, full region of interest 48.6 (42.5) 40.0 (10.0, 67.0) 45.0 (39.8) 40.0 (7.0, 72.0) –3.6 (–22.2, 15.1) 0.70 0.55
LCBI, worst 10 mm 141.9 (123.0) 147.0 (29.0, 201.0) 131.2 (111.2) 128.5 (29.0, 188.0) –10.7 (–54.9, 33.4) 0.62 0.46
LCBI, worst 4 mm 220.2 (157.4) 242.5 (69.0, 310.0) 206.5 (157.7) 201.0 (60.0, 305.0) –13.7 (–68.3, 40.9) 0.61 0.42
Patients with follow-up NIRS at 12 months (n=77)
LCBI, full region of interest 43.6 (53.9) 28.0 (5.0, 63.0) 46.5 (44.6) 35.0 (9.0, 66.0) 2.8 (–8.8, 14.5) 0.63
LCBI, worst 10 mm* 123.0 (121.7) 98.0 (21.5, 189.0) 130.2 (115.7) 104.5 (36.5, 196.0) 7.2 (–14.8, 29.3) 0.52
LCBI, worst 4 mm* 195.6 (166.5) 174.5 (52.5, 324.0) 206.9 (154.5) 190.0 (77.0, 324.0) 11.2 (–19.7, 42.2) 0.47
All patients (N=103)
LCBI, full region of interest 44.9 (51.1) 33.0 (6.0, 67.0) 46.1 (43.2) 35.0 (8.0, 72.0) 1.2 (–8.5, 11.0) 0.80
LCBI, worst 10 mm* 127.8 (121.7) 107.0 (25.0, 197.0) 130.5 (114.0) 109.0 (30.0, 194.0) 2.7 (–16.9, 22.2) 0.79
LCBI, worst 4 mm* 201.9 (163.8) 182.5 (60.0, 319.0) 206.8 (154.5) 192.0 (72.0, 323.0) 4.9 (–21.7, 31.4) 0.72
*One patient had missing follow-up measurements. ¶based on linear mixed models (patient as random intercept) to test if change is different from 0. ‡ based on two-sample Student’s t-tests 
(equal variances not assumed) for the difference in change between patients with 6 versus 12 months of follow-up. CI: confidence interval; IQR: interquartile range; LCBI: lipid core burden 
index; SD: standard deviation
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Online Figure 1. Serum cholesterol levels at baseline and follow-up. High-intensity rosuvastatin therapy during a median follow-up of 
372 days resulted in a significant decrease in serum LDL-c (A) and increase in HDL-c levels (C), despite the fact that 95% of the patients were 
already on standard-of-care statin therapy at baseline. The degree of reduction in LDL-c was related to the baseline LDL-c level (B). Such 
a correlation was not observed with respect to HDL-c (D). HDL-c: high-density lipoprotein cholesterol; LDL-c: low-density lipoprotein 
cholesterol
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already on standard-of-care statin therapy at baseline. The degree of reduction in LDL-c was related to 
the baseline LDL-c level (B). Such a correlation was not observed with respect to HDL-c (D). HDL-c: high-
density lipoprotein cholesterol; LDL-c: low-density lipoprotein cholesterol
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Online Figure 2. Change in LDL-c in relation to change in necrotic core and LCBI. Changes in NC and LCBI were independent of changes in 
LDL levels under rosuvastatin therapy. A) NC volume; B) NC percentage;  C) Full region of interest; D) LCBImax4mm. LCBI: lipid core burden 
index; LCBImax4mm: the 4 mm segment with the highest LCBI; LDL-c: low-density lipoprotein cholesterol; NC: necrotic core
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Changes in NC and LCBI were independent of changes in LDL levels under rosuvastatin therapy. A) NC 
volume; B) NC percentage; C) Full region of interest; D) LCBImax4mm. LCBI: lipid core burden index; LCBImax4mm: 
the 4 mm segment with the highest LCBI; LDL-c: low-density lipoprotein cholesterol; NC: necrotic core
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absTRaCT
background: Angiotensin-converting-enzyme inhibition reduces the risk of cardio-
vascular events at a group level. Presumably, the absolute effect of treatment varies 
between individuals. We sought to develop multivariable prediction scores to estimate 
individual treatment effect of perindopril in patients with stable coronary artery disease 
(sCAD).
Methods: In EUROPA trial participants, we estimated the individual patient 5-year 
absolute risk reduction (ARR) of major adverse cardiovascular events (MACE) by perin-
dopril. Predictions were based on a new Cox proportional-hazards model with clinical 
characteristics and an external risk score in combination with the observed relative risk 
reduction. Second, a genetic profile modifying the relative efficacy of perindopril was 
added. The individual patient ARR was defined as the difference in MACE risk with and 
without treatment. The group level impact of selectively treating patients with the larg-
est predicted treatment effect was evaluated using net benefit analysis.
Results: The risk score combining clinical and genetic characteristics estimated the 
5-year absolute treatment effect to be absent or adverse in 27% of patients. On the other 
hand, the risk score estimated a small 5-year ARR of ≤2% (NNT5 ≥ 50) in 20% of patients, 
a modest ARR of 2–4% (NNT5 25–50) in 26%, and a large ARR of ≥4% (NNT5 ≤ 25) in 28%. 
The external risk score yielded similar predictions. Selective prediction-based treatment 
resulted in higher net benefit compared to treat everyone at any treatment threshold.
Conclusion: A prediction score combining clinical characteristics and genetic informa-
tion can quantify the ARR of MACE by perindopril for individual patients with sCAD and 
may be used to guide treatment decisions.
Trial registration number: ISRCTN37166280
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1. InTRODuCTIOn
Activation of the renin–angiotensin system (RAS) has an important role in the de-
velopment of cardiovascular disease [1]. The beneficial effects of blocking RAS by 
angiotensin-converting-enzyme inhibitors (ACE-i) were first demonstrated in patients 
with heart failure [2,3]. Further studies showed the efficacy of ACE-i in a wider range 
of clinical conditions and these agents are currently recommended for the treatment 
of patients with hypertension, recent myocardial infarction and stable coronary artery 
disease (sCAD) [4]. One of the landmark trials in patients with sCAD is the EUROPA trial, 
evaluating the effect of perindopril on the occurrence of new major adverse cardiovas-
cular events (MACE) in sCAD patients without heart failure. The trial found an average 
relative reduction in MACE of 20% [5]. The average 4-year absolute treatment effect of 
perindopril was 2%, translating to an average 4-year number-needed-to-treat (NNT4) of 
50 patients to prevent one event [5]. In search of patients who are most likely to benefit, 
stratified analyses based on clinical characteristics and levels of baseline risk revealed 
similar relative risk reductions across all subgroups [6,7]. However, genetic variations in 
pharmacodynamic pathways affected by ACE-i were shown to influence the efficacy of 
perindopril [8]. Three polymorphisms located in the angiotensin-II type 1 receptor and 
bradykinin type 1 receptor genes were associated with a larger, smaller or even adverse 
effect of perindopril. To quantify the effect of treatment for individual patients, relative 
risk reductions need to be interpreted in combination with absolute event risks [9–12]. 
In general, patients with higher baseline risk tend to benefit more from treatment in 
terms of absolute risk reduction [13,14]. Baseline risk is determined by the combined 
action of multiple risk factors such as age, cholesterol and blood pressure [15]. In the 
present study we sought to develop prediction scores based on a combination of mul-
tiple patient-specific clinical and genetic characteristics to estimate the absolute risk 
reduction of MACE with perindopril for individual patients with sCAD. In clinical practice, 
these scores can be used to quantify treatment benefit at an individual patient level and 
to guide treatment decisions.
2. MeTHODs
The design, rationale and outcomes of the EUROPA trial and the PERindopril GENetic as-
sociation study (PERGENE) substudy have been described elsewhere [16,17]. Briefly, the 
EUROPA trial was a randomized, double blind study evaluating the effect of perindopril 
8mg once daily versus placebo on major cardiovascular adverse events (MACE) compris-
ing cardiovascular death, myocardial infarction (MI), and resuscitated cardiac arrest in 
12,218 patients with sCAD. Eligible patients were men and women of 18 years or older, 
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with evidence of coronary heart disease documented by previous MI (>3 months before 
screening), percutaneous or surgical coronary revascularization (>6 months before 
screening), angiographic evidence of at least 70% narrowing of at least one major coro-
nary artery, or a history of typical chest pain in male patients with an abnormal stress 
test. Exclusion criteria included clinically evident heart failure, planned revascularization 
procedure, hypotension (sitting systolic blood pressure <110 mm Hg), uncontrolled 
hypertension (systolic blood pressure >180 mm Hg and/or diastolic blood pressure 
>100 mm Hg), use of ACE-i or angiotension-2 receptor blockers in the last month, 
renal insufficiency (serum creatinine >150 μmol/L), and serum potassium >5.5mmol/L. 
PERGENE is a substudy of the EUROPA trial designed to investigate whether common 
genetic variation is related to risk of future events and modifies the treatment effect 
of perindopril [8]. Blood samples were received from 10060 patients and 8726 patients 
had complete genotype data on rs275651, rs5182 and rs12050217, the three single 
nucleotide polymorphisms (SNPs) identified to modify the effect of perindopril [8, 18]. 
A genetic profile was constructed by counting the number of unfavorable alleles and 
grouping them into 3 categories: ≤1 unfavorable allele (reference), 2 unfavorable alleles 
and ≥3 unfavorable alleles. Approval for the trial was obtained from the institutional 
ethics committee of each center and all participants provided written informed consent.
2.1. Model derivation
The individual patient absolute treatment effect on MACE was estimated with clinical 
models and with models combining clinical and genetic characteristics. First, we fitted 
a new Cox proportional hazards model (i.e. EUROPA score) based on a set of clinical 
characteristics together with a treatment variable (placebo vs. active treatment) [7]. The 
prespecified predictors were: sex, age, systolic blood pressure, cholesterol, body-mass 
index (BMI), diabetes, smoking, estimated glomerular filtration rate (eGFR; by CKD-
EPI equation [19]), symptomatic CAD, family history of CAD, prior stroke or transient 
ischemic attack, prior MI, prior coronary revascularization and prior peripheral arterial 
disease and treatment status. Restricted cubic splines were used to assess the linearity 
assumption for continuous predictors. If the association between a continuous predic-
tor and the outcome was not linear, the predictor was transformed to improve model fit 
[20,21]. As a result, age, BMI and eGFR were included both as linear and squared terms.
We used the Lasso method (i.e. penalized partial maximum likelihood with a restriction 
on the sum of the absolute coefficients of standardized predictors) to select the model 
and shrink the model coefficients to minimize over-optimism [22,23]. The interaction 
between treatment and baseline risk was evaluated but not significant [24]. The model 
was fitted for the prediction of 4.3-year (median follow-up) risks and extrapolated to 
yield 5-year estimates. The individual patient absolute risk reduction (ARR) was defined 
as the difference between estimated on-treatment and off-treatment risk.
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Second, we evaluated the combination of clinical and genetic characteristics to pre-
dict absolute treatment effect for individual patients. Hereto, we expanded the EUROPA 
model with a genetic profile (3-level categorical variable) and the interaction between 
perindopril treatment and this profile (i.e. EUROPA-GEN score). Again, the Lasso method 
was used to select the model and shrink the coefficients. The clinical model was fitted in 
the full EUROPA cohort, whereas the model with additional genetic variables was fitted 
in the PERGENE subsample. All models were evaluated in the PERGENE subsample to 
ensure comparability of results.
Supplementary analyses encompassed the use of an externally developed risk algo-
rithm, the SMART risk score, together with the relative treatment effect observed in the 
trial [25]. The baseline risk of the SMART risk score was recalibrated to the 5-year disease 
incidence of the target population. Data on HDL cholesterol, high sensitivity C-reactive 
protein and history of abdominal aortic aneurysm were not available and were set to 
zero. In addition, the genetic profile and the treatment interaction of perindopril with 
this profile were added to this model. The Lasso method was used to select and shrink 
the newly added variables.
Data was missing in 10.1% of participants for the variable ‘years since first vascular 
event’ and in <1% for all other variables. Missing data were reduced by single imputa-
tion methods using predictive mean matching [26].
2.2. Model performance
Discrimination of the risk scores was assessed by calculation of Harrell’s c-statistic [21]. 
Calibration of predicted risk was assessed by plotting observed 4.3-year event free sur-
vival against the average predicted 4.3-year event free survival within deciles and was 
formally checked by the Gronnesby and Borgan test [27,28]. Since the actual interest 
was the accuracy of predicted ARR rather than risk, we also assessed whether predicted 
ARR was in agreement with observed ARR by comparing observed survival within quin-
tiles of patients with similar estimated ARR from the placebo and intervention group. 
Optimally, the observed survival difference between these paired quintiles should be 
similar to the estimated ARR.
2.3. Distribution of absolute treatment effect and net benefit
The distributions of predicted individual 5-year ARR of MACE were displayed in histo-
grams. Next, we evaluated the incremental value of applying therapeutic prediction 
models in clinical practice using the net benefit method [29]. The calculation of net 
benefit is based on the weighing of positive and negative effects of treatment. The 
severity of treatment disadvantages is expressed relative to the outcome by a threshold 
NNT. For example, a 5-year threshold NNT of 50 implies that the disadvantages of treat-
ing 50 patients for 5 years are considered to be well balanced by the benefit obtained 
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by preventing one outcome. Net benefit is calculated as the observed ARR in patients 
for whom the treatment recommended by the prediction algorithm is congruent with 
randomized allocation minus the disadvantages of treatment. The latter is defined as 
the proportion of patients treated weighted by the inverse of the threshold NNT (net 
benefit = ARR − proportion of patients treated * [1/threshold NNT]). Net benefit can 
be interpreted as the excess number of events prevented per 100 patients on top of 
the minimally required number of events prevented to offset treatment disadvantages.
We considered the following treatment strategies; (i) treat no one, (ii) treat everyone 
or (iii) prediction-based treatment (i.e. selective treatment of patient whose predicted 
treatment effect exceeds the specified threshold NNT). Lastly,we showed the impact of 
using a prediction-based treatment strategy in clinical practice. Statistical analyses were 
conducted in R, version 2.15.2 (RDevelopment Core Team, Vienna, Austria) with Harrell’s 
Regression Modelling Strategies package and Goeman’s ‘penalized’ package.
3. ResulTs
Baseline characteristics of the PERGENE participants (n = 8726) are shown in Table 1 and 
are similar to those of the whole EUROPA population. During a median follow-up of 4.3 
years 794 major cardiovascular events occurred. The hazard ratio of the overall treat-
ment effect for MACE was 0.80 (95% CI 0.71–0.91) favoring treatment with perindopril.
3.1. Model derivation & performance
3.1.1. Clinical model
The EUROPA models are presented in Box 1. All predictors in the EUROPA model were 
retained. Detailed statistics are presented in Supplement Table 1. Discrimination was 
moderate with a c-statistic of 0.67 [95% CI 0.65–0.69]. The EUROPA model showed good 
risk calibration (p-value 0.34) (Supplement Fig. 1). The ARR calibration plot showed an 
acceptable agreement between predicted and observed ARR (Fig. 1). The externally 
developed SMART model is shown in Supplement Box 1.
3.1.2. Clinical model combined with genetic profile
During model selection all clinical, genetic and interaction variables were retained in 
the EUROPA-GEN score (Box 1). Detailed statistics are available in Supplement Table 1. 
Discrimination was moderate with a c-statistic of 0.68 [95% CI 0.66–0.70]. The EUROPA-
GEN models showed good visual calibration (although contradicted by a p-value of 0.01 
by the formal test statistics) (Supplement Fig. 1). Notably, the ARR calibration plot of the 
expanded model showed a wider range of predicted and observed treatment effects. 
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The agreement between predicted and observed absolute treatment effect was gener-
ally close (Fig. 1). The SMART-GEN model is shown in Supplement Box 1 and detailed 
model statistics are presented in Supplement Table 1.
3.2. Distribution of treatment effect of perindopril
The EUROPA score predicted a small 5-year ARR ≤2% (NNT5≥50) in 60.1% of patients. The 
predicted 5-year ARR was between 2 and 4% (NNT5 25–50) in 33.5% of patients and ≥4% 
Table 1. baseline characteristics of 8726 euROPa participants with available genetic profile and 
stratified according to predicted 5-year absolute risk reduction (aRR) by the euROPaGen score.
Total population
(n = 8726)
<2% ARR
(n =4077)
≥2% ARR
(n= 4649)
Clinical characteristics
Age (years) 59.8 (9.3) 58.8 (8.9) 60.7 (9.5)
Gender, % female 14.5 17.3 12.0
Hypertension, % 28.5 27.2 29.7
Diabetes, % 12.7 8.9 16.1
Current smoking, % 14.7 12.8 16.5
Duration of vascular disease, years 4.3 (4.7) 3.9 (4.3) 4.6 (4.9)
Body mass index (kg/m²) 27.5 (3.5) 27.3 (3.2) 27.6 (3.7)
Symptomatic CAD†, % 25.4 19.8 30.4
Family history of CAD, % 27.2 27.2 27.2
Prior myocardial infarction, % 65.4 59.9 70.1
Prior revascularization, % 54.6 59.7 50.1
Prior stroke or TIA, % 3.5 2.6 4.4
Prior PVD, % 7.4 5.1 9.4
Total cholesterol (mmol/L) 5.4 (1.0) 5.3 (1.0) 5.5 (1.1)
eGFR (mL/min/1.73 m²) 75 (64–87) 77 (66–89) 73 (62–86)
Randomized treatment, % 49.7 50.4 49.1
Systolic blood pressure (mm Hg) 137 (15) 136 (15) 138 (15)
Diastolic blood pressure (mm Hg) 82 (8) 82 (8) 82 (8)
Genetic profile
≤1 unfavorable allele, % 41.1 2.7 74.7
2 unfavorable alleles, % 32.4 40.5 25.3
≥3 unfavorable alleles, % 26.5 56.8 0
Summary statistics for continuous variables are presented as mean (standard deviation) or as median 
(interquartile range). Categorial variables are presented as precentages.
ARR: absolute risk reduction. eGFR: estimated glomerular filtration rate estimated by CKD-EPI equation, 
LDL: low density lipoprotein, HDL: high density lipoprotein, TIA: transient ischemic attack, PVD: peripheral 
vascular disease.
† Agina pectoris or previous heart failure.
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(NNT5 ≤ 25) in 6.4% of patients (Fig. 2). The SMART score identified similar proportions of 
patients in these categories of absolute treatment effect (Supplement Fig. 2).
The EUROPA-GEN score predicted an absent or adverse treatment effect in 26.5% 
of patients (Fig. 2). These adverse responders were characterized by an unfavorable 
genetic profile (i.e. ≥3 unfavorable alleles) and were at higher cardiovascular risk when 
treated with perindopril compared with placebo. Alternatively, the EUROPA-GEN score 
predicted a large 5-year ARR of ≥4% (NNT5 ≤ 25) in 27.7% of patients. The SMART-GEN 
score identified similar proportions per category (Supplement Fig. 2). Table 1 displays 
the characteristics of patients stratified according to predicted treatment effect, show-
ing higher risk factor levels and a skewed genetic profile in patients with a larger ARR.
box 1. The euROPa risk scores
Individual patient off−treatment risk : “treatment” = 0 (nO)
Individual patient on−treatment risk : “treatment” = 1 (Yes)
A) EUROPA score
5−year MaCe risk (%) = (1 – 0.91exp(a + 6.415)) × 100%
A = age * −0.1324 + age² * 0.0013 + female sex * −0.4643 + SBP * 0.0041 + total cholesterol * 0.1499 + eGFR 
eGFR *−0.0339 + eGFR² * 0.0002 + BMI *−0.2590 + BMI² * 0.0049 + diabetes * 0.4481 + current smoking * 0.3876 
+ family history of CAD * 0.1662 + prior MI * 0.3671 + prior TIA or stroke * 0.4446 + prior PVD * 0.5092 + prior 
coronary revascularization * −0.2235 + symptomatic CAD * 0.3981 + treatment *−0.2167
B) EUROPA-GEN score
5−year MaCe risk (%) = (1 – 0.91exp(a + 7.390)) × 100%
A = age * −0.1351 + age² * 0.0013 + female sex * −0.5474 + SBP * 0.0040 + total cholesterol * 0.1237 + eGFR eGFR 
*−0.0358 + eGFR² * 0.0002 + BMI *−0.2958 + BMI² * 0.0056 + diabetes * 0.4673 + current smoking * 0.4449 + family 
history of CAD * 0.0791 + prior MI * 0.4055 + prior TIA or stroke * 0.4433 + prior PVD * 0.5340 + prior coronary 
revascularization *−0.1582 + symptomatic CAD * 0.4080 + genetic profile 1 *−0.2062 + genetic profile 2 *−0.5112 
+ treatment * −0.5466 + treatment & 2 unfavorable alleles * 0.3207 + treatment & ≥3 unfavorable alleles * 0.7498
placebo)were unable to accurately pinpoint the expected individual pa-
tient treatment beneﬁt as was illustrated by the weak relation between
predicted and observed ARR. Conversely, the prediction scores with
both clinical and genetic variables combined the patient's baseline risk
with an efﬁcacy measure (i.e. azard r io) that was applicable o the
patient's speciﬁc genetic proﬁle and yielded accurate estimates of indi-
vidual treatment effect. The patient-speciﬁc ARR can be translated to an
individualized NNT (iNNT), which refers to the number of patients with
the same characteristics as the patient under care that require treat-
ment for a speciﬁc time to prevent one event (Box 3)[11].
The effect of implementing an individualized treatment strategy in
clinical practice was evaluated at a group level [29]. Selective drug pre-
scription, based on an in ividu lized treatment prediction algorithm,
can direct treatment to those patients who might expect the largest
beneﬁt and least harm of treatment. The choice of an appropriate treat-
ment threshold is difﬁcult as the threshold comprises adverse effects of
the drug, the inconvenience of daily taking a drug and monetary costs.
Notably, the frequency of adverse effects is difﬁcult to estimate based
on trial results as only patientswho tolerated perindoprilwere random-
ized after a run-in period. For randomized patients, the difference in ad-
herence to allocated therapy was 3.4% in the EUROPA [5]. Hence,
treating for example 100 patients in clinical practice will result in at
least 3 patients experiencing an adverse effect prompting them to dis-
continue the drug. Secondly, disadvantages include the inconveniences
of 100 patients who need to take perindopril daily for 5 years (i.e. 500
person-years of treatment). Thirdly, there are economic costs of
p rindopril prescription. At a 5-year threshold NNT of 100, we consider
all the negative effects of treating 100 patients together to be balanced
by the prevention of, for example, one MACE. We acknowledge that
this summary of positive and negative effects is incomplete and subject
to interpretation. Therefore, we speciﬁed a range of treatment thresh-
olds, deﬁned as t e number f p tients one would be willing to treat
to prevent one adverse cardiovascular outcome, to allow clinicians
and patients to make their own appraisal of treatment risks and bene-
ﬁts. Further, the treatment thresholdmay change over time as for exam-
ple drug costs decrease. A prediction-based treatment strategy using the
EUROPA-GEN or SMART-GEN treatment score yielded the highest net
beneﬁt at any treatment threshold considered. Hence, implementing
these scores in clinical practice can improve the balance between num-
ber of patients treated and number of advers cardiovascular outcomes
prevented, irrespective of the treatment threshold.
Strengths of the present study include the large number of available
events to derive treatment scores, the use of both clinical and genetic
data and the use of existing and newly developed prediction scores.
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Fig. 1. Calibration plots of predicted versus observed 4.3 year absolute risk reduction (ARR) of major cardiovascular events (MACE) in quintiles for different prediction scores.
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Fig. 2. Distribution of 5-year absolute risk reduction (ARR) of major cardiovascular events with perindopril treatment for individual patients with stable CAD.
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3.3. net benefit and clinical consequences of individualized prediction of 
treatment effect of perindopril
Across the entire range of 5-year treatment threshold NNTs, the clinical EUROPA score 
was not associated with higher net benefit at a population level compared to treating 
everyone or no one (Fig. 3). Hence, this model does not succeed in accurately directing 
treatment to sCAD patients who can anticipate the largest benefit from perindopril. On 
the other hand, the EUROPA-GEN score showed higher net benefit compared to treating 
everyone or no one across a wide range of treatment thresholds (Fig. 3). Even if the 
treatment threshold is infinite, suggesting one is prepared to treat a vast number of 
patients (e.g. >250) for 5 years to prevent a single event, prediction-based treatment is 
superior. This could be expected since prediction-based treatment limits prescription 
to the 73.5% of sCAD patients with an estimated positive effect, while withholding 
treatment for the 26.5% of patients with an estimated adverse or null effect (Table 2). 
Results were similar for the SMART risk scores with and without genetic characteristics 
(Supplement Fig. 3). When restricting treatment to patients with larger predicted treat-
ment effects, the average 5-year NNT among treated patients could be reduced from 42 
to 12 depending on the choice of treatment threshold (Table 2).
Table 2. Consequences for clinical practice based on euROPa-Gen score.
5-year threshold 
NNT
Tx-strategy Tx-rate* 5-year average 
ARR†
5-year average 
NNT†
– Treat all 100% 2.4% 42
250 Prediction-based Tx 73% 3.9% 25
100 Prediction-based Tx 70% 4.1% 25
50 Prediction-based Tx 53% 4.9% 20
25 Prediction-based Tx 28% 6.7% 15
17 Prediction-based Tx 13% 8.7% 12
Tx: Treatment. *Percentage of total population treated with perindopril. †Predicted average reduction in 
absolute risk of MI, resuscitated cardiac arrest and vascular death in selection of patients actively treated 
with perindopril.
4. DIsCussIOn
In the present study we demonstrated that therapeutic prediction models based on clinical 
and genetic characteristics were able to quantify the ARR of major cardiovascular events 
by perindopril for individual patients with sCAD. Of all participants, 27% had an absent or 
adverse treatment effect whereas 28% had a large estimated 5-year ARR of ≥4% (NNT5 ≤ 
25). Selective treatment of patients based on a prediction score can result in a more opti-
mal trade-off between the number of events prevented and number of patients treated.
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placebo)were unable to accurately pinpoint the expected individual pa-
tient treatment beneﬁt as was illustrated by the weak relation between
predicted and observed ARR. Conversely, the prediction scores with
both clinical and genetic variables combined the patient's baseline risk
with an efﬁcacy measure (i.e. hazard ratio) that was applicable to the
patient's speciﬁc genetic proﬁle and yielded accurate estimates of indi-
vidual treatment effect. The patient-speciﬁc ARR can be translated to an
individualized NNT (iNNT), which refers to the number of patients with
the same characteristics as the patient under care that require treat-
ment for a speciﬁc time to prevent one event (Box 3)[11].
The effect of implementing an individualized treatment strategy in
clinical practice was evaluated at a group level [29]. Selective drug pre-
scription, based on an individualized treatment prediction algorithm,
can direct treatment to those patients who might expect the largest
beneﬁt and least harm of treatment. The choice of an appropriate treat-
ment threshold is difﬁcult as the threshold comprises adverse effects of
the drug, the inconvenience of daily taking a drug and monetary costs.
Notably, the frequency of adverse effects is difﬁcult to estimate based
on trial results as only patientswho tolerated perindoprilwere random-
ized after a run-in period. For randomized patients, the difference in ad-
herence to allocated therapy was 3.4% in the EUROPA [5]. Hence,
treating for example 100 patients in clinical practice will result in at
least 3 patients experiencing an adverse effect prompting them to dis-
continue the drug. Secondly, disadvantages include the inconveniences
of 100 patients who need to take perindopril daily for 5 years (i.e. 500
person-years of treatment). Thirdly, there are economic costs of
perindopril prescription. At a 5-year threshold NNT of 100, we consider
all the negative effects of treating 100 patients together to be balanced
by the prevention of, for example, one MACE. We acknowledge that
this summary of positive and negative effects is incomplete and subject
to interpretation. Therefore, we speciﬁed a range of treatment thresh-
olds, deﬁned as the number of patients one would be willing to treat
to prevent one adverse cardiovascular outcome, to allow clinicians
and patients to make their own appraisal of treatment risks and bene-
ﬁts. Further, the treatment thresholdmay change over time as for exam-
ple drug costs decrease. A prediction-based treatment strategy using the
EUROPA-GEN or SMART-GEN treatment score yielded the highest net
beneﬁt at any treatment threshold considered. Hence, implementing
these scores in clinical practice can improve the balance between num-
ber of patients treated and number of adverse cardiovascular outcomes
prevented, irrespective of the treatment threshold.
Strengths of the present study include the large number of available
events to derive treatment scores, the use of both clinical and genetic
data and the use of existing and newly developed prediction scores.
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Further, the present study is theﬁrst to provide a treatment score to cal-
culate an individualized estimate of the effect of perindopril. These esti-
mates may help physicians to engage patients in shared-decision
making by facilitating an appraisal of risks and beneﬁts of treatment at
an individual patient level. In addition, we evaluated the group level ef-
fects of implementing a prediction score in clinical practice, which is rel-
evant to guideline makers. Potential limitations of our study also merit
consideration. One of themain concerns of developing a new prediction
score is that a score is likely to perform optimistically if tested in the
sample from which it was derived [20]. To reduce optimism, we used
penalized model estimation based on cross-validation and used a limit-
ed number of prespeciﬁed predictors. The effect-size of treatment inter-
actions by genetic proﬁle could not be based on external data, although
the magnitude and directions of the interactions have been reproduced
in ex-vivo experiments and in the PROGRESS trial [8,34]. In addition, the
risk of chance ﬁndings was greatly reduced by only evaluating SNPs in
12 candidate genes that are part of biological pathways affected by
ACE-i. This is different from genome wide association studies without
a speciﬁc biological hypothesis. Other potential limitations include the
generalizability of ﬁndings. As with the average trial result, the treat-
ment prediction scores apply to patients who would be eligible for
inclusion in the EUROPA trial. Since the number of female participants
was relatively small, the models should be used with caution in female
patients. Further, current predictions apply to a 5-year time period. In
addition, the individualized effect estimates were not accompanied by
uncertainty margins. In the setting op medical decision making, the in-
terpretation of such margins can be difﬁcult since the point estimate is
the most likely value for an individual patient [35]. Further, the use of
a prediction score to select patients for treatment is more time consum-
ing than treating everyone. However, the widespread use of electronic
patient records in clinical practice may facilitate the use of prediction
rules by automatically feeding information to risk calculators (Supple-
ment Fig. 4). Nevertheless, genetic information regarding the SNPs
thatmodify treatment effect is not routinely assessed in clinical practice.
Given the promising results and potential clinical implications, external
validation of treatment prediction algorithms including genetic infor-
mation should be pursued.
In conclusion, treatment effect prediction scores based on clinical
and genetic characteristics can quantify the ARR ofmajor cardiovascular
events for individual patients with sCAD. The use of a therapeutic pre-
diction score in clinical practice can improve the balance between the
number of patients treated and the number of events prevented com-
pared with one-size-ﬁts-all approaches such as treating no one or
everyone.
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Fig. 3.Net beneﬁt curves of different treatment strategies for major cardiovascular events
(MACE). Net beneﬁt is calculated as the observed ARR ofMACE (%) in patients whose ran-
domized allocation is similar to recommendations fromthe treatment scoreminus thedis-
advantages of treatment. The disadvantages of treatment are expressed as the proportion
of patients receiving treatment weighted by the threshold NNT. First, a (range of) thresh-
old NNT should be determined and next the strategy associated with the highest net ben-
eﬁt for this (range of) threshold can be extracted from the graph. The threshold NNT may
vary among clinicians and patients. The treat all line originates at the average ARR ob-
served in the trial, since the negative effects of treatment are assumed to be zero at an in-
ﬁnite threshold NNT5. Treat none is associated with zero net beneﬁt.
Table 2
Consequences for clinical practice based on EUROPA-GEN score.
5-year threshold NNT Tx-strategy Tx-rate* 5-year average ARR† 5-year average NNT†
– Treat all 100% 2.4% 42
250 Prediction-based Tx 73% 3.9% 25
100 Prediction-based Tx 70% 4.1% 25
50 Prediction-based Tx 53% 4.9% 20
25 Prediction-based Tx 28% 6.7% 15
17 Prediction-based Tx 13% 8.7% 12
Tx: Treatment. *Percentage of total population treated with perindopril. †Predicted average reduction in absolute risk of MI, resuscitated cardiac arrest and vascular death in selection of
patients actively treated with perindopril.
Box 3
Predicted 5-year absolute risk reduction of MACE when treated with
perindopril for two different patient profiles.
Patient A
A asymptomatic 60-year old non-smoking male patient without di-
abetes, an SBP of 130mmHg, a BMI of 25 kg/m2, no family histo-
ry of CAD, no prior MI, no prior stroke, no prior PVD, a CABG
procedure 2 years ago, a TC of 6 mmol/L, an eGFR of 60 ml/min
and 2 unfavorable alleles.
➔ 5-year ARR with perindopril is 1.1% (individual NNT5 = 88)
Patient B
A symptomatic 60-year old smokingmale patientwith diabetes, an
SBP of 150 mm Hg, a BMI of 30 kg/m2, no family history of CAD,
no prior MI, no prior stroke, no prior PVD, no prior revasculariza-
tion, a TC of 6 mmol/L, an eGFR of 60ml/min and≤1 unfavorable
allele.
➔ 5-year ARR with perindopril is 11.6% (individual NNT5 = 9)
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fig. 3. net benefit curves of different treatment strategies for ajor cardiovascular events (MaCe).
Net benefit is calculated as the observed ARR of MACE (%) in patients whose randomized allocation is 
similar to recommendations from the treatment score minus the disadvantages of treatment. The disad-
vantages of treatment are expressed as the proportion of patients receiving treatm nt weighted by the 
threshold NNT. First, a (range of ) threshold NNT should be determined and next the strategy associated 
with the highest net benefit for this (range of ) threshold can be extracted from the graph. The threshold 
NNT may vary among cli icians and patients. The treat all line originates at the average ARR observed in 
the trial, since the negative effects of treatment are assumed to be zero at an infinite threshold NNT5. Treat 
none is associated with zero net benefit.
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Guidelines recommend ACE-i in patients with sCAD, especially if there are co-existing 
conditions such as hypertension, reduced left ventricular ejection fraction or chronic 
kidney disease [30,31]. These recommendations are based on the overall results of large 
randomized clinical trials showing reductions in cardiovascular events and mortality 
[5,32, 33]. Even if the relative risk reduction is constant, the absolute risk reduction with 
treatment varies and is likely to increase with baseline event risk. However, in the present 
study the relative efficacy of perindopril was influenced by the patients’ genetic profile 
and patients with similar baseline risks had different risk reductions. Consequently, the 
clinical scores with just a single treatment variable (i.e. active vs. placebo)were unable to 
accurately pinpoint the expected individual patient treatment benefit as was illustrated 
by the weak relation between predicted and observed ARR. Conversely, the prediction 
scores with both clinical and genetic variables combined the patient’s baseline risk with 
an efficacy measure (i.e. hazard ratio) that was applicable to the patient’s specific genetic 
profile and yielded accurate estimates of individual treatment effect. The patient-specific 
ARR can be translated to an individualized NNT (iNNT),which refers to the number of 
patients with the same characteristics as the patient under care that require treatment 
for a specific time to prevent one event (Box 3)[11].
The effect of implementing an individualized treatment strategy in clinical practice 
was evaluated at a group level [29]. Selective drug prescription, based on an individual-
ized treatment prediction algorithm, can direct treatment to those patients who might 
expect the largest benefit and least harm of treatment. The choice of an appropriate 
treatment threshold is difficult as the threshold comprises adverse effects of the drug, 
the inconvenience of daily taking a drug and monetary costs. Notably, the frequency 
of adverse effects is difficult to estimate based on trial results as only patients who 
tolerated perindopril were randomized after a run-in period. For randomized patients, 
the difference in adherence to allocated therapy was 3.4% in the EUROPA [5]. Hence, 
treating for example 100 patients in clinical practice will result in at least 3 patients 
experiencing an adverse effect prompting them to discontinue the drug. Secondly, 
box 3. Predicted 5-year absolute risk reduction of MaCe when treated with perindopril for two dif-
ferent patient profiles.
Patient A
A asymptomatic 60-year old non-smoking male patient without diabetes, an SBP of 130mm Hg, a BMI of 25 kg/
m², no family history of CAD, no prior MI, no prior stroke, no prior PVD, a CABG procedure 2 years ago, a TC of 6 
mmol/L, an eGFR of 60 ml/min and 2 unfavorable alleles.
→ 5-year ARR with perindopril is 1.1% (individual NNT5=88)
Patient B
Asymptomatic 60-year old smoking male patient with diabetes, an SBP of 150 mm Hg, a BMI of 30 kg/m², no 
family history of CAD, no prior MI, no prior stroke, no prior PVD, no prior revascularization, a TC of 6mmol/L, an 
eGFR of 60ml/min and ≤1 unfavorable allele.
→ 5-year ARR with perindopril is 11.6% (individual NNT5=9)
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disadvantages include the inconveniences of 100 patients who need to take perindopril 
daily for 5 years (i.e. 500 person-years of treatment). Thirdly, there are economic costs of 
perindopril prescription. At a 5-year threshold NNT of 100, we consider all the negative 
effects of treating 100 patients together to be balanced by the prevention of, for ex-
ample, one MACE. We acknowledge that this summary of positive and negative effects 
is incomplete and subject to interpretation. Therefore, we specified a range of treatment 
thresholds, defined as the number of patients one would be willing to treat to prevent 
one adverse cardiovascular outcome, to allow clinicians and patients to make their own 
appraisal of treatment risks and benefits. Further, the treatment threshold may change 
over time as for example drug costs decrease. A prediction-based treatment strategy 
using the EUROPA-GEN or SMART-GEN treatment score yielded the highest net benefit 
at any treatment threshold considered. Hence, implementing these scores in clinical 
practice can improve the balance between number of patients treated and number of 
adverse cardiovascular outcomes prevented, irrespective of the treatment threshold.
Strengths of the present study include the large number of available events to derive 
treatment scores, the use of both clinical and genetic data and the use of existing and 
newly developed prediction scores. Further, the present study is the first to provide 
a treatment score to calculate an individualized estimate of the effect of perindopril. 
These estimates may help physicians to engage patients in shared-decision making by 
facilitating an appraisal of risks and benefits of treatment at an individual patient level. 
In addition,we evaluated the group level effects of implementing a prediction score in 
clinical practice,which is relevant to guideline makers. Potential limitations of our study 
also merit consideration. One of the main concerns of developing a new prediction 
score is that a score is likely to perform optimistically if tested in the sample from which 
it was derived [20]. To reduce optimism, we used penalized model estimation based on 
cross-validation and used a limited number of prespecified predictors. The effect-size of 
treatment interactions by genetic profile could not be based on external data, although 
the magnitude and directions of the interactions have been reproduced in ex-vivo 
experiments and in the PROGRESS trial [8,34]. In addition, the risk of chance findings 
was greatly reduced by only evaluating SNPs in 12 candidate genes that are part of 
biological pathways affected by ACE-i. This is different from genome wide association 
studies without a specific biological hypothesis. Other potential limitations include the 
generalizability of findings. As with the average trial result, the treatment prediction 
scores apply to patients who would be eligible for inclusion in the EUROPA trial. Since 
the number of female participants was relatively small, the models should be used with 
caution in female patients. Further, current predictions apply to a 5-year time period. 
In addition, the individualized effect estimates were not accompanied by uncertainty 
margins. In the setting of medical decision making, the interpretation of such margins 
can be difficult since the point estimate is the most likely value for an individual patient 
Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients 427
C
h
a
p
te
r
 2
3
[35]. Further, the use of a prediction score to select patients for treatment is more time 
consuming than treating everyone. However, the widespread use of electronic patient 
records in clinical practice may facilitate the use of prediction rules by automatically 
feeding information to risk calculators (Supplement Fig. 4). Nevertheless, genetic in-
formation regarding the SNPs that modify treatment effect is not routinely assessed in 
clinical practice. Given the promising results and potential clinical implications, external 
validation of treatment prediction algorithms including genetic information should be 
pursued.
In conclusion, treatment effect prediction scores based on clinical and genetic char-
acteristics can quantify the ARR of major cardiovascular events for individual patients 
with sCAD. The use of a therapeutic prediction score in clinical practice can improve the 
balance between the number of patients treated and the number of events prevented 
compared with one-size-fits-all approaches such as treating no one or everyone.
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OnlIne suPPleMenT
supplement box 1. sMaRT treatment scores
Individual patient off-treatment risk: “treatment” = 0 (nO)
Individual patient on-treatment risk: “treatment” = 1 (Yes)
A) SMART score
5-year MaCe risk (%) = (1 − 0.91 exp(a + 1.959)) x 100%
A = age * −0.0850 + age²* 0.0015 + male sex * −0.1561 + SBP * 0.0043 + total cholesterol * 0.0959 + eGFR 
(MDRD) * −0.0532 + eGFR²* 0.0003 + diabetes *0.2232 + current smoking * 0.2617 + prior CAD * 0.1401 + prior 
TIA or stroke 0.4058 + prior PVD * 0.2832 + years since first vascular event * 0.0229 + treatment * −0.2116
B) SMART-GEN score
5-year MaCe risk (%) = (1 − 0.91 exp(a + 2.164)) x 100%
A = clinical SMART coefficients + genetic profile 1 * −0.1945 + genetic profile 2 * −0.4837 + treatment * −0.5159 
+ treatment & 2 unfavorable alleles * 0.2929 + treatment & ≥3 unfavorable alleles * 0.7231
supplement table 1. Detailed model statistics
EUROPA score Coefficients ¶ HR 95% CI LRT p-value
Age (years)* −0.1324 1.37 1.22 - 1.52 54.2 <0.01
Age (years) squared 0.0013
Female gender −0.4643 0.63 0.52 - 0.76 26.6 <0.01
Systolic blood pressure (mm Hg) 0.0041 1.00 1.00 - 1.01 4.2 0.04
Total cholesterol (mmol/L) 0.1499 1.16 1.10 - 1.23 28.4 <0.01
eGFR (ml/min/1.73m²)* −0.0339 0.85 0.77 - 0.94 14.5 <0.01
eGFR (ml/min/1.73m²) squared 0.0002 
BMI (kg/m²)* −0.2590 1.04 0.96 - 1.13 29.7 <0.01 
BMI (kg/m²) squared 0.0049
Diabetes 0.4481 1.57 1.34 - 1.82 30.2 <0.01
Current smoking 0.3876 1.47 1.26 - 1.72 22.1 <0.01
Family history of CAD 0.1662 1.18 1.03 - 1.35 5.7 0.02
Prior MI 0.3671 1.44 1.26 - 1.66 28.6 <0.01
Prior TIA or stroke 0.4446 1.56 1.22 - 2.00 10.9 <0.01
Prior PVD 0.5092 1.66 1.39 - 1.99 27.8 <0.01
Prior coronary revascularization −0.2235 0.80 0.71 - 0.91 12.4 <0.01
Symptomatic CAD† 0.3981 1.49 1.31 - 1.69 36.0 <0.01
Treatment −0.2167 0.81 0.71 - 0.91 12.7 <0.01
EUROPA-GEN scoreχ
2 unfavorable allele −0.2062 0.81 0.66 - 1.00 3.73 0.05
≥3 unfavorable alleles −0.5112 0.60 0.47 - 0.77 17.63 <0.01
Treatment −0.5466 0.58 0.46 - 0.72 24.77 <0.01
Treatment & 2 unfavorable allele 0.3207 1.38 0.99 - 1.93 3.65 0.06
Treatment & ≥3 unfavorable alleles 0.7498 2.12 1.49 - 3.04 17.31 <0.01
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supplement table 1. (continued)
SMART-GEN scoreχ
2 unfavorable allele −0.1945 0.82 0.66 - 1.01 3.37 0.07
≥3 unfavorable alleles −0.4837 0.61 0.48 - 0.79 15.85 <0.01
Treatment −0.5159 0.59 0.48 - 0.74 22.21 <0.01
Treatment & 2 unfavorable allele 0.2929 1.35 0.97 - 1.88 3.11 0.08
Treatment & ≥3 unfavorable alleles 0.7231 2.07 1.45 - 2.96 16.23 <0.01
eGFR: estimated glomerular filtration rate (CKD-EPI equation), LRT: likelihood ratio test. † Agina pectori or 
previous heart failure. ¶ Coefficients were shrunken to increase external validity, whereas unbiased HRs 
and statistics were derived from the unpenalized Cox models. *Risk model contains a linear and squared 
term for age, BMI and eGFR. Therefore the LRT and p-value for age, BMI and eGFR is computed for both 
terms together. Futhermore HR were computed for the difference between the study population’s 75th 
and 25th percentile of age (67 vs 53), BMI (29.4 vs 25.0) and eGFR (87 vs 64). χThe additional variables to 
the EUROPA and SMART risk score are presented here. Estimates of the clinical predictors in the EUROPA-
GEN score were comparable to the estimates of the EUROPA score.
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Supplement figure 1. Calibration plots of predicted versus observed 4.3-year absolute risk of 
major cardiovascular events (MACE) in deciles. 
 
 
 
 
 
 
 
 
  
supplement figure 1. Calibration plots of predicted versus observed 4.3-year absolute risk of major 
cardiovascular events (MaCe) in deciles.
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supplement  figure 2. Distribution of 5-year absolute treamtent effect of major cardiocvascular 
events (MaCe) with perindopril for individual patients with sCaD based on euROPa and sMaRT 
scores.
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supplement figure 3. net benefit curves of different treatment strategies for major cardiovascular 
events (MaCe).
Supplement figure 4. Calculation sheet 
 
  
 supplement figure 4. Calculation sheet
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absTRaCT
background: Patients with stable CAD constitute a heterogeneous group in which the 
treatment benefits by ACE-inhibitor therapy vary between individuals. Our objective 
was to integrate clinical and pharmacogenetic determinants in an ultimate combined 
risk prediction model.
Methods and results: Clinical, genetic and outcomes data were used from 8726 stable 
CAD patients participating in the EUROPA/PERGENE trial of perindopril versus placebo. 
Multivariable analysis of phenotype data resulted in a clinical risk score (range: 0-21 
points). Three SNPs (rs275651 and rs5182 in the angiotensin-II type I-receptor gene and 
rs12050217 in the bradykinin type I-receptor gene) were used to construct a pharma-
cogenetic risk score (PGXscore, range: 0-6 points). 785 patients (9.0%) experienced the 
primary endpoint of cardiovascular mortality, non-fatal MI or resuscitated cardiac arrest 
during 4.2 years of follow-up. Absolute risk reductions ranged from 1.2% to 7.5% in the 
73.5% of patients with PGXscore of 0-2. As a consequence, estimated annual numbers 
needed to treat ranged from as low as 29 (clinical risk score ≥10 and PGXscore of 0) 
to 521 (clinical risk score ≤6 and PGXscore of 2). Furthermore, our data suggest that 
long-term perindopril prescription in patients with a PGXscore of 0-2 is cost-effective.
Conclusions: Both baseline clinical phenotype, as well as genotype determine the 
efficacy of widely prescribed ACE-inhibition in stable CAD. Integration of clinical and 
pharmacogenetic determinants in a combined risk prediction model demonstrated a 
very wide range of gradients of absolute treatment benefit.
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The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary 
Artery Disease (EUROPA) and the Heart Outcomes Prevention Evaluation (HOPE) have 
demonstrated the effectiveness of angiotensin-converting enzyme (ACE)-inhibitors 
perindopril and ramipril respectively, by reduction of mortality and morbidity from 
cardiovascular events among patients with stable coronary artery disease (CAD)1,2. 
Consequently, ACE-inhibitors are recommended in clinical guidelines on secondary 
prevention in patients with stable CAD and hence widely used in this population.3–5
However, patients with stable CAD constitute a heterogeneous group in which the 
absolute risk of cardiovascular complications varies between individuals.6,7
Several approaches towards the identification of those patients that are most likely 
to benefit from ACE-inhibitor therapy have previously been reported. A previously pub-
lished post-hoc analysis of the EUROPA trial studied baseline clinical risk factors such 
as age, gender, smoking, cholesterol and blood pressure levels.6 A risk score founded 
on such baseline clinical risk factors was able to identify patients at high, medium and 
relatively low absolute risk (>3%, 1-3% and 1% per annum respectively) of experienc-
ing cardiovascular death, non-fatal myocardial infarction (MI) and resuscitated cardiac 
arrest.6 In contrast to the absolute treatment benefit, the relative treatment effect of 
perindopril, however, was not modified by the baseline level of risk.6 Similar conclusions 
were drawn after investigation of the relation between treatment benefit by perindopril 
and baseline renal function or the degree of blood pressure reduction.8–10
A novel approach towards selection of those that are likely to respond (or not) to 
ACE-inhibitor therapy is to identify information on genetic variation among patients.11 
A recent publication by our group demonstrated that genetic variation in the renin-
angiotensin-aldosterone system (RAAS) and the kallikrein-bradykinin (KB) pathway is 
associated with the treatment benefit of perindopril.12 Three single nucleotide polymor-
phisms (SNPs), two of which in the angiotensin-II type I (AT1) receptor gene and one 
in the bradykinin type I (BK1) receptor gene, were used to construct an integer-based 
pharmacogenetic risk score (PGXscore), ranging from 0 to 6 points.12 We were able to 
identify two distinct subgroups within the overall study population of 8726 patients on 
the basis of this PGXscore.12 One subgroup (73.5% of the patients) was characterized by 
a more pronounced treatment benefit, whereas no treatment benefit was apparent in 
the remaining 26.5% of patients.
This current analysis is an ultimate extension of both the previously published clinical 
risk model6 and pharmacogenetic risk profile.12 Its purpose is two-fold: 1) to investigate 
the relation between identified genetic determinants of treatment benefit and different 
levels of baseline clinical risk; 2) to integrate clinical and pharmacogenetic determinants 
in an ultimate combined risk prediction model.
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MeTHODs
study population and design
The PERindopril GENEtic association study (PERGENE) is a substudy of the EUROPA trial. 
The designs of both studies have been reported previously.1,12 In brief, the EUROPA trial 
was a randomized, double-blinded, placebo-controlled study designed to assess the 
effect of perindopril (8 mg daily) on the combined primary endpoint of cardiovascular 
mortality, non-fatal MI and resuscitated cardiac arrest in 12218 patients with stable CAD, 
but without overt heart failure or uncontrolled hypertension. The use of perindopril 
resulted in a 20% relative risk reduction (adjusted HR 0.80, 95% CI: 0.71-0.91) in the rate 
of the primary endpoint during a mean follow-up of 4.2 years.1
A DNA bio-bank was established within the EUROPA trial for the purpose of the 
PERGENE substudy, which investigates whether genetic variation is a determinant of 
the risk of future adverse cardiovascular outcome and/or treatment benefit by the use 
of perindopril.11 DNA was successfully isolated in 9454 patients, using an automated 
isolation process.11 Comprehensive coverage of genetic variation in both the RAAS and 
KB pathways was ensured by a haplotype-tagging-single nucleotide polymorphism (ht-
SNP) procedure in 12 candidate genes, as described in detail previously.11,12
Our study was approved by the Institutional Review Board of every participating cen-
ter and written informed consent for genetic association analyses was obtained from all 
patients.
Clinical risk score
Univariable and multivariable Cox’ proportional hazard regression analyses were per-
formed to study the relation between the primary endpoint (cardiovascular mortality, 
non-fatal MI and resuscitated cardiac arrest) and baseline clinical patient characteris-
tics, such as demographic and clinical variables, medical history, laboratory tests and 
concomitant medication. Interaction by treatment was investigated for each clinical 
characteristic. A final multivariable clinical risk model was constructed using a backward 
stepwise elimination procedure in which removal testing was based on the probability 
of the likelihood-ratio statistic based on the maximum partial likelihood estimates. In 
order to develop a clinical risk-scoring system, the log HRs from the final multivariable 
model were converted to an estimated risk score.6,13 Clinical risk scores were calculated 
for each of the patients of the currently described population (only those trial partici-
pants of whom both baseline clinical characteristics and (pharmaco)genetic profile were 
complete). The study population was divided into tertiles in order to distinguish low, 
medium and high clinical risk profiles.
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Pharmacogenetic risk profile and replication
The PERGENE substudy assessed 52 SNPs with the use of Taqman allelic discrimination 
assays (Applied Biosystems, Foster City, CA, USA) and Sequenom (San Diego, CA, USA) 
mass-spectrometric genotyping. Quality control for the accuracy of genotyping involved 
testing duplicates from a randomly selected group of samples (5%) for concordance 
between samples (always >99% replication). Individual SNP call rates ranged between 
95 and 98%. To ensure DNA quality, only patients who were successfully genotyped for 
more than 90% of the selected 52 SNPs were included in the PERGENE analyses (n = 
8907).12
Seven SNPs have previously been reported to significantly modify the treatment ef-
fect of perindopril in univariate analyses.12 After multivariate adjustment and correction 
for multiple testing, three SNPs remained significant modifiers of the perindopril treat-
ment effect: rs275651 and rs5182 in the angiotensin-II type I (AT1) receptor gene and 
rs12050217 in the bradykinin type I (BK1) receptor gene. These three SNPs formed the 
foundation of a previously published PGXscore, ranging from 0 to 6 points, which was 
constructed by counting the number of alleles that were associated with a decreased 
benefit of perindopril treatment.12 The association between the PGXscore and treatment 
benefit by perindopril, as found in PERGENE,12 was replicated in the PROGRESS study, 
which investigated the treatment effect of perindopril in patients with cerebrovascular 
disease.14
statistical analysis
Differences in baseline clinical characteristics between low, medium and high clinical 
risk groups were assessed by chi-square tests in case of categorical data or one-way 
analysis of variance in case of continuous data. A multivariate Cox proportional hazards 
regression model was fitted with the following covariates: clinical risk score, PGXscore, 
treatment and treatment*PGXscore interaction (full model). The baseline hazard func-
tion H0(t) was estimated by dividing the cumulative hazard at the end of follow-up 
through the exponential function of the mean of the covariates. The cumulative survival 
under perindopril treatment versus placebo at the median follow-up of 4.2 years was 
calculated for each clinical risk score within the separate pharmacogenetic risk strata 
as follows: S (4.2years) = 0.033975 * exp(0.196*clinical risk score – 0.203*PGXscore – 
0.793*treatment – 0.318*interaction term) With respect to “treatment” placebo was de-
fined as 0 and perindopril treatment as 1. The “interaction term” was the multiplication 
of the PGXscore * treatment. Absolute and relative risks, as well as crude and adjusted 
hazard ratios (HR) are presented with 95% confidence intervals (CI). Numbers needed to 
treat (NNT) in order to prevent one event per annum were calculated as the inverse of 
the absolute risk reduction at the mean clinical risk scores per stratum.
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The performance of the model consisting of clinical risk score only was compared by 
two different methods with the full model with respect to discrimination. First, the c-
index and areas under the two receiver operating characteristic curves were compared 
by a nonparametric method, as previously described by de Long et al.15 Secondly, the 
difference in model-based discrimination slopes was evaluated through integrated dis-
crimination improvement (IDI).16 Calibration of both the model consisting of clinical risk 
score only and the full model was tested with the Hosmer-Lemeshow [H-L] goodness-of-
fit test. All statistical tests were two-sided with a type I error level of 0.05, except for the 
IDI for which a conservative significance level of 0.01 was maintainted.16
We performed a cross-validation within our own dataset by bootstrap methods as 
suggested by Harrell et al.17 We constructed 300 bootstrap samples (training) from the 
full original sample with the same size as the original (test). Models were built in the 
training sets. C-indices were then obtained in these training sets (Ctraining) and compared 
with the c-indices of the models when applied to the test set (Ctest). The optimism in the 
fit from bootstrap sample i is defined as Oi = Ci,training − Ci,test. We report the mean O of these 
optimism estimates. Analyses were performed with IBM SPSS statistics version 23.0 and 
STATA version 12.
Cost-effectiveness analysis
We examined the potential cost-effectiveness of the combined clinical risk score and 
PGXscore. The time horizon was restricted to the duration of the EUROPA trial/PERGENE 
study (mean follow-up of 4.2 years). Costs were set at 15 euros for the analysis of the 
three SNPs of the PGXscore, 50 euros for perindopril (based on the current price of per-
indopril 8 mg tablets in the Netherlands), and 3,000 euros for a clinical event (a weighted 
average of the costs of treating myocardial infarction and the costs of cardiac death). The 
health loss of a clinical event within the trial duration was set at 0.6 years (a weighted 
average of the relative frequency and life-years lost from myocardial infarction (0 years) 
and cardiac death (2 years).
The following patient management strategies were examined, against the strategy of no 
perindopril treatment (as the comparator):
1) Pharmacogenetic testing only in patients with a high clinical risk score and perindo-
pril treatment only if PGXscore=0-2
2) Pharmacogenetic testing only in patients with a medium or high clinical risk score 
and perindopril treatment only if PGXscore=0-2
3) Pharmacogenetic testing in all patients and perindopril treatment only if PGX-
score=0-2
4) Perindopril treatment in all patients irrespective of PGX score.
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ResulTs
Complete data on baseline clinical patient characteristics and (pharmaco)genetic profile 
were obtained for 8726 patients (of which 4338 were allocated to perindopril and 4388 
to placebo). Median follow-up was 4.2 years (interquartile range 4.0-4.5 years), during 
which 785 patients (9.0%) experienced the primary endpoint of cardiovascular mortal-
ity, non-fatal MI or resuscitated cardiac arrest. Treatment with perindopril was protec-
tive in the overall study population; the number of patients on perindopril treatment 
that experienced the primary endpoint was 346 (8.0%) versus 439 (10.0%) on placebo 
(adjusted HR 0.80, 95% CI: 0.68-0.92) Baseline characteristics of the overall study popula-
tion and various subgroups according to the clinical risk level are provided in table 1. 
Interaction between study treatment and clinical characteristics (including concomitant 
medication) was not found.
Table 1. baseline study population characteristics
Total
population
ClInICal RIsK leVel p-value *
low Medium High
N (%) 8726 3167 (36.3) 3474 (39.8) 2085 (23.9)
Age, years 59.8 (9.3) 57.7 (8.0) 59.4 (9.2) 63.8 (10.0) <0.001
Male gender (%) 85.5 81.5 87.6 88.2 <0.001
Hypertension (%) † 29.0 23.0 28.0 39.0 <0.001
Diabetes mellitus (%) 13.0 4.0 11.0 30.0 <0.001
Hypercholesterolemia (%) ‡ 63.0 69.0 60.0 58.0 <0.001
Current smoking (%) § 15.0 6.0 16.0 25.0 <0.001
Obesity (BMI>30 kg/m²) (%) 21.3 8.2 24.0 36.7 <0.001
Symptomatic CAD (%) | | 25.4 9.5 25.9 48.9 <0.001
Family history of CAD (%) 27.0 22.0 29.0 32.0 <0.001
Previous MI (%) 65.0 44.0 73.0 84.0 <0.001
Previous revascularisation (%) 55.0 75.0 49.0 33.0 <0.001
Previous stroke or PAD (%) 8.9 0.8 5.2 27.5 <0.001
COnCOMMITanT MeDICaTIOn
Platelet-inhibitors (%) 92.0 94.0 92.0 89.0 <0.001
Beta-blockers (%) 63.0 62.0 65.0 63.0 0.104
Lipid-lowering agents (%) 55.0 64.0 53.0 46.0 <0.001
Calcium-antagonists (%) 32.0 29.0 31.0 37.0 <0.001
Systolic blood pressure (mmHg) 136.9 (15.2) 132.7 (13.9) 137.7 (15.1) 142.1 (15.5) <0.001
Diastolic blood pressure (mmHg) 81.8 (8.1) 80.6 (7.9) 82.4 (8.1) 82.7 (8.3) <0.001
Creatinine clearance (µmol/L) # 86.5 (25.7) 88.9 (22.2) 87.7 (26.6) 80.9 (28.3) <0.001
Total cholesterol (mmol/L) 5.4 (1.0) 5.1 (0.9) 5.5 (1.0) 5.7 (1.1) <0.001
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Significant baseline clinical risk predictors and the point-scoring system, which de-
rived from backward elimination, are presented in table 2. The log HRs from the final 
multivariable model that were converted to the clinical risk score are provided in the 
Online data supplement. The clinical risk score could theoretically range from 0-32, 
yet calculated individual scores within our study population ranged from 0-21 with a 
mean value of 7.67 +/- 2.83 (figure 1). The 33rd and 67th percentiles were at 6.00 and 
9.00 points respectively, and used as cut-offs in order to distinguish low, medium and 
high clinical risk levels. The skewness of the distribution (figure 1) prevented formation 
of three groups of similar size. It should be noted that the high risk group consists of 
23.9% of the overall study population (tables 1 and 3). Incidences of all known baseline 
cardiovascular risk factors were highest in the higher clinical risk groups (table 1), with 
exception of previously diagnosed hypercholesterolemia, which actually was lowest in 
the high-risk subgroup. In accordance, high-risk patients also presented with the low-
est rate of statin use. These findings, however, were counterbalanced by the fact that 
patients in the high-risk subgroup did have the highest total cholesterol levels (table 1).
The primary endpoint rates in the low, medium and high clinical risk groups were 
4.6%, 8.8% and 16.2% respectively (p<0.001, table 1). These differences in event rate 
Table 1. (continued)
Total
population
ClInICal RIsK leVel p-value *
low Medium High
OuTCOMe
Randomization, allocation to 
perindopril (%)
49.7 51.0 48.9 49.5 0.296
Primary endpoint 9.0 4.6 8.8 16.2 <0.001
Systolic / diastolic blood pressure 
reduction by perindopril (mmHg)**
8.6 / 4.0 7.3 / 3.9 9.2 / 4.1 9.6 / 4.1 <0.001 / 0.416
RIsK sCORe 0-6 7-9 10-21
Mean clinical risk score 7.67 (2.83) 4.84 (1.20) 7.93 (0.80) 11.53 (1.74) n.a.
Mean pharmacogenetic risk score 1.82 (1.13) 1.82 (1.12) 1.82 (1.12) 1.86 (1.11) 0.435
Summary statistics for continuous variables are presented as mean (standard deviation). Categorical data 
are summarized as percentages. CAD=coronary artery disease MI=myocardial infarction N.A.=not appli-
cable PAD=peripheral artery disease
* For differences between low, medium and high clinical risk levels.
† Blood pressure >140/95 mm Hg or receiving antihypertensive treatment.
‡ Previously known total cholesterol >6·5 mmol/L or receiving lipid-lowering treatment.
§ Use of tobacco within the last month
|| Stable angina pectoris or history of congestive heart failure
# Estimation by Cockroft-Gault equation
** Blood pressure reduction was calculated as the mean difference in blood pressure from screening visit 
1 to randomization after the 4-week run-in period of the Europa-trial in which all patients were treated 
with perindopril.
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Table 2. Clinical risk scores of baseline risk parameters
Continuous clinical risk parameters Clinical Risk 
score pointsAge Systolic blood pressure Creatinine 
clearance
Total cholesterol mmol/L 
(mg/dL)
<67 ≤130 >70 ≤3.5 (≤135) 0
67-69 >130-≤160 >55-≤70 >3.5-≤5.0 (>135-≤193) 1
70-72 >160 >35-≤55 >5.0-≤6.5 (>193-≤251) 2
73-76 ≤35 >6.5-≤8.0 (>251-≤309) 3
77-79 >8.0 (>309) 4
80-82 5
83-85 6
>85 7
Dichotomous clinical risk parameters
Previous stroke or PAD 3
Male gender 2
Obesity (BMI>30 kg/m²) 2
Current smoking 2
Symptomatic CAD 2
Diabetes mellitus 2
Previous MI 2
Family history of CAD 1
Previous revascularisation −1
The range of clinical risk scores = 0-32 and points for each of applicable variables need to be added to 
each other. CAD=coronary artery disease MI=myocardial infarction PAD= peripheral artery disease.
Table 3 . Distribution of patients over clinical and pharmacogenetic risk strata
Clinical risk level low Medium High
Clinical risk score 0-6 7-9 10-21
Pharmacogenetic
risk score N(%)
0 362 (4.1) 390 (4.5) 232 (2.7)
1 945 (10.8) 1037 (11.9) 618 (7.1)
2 1027 (11.8) 1144 (13.1) 655 (7.5)
≥3 833 (9.5) 903 (10.3) 580 (6.6)
Treatment benefit of perindopril was only demonstrated within the group of patients with pharmaco-
genetic risk scores < 3 (N=6410, 73.5% of the total study population). The Linear-by-Linear Association 
p-value for the entire table is 0.43.
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can be explained by the observed differences in baseline clinical risk factors, but not 
by confounding due to study drug allocation, since the latter was similar over the three 
clinical risk strata (p=0.296, table 1).
Adjusted HRs for the treatment effect of perindopril were 0.72, 0.70 and 0.91 for the 
lowest to highest clinical risk tertiles respectively. Heterogeneity of treatment effect was 
tested and ruled out (p=0.31). Thus, the relative treatment benefit was not modified by 
the baseline clinical risk level. However, baseline clinical risk level did modify absolute 
risk reductions. The use of perindopril in the overall study population (n=8726) resulted 
in a 2.23% risk reduction of the primary endpoint (95% CI: 1.03 – 3.44, annual NNT 189, 
95% CI:122-401). However, absolute risk reductions varied from 1.24% to 2.17% and 
3.97% in the lowest, medium and highest clinical risk tertiles. As a consequence, NNTs 
were inversely related to increasing clinical risk scores (table 4).
Table 4. numbers needed to treat (per annum)
Clinical risk level low Medium High
Clinical risk score 0-6 7-9 10-21
NNT per clinical risk stratum 382 218 119
NNT per pharmacogenetic risk stratum
0 93 54 29
1 164 92 50
2 521 298 164
≥3* −529 −302 −164
*Stratum with non-significant risk increase due to use of perindopril.
In separate analyses with only cardiovascular mortality or
nonfatal MI as sole endpoint, we observed directional
concordance, compared to the presented analysis of the
combined primary endpoint, with respect to NNTs over the
various clinical and pharmacogenetic risk strata.
Discrimination and Calibration of the Clinical and
Combined Risk Models
Calibration and discrimination were assessed for 2 models:
(1) the model consisting of clinical risk score only and (2) the
full model consisting of clinical risk score, PGXscore, and
treatment9PGXscore interaction.
Addition of pharmacogenetic information on top of clinical
risk proﬁle resulted in better discrimination. The c-index for
the full model (0.68; 95% CI: 0.66–0.70) was signiﬁcantly
higher than the c-index for the model consisting of the clinical
risk score only (0.66; 95% CI: 0.64–0.68; P=0.0015). The full
model also resulted in a signiﬁcantly better discrimination
when assessed with integrated discrimination improvement
(magnitude of increase in IDI: 0.00472; P=0.0002). Validation
of both models by bootstrap methods showed that the bias in
the estimated discrimination performance (c-index) is likely to
be small, because the mean optimism estimates were only
0.006 and 0.007 for the clinical risk score and the full model,
respectively. Finally, the H-L goodness-of-ﬁt tests were
nonsigniﬁcant (P=0.43 for the model with the clinical risk
Table 2. Clinical Risk Scores of Baseline Risk Parameters
Continuous Clinical Risk Parameters
Clinical
Risk
Score
PointsAge, y
Systolic
Blood
Pressure
Creatinine
Clearance
Total Cholesterol,
mmol/L (mg/dL)
<67 ≤130 >70 ≤3.5 (≤135) 0
67 to 69 >130 to ≤160 >55 to ≤70 >3.5 to ≤5.0
(>135–≤193)
1
70 to 72 >160 >35 to ≤55 >5.0 to ≤6.5
(>193–≤251)
2
73 to 76 ≤35 >6.5 to ≤8.0
(>251–≤309)
3
77 to 79 >8.0 (>309) 4
80 to 82 5
83 to 85 6
>85 7
Dichotomous Clinical Risk Parameters Clinical Risk Score Points
Previous stroke or PAD 3
Male sex 2
Obesity (BMI >30 kg/m2) 2
Current smoking 2
Symptomatic CAD 2
Diabetes mellitus 2
Previous MI 2
Family history of CAD 1
Previous revascularisation 1
The range of clinical risk scores=0 to 32 and points for each of applicable variables need
to be added to each other. BMI indicates body mass index; CAD, coronary artery disease;
MI, myocardial infarction; PAD, peripheral artery disease.
Figure 1. Clinical risk score distribution. The mean value of the
clininal risk score (N=8726) was of 7.672.83.
Table 3. Distribution of Patients Over Clinical and
Pharmacogenetic Risk Strata
Clinical risk level Low Medium High
Clinical risk score 0 to 6 7 to 9 10 to 21
Pharmacogenetic risk score N (%)
0 362 (4.1) 390 (4.5) 232 (2.7)
1 945 (10.8) 1037 (11.9) 618 (7.1)
2 1027 (11.8) 1144 (13.1) 655 (7.5)
≥3 833 (9.5) 903 (10.3) 580 (6.6)
Treatment beneﬁt of perindopril was only demonstrated within the group of patients with
pharmacogenetic risk scores <3 (N=6410, 73.5% of the total study population). The
linear-by-linear association P value for the entire table is 0.43.
Table 4. Numbers Needed to Treat (Per Annum)
Clinical risk level Low Medium High
Clinical risk score 0 to 6 7 to 9 10 to 21
NNT per clinical risk stratum 382 218 119
NNT per pharmacogenetic risk stratum
0 93 54 29
1 164 92 50
2 521 298 164
≥3* 529 302 164
*Stratum with nonsigniﬁcant risk increase attributed to use of perindopril. NNT indicates
numbers needed to treat.
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figure 1. Clinical Risk score distribution
The mean value of the clinical risk score (N=8726) was of 7.67 +/- 2.83
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The pharmacogenetic risk scoring system, based on the previously identified 3 SNPs, 
is presented the Online data supplement. Risk alleles for lack of treatment benefit were 
T, C, and G for Rs275651, Rs5182 and Rs12050217 respectively. The individual PGXscores 
range from 0-6 points with a mean value of 1.82 +/- 1.13 (table 1). Significant heteroge-
neity of treatment effect across pharmacogenetic profiles was observed. A pronounced 
treatment benefit was observed in 6410 patients (73.5%) with PGXscore <3 (adjusted HR 
0.67, 95% CI: 0.56-0.79), whereas no benefit was observed in the remaining subgroup of 
2316 patients (26.5%) with PGXscore ≥3 (adjusted HR 1.26, 95% CI: 0.97-1.67) (table 3 for 
patient distribution).
The use of perindopril in patients with PGXscores of 0 and 1 point resulted in absolute 
risk reductions of 7.50% (95% CI: 3.69 – 11.73) and 4.30% (95% CI: 2.00 – 6.53) respec-
tively. Consequently, annual numbers needed to treat were 55 (95% CI: 113 – 38) for 
patients with a PGXscore of 0 and 97 (95% CI: 210 – 63) for patients with a PGXscore of 1. 
The point estimate of the absolute risk reduction associated with the use of perindopril 
in the subgroup of PGXscore of 2 was in the same positive direction, yet non-significant 
(1.34%, 95% CI: −0.77 to 3.47 and NNT (per annum)= 311, 95% CI: −546 to 122).
In contrast, a non-significant estimated absolute risk increase of 1.32% was observed 
in patients with a PGXscore ≥3 using perindopril (95% CI for risk increase −0.97 to 3.67 
and NNT (per annum)= −315, 95% CI: −118 to 433).
Combined baseline clinical and pharmacogenetic risk profiles
Mean pharmacogenetic risk scores were identical over all three clinical risk strata 
(p=0.435, table 1) and formal testing did not trace interaction between the clinical and 
PGXscores. The distribution of patients over the various clinical and pharmacogenetic 
risk strata is given in table 3. Figures 2a-2d describe the relation between absolute risks 
of the primary endpoint, clinical risk profile and treatment for each of the separate 
pharmacogenetic risk strata. Lack of treatment benefit was observed across the entire 
spectrum of clinical risk in patients with a PGXscore ≥3 (figure 2d and figure 3).
Increasing clinical risk scores led to increasingly pronounced risk differences between 
perindopril and placebo in all pharmacogenetic strata. Hence, extremes of treatment 
effect were found in patients with high clinical risk profiles. For example, the use of 
perindopril in patients with a clinical risk score of 19 resulted in an estimated absolute 
risk reduction of 28.42% (95% CI: 22.46 – 34.09) in case of a PGXscore of 0 versus an 
estimated risk increase of 5.82% (95% CI: 1.78 – 9.83) in case of a PGXscore ≥3 (figure 3). 
Concordantly, NNTs decreased in subgroups with higher clinical risk profiles and lower 
PGXscores, both of which were associated with more pronounced treatment effects 
(table 4). Estimated numbers needed to treat were as low as 29 (95% CI: 17 – 113) in 
patients with a high clinical risk profile and a PGXscore of 0, whereas those with a low 
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clinical risk profile and a PGXscore of ≥3 did not experience any benefit (NNT= −529, 
95% CI: −105 to 189).
In separate analyses with only cardiovascular mortality or non-fatal MI as sole 
endpoint, we observed directional concordance, compared to the presented analysis 
of the combined primary endpoint, with respect to NNTs over the various clinical and 
pharmacogenetic risk strata.
score only and P=0.94 for the full model), indicating adequate
calibration for both models (Figure 4).
Cost-Effectiveness of Tailored Perindopril
Treatment on the Basis of Pharmacogenetic
Testing
The results of the cost-effectiveness analysis, against the
strategy of no treatment with perindopril as comparator, are
displayed in Table 5.
The highest number of gained life-years is observed in
strategies 3 and 4. Strategy 3 implies that all patients are
genetically tested and only those with a PGXscore of 0 to 2
are treated with perindopril. Strategy 4 implies that none of
the patients are genetically tested and all are treated with
perindopril. Strategy 4, however, is dominated by strategy 3.
The lower incremental cost-effectiveness ratio (ICER) of
strategy 3 indicates that tailored perindopril therapy on the
basis of the PGXscore will ultimately reduce costs, with a
similar effectiven ss in terms of gained life-years.
Strategy 1 results in the least life-years gained, but also
in the least costs and the lowest ICER and therefore may be
an option when strictly reasoning from the cost perspective
alone.
Figure 2. Absolute risks of the primary endpoint across different clinical (X-axis) and pharmocogenetic
risk strata (Panels A through D). P values were derived from multivariate Cox proportional hazards
regression models ﬁtted with the following covariates: clinical risk score; PGXscore; treatment; and
treatment9PGXscore interaction. PGXscore indicates pharmacogenetic risk score.
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figure 2. absolute risks of the primary endpoint across different clinical and pharmocogenetic risk 
strata
P-values were derived from multivariate Cox proportional hazards regression models fitted with the 
following covariates: clinical risk score, PGXscore, reatment and treatment*PGXscore interaction. PGX-
score= pharmacogenetic risk score
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Discrimination and calibration of the clinical and combined risk models
Calibration and discrimination were assessed for two models: A) the model consisting 
of clinical risk score only, and B) the full model consisting of clinical risk score, PGXscore 
and treatment*PGXscore interaction.
Addition of pharmacogenetic information on top of clinical risk profile resulted in 
better discrimination. The c-index for the full model (0.68, 95% CI: 0.66-0.70) was sig-
nificantly higher than the c-index for the model consisting of the clinical risk score only 
(0.66, 95% CI: 0.64-0.68) (p=0.0015). The full model also resulted in a significantly better 
discrimination when assessed with integrated discrimination improvement (magnitude 
of increase in IDI: 0.00472, p=0.0002). Validation of both models by bootstrap methods 
showed that the bias in the estimated discrimination performance (c-index) is likely to 
be small, since the mean optimism estimates were only 0.006 and 0.007 for the clinical 
Discussion
The present study highlights that clinical as well as pharma-
cogenetic determinants independently modify absolute treat-
ment beneﬁt by ACE inhibitor perindopril in a population of
patients with stable CAD. M reover, both linical and
pharmacogenetic proﬁles could be expressed in risk scores
that are fairly simple to use for clinical decision making. We
propose the use of a PGXscore on top of known clinical risk
factors for better risk stratiﬁcation and more concrete
estimation of absolute tre ment beneﬁts of ACE-inhibitor
therapy in daily clinical practice. Increasing clinical risk scores
and decreasing PGXscores were consistently and positively
related to the absolute treatment beneﬁt by ACE-inhibitor
perindopril. Impressive risk gradients and, as a consequence,
important differences in NNT were found across various
subgroups. The annual NNT in the overall study population
was 189, whereas estimates as low as 106 for the entire
clinical high-risk subgroup and even 29, in case of a combined
high clinical risk proﬁle and a PGXscore of 0, were observed.
On the other hand, the entire subgroup of patients with a
PGXscore ≥3 (26.5% of the overall study cohort) was
characterized by a lack of treatment beneﬁt, which was
consistent across all 3 clinical risk levels.
The clinical risk score in our study was based upon easily
obtainable traditional risk factors that have repeatedly proven
to be valuable predictors.18–20 The full model predicted the
highest absolute risk reductions in patients with higher
clinical risk proﬁles. In this regard, it remains important to
emphasize that formally no heterogeneity of relative treat-
ment effect was found across the various clinical risk levels.
Furthermore, the mean clinical risk score in the high-risk level
was 11.53. Scores of, for example, 19 can therefore be
regarded as extremely high. Such extreme risk scores were
under-represented in our randomized, clinical trial data, but
nevertheless such patients do present themselves in clinical
practice. It is plausible that in such extremely high-risk
individuals, the risk is largely determined by the aforemen-
tioned risk factors, and that an ACE inhibitor alone will have
relatively less effect on survival. In other words, the magni-
tude of both controllable and uncontrollable clinical risk
factors in such a patient could have a relatively more
profound ffect on the risk of reaching the primary endpoint
than the potential relative treatment beneﬁt by an ACE
inhibitor alone. Obviously, the absolute risk beneﬁt will
remain high in such patients, and treatment with an ACE-
inhibitor should therefore be warranted. This ﬁnding, how-
ever, once again emphasizes the necessity of proper
management of all controllable risk factors in patients with
stable CAD.
Figure 3. Absolute risk reduction (Y-axis on a 0 to 1 scale) by
perindopril across different levels of clinical (X-axis) and pharma-
cogenetic risk. PGXscore indicates pharmacogenetic risk score.
Figure 4. Observed versus estimated risks according to the clinical and combined (full) risk prediction
models. P values were derived from Hosmer-Lemeshow goodness-of-ﬁt test.
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figure 3. absolute risk reduction (Y-axis on a 0 to 1 scale) by perindopril across different levels of 
clinical (X-axis) and pharmacogenetic risk
PGXscore = pharmacogenetic risk score
Discussion
The present study highlights that clinical as well as pharma-
cogenetic determinants independently modify absolute treat-
ment beneﬁt by ACE inhibitor p rindopril in a population of
patients with stable CAD. Moreover, both clinical and
pharmacogenetic proﬁles could be expressed in risk scores
that are fairly simple to use for clinical decision making. We
propose the use of a PGXscore on top of known clinical risk
factors for better risk stratiﬁcation and more concrete
estimation of absolute treatment beneﬁts of ACE-inhibitor
therapy in daily clinical practice. Increasing clinical risk scores
and decreasing PGXscores were consistently and positively
related to the absolute treatment beneﬁt by ACE-inhibitor
perindopril. Impressive risk gradients and, as a consequence,
important differ nces in NNT were found across various
subgroups. The annual NNT in the overall study population
was 189, whereas estimates as low as 106 for the entire
clinical high-risk subgroup and even 29, in case of a combined
high clinical risk proﬁle and a PGXscore of 0, were observed.
On the other hand, the entire subgroup of patients with a
PGXscore ≥3 (26.5% of the overall study cohort) was
characterized by a lack of treatment beneﬁt, which w s
consistent across all 3 clinical risk levels.
The clinical risk score in our study was based upon easily
obtainable traditional risk factors that have repeatedly proven
to be valuable predictors.18–20 The full model predicted the
highest absolute risk reductions in patients with higher
clinical risk proﬁles. In this regard, it remains important to
emphasize that formally no heterogeneity of relative treat-
ment effect was found across the various clinical risk levels.
Furtherm r , the mean linical risk score i the high-risk level
was 11.53. Scores of, for example, 19 can th refore be
regarded as extremely high. Such extreme risk scores were
under-represented in our randomized, clinical trial data, but
nevertheless such patients do present themselves in clinical
practice. It is plausible that in such extremely high-risk
individuals, the risk is largely determined by the aforemen-
tioned risk factors, and that an ACE inhibitor alone will have
relatively less effect on survival. In other words, the magni-
tude of both controllable and uncontrollable clinical risk
factors in such a patient could have a relatively more
prof und effect on the risk of reaching the primary endpoint
than the potential relative treatme t ben ﬁt by an ACE
inhibitor alone. Obviously, the absolute risk beneﬁt will
remain high in such patients, and treatment with an ACE-
inhibitor should therefore be warranted. This ﬁnding, how-
ever, once again emphasizes the nec ssity of proper
management of all controllable risk factors in patients with
stable CAD.
Figure 3. Absolute risk reduction (Y-axis on a 0 to 1 scale) by
perindopril across different levels of clinical (X-axis) and pharma-
cogenetic risk. PGXscore indicates pharmacogenetic risk score.
Figure 4. Observed versus estimated risks according to the clinical and combined (full) risk prediction
models. P values were derived from Hosmer-Lemeshow goodness-of-ﬁt test.
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figure 4. Observed versus estimated risks according to the clinical and combined (full) risk predic-
tion models
P-values were derived from Hosmer-Lemeshow goodness-of-fit tests
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risk score and the full model, respectively. Finally, The H-L goodness-of-fit tests were 
non-significant (p=0.43 for the model with the clinical risk score only and p=0.94 for the 
full model), indicating adequate calibration for both models (figure 4).
Cost-effectiveness of tailored perindopril treatment on the basis of 
pharmacogenetic testing
The results of the cost-effectiveness analysis, against the strategy of no treatment with 
perindopril as comparator, are displayed in table 5.
The highest number of gained life-years is observed in strategies 3 and 4. Strategy 
3 implies that all patients are genetically tested and only those with a PGXscore of 0-2 
are treated with perindopril. Strategy 4 implies that none of the patients are genetically 
tested and all are treated with perindopril. Strategy 4 however is dominated by strategy 
3. The lower incremental cost-effectiveness ratio (ICER) of strategy 3 indicates that tai-
lored perindopril therapy on the basis of the PGXscore will ultimately reduce costs, with 
a similar effectiveness in terms of gained life-years.
Strategy one results in the least life-years gained, but also in the least costs and the 
lowest ICER and therefore may be an option when strictly reasoning from the cost per-
spective alone.
Table 5. Costs, gained life-years and incremental cost-effectiveness ratio of various treatment 
strategies, against the strategy of no treatment with perindopril as comparator.
Strategy Number of patients 
treated with 
perindopril, N (%)
Incremental 
costs 
(weighted)
Life-years 
gained 
(weighted)
ICER
1. Pharmacogenetic testing only in patients with 
a high clinical risk score (≥10) and perindopril 
treatment only if PGXscore=0-2
1505 / 8726 (17.2) 30.38 0.0017 18,139
2. Pharmacogenetic testing only in patients with 
a medium or high clinical risk score (≥7) and 
perindopril treatment only if PGXscore=0-2
4076 / 8726 (46.7) 90 0.0032 27,987
3. Pharmacogenetic testing in all patients and 
perindopril treatment only if PGXscore=0-2
6410 / 8726 (73.5) 147 0.0040 36,743
4. Perindopril treatment in all patients 
irrespective of PGXscore
8726 (100) 232 0.0035 67,230
The time horizon was restricted to the duration of the EUROPA trial/PERGENE study (mean follow-up of 
4.2 years). Costs are in euros. PGXscore = pharmacogenetic risk score. ICER = incremental cost-effective-
ness ratio
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DIsCussIOn
The present study highlights that clinical as well as pharmacogenetic determinants 
independently modify absolute treatment benefit by ACE-inhibitor perindopril in a 
population of patients with stable CAD. Moreover, both clinical and pharmacogenetic 
profiles could be expressed in risk scores that are fairly simple to use for clinical decision-
making. We propose the use of a PGXscore on top of known clinical risk factors for better 
risk stratification and more concrete estimation of absolute treatment benefits of ACE-
inhibitor therapy in daily clinical practise. Increasing clinical risk scores and decreasing 
PGXscores were consistently and positively related to the absolute treatment benefit by 
ACE-inhibitor perindopril. Impressive risk gradients and, as a consequence, important 
differences in NNTs were found across various subgroups. The annual NNT in the overall 
study population was 189, whereas estimates as low as 106 for the entire clinical high-
risk subgroup and even 29, in case of a combined high clinical risk profile and a PGXscore 
of 0, were observed. On the other hand, the entire subgroup of patients with a PGXscore 
≥3 (26.5% of the overall study cohort) was characterized by a lack of treatment benefit, 
which was consistent across all three clinical risk levels.
The clinical risk score in our study was based upon easily obtainable traditional risk 
factors that have repeatedly proven to be valuable predictors.18–20 The full model pre-
dicted the highest absolute risk reductions in patients with higher clinical risk profiles. 
In this regard, it remains important to emphasize that formally no heterogeneity of rela-
tive treatment effect was found across the various clinical risk levels. Furthermore, the 
mean clinical risk score in the high-risk level was 11.53. Scores of e.g. 19 can therefore 
be regarded as extremely high. Such extreme risk scores were underrepresented in our 
RCT data, but nevertheless such patients do present themselves in clinical practise. It is 
plausible that in such extremely high-risk individuals, the risk is largely determined by 
the aforementioned risk factors, and that an ACE-inhibitor alone will have relatively less 
effect on survival. In other words, the magnitude of both controllable and uncontrol-
lable clinical risk factors in such a patient could have a relatively more profound effect 
on the risk of reaching the primary endpoint, than the potential relative treatment 
benefit by an ACE-inhibitor alone. Obviously, the absolute risk benefit will remain high 
in such patients and treatment with an ACE-inhibitor should therefore be warranted. 
This finding, however, once again emphasises the necessity of proper management of 
all controllable risk factors in patients with stable CAD.
With this in mind, it is remarkable that a history of coronary revascularization was asso-
ciated with a modestly reduced risk for the primary endpoint (−1 point) in the presented 
risk model. This particular observation should be interpreted with some reservation, since 
several specifically designed trials, such as RITA-2,21 COURAGE22 and BARI 2D23 failed to 
demonstrate survival benefit of coronary revascularisation over optimal medical therapy.
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The pharmacogenetic risk score in our study was based upon three SNPs that have 
previously emerged after comprehensive coverage of the RAAS and KB systems and 
subsequent correction for multiple testing.12 Furthermore, the pharmacogentic risk 
score has previously been replicated in participants of the PROGRESS-trial.12 Clinical risk 
factors,6 renal function,8 degree of blood pressure reduction9 and a number of biomark-
ers24,25 have been explored within the EUROPA trial, yet only pharmacogenetic informa-
tion has permitted to distinguish responders to perindopril from non-responders (26.5% 
of all patients). Furthermore, the PGXscore accentuated striking differences in absolute 
treatment benefits of ACE-inhibitor therapy within each of the separate clinical risk 
strata.
The data that are presented here are unique. Although it is widely recognized that 
both phenotype as well as genotype play a fundamental role in health and disease 
outcome, very few reports exist that actually combine both for prognostication. To our 
best knowledge, this is the first and only manuscript that combines clinical and genetic 
information in patients with CAD. Pharmacogenetic information is successfully trans-
lated into a potential clinical utility to study the gradients of treatment effect by an ACE-
inhibitor. The sample size is large and various additional qualities of a well-designed 
placebo-controlled double-blinded RCT, such as high quality phenotypical data and 
independent event adjudication are apparent. Previous studies that have investigated 
the relation between genetic variation and treatment benefit by ACE-inhibitor therapy 
usually were characterized by small sample sizes and non-randomized designs without 
placebo controls.26 Only two studies with large sample sizes have been reported. Harrap 
and colleagues studied macrovascular events, dementia and cognitive decline in 5688 
patients with a history of cerebrovascular disease in the PROGRESS study and found no 
interaction between genetic variation and treatment benefit by perindopril.27
Negative findings were also published by the GenHAT investigators, who studied 
cardiovascular mortality and non-fatal MI in 7528 patients on a lisinopril based regi-
men in the setting of an active-controlled RCT.28 These two studies obviously differ from 
our present study in the type of study population, endpoints and study drug. The most 
remarkable difference with our study, however, is the fact that both studies solely fo-
cussed on a single ACE insertion/deletion polymorphism, thus not taking account of the 
full complexity of the RAAS and KB systems. Furthermore, our PGXscore was replicated 
in the PROGRESS study, in which a similar direction and magnitude of pharmacogenetic 
interaction was observed.12
Our findings also have some limitations. This study describes differences in treatment 
benefit across a range of clinical and genetic subgroups. The constituents of the clinical 
scoring system are all well established cardiovascular risk factors and the PGXscore has 
been replicated. Still, it is important to realize that, in general, any post-hoc analysis based 
on subgroups should primarily be regarded as hypothesis-generating. Confirmation of 
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our findings in other large datasets would invigorate the presented conclusions and 
derived clinical implications. The EUROPA trial was powered for detection of treatment 
benefit for the entire study population irrespective of clinical or pharmacogenetic risk 
categories. Thus lack of power cannot be excluded as an explanation for the observed 
non-significant treatment benefit in the higher PGX scores. On the other hand it must 
be noted the absolute numbers of study participants in PGXscores ≥ 2 are higher than 
those below (table 3).
Patients enrolled in the EUROPA trial primarily consisted of Caucasian males without 
overt heart failure, who were randomized to placebo or perindopril 8 mg daily. The 
generalizability of the presented results towards other patient groups, e.g. those with a 
higher proportion of women, heart failure, patients of other ethnicities, or those using 
other ACE-inhibitors or lower dosages of perindopril, may therefore be limited. Testing 
of these particular genetic variants in a large randomized heart failure trial would be 
required before suggesting the same phenomenon exists in that very different patient 
group.
Our combined primary endpoint consisted of cardiovascular mortality, non-fatal MI 
and resuscitated cardiac arrest. Resuscitated cardiac arrest however only occurred in 
very few instances. Therefore our results with respect to clinical and pharmacogenetic 
determinants of treatment benefit are primarily associated with the incidence of cardio-
vascular mortality and non-fatal MI.
In order to facilitate clinical utility and ease of use, we specifically chose to develop an 
integer-based risk score. Disadvantages of integer-based risk scores in general include 
the fact that not all variables have exactly the same contribution to the model. Further-
more, certain combinations of risk factors may act synergistically to increase risk in a 
manner that is more than additive. Such synergy may be underestimated in a purely 
additive integer-based risk score.29
Replication of the three SNPs that formed the PGXscore in the PROGRESS trial14 
demonstrated concordant associations between the risk score and treatment benefit by 
perindopril.12 The individual interaction terms of the three SNPs, however, did not reach 
statistical significance in that particular trial due to limited statistical power (replication 
could take place in 1051 patients only). Unfortunately larger replication cohorts are not 
available.
Although the clinical risk model consists of established cardiovascular risk factors, 
formally the combined clinical and pharmacogenetic risk score has not been indepen-
dently validated on a separate dataset.
Finally, our risk model does not contain data on circulating serum biomarkers other 
than total cholesterol and creatinine levels. A prespecified substudy of the EUROPA trial, 
called PERTINENT, actually did study bradykinin, angiotensin II, but also markers of en-
dothelial function (nitric oxide synthase) and inflammation (C-reactive protein, tumour 
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necrosis factor-α and von Willebrand factor). The use of perindopril was reflected in vari-
ous circulating biomarker levels which were interpreted as a biochemical indication of 
normalization of the angiotensin II/bradykinin balance, reduction of inflammation and 
prevention of endothelial apoptosis.24,25 Unfortunately, the cohort in which these bio-
markers were assessed was too small in order to properly study the interaction between 
the various serum biomarkers and treatment effect by perindopril on clinical endpoints.
In conclusion, our results show that a combination of phenotypical and genetic infor-
mation can be used to demonstrate a range of gradients of absolute treatment benefit by 
ACE-inhibitor therapy in an otherwise seemingly homogeneous population of patients 
with stable CAD. Clinical and pharmacogenetic profiling in individual patients may both 
clarify their distinct level of absolute risk of adverse events and furthermore also the 
degree of risk reduction by an ACE-inhibitor regimen. Refraining from ACE-inhibitor 
therapy in those patients that are expected to lack any treatment benefit may avoid un-
necessary side-effects, reduce healthcare costs and increase overall efficacy of the drug. 
Future randomized clinical trials could advance the field of individualized medicine by 
incorporation of a similar combined clinical and pharmacogenetic approach in their 
study design.
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OnlIne DaTa suPPleMenT
Individualized ACE-inhibitor Therapy in Stable Coronary Artery Disease Based on 
Clinical and Pharmacogenetic Determinants;
The PERGENE risk model
Rohit M. Oemrawsingh MD, MSc1,2, K. Martijn Akkerhuis MD PhD1, Laura C. Van Vark MD1, 
W. Ken Redekop PhD3 Goran Rudez PhD1, Willem J. Remme MD PhD4, Michel E. Bertrand 
MD PhD5, Kim M. Fox MD PhD6, Roberto Ferrari MD PhD7, A.H. Jan Danser PhD8, Moniek 
de Maat PhD9, Maarten L. Simoons MD PhD1, Jasper J. Brugts MD PhD1, Eric Boersma PhD 
MSc1; on behalf of the PERGENE investigators
Online Table 1. The regression coefficients from the final multivariable model that were converted 
to the clinical risk score.
Variable Regression coeeficients (ß)
Age (years) 0.023
Systolic bloodpressure (mmHg) 0.005
Creatinine clearance (ml/min) −0.004
Total cholesterol (mmol/L) 0.125
Previous stroke or PAD 0.552
Male gender 0.447
Obesity (BMI>30 kg/m²) 0.377
Current smoking 0.462
Symptomatic CAD 0.430
Diabetes mellitus 0.449
Previous MI 0.422
Family history of CAD 0.086
Previous revascularisation −0.168
For the continuous variables (age, systolic bloodpressure, creatinin clearance and total cholesterol) the 
regression coefficients are described per unit of increase of that particular independent variable.
Online Table 2. Pharmacogenetic risk score on the basis of allele distribution
Angiotensin-II type I-receptor Bradykinin type I receptor Pharmacogenetic
Risk score pointsSNP: Rs275651 Rs5182 Rs12050217
AA TT AA 0
AT CT AG 1
TT CC GG 2
The range of pharmacogenetic risk scores = 0-6. Risk alleles for decreased benefit of perindopril treat-
ment were T, C, and G for Rs275651, Rs5182 and Rs12050217 respectively. Points for each of the three 
separate SNPs need to be added to each other. E.g. a patient with AA, CC, AG (for Rs275651, Rs5182 and 
Rs12050217 respectively) has an individual pharmacogenetic risk score of 0+2+1 =3
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absTRaCT
aim: Previous studies have shown contradictory outcomes in ST-segment elevation 
myocardial infarction (STEMI) patients who underwent primary percutaneous coronary 
intervention (pPCI) during off-hours versus regular ‘office’ hours. We aimed to evaluate 
the relationship between pPCI timing (off-hours versus regular hours) and mortality in 
patients with STEMI undergoing pPCI.
Methods: The study population comprised 4352 consecutive STEMI patients treated 
with pPCI in a high-volume centre with a 24/7 programme during 2000–2009. Descrip-
tive statistics and multivariable survival analyses were applied to evaluate the rela-
tionship between treatment during off-hours (Monday–Friday, 6.00 pm–8.00 am and 
weekends) versus regular hours and the incidence of all-cause mortality at 30-day and 
4-year follow-up.
Results: A total of 2760 patients (63.4%) were treated during off-hours and 1592 patients 
(36.6%) during regular hours. With the exception of smoking, diabetes mellitus, use of 
glycoprotein IIb/IIIa antagonists and calcium antagonists, no major differences in base-
line characteristics were observed between the groups. Mortality at 30-day follow-up 
was similar in patients treated during off-hours and those treated during regular hours 
(7.7% vs 7.7%; hazard ratio adjusted for potential confounders 1.03; 95% CI 0.82–1.28). 
Four-year mortality was similar (17.3% vs 17.3%; adjusted hazard ratio 0.95; 95% CI 
0.81–1.11).
Conclusion: In STEMI patients who present during off-hours in a high-volume centre 
with 24/7 service, pPCI provides similar survival as patients who were treated during 
regular hours.
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InTRODuCTIOn
Randomised clinical trials have convincingly demonstrated that patients with ST-
segment elevation myocardial infarc tion (STEMI) who undergo primary percutaneous 
coronary intervention (pPCI) have better event-free survival and clinical outcomes than 
those treated with fibrinolysis.1 In order to fully benefit from the instantaneous and 
long-term effects of pPCI, patients need to be treated as soon as pos sible after symptom 
onset. Guidelines recommend that pPCI be performed within 90 minutes of the first 
medical contact.2–3 This recommendation is supported by several studies that reported 
a direct relation between (increased) time delay to pPCI and (worse) clinical outcome.4–6 
Short onset-to-treatment times are best guaranteed in hospitals with an established 
interventional cardiology programme that offers full service 24 hours per day, 7 days per 
week (24/7 programme).2–3
Since the occurrence of STEMIs are more or less ran domly distributed over time, in a 
24/7 programme, most patients will be treated during ‘off-hours’ – evening and night 
shifts and weekends. Previous studies have shown contradictory outcomes in STEMI 
patients who underwent pPCI during off-hours versus regular ‘office’ hours. However, 
most of these studies were conducted in centres using both fibrinolysis and pPCI for 
treatment of patients with STEMI, and did not evaluate long-term outcomes.7–18 In the 
year 2000, pPCI became the standard treatment for STEMI in our institution and a 24/7 
programme was estab lished. Baseline, procedural and follow-up data of all patients 
undergoing PCI in our institution were systemati cally collected. Consequently, we were 
able to evaluate the relationship between pPCI timing (off-hours versus regular hours) 
and short- and long-term outcome in STEMI patients.
MeTHODs
Patient population
The Erasmus MC is a tertiary referral and teaching hospital in the broader region of 
Rotterdam (approximately 1.9 mil lion inhabitants), located on the North bank of the 
Maas River. Between January 2000 and June 2004, the Erasmus MC was the only hospital 
in the region with pPCI facilities. From July 2004 onwards, the Maasstad hospital (also 
located in Rotterdam, on the south bank of the Maas River) started a 24/7 programme 
locally and provided regional pPCI service on Mondays and Thursdays and the first 
weekend of every month to improve service. The Erasmus MC provided pPCI service on 
the remaining days.
All consecutive patients 18 years or older who presented within 12 hours of symptom 
onset with ST-segment eleva tion myocardial infarction (STEMI) and who subsequently 
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underwent pPCI in our institution between January 2000 and December 2009 were in-
cluded in the analysis. STEMI is defined as patients presenting with ischaemic symptoms 
and persistent (>20 min) ST-segment elevation in at least two contiguous precordial 
leads or at least two adjacent limb leads by ECG.3 In total, 4541 pPCIs in 4352 patients 
were performed. In patients who were admitted more than once for pPCI (n =189), only 
the initial procedure was used for this analysis.
Patient management
Patient management was in accordance with the applicable guidelines of the European 
Society of Cardiology (ESC). Patients received an aspirin and a loading dose of clopi-
dogrel (300–600 mg) before pPCI and preferably in the ambulance. Clopidogrel (75 mg/
day) was given for at least one month in patients treated with bare metal stents (BMS), 
at least 3 months for patients treated with sirolimus-eluting stents (SES) and at least 
6 months in patients treated with paclitaxel-eluting stents (PES) or everolimus-eluting 
stents (EES). After the procedure, all patients were advised to remain on aspirin (>80 
mg/day) indefinitely. Periprocedural glycoprotein IIb/IIIa antagonists were left to the 
discretion of the treating interventional cardiologist.
Since 2000, the interventional cardiology department has the policy of using one 
particular stent as default in a given time interval. The default stent between January 
2000 and April 2002 was a BMS, between April 2002 and March 2003 a SES, between 
March 2003 and March 2007 a PES, and an EES since March 2007. Of note, during the 
study period a small number of STEMI patients was treated with another stent due to 
participation in a clinical trial compar ing stents.
Data collection
According to the approved standard data-management pro cedures in our department, 
data are collected on demograph ics, cardiovascular history, clinical risk factors and 
treatment characteristics for all patients undergoing PCI and are stored in an electronic 
database. Data elements are filled out imme diately after the completion of the PCI by 
the interventional cardiologist and the technician who assisted during the pro cedure. 
The database, which is maintained by a dedicated IT officer, is mainly designed for ad-
ministrative purposes. A systematic evaluation of data completion and data integrity is 
implemented for data that are used for research purposes.
Data management and follow-up
Mortality data related to the entire cohort was obtained from interrogation of mu-
nicipal civil registries between April and September 2011. A health questionnaire was 
sub sequently sent to all living patients with specific inquiries on rehospitalisation and 
major adverse cardiovascular events (MACE). For patients who had adverse events at 
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other centres, medical records or discharge summaries from the other institutions were 
systematically reviewed. General practitioners, referring cardiologists and patients were 
con tacted in case further information was required.
endpoint definitions
The primary endpoints were early mortality, which was defined as all-cause mortality 
within 30 days of the index event, and late mortality, which includes all-cause mortality 
at 1-year and 4-year follow-up. The secondary endpoints included repeat PCI (rePCI), 
coronary artery bypass grafting (CABG) or recurrent MI (reMI) and the composite end-
point of reMI, revascularisation (rePCI or CABG) and all-cause mortality at 30-day, 1-year 
and 4-year follow-up. ReMI at follow-up was diagnosed by recurrent typical clinical 
symp toms, the development of ST-segment elevation or left bun dle branch block on 
electrocardiography with a CK-MB rise of three times the upper limit of normal and/or 
positive troponin levels in laboratory values. rePCI was defined as a repeat percutaneous 
intervention of any lesion located in the epicardial vessels. CABG was defined as a surgi-
cal inter vention of any lesion located in the epicardial vessels.
statistical methods
Off-hours were defined as weeknights (Monday to Friday from 6.00 pm to 8.00 am) and 
weekends (from Friday 6.00 pm to Monday 8.00 am).
Continuous variables are presented as mean ± standard deviation and categorical 
variables are expressed as num bers and percentages. Student’s t-tests, Chi-square tests 
and Fisher’s exact tests were applied to evaluate differences in baseline variables be-
tween patients treated during off-hours and regular hours, as appropriate.
We intended to obtain complete information in all patients, but failed to do so for the 
medication at discharge. Using missing value analysis (MVA) we evaluated the extent of 
missing data and searched for patterns of missing data. MVA showed that there were 
6.2% missing values on average for medication at discharge. For the patients with at 
least one of the variables of interest missing, we decided to impute the missing values 
by multiple imputation.19
The incidence of events over time was studied with the use of the Kaplan-Meier meth-
od, whereas log-rank tests were applied to evaluate differences between the treatment 
groups (treatment during off-hours versus regular hours). Patients lost to follow-up were 
considered at risk until the date of last contact at which point they were censored.
Cox proportional hazard (PH) regression models were applied to evaluate the rela-
tionship between treatment during off-hours versus regular hours and the incidence 
of all-cause death at 30 days, 1 year and 4 years. The baseline clinical and procedural 
characteristics that are listed in Table 1 were con sidered as potential confounders for the 
1-year and 4-year mortality analysis. As the number of events was limited at 30 days, we 
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were only able to adjust for the following clinically relevant factors: age, sex, multi-vessel 
disease, shock, previ ous MI, renal impairment and diabetes mellitus.
Final results are presented as adjusted hazard ratios (aHR) with 95% confidence 
interval (CI). All statistical tests were two-tailed and a p-value <0.05 was considered sig-
nificant. Statistical analyses were performed with SPSS for Windows version 17.0 (SPSS 
Inc, Chicago, Illinois, USA).
Table 1. baseline and procedural characteristics according to pPCI timing.
Off-hours n =2760 Regular hours N =1592 p-value
Age (years ±SD) 60.9±12.8 61.5±12.5 0.14
Male (%, n) 73.5, 2029 75.2, 1197 0.23
Medical history
Hypertension (%, n) 40.1, 1107 38.6, 614 0.32
Hypercholesterolaemia 72.4, 1998 71.4, 1137 0.49
Diabetes mellitus (%, n) 13.0, 358 10.4, 165 0.011
Family history (%, n) 28.6, 790 27.6, 439 0.46
Current smokers (%, n) 41.8, 1154 36.0, 573 <0.001
Previous MI (%, n) 12.1, 334 13.1, 209 0.32
Previous PCI (%, n) 9.2, 147 7.9, 217 0.12
Previous CABG (%, n) 2.4, 66 3.2, 51 0.11
Renal impairment (%, n) 2.1, 57 1.8, 29 0.58
Procedural characteristics
Cardiogenic shock (%, n) 4.9, 135 4.8, 76 0.86
Vessel disease 0.63
1-vessel disease (%, n) 54.8, 1513 55.2, 878
2-vessel disease (%, n) 26.9, 742 27.6, 440
3-vessel disease (%, n) 18.3, 505 17.2, 274
Multi-vessel disease (%, n) 45.2, 1247 44.8, 714 0.83
Treated vessel 0.35
Left main (%, n) 3.5, 97 4.5, 71
RCA (%, n) 34.0, 938 35.3, 562
LCX (%, n) 14.3, 396 13.4, 213
LAD (%, n) 46.6, 1285 44.9, 715
Graft (%, n) 0.6, 17 0.9, 15
Glycoprotein IIb/IIIa antagonists (%, n) 16.5, 456 21.4, 340 <0.001
Discharge medication
Aspirin (%, n) 90.1, 2599 90.2, 1338 0.91
Calcium antagonist (%, n) 14.5 378 19.8, 294 <0.001
Beta-blockers (%, n) 51.6, 1342 54.0, 801 0.14
RAAS-inhibitors (%, n) 41.7, 1085 39.9, 592 0.25
Statins (%, n) 71,6, 1861 71.2, 1056 0.79
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ResulTs
Key characteristics
Between 1 January 2000 and 31 December 2009, a total of 4352 consecutive patients 
presenting with STEMI under went pPCI in our institution. A total of 2760 patients 
(63.4%) were treated during off-hours and 1592 patients (36.6%) during regular hours. 
Key characteristics of the two cohorts are presented in Table 1. With the exception of 
diabetes mellitus (13.0% vs 10.4%, p = 0.011), current smoking (41.8% vs 36.0%, p < 
0.001) and use of glyco protein IIb/IIIa antagonists (16.5% vs 21.4%, p < 0.001), no statis-
tically significant differences in baseline and pro cedural characteristics were observed 
between the groups. It is noteworthy that the percentage of patients presenting with 
cardiogenic shock was similar in both groups (4.9% and 4.8%, respectively, p = 0.86). 
There were also no sta tistically significant differences in discharge medication, except 
for the use of calcium antagonists (14.5% vs 19.8%, p < 0.001).
Mortality
Information on survival status at 1-year follow-up was complete for 96.5% of patients. 
The median follow-up period was 1246 days (IQR 651–2228 days).
The cumulative incidence of all-cause mortality at 30-day follow-up was similar in the 
patients treated during off-hours and those treated during regular hours 7.7% vs 7.7% 
respectively (Kaplan Meier estimates). Similarly, no statistically significant differences 
were observed in all-cause mortality at 1-year (10.9% vs 12.5%) and 4-year fol low-up 
(17.3% vs 17.3%). In fact, the cumulative incidence curves were superimposed through-
out the entire 4-year follow-up period (Figure 1A). Multivariable adjustment for potential 
36 European Heart Journal: Acute Cardiovascular Care 1(1)
mortality analysis. As the number of events was limited at 30 
days, we were only able to adjust for the following clinically 
relevant factors: age, sex, multi-vessel disease, shock, previ-
ous MI, renal impairment and diabetes mellitus.
Final results are presented as adjusted hazard ratios 
(aHR) with 95% confidence interval (CI). All statistical 
tests were two-tailed and a p-value <0.05 was considered 
significant. Statistical analyses were performed with 
SPSS for Windows version 17.0 (SPSS Inc, Chicago, 
Illinois, USA).
Results
Key characteristics
Between 1January 2000 and 31 December 2009, a total of 
4352 consecutive patients presenting with STEMI under-
went pPCI in our institution. A total of 2760 patients 
(63.4%) were treated during off-hours and 1592 patients 
(36.6%) during regular hours. Key characteristics of the 
two cohorts are presented in Table 1. With the exception 
of diabetes mellitus (13.0% vs 10.4%, p = 0.011), current 
smoking (41.8% vs 36.0%, p < 0.001) and use of glyco-
protein IIb/IIIa antagonists (16.5% vs 21.4%, p < 0.001), 
no statistically significant differences in baseline and pro-
cedural characteristics were observed between the groups. 
It is noteworthythat the percentage of patients presenting 
with cardiogenic shock was similar in both groups (4.9% 
and 4.8%, respectively, p = 0.86). There were also no sta-
tistically significant differences in discharge medication, 
except for the use of calcium antagonists (14.5% vs 
19.8%, p < 0.001).
Mortality
Information on survival status at 1-year follow-up was 
complete for 96.5% of patients. The median follow-up 
period was 1246 days (IQR 651–2228 days).
The cumulative incidence of all-cause mortality at 
30-day follow-up was similar in the patients treated during 
off-hours and those treated during regular hours 7.7% vs 
7.7% respectively (Kaplan Meier estimates). Similarly, no 
statistically significant differences were observed in all-
cause mortality at 1-year (10.9% vs 12.5%) and 4-year fol-
low-up (17.3% vs 17.3%). In fact, the cumulative incidence 
curves were superimposed throughout the entire 4-year 
follow-up period (Figure 1A). Multivariable adjustment for 
potential confounders of the relation between treatment tim-
ing and the incidence of all-cause mortality did not change 
this finding (aHR at 4 years 0.96 and 95% CI 0.81–1.12).
Non-fatal and composite endpoints
We did not find any clinically relevant difference in the 
incidence of non-fatal endpoints between patients treated 
during off-hours vs regular hours. Results were similar at 
short-term and long-term follow-up (Table 2, Figure 1B–
D). At 4-year follow-up, the crude cumulative incidences of 
reMI were 5.5% and 4.6%, the incidences of CABG were 
1.6% and 3.0%, and the incidences of rePCI were 12.9% 
and 13.4%, respectively. Again, cumulative incidence 
curves were superimposed for all these endpoints. 
Treatment timing had no contribution in multivariable Cox 
PH models that related patient characteristics with non-
fatal clinical outcomes. Adjusted HRs of treatment timing 
Figure 1. Clinical outomes according to regular vs off hours. (A) all-cause mortality, (B) reMI, (C) rePCI, (D) CABG, (E) composite 
endpoint of all-cause mortality, reMI, rePCI and CABG.
figure 1. Clinical outc mes according to regular vs off hours. (a) all-cause mortality, (b) reMI, 
(C) rePCI, (D) CabG, (e) composite endpoint of all-cause mortality, reMI, rePCI and CabG.
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confounders of the relation between treatment tim ing and the incidence of all-cause 
mortality did not change this finding (aHR at 4 years 0.96 and 95% CI 0.81–1.12).
non-fatal and composite endpoints
We did not find any clinically relevant difference in the incidence of non-fatal endpoints 
between patients treated during off-hours vs regular hours. Results were similar at short-
term and long-term follow-up (Table 2, Figure 1B–D). At 4-year follow-up, the crude cu-
mulative incidences of reMI were 5.5% and 4.6%, the incidences of CABG were 1.6% and 
3.0%, and the incidences of rePCI were 12.9% and 13.4%, respectively. Again, cumulative 
incidence curves were superimposed for all these endpoints. Treatment timing had no 
contribution in multivariable Cox PH models that related patient characteristics with 
non-fatal clinical outcomes. Adjusted HRs of treatment timing were not significant and 
close to 1 for all endpoints at all three follow-up times that we studied.
The cumulative incidence of the composite endpoint of all-cause death, reMI, PCI or 
CABG at 4-year follow-up was 29.5% in patients treated during off-hours and 29.5% in 
those treated during regular hours (Table 2, Figure 1E). The aHR was 1.05 and the 95% CI 
ranged from 0.93 to 1.18, indicating that there was no association between treat ment 
timing and the incidence of this composite endpoint.
findings in subgroups
Figure 2 shows the relationship between treatment timing and 30-day all-cause mor-
tality in a number of clinically rel evant subgroups. All in all, in the subgroups that we 
consid ered, we found no major deviations from the overall result. Except in the category 
relating to the history of MI, 95% confidence intervals of treatment effect were largely 
over lapping, and none of the formal heterogeneity tests was sta tistically significant.
DIsCussIOn
In this long-term follow-up study of STEMI patients who were treated during 2000–2009 
in a high-volume centre with 24/7 service, clinical outcomes were similar in patients un-
dergoing pPCI during off-hours and during regular hours. This similarity in outcome was 
already observed at 30 days and was maintained until 4 years after the initial procedure. 
Consistent results were seen in clinically relevant subgroups, including the elderly and 
patients with multi-vessel disease.
The quality of care delivered to STEMI patients may differ during day and night be-
cause of variations in door-to-balloon time, performance of physicians, catheterisation 
laboratory and coronary care staff. Compared to regular office hours, hospital staffing 
is generally reduced during nights and on weekends compared with weekdays. The 
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short-term outcome (after adjustment for any differences in case mix) may be regarded 
as a proxy measure of the qual ity of care during the procedure, whereas the long-term 
out come to a greater extent depends on the development of the disease, the use of 
long-term medication and (probably) the use of coronary revascularisations. Interest-
ingly, we found few differences in baseline characteristics between patients treated 
during off-hours and regular hours. Also medical treatment at discharge was similar. 
Apparently, in the region of Rotterdam, STEMI patients constitute a homogeneous 
population, regardless of the timing of presentation. Consequently, the point estimates 
of the effect of treatment timing did not change after adjustment for patient charac-
teristics. The estimates of the effect for all the endpoints indicated that treatment during 
off-hours is as safe and effective as treatment during regular hours.
Previous studies have shown contradictory results in out come in STEMI patients who 
underwent pPCI during off-hours versus regular hours. Whereas some studies showed 
de Boer et al. 37
were not significant and close to 1 for all endpoints at all 
three follow-up times that we studied.
The cumulative incidence of the composite endpoint of 
all-cause death, reMI, PCI or CABG at 4-y ar follow-up 
was 29.5% in patients treated during off-hours and 29.5% 
in those treated during regular hours (Table 2, Figure 1E). 
The aHR was 1.05 and the 95% CI ranged from 0.93 to 
1.18, indicating that there was no association between treat-
ment timing and the incidence of this composite endpoint.
Findings in subgroups
Figure 2 shows the relationship between treatment timing 
and 30-day all-cause mortality in a number of clinically rel-
evant subgroups. All in all, in the subgroups that we consid-
ered, we found no major deviations from the overall result. 
Except in the category relating to the history of MI, 95% 
confidence intervals of treatment effect were largely over-
lapping, and none of the formal heterogeneity tests was sta-
tistically significant.
Discussion
In this long-term follow-up study of STEMI patients who 
were treated during 2000–2009 in a high-volume centre with Ta
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Figure 2. Treatment during off hours in different subgroups.figure 2. Treatment during off hours in different subgroups.
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that presentation and treatment during off-hours only had limited impact on in-hospital 
mortality,7,9,12,13,15,16,18 other studies revealed higher in-hospital mortality in pPCI patients 
during off-hours than regular hours.8,10,11,14 A straightforward comparison of these 
clinical studies is com plicated by differences in patient characteristics and (medi cal) 
co-treatment, as well as by the applied definitions. For example, Henriques et al, who 
reported higher mortality after off-hour treatment, focused on the circadian patterns of 
symptom onset, including routine duty hours (0800–1800) versus off-hours irrespective 
of day of the week.8 In the study by Kostis et al,10 the significant difference in 30-day 
mortality for patients treated during off-hours disap peared after adjustment for the 
use of invasive cardiac pro cedures, which appeared less often in patients admitted at 
weekends. Furthermore, in some of the previous studies, patients were not only treated 
with pPCI, but also with fibrinolysis, which may have led to different results.9–11,15,18 Since 
2000 in our centre, pPCI is the default strategy for all STEMI patients on a 24/7 basis, 
precluding potential bias due to fibrinolysis. On the other hand, most patients treated in 
our centre are referred for pPCI by hospitals in the larger region of Rotterdam that do not 
provide a 24/7 pPCI ser vice. Although, apparently, the referral pattern is not dependent 
on the day of the week and the time of the day (as we found no differences in patient 
characteristics in relation to treatment timing), the patient selection by referral hospi tals 
might partly explain the consistent outcomes.
study limitations
Other reported predictors of outcome after pPCI include time delay from symptom 
onset to the first balloon infla tion4–6 and physician volume.20,21 Since the database that 
we used for our study was not specifically designed to address these issues, several 
relevant quality parameters have not been recorded prospectively. Still, we retrospec-
tively recorded the time between hospital admission and the start of the pPCI procedure 
(data were available for 70% of patients), and we found no differences between patients 
treated during off-hours versus those treated during regular hours (data not shown). 
The presented results are based on a single-centre experience, which limits the exter nal 
validity. Nevertheless, the Thoraxcenter Rotterdam can be considered representative for 
larger tertiary referring and teaching (academic) hospitals in Western populations.
For the follow-up on non-fatal endpoints we were dependent on the responses of 
patients on health question naires that were systematically sent to all living patients, 
with specific inquiries on rehospitalisation and MACE. Thus, we might have missed some 
non-fatal endpoints, par ticularly those that did not result in hospital admissions. We 
have no indication that under-reporting (if any) was related to the timing of the initial 
treatment. This phenomenon might have resulted in effect estimates that are biased 
towards the null. Still, we are confident that similar effects were seen for all (‘hard’ and 
‘softer’) endpoints.
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COnClusIOn
STEMI patients who were treated in a high-volume centre with a 24/7 programme have 
similar short- and long-term outcomes whether they are treated during off-hours or 
reg ular hours. Our findings, which are based on systematic monitoring of treatment 
outcome results, do not necessitate us changing our practice. Instead, these results may 
encour age other centres to expand their service.
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Part 1, “Vulnerable Blood”, focusses on the additional value of several serum biomarkers 
for the prediction of MACE on a relatively long term (4 to 10 years of follow-up). These 
markers are traditionally measured once at the start of follow-up and hence assumed to 
reflect a constant cardiovascular risk, in a similar way as traditional risk models incorpo-
rate clinical risk factors.
Chapter 2 describes a multimarker model in which Troponin (Tn), Interleukin-10, myelo-
peroxidase and placental growth factor predict 4-year MACE rates in 1090 patients with 
non ST-elevation acute coronary syndrome. This model was able to stratify a seemingly 
homogenous study population into a relative low risk (6.0% event rate when all markers 
were normal) to a very high-risk subgroup in which the MACE rate was 35.8% when 
three of four biomarkers were abnormal.
Chapters 3 and 4 focus on patients undergoing a percutaneous coronary intervention 
and conclude that C-reactive protein (CRP) is associated with long-term MACE. Lipopro-
tein A may be of interest with respect to short-term prognosis after PCI.
Part 2, “Vulnerable Period”, focusses on serum biomarkers as well, but here the train 
of thought is to capture the dynamics of coronary pathophysiology, i.e. that the risk 
of MACE within an individual patient is not constant, but variable over time. Hence 
repeated biomarker measurements are explored in the BIOMarker study to identify the 
Acute risk of a Coronary Syndrome (BIOMArCS), in order to evaluate whether fluctua-
tions in biomarker levels can predict the risk of an imminent MACE within the days to 
weeks to come.
Chapter 5 describes the rationale and study design of the multicenter, prospective 
BIOMArCS study, together with the baseline clinical characteristics of the 844 enrolled 
patients presenting with ACS, either with or without ST-elevation and at least one ad-
ditional cardiovascular risk factor.
The paradigm of the vulnerable period is based on the concept that individual patients 
with CAD actually do not have a constant risk over time. Long periods of stability, 
with minimal plaque progression and low risk of CV events, are alternated by periods 
of increased plaque instability and rapid plaque progression, during which the risk of 
sudden plaque disruption and thrombotic coronary occlusion within short time spans is 
high. This is a complex and multifactorial pathophysiological process in which temporal 
variations in distorted lipid metabolism, vascular inflammation, endothelial dysfunction, 
increased thrombogenicity and myocardial ischaemia play an important role. In order to 
be able to capture a signal of changing risks over time, frequently repeated measure-
ments are required of markers that reflect the above-mentioned pathophysiological 
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processes. In BIOMArCS venapuncture was performed every 2 weeks during the first 
six months and every month thereafter during 1-year follow-up in order to evaluate the 
obtained repeated biomarker information for risk prediction.
As per the inclusion criteria, every BIOMArCS patient had endured an index ACS in order 
to qualify for enrollment. Hence it is of great importance to understand the Tn release 
patterns and stabilization after the index ACS prior to any further evaluation of this 
marker. Chapter 6 describes the Tn washout patterns as measured with current high-
sensitivity assays. Troponin levels stabilized in approximately 2 weeks after the index 
event. Intriguingly, low individual variation but large between-patient differences were 
observed thereafter. Using the first samples taken one month after ACS, we were able to 
compose a patient specific reference value for approximately 80% of the patients with 
just two measurements.
Chapter 7 describes the primary results of BIOMArCS through an evaluation of re-
peated measurements of high-sensitivity Troponins, N-terminal prohormone of brain 
natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein. In this cohort 
of asymptomatic post ACS patients with preserved ventricular function and guideline 
based treatment for secondary prevention, we observed that those patients with per-
sistently elevated Tn and NT-proBNP levels were at a significantly higher risk of MACE 
during 1-year follow-up. In addition, 20% of the patients had asymptomatic, isolated TnI 
peaks of 10 pg/mL, which was associated with a 2.9 fold increased risk of MACE during 
follow-up. Similarly an asymptomatic, isolated CRP peak of 10 mg/L, was also associated 
with a 2.9 fold increased risk of MACE during follow-up.
In part 3, “Vulnerable Plaque”, the centre of interest is around invasive coronary imaging 
(coronary angiography, intravascular ultrasound (IVUS) and near-infrared spectroscopy 
(NIRS)) for the prediction of MACE, as well as cross-sectional analyses evaluating the 
relation between these imaging techniques and serum biomarkers.
Chapter 8 describes the design and rationale of ATHEROREMO, the European Collabora-
tive Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis study. This 
large, prospective, observational cohort study was designed to evaluate the relation 
between novel circulating biomarkers, coronary plaque characteristics as determined 
by intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) and clinical 
outcome. IVUS and NIRS imaging was performed in a 40 mm long non-stenotic segment 
of a nonculprit coronary artery in patients referred for angiography due to stable angina 
pectoris or ACS.
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Chapters 9 and 10 evaluate the prognostic value of the novel intracoronary imaging 
modality known as near-infrared spectroscopy. This technique is capable of assessing 
lipid core-containing plaques, which can subsequently be quantified as a lipid core 
burden index (LCBI). Patients with a relatively high LCBI had a 4-fold risk of MACE during 
1-year follow-up (chapter 9). A similar association was observed when follow-up was 
extended to 4 years (chapter 10).
Chapters 11 and 12 describe the prognostic value of IVUS assessments of non-stenotic 
segments during 1 and 4 years of follow-up in 581 patients. Similarly to the NIRS find-
ings, the overall conclusion here is that a higher amount of plaque burden within the 
coronary vessel wall is predictive of higher MACE rates. In addition, these NIRS and IVUS 
studies confirm that imaging of a relatively short and angiographically non-stenotic 
segment does indeed provide prognostic information, thus suggesting that the vessel 
wall characteristics in these segments seem to reflect a global measure of intracoronary 
disease burden, despite being short and relatively unobstructed.
Whereas chapters 9-12 rely on a detailed characterization of a short segment of the 
coronary vessel wall, chapter 13 focusses on the predictive value of lumen character-
istics as obtained by coronary angiography of all three epicardial vessels. The SYNTAX 
score II, a long-term mortality prediction model for patients with left main and/or three 
vessel disease, is evaluated in the setting of only one- and two-vessel disease. Syntax 
score II also proved to be an independent significant predictor for 4.5-year mortality in 
this non-left main or three vessel disease cohort.
The interlink between chapters 9-13 is that the anatomy of coronary atherosclerosis, 
whether it is obtained from vessel wall characterization or lumenography, contains 
prognostic information even after adjustment for those traditional clinical risk factors 
that form the backbone of current risk prediction models for patients with coronary 
artery disease.
The following chapters 14-19 describe the crosslink between the vulnerable plaque and 
vulnerable blood; the associations between coronary plaque characteristics and serum 
biomarkers are evaluated. With our epidemiologic studies, we do not aim to unravel 
the biologically mechanistic intricacies of the interplay between serum proteins and 
coronary plaque. Nevertheless, it is intriguing to observe that serum biomarkers as 
C-reactive protein (chapter 14) and Troponin (chapter 15), that have been described 
as independent predictors for MACE in Parts 1 and 2 of this thesis (in chapters 2, 3, 4 
and 7 respectively), are also associated with IVUS plaque characteristics. In the following 
chapters, we describe the relation between plaque characteristics and serum proprotein 
486 Chapter 26
convertase substilisin/kexin type 9 (chapter 16), serum chemokines (chapter 17), se-
rum cytokines (chapter 18) and Von Willebrand factor (chapter 19). Finally, chapter 20 
is somewhat different as it does not evaluate a potentially fluctuating serum biomarker, 
but a genetic trait; haptoglobin polymorphisms are evaluated in relation to coronary 
plaque characteristics.
Accurate risk prediction is important to understand future risks of CAD patients, but 
clearly prediction alone will not alter the outcome. For that purpose, intervention studies 
are required in those deemed at high risk. Such studies, often combined with the search 
for those patient subsets to derive most benefit from the interventions, are described in 
Part 4, “Intervention Studies”.
Chapter 21 is part of the Integrated Biomarker and Imaging Study 2 (IBIS 2), and de-
scribes the effects of a lipoprotein-associated phospholipase A2 inhibitor on repeatedly 
measured Tn levels.
Chapter 22 describes the main outcome of the IBIS 3 study, a prospective, non-
randomized trial in which the effect of high intensity statin therapy is evaluated through 
repeated IVUS (n=164) and NIRS (n=103) measurements of a non-stenotic segment of a 
nonculprit coronary artery at baseline and after 1 year follow-up. High intensity rosuva-
statin therapy resulted in a neutral effect on necrotic core and LCBI.
Chapters 23 and 24 describe 8726 patients enrolled in the randomized, placebo con-
trolled EUROPA trial, which evaluated the efficacy of perindopril in patients with stable 
CAD. In chapter 23, models are constructed to evaluate the treatment effect of perin-
dopril in terms of 5 year absolute risk reduction for MACE, based on clinical variables 
(Europa score) and clinical and pharmacogenetic variables (Europa-GEN score). Chapter 
24 describes the PERindopril GENEtic (PERGENE) risk model, which incorporates clinical 
and pharmacogenetic variables. On the basis of this cost-effective risk scoring model a 
very wide range of gradients of absolute treatment benefit on ACE-inhibitor therapy was 
demonstrated in a seemingly homogenous trial population. The PERGENE score could 
identify patient subgroups with an annual number needed to treat (NNT) as low as 29, 
as well as patients with an annual NNT as high as 521.
Finally chapter 25 describes a single center, primary PCI experience in 4352 patients, 
and more specifically whether the outcome differs between those treated during regular 
office hours and those treated during so-called off-hours. Short and long-term mortality 
were similar in both groups.
In conclusion, this thesis focusses on patients with CAD. Despite current optimal medi-
cal therapy, their residual risk for MACE on a group level is evident. Equally evident is the 
observation that the persons that comprise this heterogenous group of CAD patients, 
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differ in their individual risk profile. Serum biomarkers, coronary imaging techniques 
and (pharmaco)genetics can all be successfully deployed in order to aid further risk 
stratification, i.e. identification of those at a higher, or perhaps even very low risk of a 
coronary event. The selection of any one of these techniques differs from one instance 
to another, and depends on the formulation of the particular research question that 
needs to be answered.
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In het eerste deel van dit proefschrift, genaamd “Vulnerable Blood”, ligt de nadruk op 
de toegevoegde waarde van serum biomarkers ten behoeve van het voorspellen van 
cardiovasculaire uitkomsten op een relatief lange termijn (4-10 jaar) bij patiënten met 
coronairlijden. Deze markers worden doorgaans eenmalig gemeten bij aanvang van 
de follow-up. De aanname is dat een dergelijke eenmalige meting van een eiwit in het 
bloed een cardiovasculair risico reflecteert dat constant is over de tijd, zoals dat ook 
wordt aangenomen voor klinische risicofactoren zoals bijvoorbeeld diabetes of hyper-
tensie etc. in traditionele risico modellen.
Zo wordt de associatie van serum biomarkers als Troponine, Interleukine-10, myeol-
peroxidase, placental growth factor, C-reactive protein (CRP) en lipoproteine A met 
cardiovasculaire uitkomsten op de lange termijn aangetoond.
Deel 2, “Vulnerabele Periode”, legt eveneens de nadruk op serum biomarkers, maar hier 
is het doel om de dynamiek van de coronaire pathofysiologie te pogen te detecteren 
middels kort op elkaar volgende, dus herhaalde, biomarker metingen. De gedachten-
gang is dat het risico op een hartinfarct in een individuele patiënt niet constant over de 
tijd is, maar dat het risico wisselt in de loop der tijd. In de BIOMarker study to identify the 
Acute risk of a Coronary Syndrome (BIOMArCS) is daarom aan 844 hartinfarct patiënten 
gevraagd om gedurende de loop van 1 jaar herhaald bloed af te geven (gemiddeld 17 
keer). Uit deze herhaalde metingen blijkt dat patiënten met een chronisch verhoogde 
Troponine en NT-proBNP waarde, alsook hen die pieken in de concentratie van Troponine 
en CRP vertoonden, een hoger risico hebben op het primaire eindpunt, een combinatie 
van overlijden, hernieuwd hartinfarct of urgente coronaire revascularisatie procedures.
In deel 3, “Vulnerabele Plaque”, ligt de nadruk op invasieve afbeelding van de krans-
slagaders door middel van coronair angiografie, intravascular ultrasound (IVUS) en 
near-infrared spectroscopy (NIRS). Er wordt onder andere, voor het eerst, aangetoond 
dat de mate van cholesterol in de kransslagaders, zoals gedetecteerd met de op licht 
gebaseerde techniek NIRS, voorspellend is voor het optreden van overlijden, hartinfarct 
en urgente coronaire revascularisatie procedures.
Verder worden er cross-sectionele relaties aangetoond tussen intracoronair gemeten 
plaque karakteristieken en serum biomarkers zoals Troponine, CRP, serum proprotein 
convertase substilisin/kexin type 9 (PCSK9), serum chemokines, serum cytokines, Von 
Willebrand factor en ook met haptoglobine polymorfismen.
Accurate risico predictie voor het optreden van een hartinfarct is uiteraard belangrijk, 
echter risico predictie alleen zal de uitkomsten niet verbeteren. Voor dat doel zijn 
“Interventie Studies” benodigd die in deel 4 worden beschreven.
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Zo wordt, onder andere, het effect van een lipoprotein-geassocieerde phospholipase 
A2 inhibitor op herhaalde Troponine metingen in de Integrated Biomarker and Imaging 
Study 2 (IBIS-2) beschreven.
In de IBIS-3 studie wordt door middel van herhaalde invasieve IVUS en NIRS metingen 
het effect van hoog-intensiteits statine therapie op de kransslagaders onderzocht.
Data uit de gerandomiseerde, placebo gecontroleerde EUROPA studie naar het effect 
van de ACE-remmer perindopril zijn gebruikt om grote verschillen in het behandeleffect 
aan te tonen. Deze verschillen in behandeleffect zijn afhankelijk van zowel klinische als 
genetische patiënt karakteristieken.
Als laatst wordt het effect van het tijdstip van spoed dotterprocedures bij hartinfarct 
patiënten onderzocht.
Samenvattend ligt de nadruk van dit proefschrift op risico stratificatie bij patiënten 
met coronairlijden. In deze groep patiënten is, ondanks de huidige optimale medische 
therapie, nog altijd een evident residueel risico op hartinfarct en cardiovasculaire dood 
aanwezig. Eveneens is het evident dat de personen binnen deze heterogene groep 
verschillen in het individuele risicoprofiel. Serum biomarkers, coronaire beeld vormings-
tech nie ken en (farmaco)genetica kunnen allen succesvol ingezet worden voor verdere 
risico stratificatie, d.w.z. identificatie van patiënten met een hoger, of wellicht zelfs heel 
erg laag risico op een coronair event. De selectie van deze verschillende technieken voor 
risico stratificatie is afhankelijk van de formulering van de specifieke onderzoeksvraag.

Co
r
o
n
a
r
y 
vu
ln
er
a
b
ility
28
LIST OF  
PUBLICATIONS
28
LIST OF  
PUBLICATIONS

List of publications 497
C
h
a
p
te
r
 2
8
lIsT Of PublICaTIOns
47. Oemrawsingh RM, Akkerhuis KM, de Mulder M, Umans VA, Kietselaer B, Schotborgh 
C, Ronner E, Lenderink T, Liem A, Haitsma D, van der Harst P, Asselbergs FW, Maas A, 
Oude Ophuis AJ, Ilmer B, Dijkgraaf R, de Winter RJ, Kie The SH, Wardeh AJ, Hermans 
W, Cramer E, van Schaik RH, Hoefer IE, Doevendans PA, Simoons ML, Boersma E; 
BIOMArCS Investigators. High-Frequency Biomarker Measurements of Troponin, 
NT-proBNP, and C-Reactive Protein for Prediction of New Coronary Events After Acute 
Coronary Syndrome. Circulation. 2019 Jan 2; 139(1): 134-136.
46. Vroegindewey MM, Oemrawsingh RM, Kardys I, Asselbergs FW, van der Harst 
P,Oude Ophuis AJ, Etienne Cramer G, Maas A, Hong Kie The S, Wardeh AJ, Mouthaan 
H, Boersma E, Akkerhuis KM. The temporal pattern of immune and inflammatory 
proteins prior to a recurrent coronary event in post-acute coronary syndrome patients. 
biomarkers. 2018 Dec 4: 1-7.
45. Schuurman AS, Vroegindewey MM, Kardys I, Oemrawsingh RM, Garcia-Garcia HM, 
van Geuns RJ, Regar E, Van Mieghem NM, Ligthart J, Serruys PW, Boersma E, Akker-
huis KM. Prognostic Value of Intravascular Ultrasound in Patients With Coronary Artery 
Disease. J am Coll Cardiol. 2018 Oct 23; 72(17): 2003-2011.
44. Anroedh SS, Akkerhuis KM, Oemrawsingh RM, Garcia-Garcia HM, Brankovic M, 
Regar E, van Geuns RJ, Serruys PW, Daemen J, van Mieghem NM, Boersma E, Kardys 
I. Associations of 26 Circulating Inflammatory and Renal Biomarkers with Near-Infra-
red Spectroscopy and Long-term Cardiovascular Outcome in Patients Undergoing 
Coronary Angiography (ATHEROREMO-NIRS Substudy). Curr atheroscler Rep. 2018 
Sep 14; 20(10): 52.
43. IJsselmuiden AJJ, Zwaan EM, Oemrawsingh RM, Bom MJ, Dankers FJWM, de Boer 
MJ, Camaro C, van Geuns RJM, Daemen J, van der Heijden DJ, Jukema JW, Kraai-
jeveld AO, Meuwissen M, Schölzel BE, Pundziute G, van der Harst P, van Ramshorst J, 
Dirksen MT, Zivelonghi C, Agostoni P, van der Heyden JAS, Wykrzykowska JJ, Scholte 
MJ, Nef HM, Kofflard MJM, van Royen N, Alings M, Kedhi E. Appropriate use criteria for 
optical coherence tomography guidance in percutaneous coronary interventions: Rec-
ommendations of the working group of interventional cardiology of the Netherlands 
Society of Cardiology. neth Heart J. 2018 Aug 31.
42. Van den Berg VJ, Haskard DO, Fedorowski A, Hartley A, Kardys I, Caga-Anan M, Ak-
kerhuis KM, Oemrawsingh RM, van Geuns RJ, de Jaegere P, van Mieghem N, Regar 
E, Ligthart JMR, Umans VAWM, Serruys PW, Melander O, Boersma E, Khamis RY. IgM 
anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart 
disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the 
Integrated Imaging and Biomarker Study 3 (IBIS-3). ebioMedicine. 2018 Aug 18. pii: 
S2352-3964(18)30309-8.
498 Chapter 28
41. Vroegindewey MM, Schuurman AS, Oemrawsingh RM, van Geuns RJ, Kardys I, 
Ligthart J, Daemen J, Boersma E, Serruys PW, Akkerhuis KM. SYNTAX score II predicts 
long-term mortality in patients with one- or two-vessel disease. Plos One. 2018 Jul 2; 
13(7): e0200076.
40. Anroedh S, Hilvo M, Akkerhuis KM, Kauhanen D, Koistinen K, Oemrawsingh R, Ser-
ruys P, van Geuns RJ, Boersma E, Laaksonen R, Kardys I. Plasma concentrations of 
molecular lipid species predict long-term clinical outcome in coronary artery disease 
patients. J lipid Res. 2018 Sep; 59(9): 1729-1737.
39. Vroegindewey MM, Schuurman AS, Kardys I, Anroedh SS, Oemrawsingh RM, Lig-
thart J, Garcia-Garcia HM, van Geuns RM, Regar E, Van Mieghem NM, Serruys PW, 
Boersma E, Akkerhuis M. SYNTAX score in relation to intravascular ultrasound and 
near-infrared spectroscopy for the assessment of atherosclerotic burden in patients with 
coronary artery disease. euroIntervention. 2018 Mar 13. pii: EIJ-D-17-00827
38. Schuurman AS, Vroegindewey M, Kardys I, Oemrawsingh RM, Cheng JM, de Boer 
S, Garcia-Garcia HM, van Geuns RJ, Regar ES, Daemen J, van Mieghem NM, Serruys 
PW, Boersma E, Akkerhuis KM. Near-infrared spectroscopy-derived lipid core burden 
index predicts adverse cardiovascular outcome in patients with coronary artery disease 
during long-term follow-up. eur Heart J. 2018 Jan 21; 39(4): 295-302.
37. Oemrawsingh RM, Akkerhuis KM, Umans VA, Kietselaer B, Schotborgh C, Ronner E, 
Lenderink T, Liem A, Haitsma D, Van der Harst P, Asselbergs FW, Maas A, Oude Ophuis 
AJ, Ilmer B, Dijkgraaf R, De Winter R-J, The SHK, Wardeh AJ, Hermans W, Cramer E, 
Van Schaik RH, Hoefer IE, Doevendans PA, Simoons ML, Boersma E. Cohort profile of 
BIOMArCS: The BIOMarker study to identify the Acute risk of a Coronary Syndrome—a 
prospective multicentre biomarker study conducted in the Netherlands. bMJ Open 
2016 Dec 23; 6(12): e012929
36. Buljubasic N, Akkerhuis KM, Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, de 
Boer SP, Regar E, van Geuns RM, Serruys PW, Boersma E, Kardys I. Fibrinogen in 
relation to degree and composition of coronary plaque on intravascular ultrasound in 
patients undergoing coronary angiography. Coron artery Dis. 2017 Jan; 28(1): 23-32.
35. Brankovic M, Akkerhuis KM, Buljubasic N, Cheng JM, Oemrawsingh RM, Garcia-
Garcia HM, Regar E, Serruys PW, van Geuns RJ, Boersma E, Kardys I. Plasma cystatin 
C and neutrophil gelatinase-associated lipocalin in relation to coronary atherosclerosis 
on intravascular ultrasound and cardiovascular outcome: Impact of kidney function 
(ATHEROREMO-IVUS study). atherosclerosis. 2016 Nov; 254: 20-27.
34. Oemrawsingh RM, Garcia-Garcia HM, van Geuns RJ, Lenzen MJ, Simsek C, de Boer 
SP, Van Mieghem NM, Regar E, de Jaegere PP, Akkerhuis KM, Ligthart JM, Zijlstra F, 
Serruys PW, Boersma E. Integrated Biomarker and Imaging Study 3 (IBIS-3) to assess 
the ability of rosuvastatin to decrease necrotic core in coronary arteries. euroInterven-
tion. 2016 Aug 20; 12(6): 734-9.
List of publications 499
C
h
a
p
te
r
 2
8
33. Buljubasic N, Oemrawsingh RM, Smeets MB, Cheng JM, Regar E, van Geuns RJ, Ser-
ruys PW, Boersma E, Akkerhuis KM, Kardys I, Arslan F. Haptoglobin polymorphism in 
relation to coronary plaque characteristics on radiofrequency intravascular ultrasound 
and near-infrared spectroscopy in patients with coronary artery disease. Int J Cardiol. 
2016 Oct 15; 221: 682-7.
32. Oemrawsingh RM, Akkerhuis KM, Van Vark LC, Redekop WK, Rudez G, Remme 
WJ, Bertrand ME, Fox KM, Ferrari R, Danser AH, de Maat M, Simoons ML, Brugts JJ, 
Boersma E; PERGENE investigators. Individualized Angiotensin-Converting Enzyme 
(ACE)-Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and 
Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model. J am 
Heart assoc. 2016 Mar 28; 5(3): e002688.
31. Oemrawsingh RM, Cheng JM, García-García HM, Kardys I, van Schaik RH, Regar E, 
van Geuns RJ, Serruys PW, Boersma E, Akkerhuis KM. High-sensitivity Troponin T in re-
lation to coronary plaque characteristics in patients with stable coronary artery disease; 
results of the ATHEROREMO-IVUS study. atherosclerosis. 2016 Apr; 247: 135-41.
30. Oemrawsingh RM*, Cheng JM*,Garcia-Garcia HM, Boersma E, van Geuns RJ, Ser-
ruys PW, Kardys I, Akkerhuis KM. PCSK9 in relation to coronary plaque inflammation: 
Results of the ATHEROREMO-IVUS study. atherosclerosis. 2016 May; 248: 117-22.
 * = equal contribution
29. Buljubasic N, Akkerhuis KM, de Boer SP, Cheng JM, Garcia-Garcia HM, Lenzen 
MJ, Oemrawsingh RM, Battes LC, Rijndertse M, Regar E, Serruys PW, van Geuns 
RJ,Boersma E, Kardys I. Smoking in Relation to Coronary Atherosclerotic PlaqueBurden, 
Volume and Composition on Intravascular Ultrasound. Plos One. 2015 Oct22; 10(10): 
e0141093.
28. Cheng JM, Suoniemi M, Kardys I, Vihervaara T, de Boer SP, Akkerhuis KM, Sysi-Aho M, 
Ekroos K, Garcia-Garcia HM, Oemrawsingh RM, Regar E, Koenig W, Serruys PW, van 
Geuns RJ, Boersma E, Laaksonen R. Plasma concentrations of molecular lipid species in 
relation to coronary plaque characteristics and cardiovascular outcome: Results of the 
ATHEROREMO-IVUS study. atherosclerosis. 2015 Dec; 243(2): 560-566.
27. Eindhoven JA, van den Bosch AE, Oemrawsingh RM, Baggen VJ, Kardys I, Cuypers 
JA, Witsenburg M, van Schaik RH, Roos-Hesselink JW, Boersma E. Release of growth-
differentiation factor 15 and associations with cardiac function in adult patients with 
congenital heart disease. Int J Cardiol. 2015 Sep 14; 202: 246-251.
26. Oemrawsingh RM, Cheng JM, Akkerhuis KM, Kardys I, Degertekin M, van Geuns RJ, 
Daemen J, Boersma E, Serruys PW, van Domburg RT. High-sensitivity C-reactiveprotein 
predicts 10-year cardiovascular outcome after percutaneous coronary intervention. 
euroIntervention 2016 Jun 20; 12(3): 345-51
25. van der Leeuw J, Oemrawsingh RM, van der Graaf Y, Brugts JJ, Deckers JW, Bertrand 
M, Fox K, Ferrari R, Remme WJ, Simoons ML, Boersma E, Visseren FL.Prediction of 
500 Chapter 28
absolute risk reduction of cardiovascular events with perindopril for individual patients 
with stable coronary artery disease – results from EUROPA. Int J Cardiol. 2015 Mar 1; 
182: 194-9.
24. Oemrawsingh RM, Cheng JM, García-García HM, van Geuns RJ, de Boer SP, Simsek C, 
Kardys I, Lenzen MJ, van Domburg RT, Regar E, Serruys PW, Akkerhuis KM, Boersma E; 
ATHEROREMO-NIRS Investigators. Near-infrared spectroscopy predicts cardiovascular 
outcome in patients with coronary artery disease. J am Coll Cardiol. 2014 Dec 16; 
64(23): 2510-8.
23. Sonneveld MA, Cheng JM, Oemrawsingh RM, de Maat MP, Kardys I, Garcia-Garcia 
HM, van Geuns RJ, Regar E, Serruys PW, Boersma E, Akkerhuis KM, Leebeek FW. Von 
Willebrand factor in relation to coronary plaque characteristics and cardiovascular out-
come. Results of the ATHEROREMO-IVUS study. Thromb Haemost. 2015 Mar; 113(3): 
577-84.
22. Battes LC, Akkerhuis KM, Cheng JM, Garcia-Garcia HM, Oemrawsingh RM, de Boer 
SP, Regar E, van Geuns RJ, Serruys PW, Boersma E, Kardys I. Circulating acute phase 
proteins in relation to extent and composition of coronary atherosclerosis and cardio-
vascular outcome: results from the ATHEROREMO-IVUS study. Int J Cardiol. 2014 Dec 
20; 177(3): 847-53.
21. Oemrawsingh RM*, Cheng JM*,Garcia-Garcia HM, Akkerhuis KM, Kardys I, de Boer 
SP, Langstraat JS, Regar E, van Geuns RJ, Serruys PW, Boersma E. Relation of C-Reactive 
Protein to Coronary Plaque Characteristics on Grayscale,Radiofrequency Intravascular 
Ultrasound, and Cardiovascular Outcome in Patients With Acute Coronary Syndrome or 
Stable Angina Pectoris (from the ATHEROREMO-IVUS Study). am J Cardiol. 2014 Nov 
15; 114(10): 1497-503.
 * = equal contribution
20. Cheng JM, Oemrawsingh RM, Akkerhuis KM, Garcia-Garcia HM, de Boer SP, Battes 
LC, Buljubasic N, Lenzen MJ, de Jaegere PP, van Geuns RJ, Serruys PW, Kardys I, 
Boersma E. Circulating chemokines in relation to coronary plaque characteristics on 
radiofrequency intravascular ultrasound and cardiovascular outcome.biomarkers. 
2014 Nov; 19(7): 611-9.
19. Battes LC, Cheng JM, Oemrawsingh RM, Boersma E, Garcia-Garcia HM, de Boer SP, 
Buljubasic N, Mieghem NA, Regar E, Geuns RJ, Serruys PW, Akkerhuis KM, Kardys I. 
Circulating cytokines in relation to the extent and composition of coronary atheroscle-
rosis: results from the ATHEROREMO-IVUS study. atherosclerosis. 2014 Sep; 236(1): 
18-24
18. Cheng JM, Akkerhuis KM, Meilhac O, Oemrawsingh RM, Garcia-Garcia HM, van 
Geuns RJ, Piquer D, Merle D, du Paty E, Galéa P, Jaisser F, Rossignol P, Serruys PW, 
Boersma E, Fareh J, Kardys I. Circulating osteoglycin and NGAL/MMP9 complex con-
List of publications 501
C
h
a
p
te
r
 2
8
centrations predict 1-year major adverse cardiovascular events after coronary angiog-
raphy. arterioscler Thromb Vasc biol. 2014 May; 34(5): 1078-84.
17. Cheng JM, Garcia-Garcia HM, de Boer SP, Kardys I, Heo JH, Akkerhuis KM, Oem-
rawsingh RM, van Domburg RT, Ligthart J, Witberg KT, Regar E, Serruys PW, van 
Geuns RJ, Boersma E. In vivo detection of high-risk coronary plaques by radiofrequency 
intravascular ultrasound and cardiovascular outcome: results of the ATHEROREMO-
IVUS study. eur Heart J. 2014 Mar; 35(10): 639-47.
16. de Boer SP, van Leeuwen MA, Cheng JM, Oemrawsingh RM, van Geuns RJ, Serruys 
PW, Boersma E, Lenzen MJ. Trial participation as a determinant of clinical outcome: 
Differences between trial-participants and Every Day Clinical Care patients in the field 
of interventional cardiology. Int J Cardiol. 2013 Nov 15; 169(4): 305-10.
15. de Boer SP, Cheng JM, Garcia-Garcia HM, Oemrawsingh RM, van Geuns RJ, Regar 
E, Zijlstra F, Laaksonen R, Halperin E, Kleber ME, Koenig W, Boersma E, Serruys PW. 
Relation of genetic profile and novel circulating biomarkers with coronary plaque 
phenotype as determined by intravascular ultrasound: rationale and design of the 
ATHEROREMO-IVUS study. euroIntervention. 2014 Dec; 10(8): 953-60.
14. de Mulder M, Umans VA, Cornel JH, van der Zant FM, Stam F, Oemrawsingh RM, Ak-
kerhuis KM, Boersma E. Intensive Glucose Regulation in Hyperglycemic Acute Coronary 
Syndrome: Results of the Randomized BIOMarker Study to Identify the Acute Risk of a 
Coronary Syndrome-2 (BIOMArCS-2) Glucose Trial. JaMa Intern Med. 2013 Nov 11; 
173(20): 1896-904.
13. Panasewicz A, Pedersen SS, Veenhuis SJ, Oemrawsingh RM, van der Giessen WJ, van 
Geuns RJ, Regar E, de Jaegere PP, Serruys PW, van Domburg RT. Health-related quality 
of life in the elderly three years after percutaneous coronaryintervention. euroInter-
vention. 2013 Jul 22; 9(3): 373-81.
12. García-García HM, Oemrawsingh RM, Brugaletta S, Vranckx P, Shannon J, Davies 
R, Boersma E, Serruys PW. Darapladib effect on circulating high sensitive troponin in 
patients with acute coronary syndromes. atherosclerosis. 2012 Nov; 225(1): 142-7.
11. De Boer SPM, Oemrawsingh RM, Lenzen MJ, Van Mieghem NM, Schultz C, Akkerhuis 
KM, Van Leeuwen MAH, Zijlstra F, Van Domburg RT, Serruys PWJC, Boersma E (on 
behalf of the interventional cardiologists of the Thoraxcenter 2000–2009) Primary 
PCI during off-hours is not related to increased mortality eur Heart J: acute Cardio-
vascular Care April 2012 1: 33-39.
10. Eindhoven JA, Onuma Y, Oemrawsingh RM, Daemen J, van Nierop JW, de Jaegere PP, 
Boersma E, Serruys PW, van Domburg RT. Long-term outcome after statin treatment 
in routine clinical practice: results from a prospective PCI cohort study. euroInterven-
tion. 2012 Apr; 7(12): 1420-7.
9. Kardys I, Oemrawsingh RM, Kay IP, Jones GT, McCormick SP, Daemen J, Van Geuns 
RJ, Boersma E, Van Domburg RT, Serruys PW. Lipoprotein(a), interleukin-10, C-reactive 
502 Chapter 28
protein, and 8-year outcome after percutaneous coronary intervention. Clin Cardiol. 
2012 Aug; 35(8): 482-9.
8. Schenkeveld L, Magro M, Oemrawsingh RM, Lenzen M, de Jaegere P, van Geuns 
RJ, Serruys PW, van Domburg RT. The influence of optimal medical treatment on the 
‘obesity paradox’, body mass index and long-term mortality in patients treated with 
percutaneous coronary intervention: a prospective cohort study. bMJ Open. 2012 Feb 
9; 2: e000535.
7. Battes LC, Pedersen SS, Oemrawsingh RM, van Geuns RJ, Al Amri I, Regar E, de Jae-
gere PP, Serruys P, van Domburg RT. Beta blocker therapy is associated with reduced 
depressive symptoms 12 months post percutaneous coronary intervention. J affect 
Disord. 2012 Feb; 136(3): 751-7.
6. de Mulder M, Oemrawsingh RM, Stam F, Boersma E, Umans VA. Comparison of di-
agnostic criteria to detect undiagnosed diabetes in hyperglycaemic patients with acute 
coronary syndrome. Heart. 2012 Jan; 98(1): 37-41.
5. de Boer SP, Lenzen MJ, Oemrawsingh RM, Simsek C, Duckers HJ, van der Giessen 
WJ, Serruys PW, Boersma E. Evaluating the ‘all-comers’ design: a comparison of partici-
pants in two ‘all-comers’ PCI trials with non-participants. eur Heart J. 2011 Sep; 32(17): 
2161-7.
4. Oemrawsingh RM, Lenderink T, Akkerhuis KM, Heeschen C, Baldus S, Fichtlscherer S, 
Hamm CW, Simoons ML, Boersma E; CAPTURE investigators. Multimarker risk model 
containing troponin-T, interleukin 10, myeloperoxidase and placental growth factor 
predicts long-term cardiovascular risk after non-ST-segment elevation acute coronary 
syndrome. Heart. 2011 Jul; 97(13): 1061-6.
3. de Mulder M, Umans VA, Stam F, Cornel JH, Oemrawsingh RM, Boersma E. Intensive 
management of hyperglycaemia in acute coronary syndromes. Study design and 
rationale of the BIOMArCS 2 glucose trial. Diabet Med. 2011Oct; 28(10): 1168-75.
2. de Mulder M, Oemrawsingh RM, Stam F, Boersma E, Umans VA. Current manage-
ment of hyperglycemia in acute coronary syndromes: a national Dutch survey. Crit 
Pathw Cardiol. 2009 Jun; 8(2): 66-70; quiz 71.
1. Oemrawsingh RM, Akkerhuis KM, Boersma E. Tailor-made therapy for the prevention 
of acute coronary syndromes: future role of biomarkers in risk stratification and disease 
management. expert Rev Cardiovasc Ther. 2008 Apr; 6(4): 435-7.

Co
r
o
n
a
r
y 
vu
ln
er
a
b
ility
29
PHD
PORTFOLIO
29
PHD
PORTFOLIO

PhD Portfolio 507
C
h
a
p
te
r
 2
9
PHD PORTfOlIO suMMaRY
Year Workload
(eCTs)
Research skills
– NIHES Master of Science programme in Clinical Epidemiology 2010 70 
Presentations
*
– Netherlands Heart Foundation Papendal course 2008 0.3 
– Netherlands Heart Foundation Wetenschapsdag 2008 0.3 
– Spring Congress Netherlands Society of Cardiology (NVVC) 2008 0.3 
– Spring Congress Netherlands Society of Cardiology (NVVC) 2009 0.5 
– European Society of Cardiology Congress (Barcelona) 2009 0.6 
– American Heart Association Scientific Sessions (Orlando) 2009 0.3 
– American College of Cardiology.10 (Atlanta) 2010 0.5 
– World Congress of Cardiology (Beijing) 2010 1.5 
– European Society of Cardiology Congress (Stockholm) 2010 0.3 
– European Society of Cardiology Congress (Amsterdam) 2013 1.0 
– American Heart Association Scientific Sessions (Dallas) 2013 0.3 
– American College of Cardiology.14 (Washington) 2014 0.3 
– European Society of Cardiology Congress (Barcelona) 2014 0.6 
– Autumn Congress Netherlands Society of Cardiology (NVVC) 2014 0.5 
– WCN Congress (Amsterdam) 2015 0.5 
– Optics in Cardiology (Zurich) 2018 0.5 
* 0.3 ECTS for a poster and 0.5 ECTS for an oral presentation 
International conferences
– European Society of Cardiology Congress (Barcelona) 2009 1.5 
– American Heart Association Scientific Sessions (Orlando) 2009 1.2 
– American College of Cardiology.10 (Atlanta) 2010 1.2 
– World Congress of Cardiology (Beijing) 2010 1.2 
– European Society of Cardiology Congress (Stockholm) 2010 1.5 
– European Society of Cardiology Congress (Amsterdam) 2013 1.5 
– American Heart Association Scientific Sessions (Dallas) 2013 1.2 
– American College of Cardiology.14 (Washington) 2014 1.2 
– European Society of Cardiology Congress (Barcelona) 2014 1.5 
– European Society of Cardiology Congress (London) 2015 1.5 
– ACC New York Cardiovascular Symposium 2015 1.2 
– European Society of Cardiology Congress (Rome) 2016 1.5 
– EuroPCR incl fellows course (Paris) 2017 1.5 
– European Society of Cardiology Congress (Barcelona) 2017 1.5 
– Optics in Cardiology (Zurich) 2018 0.9 
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Year Workload
(eCTs)
– EuroPCR incl fellows course (Paris) 2018 1.5 
– CSI Frankfurt 2018 2018 1.2 
– European Society of Cardiology Congress (Munich) 2018 1.5 
seminars and workshops
– Netherlands Heart Foundation Papendal course 2008 2.0 
– Netherlands Heart Foundation Wetenschapsdag 2008 0.2 
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Dit proefschrift is het resultaat van een proces waarin velen, gedurende lange tijd hun 
bijdrage hebben geleverd. Ik heb me daarbij altijd goed gerealiseerd dat ik ook aan 
velen dank verschuldigd zou zijn, mede vanwege de grootschaligheid van met name 
BIOMArCS, waarvoor ik in 21 ziekenhuizen vele mensen op cardiologie afdelingen en 
in het laboratorium meermaals persoonlijk heb mogen ontmoeten. Teveel om iedereen 
met naam te benoemen. Zonder iemand tekort te willen doen zou ik in ieder geval de 
volgende personen in het bijzonder willen bedanken.
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belangrijkste zijn. Heel veel dank voor alle onvoorwaardelijke liefde en waardering. 
Hriday, jij bent de jongste telg, maar ook de belangrijkste. Je bent het licht in mijn 
ogen, mijn hartslag. Dank voor jouw komst en alle vreugde en verwondering die je 
hebt meegebracht en elke dag weer creëert. Lachman Oemrawsingh, onze Rama kaka 
adja. Uw overlijden in maart 2019 viel heel zwaar. U was er van jongs af aan altijd bij op 
belangrijke momenten en daarom had ik me, als vanzelfsprekend, voorgesteld dat u ook 
bij de verdediging zou zijn. Dank voor al uw warmte en steun als grootouder. U bent een 
groot voorbeeld. Ik heb u beloofd dat ik nog heel vaak (met een lach) aan u zal denken.
Mijn promotor, professor Boersma. Beste Eric, de calvinistische bescheidenheid en nuch-
terheid die jou zo kenmerken, staan haaks op de superlatieven die ik voor jou in gedachte 
heb. Ik ben 11,5 jaar geleden bij jou begonnen met wetenschappelijk onderzoek en heb 
genoeg ervaren, en met anderen samengewerkt, om op een gebalanceerde manier te 
concluderen dat jij verreweg de beste promotor bent die ik ooit heb gezien. Heel veel 
dank voor al je steun en vertrouwen. Voor de ruimte en zelfstandigheid die je bood om 
BIOMArCS invulling te geven – welke voor ons allebei een belangrijk project was waarin 
we veel voor de toekomst gingen leren. Voor de mogelijkheden die je bood om ook op an-
dere projecten (ATHEROREMO, IBIS-3, EUROPA) te schrijven. Voor de tijd die je me gunde 
in de periodes die ik ook nodig had om te werken aan mijn klinische vaardigheid. Je weet 
dat ik dit proefschrift nooit als een “academisch eindstation” heb gezien. Ik hoop nog veel 
met jou en Martijn samen te werken.
Mijn co-promotor, dr. Martijn Akkerhuis. Beste Martijn, dank voor alle begeleiding vanaf 
mijn allereerste aankomst in het Thoraxcentrum. Als jij me tijdens het oudste co-schap in 
2007 niet had geënthousiasmeerd voor BIOMArCS, was dit boekje natuurlijk nooit zo ge-
worden. Dank ook voor de vele besprekingen, waarin we standaard veel meer over andere 
leuke dingen dan research spraken. Dank voor je exacte commentaar op papers. En ook 
heel veel dank voor je oprechte steun en gedachten in de latere fases van mijn opleiding 
toen ik moest leren op mijn eigen benen te staan als aankomend medisch specialist.
I would like to thank professor Van der Steen, professor Valgimigli and professor Zijlsta 
for their evaluation of this thesis and participation in the (reading) committee. Marco and 
Felix I also have to thank for their profound and always academically justified teachings 
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in the cathlab of the Thoraxcenter. Graag zou ik ook professor Dirk-Jan Duncker en pro-
fessor Robert-Jan van Geuns bedanken. Robert-Jan specifiek ook voor zijn grote bijdrage 
aan de intracoronaire imaging studies. Professor Simoons behoeft speciale vermelding. 
Heel veel dank voor het vertrouwen en de directe opleidingstoezegging. Tijdens de 
research overleggen met Eric en Martijn kwam uw uitermate consequente werkwijze 
vaker, als leidend principe, ter sprake. U had daarmee indirect veel invloed op dit werk. 
Dr. Jeroen Vos moet ik bedanken voor zijn enthousiasme en gedreven opleiderschap 
tijdens het fellowship interventiecardiologie. Alsook voor de aanhoudende interesse in 
mijn proefschrift en de gastvrijheid bij de familie Vos thuis.
Mijn paranimfen. Allereerst dr. Jin Ming Cheng. Beste Jin, je hebt me een beetje teveel 
eer gegeven in jouw dankwoord. Maar onze compatibiliteit en samenwerking was 
inderdaad wel heel bijzonder. Ik koester onze vriendschap en hoop daarnaast ook nog 
veel met jou te kunnen werken.
Mijn broertje Nishal Bhagatsingh Gopalsingh! Ik ben supertrots op de broer die niet 
alleen op 27 juni, maar altijd naast me zal staan. Zonder het te vaak te benoemen, leer ik 
heel veel van onze verschillende perspectieven.
Mijn collega Chris Jansen. Beste Chris, ik kon met een gerust hart naar de vooroplei-
ding interne geneeskunde in de wetenschap dat jij op een uitermate gedegen, precieze 
en voortvarende manier, samen met Eric, BIOMArCS in de lucht zou zouden. Heel veel 
dank daarvoor. Zonder jou hadden we dit niet kunnen voltooien. Ook wil ik hier de 
andere kamergenoten uit Ba-561, dr. Ron Van Domburg en dr. Mattie Lenzen bedanken.
Alle BIOMArCS investigators, research verpleegkundigen, promovendi en labora-
torium medewerkers die op het project werkten, wil ik van harte bedanken. Ook wil 
ik het Interuniversitair Cardiologisch Instituut Nederland, tegenwoordig Netherlands 
Heart Institute en de Werkgroep Cardiologische Centra Nederland bedanken voor hun 
instrumentele rol en steun. Wij realiseerden ons altijd dat BIOMArCS een uitermate 
belastende studie was, maar met uw volharding is het toch voltooid. Ook de BIOMArCS 
patiënten verdienen speciale dank voor hun vele visites aan het ziekenhuis. Dr. Maarten 
de Mulder en dr. Victor Umans verdienen dank voor de samenwerking in BIOMArCS en 
BIOMArCS2 glucose. Dr. Timo Lenderink en dr. Ton Oude Ophuis voor hun aanhoudende 
enthousiasme en steun binnen de WCN.
Professor Jan Lindemans, professor Ron Van Schaik, Rens Zwang, Moniek de Waart 
en Jannette Langstraat wil ik met name noemen voor hun bijdrage vanaf het klinisch 
chemisch laboratorium van het ErasmusMC.
I would like to thank professor Patrick Serruys wholeheartedly for the great honour to work 
with him and the opportunities that he granted us in the ATHEROREMO and IBIS-3 studies. 
In that context I would also like to thank Professor Héctor García-García, Dr. Evelyn Regar, 
Dr. Sanneke de Boer, Dr. Cihan Simsek, Dr. Isabella Kardys, all the interventional cardiologists 
of the Thoraxcenter, Jurgen Ligthart and Karen Witberg. Anne-Sophie Schuurman, Maxime 
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Vroegindewey, Victor van den Berg, Nermina Buljubasic, Shardha Anroedh, Milos Brankovic 
en Fatih Arslan dank ik voor de prachtige bijdragen aan het vervolg van deze studies.
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Voorts dank aan alle leden van de KLEP-groep, Dr. Sanne Hoeks, dr. Yvette van Gestel en 
Yvonne Schotting.
Hanneke Weststrate wil ik bedanken voor onze lange en bijzondere vriendschap, de 
altijd goede gesprekken, de vele (maar toch altijd te weinig) keren koffie en het feit dat 
je me in contact stelde met Paul Swagerman, die ik wil danken voor het prachtige door 
Massimo Vignelli geïnspireerde, typografische design van dit boekje. Han, binnenkort 
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wens ik ook mijn opleiders te bedanken.
Dr. Folkert ten Cate wil ik bedanken omdat hij reeds in de onderzoeksfase, en daarmee 
ver voordat het in mijn ogen nodig was, zich over mij ontfermde. Door Arie Rietveld met 
name te noemen wil ik alle opleiders van de vooropleiding interne geneeskunde in het 
Sint Franciscus Gasthuis bedanken. Via professor Jaap Deckers, dr. Tjebbe Galema en 
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